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ABSTRACT	
	Antivirals	 play	 an	 important	 and	 decisive	 role	 in	 the	 clinical	management	 of	 influenza	and	 in	 the	 underlying	 reduction	 of	 related	morbidity	 and	mortality.	 The	 emergence	 of	antiviral	resistance,	and	particularly	of	transmissible	resistance,	poses	a	serious	threat	to	public	 health	 as	 it	 could	 render	 influenza	 antivirals	 useless	 against	 circulating	 viruses.	This	is	even	more	worrying	when	considering	the	current	paucity	of	alternative	antiviral	therapy	choices.		
	This	 PhD	 research	 project	 aimed	 at	 disclosing	 the	 susceptibility	 of	 human	 influenza	viruses	 circulating	 in	 Portugal	 to	 nationally	 approved	 antivirals,	 and	 at	 improving	 the	knowledge	 on	 the	 evolutionary	 dynamics	 underlying	 the	 emergence	 and/or	 spread	 of	influenza	variants	 resistant	or	with	decreased	susceptibility	 to	neuraminidase	 inhibitor	(NAI)	drugs.	To	this	end,	the	project	focused	on	three	main	areas:	antiviral	susceptibility	testing;	 whole-genome	 sequencing;	 and	 selective	 pressure	 (SP)	 footprints	 on	 human	influenza	neuraminidase	(NA)(NAI	target).			Antiviral	susceptibility	testing	was	performed	on	human	influenza	viruses	circulating	in	both	community	and	hospital	settings	from	2004/2005	to	2012/2013,	after	establishing	a	 technological	 platform	 for	 comprehensive	 evaluation	 of	 virus	 susceptibility	 to	 M2	protein	 inhibitors	 and	 the	 NAIs	 oseltamivir	 (OS)	 and	 zanamivir	 (ZA)	 (objective	 1).	Important	 findings	 were	 made	 on:	 the	 circulation	 of	 drug-resistant	 A(H3N2)	 (M2	inhibitors)	 and	 former	 seasonal	 A(H1N1)	 (OS)	 viruses;	 the	 cut-off	 for	 potentially	clinically	 relevant	 sub-populations	of	drug-resistant	virus;	 a	potential	novel	 amino	acid	substitution	conferring	slightly	decreased	susceptibility	to	ZA	(N2	NA)	and	a	novel	source	for	a	variant	with	decreased	susceptibility;	 and,	 the	virus	 type	or	 subtype	 specificity	of	two	 amino	 acid	 substitutions	 conferring	 reduced	 susceptibility	 to	 the	 drug.	 Overall	susceptibility	 data	 contributed	 at	 a	 better	 understanding	 of	 the	 relationship	 between	virus	NAI	 susceptibility	phenotype	and	genotype	and	of	 the	natural	variations	 in	 the	 in	
vitro	 NAI	 susceptibility	 of	 circulating	 viruses	 over	 time.	 The	 emergence	 of	 new	 drift	variants	 (former	 seasonal	 A(H1N1),	 A(H3N2)),	 the	 co-circulation	 of	 distinct	 virus	lineages	(influenza	B)	and	the	 increase	 in	OS	drug	use	(A(H1N1)pdm09)	were	 found	to	potentially	play	a	role	in	this	latter.	Influenza	viruses	exhibiting	resistance	or	decreased	susceptibility	to	OS	and/or	ZA	were	further	 evaluated	 through	 whole-genome	 sequencing	 to	 identify	 and	 characterize	 the	
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amino	acid	substitutions	specific	of	 their	genome	(objective	2).	No	genetic	support	was	found	 for	 the	 fitter	 NA	 H275Y	 OS-resistant	 former	 seasonal	 A(H1N1)	 viruses,	 but	mutations	known	to	or	that	based	on	its	structural	location	or	functional	impact	may	play	a	role	 in	the	overall	viral	 fitness,	were	 identified	 in	the	genome	of	single	or	 few	viruses	resistant	or	with	decreased	susceptibility	to	the	drug.		Large	 datasets	 of	 full-length	NA	 gene	 sequences	 of	worldwide	 circulating	 viruses	were	created	to	estimate	the	global	and	site-specific	SP	acting	on	influenza	NA,	particularly	on	the	sites	associated	with	NAI	resistance	or	reduced	susceptibility	and/or	contacting	with	the	 drug	 (objective	 3a).	 Further	 temporal	 splitting	 of	 NA	 gene	 sequences	 allowed	 to	investigate	for	the	first	time	the	impact	of	NAI	introduction	into	clinic	(1999)	and/or	its	increased	 use	 during	 2009	 A(H1N1)	 pandemic	 on	 the	 SP	 acting	 on	 NA	 (objective	 3b).	Major	findings	include:	the	potential	role	of	positive	SP	(PSP)	in	the	low-level	and	locally	variable	 spread	 of	 NA	 H275Y	 OS-resistant	 A(H1N1)pdm09	 viruses	 that	 has	 been	observed	 in	 the	 community;	 a	 potential	 risk	 of	 spread	 of	 a	 synergistic	 drug-resistant	(H275Y/S247N)	 or	 a	 RI	 (S247G)	 variant	 in	 A(H1N1)pdm09	 subtype	 and	 a	 RI	 variant	(A395E)	 in	B/Victoria	 lineage	(positive	diversifying	selection);	and	the	potential	 lack	of	impact	of	both	NAI	 introduction	 into	clinic	and	 its	 increased	use	during	2009	A(H1N1)	pandemic	 on	 the	 global	 and	 site-specific	 SP	 acting	 on	 influenza	 NA,	 with	 the	 single	exception	 of	 site	 154	 of	 B/YAM-lineage	 NA	 (framework	 active	 site	 residue).	 Overall	mapping	 of	 site-specific	 SP	 across	 the	 different	 NA	 subtypes	 or	 lineages	 allowed	 for	further	identify	7	potential	new	regions	for	drug	targeting.		
	This	 project	 marked	 the	 beginning	 of	 influenza	 antiviral	 susceptibility	 testing	 and	monitoring	 activities	 in	Portugal.	 It	 not	 only	 established	 the	 technological	 capacity	 and	capability	 required	 to	 perform	 such	 activities	 but	 also	 generated	 comprehensive	information	 on	 the	 susceptibility	 of	 circulating	 human	 influenza	 viruses,	 essential	 to	contribute	to	both	global	and	European	influenza	surveillance	on	antiviral	susceptibility.	The	 project	 also	 contributed	 at	 finding	 potential	 determinants	 of	 viral	 fitness	 in	 the	genome	of	influenza	virus	resistant	or	with	decreased	susceptibility	to	NAIs,	based	on	its	location	onto	the	protein	structure;	and	at	elucidating	the	role	of	PSP	in	the	evolutionary	pathways	to	NAI	resistance	or	reduced	susceptibility.		
Keywords:	 Influenza;	 Antiviral	 susceptibility;	 Monitoring;	 Genome-wide	 sequencing	analysis;	Positive	selective	pressure.		 	
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RESUMO	
	Os	 antivirais	 assumem	 um	 papel	 de	 grande	 relevo	 na	 prevenção	 e	 controlo	 da	 gripe	 e	consequente	 redução	 da	 morbilidade	 e	 mortalidade	 associadas	 à	 infecção	 e	 suas	complicações.	O	seu	uso	constitui	o	único	tratamento	específico	contra	o	vírus	da	gripe	e,	devido	às	 limitações	das	vacinas	atuais,	 os	 antivirais	podem	constituir	uma	 importante	estratégia	 de	 primeira	 linha	 no	 combate	 à	 gripe.	 A	 emergência	 de	 estirpes	 resistentes,	particularmente	se	transmissíveis	de	pessoa-a-pessoa,	representa	um	grave	problema	de	saúde	pública,	uma	vez	que	pode	tornar	os	antivirais	ineficazes	contra	os	vírus	influenza	em	 circulação.	O	 limitado	 leque	de	 alternativas	 antivirais	 atualmente	 disponíveis	 torna	esta	situação	ainda	mais	preocupante.		Este	 projeto	 de	 doutoramento	 pretendeu	 responder	 a	 várias	 questões	 na	 área	 da	resistência	aos	antivirais,	centradas	no	perfil	de	susceptibilidade	dos	vírus	influenza	em	circulação	e	nos	mecanismos	moleculares	associados	à	emergência	e/ou	disseminação	de	vírus	resistentes	ou	com	susceptibilidade	reduzida.	Nomeadamente:	- Qual	 o	 perfil	 de	 susceptibilidade	 dos	 vírus	 influenza	 em	 circulação	 em	Portugal	 aos	 antivirais	 aprovados	 para	 uso	 clínico?	 Qual	 o	 cenário	 a	 nível	nacional?	- Poderão	 mutações	 nos	 diferentes	 segmentos	 do	 genoma	 estar	 a	 contribuir	para	 o	 fitness	 viral	 de	 estirpes	 resistentes	 ou	 com	 susceptibilidade	 reduzida	aos	inibidores	da	neuraminidase	(NAIs)?		- Que	 pressão	 seletiva	 (SP)	 estará	 a	 atuar	 nos	 locais	 da	 neuraminidase	 (NA)	associados	ao	desenvolvimento	de	resistência	ou	redução	da	susceptibilidade	aos	NAIs?	E	nos	locais	em	contacto	com	o	antiviral	(sítio	ativo	da	proteína)?	- Qual	 o	 impacto	 da	 introdução	 dos	 NAIs	 no	 mercado	 e	 do	 seu	 maior	 uso	durante	a	pandemia	de	2009	na	SP	a	atuar	no	gene	da	NA?		
	Para	responder	a	estas	questões,	foram	seguidas	três	linhas	de	investigação	direcionadas	para:	 a	 avaliação	 e	monitorização	da	 susceptibilidade	 aos	 antivirais;	 a	 sequenciação	do	genoma	de	estirpes	resistentes	ou	com	susceptibilidade	reduzida;	e,	a	avaliação	da	SP	a	atuar	no	gene	da	NA.	
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Avaliação	fenotípica	e/ou	genotípica	da	susceptibilidade	dos	vírus	influenza	em	circulação	
aos	antivirais	específicos	para	a	gripe	Este	 estudo	 envolveu	 primeiramente	 a	 implementação	 de	 uma	 plataforma	 tecnológica	para	avaliação	da	susceptibilidade	aos	antivirais	licenciados	em	Portugal	para	uso	clínico	-	 amantadina	 (inibidor	 da	 proteína	M2)	 e	 oseltamivir	 (OS)	 e	 zanamivir	 (ZA)	 (NAIs).	 A	plataforma	 inclui:	 uma	 componente	 de	 avaliação	 genotípica	 aos	 inibidores	 da	 proteína	M2,	 em	 que	 susceptibilidade	 é	 avaliada	 através	 da	 pesquisa	 dos	 7	 marcadores	moleculares	de	resistência	na	sequência	da	proteína	M2	do	vírus;	e	três	componentes	de	avaliação	aos	NAIs	–	fenotípica	(valor	de	IC50),	genotípica	(sequenciação	do	gene	da	NA	e	da	hemaglutinina	(HA)	do	vírus),	e,	sempre	que	possível,	clínica.	No	total	foram	avaliadas	mais	de	350	estirpes	de	vírus	influenza	A	e	cerca	de	530	e	490	estirpes	de	vírus	influenza	A	 e	 B,	 em	 circulação	 em	Portugal	 entre	 os	 Invernos	 de	 2004/2005	 a	 2012/2013,	 para	determinação	 da	 susceptibilidade	 aos	 inibidores	 da	 proteína	 M2	 e	 ao	 OS	 e	 ao	 ZA,	respectivamente.	 Foi	 detectada	 resistência	 aos	 inibidores	 da	 proteína	 M2	 no	 subtipo	A(H3N2)	desde	o	 Inverno	de	2005/2006,	 a	 uma	 frequência	 contínua	de	100%	excepto	em	2006/2007	(~75%)	(S31N;	S31N+V27A),	e	no	subtipo	A(H1N1)pdm09	desde	a	sua	emergência	 (S31N).	 Praticamente	 todas	 as	 estirpes	 analisadas	 demonstraram	 ser	susceptíveis	 ao	 OS	 e	 ao	 ZA,	 excepto	 no	 anterior	 subtipo	 A(H1N1)	 sazonal	 (doravante	designado	 A(H1N1)),	 em	 que	 aproximadamente	 21%	 das	 estirpes	 de	 2007/2008	demonstraram	 ser	 resistentes	 ao	 OS	 (NA	H275Y),	 aumentando	 para	 100%	 no	 Inverno	seguinte	(2008/2009).	No	subtipo	A(H1N1)pdm09,	foi	detectado	um	caso	de	resistência	ao	 OS	 sobre	 pressão	 seletiva	 de	 uso	 do	 antiviral	 em	 uma	 doente	 grávida	imunocomprometida	(NA	H275Y),	e	foi	identificada	uma	sub-população	(<30%)	de	vírus	NA	H275Y	resistentes	num	caso	de	aparente	relevância	clínica	(suspeita	de	resistência).	As	mutações	NA	I222V	e	D198N	(numeração	N2)	estão	na	base	de	algumas	das	reduções	observadas	na	 susceptibilidade	 fenotípica	 ao	OS	 e/ou	 ao	ZA,	 tendo	 sido	 a	primeira	 vez	que	 variantes	 NA	 I222V	 foram	 identificadas	 em	 doentes	 não	 tratados.	 A	 mutação	 NA	D251G	poderá	 estar	 associada	 a	 uma	 redução	de	4	 vezes	na	 susceptibilidade	 ao	 ZA	no	subtipo	A(H3N2)	(potencial	nova	mutação).	Reduções	≤2	e	≤4	vezes	na	susceptibilidade	fenotípica	aos	NAIs	aparentam	ser	uma	característica	intrínseca	dos	vírus	influenza	A	e	B,	respectivamente,	 não	 apresentando	qualquer	 base	 genética	 (genótipo).	 A	 linha	 base	 de	susceptibilidade	aos	NAIs	(susceptibilidade	natural)	variou	ao	longo	do	tempo,	mas	sem	nenhuma	tendência	em	particular	e	essencialmente	de	um	modo	diferente	para	o	OS	e	o	ZA.	A	emergência	de	novas	variantes	genéticas	 (A(H1N1),	A(H3N2)),	 a	 co-circulação	de	
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diferentes	linhagens	(influenza	B),	e	o	maior	uso	de	OS	(A(H1N1)pdm09),	poderão	estar	na	origem	de	algumas	das	variações	observadas.			
Identificação	de	potenciais	determinantes	de	fitness	viral	no	genoma	de	vírus	resistentes	ou	
com	susceptibilidade	reduzida	aos	NAIs		Os	restantes	 segmentos	do	genoma	 (PB2,	PB1,	PA,	NP,	M	e	NS)	de	38	estirpes	de	vírus	influenza	 resistentes	 ou	 com	 susceptibilidade	 reduzida	 ao	 OS	 e/ou	 ZA	 foram	adicionalmente	 sequenciados.	 Nenhum	 dos	 segmentos	 terá	 aparentemente	 contribuído	para	o	maior	fitness	viral	da	variante	NA	H275Y	A(H1N1)	resistente	ao	OS,	em	relação	aos	vírus	homólogos	wild-type	(NA	H275),	que	resultou	no	seu	completo	predomínio	a	nível	mundial.	No	entanto,	mutações	associadas	(PB2	V667I;	NS1	D74N)	ou	que,	com	base	no	impacto	 funcional	 que	 têm,	 podem	 estar	 associadas	 (PB2	 T108A,	 D195N,	M535L;	 NEP	T48A)	a	um	aumento	do	fitness	viral,	foram	detectadas	no	genoma	de	estirpes	resistentes	ou	com	susceptibilidade	reduzida.	De	salientar	que	a	análise	do	gene	da	HA	na	primeira	parte	deste	projeto	revelou	a	presença	da	mutação	N156K	associada	a	um	maior	 fitness	viral	em	uma	estirpe	A(H1N1)pdm09	com	susceptibilidade	reduzida	ao	OS	e	ao	ZA.		
Estudo	da	pressão	seletiva	a	atuar	no	gene	da	NA		Para	 este	 estudo	 foram	 construídos	 datasets	 de	 sequências	 do	 gene	 da	 NA	 de	 vírus	influenza	 a	 circular	 a	 nível	 mundial,	 utilizando	 todas	 as	 sequências	 potencialmente	completas	 disponíveis	 nas	 bases	 de	 dados	 públicas	 GISAID	 EpiFlu™	 e	 NCBI	 Influenza	Virus	 Resource	 até	 Abril/Novembro	 de	 2013.	 Foram	 ainda	 utilizadas	 sequências	 não	publicadas	de	vírus	isolados	em	Portugal.	As	sequências	foram	adicionalmente	divididas	em	diferentes	sub-datasets	 temporais	de	modo	a	 investigar	pela	primeira	vez	o	 impacto	da	 introdução	dos	NAIs	no	mercado	(1999)	e	do	seu	maior	uso	durante	a	pandemia	de	2009	na	SP	a	atuar	no	gene	da	NA	(alvo	dos	NAIs).	No	 geral,	 os	 locais	 da	NA	 associados	 ao	 desenvolvimento	 de	 resistência	 ou	 redução	 da	susceptibilidade	aos	NAIs	e/ou	em	contacto	com	o	antiviral	encontram-se	essencialmente	sob	SP	negativa	(NSP)	(A(H3N2),	linhagem	B/Victoria	(B/VIC))	ou	sob	NSP	ou	uma	razão	dN/dS<1	não	significativa	 (A(H1N1),	 linhagem	B/Yamagata	 (B/YAM),	A(H1N1)pdm09).	No	 entanto,	 em	 todos	os	 subtipos	ou	 linhagens	de	 vírus	 influenza	 excepto	na	 linhagem	B/YAM	foram	detectados	locais	sob	SP	positiva	(PSP),	incluindo	os	sites	275	e	247	da	NA	dos	vírus	A(H1N1)pmd09	e	o	site	395	da	NA	dos	vírus	da	linhagem	B/VIC.	A	evidência	de	PSP	 nestes	 locais	 suporta	 um	 potencial	 papel	 da	 PSP	 na	 disseminação	 limitada	 e	
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geograficamente	variável	de	vírus	NA	H275Y	A(H1N1)pdm09	resistentes	ao	OS	que	tem	vindo	 a	 ser	 observada	 na	 comunidade,	 entre	 doentes	 não	 tratados;	 e	 alerta	 para	 um	potencial	 risco	 de	 disseminação	 de	 uma	 variante	 A(H1N1)pdm09	 sinergicamente	resistente	 ao	 OS	 (H275Y/S247N)	 ou	 com	 susceptibilidade	 reduzida	 (S247G)	 e	 de	 uma	variante	B/VIC	com	susceptibilidade	reduzida	(A395E).	A	PSP	detectada	no	site	275	da	NA	dos	vírus	A(H1N1)	e	nos	sites	148	e	151	da	NA	dos	vírus	A(H3N2)	pode	ser	somente	um	 artefacto	 de,	 respectivamente,	 a	 disseminação	 global	 de	 uma	 estirpe	 NA	 H275Y	resistente	ao	OS	e	o	isolamento	e	propagação	em	cultura	celular.	Quer	a	introdução	dos	NAIs	 no	 mercado,	 quer	 o	 seu	 maior	 uso	 durante	 a	 pandemia	 de	 2009,	 não	 tiveram	aparentemente	 um	 impacto	 na	 SP	 a	 atuar	 no	 gene	 da	NA,	 excepto	 no	 site	 154	 do	 sítio	ativo	da	NA	dos	vírus	B/VIC,	que	revelou	estar	sob	uma	SP	significativamente	mais	forte	durante	o	período	de	maior	uso	 antiviral.	O	mapeamento	da	SP	a	 atuar	 sobre	 todos	os	locais	 da	 NA	 nos	 diferentes	 subtipos	 ou	 linhagens	 de	 vírus	 influenza	 permitiu	 a	identificação	de	7	novos	potenciais	alvos	para	fármacos	antivirais.		Este	projeto	de	doutoramento	permitiu	dispor	da	 capacidade	 tecnológica	para	 iniciar	 a	avaliação	 e	monitorização	da	 susceptibilidade	dos	 vírus	 influenza	 aos	 antivirais	 a	 nível	nacional,	 resultando	 numa	 das	maiores	 coleções	 de	 informação	 sobre	 susceptibilidade	dos	 vírus	 influenza	 em	 circulação	 à	 data	 (10	 anos).	 Esta	 informação	 foi	 essencial	 para	contribuir	para	a	vigilância	realizada	na	Europa	e	a	nível	global	e	para	novos	avanços	no	conhecimento	sobre	a	relação	fenótipo-genótipo	na	susceptibilidade	do	vírus	aos	NAIs,		a	qual	 constitui	 um	 dos	 maiores	 desafios	 na	 área.	 Os	 restantes	 resultados	 do	 projeto	contribuíram	para	esclarecer	a	presença	de	potenciais	determinantes	de	 fitness	viral	no	genoma	de	vírus	resistentes	ou	com	susceptibilidade	reduzida	e	para	elucidar	o	papel	da	PSP	 na	 emergência	 e/ou	 disseminação	 de	 vírus	 resistentes	 ou	 com	 susceptibilidade	reduzida.	Contribuíram	ainda	para	a	identificação	de	potenciais	novos	alvos	antivirais,	o	que	constitui	uma	das	prioridades	atuais	na	área	da	gripe	devido	ao	limitado	repertório	de	alternativas	antivirais	disponíveis.		
Palavras-chave:	 Vírus	 influenza;	 Susceptibilidade	 aos	 antivirais;	 Monitorização;	Sequenciação	completa	do	genoma;	Pressão	seletiva	positiva.			 	
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THESIS	OUTLINE	
		This	 PhD	 thesis	 is	 organized	 in	 6	 chapters,	 which	 are	 preceded	 by	 an	 abstract	 and	 a	summary	 written	 in	 Portuguese.	 Chapter	 1	 presents	 an	 introductory	 review	 of	 the	subject,	 covering	 general	 aspects	 of	 influenza	 virus	 and	 influenza	 NA	 protein	 and	addressing	the	most	up-to-date	literature	on	influenza	antivirals	and	antiviral	resistance.	A	description	of	 the	 surveillance	monitoring	 activities	 for	 antiviral	 resistance	 and	 their	importance	 close	 the	 review.	 Chapter	 2	 describes	 in	 more	 detail	 the	 problems	 under	investigation	 and	 the	 purpose	 and	 significance	 of	 this	 research	 project,	 presenting	 the	design	 of	 the	 study	 and	 the	 main	 approaches	 used.	 Project	 aims	 and	 objectives	 are	specified	at	the	end	of	the	chapter.	Chapter	3	provides	a	description	of	the	material	and	methods	 used	 to	 carry	 out	 the	 project	work,	while	 the	 resulting	 data	 is	 presented	 and	discussed	in	chapters	4,	5	and	6,	with	each	chapter	covering	a	different	objective	of	the	research.	 The	 scientific	 articles	 published	 or,	 when	 absent,	 the	 oral	 communications	presented,	and	a	 list	of	 the	main	activities	carried	out,	are	 indicated	at	 the	beginning	of	these	 latter	 chapters.	 Major	 findings	 are	 listed	 at	 the	 end,	 followed	 by	 supplementary	data.	The	final	and	overall	conclusions	of	the	research	are	presented	in	a	final	concluding	remarks	section,	in	which	are	also	highlighted	potential	and	important	directions	to	take	in	future	follow-ups	of	these	investigations.		 		
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“The	ideal	scientist	thinks	like	a	poet	and	only	later	works	like	a	bookkeeper.	Keep	in	mind	that	
innovators	in	both	literature	and	science	are	basically	dreamers	and	storytellers.	In	the	early	stages	
of	the	creation	of	both	literature	and	science,	everything	in	the	mind	is	a	story.	There	is	an	imagined	
ending,	and	usually	an	imagined	beginning,	and	a	selection	of	bits	and	pieces	that	might	fit	in	
between.	In	works	of	literature	and	science	alike,	any	part	can	be	changed,	causing	a	ripple	among	
the	other	parts,	some	of	which	are	discarded	and	new	ones	added.	The	surviving	fragments	are	
variously	joined	and	separated,	and	moved	about	as	the	story	forms.	(….)	To	bring	the	end	safely	
home	is	the	goal	of	the	creative	mind.	Whatever	that	might	be,	wherever	located,	however	expressed,	
it	begins	as	a	phantom	that	rises,	gains	detail,	then	at	the	last	moment	either	fades	to	be	replaced,	or,	
like	the	mythical	giant	Antaeus	touching	Mother	Earth,	gains	strength.	Inexpressible	thoughts	
throughout	flit	along	the	edges.	As	the	best	fragments	solidify,	they	are	put	in	place	and	moved	
about,	and	the	story	grows	until	it	reaches	an	inspired	end.”	Edward	O.	Wilson,	Letters	to	a	Young	Scientist,	2013					
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1.1 INFLUENZA	VIRUS:	GENERAL	CONCEPTS		The	 influenza	 virus	 is	 a	 complex,	 constantly	 changing	 virus	 1.	 Notorious	 by	 its	 unique	ability	 to	 continually	 evade	 the	 host’s	 immune	 system,	 it	 also	 knows	 no	 boundaries,	circulating	around	the	world	within	species	and	occasionally	jumping	between	them	2.	Its	evolutionary	pathways	are	completely	unpredictable.	From	him	we	can	only	“expect	the	
unexpected”	3.			
1.1.1 Classification	and	Nomenclature			Influenza	viruses	belong	to	the	family	Orthomyxoviridae	(from	the	Greek	orthos,	straight;	and	myxa,	mucus)	 that	 is	defined	by	viruses	with	a	negative-sense,	 single-stranded	and	segmented	 RNA	 genome	 4,5.	 Presently,	 the	 family	 includes	 seven	 different	 genera:	
Influenzavirus	 A;	 Influenzavirus	 B;	 Influenzavirus	 C;	 Influenzavirus	 D;	 Thogotovirus;	
Isavirus;	 and	Quaranfilvirus	 5,6.	 Influenza	 viruses	 are	 divided	 into	 4	 genera	 (commonly	called	 types).	 The	 division	 into	 types	 A,	 B	 and	 C	 is	 based	 on	 the	 antigenic	 differences	between	 their	 nucleocapsid	 protein	 (NP)	 and	matrix	 protein	 (M1)	 7.	 Type	 D	 was	 only	recently	recognized	as	a	new	virus	genus,	separated	from	type	C,	based	on	overall	genetic	and	antigenic	differences	evidenced	by	their	highly	divergent	genomes	(≈50%),	distinct	mechanisms	 of	 protein	 expression	 (M1),	 inability	 to	 reassort	 and	 yield	 viable	 progeny	and	 lack	 of	 antibody	 cross-reactivity	 8.	 Influenza	 A,	 B	 and	 C	 viruses	 are	 evolutionary	related,	sharing	a	common	ancestor	from	which	type	A	and	B	viruses	have	diverged	more	recently,	 compared	 to	 type	 C	 5.	 Influenza	D	 virus	 emerged	 very	 recently	 (2011),	 being	more	closely	related	to	type	C	virus	9.		Influenza	A	virus	infects	a	variety	of	hosts,	 including	humans,	birds,	swine,	horses,	dogs	and,	more	 rarely,	 others	animals	 such	as	 cats,	 a	 variety	of	 sea	mammals	and	 camels	 10.	Aquatic	 birds	 are	 known	 to	 be	 its	 natural	 reservoir	 and	 the	 source	 of	 virus	 in	 other	species	 11.	 Type	 B	 and	 C	 viruses	 have	 been	 primarily	 isolated	 from	 humans	 10,	 	 while	influenza	D	virus	primarily	affects	cattle	and	is	not	known	to	infect	humans	6.	Influenza	A	virus	 is	 the	most	 diversified	 and	 is	 further	 subdivided	 into	 subtypes,	 according	 to	 the	antigenicity	 of	 their	 hemagglutinin	 (HA)	 and	 neuraminidase	 (NA)	 surface	 proteins.	Currently,	there	are	18	recognized	HA	subtypes	and	11	NA	subtypes	12.	Combinations	of	all	these	subtypes	have	been	found	in	viruses	of	avian	species,	while	only	three	HA	(H1,	
	 Literature	review	|	4		H2,	 H3)	 and	 two	 NA	 (N1,	 N2)	 subtypes	 have	 been	 found	 as	 components	 of	 human	influenza	viruses	13.	No	antigenic	subtypes	have	been	identified	among	circulating	type	B,	C	and	D	viruses	4,6.	Only	type	A	and	B	viruses	are	clinically	relevant	for	humans,	causing	influenza	epidemics.		Type	C	virus	causes	only	mild	disease	or	sub-clinic	infection	14.	Both	influenza	C	and	D	viruses	were	not	studied	in	this	PhD	work	and	therefore	will	no	longer	be	addressed	in	this	review.		The	 current	 nomenclature	 system	 for	 influenza	 viruses	 (WHO	 Memorandum	 1980	 15)	includes	 the	 genus	 (type),	 the	 species	 from	 which	 the	 virus	 was	 isolated	 (omitted	 if	human),	location	of	the	isolate,	number	of	the	isolate	and	year	of	isolation.	In	the	case	of	influenza	A	 virus,	 it	 also	 includes	 the	 specific	 subtype	 of	HA	 and	NA	proteins	 between	brackets	(e.g.	A/swine/Lisbon/44/2001	(H3N2)).				
1.1.2 Virion	Structure			The	 infectious	 virus	 particle,	 also	 called	 virion,	 of	 influenza	 A	 and	 B	 viruses	 is	 very	similar.	 Although	 being	 pleomorphic,	 it	 usually	 assumes	 a	 roughly	 spheroidal	 form	(∼100nm	 in	 diameter),	 with	 filamentous	 forms	 (1μm	 or	 longer)	 being	 frequently	observed,	 particularly	 in	 fresh	 clinical	 isolates	 5,16.	 The	 most	 distinctive	 feature	 of	influenza	 A	 and	 B	 virions	 is	 a	 layer	 of	 spikes	 projecting	 radially	 from	 the	 surface,	 as	clearly	evidenced	in	electron	micrographs	(Figure	1.1).													
	
Figure	 1.1	 Virus	 particles	 of	 the	 influenza	A/Portugal/02/2009	 (H1N1pdm09)	 isolate	 visualized	 by	transmission	electron	microscopy	(TEM).	
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(Footnote	Figure	1.1)	This	TEM	image	was	taken	in	the	context	of	the	study	developed	by	our	research	team	on	the	newly	emergent	2009	pandemic	A(H1N1)	 virus	 (published	 in	 Santos	 et	 al.	 17).	 I	 and	 another	 colleague	 prepared	 the	 virus	 for	 observation,	 through	 negative	staining,	 using	 2%	 ammonium	 molybdate.	 A	 colleague	 from	 the	 laboratory	 of	 Biology	 and	 Ecotoxicology,	 Department	 of	Environmental	Health,	Instituto	Nacional	de	Saúde	Doutor	Ricardo	Jorge,	I.P.	(Lisbon,	Portugal),	collected	the	images	of	the	virus	particles	on	a	Morgagni	268D	electron	microscope	(FEI	Company,	Eindhoven,	The	Netherlands).			These	 spike-like	 structures	 correspond	 to	HA	 (rod-shaped	spikes)	and	NA	 (mushroom-shaped	 spikes)	 proteins	 that	 project	 about	 10	 to	 14nm	 from	 the	 virus	 surface,	constituting	the	major	surface	antigens	of	the	virus	18.	On	spherical-shaped	virions	there	are	about	500	HA	and	100	NA	spikes	(HA/NA	ratio	of	5:1),	while	those	with	a	filamentous	form	 contain	 hundreds	more.	 Both	HA	 and	NA	 spikes	 are	 distributed	 around	 the	 virus	membrane	but	NA	apparently	clusters	in	the	region	where	the	budding	virus	particles	are	released	from	cells	13.				Each	 influenza	 A	 or	 B	 virion	 comprises	 an	 envelope,	 a	 matrix	 layer	 and	 a	ribonucleoprotein	 (RNP)	 core	 16.	 The	 envelope	 is	 formed	 by	 a	 lipid	 bilayer	 originated	from	the	host	cell.	Inserted	into	this	lipid	membrane	are	not	only	the	HA	and	NA	antigens,	but	also	the	M2	ion	channel	protein,	in	the	case	of	influenza	A	virions,	or	the	NB	and	BM2	proteins,	in	the	case	of	influenza	B	virions	5.	The	matrix	layer	resides	underneath	the	viral	membrane	and	is	composed	by	a	single	protein	–	M1.	M1	is	the	most	abundant	protein	of	the	virion,	having	the	responsibility	to	provide	shape	and	stability	to	the	lipid	envelope	19.	It	 is	 further	suggested	that	M1	forms	the	critical	bridge	between	the	viral	envelope	and	the	 inner	 core	 components,	 by	 interacting	 with	 both	 the	 cytoplasmic	 tails	 of	 the	membrane	 proteins	 and	 the	 viral	 RNA	 (vRNA)	 and	 NP	 5.	 The	 virion	 core	 contains	 8	segments	of	vRNA	(viral	genome).	Each	segment	is	associated	with	multiple	copies	of	NP	and	 with	 the	 viral	 RNA-dependent	 RNA	 polymerase	 composed	 by	 PB1,	 PB2	 and	 PA	proteins,	forming	the	designated	RNP	complex	4.	By	being	wrapped	around	the	NP	copies,	the	vRNA	assumes	a	helical	hairpin	form	that	is	bound	at	one	end	by	the	heterotrimeric	RNA	 polymerase	 5.	 The	 nuclear	 export	 protein	 (NEP),	 initially	 designated	 as	 non-structural	 protein	 2	 (NS2),	 is	 also	 present	 in	 the	 virus	 core,	 in	 small	 amounts	 and	probably	in	association	with	the	M1	20.		Figure	1.2	shows	the	schematic	representation	of	an	influenza	A	virion.		
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Figure	1.2	Schematic	representation	of	an	influenza	A	virus	particle.		The	hemagglutinin	 (HA),	neuraminidase	 (NA),	 and	M2	 ion	channel	proteins	are	 inserted	 into	 the	host-derived	 lipid	envelope,	while	the	matrix	protein	(M1)	is	located	underneath,	forming	a	layer.	Each	of	the	8	viral	RNA	(vRNA)	segments	is	wrapped	up	around	 nucleoprotein	 (NP)	 and	 bound	 by	 the	 heterotrimeric	 RNA	 polymerase	 (PA,	 PB1	 and	 PB2	 subunits),	 forming	 a	ribonucleoprotein	 (RNP)	 complex.	 The	 position	 of	 the	 nuclear	 export	 protein	 (NEP;	 also	 known	 as	 non-structural	 protein	 2	(NS2))	in	the	inner	core	is	not	clear	but	it	probably	interacts	with	the	M1.	Adapted	from	Cox	et	al.	4.			
1.1.3 Genome	Organization	and	Encoded	Proteins		The	 8	 RNA	 segments	 that	 constitute	 the	 genome	 of	 influenza	 A	 and	 B	 viruses	 are	numbered	in	descending	order	from	the	longest	(segment	1)	to	the	shortest	(segment	8).	The	 segments	 also	 vary	 in	 length	 according	 to	 the	 influenza	 type,	with	 all	 presenting	 a	longer	 length	 in	 influenza	 type	B	viruses	 (Table	1.1).	These	have,	 therefore,	 the	 longest	genome	 (~14600	nucleotides	 (nts)),	which	 differs	 in	 approximately	 1000	nts	 from	 the	genome	 of	 influenza	 A	 viruses	 (~13600	 nts).	 Notwithstanding,	 the	 shorter	 genome	 of	influenza	 A	 viruses,	 particularly	 the	 first	 three	 segments,	 encodes	 a	 higher	 number	 of	proteins.	Up	to	date,	it	was	found	to	encode	15	different	proteins,	contrasting	with	the	11	proteins	codified	by	the	RNA	segments	of	influenza	B	virus	genome	21,22.	Table	1.1	shows	the	 viral	 proteins	 encoded	 in	 the	 different	 RNA	 segments	 of	 influenza	 A	 and	 B	 virus	genome	and	describes	its	main	functions.		The	three	largest	vRNA	segments	encode	the	three	subunits	of	the	viral	RNA-dependent	RNA	 polymerase:	 PB2	 (segment	 1),	 PB1	 (segment	 2),	 and	 PA	 (segment	 3)	 proteins.	Segment	 2	 (also	 called	 PB1	 segment)	 encodes	 two	 additional	 proteins	 in	 influenza	 A	viruses.	The	PB1-F2	protein,	which	 is	 translated	 in	the	+1	open	reading	 frame	(ORF)	of	
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	 Literature	review	|	7		PB1	23;	and	the	PB1-N40	protein	that	is	translated	from	the	fifth	initiation	codon	(located	at	position	+40)	in	the	same	ORF	as	PB1,	consisting	in	a	N-terminally	truncated	variant	of	this	 core	 protein	 24.	 Segment	 3	 (or	 PA	 segment)	 of	 influenza	 A	 viruses	 also	 encodes	additional	proteins.	Specifically,	the	PA-X	protein,	which	is	encoded	by	an	alternative	ORF	of	PA	accessed	via	 ribosomal	 frameshifting	 25;	 and	PA-155	and	PA-N182	proteins,	 both	translated	 in	 the	 same	ORF	 as	 PA	 from,	 respectively,	 the	 eleventh	 (position	 +155)	 and	thirteenth	(position	+182)	 initiation	codons,	 forming	N-terminally	 truncated	variants	of	PA	 22.	 These	 three	 additional	 proteins,	 as	 well	 as	 the	 PB1‑F2	 and	 PB1‑N40	 proteins	encoded	 in	PB1	segment,	have	been	detected	 in	 influenza	A	virus-infected	cells,	but	are	not	known	to	be	incorporated	into	progeny	virions	26.		Genome	 segments	 4,	 5	 and	 6	 encode	 the	 HA,	 NP	 and	 NA	 proteins,	 respectively.	 In	influenza	B	viruses,	segment	6	encodes	an	additional	protein	designated	NB.	This	protein	is	 translated	 from	a	–1	ORF,	starting	 just	4	nts	upstream	of	 the	NA	coding	 frame.	Up	to	date,	NB	has	shown	to	be	completely	conserved	27.		Segment	7	encodes	 the	M1	and	a	second	protein	 that	differs	according	 to	 the	 influenza	virus	type.	In	influenza	A	viruses	encodes	the	M2	protein	via	alternative	mRNA	splicing,	while	 in	 influenza	 B	 codes	 for	 the	 BM2	 protein	 through	 a	 “stop–start”	 mechanism,	 on	which	the	termination	codon	for	M1	overlaps	with	the	initiation	codon	for	BM2	21.	Segment	8	encodes	the	non-structural	protein	1	(NS1)	and,	via	a	spliced	mRNA,	the	NEP	(NS2)	 protein.	 NS1	 has	 not	 been	 detected	 in	 the	 virion,	 hence	 its	 designation	 as	 non-structural	protein.		Recently	 discovered	 influenza	 A	 virus	 PB2-S1	 (segment	 1),	 M42	 (segment	 7)	 and	 NS3	(segment	8)	proteins	were	not	considered	as	were	either	only	express	in	former	seasonal	A(H1N1)	viruses	(PB2-S1)	or	only	found	in	a	limited	number	of	influenza	A	viruses	(M42	and	NS3)	28-30.			HA	 and	 M2	 proteins	 will	 be	 described	 in	 more	 detail	 below	 given	 its	 importance	 for	influenza	 antiviral	 susceptibility.	 The	 former	 may	 be	 involved	 in	 the	 development	 of	resistance	 to	 neuraminidase	 inhibitor	 (NAI)	 drugs,	while	 the	 latter	 is	 the	 target	 of	 the	first	available	class	of	anti-influenza	drugs	–	M2	protein	inhibitors.	NA	protein	constitutes	the	target	of	NAI	drugs	and	was	widely	studied	in	this	PhD	work.	For	this	reason,	it	will	have	its	own	section	(see	section	1.2).	
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Table	1.1	Viral	RNA	segments	of	influenza	A	and	B	virus	genome	and	encoded	proteins.		
	
Designation Length,,,,,,,,,,,,,,,,,,(influenza,virus,type) Function1 PB2 2341,nts,(A);,2369,nts,(B) PB2 759,aa,(A);,770,aa,(B) !,RNA,polymerase,subunit
!,Binding,the,5´cap,on,host,preLmRNAs,
!,Required,for,vRNA,replication,2 PB1 2341,nts,(A);,2368,nts,(B) PB1 757,aa,(A);,752,aa,(B) !,RNA,polymerase,subunit
!,Catalysing,the,sequential,addition,of,nucleotides,during,RNA,chain,elongation,
!,Contains,the,conserved,motifs,characteristic,of,RNALdependent,RNA,polymerases,
!,Binding,the,terminal,ends,of,both,vRNA,and,cRNA,to,initiate,transcription,and,replication
!,Structural,backbone,of,RNA,polymerase,(interacts,with,both,PB2,and,PA),PB1LF2 87,aa,(A),a !,Virulence,factor,by,inducing,mitochondriaLassociated,apoptosis,(proLapoptotic,activity)
!,ProLinflammatory,properties
!,Interacts,with,PB1,and,influences,the,viral,polymerase,activityPB1LN40 718,aa,(A) !,Maintaining,the,balance,between,PB1,and,PB1LF2,expression3 PA 2233,nts,(A);,2245,nts,(B) PA 716,aa,(A);,726,aa,(B) !,RNA,polymerase,subunit
!,Endonuclease,involved,in,generating,the,capped,primers,for,viral,mRNA,synthesis,(capLsnatching)
!,Required,for,vRNA,replication,
!,Interacts,with,PB1
!,Proteolytic,activityPALX 252,aa,(A) !,Modulates,the,host,response,and,viral,virulencePALN155 562,aa,(A) !,UnknownPALN182 535,aa,(A) !,Unknown4 HA 1778,nts,(A);,1882,nts,(B) HA 566,aa,(A)b;,584,aa,(B) !,Major,antigenic,determinant
!,Binding,the,sialic,acid,moieties,on,hostLcell,receptors,,promoting,virus,entry,into,target,cells
!,Promoting,fusion,between,the,virus,and,endosome,membranes,to,deliver,the,virus,genome,into,the,cell
!,Putative,structural,role,in,virus,budding,and,particle,formation5 NP 1565,nts,(A);,1841,nts,(B) NP 498,aa,(A);,560,aa,(B) !,Major,component,of,the,viral,RNP,complex
!,Mediating,the,nuclear,import,of,viral,RNP,complexes
!,Involved,in,regulating,the,switch,of,RNA,synthesis,from,transcription,to,replication
!,Target,of,the,host’s,cytotoxic,TLcell,mediated,immune,response,(internal,antigen;,typeLspecific),
Genome,segment Common,designation Lenght,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,(influenza,virus,type) ENCODED,PROTEINS
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(Table	1.1	cont.)	
	aa:	amino	acids;	cRNA:	complementary	RNA;	HA:	Hemagglutinin;	IFN:	Interferon;	M1:	Matrix	protein;	mRNA:	messenger	RNA;	NA:	Neuraminidase;	NEP:	Nuclear	export	protein;	NP:	Nucleocapsid	protein;	NS1:	Non-structural	protein	1;	NS2:	Non-structural	protein	2;	nts:	nucleotides;	RNP:	Ribonucleoprotein;	vRNA:	viral	RNA	a	Can	be	truncated	at	either	the	N-	or	C-terminal	ends;	b	The	length	differ	across	the	different	subtypes	and	may	even	differ	among	virus	strains;	c	Initial	designation	Based	on	Krug	and	Fodor	21;	Gastaminza	et	al.	31;	Braam	et	al.	32;	Gonzalez	and	Ortin	33;	Cox	et	al.	4;	Conenello	et	al.	34;	Vasin	et	al.	35;	Huarte	et	al.	36;	Sanz-Ezquerro	et	al.	37;	Shaw	and	Palese	5;	Russell	et	al.	13;	Braciale	38;	Wu	et	al.	39;	Wrigley	19;	Nayak	et	al.	40;	Wright	et	al.	10;	Chen	et	al.	23.
Designation Length,,,,,,,,,,,,,,,,,,(influenza,virus,type) Function6 NA 1413,nts,(A);,1557,nts,(B) NA 454,aa,(A)b;,486,aa,(B) !,Surface,antigen
!,Removal,of,the,sialic,acid,moieties,on,hostIcell,receptors,and,newly,synthesized,HA,and,NA,proteins,,promoting,the,release,of,progeny,virions,from,infected,cells
!,Removal,of,the,sialic,acid,moieties,on,the,mucus,and,cell,surfaces,of,the,respiratory,tract,,promoting,virus,spread,
!,Putative,role,in,assisting,virus,entry,and/or,enhancing,late,endosome/lysosome,trafickingNB 100,aa,(B) !,Unknown7 M 1027,nts,(A);,1180,nts,(B) M1 252,aa,(A);,248,aa,(B) !,Providing,shape,and,stability,to,the,lipid,envelope,I,matrix,protein
!,Forming,a,bridge,between,membrane,proteins,and,the,inner,core,components,of,the,virion,apparently,essential,for,virus,assembly,at,the,plasma,membrane,
!,Involved,in,the,nuclear,export,of,viral,RNP,complexesM2 97,aa,(A) !,ProtonIselective,channel,
!,Conducting,protons,from,the,acidified,endosomes,into,the,interior,of,the,virus,to,dissociate,the,RNP,complexes,from,the,M1,protein,,allowing,its,release,as,free,structures,ready,for,nuclear,importBM2 109,aa,(B) !,ProtonIselective,channel;,functional,equivalent,of,type,A,M2,protein,in,influenza,B,viruses8 NS 890,nts,(A);,1096,nts,(B) NS1 230,aa,(A);,281,aa,(B) !,Suppressing,virusIinduced,host,type,I,IFNImediated,antiviral,response,I,IFN,antagonist,
!,Regulating,mRNA,splicing,and,the,nuclear,export,of,cellular,mRNAs,to,maximize,viral,mRNA,synthesis
!,Stimulating,viral,mRNA,translation
!,Inducing,apoptosis,in,virusIinfected,cellsNEP,(NS2c) 121,aa,(A);,122,aa,(B) !,Mediating,the,nuclear,export,of,viral,RNP,complexes
!,Involved,in,regulating,RNA,synthesis,
Genome,segment Common,designation Lenght,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,(influenza,virus,type) ENCODED,PROTEINS
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1.1.3.1	 Hemagglutinin		HA	 is	 the	 major	 surface	 protein	 of	 influenza	 A	 and	 B	 viruses.	 It	 is	 a	 rod-shaped	homotrimer	 of	 non-covalently	 linked	monomers,	with	 the	 C-terminus	 inserted	 into	 the	viral	membrane	and	the	hydrophilic	end	projecting	as	a	spike	away	from	the	viral	surface	-	type	I	 integral	membrane	protein	4,5.	As	formerly	indicated	in	Table	1.1,	HA	is	a	major	antigenic	 determinant,	 inducing	 the	 formation	 of	 neutralizing	 antibodies	 that	 play	 an	important	role	in	protecting	the	host	against	infection	41.	It	has	two	major	functions	in	the	virus	 life	 cycle,	 both	 in	 early	 stages:	 (1)	 binding	 the	 α-2,3	 or	 α-2,6-linked	 sialic	 acid	moieties	on	host-cell	receptors,	enabling	the	attachment	of	the	viral	particle	to	the	host	cell	 (virus	 attachment);	 and	 (2)	mediating	 the	 fusion	between	 the	 virus	 and	 endosome	membranes,	allowing	the	release	of	viral	RNP	complexes	 into	the	cytoplasm	of	 the	host	cell	 (virus	uncoating).	 It	 has	 also	been	 suggested	 that	HA	may	play	 a	 structural	 role	 in	virus	budding	and	particle	formation	5.		Each	monomer	of	HA	is	synthesized	as	a	single	polypeptide	chain	(HA0)	that	undergoes	post-translational	modifications,	 including	 the	 cleavage	 by	 host-cell	 proteases	 into	 two	subunits,	HA1	and	HA2,	 linked	by	a	 single	disulfide	bond.	HA0	cleavage	 is	 triggered	by	low	 pH	 in	 the	 endosome	 and	 is	 required	 for	 infectivity	 to	 expose	 the	 hydrophobic	 N-terminus	of	HA2,	which	is	responsible	for	the	membrane	fusion	activity	of	HA,	thereby	is	common	designation	as	“fusion	peptide”	4.	In	its	native	conformation,	HA	monomers	fold	into	 two	structurally	distinct	domains:	a	globular	head	and	a	 fibrous	stem	(Figure	1.3).	The	 globular	 head	 is	 entirely	 composed	 of	 HA1	 residues	 and	 is	 formed	 by	 vestigial	esterase	(E’)	and	receptor	binding	(R)	sub-domains.	The	stem	region,	more	proximal	to	the	viral	membrane,	contains	residues	from	both	HA1	and	HA2	and	is	formed	by	F´and	F	fusion	sub-domains	13.	The	cleavage	site	between	HA1	and	HA2,	which	is	usually	a	single	arginine	residue	(monobasic	cleavage	site),	is	located	in	the	middle	of	the	stem	4,42.	Both	E´and	 F’	 sub-domains	 of	 HA1	 form	 important	 contacts	 with	 the	 HA2	 subunit	 of	 the	protein	(F	sub-domain)	43.		The	 R	 HA1	 sub-domain	 holds	 the	 receptor	 binding	 site	 (RBS)	 and	 the	 highly	 variable	antigenic	 binding	 loops	 that	 surround	 it	 (HA	 antigenic	 determinants)	 42.	 The	 RBS	 is	 a	deep	 cavity	 of	 conserved	 amino	 acid	 residues.	 Its	 base	 is	 formed	 by	 four	 conserved	residues	linked	through	hydrogen	bounds:	Y98,	W153,	H183,	and	Y195	(H3	numbering);	
	 Literature	review	|	11		while	its	edges	are	formed	by	three	conserved	elements	of	secondary	structure:	the	130-loop	(right	edge;	133–138);	 the	220-loop	(left	edge;	residues	220–229);	and	the	190-α-helix	 (top;	 residues	 189–199)	 (H3	 numbering)	 13.	 A	 second	 sialic	 acid	 binding	 site,	 for	which	the	affinity	of	sialyllactose	is	four	times	weaker	than	that	for	the	primary	site,	was	identified	between	subunits	of	the	HA	trimer,	specifically	in	an	interface	where	two	HA1	subunits	 and	 a	 HA2	 subunit	 make	 close	 contact	 44.	 Its	 biological	 significance	 is	 still	unknown	4.																
			
Figure	1.3	Structural	features	of	influenza	virus	hemagglutinin.		(A)	Native	conformation	of	the	hemagglutinin	(HA)	homotrimer	(left)	and	of	a	HA	monomer	(right).	The	two	HA	subunits,	HA1	and	HA2,	 are	 coloured	differently	 in	 the	HA	monomer,	on	which	are	also	 indicated	 the	different	 structural	domains	and	sub-domains	of	HA.	Adapted	 from	Ge	et	al.	 45.	 (B)	 Schematic	 diagram	of	 an	unfolded	HA	monomer	 from	an	 influenza	A	H3	virus,	evidencing	the	different	structural	sub-domains	within	HA1	and	HA2	subunits:	R	-	receptor	binding	(HA1	residues	117-265);	E´	-	vestigial	esterase	(HA1	residues	52-116,	266-275);	F’	-	fusion	(HA1	residues	1-51,	276-238);	F	–	fusion	(HA2,	residues	1-221)	46.				
1.1.3.2	 M2	Protein		M2	 protein	 is	 a	 single-span	 membrane	 protein	 specific	 of	 influenza	 A	 viruses	 that	tetramerizes	(disulfide-linked	homotetramer	or	two	dimers	linked	by	disulfide	bonds)	in	the	viral	membrane	to	form	pH-activated	proton-selective	channels	47,48.	It	plays	its	major	
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	 Literature	review	|	12		role	 during	 virus	 entry	 by	 conducting	 protons	 from	 the	 acidified	 endosomes	 into	 the	interior	of	the	virus,	facilitating	the	low	pH	dissociation	of	the	viral	RNP	complexes	from	M1	and	its	subsequent	release	into	cytoplasm	as	free	structures	ready	for	nuclear	import	49.	In	highly	pathogenic	avian	influenza	viruses	(H5	and	H7),	M2	is	also	essential	during	viral	 assembly	 to	 increase	 the	 pH	 of	 the	 host-cell	 trans-Golgi	 network	 and	 prevent	premature	 low	 pH-induced	 conformational	 changes	 in	 HA	 that	 would	 inhibit	 virus	release	5.	Recently,	 it	was	suggested	that	M2	protein	might	also	play	a	role	in	recruiting	the	newly	synthetized	M1	to	the	cell	surface	during	virus	budding	48.			Each	 M2	 monomer	 consists	 of	 three	 structurally	 distinct	 domains:	 a	 short	 and	 highly	conserved	N-terminal	 ectodomain	 (residues	1-23);	 a	 transmembrane	domain	 (residues	24-46);	 and	 a	 C-terminal	 cytoplasmic	 tail	 with	 palmitate	 and	 phosphate	 modifications	(residues	47-97)	48,50.	Figure	1.4	shows	the	M2	protein	in	its	native	state	(homotetramer),	evidencing	the	three	structural	domains	of	each	monomer.											
	
Figure	1.4	Structure	of	the	M2	protein	homotetramer.		The	four	monomers	of	the	M2	protein	are	coloured	differently	and	coded	from	A	to	D.	At	the	right	side	are	indicated	the	different	structural	domains	comprising	each	monomer.	Adapted	from	Martinez-Gil	and	Mingarro	51.					
1.1.4 Evolutionary	Mechanisms		
	Influenza	 viruses	 are	 characterized	 for	 evolving	 rapidly	 and	 unpredictably.	 The	molecular	mechanisms	underlying	 its	 evolution	 include	mutation,	 reassortment	 and,	 in	
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	 Literature	review	|	13		rare	 instances,	 recombination.	 Insertions	 and	 deletions	 in	 HA	 and	 NA	 genes	 have	 also	showed	to	play	a	role	in	virus	evolution,	particularly	in	type	B	viruses	52.		
Random	mutations	(antigenic	drift)	Influenza	 virus	 RNA	 polymerase	 has	 no	 proofreading	 activity,	 resulting	 in	 a	 high	mutation	 rate	 during	 replication,	 of	 approximately	 one	 error	 per	 replicated	 genome	(error	 rate	 >7.3x10-5	 per	 nucleotide	 position	 per	 replication	 cycle,	 influenza	 A	 virus	polymerase)	 53,54.	 The	 gradual	 accumulation	 of	 mutations	 in	 the	 genome	 segments	encoding	HA	and	NA	 surface	proteins	may	 result	 in	minor	 amino	 acid	 changes	 in	 their	antigenic	sites	that	cause	the	virus	to	escape	recognition	by	neutralizing	antibodies	and	allow	it	to	cause	seasonal	epidemic	outbreaks.	This	phenomenon	is	called	antigenic	drift	10.	 Antigenic	 drift	 is	 responsible	 for	 the	 need	 to	 continually	 review	 and	 periodically	update	 (approximately	 every	 2	 to	 5	 years)	 influenza	 vaccine	 composition	 55.	 Different	patterns	 of	 antigenic	 drift	 have	 been	 identified	 among	 circulating	 human	 influenza	viruses.	 Influenza	A(H3N2)	 viruses	 have	 shown	 to	 evolve	more	 rapidly,	with	 new	drift	variants	 emerging	 more	 frequently	 and	 completely	 replacing	 the	 older	 ones	 (single	lineage);	while	 antigenically	distinct	 variants	 of	 influenza	A(H1N1)	 and	B	viruses	often	co-circulate	 (multiple	 lineages),	 reflecting	 a	 slower	 emergence	 of	 new	 drift	 variants	 56.	Recently	 emerging	 A(H1N1)pdm09	 viruses	 have	 not	 yet	 drifted	 significantly,	 probably	due	to	the	lack	of	selective	pressure	in	a	predominantly	naive	population	57.		
Reassortment	events	(antigenic	shift)	Reassortment	is	the	rearrangement	of	viral	genome	segments	 in	cells	 infected	with	two	(or	more)	different	 influenza	viruses.	 It	occurs	 in	all	different	types	of	 influenza	viruses	(A,	 B,	 and	 C),	 but	 has	 not	 been	 observed	 among	 them	 10.	 Reassortment	 events	 have	occurred	 frequently	 among	 co-circulating	 human	 influenza	 viruses.	 For	 example,	 it	occurred	between	different	 influenza	A	subtypes	-	H1N1	and	H3N2,	giving	origin	to	the	A(H1N2)	variant	that	circulated	between	2000	and	2002;	and	between	the	two	influenza	B	 lineages,	 resulting	 in	 the	 B/Yamagata	 (YAM)	 HA:	 B/Victoria	 (VIC)	 NA	 variant	 that	predominated	and	became	the	currently	circulating	B/VIC-lineage	virus	58.	In	influenza	A	viruses,	reassortment	events	may	result	in	major	antigenic	changes	in	which	an	HA	or	NA	antigenically	 distinct	 from	 the	 circulating	 variant	 is	 introduced	 into	 the	 human	population.	This	phenomenon	is	called	antigenic	shift	10.	Antigenic	shift	variants	have	the	potential	to	cause	an	influenza	pandemic	(i.e.	epidemic	of	unusually	large	proportions	59),	
	 Literature	review	|	14		as	 the	 human	 population	 has	 little	 or	 no	 immunity	 against	 it.	 The	 last	 three	 influenza	pandemics	 –	 1957	 H2N2	 (‘Asian	 flu’),	 1968	 H3N2	 (‘Hong	 Kong	 flu’),	 and	 2009	 H1N1,	were	caused	by	reassortant	virus	from	human,	avian	and,	in	the	latter	case,	swine	origins	10.	In	fact,	two	reassortment	events	were	in	the	origin	of	the	new	2009	H1N1	variant.	All	genome	segments	except	NA	and	M	derived	from	the	former	triple	human/avian/swine	reassortant	virus	 that	has	been	circulating	 in	 the	North	American	pig	populations	since	1998	60.	NA	and	M	segments	were	introduced	from	the	Eurasian	avian-like	swine	H1N1	lineage.	 Reassortment	 is	 not	 the	 only	 mechanism	 leading	 to	 antigenic	 shift.	 	 Other	mechanisms	include:	direct	transmission	of	an	avian	influenza	virus	to	humans,	followed	by	 continued	adaptations	 (suggested	 for	 the	1918	H1N1	pandemic	 (‘Spanish	 flu’))	 61,62;	and,	 re-emergence	 of	 a	 previously	 circulating	 virus	 (1977	 H1N1	 virus,	 	 ‘Russian	 flu’	epidemic)	 63.	 Antigenic	 shifts	 are	 characterized	 for	 occurring	 suddenly	 and	 at	 irregular	and	unpredictable	intervals	10.		
Recombination		Recombination	 occurs	 when	 foreign	 genetic	 material,	 from	 another	 influenza	 virus	infecting	the	same	cell	or	from	the	cell	itself,	is	incorporated	into	the	viral	genome.	This	process	 is	 though	 to	 occur	 through	 template	 switching	 during	 viral	 replication	 64.	Currently,	 there	 is	 ample	 evidence	 that	 non-homologous	 recombination	 (wherein	 the	recombining	material	belongs	to	a	different	genome	segment	or	 the	host	cell)	occurs	 in	influenza	A	viruses,	 although	rarely	 65-67.	The	occurrence	of	homologous	 recombination	(wherein	 the	 recombining	material	belongs	 to	 the	same	genome	segment)	continues	 to	be	proven	68.			
1.1.5 Currently	Circulating	Subtypes	and	Lineages			Influenza	viruses	currently	circulating	among	humans	belong	to	two	distinct	influenza	A	subtypes	-	H3N2	and	2009	H1N1	pandemic,	and	two	distinct	influenza	B	lineages	-	B/VIC	and	B/YAM.	A	former	influenza	A	H1N1	subtype	circulated	in	the	human	population	until	recently	 (2011)69	when	 it	 was	 replaced	 by	 the	 current	 2009	H1N1	 pandemic	 subtype.	Both	H1N1	subtypes	as	well	as	 the	H3N2	subtype	emerged	 in	 the	human	population	 in	the	form	of	a	pandemic	virus.	Influenza	A(H1N1)	viruses	emerged	in	the	1918	pandemic,	circulated	 until	 1957	when	were	 replaced	 by	 the	 new	A(H2N2)	 pandemic	 virus	 (1957	
	 Literature	review	|	15		pandemic)	 and	 then	 re-emerged	 in	 1977	 causing	 a	 worldwide	 epidemic	 (‘Russian	 flu’	epidemic)	70.	 	 Influenza	A(H3N2)	viruses	emerged	in	the	1968	pandemic	and	since	then	have	 been	 in	 continuous	 circulation	 71.	 Unexpectedly,	 they	were	 not	 supplanted	 by	 the	A(H1N1)	 viruses	 when	 these	 re-emerged	 in	 1977,	 which	 allowed,	 for	 the	 first	 time	 in	influenza	 history,	 two	 distinct	 influenza	 A	 subtypes	 to	 co-circulate	 in	 the	 human	population	72.	Influenza	2009	H1N1	pandemic	viruses	(A(H1N1)pdm09)	caused	the	most	recent	 pandemic.	 Influenza	 B	 viruses	 were	 first	 identified	 in	 1940	 as	 a	 circulating	homogenous	group	 73.	Only	 in	 the	early	1980s	 they	diverged	 into	 the	 two	antigenically	and	 genetically	 distinct	 lineages	B/VIC	 and	B/YAM,	which	were	 named	 after	 their	 first	representatives,	 B/Victoria/02/1987	 and	 B/Yamagata/16/1988	 74.	 These	 two	 lineages	have	 been	 co-circulating	 in	 the	 human	 population	 for	 more	 than	 25	 years,	 with	 the	exception	 of	 the	 1991-2000	 decade,	 during	 which	 B/VIC-lineage	 viruses	 were	geographically	restricted	to	eastern	Asia	for	reasons	still	unknown	75.		Figure	1.5	illustrates	the	periods	of	prevalence	of	all	influenza	A	subtypes	and	influenza	B	lineages	currently	or	until	recently	circulating	among	humans.						
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.5	Timeline	of	currently	or	recently	circulating	human	influenza	A	and	B	viruses.		The	different	 influenza	pandemics	that	originated	the	current	 influenza	A	viruses	are	 indicated	above	the	corresponding	time	line.			
1.2 INFLUENZA	VIRUS	NEURAMINIDASE	PROTEIN	
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	 Literature	review	|	16		NA	 is	 the	second	major	surface	protein	of	 influenza	A	and	B	viruses.	 It	 is	a	mushroom-shaped	homotetramer	of	non-covalently	linked	monomers,	with	the	N-terminus	oriented	toward	the	interior	of	the	virus	and	the	C-terminus	projecting	as	a	spike	away	from	the	viral	surface	-	type	II	integral	membrane	protein	76,77.	NA	constitutes	the	central	protein	for	the	purpose	of	this	thesis,	as	it	is	the	target	of	NAI	drugs.			
1.2.1 Function		NA	 plays	 its	 major	 role	 at	 the	 final	 stage	 of	 viral	 infection.	 It	 removes	 α-2,3	 or	 α-2,6-linked	 sialic	 acid	moieties	 from	 host-cell	 receptors	 and	 newly	 synthesized	 HA	 and	 NA	proteins,	 facilitating	 the	 release	 of	 progeny	 virions	 and	 promoting	 its	 spread	 towards	neighbouring	uninfected	cells	78.	As	NA’s	function	opposes	to	that	of	HA	(binding	to	host-cell	receptors),	the	two	surface	proteins	work	in	concert	during	virus	infection	to	ensure	an	 optimum	balance	 between	 their	 receptor-binding	 and	 receptor-destroying	 activities	79.	 This	 balance	 is	 essential	 for	 efficient	 virus	 replication.	 NA	 also	 exerts	 its	 sialidase	activity	 on	 the	mucus	 that	 covers	 the	 respiratory	 tract	 epithelium	 (rich	 in	 sialic	 acid),	cleansing	 the	 environment	 and	 facilitating	 the	 access	 of	 virus	 particles	 to	 host	 cells,	promoting	 virus	 infection	 49.	 It	 has	 also	 been	 suggested	 that	 NA	 may	 play	 a	 role	 in	assisting	 virus	 entry	 and/or	 enhancing	 late	 endosome/lysosome	 trafficking	 5.	 Besides	these	 key	 functions	 on	 virus	 infection,	 NA	 is	 also	 the	 secondary	 surface	 antigen	 of	influenza	 viruses,	 eliciting	 the	 production	 of	 specific	 antibodies	 (host´s	 antibody-mediated	 immune	 response).	 Although	 they	 do	 not	 neutralize	 virus	 infectivity	 as	 the	antibodies	 produced	 against	 HA	 (major	 surface	 antigen),	 anti-NA	 antibodies	 can	ameliorate	 disease	 severity	 41.	 Antibody	 epitopes	 in	 NA	 are	 not,	 however,	 so	 well	characterized	 as	 they	 are	 in	 HA,	 particularly	 in	 influenza	 B	 viruses.	 NA	 functions	 are	summarized	above	in	the	Table	1.1	(section	1.1.3).			
1.2.2 Structural	Domains	and	Enzyme	Active	Site			Each	 NA	 monomer	 is	 comprised	 by	 a	 single	 polypeptide	 chain	 of	 approximately	 470	amino	acids,	arranged	into	four	functional	domains:	a	short	N-terminal	cytoplasmic	tail,	followed	by	a	hydrophobic	transmembrane	region	and	a	thin	stalk,	ending	in	a	globular	
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head	domain	that	carries	both	the	catalytic	center	(enzyme	active	site)	and	antigenic	sites	80	(Figure	1.6).																	
		
Figure	 1.6	 Schematic	 representations	 of	 the	 neuraminidase	 homotetramer	 (A)	 and	 of	 an	 unfolded	neuraminidase	monomer	(B),	with	indication	of	the	different	structural	domains.		
Panel	 A:	 the	 four	 structural	 domains	 of	 each	 neuraminidase	 (NA)	 monomer	 are	 indicated	 on	 the	 right	 side.	 The	 catalytic	globular	head	domain	is	additionally	coloured,	with	each	colour	representing	a	different	monomer.	Adapted	from	da	Silva	et	al.	81.	Panel	 B:	 NA	monomer	 from	 an	 influenza	 A	N2	 virus.	 The	 different	 coloured	 rectangles	 represent	 the	 different	 structural	domains:	CT	–	cytoplasmic	tail	(residues	1-6);	TMD	–	transmembrane	domain	(residues	7-35);	S	–	stalk	(residues	36-74);	GH	–	globular	head	(residues	75-469)	82.			The	 N-terminal	 cytoplasmic	 domain	 is	 a	 sequence	 of	 6	 polar	 amino	 acids,	 highly	conserved	across	all	influenza	A	NA	subtypes	(MNPNQK)	but	not	in	influenza	B	NA	76.	It	has	 an	 important	 role	 in	 the	 incorporation	of	 the	NA	 into	progeny	 virions	 but	 it	 is	 not	essential	for	virus	replication	4.	The	transmembrane	domain	consists	of	29	hydrophobic	amino	 acids	 (30	 and	 31	 amino	 acids	 solo	 in	 N8	 and	 N5	 NA	 subtypes,	 respectively),	extremely	variable	among	subtypes	and	predicted	to	form	a	transmembrane	helix	 in	all	of	 them	 80,83.	 This	 transmembrane	 sequence	 has	 a	 combined	 signal	 peptide-anchor	function	of	directing	the	NA	across	the	endoplasmic	reticulum	and	retaining	it	in	the	viral	membrane	 80.	 The	 stalk	 is	 the	most	 variable	 domain,	 varying	 not	 only	 in	 sequence	 but	also	in	length,	both	among	and	within	subtypes	82.	Most	NAs	have	stalks	of	approximately	
	 Literature	review	|	18		50	amino	acids,	but	deletions	of	up	to	18	amino	acids	have	been	found	in	N1	and	N2	NA	80.	 Changes	 in	 the	 stalk	 length	 are	 suggested	 to	 regulate	 the	 distance	 of	 the	 enzymatic	globular	 head	 to	 host-cell	 receptors	 84.	 The	 structure	 of	 the	 NA	 stalk	 is,	 however,	 still	unknown.	The	enzymatically	and	also	antigenically	active	globular	head	domain	contains	the	 largest	 number	 of	 conserved	 amino	 acids	 85.	 Approximately	 390	 amino	 acids	comprise	this	C-terminal	domain.			The	enzyme	active	site	presents	as	a	deep	pocket	on	the	center	of	the	globular	head.	It	is	formed	 by	 8	 functional	 residues	 that	 interact	 directly	 with	 the	 sialic	 acid	 molecule	 –	R118,	 D151,	 R152,	 R224,	 E276,	 R292,	 R371,	 and	 Y406	 (N2	 numbering);	 and	 10	framework	 residues	 implicated	 in	 the	 stabilization	 of	 the	 active	 site	 structure	 –	 E119,	R156,	W178,	S179,	D198,	I222,	E227,	E277,	N294,	and	E425	(N2	numbering)	13.	These	19	residues	are	highly	conserved	in	all	influenza	A	and	B	viruses	and	mutagenesis	studies	in	these	specific	positions	have	mainly	resulted	in	the	loss	of	enzymatic	activity	86.	Due	to	its	highly	 conserved	 structure	 and	 its	 critical	 role	 in	 virus	 infection	and	 spread,	 the	 active	site	constitutes	the	target	of	NAIs.	Although	located	independently	in	the	globular	head	of	each	individual	NA	monomer,	the	active	site	is	only	enzymatically	active	when	NA	adopts	its	mature	form	of	homotetramer	77.			 	
1.2.3 Group-Specific	Structural	Features		The	 currently	 known	 influenza	 A	 NA	 subtypes	 (N1	 -	 N11)	 cluster	 into	 three	 distinct	genetic	groups,	known	as	group	1,	group	2	and	influenza	A-like	group	3.	Group	1	includes	N1,	 N4,	 N5	 and	 N8,	 while	 N2,	 N3,	 N6,	 N7	 and	 N9	 belong	 to	 group	 2.	 The	 recent	 bat-derived	 N10	 and	 N11,	 considered	 as	 NA-like	 molecules	 due	 to	 the	 lack	 of	 sialidase	activity,	form	the	influenza	A-like	group	3	87.	Influenza	B	NA	is	genetically	far	away	from	all	 known	 influenza	 A	 NA	 subtypes,	 clustering	 in	 a	 separate	 and	 homogenous	 genetic	group	88.	The	genetically	distinct	NA	groups	have	also	distinctive	structural	features.	One	of	the	most	notable	is	displayed	by	group	1	NAs,	on	which	the	150-loop	of	the	active	site,	located	 between	 residues	 147	 to	 152	 (N2	 numbering),	 adopts	 an	 exceptional	 open	conformation,	 leading	 to	 formation	 of	 an	 additional	 cavity	 adjacent	 to	 the	 active	 site	 -	150-cavity	88.	In	all	other	NAs	this	loop	is	otherwise	in	a	close	conformation	(150-cavity	deficiency).	The	2009	N1	pandemic	is	an	atypical	group	1	NA	as	it	lacks	the	characteristic	150-cavity	 89.	 The	 influenza	 A-like	 group	 3	 NAs	 are	 distinguished	 by	 the	 unique	
	 Literature	review	|	19		architecture	of	their	active	site	that	is	present	in	a	more	open	conformation	unfavourable	for	the	binding	of	the	sialic	acid	molecule,	which	may	explain	the	lack	of	sialidase	activity	87.	Only	minor	features	characterize	the	structure	of	influenza	B	NA.	Of	notice,	the	floor	of	its	 active	 site	 is	 more	 sterically	 crowded,	 which	 indicates	 that	 the	 residues	 might	 be	tightly	constrained	to	the	observed	positions	in	the	uncomplexed	enzyme	90.			
1.2.4 Evolution	and	the	Underlying	Role	of	Positive	Selective	Pressure		NA	 has	 been	 evolving	 rapidly	 in	 all	 human	 influenza	 virus	 subtypes	 or	 lineages,	 at	 a	fixation	rate	that	varied	from	1.79	to	3.12	x10-3	nucleotide	substitutions	per	site	per	year	(subs/site/year)	 in	 former	 seasonal	 A(H1N1)	 viruses	 (herein	 designated	 as	 seasonal	A(H1N1))	91,92,	from	2.28	to	3.27	x10-3	subs/site/year	in	A(H3N2)	viruses	92-95,	and	from	1.90	 to	 2.04	 x10-3	 and	 2.25	 to	 2.30	 x10-3	 subs/site/year	 in,	 respectively,	 B/VIC	 and	B/YAM-lineage	 viruses	 92,96.	 In	 2009	 A(H1N1)	 pandemic	 viruses,	 the	 fixation	 rate	 was	estimated	 to	be	of	2.83x10-3	 subs/site/year	 92.	Recently,	 it	was	 found	 that	NA	has	been	evolving	 gradually	 in	 A(H3N2)	 viruses	 and	 not	 episodically	 as	 HA	 (sporadic	 bursts	 of	evolution)	97.			As	 a	 surface	 antigen,	 NA	 is	 under	 constant	 selection	 of	 the	 host’s	 immune	 system	(antibody-mediated	 immune	 response).	 Positive	 selection	 of	 amino	 acid	 variants	 that	allow	the	virus	to	escape	host	 immunity	(antigenic	drift;	see	section	1.1.4)	 is	one	of	the	major	forces	driving	the	evolution	of	NA	in	influenza	A	and,	to	a	lesser	extent,	influenza	B	viruses	 98.	 Natural	 selection	 operating	 in	 influenza	 virus	 NA	 can	 also	 arise	 from	interactions	with	 other	 viral	 genes,	 stability	 of	 the	 protein	 structure	 and	 adaptation	 to	new	 species	 99.	 The	worldwide	 introduction	 of	NAI	 drugs	 into	 clinical	 practice	 in	 1999	created	an	additional	source	of	selection	–	drug	use,	changing	the	environment	on	which	NA	was	 evolving.	Only	 recently	was,	 however,	 given	 a	 higher	 attention	 to	 the	 selective	pressure	(SP)	forces	acting	on	NA,	particularly	on	the	N1	NA	of	2009	A(H1N1)	pandemic	viruses.	 Until	 2010,	 virtually	 all	 studies	 investigating	 SP	 on	 influenza	 viruses	 were	focused	 on	 HA	 due	 to	 its	 role	 of	 major	 surface	 antigen	 (primary	 target	 of	 immune	response).	The	 ratio	between	 the	 rates	of	non-synonymous	 (dN)	and	 synonymous	 (dS)	substitutions	 (dN/dS	 ratio)	 constitutes	 the	 standard	 measure	 of	 SP.	 A	 dN/dS	 ratio	significantly	 less	 than	 one	 indicates	 negative	 selection;	 dN/dS	 ≈	 1	 represents	 neutral	
	 Literature	review	|	20		evolution;	and	a	dN/dS	ratio	significantly	greater	than	one	provides	evidence	of	positive	selection	100.	Global	estimates	of	 the	dN/dS	ratio	on	NA	gene	have	been	 lower	than	one	for	all	human	influenza	virus	types	and	subtypes	or	lineages	(0.19	to	0.31)	91,92,94-96,98,101-104,	 indicating	overall	negative	selection.	Similar	results	have	also	been	obtained	at	site-by-site	specific	analysis.	Many	NA	sites	were	 found	under	negative	selection	and	only	a	few	of	 them	 (1	 to	16	 sites	 (or	9	under	 the	 agreement	of	 at	 least	 two	methods))	 91,92,94-96,98,101,102,104-106	 or	 even	 none	 (2009	 N1	 pandemic	 subtype	 107)	 were	 found	 to	 be	experiencing	 positive	 selection.	 Moreover,	 all	 or	 most	 positively	 selected	 sites	 were	functionally	 important,	 belonging	 to	 antibody	 recognition	 sites	 (344	 and	 365	 in	 N1	 92;	199,	328,	334,	338,	367,	370	and	401	in	N2	94,95,104;	396	in	NA	B	98;	and	249	in	N1pdm09	105),	or	being	involved	in	either	sialic	acid/NAI	drug	binding		(151	in	N1	and	N2;	373	and	374	 in	NA	B	92),	 calcium	binding	(379	 in	N1;	345	 in	NA	B	92),	or	host	adaptation	(46	 in	N1pdm09	 101).	 Positive	 selection	was	 also	detected	 at	 seasonal	 and	2009	pandemic	N1	NA	site	275	associated	with	drug	resistance	102,105.	Most	SP	studies	have,	however,	only	included	a	small	number	of	representative	NA	coding	sequences	(75	to	345	sequences)	and/or	 covered	 short	 periods	 of	 time	 (1	 to	 11	 years).	 Also,	 none	 of	 the	 studies	 gave	 a	complete	 picture	 of	 the	 SP	 acting	 on	 all	 different	 sites	 of	 influenza	 NA	 (overall	 site-specific	 selection	map),	essential	 to	known	 the	strength	of	SP	acting	at	other	sites	 than	those	positively	and/or	negatively	selected.		
	
Importance:	SP	 studies	 are	 essential	 for	 a	 better	 understanding	 of	 the	 evolutionary	 dynamics	 of	influenza	NA.	 	Moreover,	negatively	 selected	 sites	may	constitute	potential	new	 targets	for	antiviral	drugs,	as	many	of	 the	amino	acid	substitutions	occurring	at	 these	sites	are	likely	 to	 be	 intolerable;	 while	 positively	 selected	 sites	 may	 be	 useful	 to	 identify	 key	immune	epitopes	responsible	for	protective	immunity	in	influenza	virus	infections	104.			
1.3 CLINICAL	DISEASE	AND	EPIDEMIOLOGICAL	FEATURES			
1.3.1 Clinical	Disease	and	its	Impact			Influenza	virus	causes	a	respiratory	illness	 in	most	 infected	people	108.	The	spectrum	of	clinical	 infection	 is	 broad,	 varying	 from	 relatively	 mild	 or	 even	 asymptomatic	 virus	
	 Literature	review	|	21		shedding	 to	severe	 illness,	pneumonia,	and	death	 109.	Clinical	 symptoms	are	also	varied	and	 highly	 diverse	 (fever,	 cough,	 sore	 throat,	 malaise,	 muscle	 fatigue,	 headache,	 etc.),	lacking	specificity	as	are	not	easily	distinguished	from	those	caused	by	other	respiratory	pathogens,	such	as	respiratory	syncytial	virus	or	human	metapneumovirus	108.	The	term	influenza-like	illness	(ILI)	is	therefore	used	in	the	clinic	to	designate	the	disease	based	on	exclusively	 its	 non-specific	 symptoms.	 Current	 World	 Health	 Organization	 (WHO)	definition	of	 ILI	 includes	the	presence	of	 fever	≥	38	C°	and	cough	with	onset	within	the	last	 10	 days	 110.	 Upon	 laboratory	 confirmation,	 clinical	 diagnosis	 of	 influenza	 virus	infection	 becomes	 definitive.	 Influenza	 A	 and	 B	 viruses	 cause	 the	 same	 spectrum	 of	disease	but	the	frequency	of	severe	influenza	B	virus	infections	requiring	hospitalization	is	about	 fourfold	 less	 than	 for	 influenza	A	virus	 10.	Persons	at	higher	risk	of	developing	severe	 disease	 include:	 infants	 and	 young	 children;	 the	 elderly;	 persons	 with	comorbidities,	 particularly	 asthma	 and	 other	 chronic	 cardiopulmonary	 diseases;	pregnant	women;	morbidly	obese	patients;	and,	immunosuppressed	patients	108.		Influenza	 virus	 infections	 cause	 significant	morbidity	 and	mortality	worldwide.	 Recent	WHO	 global	 estimates	 indicated	 the	 occurrence	 of	 approximately	 1	 billion	 cases	 of	influenza	virus	 infection	per	year,	with	around	3	–	5	million	cases	of	severe	illness,	and	300	 000	 –	 500	 000	 deaths	 111.	 Annual	 influenza	 epidemics	 have	 also	 a	 substantial	economic	 impact	associated	 to	 the	 lost	or	 reduced	productivity	 in	 the	work	place	or	at	home	due	to	incapacitating	illness	and	the	increased	health-care	costs	from	treating	the	disease	112.	Robust	estimates	of	the	annual	economic	burden	of	influenza	epidemics	in	the	United	States	amounted	to	$87.1	billion	113.	Both	public	health	and	economic	impacts	are	even	greater	in	the	case	of	influenza	pandemics.	The	1918	H1N1	pandemic	was	the	most	devastating	 pandemic	 in	 recent	 history,	 having	 affected	 one	 third	 of	 the	 world's	population	(~500	million	persons)	and	caused	approximately	50	million	deaths	114.			
1.3.2 Transmission	and	Seasonality			Human	 influenza	 virus	 is	 primarily	 transmitted	 from	 person	 to	 person	 via	 virus-laden	respiratory	secretions	generated	when	infected	persons	cough,	sneeze	and	possibly	talk.	Transmission	may	also	occur	through	hand	contamination	from	fomites	followed	by	self-inoculation	 into	 the	 nose,	 mouth	 or	 perhaps	 eyes	 108.	 Its	 easy	 way	 of	 transmit	 makes	
	 Literature	review	|	22		influenza	a	highly	contagious	disease,	even	more	 in	a	crowded	and	connected	world	as	that	as	we	live	today.		Human	influenza	infections	exhibit	a	clear	seasonal	cycle	in	temperate	regions	115.	They	occur	at	a	 low	 level	 throughout	 the	year	and	only	 increase	markedly	during	 the	winter	months	–	winter	seasonality	116.	As	the	northern	and	southern	hemispheres	have	winter	at	opposite	times	of	the	year,	there	are	actually	two	different	influenza	seasons	each	year.	Northern	 Hemisphere	 influenza	 season	 is	 generally	 from	 October	 to	 May,	 with	 peak	activity	in	January	or	February,	while	in	the	Southern	Hemisphere	is	usually	from	May	to	October,	with	peak	 activity	 in	 July	 or	August	 117.	 It	 is	 still	 not	 clear	why	 annual	 human	influenza	 epidemics	 follow	 this	 seasonal	 pattern	 in	 temperate	 climates.	 In	 tropical	 and	subtropical	 regions,	 human	 influenza	epidemics	often	occur	during	 the	 rainy	 season	or	transmit	year-round	without	a	well-defined	season	115.			
1.4 INFLUENZA	ANTIVIRALS	
	
1.4.1 Key	Role	in	Influenza	Management	and	Control		Annual	 vaccination	 is	 the	 mainstay	 of	 influenza	 prevention	 but	 it	 offers	 only	 limited	protection	 for	 some	patient	 groups,	 such	 as	 the	 frail	 elderly	 and	 immunocompromised	individuals,	 and	 circumstances	 (e.g.	 poor	 match	 between	 the	 vaccine	 and	 circulating	viruses).	Also,	there	are	some	individuals	that	due	to	specific	contraindications	cannot	be	immunised	(e.g.	egg	allergy)	118,119.	In	these	particular	situations,	antiviral	therapy	can	be	a	useful	complement	or	alternative	to	vaccination	for	preventing	influenza	(pre-exposure	prophylaxis).	Following	virus	infection,	vaccination	is	no	longer	a	viable	intervention	and	antiviral	drug	use	becomes	the	leading	strategy	to	combat	influenza,	either	by	treatment	or	post-exposure	prophylaxis	118.	Antivirals	 can	 be	 especially	 helpful	 in	 controlling	 influenza	 outbreaks	 in	 confined	populations	at	 increased	risk	of	severe	 illness,	such	as	 the	elderly	 in	nursing	homes	120.	By	treating	those	who	are	already	infected,	antivirals	reduce	the	probability	of	secondary	transmissions	and	help	preventing	the	spread	of	infection	121.	They	also	play	a	key	role	in	the	 frontline	 defence	 against	 an	 influenza	 pandemic	 outbreak,	 particularly	 during	 the	early	 months	 when	 a	 specific	 vaccine	 is	 unavailable,	 as	 recently	 evidenced	 during	 the	
	 Literature	review	|	23		2009	H1N1	pandemic	122.	Hence,	many	countries	continue	to	stockpile	antiviral	drugs	as	part	 of	 their	 preparedness	 plans	 for	 a	 next	 influenza	 pandemic	 123.	 People	with	 severe	influenza	 infections	or	at	higher	risk	of	complications	from	influenza	(high-risk	groups)	constitute	the	main	target	population	for	antiviral	therapy	124.			
1.4.2 Approved	Antivirals		Presently	there	are	two	classes	of	influenza	antiviral	drugs	approved	almost	universally	for	 human	 use:	 the	 M2	 protein	 inhibitors	 (also	 designated	 as	 adamantanes;	 herein	designated	as	M2	inhibitors)	and	the	NAIs	125.	The	M2	inhibitor	drug	class	was	the	first	to	be	 approved,	 dating	 from	 the	 1960s.	 It	 includes	 amantadine	 (Symmetrel®,	 Endo	Pharmaceuticals	 Inc.;	 and	 other	 generic	 equivalents),	 and	 its	 analog,	 rimantadine	(Flumadine®,	 Forest	 Pharmaceuticals	 Inc.;	 and	 other	 generic	 equivalents),	 both	 orally	available	 126.	 The	 NAI	 drug	 class	 was	 introduced	 in	 1999	 and	 now	 includes	 four	compounds:	 zanamivir	 (Relenza®,	 GlaxoSmithKline	 Inc.);	 oseltamivir	 phosphate	(Tamiflu®,	 F.	 Hoffmann-La	 Roche	 AG;	 herein	 designated	 as	 oseltamivir);	 peramivir	(Rapivab®,	BioCryst	Pharmaceuticals	 Inc.);	 and	 laninamivir	octanoate	 (Inavir®,	Daiichi	Sankyo;	herein	designated	as	laninamivir)	125.	Oseltamivir	(OS)	and	zanamivir	(ZA)	were	the	first	NAIs	to	be	available,	 in	oral	and	inhaled	formulations,	respectively,	both	dating	from	1999.	Moreover,	they	are	the	only	NAIs	approved	worldwide	49.	Peramivir	(PER)	is	only	approved	in	limited	markets	that	include	Japan	(2010;	as	Rapiacta®),	the	Republic	of	Korea	(2010;	as	Peramiflu®)	and,	very	recently,	China	(2013)	and	the	United	States	of	America	 (USA)	(2014).	 It	 constitutes	 the	only	 intravenous	option	 for	 treating	 influenza.	Laninamivir	(LAN)	is	approved	for	human	use	exclusively	in	Japan	(2010)	10,127,128,	being	available	as	an	inhaled	NAI	with	long-acting	properties.		A	 third	 class	 of	 influenza	 antiviral	 drugs	 -	 HA	 fusion	 inhibitors,	 is	 approved	 in	 Russia	since	1993	and	China	since	2006.	It	includes	a	single	compound	–	arbidol	hydrochloride	(commonly	designated	as	arbidol),	orally	administrated	 129.	Due	 to	 its	 limited	approval,	this	antiviral	drug	class	will	not	be	further	discussed	in	this	review.		In	Portugal,	amantadine	is	approved	as	anti-influenza	agent	since	1973	(as	Parkadina®),	while	OS	and	ZA	were	introduced	in,	respectively,	2002	and	1999	130.		
	 Literature	review	|	24		OS	 is	 the	 most	 widely	 used	 influenza	 antiviral	 drug	 and	 is	 now	 on	 the	 WHO	 List	 of	Essential	Medicines,	a	list	that	includes	the	most	important	medications	needed	in	a	basic	health	 system	 131.	 It	 is	 also	 the	 main	 antiviral	 drug	 that	 has	 been	 incorporated	 into	national,	international,	and	private	stockpiles	for	pandemic	preparedness	123.			Intravenous	formulations	of	OS	and	ZA	are	now	in	clinical	development	49.	These	will	be	especially	important	for	severely	ill	patients	who	cannot	take	oral	or	inhaled	medication,	such	as	those	mechanically	ventilated	123.	In	fact,	intravenous	ZA	is	already	available	via	clinical	 trial	 or	 compassionate	 use	 request	 132	 and	 has	 been	 used	 in	 critically	 ill	immunosuppressed	adults	and	children	133.	Other	investigational	anti-influenza	agents	in	late-phase	clinical	trials	target	other	viral	proteins	or	host	factors	and	include	favipiravir	(virus	 RNA	 polymerase),	 and	 nitazoxanide	 and	 fludase	 (host)	 125.	 Recently,	 favipiravir	(Avigan®,	 Toyama	 Chemical	 Co.)	 was	 approved	 in	 Japan	 for	 influenza	 pandemic	preparedness	134.			
1.4.2.1	 M2	Protein	Inhibitors		Amantadine	 (AMA)	 and	 rimantadine	 (RIM)	 were	 not	 specifically	 designed	 as	 anti-influenza	drugs.	They	were	developed	serendipitously	and	only	later	was	discovered	its	activity	against	influenza.	In	fact,	only	after	almost	25	years	of	their	development	it	was	found	that	they	target	the	M2	protein	of	influenza	A	viruses	135.	Importantly,	they	are	not	effective	against	the	analogous	BM2	channel	of	influenza	B	viruses,	which	makes	them	a	specific	 anti-influenza	 A	 agent	 49.	 Besides	 influenza,	 AMA	 is	 also	 active	 against	 human	Parkinson’s	disease	and	since	early	(1973)	is	also	approved	for	its	treatment	136.		AMA	 and	 RIM	 are	 synthetic	 tricyclic	 amines.	 Chemically,	 AMA	 is	 1-amino	 adamantane	hydrochloride	and	RIM	is	its	α-methyl	derivative	(α-methyl-1-adamantane	methylamine	hydrochloride)	 137.	 As	 structural	 analogues,	 they	 share	 mechanisms	 of	 action	 and	pharmacological	profiles.			
1.4.2.1.1			Mechanism	of	action		AMA	 and	 RIM	 block	 the	 acid-activated	 proton	 channel	 formed	 by	 the	 M2	 protein	 of	influenza	A	virus	(detailed	in	section	1.1.3.2).	By	blocking	this	channel,	they	stop	the	flow	
	 Literature	review	|	25		of	H+	ions	from	the	acidified	endosome	into	the	interior	of	the	virion	and	thereby	inhibit	the	 dissociation	 of	 the	 viral	 RNP	 complexes	 from	 the	 M1	 protein	 and	 its	 subsequent	release	 into	 the	 cytoplasm	 -	 inhibition	 of	 viral	 uncoating	 10	 (Figure	 1.7).	 In	 highly	pathogenic	avian	influenza	viruses	(H5	and	H7),	they	further	prevent	the	pH	increase	in	the	host-cell	trans-Golgi	network,	necessary	for	HA	maintain	its	conformation	during	the	transport	to	the	virus	membrane	49.					 	
				
	
Figure	1.7	 Schematic	 representation	of	 the	process	of	 (A)	 influenza	A	virus	uncoating	 and	 (B)	drug	action	of	amantadine	and	rimantadine.	
Panel	A:	The	acidic	environment	of	the	endosome,	as	a	result	of	the	flow	of	H+	protons	from	the	cytosol	into	the	endosome	by	a	H+-ATPase,	triggers	conformational	changes	in	hemagglutinin	(HA)	that	expose	the	fusion	peptide,	promoting	the	fusion	of	viral	and	 endosome	membranes.	 This	 fusion	 event	 is	 not	 sufficient	 to	 cause	 viral	 uncoating.	 In	 addition,	H+	protons	 from	 the	 late	endosome	must	enter	the	virion	through	the	M2	proton	channel,	which	opens	in	response	to	acidification	(pH-induced	channel).	The	 entry	 of	 H+	 protons	 into	 the	 virion	 causes	 dissociation	 of	 the	 matrix	 protein	 (M1)	 from	 the	 influenza	 A	 virus	ribonucleoprotein	(RNP)	complexes,	releasing	them	into	the	cytoplasm.	The	dissociation	of	M1	is	required	for	RNP	complexes	to	be	transported	to	the	cell	nucleus	where	they	are	transcribed	and	replicated.	Panel	B:	Amantadine	and	rimantadine	block	the	M2	proton	channel	function	and	thereby	inhibit	acidification	of	the	interior	of	the	virion,	M1	dissociation	and	virus	uncoating.	Adapted	from	Coen	and	Richman	138.			The	mechanism	by	which	AMA	and	RIM	block	the	M2	proton	channel	was	only	recently	elucidated	 by	 the	 study	 of	 Pielak	 et	 al.	 139.	 After	 years	 of	 controversy,	 Pielak	 and	colleagues	reported	a	nuclear	magnetic	resonance	(NMR)	structure	of	RIM	bound	inside	the	 pore	 of	 a	 drug-sensitive	 chimeric	 A/M2	 –	 BM2	 protein.	 This	 novel	 NMR	 structure	supported	the	results	of	previous	mutational	140	and	X-ray	crystallographic	structural	141	
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	 Literature	review	|	26		studies,	 confirming	 that	 the	 drug	 binds	 inside	 the	 pore	 and	 physically	 occludes	 the	channel.	 Specifically,	 it	 binds	 to	 a	 hydrophobic	 pocket	 near	 the	 N-terminal	 end	 of	 the	channel,	 formed	by	 the	methyl	groups	of	residues	V27	and	A30	 from	the	 four	subunits,	with	 the	 amino	 group	 of	 the	 drug	 appearing	 to	 be	 in	 polar	 contact	with	 the	 backbone	oxygen	of	A30	residues	139.	The	binding	occurs	when	the	channel	is	in	its	closed	state	48.				
1.4.2.1.2			Efficacy	and	use		M2	inhibitors	can	prevent	approximately	one-half	of	influenza	A	virus	infections	and	70	to	 90%	 of	 illnesses	 when	 used	 as	 prophylaxis	 142.	 Its	 treatment	 showed	 also	 to	 be	beneficial,	 shortening	 the	 duration	 of	 fever	 by	 1-day	 on	 average	 when	 administered	within	 48h	 of	 symptoms	 onset	 143.	 Also,	 it	 revealed	 to	 be	 associated	 with	 more	 rapid	symptom	 resolution,	 functional	 recovery,	 and,	 in	 some	 studies,	 resolution	 of	 small	airways	functional	abnormalities	144.		M2	inhibitors	have	now	been	available	for	about	50	years.	Its	use	has	been	very	little	in	most	countries	around	the	world	145,	but	in	some	of	them,	such	as	China	and	Russia,	they	have	been	available	 as	 over-the-counter	drugs	 and	have	been	even	 included	 in	 various	cold	 medicines	 that	 do	 not	 need	 a	 prescription	 146.	 Concerns	 about	 the	 possible	development	of	adverse	effects,	particularly	in	the	elderly,	have	limited	the	use	of	these	drugs	147.	Both	AMA	and	RIM	use	is	associated	with	several	central	nervous	system	(CNS)	side	effects,	with	other	major	 side	effects	 including	gastrointestinal	disorders	 and	anti-muscarinic	effects	142,148.	The	lack	of	demonstrated	prevention	of	complications	has	also	limited	their	use,	although	in	a	lesser	extent	147,	with	the	rapid	selection	of	drug-resistant	variants	that	could	spread	efficiently	in	the	presence	or	absence	of	drug	constituting	the	major	threat	to	their	use.	In	fact,	since	2010	M2	inhibitors	are	no	longer	recommended	by	WHO	 for	 prophylaxis	 and	 treatment	 of	 influenza	 virus	 infections	 due	 to	 the	 overall	resistance	observed	124	(see	section	1.5.1.3	for	detail).			
1.4.2.2	 Neuraminidase	Inhibitors		NAIs	were	design	to	mimic	the	natural	substrate	of	influenza	A	and	B	virus	NA	enzyme	-	sialic	 acid	 (N-acetylneuraminic	 acid,	 Neu5Ac),	 and	 to	 compete	 for	 the	 binding	 at	 the	
	 Literature	review	|	27		active	 site.	 Based	 on	 the	 structure	 of	 a	 transition-state	 analogue	 of	 sialic	 acid,	 DANA	(chemically	 2-deoxy-2,3-dehydro-N-acetylneuraminic	 acid),	 the	 NAIs	 possess	 higher	binding	affinity	than	the	Neu5Ac,	preventing	the	cleavage	of	the	natural	substrate	149.		ZA	is	a	4-deoxy-4-guanidino	analog	of	DANA,	resulting	from	the	single	substitution	of	the	hydroxyl	at	the	4'	position	on	the	sugar	ring	with	a	guanidino	group	150.	OS	is	otherwise	more	 distinct,	 possessing	 a	 cyclohexene	 ring	 instead	 of	 the	 sugar	 ring	 and	 two	 further	substitutions:	 an	 amino	 group	 replacing	 the	 hydroxyl	 at	 the	 4’	 position	 and	 a	 large	hydrophobic	pentyl	ether	group	replacing	the	glycerol	side	chain	at	the	6'	position.	OS	is	administered	in	the	form	of	a	prodrug	(oseltamivir	phosphate,	OSP)	that	is	converted	by	hepatic	 esterases	 into	 its	 active	 form,	 oseltamivir	 carboxylate	 (OSC)	 150.	 The	 high	bioavailability	of	OSP	allowed	it	to	be	the	first	NAI	orally	administrated	151.	PER	and	LAN	were	 both	 design	 most	 recently.	 PER	 is	 still	 directly	 based	 on	 DANA,	 having	 a	cyclopentane	ring	instead	of	the	sugar	ring	and	both	the	4-guanidino	group	of	ZA	and	the	6-hydrophobic	pentyl	ether	group	of	OS	150.	LAN	is	based	on	ZA,	resulting	from	the	single	substitution	 of	 a	 hydroxyl	 group	 on	 the	 glycerol	 side	 chain	 with	 an	 acyl	 group	 152.	Similarly	to	OS,	LAN	is	administrated	as	a	prodrug	(laninamivir	octanoate,	LANO)	that	is	converted	 in	 the	 lungs	 into	 LAN	 148.	 	 A	 single	 administration	 of	 LANO	 results	 in	 a	 long	retention	of	the	drug	in	the	lungs,	conferring	a	long-lasting	anti-NA	activity	(long-acting	NAI	drug)	150.	The	chemical	structure	of	all	NAIs	is	shown	below	in	Figure	1.8.			
1.4.2.2.1			Mechanism	of	action		NAIs	act	by	binding	 to	 the	active	 site	of	 the	virus	NA	protein	and	blocking	 its	 sialidase	activity	 (detailed	 in	 section	1.2.1).	 As	 a	 result,	 progeny	 virions	 fail	 to	 be	 released	 from	sialic	 acid	 receptors	 and	 aggregate	 on	 the	 surface	 of	 the	 infected	 cell,	 hampering	 the	spread	 of	 infection	 to	 neighbouring	 uninfected	 cells	 -	 inhibition	 of	 viral	 release	 and	spread	153	(Figure	1.8).	The	influenza	virions	entering	the	respiratory	tract	fail	also	to	be	released	from	sialic	acid	receptors	and	remain	trapped	in	the	mucus,	making	it	difficult	to	access	the	target	cells	and	initiate	virus	infection	154.				
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Figure	1.8	Electron	micrographs	of	Madin-Darby	canine	kidney	cells	 infected	with	 influenza	A	virus.	(A)	 Normal	 assembly	 and	 budding	 of	 virus	 in	 the	 absence	 of	 neuraminidase	 inhibitor	 (NAI);	 (B)	 Lateral	 aggregation	 and	formation	of	large	bundles	by	virus	(indicated	by	arrows)	in	the	presence	of	NAI.	Source:	Gubareva	et	al.	155.			Due	to	differences	in	their	chemical	structure,	the	4	NAI	drugs	bind	slightly	differently	to	the	 enzyme	 active	 site,	 as	 evidenced	 in	 Figure	 1.9,	 in	 which	 are	 highlighted	 the	 main	chemical	groups	involved	in	drug	binding.			
				
	
	
	
	
	
	
	
	
	
	
Figure	 1.9	 Chemical	 structures	 of	 sialic	 acid	 (1)	 and	 the	 neuraminidase	 inhibitors	 zanamivir	 (2),	oseltamivir	carboxylate	(3),	laninamivir	octanoate	(4),	and	peramivir	(5).		The	chemical	groups	responsible	for	the	major	interactions	with	the	enzyme	active	site	are	highlighted.	Source:	Farrukee	et	al.	152.			Similarly	 to	 sialic	 acid,	 ZA	 has	 a	 carboxylate	 group	 that	 interacts	with	 three	 positively	charged	residues	(R119,	R292	and	R371)	and	a	glycerol	group	that	interacts	with	residue	E276	at	the	active	site	152.	Its	4-guanidino	group	creates	an	extra	binding	interaction	with	a	pocket	 formed	by	acidic	residues	E119,	D151,	and	E227	at	 the	base	of	 the	active	site,	
1µm 
	 Literature	review	|	29		increasing	the	affinity	of	binding	in	about	1000-fold	148.	The	large	6-pentyl	ether	group	of	OS	binds	 to	a	hydrophobic	pocket	 that	 is	exposed	by	 the	 reorientation	of	 residue	E276	upon	 interaction	 with	 the	 inhibitor,	 with	 a	 similar	 affinity	 of	 binding	 of	 ZA.	 As	 PER	possesses	both	4-guanidino	group	of	ZA	and	6-pentyl	ether	group	of	OS,	it	binds	to	both	pockets,	being	a	potent	inhibitor	of	NA	49.	LAN	has	a	similar	mode	of	binding	than	ZA	156.	The	 slightly	 different	 ways	 in	 which	 the	 4	 NAIs	 bind	 to	 the	 active	 site	 may	 result	 in	different	antiviral	activities.			
1.4.2.2.2			Efficacy	and	use		ZA	and	OS	can	prevent	around	70	to	90%	of	illnesses	when	used	as	either	post-exposure	prophylaxis	for	close	contacts,	such	as	household	members,	or	as	seasonal	prophylaxis	in	the	community	 for	otherwise	healthy	adults	and	children	49.	However,	recent	data	 from	2009	 A(H1N1)	 pandemic,	 wherein	 OS	 was	 mainly	 used,	 evidenced	 the	 occurrence	 of	asymptomatic	 infections	 and	 the	 development	 of	 drug	 resistance	 during	 or	 after	 post-exposure	 prophylaxis.	 Early	 NAI	 treatment	 is	 therefore	 now	 preferred	 over	 post-exposure	 prophylaxis	 49.	 NAI	 treatment	 is	 increasingly	more	 beneficial	 as	 early	 as	 it	 is	instituted,	particularly	within	the	48h	of	the	onset	of	symptoms.	 In	healthy,	ambulatory	adults	and	children,	ZA	and	OS	treatment	significantly	reduce	the	duration	of	illness	(1–3	days	ZA;	0.5–4.1	days	OS)	when	started	within	48h	after	symptom	onset.	Drug	treatment	has	also	been	associated	with	a	significant	reduction	in	the	use	of	antibiotic	therapy	for	lower	 respiratory	 tract	 complications	 and/or	 sinusitis	 (ZA)	 or	 otitis	 media	 (OS)	 148.	Additionally,	it	apparently	reduces	the	amount	of	virus	shed	10.	Recent	data	from	PER	and	LAN	clinical	studies	showed	treatment	efficacy	results	comparable	to	those	found	for	the	former	NAIs	157-160.	OS	is	apparently	 less	effective	for	the	treatment	of	 influenza	B	virus	infections	 compared	 with	 influenza	 A	 152.	 The	 same	 cannot	 yet	 be	 concluded	 for	 the	remaining	 NAIs	 (ZA,	 PER,	 and	 LAN),	 as	 the	 number	 of	 clinical	 studies	 comparing	influenza	 A	 versus	 influenza	 B	 data	 is	 still	 very	 limited.	 Nevertheless,	 the	 significantly	lower	 susceptibility	 that	 influenza	 B	 viruses	 have	 been	 exhibiting	 in	 vitro	 to	 all	 NAIs	supports	 a	 similar	 difference	 on	 clinical	 effectiveness	 152.	 Clinical	 data	 regarding	 NAI	therapy	on	high-risk	patients	is	also	very	limited,	but	observational	studies	have	shown	improved	clinical	outcome,	including	reduced	mortality	49,126.		
	 Literature	review	|	30		Over	the	years	there	has	been	a	gradual	increase	in	the	use	of	NAIs,	with	its	highest	peak	during	 the	 2009	 H1N1	 pandemic.	 Their	 use	 has	 also	 varied	 widely	 across	 countries,	reflecting	 different	 national	 public	 health	 policies	 161.	 Countries	 such	 as	 Japan	 and	 the	USA	use	the	greatest	volumes	and	regularly	treat	 influenza-infected	patients	presenting	at	 either	 general	 practitioners	 or	 hospital	 clinics;	 while	 most	 worldwide	 countries,	including	 Portugal,	 use	 only	 little	 volumes	 of	 NAIs	 to	 essentially	 treat	 severely	 ill	hospitalised	patients	125.	Aside	from	the	treatment	of	seasonal	influenza,	many	countries	have	stockpiled	large	volumes	of	NAIs,	mainly	OS,	as	part	of	their	pandemic	preparedness	plans.	All	NAIs	are	generally	well	tolerated,	with	only	minor	side	effects	reported	126,148.	OS	 remains	 the	 most	 prescribed	 influenza	 antiviral	 drug,	 mainly	 by	 its	 ease	 mode	 of	administration	(oral	formulation),	with	its	sales	exceeding	those	of	ZA	by	at	least	10-fold.	In	Japan	the	use	of	LAN	has	recently	surpassed	that	of	OS	145.				
1.5 ANTIVIRAL	RESISTANCE		As	with	any	antimicrobial	agent,	the	development	of	resistance	against	M2	inhibitors	and	NAIs	 can	 indicate	 that	 their	 therapeutic	 benefits	 are	 reduced	 or	 even	 abrogated,	rendering	 them	 useless	 for	 treating	 or	 preventing	 influenza	 145.	 Considering	 that	 the	repertoire	of	both	M2	inhibitors	and	NAIs	is	very	limited,	the	emergence	of	drug-resistant	influenza	variants	can	pose	a	serious	threat	to	global	public	health.			
1.5.1 Resistance	to	M2	Protein	Inhibitors	
	
1.5.1.1	 Mechanisms	of	Resistance	
	The	 molecular	 basis	 of	 influenza	 A	 virus	 resistance	 to	 M2	 inhibitors	 has	 been	 well	characterised	and	is	associated	with	amino	acid	substitutions	at	5	key	residues	within	the	transmembrane	(TM)	domain	of	the	M2	protein	–	residues	26,	27,	30,	31,	and	34	146.		All	5	residues	are	located	in	the	N-terminal	portion	of	the	TM	region	(Figure	1.10),	but	while	residues	27,	30	and	34	are	pore-lining,	residues	26	and	31	are	rather	 in	the	helix–helix	packing	 interface	 50,162.	 So	 far,	7	 amino	acid	 substitutions	have	been	 reported	 to	 confer	M2	 inhibitor	 resistance,	 including	 L26F,	 V27A,	 A30T,	 A30V,	 S31N,	 S31D	 and	 G34E	 	 -	
	 Literature	review	|	31		established	molecular	markers	of	resistance	163,164.	Most	drug-resistant	variants	contain	one	 of	 these	 amino	 acid	 changes,	 but	 variants	 with	 dual	 mutations	 have	 also	 been	described	 (e.g.	 V27A/S31N).	 Moreover,	 it	 is	 observed	 a	 complete	 cross-resistance	between	AMA	and	RIM	146.												
Figure	 1.10	 Mapping	 of	 the	 amino	 acid	 residues	 associated	 with	 M2	 inhibitor	 resistance	 onto	 the	transmembrane	domain	of	influenza	A	virus	M2	protein.		Top	view	(A)	and	side	view	(B)	of	the	homotetrameric	M2	proton	channel	transmembrane	domain	(PDB	ID:	2KQT).	Both	protein	surface	(grey)	and	helices	(green)	are	displayed.	Residues	26,	27,	30,	31	and	34	(numbered	1-5)	associated	with	drug	resistance	are	displayed	in	red,	with	the	corresponding	side	chains	being	displayed	as	sticks	on	a	single	helix	only.	Amantadine	(number	6)	is	 shown	 in	blue	at	 the	proposed	binding	 site.	One	of	 the	 four	monomeric	 transmembrane	domains	was	 left	 out	 from	B.	The	image	was	generated	using	PYMOL.	Source:	van	der	Vries	165.			Resistance-conferring	mutations	have	been	proposed	to	either	reduce	the	binding	affinity	of	the	drug	(V27A,	A30T/V,	and	G34E;	pore-lining	residues)	or	cause	an	expansion	of	the	M2	channel	 and	disrupt	 the	drug-binding	pocket	 (L26F	and	S31N;	helix–helix	 interface	residues)	139.	More	important	than	lining	the	interior	of	the	pore,	residues	V27	and	A30	are	directly	involved	in	the	formation	of	the	hydrophobic	pocket	to	which	the	drug	binds	(detailed	 in	 section	 1.4.2.1.1).	 Amino	 acid	 substitutions	 at	 these	 residues	 are	 likely	 to	change	the	physical	or	chemical	properties	of	the	pocket	and	thereby	affect	drug	affinity	139.	In	fact,	the	V27A	mutation	showed	to	significantly	reduce	the	hydrophobic	surface	of	the	inhibited	pocket	166.	The	substitution	of	the	pore-lining	residue	G34	with	the	bulkier	glutamic	 acid	 (E)	 may	 probably	 result	 in	 steric	 collision	 with	 the	 amino	 and	 methyl	groups	 of	 the	 drug	 139;	while	 bulky	 side	 chain	 substitutions	 at	 the	 helix–helix	 interface	(L26F,	S31N)	may	probably	prevent	the	two	adjacent	TM	helices	from	being	close	enough	
	 Literature	review	|	32		to	 form	 the	 binding	 structure	 139.	 The	 significantly	 weaker	 TM	 helix-helix	 packing	recently	observed	in	S31N	drug-resistant	mutants	supports	this	latter	167.			
1.5.1.2	 Characteristics	of	Drug-Resistant	Variants		
	M2	 inhibitor-resistant	 variants	 emerge	 rapidly	 after	 exposure	 to	 the	 drug,	 specifically	within	2	to	5	days	after	 initiating	drug	treatment.	They	are	detectable	 in	approximately	30%	 of	 treated	 immunocompetent	 children	 and	 adults,	 but	 in	 immunocompromised	patients	this	frequency	can	exceed	50%	due	to	prolonged	virus	replication	168,169.	A	more	detailed	 study	 detected	 resistant	 variants	 in	 up	 to	 80%	 of	 AMA-treated	 children	 using	molecular	cloning	techniques	170.	Drug-resistant	 variants	 are	 genetically	 stable,	 do	 not	 show	 impaired	 growth	characteristics	 in	vitro,	and	are	not	reduced	in	infectivity	or	virulence	in	animal	models.	Also,	they	cause	typical	influenza	illness	in	humans	and	are	transmissible	from	person-to-person	under	conditions	of	close	contact	168,171.			
1.5.1.3	 Resistance	Among	Circulating	Human	Influenza	Viruses		Until	 1995,	 the	 global	 frequency	 of	 M2	 inhibitor	 resistance	 among	 human	 influenza	A(H3N2)	 viruses	 was	 extremely	 low	 (0.8%;	 virtually	 S31N	 variant),	 and	 no	 resistance	was	observed	in	H1N1	subtype	172,173.			Between	 1995	 and	 2002,	 drug-resistant	 A(H3N2)	 viruses	 continued	 to	 be	 detected	 at	negligible	 frequencies	 in	 most	 regions	 around	 the	 world,	 but	 increased	 slightly	 in	frequency	 in	 China	 and	 other	 Asian	 countries	 (<10%)	 174.	 	 This	 preceded	 the	 high	increase	observed	in	2003	and	2004,	wherein	drug	resistance	reached	alarming	levels	in	China	(57.5%	and	73.8,%	respectively)	and	Hong	Kong	(18.3%	and	69.6%,	respectively).	Virtually	all	drug-resistant	viruses	contained	a	single	S31N	substitution	in	the	M2	protein	146.	During	 the	 following	 two	years,	 related	drug-resistant	S31N	viruses	spread	 to	most	regions	 of	 the	 world,	 including	 Southeast	 Asia/Australasia,	 Japan	 and	 North	 America,	where	 the	 frequency	 of	 resistance	 reached	 42.1%,	 65.3%	 and	 92.3%,	 respectively.	 By	2006,	virtually	all	A(H3N2)	viruses	circulating	worldwide	were	resistant	to	M2	inhibitors	
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174.	An	increased	over-the-counter	use	of	M2	inhibitors	in	some	regions	of	Southeast	Asia,	including	 China,	 possibly	 in	 association	with	 the	 outbreaks	 of	 severe	 acute	 respiratory	syndrome	 (SARS)	 and	 highly	 pathogenic	 A(H5N1)	 avian	 influenza	 virus	 in	 2003,	 may	have	played	a	role	in	the	initial	local	increase	in	resistance	175.		But,	it	cannot	explain	the	rapid	 and	 global	 spread	 of	 drug-resistant	 S31N	viruses	 that	may	have	 instead	 resulted	from	 genetic	 hitchhiking	 to	 advantageous	 mutations	 in	 other	 segments	 (such	 as	 HA	S193F	 and	 D225N	 mutations	 near	 the	 RBS),	 following	 a	 reassortment	 event	 175.	 This	reassortment	event,	which	most	 likely	occurred	 in	early	2005	in	Hong	Kong,	 involved	a	4+4	 segment	 exchange	 between	 drug-resistant	 viruses	 bearing	 the	M2	 S31N	mutation	and	sensitive	viruses	with	an	antigenically	A/Wisconsin/67/2005-like	HA,	resulting	in	a	new	lineage	of	M2	inhibitor-resistant	A(H3N2)	viruses,	designated	as	N-lineage	175,176.	All	globally	circulating	drug-resistant	S31N	viruses	were	found	to	belong	to	this	lineage	176.		At	 the	 same	 time	 that	 drug-resistant	 S31N	 A(H3N2)	 viruses	 began	 to	 spread	 globally	(2005-2006),	the	same	mutation	started	to	be	detected	in	seasonal	A(H1N1)	viruses,	at	a	global	frequency	of	15.6%.	High	levels	of	drug	resistance	were,	however,	found	in	several	Southeast	Asian	 countries,	 particularly	China	 (77.1%),	 and	also	 in	Canada	 (33.3%)	and	Europe	(44.8%)	177.	The	most	probable	explanation	is	that,	possibly	in	another	example	of	mutation	hitchhiking,	the	S31N	substitution	become	associated	with	a	group	of	viruses	antigenically	 classified	 as	 A/Hong	 Kong/2652/2006-like	 (Hong	 Kong-like	 lineage;	 HA	genetic	 clades	 2A	 and	 2C)	 145,174.	 During	 2006,	 A/Hong	 Kong/2652/2006-like	 viruses	began	circulating	more	widely,	thereby	increasing	the	frequency	of	drug-resistant	viruses	in	 many	 countries	 around	 the	 world,	 reaching	 100%	 in	 several	 of	 them,	 such	 as	 the	Philippines	and	South	Korea	174,178.	However,	in	2007	a	new	antigenic	group	of	seasonal	A(H1N1)	virus	sensitive	to	M2	inhibitors	-	A/Brisbane/59/2007-like	lineage	(HA	genetic	clade	2B),	emerged	and	began	to	replace	the	drug-resistant	A/Hong	Kong/2652/	2006-like	viruses	145.	By	the	end	of	2008,	the	overall	frequency	of	drug	resistance	had	already	dropped	to	negligible	levels,	as	A/Hong	Kong/2652/2006-like	viruses	became	extinct	174.		Recently	 emerging	 2009	 pandemic	 A(H1N1)	 viruses	 were	 naturally	 resistant	 to	 M2	inhibitors.	 They	 contained	 the	 M2	 gene	 from	 the	 Eurasian	 avian-like	 swine	 A(H1N1)	lineage	 viruses	 that	 carry	 the	 S31N	 substitution	 since	 1989	 145,179.	 By	 2011,	 naturally	resistant	 A(H1N1)pdm09	 viruses	 had	 completely	 replaced	 drug-sensitive	 seasonal	A(H1N1)	 viruses	 69,	 resulting	 in	 an	 overall	 M2	 inhibitor	 resistance	 among	 circulating	
	 Literature	review	|	34		human	influenza	A	viruses.	This	situation	has	remained	unchanged	to	the	present	day	174,	even	after	more	than	5	years	in	the	absence	of	drug-selective	pressure	(M2	inhibitor	use	not	recommended	by	WHO	since	2010).		M2	 inhibitor	 resistance	 has	 also	 been	 detected	 in	 potentially	 pandemic	 A(H5N1)	 and	A(H7N9)	 avian	 viruses.	 But,	while	 in	A(H5N1)	 subtype	 the	 frequency	 of	 resistance	 has	been	varying	widely	according	to	the	genetic	lineage,	all	A(H7N9)	viruses	causing	human	infection	to	date	have	shown	to	be	resistant	to	this	antiviral	drug	class	(S31N)	174.			
1.5.2 Resistance	to	Neuraminidase	Inhibitors		
1.5.2.1	 Mechanisms	of	Resistance		Resistance	to	NAIs	can	emerge	as	a	result	of	amino	acid	substitutions	in	either	the	NA	or	HA	 gene	 168.	 Amino	 acid	 substitutions	 in	 NA	 (drug	 target)	 can	 decrease	 the	 binding	affinity	 of	 the	 inhibitor,	 while	 those	 in	 HA	 affect	 virus	 susceptibility	 by	 disrupting	 the	delicate	HA-NA	functional	balance	required	during	virus	entry	and	release	from	cells	for	efficient	 replication.	 Specifically,	 they	 decrease	 the	 receptor	 binding	 affinity	 of	 HA,	making	the	release	of	progeny	virions	less	dependent	on	NA	activity	168.	Since	their	effect	is	 independent	 on	 how	 NA	 is	 inhibited,	 HA	 amino	 acid	 substitutions	 confer	 cross-resistance	to	all	NAI	drugs	180.	The	molecular	basis	for	NAI	resistance	is,	however,	not	yet	fully	characterised.					 1.5.2.1.1	Neuraminidase	amino	acid	substitutions	
	NA	H274Y	substitution	(N2	numbering)	 in	N1	NA	 influenza	viruses	(seasonal	A(H1N1),	A(H1N1)pdm09	and	A(H5N1))	 is	presently	the	only	amino	acid	change	known	to	cause	clinical	resistance	to	NAI	drugs,	specifically	to	OS	–	single	molecular	marker	of	resistance	181.	Several	other	NA	amino	acid	substitutions,	most	of	them	influenza	type-	or	subtype-specific	 and	 some	 also	 drug-specific,	 are	 associated	with	 reduced	 NAI	 susceptibility	 in	
vitro,	but	its	clinical	impact	is	less	clear	or	even	completely	unknown	182.	This	is	the	case	of	 NA	H274Y	 substitution	 regarding	 PER	 susceptibility	 and/or	 in	 influenza	 type	 B	 NA.	
	 Literature	review	|	35		New	amino	acid	changes	are	continually	being	detected	and	added	to	this	group.	Based	on	the	fold-change	increase	that	these	amino	acid	changes	induced	in	IC50	(concentration	of	 drug	 required	 to	 inhibit	 a	 standardised	 amount	 of	 NA	 activity	 by	 50%;	 phenotypic	assay),	compared	to	sensitive	wild-type	viruses,	their	effect	on	NAI	susceptibility	is	now	classified	 into	 three	 categories:	 normal	 inhibition	 (NI)	 -	 fold-change	 increase	 <10	(influenza	A)	or	<5	(influenza	B);	reduced	 inhibition	(RI)	 -	 fold-change	 increase	10-100	(influenza	A)	or	5-50	(influenza	B);	highly	reduced	inhibition	(HRI)	-	fold-change	increase	>100	 (influenza	A)	 or	 >50	 (influenza	B)	 183.	 These	new	 categories	were	defined	by	 the	WHO	Expert	Working	Group	on	Surveillance	of	Influenza	Antiviral	Susceptibility	(AVWG)	to	ensure	consistent	reporting	of	NAI	susceptibility	data.		Table	 1.2	 summarizes	 the	 NA	 amino	 acid	 substitutions	 known	 to	 confer	 resistance	 or	reduced	 susceptibility	 to	NAIs	 in	vitro	 in	 human	 influenza	 A	 and	 B	 viruses.	 It	 not	 only	includes	 the	 amino	 acid	 substitutions	 known	 to	 occur	 clinically,	 either	 naturally	 or	associated	 with	 drug	 use,	 but	 also	 those	 identified	 through	 surveillance	 activities	 or	reverse	genetic	(RG)	studies	or	selected	in	cell	culture	or	in	vivo	experiments.	Amino	acid	substitutions	 causing	NI	 are	 also	 indicated	 if	 the	 reduction	 in	 susceptibility	 is	 equal	 or	greater	than	two-fold	and	confirmed	by	RG.	For	consistency,	amino	acid	substitutions	are	indicated	 using	 standard	 N2	 numbering	 in	 both	 the	 table	 and	 throughout	 this	 review,	unless	otherwise	specified.		Most	amino	acid	substitutions	affecting	influenza	A	and	B	virus	susceptibility	to	NAIs	are,	as	expected,	 located	in	or	close	to	the	NA	active	site	(drug-binding	pocket).	For	some	of	the	 substitutions	 located	 distantly	 from	 this	 site,	 such	 as	 N70S,	 D429G,	 and	 M449V	substitutions,	it	is	difficult	to	understand	how	they	may	have	an	impact	on	the	active	site	and	affect	the	binding	affinity	of	the	drug.	Structural	NA	differences	explain	the	influenza	virus	 type-	 or	 subtype-specific	 character	 of	most	 amino	 acid	 changes	 and	 the	 different	levels	of	reduction	caused	by	a	non-specific	mutation	on	different	NA	backgrounds.	Most	virus-specific	 substitutions	 belong	 to	 type	 B	 influenza,	 with	 many	 of	 them	 further	exhibiting	lineage	specificity	and	some	causing	different	levels	of	reduction	on	B/VIC	and	B/YAM-lineage	 backgrounds	 184.	 Drug	 specificity	 is	 explained	 by	 structural	 differences	among	the	4	NAIs	that	result	in	different	binding	interactions	with	the	NA	active	site,	as	detailed	 above	 in	 section	 1.4.2.2.1.	 Some	 cross-reduced	 susceptibility	 is	 observed	between	 OS	 and	 PER	 (e.g.	 E119V,	 H274Y,	 and	 N294S)	 and	 between	 the	 later	 and	 ZA	
	 Literature	review	|	36		and/or	 LAN	 (e.g.	 E119G,	 Q136K/R,	 and	 Q140R)	 on	 N1	 and/or	 influenza	 B	 NA	backgrounds.	The	effect	of	most	substitutions	on	LAN	susceptibility	is	still	missing.	But,	it	is	 expected	 to	 be	 similar	 to	 that	 on	 ZA	 susceptibility	 based	 on	 the	 high	 structural	similarity	 of	 both	 drugs	 and	 on	 the	 similar	 phenotypic	 profile	 observed	 for	 most	substitutions	with	a	known	effect.		NA	E119V	mutation	in	either	N1pdm09	or	influenza	B	NA	and	P141S	mutation	 in	 influenza	B	NA	are	 the	most	worrying	 substitutions	as	 they	confer	reduced	susceptibility	to	all	NAI	drugs	available.		
Table	1.2	Neuraminidase	amino	acid	substitutions	associated	with	neuraminidase	inhibitor	resistance	or	reduced	susceptibility	in	vitro	in	human	influenza	A	and	B	viruses.	
N2 N1 B Oseltamivir Zanamivir Peramivir Laninamivir41 43 40 A(H3N2) RI<(12) NI<(1) Unk Unk Surv68 70 67 A(H1N1) NI<(3) RI<(31D46) Unk Unk Clin/No107 107 105 B NI/RI<(4D10) NI/RI<(1D42) RI/HRI<(6D681) NI/RI<(1D12) Clin/No;<RG116 116 114 B NI<(2) NI<(2) RI<(6) NI<(3) SurvA(H1N1) RI/HRI<(15/1727) HRI<(136/2144) HRI<(5050) Unk RGA(H1N1)pmd09 RI<(60) HRI<(571) RI<(25) Unk RGA(H3N2) RI/HRI<(18D2075) NI<(1D7) NI<(1D3) NI<(3D4) Clin/OS;<Surv;<RG;<In<vitroB HRI<(300) NI<(2) HRI<(531) Unk RGA(H1N1)pmd09 RI<(17) RI<(90) RI<(12) RI<(82) RGB HRI<(918D3171) HRI<(271D12538) HRI<(5491D13780) HRI<(421D2163) Surv;<RGA(H1N1)pmd09 RI<(25) HRI<(827) HRI<(286) HRI<(702) Clin/ZA;<RGA(H3N2) NI<(2) RI<(32) NI<(2) Unk RGB HRI<(>300) HRI<(>560) HRI<(>1598) Unk RGA(H1N1)pdm09 NI<(3D7) HRI<(832D1306) <RI<(51) HRI<(327) Clin/ZA;<RGB RI/HRI<(31D2273) RI/HRI<(33D4167) HRI<(5491D8089) HRI<(421D2163) RG;<In<vitro/ZAA(H3N2) HRI<(208)< RI<(17)< NI<(3)< Unk Clin/OS;<In<vitro/NoA(H1N1) NI<(1) RI/HRI<(36D327) RI<(75D80) Unk Clin/No;<SurvA(H1N1)pmd09 NI<(1) HRI<(86D749) HRI<(143) RI<(42D45) Surv;<RG;<In<vitro/NoA(H3N2) NI<(1D7) RI/HRI<(30D132) Unk Unk SurvA(H1N1)pmd09 NI<(1) HRI<(200) HRI<(234) RI<(33) SurvB NI<(3) NI<(1) RI<(13) NI<(1) SurvB NI<(1) NI<(1D2) RI<(17) NI<(1) RGB NI<(1) NI/RI<(1D15) RI/HRI<(16D91) NI/RI<(1D7) Surv;<In<vitro/No;<RG141 141 139 B RI/HRI<(10D68) RI/HRI<(25D160) NI/RI/HRI<(1D322) NI/RI/HRI<(3D142) Surv;<In<vitro/No;<RG142 142 140 B RI/HRI<(9D184) NI/RI/HRI<(1D1037) NI/RI/HRI<(1D321) NI/RI/HRI<(2D1197) Surv;<In<vitro/No;<RG144 144 142 B NI<(2) NI<(1) RI<(6) NI<(1) Surv148 148 146 A(H3N2) NI<(6) NI<(1) NI<(1) NI<(3) RGA(H1N1)pmd09 NI<(3) RI<(19) RI<(14) NI<(5) SurvA(H3N2) RI<(11) NI<(2) Unk Unk RGA(H3N2) NI<(2) RI<(29) Unk Unk SurvA(H3N2) NI<(1) HRI<(>1500) Unk Unk RGA(H3N2) NI<(8) HRI<(164) Unk Unk SurvB NI<(1) NI<(1) RI<(8) NI<(1) Surv152 152 150 B HRI<(100D252) NI/RI/HRI<(5D1000) HRI<(214D400) Unk Clin/No;<Clin/ZA;<Surv;<RG153 153 151 B NI<(1) RI<(7) Unk Unk Surv155 155 153 A(H1N1) RI/HRI<(10D123) RI/HRI<(45D555) RI<(28D37) Unk Surv;<RG;<In<vitro/NoA(H1N1)pdm09 RI<(16) NI<(7) Unk Unk SurvB RI<(8D26) NI/RI<(2D7) RI<(6D18) NI<(2) Clin/No;<Surv;<RGA(H1N1)pdm09 RI<(17) NI<(6) NI<(2) NI<(2) RGB NI/RI<(4D10) NI/RI<(2D10) NI/RI<(2D5) NI<(2D3) Clin/No;<Clin/OS;<Surv;<RGB RI/HRI<(15/57) RI<(14) HRI<(168) Unk Surv;<RG201 202 200 B RI<(5D8) RI<(5D7) Unk Unk SurvA(H1N1) NI<(3) NI<(2) NI<(1) Unk RGA(H1N1)pdm09 NI<(6) NI<(2) NI<(2D3) NI<(1) RGA(H3N2) NI<(2/4) Unk Unk Unk RGB NI/RI<(4D5) NI<(2D3) RI<(7D9) NI<(2D4) Surv;<RGA(H1N1) NI<(8) NI<(1) NI<(1) Unk RGA(H1N1)pdm09 RI<(12D39) NI<(5D6) NI<(1D4) Unk Surv;<RGA(H1N1)pdm09 RI<(28D45) RI<(10D12) RI<(10) Unk Clin/No;<Clin/OS/ZA;<RGA(H3N2) NI/RI<(9D18) NI<(2D5) Unk Unk RGB HRI<(65D190) NI/RI<(4D13) RI<(12D49) NI/RI<(1D5) Clin/OS;<RGA(H1N1)pdm09 NI<(6) NI<(2) Unk Unk RGA(H3N2) RI<(16) Unk Unk Unk RG;<In<vivo/OSB RI<(5D14) NI/RI<(2D7) RI<(6D43) NI<(3D4) Clin/No;<Surv;<RGB HRI<(92D141) RI<(5) HRI<(82D223) NI<(3D4) RG
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	A(H1N1):	 former	 seasonal	 A(H1N1);	 Clin:	 Clinic;	 Del:	 deletion;	HRI:	Highly	Reduced	 Inhibition;	NA:	Neuraminidase;	NI:	Normal	 Inhibition;	 OS:	Oseltamivir;	RG:	Reverse	Genetics;	RI:	Reduced	Inhibition;	Surv:	Surveillance;	Unk:	Unknown;	x:	times;	ZA:	Zanamivir	a	 Numbering	 based	 on	 the	 alignment	 of	 NA	 sequences	 from	 A/Brisbane/59/2007	 (former	 seasonal	 A(H1N1)),	 A/California/07/2009	(A(H1N1)pdm09),	 A/turkey/Turkey/01/2005	 (A(H5N1)),	 A/Singapore/01/1957	 (A(H2N2)),	 A/Perth/16/2009	 (A(H3N2)),	 A/Hong	Kong/1074/1997	 (A(H9N2)),	 A/duck/Jiangsu/1-15/2011	 (A(H4N2)),	 A/Anhui/01/2013	 (A(H7N9)),	 A/Jiangxi-Donghu/346/2013	 (A(H10N8)),	B/Brisbane/60/2008	 (B/Victoria	 lineage),	 and	 B/Bangladesh/3333/2007	 (B/Yamagata	 lineage);	 b	 Chemiluminescent	 NA-Star®,	 fluorescent	MUNANA-based	and/or	colorimetric	(fetuin)	NA	inhibition	assays;	 	c	Not	found	in	the	clinical	 	specimen;	 	d	Not	found	in	the	clinical	specimen	in	former	seasonal	A(H1N1)	and	A(H3N2)	subtypes;	e	Present	in	the	clinical	specimen	but	in	only	2.7%	of	the	virus	population;	f	Detected	as	a	mixed	virus	population;	g	Detected	as	a	mixed	virus	population	in	A(H1N1)pdm09	subtype;	h	Precise	N2	numbering	cannot	be	given	as	influenza	B	NA	carries	an	insertion	in	the	alignment	compared	to	A(H3N2)	NA.	Amino	 acid	 substitutions	 conferring	 reduced	 susceptibility	 to	 NA	 inhibitors	 (NAIs)	 in	 vitro	 are	 shown	 separately	 from	 those	enhancing	 the	 level	 of	 reduction	 –	 synergistic	 amino	 acid	 substitutions.	 NAI	 phenotypes	 follow	 the	 IC50	 fold-change	 criteria	defined	by	the	WHO	Expert	Working	Group	on	Surveillance	of	 Influenza	Antiviral	Susceptibility	(WHO	AVWG)	for	 influenza	A	(NI:	<10-fold,	RI:	10	to	100-fold,	HRI:	>100-fold)	and	B	viruses	(NI:	<5-fold,	RI:	5	to	50-fold,	HRI:	>50-fold).	H274Y	amino	acid	substitution	is	shown	in	bold	for	N1	NA	influenza	viruses	and	OS	as	it	is	known	to	cause	clinical	resistance.	After	the	designation	of	the	synergistic	amino	acid	substitution,	 it	 is	 indicated,	 in	a	separated	sub-column,	the	amino	acid	substitution(s)	conferring	the	reduction	in	susceptibility.	Whenever	the	synergy	involved	two	amino	acid	substitutions	conferring	RI	or	HRI	(e.g.	E119G	or	I222R	with	H274Y),	it	was	considered	as	synergistic	the	substitution	with	the	lowest	effect	on	susceptibility.	Only	the	phenotype	on	which	the	synergistic	effect	was	observed	is	shown,	with	the	level	of	synergy	being	highlighted	in	golden	brown	and	bold.		
N2 N1 B Oseltamivir Zanamivir Peramivir Laninamivir224 225 223 A(H3N2) HRI<(>4000) RI<(>50) Unk Unk RG226 227 225 A(H3N2) RI<(14) NI<(1) Unk Unk Surv245F248 246F249 244F247 A(H3N2) HRI<(157F222) NI/RI<(3F21) NI<(1) NI<(1) Clin/OS;<Surv;<RGA(H1N1)pdm09 RI<(15) NI<(1) NI<(1) NI<(1) Clin/SurvA(H1N1)pdm09 NI<(3F8) NI<(2F5) NI<(1F2) Unk Surv;<RGB RI<(24) RI<(39) RI<(5) NI<(3) Surv265 266 264 B NI<(2) NI<(<1) RI<(7F8) NI<(1) Surv
A(H1N1) HRI)(321,2597) NI<(1F2) HRI<(111F1095) Unk Surv;<RG
A(H1N1)pdm09 HRI)(221,1637) NI<(1F6) RI/HRI<(50F751) NI<(1F2) Clin/OS;<Surv;<In<vitroB NI/RI<(2F12) NI<(1) RI/HRI<(15F322) NI<(1F2) Surv;<RGB Unk NI<(1F3) NI<(1) NI<(1F3) RG276 277 275 A(H3N2) RI<(15) HRI<(160) Unk Unk RGA(H1N1) NI<(1) RI<(18) Unk Unk RGA(H3N2) HRI<(>1000) NI/RI/HRI<(3F134)< RI/HRI<(14F719) Unk Clin/OS;<Surv;<RG;<In<vitro/ZAB HRI<(>300) RI<(29)< HRI<(502) Unk RGA(H1N1) RI/HRI<(40/197) NI<(1/5) RI<(12) Unk RGA(H1N1)pdm09 HRI<(124F208) NI<(3F9) RI<(12) NI<(3) Surv;<RGA(H3N2) HRI<(300F1879) NI<(8) NI<(1) Unk Clin/OS;<RGB RI/HRI<(17F61) NI<(1F4) RI<(12F31) NI<(2) Clin/No;<RG325 325 325 A(H1N1)pdm09 RI<(19) NI<(8) NI<(3) Unk Surv358F359h 355F356 360 B NI<(2) NI<(2) HRI<(165) NI<(<3) SurvA(H3N2) RI<(45) RI<(15) Unk Unk RGB HRI<(101/407) RI/HRI<(29/145) HRI<(352) Unk Surv;<RG390 386 395 B RI<(5) NI<(1) RI<(5) NI<(<3) Surv402 398 407 B NI<(4) RI<(7) Unk Unk Clin/OS;<Surv429 429 432 B NI<(1) NI<(1) RI<(41) NI<(<3) Surv442 442 440 B NI<(2) NI<(2) RI<(7) NI<(1) Surv449 449 449 B NI<(3) NI<(3) RI<(5) RI<(5) Surv313+427 313+427 313+430 A(H1N1)pmd09 RI<(10F43) NI/RI<(3F20) NI<(4) Unk Surv72+439 74+439 71+439 B NI<(1) NI<(1) RI<(19) RI<(1) Surv144+147 144+147 142+145 B RI<(5) NI<(4) HRI<(487) NI<(<3) Surv150+344 150+341 148+343 B NI<(1) NI<(1) RI<(7) NI<(1) SurvE119V A(H1N1) F HRI<(391)<3x F F RGN294S+H274Y A(H1N1) HRI<(336)<3x RI<(12)<15x F F RGI117M N294S+H274Y A(H1N1) F RI<(11)<9x F F RG119 119 117 E119G H274Y A(H1N1)pdm09 F F HRI<(93433)<298x F Clin/ZA<cloning148 148 146 T148I E119V A(H3N2) HRI<(6154)<22x HRI<(1050)<350x HRI<(119)<119x HRI<(722)<180x RGD151N H274Y A(H1N1) HRI<(799)<2x F HRI<(718)<5x F SurvD151G H274Y A(H1N1) HRI<(1189)<3x RI<(14))7x HRI<(1161)<9x F Surv198 199 197 D198N H274Y A(H1N1)pdm09 HRI<(298)<6x F F F Clin/OSA(H1N1) F F HRI<(893)<3x F RGA(H1N1)pdm09 F F HRI<(1331)<5x RGN294S+H274Y A(H1N1) HRI<(300)<3x RI<(13)<11x F F RGI222K H274Y A(H1N1)pdm09 F NI<(7)<6x F F In<vitroI222R H274Y A(H1N1)pdm09 F RI<(13/16)<13x/16x HRI<(17347)<26x F Clin/OS;<RG246 247 245 S246N H274Y A(H1N1)pdm09 HRI<(7073)<11x NI<(5)<5x HRI<(704)<3x F Surv
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(Footnotes	Table	1.2	cont.)	The	 section	of	 the	 table	 regarding	 the	 amino	acid	 substitutions	 conferring	 reduced	 susceptibility	was	based	on	 the	 summary	table	that	has	been	developed	by	the	WHO	AVWG	185,186.	NA	substitutions	conferring	NI	were	only	included	if	their	effect	is	equal	or	greater	than	two-fold	and	confirmed	by	RG.	References	for	synergistic	amino	acid	substitutions	include	Choi	et	al.	187,	Tamura	
et	al.	188,	Tamura	et	al.	189,	Okomo-Adhiambo	et	al.	190,	Ghedin	et	al.	191,	Hurt	et	al.	192,	Pizzorno	et	al.	193,	Huang	et	al.	194,	Pizzorno	et	
al.	195,	and	Hurt	et	al.	196.				Several	 amino	 acid	 substitutions	 in	 NA	 have	 shown	 to	 enhance	 the	 level	 of	 reduced	susceptibility	 conferred	 by	 H274Y,	 alone	 or	 in	 combination	 with	 N294S,	 and	 E119V	 -	synergistic	amino	acid	substitutions	(Table	1.2).	These	substitutions	have	essentially	no	or	 only	 little	 effect	 on	 virus	 susceptibility,	 with	 exception	 of	 E119G	 and	 I222R	substitutions	 in	N1pdm09	NA.	 These	 confer	 RI	 or	HRI	 ((H)RI),	 but	 its	 combined	 effect	with	 H274Y	 exceeds	 the	 additive	 effect	 of	 their	 individual	 contributions.	 Since	 both	E119G	and	I222R	substitutions	have	lower	effect	on	susceptibility	than	H274Y,	they	were	considered	the	synergistic	element	of	the	combination.		Structural	basis	 for	 reduced	susceptibility	 to	NAIs	may	 involve	 (1)	 inhibition	of	 the	 full	rotation	of	residue	E276,	preventing	the	formation	of	the	hydrophobic	pocket	on	which	the	 large	 6-pentyl	 ether	 group	 of	 OS	 and	 PER	 binds	 (H274Y	 in	 N1	 NA;	 R292K	 in	 N2	NA)150,197;	(2)	conformational	changes	on	the	binding-pocket	(I222R	in	N1	NA)	198;	or	(3)	disruption	of	 the	hydrogen	bonds	established	with	the	carboxylate	group	(N294S	in	N1	NA)	or	the	N-acetyl	group	(D198E	in	influenza	B	NA)	of	the	drug	150.				
1.5.2.1.2	Hemagglutinin	amino	acid	substitutions		Two	amino	acid	substitutions	at	position	221	of	the	HA1	HA	of	seasonal	A(H1N1)	viruses	(225	in	H3	numbering)	are	currently	known	to	confer	reduced	NAI	susceptibility	in	vitro	–	 D221G	 (≤100-fold	 reduction)	 and	 D221N	 (≤10-fold	 reduction)	 199.	 The	 clinical	significance	of	such	reductions	 is,	however,	still	unknown.	Residue	D221	belongs	to	the	HA	RBS	and	is	directly	involved	in	the	binding	to	sialic	acid	200.			Several	 HA1	 HA	 amino	 acid	 substitutions	 have	 been	 identified	 in	 influenza	 virus	recovered	 from	 patients	 undergoing	 antiviral	 therapy,	 many	 of	 whom	immunocompromised.	 Specifically,	 T198I	 and	 S285A	 substitutions	 in	 influenza	 B	 HA	
	 Literature	review	|	39		(T188I	 and	 S271A	 in	 H3	 numbering);	 and	 R142G,	 Y195F,	 I239R,	 V226I	 and	 S262N	substitutions	 in	 H3	 HA	 201-203.	 HA1	 HA	 substitutions	 have	 also	 been	 selected	 in	 vitro	following	 passaging	 under	 NAI	 drug	 pressure,	 namely:	 K130E,	 V132A	 and	 K153E	substitutions	 in	 2009	H1	 pandemic	HA	 (K133E,	 V135A,	 and	K156E	 in	H3	 numbering);	and	 P194L	 substitution	 in	 H3	 HA	 204.	 Only	 the	 substitutions	 selected	 in	 cell	 lines	expressing	 the	 same	 type	of	 receptors	 than	human	respiratory	 cells	 (overexpression	of	α2,6-linked	receptors)	were	considered.	The	effect	of	all	above-mentioned	substitutions	in	NAI	susceptibility	is	still	unknown	but	the	location	of	most	of	them	in	or	near	the	RBS	supports	a	potential	role	in	susceptibility.			
1.5.2.2	 Characteristics	of	Drug-Resistant	Variants			Influenza	variants	resistant	or	with	(H)RI	to	OS	emerge	at	a	low	frequency	after	exposure	to	the	drug.	They	are	detectable	in	<1	to	4%	of	OS-treated	immunocompetent	adults,	with	the	 frequency	 increasing	 up	 to	 4-8%	 in	 the	 pediatric	 population,	 possibly	 due	 to	prolonged	 virus	 shedding	 150.	 Higher	 frequencies	 have	 been	 observed	 in	 some	 clinical	therapeutic	 settings,	 such	 as	 in	 young	 hospitalized	 children	 (16	 to	 27%)	 150,	immunocompromised	patients	under	prolonged	treatment	202,205,206	and	human	cases	of	influenza	A(H5N1)	virus	infection	(25%)	207.	OS-resistant	or	(H)RI	variants	can	emerge	as	early	as	48h	after	initiating	drug	treatment	150.	Influenza	variants	showing	(H)RI	by	PER	emerge	 at	 similar	 rates	 than	 those	 observed	 for	 OS,	 varying	 from	 <1	 to	 6.1%	 among	treated	 adults	 and	 children	 149.	 Reduced	 susceptibility	 to	 ZA	 following	 clinical	 use	 has	been	otherwise	only	rarely	observed	49.		Early	experience	of	NAI	 resistant	or	H(RI)	variants	with	some	of	 the	most	 common	NA	amino	 acid	 changes,	 including	 H274Y	 in	 seasonal	 A(H1N1)	 and	 R292K	 in	 A(H3N2)	backgrounds,	 showed	 that	 such	mutant	viruses	were	compromised	 in	 their	NA	enzyme	activity	 and	 stability	 and	 in	 their	 infectivity	 in	 vitro	 and	 in	 animal	models	 208-210.	 Also,	their	 poor	 infectivity	 showed	 to	 affect	 virus	 transmissibility	 in	 animal	 models	 210,211.	Resistance	 or	 reduced	 susceptibility	 to	 NAIs	 was	 therefore	 considered	 unlikely	 to	 be	clinically	relevant.	However,	the	emergence	of	an	epidemic	H274Y	OS–resistant	seasonal	A(H1N1)	 variant	 in	 late	 2007	 (detailed	 below	 in	 section	 1.5.2.3.1)	 showed	 that	H274Y	mutation	can	be	tolerated	 in	 the	virus	population	without	 fitness	 loss	and	may	even	be	
	 Literature	review	|	40		advantageous	 in	certain	genetic	backgrounds	212.	The	presence	of	 fitness-compensatory	amino	acid	substitutions	in	virus	NA	has	been	considered	to	be	on	the	basis	of	this	fit	and	transmissible	 H274Y	 variant	 174.	 This	 compensatory	 role	 is	 currently	 attributed	 to	 NA	R222Q,	 V234M,	 D344N	 and	 D354G	 substitutions	 (N1	 numbering)	 181.	 Another	 set	 of	compensatory	substitutions	for	H274Y	mutation	might	be	present	in	recently	circulating	2009	A(H1N1)	 pandemic	 viruses.	 Transmission	 of	H274Y	OS-resistant	 A(H1N1)pdm09	viruses	has	occurred	to	a	limited	extent	(detailed	in	section	1.5.2.3.2),	and	in	vivo	studies	showed	 that	 the	 H274Y	 mutant	 virus	 is	 at	 least	 as	 virulent	 as	 the	 wild-type	A(H1N1)pdm09	virus	in	mice	and	ferrets,	in	spite	of	the	airborne	transmission	being	less	efficient	 213,214.	NA	V241I	and	N369K	substitutions	(N1	numbering)	may	be	playing	 this	compensatory	role,	as	evidenced	by	their	ability	to	restore	the	detrimental	fitness	effect	of	 H274Y	 181.	 A(H3N2)	 and	 influenza	 B	 (H)RI	 variants	 containing	 NA	 E119V	 and	 NA	E119A	or	H274Y	mutations,	respectively,	showed	good	in	vitro	and	in	vivo	replication	and	therefore	should	be	closely	monitored	174.			
1.5.2.3	 Resistance	Among	Circulating	Human	Influenza	Viruses		No	 pre-existing	 resistance	 or	 reduced	 susceptibility	 to	 NAIs	 was	 identified	 among	globally	 representative	 human	 influenza	 A	 and	 B	 viruses	 circulating	 prior	 to	 their	introduction	into	clinical	practice	(from	1996	to	1999)	215.	Moreover,	only	NA	H274Y	OS-resistant	 N1	 variants	 (seasonal	 and	 2009	 pandemic	 A(H1N1))	 have	 been	 frequently	detected	to	date	216.	N1	H274Y	mutation	is	also	know	to	confer	(H)RI	by	PER	in	vitro,	as	detailed	above	in	Table	1.2.			
1.5.2.3.1			Global	emergence	of	oseltamivir	resistance	among	former	seasonal	
A(H1N1)	viruses		During	 the	 period	 from	 NAI	 market	 release	 (1999)	 to	 2007,	 NA	 H274Y	 OS-resistant	seasonal	A(H1N1)	viruses	were	detected	at	a	very	 low	global	 frequency	 (≤0.5%)	 217,218.	Even	 in	 Japan,	 where	 public	 health	 policies	 supported	 extensive	 NAI	 drug	 use,	 OS	resistance	emerged	at	a	very	low	frequency	(~1.6%)	219.	However,	in	late	2007,	seasonal	A(H1N1)	 viruses	 harbouring	 NA	 H274Y	 mutation	 began	 to	 circulate	 at	 an	 increasing	
	 Literature	review	|	41		frequency	 in	Europe.	Many	European	countries	detected	 the	mutation	 in	>20%	of	 their	circulating	viruses,	with	France	and	Norway	reporting	frequencies	above	40%	(47%	and	68%,	 respectively)	 145.	 Moreover,	 resistant	 viruses	 were	 coming	 from	 patients	 not	undergoing	OS	therapy.	NA	H274Y	OS-resistant	viruses	spread	rapidly	to	North	America	and	then,	by	the	middle	of	2008,	were	circulating	in	Asia	and	the	Southern	Hemisphere	174.	In	addition	to	spread	rapidly,	they	also	outcompeted	the	sensitive	counterparts	from	circulation,	so	that,	by	late	2008,	virtually	all	circulating	A(H1N1)	viruses	were	resistant	to	 the	 drug	 220.	 This	 situation	 continued	 until	 seasonal	 A(H1N1)	 viruses	 started	 to	 be	replaced	 by	 the	 OS-sensitive	 A(H1N1)	 virus	 that	 caused	 the	 2009	 pandemic,	 with	 the	overall	frequency	of	resistance	dropping	to	negligible	levels	as	seasonal	A(H1N1)	viruses	become	 extinct	 174.	 To	 date,	 it	 is	 still	 unknown	 why	 NA	 H274Y	 OS-resistant	 seasonal	A(H1N1)	 viruses	 spread	 globally	 over	 their	 sensitive	 counterparts,	 even	 more	 in	 a	context	of	overall	low	drug	use.	The	presence	of	fitness-compensatory	mutations	in	virus	NA	may	explain	the	emergence	of	a	 fit	and	transmissible	NA	H274Y	variant,	but	 it	does	not	explain	why	OS-resistant	viruses	surpassed	their	sensitive	counterparts.	All	 fitness-compensatory	mutations	were	also	present	 in	 the	NA	H274Y	seasonal	A(H1N1)	viruses	that	 did	not	 spread	worldwide	 (clade	2C	OS-resistant	 viruses)	 221,222.	 It	 is	 possible	 that	amino	acid	changes	located	at	any	of	the	other	segments	of	influenza	virus	genome	may	have	contributed	for	these	fitter	NA	H274Y	OS-resistant	viruses,	highlighting	the	need	of	extending	genetic	analysis	to	the	whole	genome.			
1.5.2.3.2	Risk	of	spread	of	oseltamivir-resistant	A(H1N1)pdm09	viruses		To	 date,	 the	 frequency	 of	 OS	 resistance	 among	 circulating	 A(H1N1)pdm09	 viruses	 has	remained	 low	on	 a	 global	 scale	 (<2%)	 174.	 Earlier	NA	H274Y	OS-resistant	 viruses	were	mainly	 recovered	 from	 immunocompromised	 patients	 undergoing	 OS	 treatment	 for	prolonged	periods	145.	But,	in	2011,	reports	from	the	United	Kingdom,	Netherlands,	USA,	and	the	Asia-Pacific	region	revealed	an	overall	increase	in	the	proportion	of	OS-resistant	viruses	 from	 untreated	 community	 patients,	 suggesting	 a	 potential	 low-level	transmission	of	resistant	viruses	in	the	community	145.	Moreover,	it	was	detected	for	the	first	 time	a	widespread	community	cluster	of	related	OS-resistant	cases	with	no	known	exposure	 to	 the	 drug,	 in	 Australia	 223.	 Three	 other	 community	 clusters	 involving	 OS-resistant	 viruses	were	 recently	 identified	 during	 the	 2013/2014	Northern	Hemisphere	
	 Literature	review	|	42		influenza	season.	Specifically,	two	larger	clusters	in	Japan	and	the	USA	and	a	third	one	in	China,	 smaller	 and	 possibly	 derived	 from	 the	 cluster	 in	 Japan	 181.	 These	 latter	 cluster	events	confirmed	that	A(H1N1)pdm09	viruses	harbouring	NA	H274Y	mutation	are	able	to	replicate	and	transmit	between	humans	as	efficiently	as	sensitive	wild-type	viruses	125,	leading	 to	 serious	 concerns	about	 the	occurrence	of	 seasonal	epidemics	of	OS-resistant	A(H1N1)pdm09	viruses.				
1.5.2.3.3	Reduced	susceptibility	in	A(H3N2)	and	influenza	B	viruses		
	A(H3N2)	 and	 influenza	 B	 viruses	 exhibiting	 (H)RI	 by	 NAIs	 have	 been	 rarely	 reported	among	circulating	viruses.	Of	note,	a	limited	cluster	of	influenza	B	viruses	harbouring	NA	I222V	 mutation,	 which	 confers	 RI	 by	 OS	 and	 PER,	 was	 detected	 in	 the	 USA	 during	2010/2011	 224.	 Also,	 the	 genetic	 similarity	 exhibited	 by	NA	D198N	 influenza	 B	 viruses	circulating	 in	Australia	and	China	during	2014/2015	may	 indicate	a	potential	 low-level	transmission	of	a	RI	variant	in	the	community	setting	125.	NA	D198N	mutation	is	known	to	confer	RI	by	OS,	ZA	and	PER	(see	Table	1.2	above	for	detail).				Latest	global	susceptibility	surveillance	data	indicates	that	>99%	of	the	human	influenza	viruses	circulating	worldwide	during	2014/2015	were	sensitive	to	all	4	NAIs	125.		Regarding	potentially	pandemic	viruses,	OS	resistance	(NA	H274Y)	has	been	observed	in	A(H5N1)	avian	viruses	recovered	from	patients	undergoing	OS	treatment,	while	A(H7N9)	avian	viruses	have	been	predominantly	sensitive	to	NAIs	174.			
1.6 SURVEILLANCE	FOR	ANTIVIRAL	RESISTANCE		Surveillance	 activities	 for	 tracking	 the	 emergence	 of	 antiviral	 resistance	 in	 circulating	influenza	viruses	 improved	significantly	after	 the	 introduction	of	NAI	drug	class.	Global	and	 European	 susceptibility	 surveillance	 networks	 were	 created,	 using	 the	 existing	influenza	surveillance	systems	coordinated	by	WHO	-	Global	 Influenza	Surveillance	and	Response	System	(GISRS),	and	the	European	Centre	 for	Disease	Prevention	and	Control	
	 Literature	review	|	43		(ECDC)	 -	European	 Influenza	Surveillance	Network	(EISN).	Globally,	 the	Neuraminidase	Inhibitor	 Susceptibility	 Network	 (NISN,	 1999-2006)	 conducted	 antiviral	 susceptibility	testing	on	virus	isolates	provided	by	the	WHO	Collaborating	Centres	(WHO	CCs),	using	a	uniquely	all-encompassing	approach	that	linked	WHO	CCs	and	drug	companies	with	the	WHO	 GISRS	 168,225.	 The	 European	 Surveillance	 Network	 for	 Vigilance	 against	 Viral	Resistance	(VIRGIL,	2004–2008)	provided	antiviral	susceptibility	data	for	more	than	30	countries	 in	 Europe	 225.	 Both	 global	 and	 European	 networks	 increased	 antiviral	susceptibility	 testing	capacity	and	enabled	 the	sharing	of	 resources,	expertise	and	data,	the	standardization	of	methodologies	and	a	multidisciplinary	communication.	They	also	ensured	the	training	and	the	accomplishment	of	the	individual	needs	of	each	country	and	promoted	 the	 rapid	 detection	 and	 timely	 reporting	 of	 drug	 resistance	 225.	 Currently,	antiviral	 susceptibility	 testing	 is	 directly	 carried	 out	 at	 the	 WHO	 CCs	 and	 at	 several	National	 Influenza	 Centres	 (NICs)	 of	 the	GIRS	 network	 226.	 National	 laboratories	 of	 the	ECDC	European	Reference	Laboratory	Network	for	Human	Influenza	(ERLI-Net),	most	of	which	 are	 also	WHO	NICs,	 are	 also	 testing	 for	 antiviral	 susceptibility.	WHO	GISRS	 and	ECDC	EISN	 reporting	mechanisms	 are	 being	used	 for	 the	 timely	 release	 and	 sharing	 of	data.	Compared	to	WHO	CCs,	national	laboratories	have	the	capacity	to	work	with	a	more	representative	 sample	 and	 to	 deliver	 the	 results	 in	 a	 more	 timely	 manner,	 which	 is	critical	 for	 the	 early	 detection	 of	 resistant	 variants	 in	 either	 the	 community	 or	 clinical	management	 226.	 In	 fact,	 Denmark	 reported	 the	 first	 case	 of	 OS	 resistance	 in	A(H1N1)pdm09	subtype,	three	months	after	the	emergence	of	the	new	virus	227.	Practical	guidelines	 for	 national	 laboratories	 testing	 influenza	 virus	 susceptibility	were	 recently	provided	by	the	expert	working	groups	that	were	established	under	the	umbrella	of	the	WHO	 GISRS	 and	 the	 ECDC	 EISN	 –	WHO	 AVWG	 and	 ECDC	 Antiviral	 Susceptibility	 Task	Group	 228,229.	 Both	 groups	 have	 also	 the	 role	 of	 providing	 advice	 on	 the	 system	surveillance	 strategies	 for	 influenza	 antiviral	 susceptibility	 183,229.	 Due	 to	 the	 overall	resistance	 to	 M2	 inhibitor	 drugs	 since	 2009,	 M2	 inhibitor	 susceptibility	 testing	 is	 no	longer	considered	a	priority	229.			
1.6.1 Clinical	and	Laboratory	Surveillance		Drug	resistance	can	be	defined	(1)	clinically,	when	a	treated	person	is	refractory	to	drug	treatment	or	occurs	person-to-person	transmission	of	a	virus	that	is	not	sensitive	to	drug	
	 Literature	review	|	44		treatment;	(2)	phenotypically,	by	measuring	the	drug	susceptibility	of	a	virus	isolate	in	a	model	 system,	with	 resistance	 implying	a	measurable	alteration	 in	a	virus	property;	or	(3)	genetically,	by	a	change	in	the	virus	genome	associated	with	a	measurable	phenotypic	loss	of	susceptibility	and/or	clinical	resistance	161.		Since	 the	 molecular	 basis	 of	 M2	 inhibitor	 resistance	 is	 well	 established	 (see	 section	1.5.1.1	 for	 detail),	 genotypic	 evaluation	of	 virus	 susceptibility	 through	molecular-based	assays	 is	 sufficient	 to	 monitor	 the	 susceptibility	 of	 circulating	 influenza	 virus	 to	 this	antiviral	 drug	 class.	 Laboratory	 surveillance	 of	 influenza	 virus	 susceptibility	 to	 NAIs	implies	 otherwise	 both	 phenotypic	 and	 genotypic	 evaluations	 229,	 with	 NA	 inhibition	assays	 constituting	 the	 gold	 standard	 for	 phenotypic	 susceptibility	 testing	 228.	 Only	 the	presence	of	NA	H274Y	mutation	in	N1	NA	influenza	viruses	can	be	exclusively	analysed	through	genotypic	testing	–	single	molecular	marker	of	NAI	resistance.			
1.6.2 Why	is	so	important	monitoring	influenza	antiviral	susceptibility?			Influenza	 antiviral	 susceptibility	 monitoring	 activities	 are	 important	 for	 individual	patient	 treatment.	 Monitoring	 the	 emergence	 of	 viruses	 resistant	 or	 with	 (H)RI	 in	hospitalized	patients	allows	to	make	decisions	on	possible	changes	to	antiviral	treatment.	Moreover,	 information	 on	 the	 frequency	 of	 circulating	 influenza	 viruses	 with	 natural	resistance	or	(H)RI	in	the	community	setting	is	essential	for	making	first	choice	antiviral	drug	 treatment	decisions	 and	 to	 advise	public	 health	policy-makers	 on	 antiviral	 use	 or	strategic	 stockpiling	 229.	 Monitoring	 activities	 are	 also	 important	 for	 early	 detection	 of	resistant	or	(H)RI	variants,	particularly	those	with	good	viral	 fitness	that	can	be	readily	transmissible	and	become	dominant	among	circulating	viruses	229.				
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2			STUDY	DESCRIPTION		
	
2.1	STUDY	GROUNDS		Antiviral	 resistance	 in	 influenza	 may	 not	 only	 emerge	 during	 patient	 treatment	 or	prophylaxis	 but	 also	 spontaneously	 in	 the	 absence	 of	 drug-selective	 pressure	 1.	 The	potential	 risk	 of	 emergence	 of	 influenza	 variants	 naturally	 resistant	 to	 antiviral	 drugs,	associated	 with	 the	 rapid	 and	 unpredictable	 nature	 of	 influenza	 virus	 evolution,	highlights	the	need	for	active	and	sustained	surveillance	for	drug	resistance	in	circulating	influenza	 viruses.	 National	 surveillance	 activities	 are	 important	 for	 (1)	 the	 early	detection	of	drug-resistant	 variants	 in	 the	 community	or	 in	 clinical	management	 2;	 and	(2)	 improving	 the	 coverage	 and	 representativeness	 of	 the	 antiviral	 susceptibility	 data	collected	on	a	global	scale,	in	which	are	based	the	guidelines	and/or	recommendations	on	the	 use	 of	 influenza	 antivirals	 and	 on	 their	 strategic	 stockpiling	 as	 part	 of	 pandemic	preparedness.	 Implementing	 antiviral	 susceptibility	 testing	 in	 Portugal	 was	 therefore	essential,	comprising	the	first	objective	of	this	research	project.	We	purposed	to	evaluate	and	monitor	 the	 susceptibility	 of	 human	 influenza	 viruses	 from	 all	 different	 types	 and	subtypes	 circulating	 at	 national	 level	 since	 2004/2005,	 expecting	 to	 cover	 both	community	 and	 hospital	 settings.	 Influenza	 viruses	 were	 recovered	 from	 community	patients	presenting	with	influenza-like	illness	(ILI)	to	healthcare	systems	covered	by	the	National	 Influenza	 Surveillance	 Programme	 (2004/2005	 to	 2008/2009),	 and	 from	patients	 either	 admitted	 to	 the	 emergency	 unit	 or	 hospitalized	 at	 the	 Hospital	 Curry	Cabral	 (HCC,	Centro	Hospitalar	de	Lisboa	Central,	EPE)	(from	2009	onwards).	HCC	was	the	national	reference	hospital	 for	both	 laboratory	diagnosis	and	hospitalization	during	2009	 A(H1N1)	 influenza	 pandemic	 and	 is	 the	 national	 reference	 hospital	 for	 rapid	laboratory	 confirmation	 of	 	 suspected	 cases	 of	 clinical	 resistance	 to	 influenza	 antiviral	drugs.		The	 efficient	 fitness	 and	 transmissibility	 of	 the	 neuraminidase	 (NA)	H275Y	oseltamivir	(OS)-resistant	 former	 seasonal	 A(H1N1)	 variant	 that	 emerged	 in	 late	 2007,	 have	 been	attributed	 to	 the	 presence	 of	 additional	 amino	 acid	 substitutions	 in	 NA	 –	 potentially	R222Q,	V234M,	D344N	and	D354G	(N1	numbering)	3,4.	These	substitutions	counteracted	the	 detrimental	 effect	 of	 the	 H275Y	 substitution	 on	 NA	 enzyme	 activity	 and	 virus	replicative	 properties	 5-8.	 However,	 its	 presence	 cannot	 explain	why	NA	H275Y	 former	
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seasonal	 A(H1N1)	 viruses	 spread	 over	 their	 OS-sensitive	 counterparts,	 outcompeting	them	from	circulation.	They	were	also	found	in	NA	H275Y	viruses	from	a	different	clade	(clade	 2C)	 than	 the	 one	 that	 spread	 worldwide,	 fixing	 NA	 H275Y	 in	 A(H1N1)	 virus	population	 (clade	 2B)	 9,10.	 Based	 on	 this,	 it	 has	 been	 suggested	 that	 NA	 H275Y	substitution	 may	 have	 occurred	 coincidentally	 with	 other	 advantageous	 mutation(s)	located	 elsewhere	 in	 the	 viral	 genome	 and	 hitchhiked	 to	 fixation	 along	 with	 them	(mutation	 hitchhiking)	 10,11.	With	 the	 aim	 of	 contributing	 at	 a	 better	 understanding	 of	which	mutations	in	viral	genome	may	have	played	a	role	in	the	enhanced	viral	fitness	of	NA	H275Y	OS-resistant	viruses,	we	purposed	 to	determine	 the	complete	genome	of	NA	H275Y	 OS-resistant	 former	 seasonal	 A(H1N1)	 viruses	 circulating	 in	 Portugal	 and	 to	identify	and	characterize	their	specific	amino	acid	substitutions.	We	further	proposed	to	extend	this	whole-genome	analysis	to	all	other	influenza	viruses	identified	as	resistant	or	with	decreased	susceptibility	to	neuraminidase	inhibitor	(NAI)	drugs,	in	order	to	assess	potential	risks	of	spread,	by	looking	for	mutations	that	may	enhance	virus	fitness.		NAIs	 are	 presently	 the	 only	 approved	 antivirals	 effective	 against	 circulating	 human	influenza	viruses,	targeting	the	virus	NA	protein	that	is	also	under	selective	pressure	(SP)	from	the	host’s	antibody-mediated	immune	response	(second	major	surface	antigen)	12.	SP	 may	 therefore	 play	 an	 important	 role	 in	 the	 molecular	 dynamics	 underlying	 the	emergence	and	spread	of	influenza	variants	resistant	or	with	(highly)	reduced	inhibition	((H)RI)	to	NAIs	in	vitro.	Over	the	last	few	years,	several	research	studies	have	estimated	both	global	and	site-specific	SP	acting	on	NA,	but	only	a	few	of	them	investigated	the	SP	acting	 on	 the	 sites	 associated	 with	 NAI	 resistance	 or	 (H)RI	 13-19.	 Furthermore,	 only	 a	limited	 number	 of	 the	 sites	 currently	 associated	 with	 (H)RI	 was	 considered	 in	 the	different	 analyses	 and	 none	 of	 the	 studies	 focused	 on	 type	 B	 influenza	 NA.	 Hence,	 we	purposed	 to	 study	 the	 SP	 acting	on	 the	 influenza	NA	of	 all	 virus	 subtypes	 and	 lineages	circulating	 among	 humans	 (former	 seasonal	 A(H1N1),	 A(H3N2),	 B/Victoria	 and	B/Yamagata-lineage,	and	A(H1N1)pdm09),	 focusing	 the	analysis	on	 the	sites	associated	with	NAI	 resistance	or	 (H)RI	 and	on	 further	 sites	 contacting	directly	 or	 indirectly	with	the	 drug	 (active	 site).	 NA	 sequence	 datasets	 were	 constructed	 using	 all	 potentially	complete	NA	sequences	of	influenza	viruses	circulating	worldwide	available	at	the	Global	Initiative	 on	 Sharing	 All	 Influenza	 Data	 (GISAID)	 EpiFlu™	 and	 the	 National	 Center	 for	Biotechnology	 Information	 (NCBI)	 Influenza	 Virus	 Resource	 databases.	 Unpublished	sequences	 from	 viruses	 circulating	 in	 Portugal	were	 further	 added	 to	 the	 datasets.	We	
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further	 proposed	 to	 investigate	 for	 the	 first	 time	 the	 impact	 of	 NAI	 introduction	 into	clinic	 (1999)	and	 its	 increased	use	during	2009	A(H1N1)	pandemic	on	both	global	and	site-specific	SP	acting	on	influenza	NA.	For	that,	sequences	were	split	into	three	temporal	sub-datasets	defined	by	the	occurrence	of	such	events:	(1)	before	1999	(no	NAI	use);	(2)	1999-2008	 (low	 overall	 NAI	 use);	 and	 (3)	 from	 2009	 onwards	 (increased	 NAI	 use).	A(H1N1)pdm09	NA	 sequences	were	 exceptionally	 split	 into	 two	 temporal	 sub-datasets	defined	 by	 the	 end	 of	 the	 pandemic	 period	 (10/08/2010),	 after	 which	 	 occurred	 a	decrease	in	NAI	use	20.			In	 summary,	 this	 PhD	 project	 followed	 three	 main	 lines	 of	 research:	 (1)	 antiviral	susceptibility	 testing;	 (2)	whole-genome	 sequencing;	 and,	 (3)	 selective	 pressure	 acting	on	influenza	NA.			
2.2	AIM	AND	OBJECTIVES		This	 research	 project	 aimed	 at	 disclosing	 the	 susceptibility	 of	 human	 influenza	 viruses	circulating	in	Portugal	to	nationally	approved	antivirals;	and	at	improving	the	knowledge	on	 the	 evolutionary	 dynamics	 underlying	 the	 emergence	 and/or	 spread	 of	 influenza	variants	resistant	or	with	decreased	susceptibility	to	NAI	antiviral	drugs.		It	comprised	three	general	objectives,	with	the	first	and	third	ones	further	including	four	and	two	specific	objectives,	respectively.			
1st	General	Objective	To	 evaluate	 and	 monitor	 the	 susceptibility	 of	 human	 influenza	 viruses	 circulating	 in	Portugal	from	2004/2005	onwards,	in	both	community	and	hospital	settings,	to	the	three	antivirals	 approved	 nationally	 for	 clinical	 use	 –	 amantadine	 (M2	 protein	 inhibitor),	oseltamivir	(OS)	and	zanamivir	(ZA)	(NAIs).		
Specific	Objectives	1(a)	To	establish	a	technological	platform	for	phenotypic	and/or	genotypic	evaluation	of	influenza	virus	susceptibility	to	M2	protein	inhibitors	and	both	NAIs	OS	and	ZA;	1(b)	To	determine	the	antiviral	susceptibility	profile	of	human	influenza	viruses	from	all	
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different	 types	 and	 subtypes	 (former	 seasonal	 A(H1N1),	 A(H3N2),	 B	 and	A(H1N1)pdm09);		1(c)	 To	 analyze	 the	 relationship	 between	 reduced	 NAI	 susceptibility	 phenotypes	 and	genotypic	 background	 and,	whenever	 possible,	 between	 these	 and	 patient	 clinical	data;	1(d)	 To	 detect	 variations	 or	 trends	 in	 the	 natural	 in	 vitro	 susceptibility	 of	 circulating	viruses	to	NAIs	over	time	(baseline	phenotypic	drug	susceptibility).			
2nd	General	Objective	To	 identify	 and	 characterize	 the	 amino	 acid	 substitutions	 specific	 of	 the	 genome	 of	influenza	viruses	resistant	or	with	decreased	susceptibility	to	OS	and/or	ZA.				
3rd	General	Objective	To	 study	 the	 selective	 pressure	 (SP)	 acting	 on	 the	 NA	 gene	 of	 worldwide	 circulating	viruses	 from	 all	 human	 influenza	 subtypes	 and	 lineages	 -	 former	 seasonal	 A(H1N1),	A(H3N2),	B/Victoria-lineage,	B/Yamagata-lineage	and	A(H1N1)pdm09.		
Specific	objectives	3(a)	To	estimate	the	SP	acting	on	the	sites	associated	with	NAI	resistance	or	(H)RI	in	vitro	and	on	further	sites	contacting	directly	or	indirectly	with	the	drug	(active	site);	3(b)	To	investigate	the	impact	of	NAI	introduction	into	clinic	(1999)	and	its	increased	use	during	2009	A(H1N1)	pandemic	on	the	global	and	site-specific	SP	acting	on	human	influenza	NA.				
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3	MATERIAL	AND	METHODS		
3.1	MATERIAL		This	 section	 describes	 the	 key	 biological	materials,	 chemical	 commercial	 products	 and	influenza	 virus	 sequences	 available	 in	 public-access	 databases	 used	 in	 this	 study.	 All	remaining	materials	are	indicated	within	the	description	of	the	procedure	in	which	they	were	used,	in	the	following	methods	section	(section	3.2).				 	
3.1.1	Influenza	Virus	Isolates	and	Influenza-Positive	Clinical	Specimens					All	influenza	viruses	isolated	at	the	National	Influenza	Centre	(NIC),	Instituto	Nacional	de	Saúde	 Doutor	 Ricardo	 Jorge	 (INSA),	 IP,	 between	 2004/2005	 and	 2008/2009	 influenza	seasonsA,	were	 selected	 for	 antiviral	 susceptibility	 testing.	 This	 involved	 a	 total	 of	 421	virus	 isolates	 (102	 former	 seasonal	 A(H1N1);	 187	 A(H3N2);	 and	 132	 influenza	 B),	recovered	 from	 more	 than	 30%	 of	 all	 influenza-positive	 clinical	 specimens	 detected	during	 those	 seasons	 (Table	 3.1).	 	 Clinical	 specimens	 (mostly	 nasopharyngeal	 and	oropharyngeal	 swabs)	 were	 collected	 from	 influenza-like	 illness	 (ILI)	 patients	 who	consulted	 with	 a	 sentinel	 medical	 practitioner	 or	 attended	 an	 emergency	 unit	participating	 in	 the	 National	 Influenza	 Surveillance	 Programme.	 The	 accompanying	notification	forms	included	information	on	antiviral	prescription	and/or	exposure	(either	by	direct	use	or	contact	with	a	patient	on	therapy)	since	2005/2006.	In	2009,	 the	source	 for	 influenza	viruses	changed,	with	the	Hospital	Curry	Cabral	(HCC,	Centro	 Hospitalar	 de	 Lisboa	 Central,	 EPE),	 providing	 influenza-positive	 clinical	specimens	 (mostly	 nasopharyngeal	 and	 oropharyngeal	 swabs)	 from	 patients	 either	admitted	 to	 the	 emergency	 unit	 or	 hospitalized.	 	 This	 change	 implied	 performing	 viral	isolation	 before	 antiviral	 susceptibility	 testing.	 All	 positive	 clinical	 specimens	 collected	until	 the	 2012/2013	 influenza	 season	 were	 considered	 for	 study	 and	 used	 for	 viral	isolation.	 The	 only	 exception	 were	 those	 testing	 positive	 for	 the	 new	 pandemic	 virus	during	the	2009	pandemic	periodB	that,	due	to	the	very	high	number	of	virus	detections	(n=577),	 were	 selected	 using	 5	 main	 criteria.	 Specifically:	 (1)	 collected	 from	 patients																																																									A	By	convention,	the	influenza	season	in	Europe	is	considered	to	begin	with	week	40	of	any	given	year	(early	October),	extending	through	week	20	of	the	following	year	(mid-May)	1.							B	Period	from	11th	June	2009	to	9th	August	2010	-	WHO	pandemic	alert	Phase	6.		
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suspected	of	harbouring	drug-resistant	virus	 (clinical	 suspicion	of	drug-resistance);	 (2)	known	association	to	antiviral	drug	use;	(3)	collected	from	high-risk	group	patients;	(4)	collected	 from	 deceased	 patients	 or	 patients	 with	 severe	 disease;	 and	 (5)	 distribution	over	 time	and	 space	 (data	 representativeness).	Overall,	 321	 clinical	 specimens	positive	for	 influenza	 virus	 (2	 former	 seasonal	 A(H1N1);	 38	A(H3N2);	 26	 influenza	 B;	 and	 255	A(H1N1)pdm09),	were	selected	for	studying	antiviral	susceptibility	(Table	3.1).	Effective	study	sample	is	described	in	chapter	4.			
Table	 3.1	Number	 of	 influenza	 virus	 isolates	 and	 influenza-positive	 clinical	 specimens	 selected	 for	antiviral	susceptibility	testing.			
	
	
	
		
	
		
	seasonal	A(H1N1):	former	seasonal	A(H1N1)	a	In	brackets	is	indicated	from	which	percentage	of	the	total	influenza	type/subtype-matched	positive	clinical	specimens,	the	virus	isolates	were	recovered;	 b	Period	 from	11th	 June	2009	 to	9th	August	2010	 -	WHO	pandemic	alert	Phase	6;	 c	Represents	28.2%	(163/577)	of	 the	 total	 clinical	specimens	positive	for	A(H1N1)pdm09	virus	during	that	period.		Among	 all	 virus	 isolates	 and	 clinical	 specimens	 selected	 for	 study,	 33	 (14	 isolates;	 19	clinical	specimens)	were	from	cases	of	influenza	virus	infection	associated	with	antiviral	
seasonal'A(H1N1) 6'(100%) seasonal'A(H1N1) 2A(H3N2) 89'(25.3%) A(H3N2) 5B 35'(48.6%) B 10TOTAL 130'(30.2%) A(H1N1)pdm09 163cseasonal'A(H1N1) 46'(65.7%) TOTAL 180A(H3N2) 1'(16.7%) seasonal'A(H1N1) AB 49'(55.1%) A(H3N2) 2TOTAL 96'(58.9%) B 5seasonal'A(H1N1) A A(H1N1)pdm09 69A(H3N2) 76'(25.2%) TOTAL 76B 2'(66.7%) seasonal'A(H1N1) ATOTAL 78'(25.7%) A(H3N2) 30seasonal'A(H1N1) 29'(54.7%) B 2A(H3N2) A A(H1N1)pdm09 AB 45'(66.2%) TOTAL 32TOTAL 74'(61.2%) seasonal'A(H1N1) Aseasonal'A(H1N1) 21'(32.8%) A(H3N2) 1A(H3N2) 21'(8.4%) B 9B 1'(16.7%) A(H1N1)pdm09 23TOTAL 43'(13.4%) TOTAL 33seasonal'A(H1N1) 102'(52.8%) seasonal'A(H1N1) 2A(H3N2) 187'(20.5%) A(H3N2) 38B 132'(55.5%) B 26TOTAL 421'(31.4%) A(H1N1)pdm09 255TOTAL 321
INFLUENZA)POSITIVE/CLINICAL/SPECIMENS ' (Hospital'Curry'Cabral)'Pandemic'period'/'Influenza'season Influenza'virus'type/subtype Number
TOTALTOTAL
2009'pandemic'periodb
2010/2011
2011/2012
2012/2013
INFLUENZA/VIRUS/ISOLATES' (National'Influenza'Centre)'Influenza'season Influenza'virus'type/subtype Number'a
2004/2005
2005/2006
2006/2007
2007/2008
2008/2009
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use,	 with	 5	 specimens	 (3+2)	 belonging	 to	 the	 same	 two	 cases	 –	 30	 cases	 in	 total	 (29	oseltamivir	(OS);	1	zanamivir	(ZA)).	Nevertheless,	only	10	of	the	clinical	specimens	were	effectively	associated	with	drug	use,	having	been	collected	during	and	particularly	after	antiviral	therapy.		Four	of	these	specimens	were	received	with	a	high	level	of	suspicion	of	clinical	 resistance	 to	 OS	 (A(H1N1)pdm09	 virus	 infection).	 Detailed	 information	 can	 be	found	in	Table	3.2.				
Table	 3.2	Epidemiological,	 clinical	 and	 laboratorial	 information	 concerning	 the	 4	 cases	 of	 influenza	A(H1N1)pdm09	virus	infection	received	with	clinical	suspicion	of	oseltamivir	resistance.		
	
		
	
	AT:	Antiviral	therapy;	Ct:	threshold	cycle	(real-time	PCR	assay);	HIV+:	Positive	for	HIV	infection;	NR:	Not	referred;	ZA:	Zanamivir	a	Rapid	initial	screening	performed	at	the	Hospital	Curry	Cabral.			Reference	 influenza	 viruses,	 kindly	 provided	 by	 Dr	 Alan	 Hay	 (National	 Institute	 for	Medical	Research	(NIMR),	Mill	Hill,	London,	United	Kingdom	(UK)),	and	influenza	viruses	with	known	antiviral	 susceptibility	profile	 circulating	 in	Portugal	were	used	 for	 (1)	 the	establishment	 and	 quality	 control	 of	 phenotypic	 neuraminidase	 (NA)	 inhibition	 assays	(detailed	 in	 section	 3.2.1.3);	 and,	 (2)	 optimization	 of	 the	 one-step	RT-PCR	 protocol	 for	whole	genome	sequencing	of	former	seasonal	A(H1N1),	A(H3N2)	and	influenza	B	viruses.	
	
	
3.1.2	MDCK	and	MDCK-SIAT1	Cell	Lines		MDCK	(Madin-Darby	canine	kidney)	 cells	were	kindly	provided	by	Dr	Alan	Hay	 (NIMR,	Mill	 Hill,	 London,	 UK),	 and	 MDCK-SIAT1	 cells	 (MDCK	 cells	 transfected	 with	 cDNA	 of	
1 2 3 4(pandemic*period) (2010/2011) (2010/2011) (2010/2011)Age*(years) 15 1 27 61Gender Male Male Female MaleUnderlying*risk*conditions NR Premature*bronchopulmonary*dysplasia HIV+;*Pregnant NRNR Severe Severe,*loss*of*the*fetus SevereNR Positive*virus*detection*after*15*days*of*treatment NR Positive*virus*detection*after*10*days*of*treatmentStarting*date*not*provided 20*days Starting*date*not*provided >=10*daysNR NR Deceased NRR Initiated*treatment*with*ZA;*from*Guinea,*AfricaNot*performed Not*present Present*(Ct=13) Present*as*quasiRspecies*(Ct=27)
Other*observationsN1*NA*H275Y*screening*result *a
Case
Patient
Evidence*of*failureTime*from*the*start*of*AT*to*specimen*collection
Clinical*disease
Clinical*outcome
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human	 β-galactoside	 α2,6-sialyltransferase	 (SIAT1))	were	 obtained	 from	 the	 European	Collection	of	Authenticated	Cell	Cultures	(ECACC)	(Public	Health	England,	Salisbury,	UK).		MDCK	 cells	 were	 used	 to	 propagate	 influenza	 viruses	 from	 2004/2005	 to	 2008/2009	seasons	 that	were	already	MDCK	cell-adapted,	when	 it	was	necessary	 to	 increase	virus	titre	or	virus	stock	volume.	MDCK-SIAT1	cells	were	used	for	isolation	of	influenza	viruses	from	 clinical	 specimens	 from	 the	 2009	 pandemic	 period	 to	 the	 2012/2013	 influenza	season.	Both	cell	lines	were	used	for	producing	the	virus	control	panels.					
3.1.3	Guinea	Pig	Red	Blood	Cells	
	Guinea	pig	red	blood	cells	(RBCs)	were	obtained	from	the	Instituto	de	Higiene	e	Medicina	Tropical	 (IHMT)(Lisbon,	 Portugal),	 having	 been	 collected	 into	 Alsever’s	 solution	 (anti-clotting	agent).	These	RBCs	were	used	for	detection	and	titration	of	influenza	viruses	by	haemagglutination	assay.				
3.1.4	Neuraminidase	Inhibitors	–	Oseltamivir	and	Zanamivir	
	Oseltamivir	carboxylate,	the	active	metabolite	of	the	prodrug	oseltamivir	phosphate,	was	kindly	 provided	 by	 F.	 Hoffmann-La	 Roche	 Ltd	 (Basel,	 Switzerland).	 For	 simplicity,	oseltamivir	carboxylate	is	abbreviated	as	oseltamivir	(OS)	throughout	the	text.	Zanamivir	(ZA)	was	kindly	provided	by	GlaxoSmithKline	 (Hertfordshire,	UK).	Both	antivirals	were	received	through	a	Material	Transfer	Agreement.		OS	 and	 ZA	 were	 used	 in	 the	 fluorescent	 and	 chemiluminescent	 NA	 inhibition	 assays	carried	out	 for	phenotypic	evaluation	of	 influenza	virus	susceptibility	 to	neuraminidase	inhibitor	(NAI)	drugs.			
	
3.1.5	Light-Emitting	Phenotypic	Substrates	
	MUNANA	 (2´	 2´-(4-Methylumbelliferyl)-α-D-N-acetylneuraminic	 acid	 sodium	 salt	hydrate)	substrate	was	obtained	 from	Sigma-Aldrich	(Schnelldorf,	Germany),	while	NA-Star®	substrate	was	supplied	in	the	commercial	kit	NA-Star®	Influenza	Neuraminidase	Inhibitor	 Resistance	Detection,	 distributed	 exclusively	 by	Applied	Biosystems	 and	 here	
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obtained	from	Applera	Internacional	Inc	(Nieuwerkerk	aan	den	Ijssel,	The	Netherlands).	MUNANA	 and	 NA-Star®	 are,	 respectively,	 the	 fluorescent	 and	 chemiluminescent	substrates	of	NA	inhibition	assays.				
3.1.6	Neuraminidase	Sequences	of	Worldwide	Circulating	Human	Influenza	Viruses		NA	gene	sequences	of	worldwide	circulating	viruses	 from	all	human	influenza	subtypes	or	 lineages,	 were	 retrieved	 from	 the	 Global	 Initiative	 on	 Sharing	 All	 Influenza	 Data	(GISAID)	 EpiFlu™	 Database	 (http://platform.gisaid.org),	 and	 the	 National	 Center	 for	Biotechnology	 Information	 (NCBI)	 Influenza	 Virus	 Resource	 Database	(https://www.ncbi.nlm.nih.gov/genomes/FLU).	 All	 available	 sequences	 with	 a	potentially	 complete	 coding	 region	 (1410	 nucleotides	 (nts),	 former	 seasonal	 A(H1N1);	1407nts,	A(H3N2)	and	A(H1N1)pdm09;	1398nts,	 influenza	B)	were	collected	 for	 study.	To	these	sequences	were	further	added	unpublished	sequences	of	viruses	circulating	 in	Portugal	since	2000/2001.			
Table	 3.3	 Number	 and	 time	 period	 covered	 by	 the	 neuraminidase	 gene	 sequences	 of	 worldwide	circulating	human	influenza	viruses	collected	for	study.		
GISAID&EpiFlu™&Database NCBI&Influenza&Virus&Resource&Database Portugal TOTAL1 Before&1999 198 215 0 413 1918&F&1998&(81)2 1999F2008 2022 1408 54 3484 1999&F&2008&(10)3 From&2009&onwards 406 400 12 818 2009&F&2011&(3)F 2626 2023 66 4715 1918&F&2011&(94)1 Before&1999 1012 978 0 1990 1968&F&1998&(31)2 1999F2008 3386 2987 71 6444 1999&F&2008&(10)3 From&2009&onwards 5055 1271 2 6328 2009&F&2013&(5)F 9453 5236 73 14762 1968&F&2013&(46)1 Before&1999 75 F 0 75 1972&F&1998&(27)2 1999F2008 478 F 4 482 1999&F&2008&(10)3 From&2009&onwards 2227 F 1 2228 2009&F&2013&(5)F 2780 F 5 2785 1972&F&2013&(42)1 Before&1999 101 F 0 101 1973&F&1998&(26)2 1999F2008 533 F 20 553 1999&F&2008&(10)3 From&2009&onwards 1503 F 0 1503 2009&F&2013&(5)F 2137 F 20 2157 1973&F&2013&(41)1 Before&1999 F 201 F F 1940&F&1998&(59)2 1999F2008 F 1183 F F 1999&F&2008&(10)3 From&2009&onwards F 1388 F F 2009&F&2013&(5)F F 2772 F F 1940&F&2013&(74)1 (PreF)pandemic&periodd 5860 5808 44 11712 2009&F&09/08/2010&(1.8)2 PostFpandemic&period 2027 894 13 2934 10/08/2010&F&2013&(2.8)F 7887 6702 57 14646 2009&F&2013&(5)
Former&seasonal&A(H1N1) 04/01/2012&bTOTAL
Influenza&virus&(sub)type&or&lineage Temporal&subFdataset Accession&datea
Number Time&period&covered&(years)
A(H3N2) 07/04/2013TOTAL
B/Victoria 11/10/2013TOTAL
A(H1N1)pdm09 30/04/2013TOTAL
B/Yamagata 11/10/2013TOTAL
Bc 11/10/2013TOTAL
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(Footnotes	Table		3.3)	a	Date	of	accession	 to	databases	 (i.e.	date	 in	which	 the	sequences	were	 retrieved);	 b	Re-search	 in	early	2013	revealed	very	 few	new	sequences	available,	avoiding	the	need	of	updating	preliminary	sequence	sub-datasets	and	re-performing	sequence	treatment	and	data	analysis;	c	B	lineage	information	was	not	available	for	most	neuraminidase	(NA)	sequences	available	at	NCBI	database;	d	Pre-pandemic	(late	March	to	10th	June	2009)	or	pandemic	(11th	June	2009	to	9th	August	2010)	period.	Sequences	were	grouped	according	to	the	temporal	split	here	proposed	to	investigate	the	impact	of	the	different	contexts	of	NA	inhibitor	 (NAI)	 drug	 use	 in	 the	 selective	 pressure	 acting	 on	NA	 (three	 or	 two	 time	 periods).	 	When	 completely	 treated	 (see	section	3.2.3.1),	the	sequences	were	merged	to	form	total	datasets.			These	sequences	were	used	to	study	the	selective	pressure	(SP)	acting	on	the	NA	gene	of	all	 influenza	 virus	 subtypes	 or	 lineages	 circulating	 among	 humans.	 	 The	 temporal	 split	purposed	in	this	study,	into	three	(before	1999,	1999-2008,	from	2009	onwards)	or	two	((pre-)pandemicC	 and	 post-pandemic	 periods;	 A(H1N1)pdm09)	 time	 periods	 according	to	the	differences	in	NAI	global	use	(detailed	in	chapter	2),	was	taken	into	consideration	for	 retrieving	 and	 handling	 NA	 sequences.	 Only	 when	 completely	 treated	 (see	 section	3.2.3.2),	 the	sequences	were	merged	to	 form	total	datasets.	Detailed	 information	on	the	number	and	time	period	covered	by	NA	sequences	can	be	found	in	Table	3.3.				
3.2	METHODS		
3.2.1	Laboratory	Procedures		
3.2.1.1	Culture	of	MDCK	and	MDCK-SIAT1	Cells			
3.2.1.1.1	Recovery	of	frozen	cells		
		Low-passage	 MDCK	 and	 MDCK-SIAT1	 cells	 were	 recovered	 from	 liquid	 nitrogen	temperature	(-196°C),	following	the	recommendations	of	the	ECACC	2.	Briefly,	the	frozen	cell	ampoule	was	transferred	in	ice	to	a	37°C	water	bath	for	rapid	thawing	(1-2	minutes).	Once	thawed,	the	whole	content	of	the	ampoule	was	slowly	transferred	to	a	15ml	conical	centrifuge	 tube	 containing	 5ml	 of	 pre-warmed	 base	 medium.	 For	 MDCK	 cells,	 this	medium	 contained	 1x	 Eagle's	 minimum	 essential	 medium	 (MEM;	 Gibco,	 Paisley,	 UK),	2mM	 L-glutamine	 (Gibco)	 and	 1x	 non-essential	 amino	 acids	 (NEAA;	 Gibco);	 while	 for	MDCK-SIAT1	cells,	 it	 contained	1x	Dulbecco's	modified	Eagle's	medium	(DMEM;	Gibco)																																																									C	Pre-pandemic	(late	March	to	10th	June	2009)	or	pandemic	(11th	June	2009	to	9th	August	2010)	period.	
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supplemented	 with	 2mM	 L-glutamine,	 1x	 NEAA	 and	 24mM	 HEPES	 (Gibco).	 Cell	suspension	 was	 centrifuged	 at	 300xg	 for	 5	 minutes	 (min)	 for	 removing	 the	cryoprotectant	 and	 the	 cell	 pellet	 was	 resuspended	 in	 2ml	 of	 fresh	 complete	 growth	medium	prepared	for	seeding	the	cells	in	tissue	culture	flaks	(7ml	for	25cm2	flasks;	15ml	for	 75cm2	 flasks).	 Complete	 growth	 medium	 included	 pre-warmed	 base	 medium	supplemented	with	8%	(v/v)	heat-inactivated	fetal	bovine	serum	(FBS,	Gibco)	for	MDCK	cells	and	with	10%	(v/v)	FBS	and	1	mg/ml	antibiotic	G418	sulfate	 (Geneticin®,	Gibco)	for	MDCK-SIAT1	cells.	Cells	were	then	seeded	by	adding	the	cell	suspension	to	a	25cm2	or	75cm2	 flask	 containing	 the	 remaining	 volume	 of	 the	 growth	 medium,	 followed	 by	incubation	at	37ºC	until	 achieving	 total	 confluence	 (generally	24h	 for	25cm2	 flasks	and	48h	for	75cm2	flasks).			
3.2.1.1.2	Cell	maintenance			Cells	 were	 transferred	 to	 maintenance	 medium	 when	 completely	 confluent.	 Growth	medium	was	discarded	from	the	flask	and	the	cell	monolayer	was	washed	twice	with	pre-warmed	 phosphate	 buffered	 saline	 (PBS)	 without	 Ca2+/Mg2+	 (Gibco).	 Pre-warmed	maintenance	medium	was	 added	 to	 the	 flask,	 adding	 7ml	 to	 25cm2	 flasks	 and	 15ml	 to	75cm2	 flasks.	 For	 MDCK	 cells,	 this	 medium	 consisted	 in	 the	 base	 medium,	 while	 for	MDCK-SIAT1	cells	 it	consisted	 in	the	base	medium	further	supplemented	with	1	mg/ml	G418	sulfate.	Cells	were	then	incubated	at	30ºC	during	a	maximum	of	5	days.			
3.2.1.1.3	Cell	passage	(subculture)		Cells	were	passaged	within	the	5	days	of	maintenance,	preferably	at	day	2	to	4,	to	prevent	the	 culture	 dying	 and	 to	 have	 cultures	 for	 viral	 isolation	 and/or	 propagation.	Maintenance	medium	was	discarded	from	the	flask	and	the	cell	monolayer	was	washed	twice	with	pre-warmed	PBS.	After	that,	pre-warmed	0.05%	(v/v)	trypsin–EDTA	(Gibco)	was	added	to	the	flask,	adding	the	necessary	volume	to	cover	the	entire	monolayer	(2ml	to	 25cm2	 flasks;	 3ml	 to	 75cm2	 flasks).	 Trypsin-EDTA	was	maintained	 in	 direct	 contact	with	 the	 cell	monolayer	 at	 room	 temperature,	 until	 the	monolayer	 become	 opaque	 (1-2min).	 All	 volume	 of	 trypsin-EDTA	 was	 then	 removed	 and	 the	 flask	 was	 incubated	 at	
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37ºC	until	all	cells	have	become	detached.	During	this	incubation	period,	the	side	of	the	flask	 containing	 the	 cell	monolayer	was	 gently	 tapping	 every	 few	min	 for	 checking	 cell	detachment.	Once	complete	cell	detachment	was	observed,	4.5ml	(25cm2	flasks)	or	9ml	(75cm2	flasks)	of	pre-warmed	base	medium	were	pipetted	directly	against	the	side	of	the	flask	that	contained	the	cell	monolayer,	 followed	by	successive	up	and	down	pipetting’s	for	mixing	and	for	breaking-up	any	cell	clumps.	Cell	suspension	was	then	supplemented	with	 10%	 (v/v)	 FBS	 (0.5ml	 for	 25cm2	 flasks;	 1ml	 for	 75cm2	 flasks),	 mixing	 gently	 for	reducing	air	bubble	formation	that	could	cause	cell	wall	disruption.	MDCK	 cell	 suspension	was	 directly	 diluted	 in	 complete	 growth	medium	 for	 producing	new	maintenance	cultures	and	 in	complete	growth	medium	further	supplemented	with	1x	penicillin-streptomycin-neomycin	antibiotic	mixture	(PSN;	Gibco)	for	preparing	tubes	(round,	7ml)	and/or	 flasks	 (25cm2	or	75cm2)	 for	viral	 isolation	and/or	propagation.	 	A	split	 ratio	 of	 1:5	 was	 used	 for	 obtaining	 flasks	 with	 80–90%	 confluence	 (confluence	suitable	for	viral	inoculation)	in	48	hours	(1.4ml	suspension	in	5.6ml	medium	for	25cm2	flasks;	3ml	suspension	in	12ml	medium	for	75cm2	flasks).	A	split	ratio	of	1:3	was	used	for	getting	tubes	with	the	same	suitable	confluence	in	24	hours	(1ml	suspension	per	tube).	MDCK-SIAT1	was	a	more	recent	cell	line	and	thereby	no	pre-determined	straightforward	dilutions	 were	 used.	 Viable	 cell	 concentration	 was	 estimated	 for	 each	 MDCK-SIAT1	suspension	 after	 counting	 the	 viable	 cells	 with	 a	 haemocytometer	 (detailed	 in	 section	3.2.1.1.4),	 in	 order	 to	 determine	 the	 required	 volume	of	 cell	 suspension	 to	 be	 used	 for	obtaining	the	suitable	confluence	(80–90%)	on	the	desired	day.	 	For	flasks,	 this	volume	was	the	area	of	the	flask	(25	or	75)	multiplied	by	a	time-variable	factor	(for	48	hours:	2	for	25cm2	 flasks;	4	 for	75cm2	 flasks),	and	then	divided	by	 the	viable	cell	concentration;	while	for	tubes,	it	was	the	cell	seeding	density	(30x104	cell/ml	for	24	hours)	divided	by	the	 viable	 cell	 concentration.	 Cell	 suspension	 was	 then	 diluted	 in	 complete	 growth	medium	 for	 producing	 new	 maintenance	 cultures	 and	 in	 complete	 growth	 medium	containing	 2.5μg/ml	 Fungizone®	 antimycotic	 (Gibco)	 and	 1x	 PSN	 instead	 of	 1	 mg/ml	G418	 sulfate	 for	 preparing	 tubes	 and/or	 flasks	 for	 viral	 isolation	 and/or	 propagation.	Total	dilution	volumes	were	1ml,	7ml	and	15ml	for,	respectively,	tubes,	25cm2	and	75cm2	flasks.	Both	cell	lines	were	continually	subcultured	until	reaching	25	consecutive	passages	or	3	months	 of	 use,	 which	 are	 the	 recommended	 limits	 to	 guarantee	 their	 susceptibility	 to	respiratory	 viruses	 3.	 A	 new	 frozen	 ampoule	 of	 low-passage	 cells	 was	 recovered	whenever	one	of	the	limits	was	reached.		
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3.2.1.1.4	Cell	counting	using	a	haemocytometer		Cell	counting	using	a	haemocytometer	was	performed	according	to	the	recommendations	of	 the	 ECACC	 2.	 Briefly,	 a	 coverslip	 was	 moisten	 with	 water	 and	 affixed	 to	 the	haemocytometer.	 Equal	 volumes	 (20µl)	 of	 0.4%	 trypan	 blue	 stain	 (Gibco)	 and	 cell	suspension	 were	 gently	 mixed	 and	 approximately	 10µl	 of	 the	 mixture	 was	 carefully	pipetted	at	the	edge	of	the	coverslip,	flowing	underneath.	The	haemocytometer	grid	was	then	 visualized	 under	 an	 inverted	microscope	 (using	 phase	 contrast)	 for	 counting	 the	viable	 cells,	which	appeared	colourless	and	bright	 (refractile)	 for	not	 incorporating	 the	trypan	blue	(dead	cells	were	blue	and	non-refractile).	Viable	cell	counting	was	performed	in	 four	 different	 squares	 of	 the	 grid	 (1	 square=1mm2	 section),	 including	 cells	 in	 the	middle	of	square	and	cells	that	overlap	edge	on	two	sides.	Cells	overlapping	edge	on	the	other	 two	 sides	 were	 excluded.	 Viable	 cell	 concentration	 was	 estimated	 using	 the	equation	below:			
			
3.2.1.2	Influenza	Virus	Isolation	and	Propagation	in	Cell	Culture			
3.2.1.2.1	Virus	isolation	and	propagation	in	MDCK	and	MDCK-SIAT1	cells			Cell	culture	tubes	containing	MDCK	or	MDCK-SIAT1	monolayers	were	used	for	influenza	virus	 isolation	 and/or	propagation.	Growth	medium	was	discarded	 from	 the	 tubes	 and	cell	monolayer	was	washed	twice	with	pre-warmed	base	medium	(composition	detailed	in	section	3.2.1.1.1).	For	virus	isolation,	the	cell	monolayer	was	inoculated	with	250μl	of	a	mixture	containing	200μl	of	 clinical	 specimen,	25μg/ml	Fungizone®	and	10X	PSN,	pre-incubated	 at	 room	 temperature	 during	 30min;	 while	 for	 virus	 propagation,	 it	 was	inoculated	 with	 200μl	 of	 virus	 isolate.	 One	 or	 two	 tubes	 were	 additionally	 inoculated	with	200μl	of	base	medium	and	used	as	controls.	Once	inoculated,	tubes	were	incubated	at	room	temperature	during	30min	to	allow	virus	adsorption,	followed	by	addition	of	1ml	of	 infection	medium.	 This	 consisted	 in	 base	 medium	 further	 supplemented	 with	 1mM	HEPES,	 2.5μg/ml	Fungizone®,	1x	PSN	and	3μg/ml	TPCK-treated	 trypsin	 (Worthington,	Lakewood,	 NJ,	 United	 States	 of	 America	 (USA)).	 Tubes	 were	 then	 incubated	 at	 35ºC	
Viable'cell'concentration'''''''= Number'live'cells'counted'' x'2'(dilution'factor)' x'104'(square'grid'volume)'(live'cells'per'millilitre) 4'(number'squares'counted)
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(influenza	A	viruses)	or	32ºC	(influenza	B	viruses)	and	checked	daily	on	the	microscope	for	cytopathic	effect	(CPE),	during	a	maximum	of	7	days.	Influenza	virus-induced	CPE	is	non-characteristic,	 being	 assessed	 by	 the	 amount	 of	 swollen	 cells	 detached	 from	 the	growing	 surface.	 Some	 influenza	 viruses	may	 even	 replicate	without	 producing	 CPE	 in	the	 cell	monolayer.	 Culture	 supernatants	were	 tested	 by	 haemagglutination	 assay	 (see	section	3.2.1.2.2)	to	confirm	or	assess	the	presence	of	influenza	virus	when,	respectively,	75-100%	 CPE	 was	 observed	 or	 no	 CPE	 was	 observed	 after	 7	 days	 of	 inoculation.	 A	centrifugation	step	at	5000rpm	for	10min	was	performed	at	the	end,	before	storing	virus	isolates,	to	remove	excess	cells.		Virus	propagation	continued	in	25cm2	or	75cm2	flasks	of	confluent	cells	when	producing	virus	 controls,	 following	 the	 same	 procedure	 above	 described	 but	 using	 different	volumes	of	inoculum	and	infection	medium.	Specifically,	1ml	inoculum	and	6ml	infection	medium	for	25cm2	flasks;	2ml	inoculum	and	13ml	infection	medium	for	75cm2	flasks.			
3.2.1.2.2	Haemagglutination	assay	
	Haemagglutination	assay	was	used	 to	assess	or	confirm	 the	presence	of	 influenza	virus	and,	when	present,	 to	determine	virus	titre.	 	The	assay	was	performed	according	to	the	World	 Health	 Organization	 (WHO)	 recommendations	 3,	 using	 a	 96-well	 U-bottom	microtitre	 plate	 and	 0.75%	 guinea	 pig	 RBCs	 (see	 preparation	 in	 section	 3.2.1.2.3).	 The	plate	was	 positioned	 so	 that	 the	 12-well	 side	was	 horizontal	 (columns	 1	 to	 12,	 left	 to	right)	and	 the	8-well	 side	was	vertical	 (rows	A	 to	H,	 top	 to	bottom).	PBS	was	added	 to	wells	 2	 to	 12	 of	 each	 row,	 adding	 50μl	 per	 well.	 Then,	 100μl	 of	 each	 cell	 culture	supernatant	 was	 added	 to	 the	 first	 well	 of	 rows	 A–G	 (up	 to	 7	 different	 supernatants	tested	per	plate).	RBCs	controls	were	prepared	by	adding	50μl	PBS	to	two	wells	of	row	H.	Two-fold	serial	dilutions	of	 culture	supernatants	were	performed	 throughout	 the	plate,	transferring	50μl	from	the	first	to	successive	wells	of	each	row,	discarding	the	final	50μl.	After	this	dilution	step,	50μl	of	0.75%	guinea	pig	RBCs	were	added	to	each	well.	The	plate	was	 carefully	 agitated	 by	 gentle	 tapping,	 covered	 and	 incubated	 at	 room	 temperature	during	 45min.	 RBCs	 controls	were	 then	 checked	 for	 complete	 settling	 of	 the	 cells	 and,	when	 validated,	 the	 titration	 end-point	 of	 culture	 supernatants	 was	 determined,	corresponding	 to	 the	 highest	 dilution	 that	 still	 caused	 complete	 agglutination	 (RBCs	 in	suspension,	 completely	 agglutinated	 by	 the	 hemagglutinin	 (HA)	 proteins	 of	 the	 virus).	
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The	 virus	 titre	 is	 the	 reciprocal	 of	 this	 end-point	 dilution	 (e.g.	 1:256	 dilution,	 virus	titre=256),	being	given	in	haemagglutination	units		(haemagglutination	unit	=	amount	of	virus	 needed	 to	 agglutinate	 an	 equal	 volume	 of	 a	 RBCs	 suspension).	 Non-agglutinated	guinea	pig	RBCs	(halo	or	circle	of	settled	cells	on	the	bottom	of	the	well),	 indicated	that	no	virus	was	present	or	that	the	virus	was	not	present	in	a	sufficient	quantity	for	causing	agglutination.				
3.2.1.2.3	Preparation	of	guinea	pig	red	blood	cells	0.75%	suspension		Guinea	pig	RBCs	suspension	in	Alsever’s	was	transferred	to	a	conical	centrifuge	tube	(5ml	to	a	15ml	tube),	filling	the	remaining	volume	of	the	tube	(10ml)	with	PBS.	The	tube	was	gently	mixed	by	 several	 slowly	 inversions	and	 then	centrifuged	at	1800rpm	 for	10min.		The	supernatant	and	the	‘buffy’	layer	of	white	cells	were	aspirated	and	10ml	of	PBS	were	added	 to	 the	 tube.	 RBCs	 pellet	 was	 gently	 resuspended	 by	 slowly	 inverting	 the	 tube	several	times.		A	new	centrifugation	step	at	1800rpm	for	10min	was	performed,	followed	by	 aspiration	 of	 the	 supernatant.	 These	washing	 cycling	 steps	 (add	 PBS	 –	 resuspend	 –	centrifuge	–	aspirate	supernatant)	were	continually	performed	until	the	supernatant	was	clear	(indicative	of	no	cell	lysis;	usually	more	two	times).	When	that	was	verified,	it	was	removed	as	much	supernatant	as	possible	and	the	washed	RBCs	were	diluted	for	a	final	concentration	of	0.75%	(v/v).		
	
3.2.1.3	Phenotypic	Neuraminidase	Inhibition	Assays		NA	 inhibition	 assays	 required	 the	 use	 of	 a	 standard	 NA	 activity	 for	 each	 virus.	 To	determine	 the	 standard	 virus	 dose	 to	 use	 in	 each	 assay	 (virus	 dilution),	 virus	 isolates	were	titrated	based	on	their	NA	activity	(NA	activity	assay).		The	 panel	 of	 virus	 controls	 used	 for	 implementation	 and	 validation	 of	 NA	 activity	 and	inhibition	 assays	 included	 initially	 one	 former	 seasonal	 A(H1N1)	 virus	(A/Texas/36/1991	or	A/Lisboa/18/2008),	 	one	A(H3N2)	virus	 (A/Wisconsin/67/2005	or	 A/Lisboa/01/2009),	 and	 one	 influenza	 B	 virus	 (B/Memphis/20/1991	 or	B/Lisboa/09/2008),	all	susceptible	to	OS	and	ZA.	 In	2009	and	2011,	were	added	to	the	panel	one	A(H1N1)pdm09	virus	susceptible	to	both	NAIs	(A/Portugal/1/2009)	and	one	
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A(H1N1)pdm09	virus	resistant	to	OS	(A/Portugal/03/2011;	NA	H275Y),	respectively.	All	virus	 controls	 were	 tested	 in	 10	 to	 15	 independent	 assays	 before	 being	 used	 for	validation.		The	 FLUOstar	 OPTIMA	 fluorometer	 (BMG	 Labtech,	 Madrid,	 Spain),	 equipped	 with	 a	dedicated	luminescence	detection	system,	was	used	for	all	plate	readings.		
	
3.2.1.3.1	Fluorescent	MUNANA-based	assays			Fluorescent	 (FL)	 NA	 activity	 and	 inhibition	 assays	were	 performed	 using	 the	 in-house	MUNANA-based	protocol	developed	by	Public	Health	England	(PHE)(Colindale,	London,	UK)	 (SOP	 NO.	 V-6815),	 and	 based	 on	 the	 method	 of	 Potier	 et	 al.	 4.	 The	 protocol	 is	available	 to	 health	 professionals	 and	 to	 the	 general	 public	 at https://isirv.org/site/	images/stories/avg_documents/Methodology/munana_ic50_sop_for_external.pdf.	 Black	96-well	flat	bottom	plates	were	used	with	the	12-well	side	oriented	vertically	(rows	1	to	12,	 top	 to	 bottom)	 and	 the	 8-well	 side	 oriented	 horizontally	 (columns	 A	 to	 H,	 right	 to	left).			 3.2.1.3.1.1	MUNANA	neuraminidase	activity	assay			MES	assay	buffer	(pH	6.5)	containing	32.5mM	MES	(Sigma	Aldrich,	Schnelldorf,	Germany)	and	4mM	CaCl2	 (MERCK,	Darmstadt,	Germany),	was	added	 to	all	96	plate	wells,	 adding	20μl	per	well.	Duplicate	two-fold	virus	dilutions	were	performed	by	adding	20μl	of	each	virus	 isolate	to	the	 first	row	(row	1)	of	a	pair	of	columns	(from	right	to	 left,	adding	the	first	virus	to	wells	A1	and	B1,	the	second	virus	to	wells	C1	and	D1	and	so	on	until	row	1	was	filled;	up	to	4	different	virus	tested	per	plate)	and	gently	mixing	by	pipetting	up	and	down	several	times	(½	starting	dilution).	The	viruses	were	then	serial	diluted	down	the	plate	by	transferring	20μl	from	row	1	to	row	2	and	so	on,	stopping	at	row	11	(½	to	½048	dilution).	The	20μl	from	row	11	were	discarded	and	row	12	contained	only	MES	buffer,	being	used	as	a	blank	control.	A	100μM	MUNANA	substrate	solution	was	prepared	(5ml	solution	per	plate),	and	30μl	of	the	fresh	solution	were	added	to	all	wells.	To	ensure	that	the	components	of	each	well	were	well	mixed,	the	plate	was	carefully	agitated	by	gentle	tapping	and	centrifuged	at	800rpm	during	30	seconds	(sec).	An	incubation	period	at	37ºC	
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for	 60min	 with	 shaking	 and	 in	 the	 dark	 followed	 this	 quick	 centrifugation	 step.	 The	reaction	ended	with	 the	addition	of	150μl	of	a	 stop	solution	 (pH	10.7)	 containing	0.1M	glycine	 (MERCK)	 and	 25%	 ethanol	 (Carlo	 Erba	 Reagents,	Milan,	 Italy)	 to	 all	wells.	 The	plate	was	then	placed	in	the	fluorometer	and	read	within	20min	of	adding	stop	solution,	using	an	excitation	wavelength	of	355nm	and	an	emission	wavelength	of	460nm.	Raw	activity	data	was	 analysed	 statistically	 (see	 section	3.2.2.1)	 to	determine,	 for	 each	virus	 isolate,	 the	dilution	 in	which	enzyme	activity	 yielded	35000	 relative	 fluorescence	units	(RFUs).	This	standard	NA	activity	was	based	on	previous	experiences	that	indicated	its	 position	within	 the	 linear	 range	 of	 the	NA	 activity	 curve	 of	most	 viruses.	 It	 usually	implies	 a	 virus	 titre	 equal	 or	 higher	 than	 16	 haemagglutination	 units.	 Assay	 validation	criteria	 included	 (1)	 the	 shape	 of	 the	 curve	 when	 plotting	 statistically	 treated	 RFUs	against	 virus	 dilution	 (sigmoid);	 (2)	 replicate	 correlation	 (curve	 match	 and	 virus	dilutions	 not	 differing	 more	 than	 one	 dilution	 factor),	 and;	 (3)	 control	 performance	(values	within	the	validation	limits;	detailed	in	section	3.2.2.1.2).			 3.2.1.3.1.2	MUNANA	neuraminidase	inhibition	assay			NA	inhibition	assay	was	performed	on	the	same	day	or	no	more	than	24	hours	apart	of	the	 NA	 activity	 assay.	 Ideally,	 each	 virus	 isolate	 was	 assayed	 on	 two	 separate	 96-well	plates,	 to	assess	the	susceptibility	to	OS	and	ZA	at	 the	same	time.	Duplicate	dilutions	of	each	 virus	 were	 performed	 in	 MES	 assay	 buffer	 according	 to	 the	 dilution	 factor	determined	 in	 previous	 activity	 assay	 (minimum	 total	 volume	 of	 200μl	 per	 plate).	 All	viruses	 that	 showed	 insufficient	 NA	 activity	 for	 inhibition	 testing	 (RFU	 of	 ½	 dilution	<35000)	 were	 not	 included	 and	 were	 submitted	 to	 further	 cell	 passage	 for	 increasing	virus	titre.	Each	diluted	virus	(up	to	4	different	virus	per	plate)	was	added	to	wells	1	to	11	of	a	pair	of	columns,	adding	10μl	per	well	(from	right	to	left,	the	first	virus	was	added	to	A+B	wells	1-11,	 the	second	virus	 to	C+D	wells	1-11	and	so	on;	Figure	3.1).	An	equal	volume	of	MES	buffer	was	added	to	all	columns	(A–H)	of	row	12.	Four-fold	dilutions	of	each	antiviral	(OS	and	ZA)	were	then	prepared,	beginning	at	20000nM	(Table	3.4).	Each	antiviral	dilution	was	added	to	a	full	row	of	the	plate,	adding	10μl	per	well	(from	top	to	bottom,	20000nM	dilution	was	added	to	row	1	of	A-H	columns,	5000nM	dilution	to	row	2	of	A-H	columns	and	so	on;	Figure	3.1).	To	ensure	that	virus	and	antiviral	were	well	mixed,	the	 plate	 was	 carefully	 agitated	 by	 gentle	 tapping	 and	 centrifuged	 at	 800rpm	 during	
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30sec.	The	plate	was	then	incubated	at	37ºC	for	60min	with	shaking.	All	following	steps,	including	 preparation	 and	 addition	 of	 a	 fresh	 100μM	 MUNANA	 solution,	 mixing,	incubation,	addition	of	stop	solution	and	plate	reading,	were	performed	as	in	NA	activity	assay	(see	section	3.2.1.3.1.1).				
Table	3.4	Antiviral	dilution	preparation	in	MUNANA	neuraminidase	inhibition	assay.		The	volumes	indicated	are	for	one	working	plate.																							
Figure	3.1	Plate	layout	for	adding	the	viruses	and	antiviral	dilutions	in	MUNANA	neuraminidase	inhibition	assay.			Raw	inhibition	data	was	analysed	statistically	(see	section	3.2.2.1)	to	determine,	for	each	virus	isolate	and	NAI,	the	concentration	of	antiviral	required	to	inhibit	the	standardised	
1 40μl&of&100μM&antiviral&working&solution&+&160μl&MES&buffer 20000 40002 50μl&of&step&1&+&150&MES&buffer 5000 10003 50μl&of&step&2&+&150&MES&buffer 1250 2504 50μl&of&step&3&+&150&MES&buffer 312.5 62.55 50μl&of&step&4&+&150&MES&buffer 78.13 15.636 50μl&of&step&5&+&150&MES&buffer 19.53 3.917 50μl&of&step&6&+&150&MES&buffer 4.88 0.988 50μl&of&step&7&+&150&MES&buffer 1.22 0.249 50μl&of&step&8&+&150&MES&buffer 0.31 0.06110 50μl&of&step&9&+&150&MES&buffer 0.076 0.01511 MES&buffer&only Virus/Substrate&control 012 MES&buffer&only Substrate/Buffer&control&(blank) 0
Step Dilution&series Antiviral&concentration&(nM) &‘In&Assay’&concentration&(nM)
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amount	 of	 virus	 NA	 activity	 by	 50%	 (IC50).	 Assay	 validation	 criteria	 included	 (1)	 the	shape	of	the	curve	when	plotting	statistically	treated	RFUs	against	antiviral	concentration	(sigmoid);	 (2)	 replicate	 correlation	 (curve	 match	 and	 IC50	 difference	 <30%);	 (3)	 NA	activity	 in	virus	control	wells	 (~35000RFUs);	and,	 (4)	control	performance	(IC50	values	within	the	validation	limits;	detailed	in	section	3.2.2.1.2).	IC50	values	were	then	analysed	statistically	(detailed	in	section	3.2.2.3)	to	assess	virus	susceptibility	phenotype	to	OS	and	ZA.			
3.2.1.3.2	Chemiluminescent	NA-Star®	kit	assays				Chemiluminescent	 (CL)	 methodology	 was	 used	 for	 confirmation	 of	 fluorescent-based	susceptibility	results,	particularly	of	IC50	outlier	values	and	whenever	it	was	observed	a	significant	difference	between	the	results	of	inter-assay	virus	replicates.		NA	 activity	 and	 inhibition	 assays	 were	 carried	 out	 using	 the	 NA-Star®	 influenza	 NAI	resistance	detection	kit	(Applied	Biosystems),	following	the	manufacturer’s	instructions.	The	only	exception	were	the	antiviral	dilutions	that	were	prepared	differently	to	match	those	use	 in	 fluorescent	MUNANA	assay	(Table	3.5),	and	 the	 final	volume	of	NA-Star	®	substrate	working	 solution	 that	was	 reduced	 to	2.5ml	per	plate.	A	quick	 centrifugation	step	(800rpm	during	30sec)	was	also	added	to	both	activity	and	inhibition	protocols	after	adding	antiviral	and/or	substrate	solution,	to	ensure	that	well	contents	were	well	mixed.				
Table	3.5	Antiviral	dilution	preparation	in	NA-Star®	kit	neuraminidase	inhibition	assay.		The	volumes	indicated	are	for	one	working	plate.											
1 38.4μl(of(100μM(antiviral(working(solution(+(361.6μl(NA<Star®(buffer 9600 40002 100μl(of(step(1(+(300μl(NA<Star®(buffer 2400 10003 100μl(of(step(2(+(300μl(NA<Star®(buffer 600 2504 100μl(of(step(3(+(300μl(NA<Star®(buffer 150 62.55 100μl(of(step(4(+(300μl(NA<Star®(buffer 37.5 15.636 100μl(of(step(5(+(300μl(NA<Star®(buffer 9.38 3.917 100μl(of(step(6(+(300μl(NA<Star®(buffer 2.34 0.988 100μl(of(step(7(+(300μl(NA<Star®(buffer 0.59 0.249 100μl(of(step(8(+(300μl(NA<Star®(buffer 0.15 0.06110 100μl(of(step(9(+(300μl(NA<Star®(buffer 0.037 0.01511 NA<Star®(buffer(only Virus/Substrate(control 012 NA<Star®(buffer(only Substrate/Buffer(control((blank) 0
Step Dilution(series Antiviral(concentration((nM) (‘In(Assay’(concentration((nM)
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NA-Star®	 accelerator	 was	 quickly	 added	 at	 the	 end	 using	 a	 multi-channel	 pipette	(luminescence	reader	not	equipped	with	on-board	injectors).			Raw	activity	assay	data	(obtained	in	relative	light	units	(RLUs))	was	analysed	statistically	(see	section	3.2.2.1)	to	determine,	for	each	virus	isolate,	the	dilution	that	yielded	a	signal	to	noise	 ratio	 (S/N)	of	40.	This	 cut	 off	was	pre-established	by	 the	manufacturer	 (base-experience	 recommendation),	 usually	 implying	 a	 virus	 titre	 equal	 or	 higher	 than	 16	haemagglutination	 units.	 Activity	 assays	were	 only	 performed	 in	 an	 initial	 phase,	 until	determining	 an	 optimal	 virus	 dilution	 for	 each	 influenza	 type	 or	 subtype.	 According	 to	the	 manufacturer,	 similar	 and	 accurate	 IC50	 values	 are	 achieved	 over	 a	 wide	 range	 of	virus	dilutions	(100-fold	difference	 in	virus	concentration).	The	½0	dilution	revealed	to	be	 optimal	 for	 former	 seasonal	 A(H1N1)	 (herein	 designated	 as	 seasonal	 A(H1N1)),	A(H3N2),	and	influenza	B	viruses.	Virus	isolates	with	insufficient	NA	activity	(S/N	<40	in	activity	assay	or	in	virus	control	wells	in	inhibition	assay)	were	submitted	to	further	cell	passage	 for	 increasing	virus	 titre.	Raw	data	 from	 inhibition	assay	 (RLUs)	was	analysed	statistically	 (see	 section	 3.2.2.1)	 to	 determine	 the	 IC50	 values,	 which	 were	 further	analysed	(see	section	3.2.2.3)	to	assess	virus	susceptibility	phenotype	to	OS	and/or	ZA.		Chemiluminescent	 assays	 were	 validated	 using	 the	 same	 criteria	 as	 in	 fluorescent	MUNANA-based	 assays	 (S/N	 RLUs	 instead	 of	 treated	 RFUs	 in	 curve	 shape	 criterion;	S/N~40	in	virus	control	wells	criterion).				
3.2.1.4	Genotypic	Molecular-Based	Methods	
	
3.2.1.4.1	Viral	RNA	extraction		Viral	 RNA	 was	 extracted	 from	 cell-culture	 isolates	 or	 clinical	 specimens	 using	 the	QIAamp®	 Viral	 RNA	 Mini	 Kit	 (QIAGEN,	 Hilden,	 Germany),	 according	 to	 the	manufacturer’s	 instructions.	 Purified	RNA	was	 recovered	 into	60μl	nuclease-free	water	(Promega,	 San	 Luis	 Obispo,	 CA,	 USA)	 and	 used	 straightway	 or	 stored	 at	 -20ºC	 until	further	use.			
3.2.1.4.2	Sanger	sequencing	
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3.2.1.4.2.1	Reverse	transcription	-	polymerase	chain	reaction	amplification			Neuraminidase	gene	of	former	seasonal	A(H1N1),	A(H3N2)	and	influenza	B	viruses	A	 two-step	 reverse	 transcription	 -	 polymerase	 chain	 reaction	 (RT-PCR)	 protocol	 was	used	to	amplify	the	complete	coding	region	of	the	NA	gene	of	seasonal	A(H1N1),	A(H3N2)	and	 influenza	 B	 viruses.	 RT	 reaction	 was	 performed	 according	 to	 Ellis	 et	 al.	 5.	 Briefly,	22.2μl	RNA	were	added	to	17.8μl	of	a	master	mix	containing,	at	a	final	concentration,	1x	PCR	buffer	minus	Mg	(Invitrogen,	Carlsbad,	CA,	USA),	7.5mM	MgCl2	(Invitrogen),	1.5mM	of	 each	 deoxynucleoside	 triphosphate	 (dNTP;	 Roche,	 Barcelona,	 Spain),	 0.4μM	 random	hexamer	primer	 (GE	Healthcare,	 Little	Chalfont	Bucks,	UK),	 16U	 recombinant	RNasin®	ribonuclease	 inhibitor	 (Promega),	 and	 200U	 Moloney	 murine	 leukemia	 virus	 reverse	transcriptase	(M-MLV	RT;	Invitrogen).	Reaction	conditions	included	an	initial	incubation	step	 at	 room	 temperature	 for	 10min	 (random	 primer	 extension),	 followed	 by	 two	additional	incubation	steps,	the	first	at	37°C	for	45min	(RT)	and	the	second	at	100°C	for	5	min	(denaturation),	and	a	final	cooling	step	at	8ºC.	PCR	amplification	was	performed	with	three	 primer	 pairs,	 specific	 of	 each	 influenza	 virus	 type	 or	 subtype	 (detailed	 in	 Table	S3.1,	 Supplementary	 data).	 Each	 PCR	 reaction	 mixture	 included	 10µl	 complementary	DNA	(cDNA)	and	40µl	of	a	master	mix	containing,	at	a	final	concentration,	1x	PCR	buffer	minus	Mg,	1mM	(N1,	NA	B)	or	1.25mM	(N2)	MgCl2,	0.25μM	(N1,	NA	B)	or	0.1μM		(N2)	of	each	 primer	 (Invitrogen),	 and	 1.5U	Taq	DNA	polymerase	 (Invitrogen).	 Thermal	 cycling	conditions	were	performed	as	follows:	94ºC	for	2min	(initial	denaturation);	35	cycles	of	94ºC	 for	1min	 (denaturation),	50ºC	 (N1,	N2)	or	52ºC	 (NA	B)	 for	1min	 (annealing),	 and	72ºC	for	2min	(extension);	72ºC	for	5min	(final	extension);	and	cooling	at	8ºC.	Resulting	amplicons	were	 approximately	 490	 to	 700	 base	 pairs	 (bp)	 (Table	 S3.1,	 Supplementary	data).				HA1	domain	of	hemagglutinin	gene	of	former	seasonal	A(H1N1),	A(H3N2)	and	influenza	B	viruses	The	HA1	domain	of	seasonal	H1,	H3	and	influenza	B	HA	genes	was	amplified	using	a	two-step	RT-PCR	protocol.	RT	reaction	was	performed	as	described	above	for	full-length	NA	amplification.	 PCR	primers	were	 designed	 by	 PHE	 (Colindale,	 London,	UK),	 including	 a	single	pair	for	either	seasonal	H1	or	influenza	B	HA	type/subtype	and	two	different	pairs	for	H3	HA	subtype	(see	Table	S3.2,	Supplementary	data	for	detail).	PCR	reaction	mixture	
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was	 prepared	 by	 adding	 10µl	 cDNA	 to	 40µl	 of	 a	 master	 mix	 containing,	 at	 a	 final	concentration,	 1x	 PCR	 buffer	minus	Mg,	 1.5mM	MgCl2,	 0.2mM	 of	 each	 dNTP,	 0.5μM	 of	each	 primer	 (Invitrogen),	 and	 0.75U	 Taq	 DNA	 polymerase.	 Thermal	 cycling	 conditions	included:	94ºC	for	2min;	35	cycles	of	94ºC	for	1min,	50ºC	or	57ºC	(H3	primer	pair	G/CII)	for	 1min	 and	 72ºC	 for	 2min;	 72ºC	 for	 5min;	 and	 cooling	 at	 8ºC.	 Amplicons	 were	approximately	760	to	1180bp	(Table	S3.2,	Supplementary	data).				Former	seasonal	A(H1N1),	A(H3N2)	and	influenza	B	virus	genome		All	 genome	 segments	 of	 seasonal	 A(H1N1),	 A(H3N2)	 and	 influenza	 B	 viruses,	 with	exception	 of	 NA	 segment	 (methodology	 described	 above),	 were	 amplified	 using	 an	optimized	version	of	the	one-step	RT-PCR	protocol	developed	by	PHE	(Colindale,	London,	UK)	 and	 kindly	 provided	 by	 Dr	Monica	 Galiano.	 The	 influenza	 type-specific	 primer	 set	used	for	PCR	amplification	was	designed	by	Hoffmann	et	al.	6,7	and	later	redesigned	by	Dr	Rod	Daniels	(NIMR,	Mill	Hill,	London,	UK).	Protocol	optimization	involved	adjustments	in	the	 annealing	 temperature	 of	 the	 primers	 that	 resulted	 in	 the	 use	 of	 a	 49ºC	 to	 60ºC	temperature	gradient	 instead	of	the	single	55ºC	annealing	temperature.	 It	also	involved	testing	different	combinations	of	primers.	Final	annealing	temperatures	and	primer	pairs	are	detailed	in	Table	S3.3,	Supplementary	data.		SuperscriptTM	III	RT	and	Platinum®	Pfx	DNA	polymerase	kits	(Invitrogen)	were	used	for	RT-PCR	amplification.	Each	reaction	mixture	included	10µl	RNA	and	40µl	of	a	master	mix	containing,	at	a	final	concentration,	1.5x	Buffer	Pfx	(Pfx	kit),	1mM	MgSO4	(Pfx	kit),	0.4mM	of	each	dNTP	(Invitrogen),	0.2μM	of	each	primer	(Invitrogen),	20U	recombinant	RNasin®	ribonuclease	 inhibitor,	 200U	 SuperscriptTM	 III	 RT	 and	 1.25U	 Platinum®	 Pfx	 DNA	polymerase	 (proof-reading).	 Optimized	 cycling	 conditions	 were	 performed	 as	 follows:	50ºC	for	30min	(RT);	94ºC	for	10min	(initial	denaturation);	35	cycles	of	94ºC	for	30sec	(denaturation),	49ºC-60ºC	for	30sec	(annealing),	and	68ºC	for	2min	(extension);	68ºC	for	10min	 (final	 extension);	 and	 cooling	 at	 8ºC.	 Amplicons	 were	 approximately	 554	 to	1594bp	(Table	S3.3,	Supplementary	data).		When	 the	 amplified	 products	 were	 undetectable	 or	 detectable	 at	 low	 amounts	 by	 gel	electrophoresis	 (detailed	 in	 section	 3.2.1.4.2.2),	 it	 was	 performed	 a	 nested	 PCR,	 also	developed	by	PHE.	Reaction	mixture	 and	 cycling	 conditions	were	 very	 similar	 to	 those	used	for	RT-PCR.	Differences	included	the	absence	of	RNasin	and	Superscript	RT	from	the	
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master	mix	and	of	a	RT	step	in	thermal	cycling	conditions,	and	the	use	of	2µl	DNA	to	48µl	master	mix.			2009	A(H1N1)	pandemic	influenza	virus	genome		Influenza	A(H1N1)pdm09	virus	genome	segments	were	amplified	using	the	one-step	RT-PCR	 protocol	 developed	 by	 the	 Centers	 for	 Disease	 Control	 and	 Prevention	(CDC)(Atlanta,	GA,	USA)	and	recommended	and	made	available	by	WHO	8.	The	protocol	was	 used	 with	minor	modifications	 on	 primer	 pairs	 that	 included	 the	 use	 of	 different	primer	combinations	for	NA	segment	and	a	reduction	in	the	number	of	primer	pairs	used	for	all	other	segments	except	the	M	segment.	Also,	some	primer	sequences	were	changed,	by	 replacing	 one	 or	 few	 nucleotides	 with	 a	 degenerated	 one,	 to	 guarantee	 an	 optimal	match	to	circulating	viruses.	Final	primer	pairs	and	sequences	are	shown	in	Table	S3.4,	Supplementary	data.	All	 forward	 (fw)	and	reverse	 (rev)	primers	 included	 the	sequence	of,	respectively,	M13-fw	and	M13-rev	universal	primers,	allowing	the	use	of	a	posterior	M13	universal	sequencing	strategy.	One-step	RT-PCR	reaction	was	performed	using	the	AccessQuick™	RT-PCR	kit	(Promega)	per	 the	manufacturer´s	 instructions.	 Briefly,	 15µl	 reaction	mixtures	 were	 prepared	 by	adding	 2µl	 RNA	 to	 13µl	 of	 a	 mixture	 containing,	 at	 a	 final	 concentration,	 1x	AccessQuickTM	master	mix	(Tfl	DNA	Polymerase,	dNTPs,	MgSO4	and	reaction	buffer),	1.5U	avian	myeloblastosis	virus	RT	(AMV	RT),	and	1μM	of	each	primer	(Invitrogen).	Thermal	cycling	conditions	included:	48ºC	for	45min;	94ºC	for	2min;	30	cycles	of	94ºC	for	20sec,	50ºC	 for	30sec,	 and	72ºC	 for	1min;	72ºC	 for	7min;	and	cooling	at	8ºC.	Amplicons	were	approximately	447	to	790bp	(Table	S3.4,	Supplementary	data).			 3.2.1.4.2.2	Agarose	gel	electrophoresis		RT-PCR	 products	 were	 size	 fractioned	 and	 visualized	 on	 GelRed-stained	 agarose	 gels.	Gels	 were	 prepared	 using	 1.2%	 agarose	 (SeaKem®	 LE	 agarose,	 Lonza,	 Rockland,	 ME,	USA)	 and	 0.25x	 GelRedTM	 (Biotium,	 Hayward,	 CA,	 USA)	 in	 1x	 Tris-Borate-EDTA	 (TBE;	0.09M	 Tris,	 0.09M	 Boric	 acid	 and	 2.5mM	 EDTA).	 DNA	 samples	 were	 mixed	 with	 the	appropriate	 volume	 of	 DNA	 loading	 buffer	 before	 being	 loaded	 into	 wells,	 using	bromophenol	 blue/xylene	 cyanol	 DNA	 loading	 dye	 (0.25%	 bromophenol	 blue,	 0.25%	
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xylene	cyanol,	15%	ficoll	and	120mM	EDTA)	or	5x	Orange	G	loading	dye	(Sigma-Aldrich).	Electrophoresis	was	 carried	out	at	80-120	volts	 (V)	during	45-60min	 in	1x	TBE	buffer.	DNA	was	then	visualised	by	ultraviolet	(UV)	transillumination	to	check	size	and	quality.	The	 size	 of	 DNA	 bands	 was	 estimated	 by	 comparison	 with	 linear	 DNA	 standards	 of	known	molecular	weight	 (100bp	DNA	 ladder,	 Invitrogen)	 that	 ran	 along	with	 samples.	The	 intensity	 of	 staining	 and	 thickness	 of	 DNA	 bands	 were	 analysed	 to	 estimate	 the	volume	 of	 DNA	 sample	 to	 be	 used	 in	 sequencing	 reaction	 when	 the	 posterior	 RT-PCR	product	 purification	 was	 performed	 using	 ExoSAP-ITTM	 reagent	 (photometric	 DNA	quantitation	not	possible).			 3.2.1.4.2.3	DNA	purification	and	quantitation		RT-PCR	 products	 were	 purified	 using	 the	 QIAquick	 PCR	 Purification	 kit	 (QIAGEN)	 or	ExoSAP-ITTM	PCR	cleanup	reagent	(USB,	GE	Healthcare),	according	to	the	manufacturer’s	instructions.	DNA	purified	with	QIAquick	kit	was	recovered	into	30μl	nuclease-free	water	and	 quantified	 (in	 μg/ml)	 by	 ultraviolet-visible	 spectrophotometry	 using	 a	BioPhotometer.	 Photometric	 measurements	 were	 performed	 on	 60μl	 of	 a	 1:60	 DNA	dilution	in	nuclease-free	water	(blank).			 3.2.1.4.2.4	Automated	DNA	sequencing		Nucleotide	 sequences	 were	 obtained	 by	 primer-walking	 (seasonal	 A(H1N1),	 A(H3N2),	and	influenza	B;	see	Tables	S3.1	to	S3.3,	Supplementary	data	for	primer	details)	or	M13	universal	(A(H1N1)pdm09)	sequencing	approach.	Cycle	sequencing	was	performed	using	the	 BigDye®	 Terminator	 Cycle	 Sequencing	 kit	 v1.1	 (Applied	 Biosystems)	 per	 the	manufacturer´s	 instructions.	 Each	 reaction	 mixture	 contained	 1μl	 BigDye®	 ready	reaction	mix,	3.2pmol	sequencing	primer	(Invitrogen),	10ng	(photometric	quantification)	or	0.5-2μl	(band	analysis)	purified	DNA,	and	nuclease	free-water	up	to	a	volume	of	10μl.	Thermal	cycling	conditions	included:	96ºC	for	4min;	25	cycles	of	96ºC	for	10sec,	50ºC	for	5sec,	 and	60ºC	 for	4min;	60ºC	 for	8min;	 and	cooling	at	8ºC.	DNA	sequences	were	 then	obtained	using	an	automatic	sequencer	ABI	PRISM®	3130xL	Genetic	Analyser	(Applied	Biosystems)	 after	 sample	purification	using	96-well	DyeEx96	 spin	plates	 (DyeEx96	Kit,	
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QIAGEN),	 both	 according	 the	 manufacturer’s	 instructions.	 These	 two	 last	 procedures	were	performed	at	the	Technology	and	Innovation	Unit,	INSA,	IP	(Lisbon,	Portugal).			
3.2.1.4.3	Pyrosequencing		Pyrosequencing	technology	was	used	to	(1)	detect	the	molecular	markers	of	resistance	to	M2	 protein	 inhibitors	 (L26F,	 V27A,	 A30T/V,	 S31N/D	 and	 G34E;	 M	 gene,	 M2	 protein-coding	 region);	 and	 (2)	 quantify	 NA	 H275Y	 and	 NA	 D197N	 amino	 acid	 variants	 in,	respectively,	A(H1N1)pdm09	and	influenza	B	virus	quasispecies	(NA	gene).	Pyrosequencing	 reaction	 was	 performed	 after	 RT-PCR	 amplification	 and	 sample	preparation.	All	procedures	were	carried	out	at	 the	PHE	(Colindale,	London,	UK),	using	in-house	protocols.	Influenza	A	M2	amplification	and	pyrosequencing	protocols	were	the	original	pyrosequencer	manufacturer’s	protocols,	described	in	Bright	et	al.	9,	with	minor	modifications.	 Both	 RT-PCR	 reaction	mixture	 and	 cycling	 conditions	were	 adjusted	 for	A(H1N1)pdm09	 NA	 H275Y	 (protocol	 available	 at	 https://isirv.org/site/index.php/	methodology/pyrosequencing)	 and	 influenza	 B	 NA	 D197N	 pyrosequencing,	 using	 the	PyroMark®	 Assay	 Design	 SW	 2.0	 tool	 (QIAGEN)	 for	 primer	 design.	 PyroMark®	 Q96	Vacuum	 workstation	 and	 ID	 pyrosequencer	 (QIAGEN)	 were	 used	 for,	 respectively,	sample	preparation	and	pyrosequencing	reactions.	Both	equipments	were	used	per	 the	manufacturer’s	instructions.				 3.2.1.4.3.1	One-step	reverse	transcription	-	polymerase	chain	reaction			RT-PCR	 was	 performed	 using	 the	 QIAGEN®	 OneStep	 RT-PCR	 kit	 according	 to	 the	manufacturer´s	 instructions	 and	 a	 single	 primer	 pair,	 in	which	 one	 of	 the	 primers	was	biotin-labelled	at	its	5’	end	(see	Table	S.3.5,	Supplementary	data	for	detail).	Each	reaction	mixture	was	prepared	by	adding	5μl	(M2)	or	2.5μl	(NA)	RNA	to	a	master	mix	containing	10μl	5x	QIAGEN	OneStep	RT-PCR	buffer,	2μl	dNTP	mix	(QIAGEN	kit),	3μl	of	each	10μM	primer	(Metabion,	Martinsried,	Germany),	2μl	QIAGEN	OneStep	RT-PCR	enzyme	mix,	and	RNase-free	 water	 (QIAGEN	 kit)	 up	 to	 a	 volume	 of	 45μl	 (M2)	 or	 47.5μl	 (NA).	 Thermal	cycling	conditions	were	performed	as	follows:	50ºC	for	30min;	95ºC	for	15min;	35	(M2)	or	40	(NA)	cycles	of	94ºC	for	1min	(M2)/30sec	(NA),	55ºC	for	1min	(M2)	or	62ºC	for	30	
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sec	(NA),	and	72ºC	for	1min;	72ºC	for	10min;	and	cooling	at	8ºC.	Biotinylated	amplicons	were	264bp	 for	M2,	 covering	 the	 region	extending	between	nucleotides	764	and	1027,	and	 242bp	 for	 NA,	 covering	 the	 region	 extending	 between	 nucleotides	 800	 to	 1041	(A(H1N1)pdm09)	or	483	to	724	(influenza	B).				 3.2.1.4.3.2	Sample	preparation		Biotin-labelled	RT-PCR	products	were	cleaned	and	denatured	into	single-stranded	DNA.	A	 master	 mix	 containing,	 per	 sample,	 3μl	 streptavidin	 SepharoseTM	 high	 performance	beads	(GE	Healthcare,	Little	Chalfont	Bucks,	UK),	17μl	PyroMark	binding	buffer	(QIAGEN)	and	40μl	nuclease-free	water,	was	prepared	and	distributed	across	a	96	deep-well	PCR	plate	(60μl/well).	RT-PCR	products	were	added	into	each	well	of	the	plate,	adding	20μl	of	product.	 The	 plate	 was	 incubated	 at	 room	 temperature	 for	 10min	 while	 shaking	 at	1400rpm,	 for	 immobilisation	 of	 the	 amplified	 products	 to	 the	 streptavidin	 coated	sepharose	 beads	 (biotin-streptavidin	 bond).	 Single-stranded	 DNA	 products	 were	 then	obtained	 using	 the	 PyroMark®	 Q96	 Vacuum	 workstation.	 	 DNA-coated	 beads	 were	collected	 using	 the	 96-pin	 vacuum	 tool	 and	 were	 put	 through	 a	 series	 of	 steps	 that	included	 (1)	washing	with	70%	ethanol;	 (2)	denaturing	of	 the	double-stranded	DNA	 in	0.2M	NAOH	to	leave	only	the	labelled	single-stranded	DNA	coated	to	the	beads;	and	(3)	washing	 with	 10mM	 Tris	 Acetate	 pH	 7.6	 buffer	 to	 remove	 any	 unbound	 DNA.	 Single	stranded	DNA-coated	 beads	were	 then	 released	 into	 a	 PyroMark®	Q96	well	 plate	 low	(QIAGEN)	 containing	 0.44μM	 sequencing	 primer	 (Metabion;	 detailed	 in	 Table	 S3.5,	Supplementary	 data)	 in	 45μl	 PyroMark®	 annealing	 buffer	 (QIAGEN),	 by	 aligning	 the	vacuum	tool	with	 the	plate	and	 turning	off	 the	pump.	PyroMark	plate	was	 incubated	at	80ºC	 for	2min	and	 then	allowed	 to	cool	 to	 room	temperature	 for	approximately	10min	before	being	placed	into	the	pyrosequencing	machine.			 3.2.1.4.3.3	Pyrosequencing	reaction		Pyrosequencing	 reaction	 was	 performed	 on	 a	 PyroMark	 Q96	 ID	 instrument	 (QIAGEN)	using	 the	 PyroMark®	 Gold	 Q96	 Reagent	 Kit	 (enzyme	 mixture,	 substrate	 mixture,	dATPαS,	dGTP,	dCTP,	dTTP;	QIAGEN)	according	 to	 the	manufacturer´s	 instructions.	M2	
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pyrosequencing	target	region	was	44bp,	extending	between	nucleotides	784	and	827	of	the	M	gene	of	influenza	A	viruses	(seasonal	A(H1N1),	A(H3N2);	encoding	amino	acids	25	to	38	of	M2	protein).	NA	pyrosequencing	assays	targeted	shorter	regions	that	comprised	a	16bp	region	for	A(H1N1)pmd09	NA	H275Y	assay	(nucleotides	812	to	827;	amino	acids	271	to	275);	and	a		20bp	region	for	influenza	B	NA	D197N	assay	(nucleotides	581	to	600;	amino	acids	195	 to	200).	Pyrosequencing	 runs	were	performed	using	 single	nucleotide	polymorphism	(SNP)	analysis,	with	the	machine	generating	the	nucleotide	dispensation	order	 automatically,	 based	 on	 the	 expected	 sequence.	 Sequencing	 reaction	 occurred	 at	28ºC	by	stepwise	elongation	of	the	primer	upon	cyclic	dispensation	of	the	four	different	dNTPs	in	the	pre-specified	order.	A	limit	of	10%	was	considered	for	SNP	detection.			
3.2.2	Statistical	Analysis		
3.2.2.1	Phenotypic	Neuraminidase	Inhibition	Assays	
	
3.2.2.1.1	Optimal	virus	dilution	and	IC50	determination			Raw	 phenotypic	 NA	 activity	 assay	 data	 was	 analysed	 statistically	 to	 determine	 the	optimal	 virus	 dilution	 to	 be	 used	 in	 following	 NA	 inhibition	 assay	 (dilution	 yielding	35000	 RFUs	 (FL	 assay)	 or	 S/N=40	 (CL	 assay)),	 using	 Microsoft	 Office	 Excel	 2007	(Microsoft	Office	Professional	Edition	2007).	The	mean	value	for	the	blank	buffer	control	wells	 (row	 12)	 was	 calculated	 and	 taken	 from	 each	 data	 point	 (FL	 assay)	 or	 used	 to	divide	each	data	point	(CL	assay).	Data	was	then	plotted	as	RFUs	(FL	assay)	or	RLUs	(CL	assay)	 against	 virus	 dilution,	 yielding	 a	 sigmoid	 dose-response	 curve,	 and	 the	 optimal	virus	dilution	was	determined	by	point-to-point	curve	fitting,	using	the	log10	of	the	virus	dilution	 values.	 Each	 virus	 replicate	 was	 plotted	 independently	 and	 the	 optimal	 virus	dilution	was	determined	for	each	replicate	separately,	taking	the	mean	value	as	the	final	value.	 In	FL	assay,	 this	mean	value	was	 further	divided	by	 two	as	only	half	of	 the	virus	volume	used	in	activity	assay	(20μl)	is	used	in	the	following	inhibition	assay	(10μl).		A	similar	statistical	treatment	was	applied	to	raw	NA	inhibition	assay	data,	plotting	RFU	or	 RLU	 data	 against	 NAI	 drug	 concentration	 and	 using	 the	 log10	 of	 the	 drug	concentration	 values	 for	 point-to-point	 curve	 fitting	 analysis.	 The	 NA	 activity	 given	 by	
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50%	 of	 the	 virus	 control	 value	 (row	 11)	 was	 determined	 and	 used	 as	 cut-off	 for	 IC50	determination.				
3.2.2.1.2	Validation	limits	for	virus	control	performance		Validation	limits	for	virus	control	performance	in	both	NA	activity	and	inhibition	assays	were	established	at	3	 standard	deviations	 (SD)	above	and	below	 the	median,	using	 the	log10	 of	 optimal	 virus	 dilution	 or	 IC50	 value	 in	 all	 calculations.	 The	 limits	 were	established	with	a	minimum	of	10	log10	values	from	10	independent	assays.			
3.2.2.1.3	IC50	Data	Analysis			Log10	IC50	values	were	calculated	and	used	for	determining	upper	and	lower	cut-offs	by	scaled	 median	 absolute	 deviation	 (SMAD)	 robust	 method,	 according	 to	 the	recommendations	of	the	Analytical	Methods	Committee	of	the	Royal	Society	of	Chemistry	10.	Each	cut-off	comprised	two	levels:	a	mild	level,	established	at	1.65	SD	above	(upper)	or	below	 (lower)	 the	median;	 and	 an	 extreme	 level,	 established	 at	 3	 SD	 above	 (upper)	 or	below	 (lower)	 the	median.	 	 Influenza	viruses	 exhibiting	 an	 IC50	 value	 above	and	below	upper	 and	 lower	 mild/extreme	 cut-offs,	 respectively,	 were	 considered	 as	 outlier.	 All	viruses	classified	as	outlier	were	retested	twice	and	the	mean	IC50	was	taken	as	the	final	value.	Once	 identified,	 outlier	 IC50	 values	were	 removed	 from	data	 to	 calculate	 the	 IC50	baseline	median.	 IC50	 cut-offs	 and	baseline	median	were	determined	 for	 each	 influenza	virus	 type	 or	 subtype	 and	 for	 each	 influenza	 season	 or	 time	 period	 (2009	 pandemic	period),	using	a	minimum	of	15	IC50	values	from	different	virus	isolates.	When	less	than	15	 isolates	 were	 assayed,	 IC50	 values	 were	 analysed	 against	 the	 cut-offs	 and	 median	baseline	estimated	for	the	influenza	type	or	subtype-matched	viruses	from	the	previous	or	 following	 influenza	 season.	 Overall	 IC50	 baseline	 median	 was	 determined	 for	 each	influenza	virus	type	or	subtype	and	influenza	B	lineage.	IC50	values	were	further	divided	by	the	baseline	median	to	determine	the	fold	difference	and	classify	the	viruses	according	to	 the	 new	 standardised	 definitions	 for	 reporting	 NAI	 susceptibility	 data	 -	 normal	inhibition	 (NI)	 (fold-change	 increase	 <10	 (influenza	 A)	 or	 <5	 (influenza	 B));	 reduced	inhibition	 (RI)	 (fold-change	 increase	 10-100	 (influenza	 A)	 or	 5-50	 (influenza	 B));	 and	
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highly	 reduced	 inhibition	 (HRI)	 (fold-change	 increase	 >100	 (influenza	 A)	 or	 >50	(influenza	B))	11.	The	 standard	 error	 (SE)	 of	 IC50	 baseline	 (or	 outlier)	 median	 estimates	 was	 calculated	manually	 by	 dividing	 the	 SD	 of	 the	 IC50	 values,	 previously	 determined	 through	 SMAD	statistical	method,	 by	 the	 square	 root	 of	 the	 sample	 size.	 The	 existence	 of	 statistically	significant	differences	among	the	IC50	baseline	(or	outlier)	median	of	circulating	influenza	viruses	over	time,	was	initially	assessed	by	a	Kruskal-Wallis	H	test	and	then,	if	confirmed,	by	 post	 hoc	 pairwise	 comparisons	 using	 Dunn's	 (1964)	 procedure	 with	 a	 Bonferroni	adjustment.	When	at	 least	one	of	the	median	estimates	was	based	on	less	than	5	values	(n<5),	 pairwise	 comparisons	 were	 exceptionally	 performed	 using	 multiple	 Mann-Whitney	U	tests	to	get	the	exact	p-value.	The	Mann-Whitney	U	test	was	also	used	when	only	two	median	estimates	were	available	for	comparison.	The	same	statistical	approach	was	used	to	compare	the	IC50	baseline	median	of	influenza	viruses	from	different	types	or	subtypes/lineages,	either	within	each	influenza	season/time	period	or	during	the	overall	time	 period.	 OS	 and	 ZA	 IC50	 baseline	 median	 estimates	 were	 compared	 through	 a	Wilcoxon	 Signed-Ranked	 test,	 excluding	 all	 non-paired	 IC50	 values	 from	 the	 analysis.	Asymptotic	 (standard)	 and	 exact	 p-values	 were	 considered	 statistically	 significant	 at	≤0.05.	All	statistical	analyses	were	performed	in	SPSS	v22.0	software	(IBM,	Armonk,	New	York,	 USA;	 http://www.ibm.com/software/analytics/spss),	 using	 log10-transformed	non-outlier	IC50	values.					
3.2.2.2	Frequency	of	Influenza	Antiviral	Drug	Prescription			The	 frequency	 of	 influenza	 antiviral	 drug	 prescription	 in	 ILI	 patients	 presenting	 to	healthcare	 systems	 covered	 by	 the	 National	 Influenza	 Surveillance	 Programme	 was	estimated	 for	 the	 2005/2006	 to	 2008/2009	 influenza	 seasons,	 using	 the	 information	available	 in	 ILI	 notification	 forms.	 Estimated	 frequencies	were	 then	 compared	 in	 SPSS	v17.0	 software	 using	 a	 Person	 Chi-Square	 test	 and	 considering	 a	 p-value	 ≤0.05	 for	statistical	significance.			
3.2.3	Bioinformatics		
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3.2.3.1	Sanger	Sequencing			Sequence	trace	files	generated	by	automated	DNA	sequencing	were	viewed	and	checked	for	 size	 and	 quality	 using	 Applied	 Biosystems	 Sequence	 Scanner	 software	 v1.0	(https://products.appliedbiosystems.com).	Once	checked,	trace	files	were	assembled	and	edited	 using	 the	 SeqMan	program	 from	Lasergene	 software	 package	 v7.0.0	 (DNASTAR,	Madison,	 WI,	 USA;	 http://www.dnastar.com),	 to	 obtain	 the	 consensus	 DNA	 protein-coding	sequence.			
3.2.3.2	Alignment	of	Sequences	and	Mutational	Analysis		Sequence	 alignments	were	 performed	 by	 Clustal	W	method	 in	MEGA5	 software	 v5.2.2	(http://www.megasoftware.net),	 including	 sequences	 from	 influenza	 reference	 viruses	retrieved	 from	 GISAID	 EpiFlu™	 or	 NCBI	 Influenza	 Virus	 Resource	 Database.	 Reference	viruses	 included	 the	 vaccine	 viruses	 for	 the	 Northern	 Hemisphere	 2004/2005	 to	2012/2013	influenza	seasons	and	other	reference	viruses	from	the	same	period,	defined	in	the	WHO	reports	for	the	annual	consultations	on	the	composition	of	influenza	vaccines	(available	at	https://www.crick.ac.uk/research/worldwide-influenza-centre/annual-and	-interim-reports/).	Sequences	from	earlier	reference	viruses	(3	to	4	sequences)	were	also	included	 to	 root	 the	 phylogenetic	 trees	 (outgroup)	 and	 provide	 directionality	 to	 the	evolutionary	histories.	Detailed	 information	on	 the	reference	sequences	used,	 including	accession	number,	is	presented	in	the	supplementary	data	of	chapter	4	(Table	S4.2)	and	chapter	 5	 (Table	 S5.2).	 Once	 aligned,	 sequences	were	manually	 checked	 and	 edited	 to	remove	 any	 non-coding	 region,	 and	 were	 further	 translated	 into	 their	 amino	 acid	sequence.	 Amino	 acid	 substitutions	 were	 then	 identified	 against	 the	 corresponding	consensus	 sequence.	 All	 these	 latter	 procedures	 were	 performed	 in	 MEGA5	 software.	Whenever	 possible,	 amino	 acid	 substitutions	were	mapped	onto	 the	 three-dimensional	structure	of	the	protein,	using	PyMOL	software	educational	version	1.3.	Protein	structure	files	were	retrieved	from	the	RCSB	Protein	Data	Bank	(PDB)	(http://www.rcsb.org/pdb).			
3.2.3.3	Phylogenetic	Analysis		
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Phylogenetic	trees	of	the	NA	and	HA	genes	of	each	influenza	virus	type	or	subtype	were	constructed	 by	 maximum-likelihood	 (ML)	 method,	 using	 the	 PhyML3.0	 platform	available	 in	 SeaView	 software	 package	 v.4.4.0	 (http://doua.prabi.fr/software/seaview),	after	 determining	 the	 best-fit	 model	 of	 nucleotide	 substitution.	 This	 model	 was	determined	 in	 jModelTest	 program	 v.2.1.2	 (https://code.google.com/p/jmodeltest2/),	according	 to	Akaike’s	 information	 criterion	 (AIC),	 using	 a	 95%	 confidence	 interval	 and	likelihood	scores	estimated	with	11	substitution	schemes	(88	candidate	models).	Model	selection	was	performed	for	all	different	sets	of	 influenza	virus	type	or	subtype	aligned	sequences.	Based	on	the	results	obtained,	it	was	then	selected	the	best-fit	agreed	model	for	each	gene.	Branch	support	values	were	estimated	by	an	approximate	likelihood-ratio	test	 (aLRT)	 based	 on	 a	 Shimodaira-Hasegawa-like	 procedure	 (aLRT	 (SH-like)).	 Both	subtree-pruning-and-regrafting	 (SPR)	 and	 nearest-neighbour-interchange	 (NNI)	rearrangement	 operations	 were	 selected	 to	 optimise	 tree	 topology,	 using	 10	 random	starting	 trees.	 Once	 constructed,	 ML	 trees	 were	 visualized	 and	 edited	 using	 FigTree	program	v1.4.0	(http://tree.bio.ed.ac.uk/software/figtree/)	and	further	annotated	using	Adobe	Illustrator	CS5	(http://www.adobe.com/products/illustrator.html).				
3.2.3.4	Selective	Pressure	Analysis		The	 worldwide	 NA	 gene	 sequences	 collected	 for	 each	 time	 period	 (detailed	 above	 in	section	 3.1.6),	 were	 subjected	 to	 a	 5-step	 sequence	 treatment	 that	 included:	 (1)	identifying	the	sequences	shared	by	GISAID	EpiFlu™	and	NCBI	Influenza	Virus	Resource	databases	 and	 the	 sequences	 repeated	 within	 each	 one;	 (2)	 removing	 the	 shared	sequences	 from	 one	 of	 the	 source	 files	 using	 MEGA5	 software;	 (3)	 merging	 the	 three	sequence	 source	 files	 (GISAID,	 NCBI,	 Portugal)	 available	 for	 each	 time	 period	 and	influenza	 virus	 subtype	 or	 lineage,	 aligning	 the	 sequences	 by	 Clustal	 W	 method	 and	removing	all	sequences	containing	gaps	or	with	a	not	complete	coding	region	in	MEGA5;	(4)	 removing	 redundant	 sequences	 (100%	 threshold)	 and	 sequences	 containing	degenerate	 or	 untranslatable	 nucleotides,	 using	 Jalview	 program	 v2.8	(http://www.jalview.org);	and	(5)	removing	the	repeated	sequences	initially	identified	if	still	 present	 in	 the	 final	 sub-dataset,	 using	 MEGA5.	 An	 additional	 step	 was	 performed	between	steps	2	and	3	 for	 the	 influenza	B	NA	sequences	retrieved	 from	NCBI	 Influenza	Virus	 Resource	 database,	 as	 no	 lineage	 information	 was	 available	 for	most	 sequences.	
Material	and	Methods	|	90	
	
The	 sequences	 were	 aligned	 with	 B/Victoria	 and	 B/Yamagata-lineage	 reference	sequences	by	Clustal	W	method	in	MEGA5.	Reference	sequences	were	selected	according	to	 the	 WHO	 annual	 reports	 (see	 section	 3.2.3.2)	 and	 retrieved	 from	 GISAID	 EpiFlu™	database.	A	ML	phylogenetic	tree	was	then	constructed	as	described	in	previous	section	3.2.3.3	and	a	B	lineage	was	assigned	to	each	virus	sequence,	according	to	its	position	on	the	 tree.	 Total	 sequence	 datasets	 were	 constructed	 by	 merging	 treated	 temporal	 sub-datasets.	A	sequence	similarity	threshold	of	99.99%	was	further	applied	to	A(H3N2)	and	A(H1N1)pdm09	datasets	to	reduce	the	number	of	total	sequences	to	below	4000,	which	was	 the	 limit	 of	 the	 program	 later	 used	 for	 SP	 analysis.	 Sequence	 reduction	 was	performed	using	 the	CD-HIT-EST	program	 from	CD-HIT	 software	package,	 available	 on	the	web	server	CD-HIT	Suite	(http://weizhong-lab.ucsd.edu/cdhit_suite).	Sequence	diversity	 (number	of	base	 substitutions	per	 site	 from	a	mean	of	 all	 sequence	pairs)	was	 estimated	 by	Maximum	 Composite	 Likelihood	method	 in	MEGA5,	 using	 the	standard	gamma	distribution	(shape	parameter	=	1.327)	of	rate	variation	among	sites.	A	total	of	500	bootstrap	replications	were	used	to	estimate	the	associated	standard	error.	The	 presence	 of	 potential	 recombination	 breakpoints	 was	 further	 analysed	 in	 total	sequence	 datasets	 by	 genetic	 algorithm	 recombination	 detection	method,	 using	 HyPhy	software	v2.2	(http://hyphy.org;	SingleBreakpointRecomb.bf	batch	 file).	Since	no	single	phylogenetic	tree	can	accurately	describe	the	evolutionary	relationships	of	recombinant	sequences,	it	was	important	to	ruled	out	or	accounted	for	recombination	as	its	presence	could	mislead	inferences	of	selection	12.	ML	phylogenetic	trees	were	inferred	as	described	in	section	3.2.3.3,	selecting	the	best-fit	model	 of	 nucleotide	 substitution	 based	 on	 seasonal	 A(H1N1)	 total	 sequence	 dataset.	Phylogenetic	 trees	 of	 sequence	 alignments	 with	 more	 than	 3000	 sequences	 were	exceptionally	inferred	in	RAxML	version	8,	using	standard	nonparametric	bootstrap	(500	replicates)	for	estimating	branch	support	values.	All	SP	analyses	were	carried	out	in	HyPhy	software,	after	determining	the	time-reversible	model	that,	composed	with	Muse-Gaut	94	model,	resulted	in	the	best-fit	codon	model	for	influenza	NA.	Model	 selection	was	 performed	 by	 analysing	 the	 seasonal	 A(H1N1)	 total	sequence	 dataset	 through	 CodonModelCompare.bf	 procedure,	 using	 AIC.	 SP	 analyses	included:	(1)	estimating	the	global	ratio	between	non-synonymous	(dN)	and	synonymous	(dS)	substitution	rates		(dN/dS	ratio)	with	95%	confidence	intervals,	using	the	standard	AnalyzeCodonData.bf	 procedure;	 (2)	 estimating	 the	 site-specific	 dN/dS	 ratios	 and	identifying	the	sites	under	positive	selection	by	both	single-likelihood	ancestor	counting	
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(SLAC)	 and	 two	 rate	 fixed	 effects	 likelihood	 (FEL)	 methods,	 available	 in	QuickSelectionDetection.bf	batch	 file;	 and	 (3)	 identifying	 the	 codons	under	different	 SP	among	 the	 different	 time	 periods	 studied	 (differential	 selection	 analysis),	 	 using	 the	CompareSelectivePressure.bf	 procedure.	 A	 significance	 level	 of	 ≤0.05	 was	 set	 for	 all	analyses.	 Positively	 selected	 sites	 were	 further	 mapped	 onto	 the	 three-dimensional	structure	 of	 the	 influenza	 NA	 subtype	 or	 lineage	 in	 which	 were	 detected,	 using	 the	methodology	previously	described	for	amino	acid	substitutions	(see	section	3.2.3.1).			
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Table	S3.1	Primer	set	used	for	full-length	amplification	and	sequencing	of	the	neuraminidase	gene	of	former	seasonal	A(H1N1),	A(H3N2)	and	influenza	B	viruses.		
				
		
		
			
bp:	base	pairs;	Fw:	Forward;	Rev:	Reverse	The	x	indicates	in	which	procedure	the	primer	was	used.				
Table	S3.2	Primer	set	used	for	amplification	and	sequencing	of	the	HA1	domain	of	the	hemagglutinin	gene	of	former	seasonal	A(H1N1),	A(H3N2)	and	influenza	B	viruses.									
	bp:	base	pairs;	Fw:	Forward;	Rev:	Reverse	a	Maximum	length	for	sequence	readings	with	good	quality	The	x	indicates	in	which	procedure	the	primer	was	used.				
Designation Direction Sequence/(5´3/3´) Amplification Sequencing Amplicon SequenceAH3G Fw AAGCAGGGGATAATTCTATT x x ≈700/aAH3CII Rev GCTTCCATTTGGAGTGATGC x x ≈700/aAH3B Fw AGCAAAGCTTACAGCAACTG x x ≈700/aAH3I Rev TCCCTCCCAACCATTTTCCTA x x ≈700/aAH1G Fw AAGCAGGGGAAAATAAAAAC x x ≈700/aAH1H Rev CCATCCATCTATCATTCCAG x x ≈700/aAH1M Rev TGATGCGTTTGAGGTGATGAT x 3 ≈700/aBHAE Fw GAAGCAGAGCATTTTCTAAT x x ≈700/aBHAG Rev ATCATTCCTTCCCATCCTCC x x ≈700/aBHAB35 Fw GCACGACAGAACAAAAAT x 3 ≈700/a
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EXPECTED/SIZE/(bp)
932
B 3
A
PROCEDUREInfluenza/virus/type/subtype Segment
B
3
Designation Direction Sequence/(5´3/3´) Amplification Sequencing Amplicon SequenceNA231 Fw AGCAAAAGCAGGAGTAAAGAT x x 515NA23515 Rev GAACACCCAAYTCATTCATCAATA x x 515NA23386 Fw TCATGCGATCCTGACAART x x 579NA23964 Rev ACTGGAAACAATGCTATAATCCTT x x 579NA23770 Fw GATACTAAAATACTATTCATTGAG x x 698NA231467 Rev AGTAGAAACAAGGAGTTTTT x 3NA231001 Fw AAAAACGACAGCTCCAG x 3 467NA131 Fw AGCAAAAGCAGGAGTTTA x x 659NA13659 Rev AGTTATTATKCCGTTGTATTTTAG x 3NA13452 Rev ATGTTTGTCATTTAATAGAGCA x 3 452NA13351 Fw AAAGGAGATGTTTTTGTCATA x 3 309NA13535 Fw CAAAGTTTGAATCAGTTGC x x 494NA131028 Rev ATTACAGCTGCCCTYTCCATCTTT x x 494NA13888 Fw TGTGTATGCAGGGACAACT x x 576NA131463 Rev AGTAGAAACAAGGAGTTTTT x 3NA131104 Fw ACTAAAAGTAACAGACTTAGAAAG x 3 3601B Fw CCAAAATGAACAATGCTACC x x 653653B Rev TATGTGTCAGTRTATGCTTCTCCA x x 653359B Rev CTTATTATCAAGGGAGCTGAGTTT x 3 359495B Fw RGGCAAAATMCCAACAGTAG x x 5451039B Rev TGTYCCCATTAGATTCRCAAG x x 545857B Fw CYAGCAATAAAACCATAGAATGTG x x 6071463B Rev TCAAACAAAATAGGAACAAAG x 31107B Fw CTCTCGAACRATGTCTAAAACYAA x 3 357
N132 494
N133
B
B31 653
B32 545
B33 607
576
Influenza/virus/type/subtype Segment PRIMER EXPECTED/SIZE/(bp)
A(H3N2)
N2/3/1 515
N2/3/2 579
PROCEDURE
N233 698
A(H1N1)
N131 659
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Table	 S3.3	 Primer	 set	 used	 for	 amplification	 and	 sequencing	 of	 all	 genome	 segments	 except	 NA	 of	former	 seasonal	 A(H1N1),	 A(H3N2)	 and	 influenza	 B	 viruses,	 with	 	 indication	 of	 the	 corresponding	annealing	temperatures.		
						
Designation DIR Sequence0(5´403´) AMP Ta0(ºC) SEQ Amplicon SequenceBm4PB241 Fw TATTGGTCTCAGGGAGCRAAAGCAGGTC x 4HPB2R960 Rev GCATATRTCCACAGCTTGTTCTTC x x ≈7000aHPB2R421 Rev GGCCAAAGGTTCCATGTTTTAACC 4 x 4 435A(H3N2)0(amp)0000type0A0(seq) HPB2F841 Fw GTATCAGCAGATCCACTAGCATCT x x 619A(H1N1) HPB2F398 Fw GGTTAAAACATGGAACCTTTGGCC x 4type0A HPB2R1459 Rev TCCTCTCATTGACATCTC x 4PB241105F Fw TAYGARGARTTCACAATGGT x x ≈7000aBm4PB242341R Rev ATATGGTCTCGTATTAGTAGAAACAAGGTCGTTT x 4HPB2F1441 Fw GAGATGTCAATGAGAGGA 4 x 4 ≈7000aHPB2F1785 Fw GGCCATTAGAGGCCAATACAGTGG 4 x 4 557Bm4PB141 Fw TATTGGTCTCAGGGAGCRAAAGCAGGCA x x ≈7000aPB141262R Rev TTRAACATGCCCATCATCAT x 4HPB1F370 Fw CAAACAAGGGTGGACAAACT 4 x 4 ≈7000aHPB1R389 Rev AGTTTGTCCACCCTTGTTTG 4 x 4 403PB141123F Fw CARATACCNGCAGARATGCT x x ≈7000aBm4PB142341R Rev ATATGGTCTCGTATTAGTAGAAACAAGGCATTT x 4HPB1F1711 Fw AGAGGWGACACACAAATWCA 4 x 4 647Bm4PA41 Fw TATTGGTCTCAGGGAGCRAAAGCAGGTAC x x ≈7000aPA41498R Rev TNGTYCTRCAYTTGCTTATCAT x 4HPAF597 Fw TCGTCAGTCCGAAAGAGGCGAAGA 4 x 4 ≈7000aHPAR620 Rev TCTTCGCCTCTTTCGGACTGACGA 4 x 4 634HPAF960 Fw AACATTCTTTGGATGGAAAGAACC x x ≈7000aBm4PA42233R Rev ATATGGTCTCGTATTAGTAGAAACAAGGTACTT x 4HPAF1435 Fw AATGCATCCTGTGCAGCAATGGA 4 x 4 ≈7000aHPAF1801 Fw GAGAGCATGATTGAAGCYGAGTCC 4 x 4 448type0A HAFUc Fw TATTCGTCTCAGGGAGCAAAAGCAGGGG x 4A(H3N2) H3HAR650 Rev TTGGTCACTGTCCGTACTCGGGTG x x 664A(H1N1) H1HAR1087 Rev AAACCGGCAATGGCTCCAAA x x ≈7000aA(H1N1) H1HAR623 Rev GATGAACACCCCATAGTACAAGGA 4 x 4 637A(H3N2) H3HAF567 Fw CTGAACGTGACTATGCCAAACAAT x x ≈7000aA(H1N1) H1HAF552 Fw TACCCAAACCTGAGCAAGTCCTAT x x ≈7000atype0A HARUc Rev ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT x 4A(H3N2) H3A2F1 Fw AGGCATATTCGGCGCAATCGCAGG 4 x 4 ≈7000aA(H1N1) H1HA2F1 Fw ACATCCCATCCATTCAATCCAGAG 4 x 4 ≈7000aNPFUc Fw TATTCGTCTCAGGGAGCAAAAGCAGGGTWRATAATC x x ≈7000aNPRUc Rev ATATCGTCTCGTATTAGTAGAAACAAGGGTAWTTTT x 4HNPR509 Rev ACAAGAGCTCTTGTCCTCTGGTA 4 x 4 523NPUF525448 Fw CCCAGRATGTGYTCYYTRATGCA 4 x 4 ≈7000aHNPF986 Fw CCTAATCAGACCDAACGAGAATCC 4 x 4 595MFUc Fw TATTCGTCTCAGGGAGCAAAAGCAGGTAGA x 4MRUc Rev ATATCGTCTCGTATTAGTAGAAACAAGGTAGTTTTT x x ≈7000aHMR400 Rev GGCAAGTGCACCAGCAGAATA 4 x 4 414HMF581 Fw GCTAAGGCTATGGAGCAAATGGCT 4 x 4 462NSFUc Fw TATTCGTCTCAGGGAGCAAAAGCAGGGTG x x ≈7000aNSRUc Rev ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTTTT x 4HNSF481 Fw GAAGAGGGAGCAATTGTTGGCGAA 4 x 4 425HNSR504 Rev TTCGCCAACAATTGCTCCCTCTTC 4 x 4 518
PB241(
B) 49 6190(H3N2)010620(H1N1)
PB242 520(H3N2)0550(H1N1) 1252
Segment PRIMER PROCEDURE EXPECTED0SIZE0(bp)
IN
FL
U
EN
ZA
)A
PB2
PB241(A) 580(H3N2)000550(H1N1) 974
PA
PA41 550(H3N2)0520(H1N1) 1512
PA42(B) 550(H3N2)0520(H1N1) 1289
PB1 PB141
550(H3N2)0580(H1N1) 1276
PB142 520(H3N2)0550(H1N1) 1234
NP 4
580(H3N2)0550(H1N1) 1594
M 4 580(H3N2)0600(H1N1) 1056
HA
HA41 550(H3N2)0520(H1N1) 6640(H3N2)011010(H1N1)
HA42
550(H3N2)0520(H1N1) 12110(H3N2)012390(H1N1)
NS 4 550(H3N2)0580(H1N1) 919
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	(Table	S3.3	cont.)											
	AMP:	Amplification;	bp:	base	pairs;	DIR:	Direction;	Fw:	Forward;	Rev:	Reverse;	SEQ:	sequencing;	Ta:	annealing	temperature	a	Maximum	length	for	sequence	readings	with	good	quality	The	x	indicates	in	which	procedure	the	primer	was	used.						
Designation DIR Sequence0(5´403´) AMP Ta0(ºC) SEQ Amplicon SequenceBPB2F1U Fw TATTCGTCTCAGGGAGCAGAAGCGGAGCGTTTTCAAGATG x x ≈7000aBPB2R1233 Rev CCTAGTGTCTTGAGAAAATACCAT x x ≈7000aBPB2_177R Rev ATGTCACCCTTGGTYARAGC 4 x 4 191BPB2F1102 Fw ATACAGAARATTGGAATATGGCA x 4BPB2_1670R Rev CTGAGCCTTCAGTGTTACCAAA x x 569BPB2_1385F Fw ATCACCCAAAGCAAGTGARC x x ≈7000aBPB2REU Rev ATATCGTCTCGTATTAGTAGAAACACGAGCATTTTTCAC x 4BPB2_1875F Fw TTGCCCTTTTGTTTCTCACC 4 x 4 451BPB1F1U Fw TATTCGTCTCAGGGAGCAGAAGCGGAGCCTTTAAGATG x 4BPB1R1255 Rev CATATTAAACATTCCCATCATCAT x 4BPB1_351F Fw TGGAGGCACTAATGGTCACA 4 x 4 ≈7000aBPB1_854F Fw GAAGGCCAAACTGTCAAAYGC 4 x 4 402BPB1_687R Rev TAGTTTGCCCCTTTCAGCRT 4 x 4 701BPB1F1031 Fw ACCAGAGACAGCCCAATTTGGTT x 4BPB1REU Rev ATATCGTCTCGTATTAGTAGAAACACGAGCCTTTTTTCA x 4BPB1_1357F Fw TTGCTCTGTTTGTTAATGCAAAA 4 x 4 ≈7000aBPB1_1881F Fw GGCGATTACTTCACCCTCAA 4 x 4 422PPB1_1669R Rev CTCCTCTGTGGCATTTGTAG 4 x 4 639BPAF1U Fw TATTCGTCTCAGGGAGCAGAAGCGGTGCGTTTGATTTG x 4BPAR1392 Rev GTGTGRAAAAGYACATACTTCATCAT x 4BPA_330F Fw CCAAAGTATCTGGCTGATTTG 4 x 4 ≈7000aBPA_642R Rev GGAGAAACCAGCTGGAACAG 4 x 4 657BPA_803F Fw AAGACCAATAGGGCCTCACA x 4BPAREU Rev ATATCGTCTCGTATTAGTAGAAACACGTGCATTTTTRAT x 4BPA_1308F Fw CCGTGGAGCATGTAGGGAGT 4 x 4 ≈7000aBPA_1816F Fw TGACCAAAGCTTGTTTCAAGG 4 x 4 459BPA_1631R Rev TTTTCCCTCCCACTCACAAA 4 x 4 ≈7000aBHAF1U Fw TATTCGTCTCAGGGAGCAGAAGCAGAGCATTTTCTAATATC x x ≈7000aBHA_1168R Rev ACTGCYACTCCATGTGCYC x x ≈7000aBHA_680R Rev CTCCATTRGCAGATGAGGTGAA 4 x 4 694BHA_868F Fw GTTGCCTCAAAAGGTGTGGT x x ≈7000aBHAREU Rev ATATCGTCTCGTATTAGTAGTAACAAGAGCATTTTTCAAT x x ≈7000aBNPF1U Fw TATTCGTCTCAGGGAGCAGAAGCASAGCATTTTCTYGTG x 4BNP_619R Rev GCCTTTGATCTTTGGAAACAG x x 633BNP_308F Fw GGACTCAACGATGACATGGA x x ≈7000aBNP_1633R Rev CTGTGTCCCTCCCAAAGAAG x 4BNP_805F Fw GGCAGACAGAGGGCTATTGA 4 x 4 ≈7000aBNP_1320F Fw TGATGTCCATCAAGCTCCAG x x 570BNPREU Rev ATATCGTCTCGTATTAGTAGAAACAACAGCATTTTTTACA x 4BMF1U Fw TATTCGTCTCAGGGAGCAGAAGCASGCACTTTCTTAARATG x 4BM_564R Rev TCCTTTTCCCATTCCATTCA x x 578BM_256F Fw CACAGAGCCCCTATCAGGAA x x ≈7000aBMREU Rev ATATCGTCTCGTATTAGTAGAAACAACGCACTTTTTCCAG x 4BM_768F Fw TGCTCGAACCATTTCAGATTC 4 x 4 469BNSF1U Fw TATTCGTCTCAGGGAGCAGAAGCAGAGSATTTGTTTAGTC x 4BNSREU Rev ATATCGTCTCGTATTAGTAGTAACAAGAGGATTTTTATT x 4BNS_203F Fw TCACAACAAAAGTGAGCCTGA 4 x 4 ≈7000aBNS_727F Fw CCATCGGATCCTCAACTCAC 4 x 4 417BNS_512R Rev CGTATATCCCTTTTTATTGTCAAACG 4 x 4 526
Segment PRIMER PROCEDURE EXPECTED0SIZE0(bp)
IN
FL
U
EN
ZA
)B
PB2
PB241 55 1247
PB242(A) 49 569
PB242(B) 55 941
55 1272
PA
PA41 55 1406
PA42(B) 49 1472
PB1
PB141 58 1269
PB142
HA HA(A) 49 1182HA(B) 52 1062
NP
NP(A) 55 633
NP(B) 49 1326
NP(C) 52 570
NS 4 55 1157
M M(A) 49 578M(B) 55 981
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Table	S3.4	Primer	set	used	for	amplification	of	influenza	A(H1N1)pdm09	virus	genome	segments.		
	bp:	base	pairs	The	 M13-forward	 or	 M13-reverse	 universal	 primer	 sequence	 (18-nucleotide	 length)	 included	 in	 the	 sequence	 of	 each	amplification	primer	is	indicated	in	italic	and	dark	grey.				
Table	S3.5	Primer	set	used	for	amplification	and	pyrosequencing	of	 the	 influenza	A	virus	M2	protein	region	 associated	with	M2	 inhibitor	 resistance	 (M	 gene)	 and	 of	 the	 A(H1N1)pdm09	 and	 influenza	 B	virus	 neuraminidase	 region	 including	 amino	 acid	 positions	 275	 (H275Y)	 and	 197	 (D197N),	respectively.												bp:	base	pairs	The	primers	 labelled	with	 a	 biotin	molecule	 at	 their	 5´end	 are	 indicated	with	 an	 asterisk	 (*).	 The	direction	of	 the	 sequencing	primers	is	indicated	under	brackets	after	their	designation.	
Designation Sequence.(5´2.3´)M2.Forward CAGATGCARCGATTCAGTGM2.Reverse.* AGTAGAAACAAGGTAGTTTTTTACTCM2.Sequencing.(forward) CAGATGCAGCAATTCAGTG 2PanSwH1N1.275Forward.* GGGAAAGATAGTCAAATCAGTCGAPanSwH1N1.275Reverse TAGACGATACTGGACCACAACTGPanSwH1N1.275.Sequencing.(reverse) CAGGAGCATTCCTCA 2B.1972221.Forward TTCAGTCAAATTGGGCAAAATCB.1972221.Reverse.* AGCTGGGCCATCAGTTATCATAAGB.1972221.Sequencing.(forward.) GGACATATATCGGAGTTG 2
A
NA
264
Expected.size.amplicon...(bp)
242
M
242
PRIMER
B
Gene.segment Influenza.virus.type/subtype
A(H1N1)pdm09
Designation Sequence.(5´2.3´) Designation Sequence.(5´2.3´)1 1 TGTAAAACGACGGCCAGTCTCGAGCAAAAGCAGGTCAA 575 CAGGAAACAGCTATGACCYAGCTGTGAYTCYGATGT 6113 487 TGTAAAACGACGGCCAGTCCTGGTCAYGCAGACCTCAG 1019 CAGGAAACAGCTATGACCCCAAARCTGAAGGAYGARCTGAT 5695 946 TGTAAAACGACGGCCAGTCCRACWGAAGAACAAGCTGT 1509 CAGGAAACAGCTATGACCGGAGTATTCATCYACACCCAT 6007 1447 TGTAAAACGACGGCCAGTCCAAGYACMGAGATGTCAATGAGA 2186 CAGGAAACAGCTATGACCTTRCTCARTTCATTGATGCT 7768 1683 TGTAAAACGACGGCCAGTCAACACTTATCAATGGATAAT 2341 CAGGAAACAGCTATGACCTAGTAGAAACAAGGTCGTT 6951 22 TGTAAAACGACGGCCAGTAGCAAAAGCAGGCAAACCAT 534 CAGGAAACAGCTATGACCTCTATTAGCCTCCCWGAYTCATT 5493 389 TGTAAAACGACGGCCAGTACAAGRGTGGACAAATRAC 1041 CAGGAAACAGCTATGACCCTGAACCAYTCAGGYTGATTT 6895 974 TGTAAAACGACGGCCAGTAATCAAAAYCCTMGAATGTT 1566 CAGGAAACAGCTATGACCAGCTCCATGCTRAAATTRGC 6297 1489 TGTAAAACGACGGCCAGTATGAGYAAAAAGAAGTCYTA 1954 CAGGAAACAGCTATGACCTCAATYTCYTTATGGCTGAC 5028 1532 TGTAAAACGACGGCCAGTGCYAATTTYAGCATGGAGCT 2321 CAGGAAACAGCTATGACCAGTAGAAACAAGGCATTT 8261 0 TGTAAAACGACGGCCAGTAGCAAAAGCAGGTACTGAT 493 CAGGAAACAGCTATGACCTAGTCSGCCTTTGTGGCCATYTC 5293 361 TGTAAAACGACGGCCAGTTATGAYTACAARGAGAA 989 CAGGAAACAGCTATGACCGGTTCTTTCCATCCAAAGAATGTT 6655 894 TGTAAAACGACGGCCAGTAAATTRAGCATTGARGAYCCG 1662 CAGGAAACAGCTATGACCTCWAGTCTYGGGTCAGTGAG 8057 1444 TGTAAAACGACGGCCAGTAATGCATCCTGTGCAGCAATGGA 2057 CAGGAAACAGCTATGACCTTGTCCCTAAGAGCCTGAACAA 6508 1787 TGTAAAACGACGGCCAGTATGAARTGGGGAATGGAGATGAG 2233 CAGGAAACAGCTATGACCAGTAGAAACAAGGTACCTTTT 4831 1 TGTAAAACGACGGCCAGTATACGACTAGCAAAAGCAGGGG 461 CAGGAAACAGCTATGACCTCATGATTGGGCCAYGA 4972 351 TGTAAAACGACGGCCAGTACRTGTTACCCWGGRGATTTCA 943 CAGGAAACAGCTATGACCGAAAKGGGAGRCTGGTGTTTA 6294 736 TGTAAAACGACGGCCAGTAGRATGRACTATTACTGGAC 1340 CAGGAAACAGCTATGACCTTCTKCATTRTAWGTCCAAA 6236 1204 TGTAAAACGACGGCCAGTAAGATGAAYACRCARTTCACAG 1778 CAGGAAACAGCTATGACCGTGTCAGTAGAAACAAGGGTGTTT 5931 1 TGTAAAACGACGGCCAGTCAGGGTAGATAATCACTCAC 553 CAGGAAACAGCTATGACCAGAGCACATYCTGGGATCCAT 5893 513 TGTAAAACGACGGCCAGTTGGCATTCHAATTTRAATGAT 1042 CAGGAAACAGCTATGACCCTGRCTCTTGTGTGCDGG 5665 872 TGTAAAACGACGGCCAGTTTCTGAGRGGRTCAGTTGCTC 1565 CAGGAAACAGCTATGACCAGTAGAAACAAGGGTATTTTTC 7301 0 TGTAAAACGACGGCCAGTAGCAAAAGCAGGAGT 600 CAGGAAACAGCTATGACCCTGGACCRGAAATTCC 636223 318 TGTAAAACGACGGCCAGTTACACAAAAGACAAYAGC 1063 CAGGAAACAGCTATGACCCATATYTGTATGAAAACC 782425 726 TGTAAAACGACGGCCAGTAATGGRCARGCCTCRTACAA 1452 CAGGAAACAGCTATGACCAGTAGAAACAAGGAG 7621 0 TGTAAAACGACGGCCAGTAGCAAAAGCAGGTAG 473 CAGGAAACAGCTATGACCGCAATCTGYTCACAKGT 5092 223 TGTAAAACGACGGCCAGTCACCGTGCCCAGTGAGCG 750 CAGGAAACAGCTATGACCTCAYTTGAAYCGYTGCAT 5643 383 TGTAAAACGACGGCCAGTTCTGCTGGWGCACTTGCCAGTTG 1027 CAGGAAACAGCTATGACCAGTAGMAACAAGGTAGT 6811 24 TGTAAAACGACGGCCAGTAGCAAAAGCAGGGTGACAAAGACA 482 CAGGAAACAGCTATGACCTCGGTGAAAGCCCTTA 4952 250 TGTAAAACGACGGCCAGTTGAGGCWYTTAAAATGACCA 890 CAGGAAACAGCTATGACCAGTAGAAACAAGGGTGTTTTTTAT 677NS
Segment
PB1
PA
HA
NP
NA
M
FORWARD.PRIMER REVERSE.PRIMER Expected.size.amplicon......(bp)
PB2
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																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	101												I	 carried	 out	 most	 activities,	 methodologies	 and	 data	 analysis	 underlying	 the	 results	 presented	 in	 this	chapter.	A	 low	percentage	(about	20%)	of	 the	 influenza	A(H1N1)pdm09	virus	M	gene	sequences	used	 for	genotypic	evaluation	of	M2	inhibitor	susceptibility	were	obtained	by	a	team	colleague,	in	the	context	of	the	study	developed	for	whole-genome	characterization	of	the	newly	emerging	pandemic	virus.	The	phenotypic	susceptibility	 profile	 of	 former	 seasonal	 A(H1N1),	 A(H3N2)	 and	 influenza	 B	 viruses	 from	 2004/2005	 to	2008/2009	to	zanamivir	was	essentially	determined	by	Mafalda	Uva,	in	the	context	of	her	Master´s	thesis	in	Applied	Microbiology	 (Faculdade	 de	 Ciências,	 Universidade	 de	 Lisboa).	 A	 team	 colleague	 carried	 out	 the	chemiluminescent	 NA	 inhibition	 assays	 necessary	 for	 confirming	 the	 fluorescent-based	 phenotypic	susceptibility	profile	of	a	limited	number	of	viruses	from	2004/2005	to	2007/2008	to	oseltamivir.	The	same	colleague	 also	 sequenced	 the	 HA1	 subunit	 of	 the	 HA	 protein	 of	 the	 phenotypic	 outlier	 viruses	 from	2004/2005	to	2008/2009.	Some	NA	and	HA	sequences	of	non-outlier	 former	seasonal	A(H1N1),	A(H3N2)	and	 influenza	 B	 viruses	 from	 2004/2005	 to	 2006/2007	 (retrospective	 analysis)	 were	 available	 in	 the	laboratory	sequence	database,	having	been	obtained	to	study	the	evolutionary	dynamics	of	 the	two	major	influenza	virus	antigens.	The	NA	and	HA	sequences	of	the	non-outlier	A(H1N1)pdm09	viruses	from	2009	to	2010/2011	were	obtained	by	me	and	two	other	colleagues	in	the	context	of	the	study	developed	for	whole-genome	 characterization	 of	 the	 pandemic	 virus.	 Lastly,	 the	NA	 and	HA	 sequences	 of	 the	 A(H1N1)pdm09	virus	population	present	 in	 the	 three	respiratory	specimens	(one	 from	before	and	two	from	after	starting	antiviral	 therapy)	 were	 obtained	 by	 João	 Louro	 in	 the	 context	 of	 his	 Master´s	 thesis	 in	 Pharmaceutical	Sciences	 (Faculdade	 de	 Farmácia,	 Universidade	 de	 Lisboa).	 This	 sequencing	 work	 was	 performed	 at	 the	Public	Health	England	(Colindale,	London,	United	Kingdom).									 FCG-funded	research	projects	“Vigilância	e	Monitorização	da	Susceptibilidade	aos	Antivirais	Específicos	para	a	Gripe”	(FCG	76676)	“Avaliação	e	Caracterização	da	Emergência	das	Resistências	aos	Antivirais	Específicos	para	a	Gripe	no	Contexto	da	
Infecção	Respiratória	Aguda”	(SDH49;	ACSS	reinforcement	grant)		
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4	 PHENOTYPIC	 AND/OR	 GENOTYPIC	 ANTIVIRAL	 SUSCEPTIBILITY	 PROFILES	 OF	
HUMAN	INLUENZA	VIRUSES	CIRCULATING	IN	PORTUGAL		
	
	
“Then	there	is	the	danger	that	the	ignorant	man	may	easily	underdose	himself	and	by	exposing	his	
microbes	to	non-lethal	quantities	of	the	drug	make	them	resistant.”	Alexander	Fleming,	Penicillin,	Nobel	Lecture,	December	11,	1945			In	 this	 chapter	 are	 presented	 and	 discussed	 the	 results	 of	 the	 antiviral	 susceptibility	testing	performed	on	human	influenza	viruses	circulating	in	Portugal	from	2004/2005	to	2012/2013	seasons,	 in	both	community	and	hospital	settings	(1st	general	objective;	see	section	 2.2,	 Study	 Description).	 Virus	 susceptibility	 to	 M2	 protein	 inhibitors	 (herein	designated	as	M2	inhibitors;	amantadine	(AMA)	and	rimantadine	(RIM))	was	determined	by	genotypic	 testing,	while	a	 combined	 laboratorial	approach	 involving	phenotypic	and	genotypic	 testing	 was	 used	 to	 evaluate	 the	 susceptibility	 to	 the	 neuraminidase	 (NA)	inhibitors	(NAIs)	oseltamivir	(OS)	and	zanamivir	(ZA).				The	 main	 activities	 carried	 out	 during	 this	 study	 are	 summarized	 below	 for	 a	 better	understanding	of	the	underlying	work.	
														
BOX	4.1	-	MAIN	ACTIVITIES	
• Implementation	 of	 fluorescent	 MUNANA-based	 and	 chemiluminescent	 NA-Star®	 kit	 NA	inhibition	assays.	
• Implementation	 of	 Sanger	 sequencing	 protocols	 targeting	 the	 M2	 and	 HA	 coding	 regions	 of	former	 seasonal	 A(H1N1),	 A(H3N2)	 and	 influenza	 B	 viruses	 (integrated	 in	 whole-genome	sequencing	protocol	implementation).		
• Isolation	and/or	propagation	of	human	influenza	viruses	in	MDCK	or	MDCK-SIAT1	cells.		
• M2	 gene	 pyrosequencing	 or	 Sanger	 sequencing	 of	 circulating	 human	 influenza	 A	 viruses,	followed	by	screening	of	the	7	established	molecular	markers	of	M2	inhibitor	resistance	(L26F,	V27A,	A30T/V,	S31N/D,	G34E)	in	the	M2	protein	sequences.	
• Determination	 of	 the	 OS	 and	 ZA	 IC50	 values	 of	 circulating	 human	 influenza	 viruses	 by	fluorescent	MUNANA-based	assay.	
• Statistical	determination	of	OS	and	ZA	IC50	cut-offs,	baseline	median	and	fold-change	thresholds,	for	each	influenza	virus	type	or	subtype	and	influenza	season/pandemic	period.	
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4.1	RESULTS		The	 results	 are	organized	 in	5	main	 sub-sections	as	 follows:	 (1)	 technological	platform	for	evaluation	of	antiviral	susceptibility;	(2)	target	population	and	study	sample;	(3)	M2	inhibitor	susceptibility	 testing;	 (4)	oseltamivir	and	zanamivir	susceptibility	 testing;	and	(5)	antiviral	prescription	on	influenza-like	illness	patients	(complementary	study).				 		
4.1.1	Technological	Platform	for	Evaluation	of	Antiviral	Susceptibility			A	technological	platform	for	comprehensive	evaluation	of	influenza	virus	susceptibility	to	the	three	antivirals	licensed	in	Portugal	for	clinical	use	-	AMA	(M2	inhibitor)	and	OS	and	ZA	 (NAIs),	 was	 designed	 in	 late	 2007	 according	 to	 the	 approaches	 and	methodologies	recommended	by	the	 former	European	Surveillance	Network	 for	Vigilance	against	Viral	
BOX	4.1	-	MAIN	ACTIVITIES	(cont.)	
• Identification	of	the	OS	and	ZA	IC50	outlier	viruses	and	of	the	viruses	exhibiting	(highly)	reduced	inhibition	to	OS	and/or	ZA	in	vitro.	
• Confirmation	 of	 fluorescent-based	 NAI	 susceptibility	 phenotypes	 by	 chemiluminescent	 assay	(carried	out	for	a	limited	number	of	viruses).	
• NA	 and	 HA	 gene	 sequencing	 of	 IC50	 outlier	 viruses	 and	 of	 further	 viruses	 recovered	 from	patients	during	or	after	antiviral	therapy,	and	of	≈25%	of	the	non-outlier	type/subtype-matched	viruses	from	the	same	influenza	season/pandemic	period.	
• Identification	of	the	NA	and/or	HA	amino	acid	substitutions	specific	of	IC50	outlier	viruses	and	of	further	 viruses	 recovered	 from	 patients	 during	 or	 after	 antiviral	 therapy,	 followed	 by	 their	characterization	 regarding	 association	 to	 NAI	 resistance	 or	 decreased	 susceptibility	 and	location	onto	the	protein	structure.	
• Screening	 of	 the	 HA	 amino	 acid	 substitutions	 identified	 in	 influenza	 viruses	 recovered	 from	patients	 under	 antiviral	 therapy	 or	 selected	 in	 vitro	 following	 serial	 passage	 under	 NAI	 drug	pressure	in	all	sequences	obtained.	
• Analysis	 of	 the	 evolutionary	 relationships	among	 the	NA	and	HA	genes	of	 IC50	 outlier	viruses	and/or	viruses	recovered	from	patients	during	or	after	antiviral	therapy	and	of	non-outlier	and	worldwide	reference	viruses	from	the	same	influenza	virus	type	or	subtype.	
• Analysis	of	the	relationship	between	decreased	NAI	susceptibility	phenotypes	and	NA	genotypic	background	and,	whenever	possible,	between	these	and	patient	clinical	data.		
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	105		Resistance	 (VIRGIL)	 1,2.	 The	 platform	was	 progressively	 established	 between	 2008	 and	2009	combining	(1)	newly	implemented	methodologies	and/or	protocols;	(2)	sequencing	strategies	and	protocols	available	and	in	use	in	the	laboratory	to	study	the	evolutionary	dynamics	 of	 circulating	 influenza	 viruses;	 and	 	 (3)	 the	 state-of-the-art	 pyrosequencing	technology	available	at	 the	 former	Health	Protection	Agency	 (HPA)	 (Colindale,	London,	United	Kingdom	(UK),	which	is	now	part	of	Public	Health	England	(PHE)),	in	the	context	of	 the	 close	 collaboration	 established	with	 HPA	 in	 both	 research	 projects	 funding	 this	work	(project	partner).	Moreover,	it	was	strengthened	in	2012	by	implementing	a	Sanger	sequencing	alternative	to	M2	pyrosequencing	(M	gene)	and	by	expanding	hemagglutinin	(HA)	gene	sequencing	to	the	entire	coding	region	(previous	protocol	only	targeted	HA1	subunit).	Over	the	last	 few	years,	minor	but	 important	updates	have	been	performed	in	the	 platform,	 essentially	 at	 interpretation	 level,	 based	 on	 the	 recommendations	 and	information	issued	by	both	the	World	Health	Organization	(WHO)	Expert	Working	Group	on	Surveillance	of	Influenza	Antiviral	Susceptibility	(AVWG)	and	the	European	Centre	for	Disease	Prevention	and	Control	(ECDC)	Antiviral	Susceptibility	Task	Group	3-5.					The	 platform	 includes	 a	 genotypic	 platform	 for	 M2	 inhibitor	 susceptibility	 testing	(complete	cross-resistance	between	AMA	and	RIM	6)	and	a	twofold	phenotypic-genotypic	platform	 combined,	 whenever	 possible,	 with	 patient	 clinical	 data,	 for	 OS	 and	 ZA	susceptibility	 testing	 (Figure	 4.1).	 Two	 alternative	 sequencing	 methodologies	 are	available	 for	 genotypic	 testing	 of	 M2	 inhibitor	 susceptibility:	 (1)	 pyrosequencing	 of	 a	short	 M	 gene	 region	 covering	 the	 5	 well-known	 amino	 acid	 sites	 in	 influenza	 A	 M2	protein	 associated	 with	 drug	 resistance	 (26,	 27,	 30,	 31	 and	 34)	 (see	 section	 3.2.1.4.3,	Material	 and	 Methods);	 and	 (2)	 Sanger	 sequencing	 of	 the	 entire	 coding	 region	 of	 M2	protein	(see	RT-PCR	virus	genome	amplification	protocols	in	section	3.2.1.4.2.1,	Material	and	 Methods).	 Resistance	 is	 evaluated	 through	 the	 screening	 of	 the	 7	 established	molecular	markers	 of	 clinical	 resistance	 in	M2	protein	 sequence	 (L26F,	V27A,	A30T/V,	S31N/D,	G34E).	OS	and	ZA	susceptibility	testing	is	 intended	to	cover	the	three	different	levels	 at	 which	 antiviral	 resistance	 can	 be	 defined:	 phenotypically,	 genetically	 and	clinically.	Two	different	NA	inhibition	assays	comprise	the	phenotypic	component	of	the	platform:	fluorescent	MUNANA-based	assay	(see	section	3.2.1.3.1,	Material	and	Methods),	used	 as	 reference	 assay;	 and	 chemiluminescence	 NA-Star®	 kit	 assay	 (see	 section	3.2.1.3.2,	Material	and	Methods),	used	to	confirm	fluorescent-based	results,	particularly	IC50	 outlier	 values	 and	 whenever	 it	 is	 observed	 a	 significant	 difference	 between	 the	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	106		results	of	 inter-assay	virus	replicates.	NA	inhibition	assay	data	 is	used	to	determine	the	concentration	of	OS	or	ZA	required	to	inhibit	a	standardised	amount	of	virus	NA	activity	by	50%	(IC50	value)	(detailed	in	section	3.2.2.1.1,	Material	and	Methods).	Further	analysis	of	 IC50	 data,	 including	 determination	 of	 statistical	 cut-offs,	 baseline	 median	 (median	without	 IC50	 outlier	 values)	 and	 fold-change	 thresholds	 allow	 to	 assess	 the	 virus	susceptibility	to	the	drug	(see	section	3.2.2.1.3,	Material	and	Methods).	Phenotypic	drug	susceptibility	profiles	are	defined	according	to	the	new	inhibition	categories	established	by	the	WHO	AVWG:		normal	inhibition	(NI)	(fold-change	increase	<10	(influenza	A)	or	<5	(influenza	B));	reduced	inhibition	(RI)	(fold-change	increase	10-100	(influenza	A)	or	5-50	(influenza	B));	highly	reduced	inhibition	 (HRI)	 (fold-change	 increase	>100	 (influenza	A)	or	>50	(influenza	B))	4.				
		
Figure	4.1	 Schematic	 representation	of	 the	 technological	platform	established	 for	 influenza	antiviral	susceptibility	testing.		aa:	amino	acid;	 IC50:	Concentration	of	antiviral	required	to	 inhibit	a	standardised	amount	of	virus	NA	activity	by	50%;	HA:	Hemagglutinin;	HRI:	Highly	reduced	inhibition;	NA:	Neuraminidase;	NAI:	NA	inhibitor;	NI:	Normal	inhibition;	RI:	Reduced	inhibition		
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																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	107		IC50	outlier	 influenza	viruses,	 including	all	upper	outlier	viruses	and	≈25%	of	 the	 lower	outlier	 viruses,	 and	 ≈25%	 of	 the	 non-outlier	 viruses	 from	 the	 same	 influenza	 type	 or	subtype	and	season	(randomly	selected),	are	further	evaluated	through	genotypic	testing	(Figure	4.1).	 Influenza	viruses	recovered	from	patients	during	or	after	antiviral	therapy	but	 not	 classified	 as	 outlier	 or	 not	 possible	 to	 evaluate	 by	 phenotypic	 testing	(unsuccessful	 virus	 isolation),	 also	 comprise	 this	 group,	 as	 well	 as	 the	 corresponding	viruses	from	before	therapy,	whenever	available.		Genotypic	 testing	 of	 NAI	 susceptibility	 involves	 both	 NA	 and	 HA	 full-length	 gene	sequencing	 (Sanger	method;	see	section	3.2.1.4.2,	Material	and	Methods),	using	 the	cell	passage	 isolate	 characterized	 by	 phenotypic	 assay.	 Clinical	 specimens	 are	 only	 used	 if	related	 to	 antiviral	 therapy	 or	 to	 confirm	 the	 presence	 of	 a	 specific	 amino	 acid	substitution	in	the	original	virus	population	(possibility	of	cell	culture	artefacts).	The	NA	and/or	HA	amino	acid	substitutions	specific	of	IC50	outlier	viruses	and	of	further	viruses	recovered	 from	 patients	 during	 or	 after	 antiviral	 therapy	 are	 then	 identified	 and	characterized	 regarding	 their	 association	 to	 NAI	 resistance	 or	 decreased	 susceptibility	(see	 Table	 1.2,	 Literature	 Review	 for	 NA	 substitutions;	 HA	 D221G/N,	 seasonal	 H1	numbering)	and	their	location	onto	the	protein	structure.	NA	amino	acid	substitutions	at	or	 near	 the	 active	 site	 may	 affect	 drug	 binding	 affinity	 and	 consequently	 virus	susceptibility;	while	HA	amino	acid	substitutions	located	at	or	near	the	receptor	binding	site	 (RBS)	may	 change	 receptor	 binding	 affinity	 and	disturb	 the	HA-NA	balance,	which	may	result	in	altered	virus	fitness	or	even	in	altered	virus	susceptibility	if	it	changes	the	requirements	 for	 NA	 activity	 (NA	 inhibition	 assay	 only	 accounts	 for	 NA-mediated	susceptibility).	Genotypic	analysis	of	HA	gene	also	comprises	the	screening	of	the	amino	acid	substitutions	identified	in	influenza	viruses	recovered	from	patients	under	antiviral	therapy	 or	 selected	 in	 vitro	 after	 serial	 passage	 under	 NAI	 drug	 pressure	 (see	 section	1.5.2.1.2,	Literature	Review).			Patient	clinical	data	 is	essential	 for	evaluating	 the	relationship	of	decreased	phenotypic	susceptibility	and/or	the	presence	of	specific	amino	acid	substitutions	in	NA	and/or	HA	with	NAI	 drug	 use	 and,	 particularly,	 its	 clinical	 effectiveness.	 However,	 comprehensive	patient	clinical	data	is	usually	difficult	to	obtain.					
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4.1.2	Target	Population	and	Study	Sample	
	Antiviral	susceptibility	testing	was	performed	on	human	influenza	viruses	circulating	in	Portugal	 from	 2004/2005	 to	 2012/2013	 among	 both	 community	 and	 hospitalized	patients,	 either	 or	 not	 under	 influenza	 antiviral	 therapy	 (target	 population).	 Influenza	viruses	 from	 2004/2005	 to	 2007/2008	were	 retrospectively	 studied	 to	 cover	 the	 first	seasons	 for	 which	 was	 available	 information	 on	 the	 susceptibility	 of	 influenza	 viruses	circulating	in	Europe	to	antiviral	drugs,	generated	by	the	former	VIRGIL	network	(2004	to	2008)	7.				Effective	study	sample	comprised	most	influenza	viruses	selected	for	study	(presented	in	section	 3.1.1,	 Material	 and	 Methods).	 A	 total	 of	 357	 influenza	 A	 viruses	 (84	 former	seasonal	A(H1N1),	142	A(H3N2)	and	131	A(H1N1)pdm09)	were	tested	for	M2	inhibitor	susceptibility,	while	 a	 total	 of	 526	 (93	 former	 seasonal	A(H1N1),	 144	A(H3N2),	 142	B,	147	A(H1N1)pdm09)	and	491	(76	 former	seasonal	A(H1N1),	139	A(H3N2),	129	B,	147	A(H1N1)pdm09)	influenza	viruses	were	tested	for,	respectively,	OS	and	ZA	susceptibility	(Table	4.1).	Most	influenza	viruses	were	tested	using	a	2nd	to	4th	cell	passage	isolate.	The	 percentage	 of	 A(H3N2)	 and	 A(H1N1)pdm09	 viruses	 tested	 for	 M2	 inhibitor	susceptibility	 decreased	 significantly	 after	 2008/2009	 and	 the	 2009	 pandemic	 period,	respectively,	given	the	overall	resistance	observed	to	this	antiviral	drug	class.	Virtually	all	viruses	 not	 evaluated	 through	OS	 or	 ZA	 phenotypic	 susceptibility	 testing	 had	 issues	 of	either	 not	 enough	 volume	of	 clinical	 specimen	 for	 virus	 isolation	 or	 unsuccessful	 virus	isolation	or	propagation	 in	cell	 culture.	Since	ZA	susceptibility	was	only	 tested	after	OS	susceptibility	until	2008/2009,	occasional	further	propagation	in	cell	culture	was	needed	and	 sometimes	 was	 unsuccessful,	 explaining	 the	 lower	 number	 of	 viruses	 evaluated	against	 ZA	 (Table	 4.1).	 The	 influenza	 viruses	 evaluated	 through	 NA	 and/or	 HA	 gene	sequencing	 included	 the	 viruses	 that	 were	 predetermined	 to	 be	 further	 evaluated	 by	genotypic	NAI	 susceptibility,	with	 the	 few	 exceptions	 being	 described	 below	 in	 section	4.1.4.2.	 It	 also	 included	 additional	 viruses	 (non-outlier)	 for	 which	 the	 NA	 and/or	 HA	sequences	 were	 obtained	 in	 the	 context	 of	 the	 on-going	 laboratory	 study	 on	 the	evolutionary	 dynamics	 of	 the	 two	 major	 influenza	 virus	 antigens.	 These	 additional	sequences	 increased	 the	 robustness	 of	 both	 genetic	 and	 phylogenetic	 comparative	analyses	performed.			
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Table	4.1	Number	(percentage)	of	 influenza	viruses	evaluated	by	each	genotypic	and/or	phenotypic	antiviral	 susceptibility	 testing	 performed	 to	 assess	 M2	 inhibitor	 and	 oseltamivir	 and	 zanamivir	neuraminidase	inhibitor	susceptibility.																								
	HA:	Hemagglutinin;	NA:	Neuraminidase;	NAI:	Neuraminidase	Inhibitor	a	Period	between	11th	 June	2009	and	9th	August	2010	(WHO	pandemic	alert	Phase	6);	 b	 Percentage	estimates	based	on	the	number	of	 influenza	viruses	 selected	 for	 study;	 c	 Percentage	 estimates	 based	 on	 the	 number	 of	 influenza	 viruses	 evaluated	 through	 phenotypic	 oseltamivir	susceptibility	testing;	d	No	former	seasonal	A(H1N1)	viruses	were	detected	in	Portugal	after	the	pandemic	2009	period;	e	No	influenza	virus	was	detected	 during	 this	 influenza	 season;	 f	No	 influenza	 virus	 was	 evaluated	 through	 phenotypic	 susceptibility	 testing;	 g	 Influenza	 B	 viruses	 are	naturally	resistant	to	M2	inhibitors	(lack	of	M2	target	protein);	h	Percentage	of	the	overall	influenza	A	viruses	selected	for	study	(N=593).			The	viruses	from	16	of	the	30	cases	of	influenza	virus	infection	associated	with	NAI	drug	use	 (detailed	 in	 section	 3.1.1,	 Material	 and	 Methods)	 were	 among	 the	 total	 viruses	evaluated	 to	M2	 inhibitor	and	both	OS	and	ZA	susceptibility.	However,	only	 the	viruses	
Oseltamivir Zanamivir NA/sequencing HA/sequencing2004/2005 6 6/(100.0) 4/(66.7) 3/(50.0) 2/(50.0) 2/(50.0)2005/2006 46 45/(97.8) 39/(84.8) 27/(58.7) 11/(28.2) 12/(30.8)2006/2007 Ce C C C C C2007/2008 29 18/(62.1) 29/(100.0) 28/(96.6) 23/(79.3) 15/(51.7)2008/2009 21 15/(71.4) 21/(100.0) 18/(85.7) 21/(100.0) 11/(52.4)Pandemic/period 2 0/(0.0) 0/(0.0) 0/(0.0) Cf CfTOTAL 104 84/(80.8) 93/(89.4) 76/(73.1) 57/(61.3) 40/(43.0)2004/2005 89 76/(85.4) 76/(85.4) 71/(79.8) 20/(26.3) 19/(25.0)2005/2006 1 1/(100.0) 1/(100.0) 1/(100.0) 1/(100.0) 1/(100.0)2006/2007 76 51/(67.1) 20/(26.3) 20/(26.3) 14/(70.0) 12/(60.0)2007/2008 Ce C C C C C2008/2009 21 10/(47.6) 20/(95.2) 20/(95.2) 14/(70.0) 14/(70.0)Pandemic/period 5 0/(0.0) 0/(0.0) 0/(0.0) Cf Cf2010/2011 2 0/(0.0) 0/(0.0) 0/(0.0) Cf Cf2011/2012 30 3/(10.0) 26/(86.7) 26/(86.7) 9/(34.6) 9/(34.6)2012/2013 1 1/(100.0) 1/(100.0) 1/(100.0) 1/(100.0) 1/(100.0)TOTAL 225 142/(63.1) 144/(64.0) 139/(61.8) 59/(41.0) 56/(38.9)2004/2005 35 Cg 33/(94.3) 24/(68.6) 4/(12.1) 13/(39.4)2005/2006 49 Cg 49/(100.0) 47/(95.9) 4/(8.2) 13/(26.5)2006/2007 2 Cg 2/(100.0) 2/(100.0) 2/(100.0) 2/(100.0)2007/2008 45 Cg 45/(100.0) 43/(95.6) 18/(40.0) 12/(26.7)2008/2009 1 Cg 1/(100.0) 1/(100.0) 1/(100.0) 1/(100.0)Pandemic/period 10 Cg 3/(30.0) 3/(30.0) 3/(100.0) 2/(66.7)2010/2011 5 Cg 2/(40.0) 2/(40.0) 2/(100.0) 2/(100.0)2011/2012 2 Cg 1/(50.0) 1/(50.0) 1/(100.0) 1/(100.0)2012/2013 9 Cg 6/(66.7) 6/(66.7) 3/(50.0) 3/(50.0)TOTAL 158 C/g 142/(89.9) 129/(81.6) 38/(26.8) 49/(34.5)Pandemic/period 163 116/(71.2) 116/(71.2) 116/(71.2) 44/(37.9) 44/(37.9)2010/2011 69 13/(18.8) 26/(37.7) 26/(37.7) 13/(50.0) 13/(50.0)2011/2012 Ce C C C C C2012/2013 23 2/(8.7) 5/(21.7) 5/(21.7) 3/(60.0) 3/(60.0)TOTAL 255 131/(51.4) 147/(57.6) 147/(57.6) 60/(40.8) 60/(40.8)
742 357&(61.1h) 526&(70.9) 491&(66.2) 214&(40.7) 205&(39.0)
Former/seasonal/A(H1N1)/d
A(H3N2)
B
A(H1N1)pdm09
TOTAL
Influenza/virus/type/subtype Influenza/season//2009/pandemic/period/a
Number/of/viruses/selected/for/study/
M2/inhibitor/susceptibility/testing/C/Genotypic/b
NAI/susceptibility/testingPhenotypic//////////////////////////////////////////////(MUNANACbased/assay)b Genotypicc
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	110		from	 3	 cases	 were	 effectively	 recovered	 from	 the	 patient	 after	 initiation	 of	 antiviral	therapy.	Specifically,	the	viruses	from	two	of	the	cases	of	A(H1N1)pdm09	virus	infection	received	 with	 a	 high	 level	 of	 suspicion	 of	 clinical	 resistance	 to	 OS	 (case	 1,	A/Portugal/28/2009	 virus	 isolate;	 and	 case	 3,	 A/Portugal/03/2011	 virus	 isolate;	 see	Table	3.2,	Material	and	Methods);	and	a	virus	from	a	case	of	A(H3N2)	virus	infection	from	2012/2013	 (A/Portugal/56/2013	 virus	 isolate).	 	 The	 NA	 and	 HA	 genes	 of	 the	 virus	population	 present	 in	 the	 clinical	 specimens	 yielding	 A/Portugal/28/2009	 and	A/Portugal/56/2013	 isolates	 were	 also	 sequenced	 (not	 included	 in	 the	 numbers	presented	 at	 Table	 4.1).	 The	 same	 was	 not	 performed	 for	 virus	 isolate	A/Portugal/03/2011	 as	 preliminary	 HCC	 results	 had	 already	 identify	 NA	 H275Y	 OS-resistant	marker	 in	 the	entire	virus	population	of	 the	specimen	(see	Table	3.2,	Material	and	Methods).	NA	and	HA	gene	 sequencing	was	also	performed	on	 two	post-treatment	clinical	 specimens	 (from	 during	 and	 after	 drug	 use)	 from	 an	 additional	 case	 of	A(H1N1)pdm09	 virus	 infection	 (2012/2013),	 for	 which	 virus	 isolation	 was	 only	successfully	 performed	 for	 the	 clinical	 specimen	 collected	 before	 drug	 use	(A/Portugal/55/2013	isolate)	(also	not	taken	into	consideration	for	Table	4.1).		The	 viruses	 from	 the	 two	 other	 cases	 of	 A(H1N1)pdm09	 virus	 infection	 suspected	 of	clinical	 resistance	 to	OS	 (case	2	 and	4;	 see	Table	 3.2,	Material	 and	Methods),	were	not	possible	 to	 study	 (unsuccessful	 virus	 isolation).	 But,	 for	 the	 latter	 case	 (case	 4),	 it	was	possible	 to	quantify	 the	mixed	NA	H275Y/H	virus	population	by	pyrosequencing,	using	the	 RNA	 extracted	 material	 available	 –	 73.8%	 wild-type	 H275,	 26.2%	 mutant	 H275Y	(data	not	shown;	quantitation	performed	at	the	PHE,	Colindale,	London,	UK).					
4.1.3	M2	Inhibitor	Susceptibility	Testing		Resistance	 to	 M2	 inhibitors	 was	 found	 in	 A(H3N2)	 and	 A(H1N1)pdm09	 subtypes.	 An	overall	resistant	profile	was	observed	for	A(H1N1)pdm09	subtype,	with	all	131	viruses	tested	 harboring	 the	M2	 S31N	 resistant	marker	 (naturally-resistant	 viruses),	while	 the	profile	 of	 circulating	 A(H3N2)	 viruses	 shifted	 from	 susceptible	 to	 resistant	 during	 the	time	 period	 analyzed	 (Figure	 4.2).	 All	 A(H3N2)	 viruses	 from	 2004/2005	 (n=76)	 were	susceptible	 to	 this	 antiviral	 drug	 class.	 The	 single	A(H3N2)	 virus	 from	2005/2006	was	the	 first	 to	 exhibit	 drug	 resistance,	 followed	 by	 13	 (74.5%)	 of	 the	 51	 viruses	 from	2006/2007.	An	overall	resistance	(100.0%)	was	observed	in	2008/2009,	2011/2012	and	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	111		2012/2013	 (both	pandemic	 period	 and	2010/2011	with	 no	 virus	were	 tested)	 (Figure	4.2).		The	frequency	of	M2	inhibitor	resistance	among	circulating	A(H3N2)	viruses	was	of	approximately	37%	for	the	total	time	period	(2004/2005	to	2012/2013).						
		 	 	 			 			
	
Figure	4.2	Susceptibility	profile	of	circulating	influenza	A(H3N2)	viruses	to	M2	protein	inhibitors.		The	 resistant	 molecular	 marker(s)	 found	 in	 the	 M2	 protein	 sequences	 are	 indicated	 within	 brackets	 after	 the	 resistance	frequency.				All	A(H3N2)	resistant	viruses	carried	the	S31N	amino	acid	substitution	in	the	M2	protein,	with	three	(5.7%,	3/53)	viruses	from	2008/2009	further	carrying	the	V27A	substitution	(double	V27A/S31N	mutant	viruses)	(Figure	4.3).			All	former	seasonal	A(H1N1)	viruses	(herein	designated	as	seasonal	A(H1N1))	showed	to	be	susceptible	to	M2	inhibitors.	None	of	the	established	molecular	markers	of	resistance	was	 found	 in	 the	 M2	 protein	 sequences	 of	 the	 total	 84	 seasonal	 A(H1N1)	 viruses	analysed.				
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Figure	4.3	Representative	M2	gene	pyrograms	of	 influenza	A(H3N2)	viruses	 susceptible	 (wild-type)	(A)	and	resistant	(S31N)	(B)	to	M2	protein	inhibitors.	The	figure	displays	the	pyrograms	obtained	for	the	A/Lisboa/14/2007	(A)	and	A/Lisboa/01/2007	(B)	A(H3N2)	virus	 isolates	from	2006/2007.	Pyrograms	were	obtained	through	SNP	(single	nucleotide	polymorphism)	pyrosequencing	analysis	using	the	PyroMark®	 Q96	 ID	 (QIAGEN)	 platform.	 Yellow	 areas	 indicate	 the	 5	 positions	 at	 which	 the	 SNPs	 that	 cause	 M2	 inhibitor	resistance	can	occur	(positions	26,	27,	30,	31	and	34	of	the	M2	protein).	At	the	top	of	each	position	is	given	the	percentage	of	wild-type	(susceptible)	versus	mutant	(resistant)	virus.	A	limit	of	10%	was	considered	for	resistance	detection.	The	nucleotide	change	from	G	to	A	that	underlays	the	resistant	S31N	SNP	is	highlighted	in	the	figure.	The	pyrogram	of	the	A(H3N2)	susceptible	virus	(A)	shows	the	sequence	AC	CCG	CTT	GTT	GTT	GTT	GCC	GCG	AGT	ATC	ATT	GGG	AT,	while	the	resistant	S31N	sequence	(B)	is	AC	CCG	CTT	GTT	GTT	GTT	GCC	GCG	AAT	ATC	ATT	GGG	AT.				
4.1.4	Oseltamivir	and	Zanamivir	Susceptibility	Testing	
	
4.1.4.1	Phenotypic	Testing		
	
4.1.4.1.1	IC50	outlier	viruses	and	virus	phenotypic	susceptibility	profiles	
	 4.1.4.1.1.1	Oseltamivir		All	or	nearly	all	(84.6%	to	97.4%)	influenza	viruses	from	the	different	types	or	subtypes	and	 influenza	 seasons	 or	 2009	 pandemic	 period,	 exhibited	 an	 IC50	 value	 within	 the	normal	range	(range	of	values	between	the	lower	and	upper	mild	cut-offs)	-	non-outlier	viruses	 (Table	4.2).	Only	 for	 a	 single	 season	within	each	 influenza	 type	or	 subtype	 this	was	not	observed,	with	the	frequency	of	non-outlier	viruses	being	comparatively	lower.	
A 
B 
SUSCEPTIBLE VIRUS (AGT – wild-type S31) 
RESISTANT VIRUS (AAT – mutant S31N) 
Position 31 
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	113		Specifically,	 for	 2007/2008	 in	 seasonal	 A(H1N1)	 (62.1%),	 2006/2007	 in	 A(H3N2)	(70.0%),	2010/2011	in		influenza	B	(50.0%),	and	2012/2013	in	A(H1N1)pdm09	(20.0%)	type/subtype.	 Also,	 none	 of	 the	 seasonal	 A(H1N1)	 and	 influenza	 B	 viruses	 from	2008/2009	were	 non-outlier.	 IC50	 value	 ranges	 of	 non-outlier	 viruses	 can	 be	 found	 at	Table	4.2.				
Table	4.2	Summary	of	phenotypic	oseltamivir	IC50	outlying	results.																															
VIC:	Victoria;	YAM:	Yamagata	a	The	predominant	 influenza	B	 lineage	is	 indicated	within	brackets	after	the	designation	of	the	time	period	(lineage	differentiation	based	on	the	antigenic	and/or	genetic	characteristics	of	the	virus	hemagglutinin);	b	No	influenza	virus	was	detected.	These	results	were	obtained	 through	statistical	analysis	of	 the	phenotypic	 IC50	data	generated	by	 fluorescent	MUNANA-based	neuraminidase	inhibition	assay.		Non-outlier	IC50	values	are	located	between	the	lower	and	upper	mild	cut-offs	(normal	range).	Upper	outlier	viruses	had	an	 IC50	value	above	mild	 (median+1.65	Standard	Deviations	 (SD))	or	extreme	(median+3SD)	upper	cut-offs,	while	 lower	outlier	viruses	exhibited	an	 IC50	value	below	mild	 (median-1.65SD)	or	extreme	(median-3SD)	 lower	cut-offs.	The	total	number	of	upper	and	total	outlier	viruses	is	highlighted	in	bold	and	italic.				
Mild Extreme TOTAL Mild Extreme TOTAL2004/2005 4 44(100.0) 1.634;42.13 04(0.0) 04(0.0) 0"(0.0) 04(0.0) 04(0.0) 04(0.0) 0"(0.0)2005/2006 39 374(94.9) 0.884;42.60 14(2.6) 04(0.0) 1&(2.6) 14(2.6) 04(0.0) 14(2.6) 2&(5.1)2006/2007 ;b ; ; ; ; ; ; ; ; ;2007/2008 29 184(62.1) 1.534;42.60 14(3.4) 64(20.7) 7&(24.1) 34(10.3) 14(3.4) 44(13.8) 11&(37.9)2008/2009 21 04(0.0) ; 04(0.0) 214(100.0) 21&(100.0) 04(0.0) 04(0.0) 04(0.0) 21&(100.0)Pandemic4period 0 ; ; ; ; & ; ; ; &TOTAL 93 594(63.4) 0.884;42.60 24(2.2) 274(29.0) 29&(31.2) 44(4.3) 14(1.1) 54(5.4) 34&(36.6)2004/2005 76 744(97.4) 0.224;40.61 04(0.0) 04(0.0) 0"(0.0) 24(2.6) 04(0.0) 24(2.6) 2&(2.6)2005/2006 1 14(100.0) 0.24 04(0.0) 04(0.0) 0"(0.0) 04(0.0) 04(0.0) 04(0.0) 0"(0.0)2006/2007 20 144(70.0) 0.354;40.47 14(5.0) 14(5.0) 2&(10.0) 24(10.0) 24(10.0) 44(20.0) 6&(30.0)2007/2008 ;b ; ; ; ; & ; ; ; &2008/2009 20 204(100.0) 0.284;40.54 04(0.0) 04(0.0) 0"(0.0) 04(0.0) 04(0.0) 04(0.0) 0"(0.0)Pandemic4period 0 ; ; ; ; & ; ; ; &2010/2011 0 ; ; ; ; & ; ; ; &2011/2012 26 224(84.6) 0.614;41.15 14(3.8) 14(3.8) 2&(7.7) 24(7.7) 04(0.0) 24(7.7) 4&(15.4)2012/2013 1 14(100.0) 1.01 04(0.0) 04(0.0) 0"(0.0) 04(0.0) 04(0.0) 04(0.0) 0"(0.0)TOTAL 144 1324(91.7) 0.224;41.15 24(1.4) 24(1.4) 4&(2.8) 64(4.2) 24(1.4) 84(5.6) 12&(8.3)2004/20054(YAM) 33 314(93.9) 9.74;419.39 14(3.0) 04(0.0) 1&(3.0) 14(3.0) 04(0.0) 14(3.0) 2&(6.1)2005/20064(VIC) 49 444(89.8) 16.724;426.72 24(4.1) 04(0.0) 2&(4.1) 34(6.1) 04(0.0) 34(6.1) 5&(10.2)2006/2007 2 24(100.0) 14.194;423.45 04(0.0) 04(0.0) 0"(0.0) 04(0.0) 04(0.0) 04(0.0) 0"(0.0)2007/20084(YAM) 45 454(100.0) 11.94;433.61 04(0.0) 04(0.0) 0"(0.0) 04(0.0) 04(0.0) 04(0.0) 0"(0.0)2008/20094(VIC) 1 04(0.0) ; 14(100.0) 04(0.0) 1&(100.0) 04(0.0) 04(0.0) 04(0.0) 1&(100.0)Pandemic4period4(VIC) 3 34(100.0) 44.224;469.14 04(0.0) 04(0.0) 0"(0.0) 04(0.0) 04(0.0) 04(0.0) 0"(0.0)2010/2011 2 14(50.0) 23.57 14(50.0) 04(0.0) 1&(50.0) 04(0.0) 04(0.0) 04(0.0) 1&(50.0)2011/20124(YAM) 1 14(100.0) 21.59 04(0.0) 04(0.0) 0"(0.0) 04(0.0) 04(0.0) 04(0.0) 0"(0.0)2012/20134(YAM) 6 64(100.0) 16.544;435.86 04(0.0) 04(0.0) 0"(0.0) 04(0.0) 04(0.0) 04(0.0) 0"(0.0)TOTAL 142 1334(93.7) 9.74;469.14 54(3.5) 04(0.0) 5&(3.5) 44(2.8) 04(0.0) 44(2.8) 9&(6.3)Pandemic4period 116 1044(89.7) 0.504;41.07 34(2.6) 34(2.6) 6&(5.2) 54(4.3) 14(0.9) 64(5.2) 12&(10.3)2010/2011 26 234(88.5) 0.694;41.21 24(7.7) 14(3.8) 3&(11.5) 04(0.0) 04(0.0) 04(0.0) 3&(11.5)2011/2012 ;b ; ; ; ; & ; ; ; &2012/2013 5 14(20.0) 0.91 24(40.0) 24(40.0) 4&(80.0) 04(0.0) 04(0.0) 04(0.0) 4&(80.0)TOTAL 147 1284(87.1) 0.504;41.21 74(4.8) 64(4.1) 13&(8.8) 54(3.4) 14(0.7) 64(4.1) 19&(12.9)
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																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	114		The	 overall	 range	 of	 IC50	non-outlier	 values	was	 very	 similar	 between	A(H3N2)	 (0.22	 -	1.15nM)	and	A(H1N1)pdm09	(0.50	-	1.21nM)	subtypes,	varying	from	0.88	to	2.60nM	in	seasonal	 A(H1N1)	 viruses.	 Influenza	 B	 non-outlier	 viruses	 exhibited	 the	 highest	 IC50	values	that	overall	ranged	from	9.7	to	69.14nM.	The	three	influenza	B	non-outlier	viruses	from	the	pandemic	period	presented	IC50	values	considerably	higher	(44.22	-	69.14nM)	than	 those	 yielded	 by	 all	 other	 non-outlier	 viruses	 (11.9	 -	 35.86nM).	 	 But,	 the	 use	 of	pandemic	 period	 –	 2012/2013	 combined	 cut-offs,	 due	 to	 the	 low	 number	 of	 viruses	tested,	 may	 be	 the	 reason	 why	 such	 viruses	 were	 not	 classified	 as	 outlier	 (see	 Figure	4.4C).			IC50	outlier	viruses	belonged	to	all	4	categories	 -	upper	mild	(UM),	upper	extreme	(UE),	lower	mild	(LM),	and	lower	extreme	(LE).	The	only	exception	was	in	type	B	influenza,	in	which	only	mild	outlier	viruses	were	identified	(UM	and	LM).	Considering	its	distribution	across	the	different	categories,	outlier	viruses	were	detected	at	 frequencies	that	ranged	from	0.7%	to	4.8%	(overall	frequencies),	except	seasonal	A(H1N1)	UE	outlier	viruses	that	represented	nearly	30.0%	of	the	viruses	tested	(Table	4.2).	Additional	information	on	OS	IC50	outlier	viruses	is	presented	at	Figure	4.4	A-D,	in	which	are	also	indicated	the	IC50	cut-offs	and	baseline	median	(median	without	outlier	values).			The	 frequency	of	 seasonal	A(H1N1)	 IC50	outlier	viruses	 increased	 throughout	 influenza		seasons.	Initially	estimated	at	0.0%	(2004/2005),	it	increased	to	5.1%	in	2005/2006	and	then	 to	 37.9%	 in	 2007/2008,	 reaching	 100%	 in	 2008/2009	 (Table	 4.2).	 Most	 outlier	viruses	 from	2007/2008	 (n=6;	 20.7%)	 and	 all	 outlier	 viruses	 from	2008/2009	 (n=21),	were	UE	 outliers,	 exhibiting	 extremely	 high	OS	 IC50	 values	 that	were	 ≈160	 to	 615-fold	higher	 than	 the	 baseline	 median	 for	 2007/2008	 (1.97nM)	 (Figure	 4.4A).	 The	 two	seasonal	 A(H1N1)	 UM	 outlier	 viruses	 identified	 -	 virus	 isolates	 A/Lisboa/25/2006	(2005/2006)	 and	 A/Lisboa/08/2008	 (2007/2008),	 presented	 an	 IC50	 value	 ≈2-fold	higher	 than	 the	 corresponding	 baseline	 median.	 The	 fold	 decrease	 in	 IC50	 relative	 to	baseline	median	exhibited	by	the	5	seasonal	A(H1N1)	lower	outlier	viruses	(4	LM	and	1	LE)	was	also	very	small	(≤2-fold)	(Figure	4.4A)				
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Figure	4.4	Oseltamivir	IC50	values	of	circulating	former	seasonal	A(H1N1)	(A),	A(H3N2)	(B),	influenza	B	(C)	and	A(H1N1)pdm09	(D)	viruses.	
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(Footnotes	Figure	4.4)	Mild	outlier	cut-offs	were	established	at	1.65	standard	deviations	(SD)	above	(upper)	or	below	(lower)	the	median,	while	a	3SD	was	considered	for	extreme	cut-offs.	IC50	values	are	displayed	in	different	colours	according	to	their	outlier	status	and	category	(non-outlier,	upper	mild/upper	extreme/lower	mild/lower	extreme	outlier).	An	additional	colour	was	used	 in	 the	 IC50	plot	of	influenza	B	viruses	 (plot	C)	 to	differentiate	 the	non-outlier	 IC50	values	of	B/Victoria	and	B/Yamagata-lineage	viruses	 (lineage	differentiation	 based	 on	 the	 antigenic	 and/or	 genetic	 characteristics	 of	 the	 virus	 hemagglutinin).	 IC50	 outlier	 cut-offs	 and	baseline	median	 (median	without	outlier	values)	are	displayed	using	 the	 same	colour-coded	system	used	 for	 IC50	values.	The	designation	 of	 each	 outlier	 virus	 is	 indicated	 near	 the	 corresponding	 IC50	 data	 point,	 followed	 by	 the	 fold-change	 IC50	increase/decrease	 compared	 to	 the	baseline	median,	 indicated	within	brackets.	 	 The	 influenza	B	 lineage	 to	which	 the	outlier	virus	belongs	 is	also	 indicated	 inside	 the	brackets	 (exclusive	of	plot	C).	The	 IC50	baseline	median	value	 is	displayed	alongside	with	 the	marker.	 The	 IC50	 cut-offs	 that	were	occasionally	 used	 for	 analysing	 IC50	 values	 from	previous	or	 following	 influenza	seasons	for	which	less	than	15	different	viruses	were	tested	are	indicated	in	the	x-axis,	below	the	season	of	the	analysed	values.	Pandemic	period	-	2012/2013	combined	cut-offs	were	used	for	type	B	influenza	(plot	C),	as	the	12	different	viruses	from	these	4-consecutive	time	periods	were	tested	together.			A(H3N2)	 OS	 IC50	 outlier	 viruses	 were	 only	 detected	 in	 2004/2005	 (n=2;	 2.6%),	2006/2007	 (n=6;	 30.0%),	 and	 2011/2012	 (n=4;	 15.4%),	 with	 half	 (6/12)	 of	 them	belonging	to	the	LM	outlier	category	(Table	4.2).	The	two	UM	outlier	viruses	identified	-	virus	 isolates	 A/Lisboa/01/2007	 (2006/2007)	 and	 A/Portugal/29/2012	 (2011/2012),	and	the	UE	outlier	virus	 from	2006/2007	(virus	 isolate	A/Lisboa/54/2007)	exhibited	a	≤2-fold	 higher	 OS	 IC50	 value,	 compared	 to	 the	 corresponding	 baseline	 median	 (Figure	4.4B).	 The	 UE	 outlier	 virus	 from	 2011/2012	 (virus	 isolate	 A/Portugal/43/2012)	presented	an	IC50	value	4-fold	higher	than	baseline	median.	All	8	lower	outlier	viruses	(6	LM	and	2	LE),	 presented	 a	≤2-fold	decrease	 in	 IC50	 relative	 to	baseline	median	 (Figure	4.4B).		Influenza	B	OS	IC50	outlier	viruses	were	detected	in	2004/2005	(n=2;	6.1%),	2005/2006	(n=5;	 10.2%),	 2008/2009	 (n=1;	 100.0%),	 and	 2010/2011	 (n=1;	 50.0%),	 distributing	almost	 equitably	 between	 the	 two	 mild	 outlier	 categories	 –	 UM	 (n=5);	 and	 LM	 (n=4)	(Table	 4.2).	 A	 ≤2-fold	 increase	 or	 decrease	 in	 IC50	 relative	 to	 baseline	 median	 was,	respectively,	observed	for	all	UM	and	LM	outlier	viruses	(Figure	4.4C).	All	influenza	B	UM	outlier	 viruses	 belong	 to	 the	 B/Victoria	 (B/VIC)	 lineage,	 with	 exception	 of	 the	 virus	isolate	B/Lisboa/12/2005	 from	2004/2005	 (B/Yamagata	 (B/YAM)	 lineage).	Due	 to	 the	very	 limited	 number	 of	 viruses	 from	 the	 non-predominant	 B	 lineage	 in	 each	 influenza	season	 or	 pandemic	 period,	 the	 IC50	 values	 exhibited	 by	 the	 viruses	 from	 each	 lineage	could	not	be	analysed	separately.	However,	as	it	is	possible	to	observe	in	Figure	4.4C,	the	non-outlier	IC50	values	exhibited	by	B/VIC-lineage	viruses	tended	to	be	higher	than	those	from	B/YAM-lineage	viruses.	Only	for	2007/2008	this	was	not	observed.		
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	118		The	 frequency	 of	 A(H1N1)pdm09	OS	 IC50	outlier	 viruses	was	 similar	 for	 the	 pandemic	period	 (10.3%)	 and	 the	 2010/2011	 season	 (11.5%),	 but	 then	 increased	 greatly	 in	2012/2013	(80.0%)(Table	4.2).	This	increase	may,	however,	be	simply	an	artefact	of	the	analysis	 of	 the	 few	 IC50	 values	 of	 this	 season	 against	 the	 outlier	 cut-offs	 estimated	 for	2010/2011.	Most	A(H1N1)pdm09	outlier	viruses	were	upper	outlier,	belonging	to	either	UM	(n=7;	4.8%)	or	UE	(n=6;	4.1%)	categories	(Table	4.2).	The	UE	outlier	virus	detected	in	 2010/2011	 -	 virus	 isolate	A/Portugal/03/2011,	 exhibited	 an	 extremely	 high	OS	 IC50	value	(219.95nM)	that	was	≈250-fold	higher	than	the	baseline	median	(Figure	4.4D).	The	two	UE	 outlier	 viruses	 from	 the	 pandemic	 period	 –	 virus	 isolates	A/Portugal/17/2009	and	A/Portugal/82/2009,	exhibited	IC50	values,	respectively,	3	and	4-fold	higher	than	the	baseline	median.	All	remaining	upper	outlier	viruses	(3	UE,	and	7	UM)	presented	≤2-fold	higher	 OS	 IC50	 values.	 An	 ≈2-fold	 decrease	 in	 IC50	 relative	 to	 baseline	 median	 was	observed	for	all	A(H1N1)pdm09	lower	outlier	viruses	(5	LM,	and	1LE)	(Figure	4.4D).		Phenotypic	 drug	 susceptibility	 profiles	were	 defined	 according	 to	 the	WHO	AVWG	 IC50	fold-change	criteria,	as	detailed	in	section	4.1.1.	Based	on	these	criteria,	27	(29.0%)	of	the	93	 seasonal	 A(H1N1)	 viruses	 showed	 HRI	 by	 OS	 (≈160	 to	 615-fold	 higher	 IC50),	corresponding	 to	 the	 27	 UE	 outlier	 viruses	 identified	 (6	 from	 2007/2008;	 21	 from	2008/2009)	 (Figure	 4.4A).	 One	 (0.7%)	 A(H1N1)pdm09	 virus	 from	 2010/2011	 -	 virus	isolate	A/Portugal/03/2011	(UE	outlier),	also	showed	HRI	by	the	drug	(≈250-fold	higher	IC50;	Figure	4.4D).	The	remaining	66	seasonal	A(H1N1)	and	146	A(H1N1)pdm09	viruses,	as	well	as	all	144	A(H3N2)	and	142	influenza	B	viruses	analysed,	showed	NI	by	OS	(≤4-fold	(A(H1N1)pdm09,	A(H3N2))	or	≤2-fold	(seasonal	A(H1N1),	influenza	B)	higher	IC50)	(Figure	4.4A-D).				 4.1.4.1.1.2	Zanamivir		All	 or	 nearly	 all	 (80.8%	 to	 98.6%)	 influenza	A	 viruses	 from	 the	different	 subtypes	 and	influenza	 seasons	 or	 2009	 pandemic	 period,	 exhibited	 an	 IC50	 value	within	 the	 normal	range	(Table	4.3).	The	only	exception	were	the	A(H1N1)pdm09	viruses	from	2012/2013,	in	which	only	one	(20.0%)	of	the	viruses	had	an	IC50	value	within	this	range.	Regarding	influenza	B	viruses,	all	or	nearly	all	(90.7%,	95.7%)	viruses	from	2005/2006,	2007/2008,	and	the	two	latter	seasons	(2011/2012	and	2012/2013)	were	non-outlier,	while	none	or	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	119		only	 one	 (50.0%)	 of	 the	 viruses	 from	 the	 remaining	 influenza	 seasons	 and	 2009	pandemic	period	had	an	 IC50	value	within	 the	normal	 range.	The	only	exception	was	 in	2004/2005,	with	70.8%	of	 the	viruses	presenting	a	value	within	 this	range	(Table	4.3).	IC50	value	ranges	of	non-outlier	viruses	are	presented	in	Table	4.3.				
Table	4.3	Summary	of	phenotypic	zanamivir	IC50	outlying	results.																											
	VIC:	Victoria;	YAM:	Yamagata	a	The	predominant	 influenza	B	 lineage	is	 indicated	within	brackets	after	the	designation	of	the	time	period	(lineage	differentiation	based	on	the	antigenic	and/or	genetic	characteristics	of	the	virus	hemagglutinin);	b	No	influenza	virus	was	detected.	These	results	were	determined	and	annotated	as	described	in	Table	4.2.			The	lowest	overall	 IC50	values	exhibited	by	non-outlier	 influenza	A	viruses	were	similar	across	the	different	subtypes	(0.32	to	0.44nM)	(Table	4.3).	The	same	similarity	was	not,	however,	observed	at	the	upper	limit	of	the	overall	range.	Seasonal	A(H1N1)	non-outlier	viruses	yielded	higher	 IC50	values	that	ranged	up	to	3.97nM,	 followed	by	A(H3N2)	non-
Mild Extreme TOTAL Mild Extreme TOTAL2004/2005 3 35(100.0) 1.105:51.76 05(0.0) 05(0.0) 0"(0.0) 05(0.0) 05(0.0) 05(0.0) 0"(0.0)2005/2006 27 275(100.0) 0.525:53.97 05(0.0) 05(0.0) 0"(0.0) 05(0.0) 05(0.0) 05(0.0) 0"(0.0)2006/2007 :b : : : : : : : : :2007/2008 28 265(92.9) 0.445:51.73 05(0.0) 05(0.0) 0"(0.0) 25(7.1) 05(0.0) 25(7.1) 2&(7.1)2008/2009 18 175(94.4) 0.675:51.90 05(0.0) 05(0.0) 0"(0.0) 15(5.6) 05(0.0) 15(5.6) 1&(5.6)Pandemic5period 0 : : : : & : : : &TOTAL 76 735(96.1) 0.445:53.97 05(0.0) 05(0.0) 0"(0.0) 35(3.9) 05(0.0) 35(3.9) 3&(3.9)2004/2005 71 705(98.6) 0.345:51.74 05(0.0) 05(0.0) 0"(0.0) 15(1.4) 05(0.0) 15(1.4) 1&(1.4)2005/2006 1 15(100.0) 0.73 05(0.0) 05(0.0) 0"(0.0) 05(0.0) 05(0.0) 05(0.0) 0"(0.0)2006/2007 20 195(95.0) 0.365:50.73 05(0.0) 05(0.0) 0"(0.0) 05(0.0) 15(5.0) 15(5.0) 1&(5.0)2007/2008 :b : : : : : : : : :2008/2009 20 195(95.0) 0.325:50.58 05(0.0) 05(0.0) 0"(0.0) 15(5.0) 05(0.0) 15(5.0) 1&(5.0)Pandemic5period 0 : : : : & : : : &2010/2011 0 : : : : & : : : &2011/2012 26 245(92.3) 0.685:51.52 15(3.8) 15(3.8) 2&(7.7) 05(0.0) 05(0.0) 05(0.0) 2&(7.7)2012/2013 1 15(100.0) 1.1 05(0.0) 05(0.0) 0"(0.0) 05(0.0) 05(0.0) 05(0.0) 0"(0.0)TOTAL 139 1345(96.4) 0.325:51.74 15(0.7) 15(0.7) 2&(1.4) 25(1.4) 15(0.7) 35(2.2) 5&(3.6)2004/20055(YAM) 24 175(70.8) 5.625:59.72 25(8.3) 05(0.0) 2&(8.3) 25(8.3) 35(12.5) 55(20.8) 7&(29.2)2005/20065(VIC) 47 455(95.7) 9.665:524.03 05(0.0) 05(0.0) 0"(0.0) 05(0.0) 25(4.3) 25(4.3) 2&(4.3)2006/2007 2 15(50.0) 3.93 15(50.0) 05(0.0) 1&(50.0) 05(0.0) 05(0.0) 05(0.0) 1&(50.0)2007/20085(YAM) 43 395(90.7) 1.645:59.16 15(2.3) 05(0.0) 1&(2.3) 15(2.3) 25(4.7) 35(7.0) 4&(9.3)2008/20095(VIC) 1 05(0.0) : 15(100.0) 05(0.0) 1&(100.0) 05(0.0) 05(0.0) 05(0.0) 1&(100.0)Pandemic5period5(VIC) 3 05(0.0) : 35(100.0) 05(0.0) 3&(100.0) 05(0.0) 05(0.0) 05(0.0) 3&(100.0)2010/2011 2 05(0.0) : 25(100.0) 05(0.0) 2&(100.0) 05(0.0) 05(0.0) 05(0.0) 2&(100.0)2011/20125(YAM) 1 15(100.0) 7.45 05(0.0) 05(0.0) 0"(0.0) 05(0.0) 05(0.0) 05(0.0) 0"(0.0)2012/20135(YAM) 6 65(100.0) 5.715:58.72 05(0.0) 05(0.0) 0"(0.0) 05(0.0) 05(0.0) 05(0.0) 0"(0.0)TOTAL 129 1095(84.5) 1.645:524.03 105(7.8) 05(0.0) 10&(7.8) 35(2.3) 75(5.4) 105(7.8) 20&(15.5)Pandemic5period 116 1105(94.8) 0.405:50.99 45(3.4) 05(0.0) 4&(3.4) 25(1.7) 05(0.0) 25(1.7) 6&(5.2)2010/2011 26 215(80.8) 0.415:50.80 15(3.8) 15(3.8) 2&(7.7) 25(7.7) 15(3.8) 35(11.5) 5&(19.2)2011/2012 :b : : : : : : : : :2012/2013 5 15(20.0) 0.81 05(0.0) 45(80.0) 4&(80.0) 05(0.0) 05(0.0) 05(0.0) 4&(80.0)TOTAL 147 1325(89.8) 0.405:50.99 55(3.4) 55(3.4) 10&(6.8) 45(2.7) 15(0.7) 55(3.4) 15&(10.2)
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																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	120		outlier	 viruses	 that	 exhibited	 a	 maximum	 IC50	 value	 of	 1.74nM,	 	 and	 then	 by	A(H1N1)pdm09	non-outlier	viruses,	which	IC50	values	extended	up	to	0.99nM.	Influenza	B	 non-outlier	 viruses	 exhibited	 far	 higher	 IC50	 values	 distributed	 over	 a	 much	 wider	range	 that	overall	varied	 from	1.64	 to	24.03nM	(Table	4.3).	Notably,	 the	highest	values	within	 this	 range	 were	 exhibited	 by	 the	 non-outlier	 viruses	 from	 2005/2006,	 with	 all	belonging	to	the	B/VIC	lineage	(9.66	to	24.03nM).	Influenza	B	non-outlier	viruses	from	all	other	seasons	were	predominantly	or	exclusively	from	B/YAM	lineage	(Figure	4.5C).																
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Figure	4.5	Zanamivir	IC50	values	of	circulating	former	seasonal	A(H1N1)	(A),	A(H3N2)	(B),	influenza	B	(C)	and	A(H1N1)pdm09	(D)	viruses.		IC50	 values,	 cut-offs	 and	 baseline	 median	 estimates	 were	 determined	 and/or	 annotated	 as	 described	 in	 Figure	 4.4.	 All	complementary	annotations	to	IC50	plots	are	also	described	in	this	previous	figure.			ZA	IC50	outlier	viruses	belonged	to	virtually	all	4	categories,	except	in	seasonal	A(H1N1)	subtype,	in	which	all	three	outlier	viruses	were	LM	(Table	4.3).	Only	few	outlier	viruses	
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																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	122		were	 also	 detected	 in	 A(H3N2)	 subtype	 (n=5;	 3.6%),	 with	 the	 number	 increasing	considerably	in	both	influenza	type	B	(n=20;	15.5%)	and	A(H1N1)pdm09	subtype	(n=15;	10.2%).	Additional	information	on	ZA	IC50	outlier	viruses	is	presented	at	Figure	4.5	A-D,	in	which	are	also	indicated	the	IC50	cut-offs	and	baseline	median.		The	three	seasonal	A(H1N1)	LM	outlier	viruses	were	 from	2007/2008	(n=2;	7.1%)	and	2008/2009	 (n=1;	 5.6%),	 presenting	 an	 ≈3-fold	 decrease	 in	 IC50,	 compared	 to	 the	corresponding	baseline	median	(Table	4.3;	Figure	4.5A).		Two	A(H3N2)	viruses	 from	2011/2012	were	 identified	as	upper	outlier	–	virus	 isolates	A/Portugal/43/2012	 (UE	 outlier)	 and	 A/Portugal/53/2012	 (UM	 outlier),	 exhibiting,	respectively,	a	4	and	≈2-fold	higher	ZA	IC50	value	than	the	baseline	median	(Figure	4.5B).	An	≈2	to	3-fold	decrease	in	IC50	relative	to	baseline	median,	was	observed	for	the	three	A(H3N2)	lower	outlier	viruses	identified	(2	LM	and	1	LE).		Influenza	B	IC50	outlier	viruses	were	detected	in	all	influenza	seasons	except	the	two	later	ones	(2011/2012	and	2012/2013),	and	 in	the	2009	pandemic	period.	The	frequency	at	which	outlier	viruses	were	detected	varied	between	4.3%	and	50.0%	during	 the	 first	4	seasons,	 settling	 at	 100.0%	 from	 2008/2009	 onwards	 (Table	 4.3).	 Half	 (10/20)	 of	 the	outlier	 viruses	 identified	 were	 UM	 outlier,	 with	 the	 fold	 increase	 in	 IC50	 relative	 to	baseline	median	increasing	slightly	over	time.	Specifically,	from	≤2-fold	in	2004/2005	to	≈3-fold	 between	 2006/2007	 and	 2008/2009,	 and	 then	 to	 ≈4-fold	 in	 both	 pandemic	period	 and	 2010/2011	 (Figure	 4.5C).	 Only	 the	 virus	 isolate	 B/Portugal/01/2011	 from	2010/2011	 exhibited	 a	 3-fold	 higher	 IC50	value.	 It	 is	 important	 to	 note	 that	 both	 UM	outlier	viruses	from	2006/2007	(virus	isolate	B/Lisboa/02/2007)	and	2008/2009	(virus	isolate	 B/Lisboa/01/2009)	 belonged	 to	 the	 B/VIC	 lineage	 and	 were	 identified	 against	statistical	 cut-offs	 based	 on	 essentially	 IC50	 values	 from	 B/YAM-lineage	 viruses	(2007/2008).	 If	 analysed	 against	 the	 cut-offs	 estimated	 for	 2005/2006	 that	 were	exclusively	based	on	B/VIC-lineage	IC50	values,	both	virus	isolates	would	lose	their	status	of	 outlier.	However,	 it	was	 followed	 the	 same	 approach	used	 in	 the	 analysis	 of	OS	 IC50	data.	 The	 fold	 decrease	 in	 IC50	 relative	 to	 baseline	 median	 observed	 for	 lower	 outlier	viruses	 (3	 LM	 and	 7	 LE)	 also	 increased	 slightly	 over	 time.	 It	 started	 at	 ≤2-fold	 in	2004/2005	and	 then	 increased	 to	≈3-fold	 in	2005/2006	and	 to	a	 range	between	4	and	≈8-fold	 in	 2007/2008	 (Figure	 4.5C).	 All	 lower	 outlier	 viruses	 except	 one	 (virus	 isolate	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	123		B/Lisboa/13/2006)	 belonged	 to	 the	 B/YAM	 lineage.	 The	 tendency	 of	 B/VIC-lineage	viruses	for	exhibiting	higher	non-outlier	IC50	values,	compared	to	B/YAM-lineage	viruses,	observed	 in	OS	 susceptibility	 (see	 section	 4.1.4.1.1.1)	was	 not	 observed	 for	 ZA	 (higher	values	in	2007/2008,	but	not	in	2004/2005)	(Figure	4.5C).				The	frequency	of	A(H1N1)pdm09	ZA	IC50	outlier	viruses	increased	over	time.	Specifically,	from	 5.2%	 (n=6)	 in	 the	 pandemic	 period	 to	 19.2%	 (n=5)	 in	 2010/2011,	 and	 then	 to	80.0%	 (n=4)	 in	 2012/2013	 (Table	 4.3).	However,	 as	 above-mentioned	 for	OS,	 the	 high	outlier	 frequency	observed	 in	 this	 later	 season	might	be	an	artefact	of	having	analysed	the	 values	 against	 the	 IC50	 cut-offs	 estimated	 for	 2010/2011.	 Most	 A(H1N1)pdm09	outlier	viruses	were	upper	outlier	(n=10;	66.7%),	equitably	distributed	between	UM	and	UE	 outlier	 categories	 (Table	 4.3).	 An	 ≈2	 to	 3-fold	 increase	 in	 IC50	 relative	 to	 baseline	median	was	observed	for	all	upper	outlier	viruses	(Figure	4.5D).	The	5	A(H1N1)pdm09	viruses	identified	as	lower	outlier	(4	LM	and	1	LE)	presented	an	≈2-fold	decrease	in	IC50.				According	 to	 the	WHO	AVWG	IC50	 fold-change	criteria	 (detailed	 in	 section	4.1.1),	 all	76	seasonal	 A(H1N1),	 139	 A(H3N2),	 129	 influenza	 B,	 and	 147	 A(H1N1)pdm09	 viruses	showed	NI	by	ZA	(≤2-fold	(seasonal	and	2009	pandemic	A(H1N1))	or	≤4-fold	(A(H3N2),	influenza	B)	higher	IC50)		(Figure	4.5A-D).			
4.1.4.1.2	 Baseline	 level	 of	 phenotypic	 susceptibility	 –	 variation	 over	 time	 and	 overall	
estimates	
	The	 baseline	 level	 of	 phenotypic	 susceptibility	 is	 given	 by	 the	 IC50	 baseline	 median	(standard	measure),	representing	the	natural	in	vitro	susceptibility	of	circulating	viruses	to	the	drug.	In	this	study,	an	IC50	outlier	median	was	also	exceptionally	used	as	a	measure	of	 baseline	 susceptibility,	 since	 all	 seasonal	 A(H1N1)	 viruses	 from	 2008/2009	 were	outlier,	exhibiting	extremely	high	OS	IC50	values.	Figure	4.6	shows	the	IC50	baseline	and	outlier	 (seasonal	 A(H1N1)	 plot,	 OS)	median	 estimates	 plotted	 against	 time.	 Single	 IC50	non-outlier	 values	 were	 also	 included	 to	 have	 a	 reference	 for	 the	 natural	 in	 vitro	susceptibility	 of	 the	 viruses	 of	 that	 influenza	 season.	 IC50	 data	 was	 plotted	 in	 reverse	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	124		order	 to	 evidence	 the	 inverse	 relationship	 between	 IC50	 and	 drug	 susceptibility	 (the	higher	the	IC50	is,	the	lower	the	susceptibility	will	be).		Overall,	 the	 baseline	 level	 of	 phenotypic	 susceptibility	 of	 circulating	 human	 influenza	viruses	varied	over	time	(2004/2005	to	2012/2013),	but	with	no	particular	trend	and	in	essentially	different	ways	to	OS	and	ZA.			A	 small	 but	 statistically	 significant	 decrease	 in	 the	 natural	 susceptibility	 of	 circulating	seasonal	 A(H1N1)	 viruses	 to	 OS	 was	 observed	 between	 2005/2006	 and	 2007/2008	(p=0.022),	 preceding	 the	 marked	 (≈270-fold)	 and	 significant	 decrease	 in	 2008/2009	(526.35nM,	 IC50	 outlier	 median;	 p=0.001)(Figure	 4.6).	 The	 natural	 susceptibility	 of	circulating	 seasonal	 A(H1N1)	 viruses	 to	 ZA	 also	 changed	 significantly	 between	2005/2006	and	2007/2008	(p=0.003),	increasing	≈2-fold	between	the	two	seasons.		The	 natural	 susceptibility	 of	 circulating	A(H3N2)	 viruses	 to	 both	OS	 and	 ZA	 decreased	significantly	 between	 2008/2009	 and	 2011/2012	 (2-fold	 decrease;	 p<0.005)	 (Figure	4.6).	The	baseline	 level	of	susceptibility	 in	this	 later	season	was	also	significantly	 lower	(≈2-fold)	 compared	 to	 that	before	2008/2009	 (p<0.005),	with	 exception	of	2004/2005	for	ZA	(p=0.155).	The	single	OS	and	ZA	IC50	non-outlier	values	available	 for	2012/2013	were	higher	 than	 the	baseline	median	estimated	 for	2011/2012	 (Figure	4.6).	However,	the	values	were	within	the	OS	or	ZA	IC50	non-outlier	value	range	obtained	for	this	season,	as	 evidenced	 in	 previous	 Figures	 4.4B	 (OS)	 and	 4.5B	 (ZA),	 which	 suggested	 similar	natural	susceptibility	to	both	drugs.		The	influenza	B	viruses	from	the	pandemic	period	exhibited	a	significantly	lower	(2	to	3-fold)	natural	susceptibility	to	OS,	compared	to	the	viruses	from	all	influenza	seasons	for	which	 the	 IC50	 baseline	 median	 was	 estimated	 and	 possible	 to	 compare	 statistically	(pexact<0.0005,	except	with	2012/2013	(pexact=0.024))	(Figure	4.6).	However,	this	may	be	an	 artefact	 of	 the	 use	 of	 pandemic	 period	 –	 2012/2013	 combined	 cut-offs	 that,	 as	referred	 above	 (see	 section	 4.1.4.1.1.1),	 probably	 prevented	 the	 three	 considerably	higher	 OS	 IC50	 values	 of	 the	 pandemic	 period	 to	 be	 classified	 as	 outlier.	 The	 natural	susceptibility	of	circulating	influenza	B	viruses	to	OS	had	already	decreased	significantly	after	2004/2005,	as	evidenced	by	the	statistically	significant	differences	between	the	IC50	baseline	 median	 of	 2004/2005	 and	 all	 following	 influenza	 seasons	 and	 the	 pandemic	period	 (p(exact)<0.0005,	 except	with	2012/2013	 (p=0.001))	 (Figure	4.6).	Only	 compared	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	125		to	2005/2006	 this	 significant	difference	was	not	observed	 (pexact=0.212),	but	 this	 could	be	 related	 with	 the	 very	 small	 IC50	sample	 size	 for	 this	 season	 (n=2).	 Regarding	 ZA,	 a	significantly	 lower	 (2	 to	 ≈4-fold)	 natural	 susceptibility	 to	 the	 drug	 was	 detected	 in	2005/2006,	compared	to	all	other	influenza	seasons	for	which	the	IC50	baseline	median	was	estimated	(p<0.0005,	except	with	2012/2013	(p=0.023))	(Figure	4.6).	This	may	be	related	with	 the	 co-circulation	 of	 two	 distinct	 lineages	 of	 influenza	 B	 viruses,	 since	 all	non-outlier	ZA	IC50	values	in	2005/2006	were	from	B/VIC-lineage	viruses;	while	those	in	all	 other	 influenza	 seasons	 were	 exclusively	 or	 predominantly	 from	 B/YAM-lineage	viruses	 (see	 Figure	 4.5C).	 In	 fact,	 when	 comparing	 the	 overall	 natural	 susceptibility	 of	B/VIC	 and	 B/YAM-lineage	 viruses	 (data	 not	 shown),	 this	 revealed	 to	 be	 significantly	lower	 for	 B/VIC-lineage	 viruses,	 not	 only	 to	 ZA	 (p<0.0005;	 VICIC50=14.35nM,	YAMIC50=4.82nM)	but	also,	although	less	significantly,	to	OS		(p=0.002;	VICIC50=21.27nM,	YAMIC50=17.28nM).		The	natural	susceptibility	of	circulating	A(H1N1)pdm09	viruses	to	OS	decreased	slightly	but	 significantly	 between	 the	 pandemic	 period	 and	 2010/2011	 (p=0.001)	 (Figure	 4.6).	No	 significant	 variation	 was	 observed	 between	 these	 two	 time	 periods	 in	 the	 virus	natural	susceptibility	to	ZA	(p=0.272).	Also,	although	the	single	ZA	IC50	non-outlier	value	available	 for	 2012/2013	 was	 higher	 than	 the	 baseline	 median	 estimated	 for	 the	pandemic	period	and	2010/2011,	 it	was	within	both	 IC50	non-outlier	value	 ranges	 (see	Figure	4.5D),	suggesting	a	similar	natural	susceptibility	to	the	drug.		The	 natural	 in	 vitro	 susceptibility	 of	 circulating	 viruses	 to	 OS	 and	 ZA	 differed	 in	 all	influenza	 virus	 types	 and	 subtypes,	 as	 evidenced	 in	 Figure	 4.6	 by	 comparison	 of	 the	corresponding	 IC50	data	 in	 side-by-side	plots.	This	difference	was	observed	 individually	in	 the	 different	 influenza	 seasons	 or	 pandemic	 period	 and	 also	 globally	 (total	 time	period).	 Seasonal	 A(H1N1)	 (except	 those	 from	 2005/2006),	 A(H1N1)pdm09	 and,	particularly,	 influenza	 B	 viruses	 exhibited	 a	 lower	 natural	 susceptibility	 to	 OS	(respectively,	 ≤2-fold,	 ≤3-fold,	 and	 ≤5-fold	 lower),	 while	 the	 inverse	 was	 observed	 for	A(H3N2)	subtype	(≤3-fold	higher	susceptibility).	All	observed	differences	possible	to	test	statistically	 were	 found	 to	 be	 significant	 (p(exact)<0.0005,	 except	 for	 A(H3N2)	 in	2006/2007	 (pexact=0.009),	 2008/2009	 (p=0.053)	 and	 2011/2012	 (p=0.001),	 and	 for	influenza	 B	 in	 2012/2013	 (pexact=0.031)).	 Only	 the	 seasonal	 A(H1N1)	 viruses	 from	2005/2006	 exhibited	 similar	 natural	 susceptibility	 to	 OS	 and	 ZA,	 as	 confirmed	 by	statistical	comparison	(p=0.946).	
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Figure	 4.6	 Baseline	 level	 of	 phenotypic	 susceptibility	 of	 circulating	 former	 seasonal	 A(H1N1),	A(H3N2),	influenza	B	and	A(H1N1)pdm09	viruses,	to	oseltamivir	(left)	and	zanamivir	(right).		
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(Footnotes	Figure	4.6)	The	baseline	level	of	phenotypic	susceptibility	is	given	by	the	IC50	baseline	median	(median	without	IC50	outlier	values;	standard	measure).	The	oseltamivir	(OS)	IC50	outlier	median	of	the	former	seasonal	A(H1N1)	viruses	from	2008/2009	was	exceptionally	used	as	a	measure	of	their	baseline	susceptibility,	since	all	viruses	tested	were	found	to	be	upper	extreme	outlier	to	OS.	Single	IC50	non-outlier	values	are	also	 indicated	 to	have	a	 reference	 for	 the	baseline	susceptibility	 in	 that	 influenza	season.	A	colour	coded-system	composed	by	three	different	shades	of	blue	was	used	to	display	these	three	different	types	of	IC50	data	(baseline	median,	outlier	median,	single	value).	IC50	data	are	plotted	against	time	in	reverse	order	due	the	inverse	relationship	between	IC50	and	phenotypic	susceptibility	(higher	IC50	è	lower	phenotypic	susceptibility).	The	vertical	bars	represent	the	standard	error	(SE)	 of	 the	 IC50	 median	 estimates.	 When	 these	 vertical	 bars	 are	 not	 clearly	 visible	 (extremely	 small	 SE),	 the	 exact	 value	 is	displayed	in	brackets	below	the	corresponding	IC50	median	marker.	A	coloured	background	highlights	the	overall	IC50	baseline	median	 estimates.	 The	 existence	 of	 statistically	 significant	 differences	 among	 IC50	 baseline	 or	 outlier	 median	 estimates	 was	initially	assessed	by	a	Kruskal-Wallis	H	test	and	then,	if	confirmed,	by	post	hoc	pairwise	comparisons	performed	using	Dunn's	(1964)	procedure	with	a	Bonferroni	adjustment.	A(H1N1)pdm09	IC50	baseline	median	estimates	 for	the	pandemic	period	and	2010/2011	were	exceptionally	compared	by	a	Mann-Whitney	U	test.	Also,	multiple	Mann-Whitney	U	tests	were	used	in	former	seasonal	 A(H1N1)	 and	 influenza	 B	 type/subtype	 to	 calculate	 the	 exact	 statistical	 significance	 when	 comparing	 IC50	 median	estimates	on	which	at	 least	one	was	based	on	 less	 than	5	values	(n<5).	No	statistical	 inference	could,	however,	be	performed	between	the	influenza	B	OS	IC50	baseline	median	for	2006/2007	(n=2)	and	the	pandemic	period	(n=3)	or	2012/2013	(n=6),	as	both	samples	were	too	small	to	apply	the	test.	The	horizontal	punctuated	grey	lines	in	the	influenza	B	OS	plot	represent	this	lack	of	 statistical	 comparison	 (N/C:	 Not	 compared).	 Both	 asymptotic	 (standard)	 and	 exact	 p-values	 were	 considered	 statistically	significant	 at	 ≤0.05.	 The	 horizontal	 punctuated	 blue	 lines	 represent	 the	 statistically	 significant	 differences	 found,	 with	 the	asterisk	(*)	and	the	asterisk	followed	by	an	E		(*E)	further	indicating	if	the	significant	differences	were	based	on,	respectively,	asymptotic	or	exact	p-values.				Influenza	virus	type-	and	subtype-specific	differences	were	also	observed	in	the	natural	susceptibility	 of	 circulating	viruses	 to	OS	 and	ZA.	The	only	 exception	was	observed	 for	ZA,	with	A(H3N2)	and	A(H1N1)pdm09	viruses	exhibiting	a	 similar	overall	 IC50	baseline	median	 (0.68nM	 and	 0.62nM,	 respectively)	 (Figure	 4.6),	 confirmed	 by	 statistical	comparison	 (p=0.178).	 The	 variation	 observed	 in	 the	 overall	 natural	 susceptibility	 of	circulating	 viruses	 was	 similar	 to	 both	 NAIs	 and	 ordered	 as	 follows:	 influenza	 B	 <	seasonal	 A(H1N1)	 <	 A(H1N1)pdm09	 <oseltamivir/~zanamivir	 A(H3N2).	 The	 variations	observed	individually	in	the	different	influenza	seasons	or	pandemic	period	followed	this	overall	 ordering.	 Evidence	 for	 significant	 differences	 was	 found	 in	 all	 virus	 type	 or	subtype	 comparisons	 possible	 to	 test	 statistically	 (p(exact)<0.0005,	 except	 in	 2006/2007	between	 influenza	 B	 and	 A(H3N2)	 (pexact=0.017)	 for	 OS;	 and	 in	 2004/2005	 between	seasonal	A(H1N1)	and	A(H3N2)	(pexact=0.031)	or	influenza	B	(pexact=0.002)	for	ZA).				
4.1.4.2	Genotypic	Testing			OS	and/or	ZA	IC50	upper	outlier	viruses	(UM	and	UE)	were	evaluated	through	NA	and	HA	gene	 sequencing.	 The	 only	 exception	 were	 two	 A(H1N1)pdm09	 upper	 outlier	 viruses	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	128		from	2012/2013	–	virus	isolates	A/Portugal/51/2013	and	A/Portugal/52/2013	(OS	UM	outlier;	 ZA	 UE	 outlier),	 for	 which	 was	 not	 available	 sufficient	 volume	 to	 perform	genotypic	testing.	Also,	only	half	(11/21)	of	the	seasonal	A(H1N1)	OS	UE	outlier	viruses	from	 2008/2009	were	 characterized	 regarding	 their	 HA	 sequence,	 and	HA	 sequencing	was	 unsuccessful	 for	 one	 influenza	 B	 ZA	UM	outlier	 virus	 from	 the	 pandemic	 period	 –	virus	isolate	B/Portugal/01/2009.		More	 than	 25%	 (limit	 set)	 of	 the	 lower	 outlier	 viruses	 detected	within	 each	 influenza	season	 or	 pandemic	 period	 for	 each	 influenza	 virus	 type	 or	 subtype,	 were	 evaluated	through	 genotypic	 testing.	 Only	 the	 influenza	 B	 lower	 outlier	 viruses	 from	 2004/2005	and	 2005/2006	 were	 not	 characterized	 regarding	 their	 NA	 and	 both	 NA	 and	 HA	sequences,	respectively.		
	
	4.1.4.2.1	Neuraminidase	and	hemagglutinin	amino	acid	substitutions		
	 4.1.4.2.1.1	Former	seasonal	influenza	A(H1N1)	viruses			The	 relevant	 NA	 and	 HA	 amino	 acid	 substitutions	 identified	 in	 seasonal	 A(H1N1)	phenotypic	outlier	viruses	are	presented	in	Table	4.4,	including	their	specific	amino	acid	substitutions	and	further	substitutions	associated	with	NAI	resistance.		NA	H275Y	amino	acid	 substitution	known	 to	 confer	HRI	by	OS	 and	peramivir	 (PER)	 in	
vitro	 and	 to	 cause	 clinical	 resistance	 to	 OS	 in	 influenza	 N1	 NA	 viruses	 (see	 Table	 1.2,	Literature	Review	for	detail),	was	identified	in	all	27	seasonal	A(H1N1)	UE	outlier	viruses	showing	HRI	by	OS	(6	from	2007/2008;	21	from	2008/2009).	These	viruses	also	carried	the	NA	D354G	reversion	amino	acid	substitution	that,	together	with	R222Q,	V234M	and	D344N	amino	acid	substitutions,	these	latter	yielded	by	all	seasonal	A(H1N1)	outlier	and	non-outlier	 viruses	 from	 2007/2008	 onwards,	 probably	 compensated	 for	 the	 fitness	deficits	of	H275Y	substitution	(potential	 fitness-compensatory	substitutions;	detailed	 in	section	1.5.2.2,	Literature	Review).	NA	D354G	 is	 considered	a	 reversion	substitution	as	was	 present	 in	 the	 seasonal	 A(H1N1)	 viruses	 circulating	 prior	 to	 2007/2008.	 In	2007/2008,	the	circulating	viruses	acquired	the	NA	G354D	substitution	that	reverted	to	D354G	in	exclusively	NA	H275Y	variant	viruses.	According	to	the	1918	N1	NA	structure,	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	129		residue	354	 is	 located	at	 the	NA	surface,	on	 the	opposite	 side	of	 the	active	 site	 (Figure	4.7A).					
Table	 4.4	 Former	 seasonal	 A(H1N1)	 phenotypic	 outlier	 virus	 neuraminidase	 and	 hemagglutinin	specific	 amino	 acid	 substitutions	 and	 further	 substitutions	 associated	with	 neuraminidase	 inhibitor	resistance.			
	E’:	Vestigial	esterase;	HRI:	Highly	reduced	inhibition;	LEo:	Lower	extreme	outlier;	LMo:	Lower	mild	outlier;	OS:	Oseltamivir;	R:	Receptor	binding;	TM:	Transmembrane;	UEo:	Upper	extreme	outlier;	UMo:	Upper	mild	outlier;	ZA:	Zanamivir	Colour	legend:			Associated	with	HRI	by	OS	and	peramivir	in	vitro	and	know	to	cause	clinical	resistance	to	OS	-	influenza	N1	neuraminidase	(NA)	viruses				Potential	compensatory	substitution	of	the	fitness	deficits	of	NA	H275Y	substitution	in	former	seasonal	A(H1N1)	viruses	a	 Position	numbering	without	 the	N-terminal	 signal	 sequence	 (amino	 acid	 residues	1-17);	 b	 LMo	against	 ZA;	 c	Identified	 in	 all	 former	 seasonal	A(H1N1)	 viruses	 from	2007/2008	onwards	 tested	 (outlier	 and	non-outlier)	 and	 in	 virtually	 all	 reference	 viruses	 from	2005/2006	 (V234M)	or	2006/2007	 (R222Q	and	D344N)	onwards	 -	 exceptionally	 identified	 against	 the	NA	 sequences	 of	 the	 viruses	 circulating	before	 that	 (consensus	sequence	with	 222Q,	 234M	 and	 344N);	 d	Reversion	 substitution	 characteristic	 of	 the	NA	H275Y	 variant	 viruses	 circulating	 since	 2007/2008	 -	exceptionally	identified	against	the	NA	sequences	of	the	H275	wild-type	viruses	from	2007/2008	(consensus	sequence	with	354G);	e	Mixed	virus	population;	f	Shared	by	all	NA	H275Y	variant	viruses	from	2008/2009	(tested	+	reference);	also	detected	in	few	previously	circulating	H275	wild-type	and	H275Y	mutant	reference	viruses	(from	2006	to	2008);	g	Not	sequenced.	
TM	domain E'																											sub-domain2005/2006 A/Lisboa/25/2006 OS	UMoA/Lisboa/08/2008 OS	UMo - - - R222Qc V234Mc D344Nc - - - - - - V201I -A/Lisboa/02/2008 OS	UEo,	HRI - - - R222Qc V234Mc H275Y D344Nc D354Gd - -A/Lisboa/03/2008 OS	UEo,	HRI - - - R222Qc V234Mc H275Y D344Nc D354Gd - -A/Lisboa/11/2008 OS	UEo,	HRI - - - R222Qc V234Mc H275Y D344Nc D354Gd - -A/Lisboa/20/2008 OS	UEo,	HRI - - - R222Qc V234Mc H275Y D344Nc D354Gd - - M271I -A/Lisboa/27/2008 OS	UEo,	HRI - - - R222Qc V234Mc H275Y D344Nc D354Gd - - - E194K E165K -A/Lisboa/28/2008 OS	UEo,	HRI - - - R222Qc V234Mc E259K/Ee H275Y D344Nc D354Gd - - D186G N71D/Ne -A/Lisboa/29/2008 OS	UEo,	HRI - I54T - R222Qc V234Mc H275Y D344Nc D354Gd T435R - - G152E A189T	fA/Lisboa/39/2008 OS	UEo,	HRI - G41R I48M R222Qc V234Mc I241L H275Y D344Nc D354Gd - - A189T	f -A/Lisboa/40/2008 OS	UEo,	HRI - - - R222Qc V234Mc H275Y D344Nc D354Gd - - - A189T	f E242GA/Lisboa/41/2008 OS	UEo,	HRI - V75F - R222Qc V234Mc H275Y D344Nc D354Gd - - - A189T	f -A/Lisboa/2/2009 OS	UEo,	HRI - - - R222Qc V234Mc H275Y D344Nc D354Gd - - - A189T	f -A/Lisboa/3/2009 OS	UEo,	HRI - - - R222Qc V234Mc H275Y D344Nc D354Gd T435R - - G152E A189T	fA/Lisboa/5/2009 OS	UEo,	HRI - G41R I48M R222Qc V234Mc I241L H275Y D344Nc D354Gd - - A189T	f -A/Lisboa/6/2009 OS	UEo,	HRI - G41R I48M R222Qc V234Mc I241L H275Y D344Nc D354Gd -A/Lisboa/7/2009 OS	UEo,	HRI - - - R222Qc V234Mc H275Y D344Nc D354Gd - - - A189T	f -A/Lisboa/13/2009 OS	UEo,	HRI - G41R - R222Qc V234Mc I241L H275Y D344Nc D354Gd S364NA/Lisboa/14/2009b OS	UEo,	HRI - G41R - R222Qc V234Mc I241L H275Y D344Nc D354Gd - - A189T	f -A/Lisboa/15/2009 OS	UEo,	HRI - G41R - R222Qc V234Mc I241L H275Y D344Nc D354Gd -A/Lisboa/16/2009 OS	UEo,	HRI - G41R I48M R222Qc V234Mc I241L H275Y D344Nc D354Gd -A/Lisboa/17/2009 OS	UEo,	HRI - G41R I48M R222Qc V234Mc I241L H275Y D344Nc D354Gd -A/Lisboa/18/2009 OS	UEo,	HRI - - - R222Qc V234Mc H275Y D344Nc D354Gd - -A/Lisboa/19/2009 OS	UEo,	HRI - G41R R222Qc V234Mc I241L H275Y D344Nc D354Gd -A/Lisboa/20/2009 OS	UEo,	HRI - G41R I48M R222Qc V234Mc I241L H275Y D344Nc D354Gd - E99G A189T	f - R75K I91FA/Lisboa/21/2009 OS	UEo,	HRI - - - R222Qc V234Mc H275Y D344Nc D354Gd T435A -A/Lisboa/23/2009 OS	UEo,	HRI - - - R222Qc V234Mc H275Y D344Nc D354Gd T435A -A/Lisboa/24/2009 OS	UEo,	HRI - G41R S105N R222Qc V234Mc I241L H275Y D344Nc D354Gd - A189T	f -A/Lisboa/25/2009 OS	UEo,	HRI - - - R222Qc V234Mc H275Y D344Nc D354Gd - -2005/2006 A/Lisboa/24/2006 OS	LMo - I116MA/Lisboa/77/2007 OS	LMo M23T - - R222Qc V234Mc D344Nc - - - -A/Lisboa/09/2008 OS	LMo - - - R222Qc V234Mc D344Nc - - - -A/Lisboa/10/2008 OS	LMo - - - R222Qc V234Mc D344Nc - - - -A/Lisboa/14/2008 OS	LEo - - - R222Qc V234Mc D344Nc - - - -A/Lisboa/19/2008 ZA	LMo - - - R222Qc V234Mc D344Nc - - - -
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(Footnotes	Table	4.4	cont.)	NA	 and	 hemagglutinin	 (HA)	 nucleotide	 sequences	 of	 tested	 (n=57	NA;	 n=40	HA)	 and	 reference	 (n=22	NA;	 n=23	HA)	 former	seasonal	A(H1N1)	viruses	were	aligned	by	Clustal	W	method,	edited	and	translated	into	the	amino	acid	sequence	in	MEGA5.	The	accession	 number	 of	 the	 nucleotide	 sequences	 of	 the	 viruses	 tested	 shared	 through	 public-access	 databases	 can	 be	 found	 in	Supplementary	 data	 (Table	 S4.1),	 as	 well	 as	 detailed	 information	 on	 the	 nucleotide	 sequences	 of	 the	 worldwide	 reference	viruses	 collected	 for	 this	 study	 (Table	 S4.2).	 NA	 and	 HA	 amino	 acid	 substitutions	 were	 identified	 against,	 respectively,	 the	seasonal	N1	and	H1	consensus	sequences,	with	exception	of	the	few	substitutions	described	above	(see	footnotes	c	and	d).	The	amino	acid	substitutions	are	indicated	using	the	subtype	specific	numbering	scheme	(seasonal	N1	and	H1	numbering)	and	are	displayed	in	order	and	by	the	structural	domain	(NA)	or	sub-domain	(HA)	of	the	protein	on	which	occurred.	The	location	of	the	NA	structural	domains	in	the	seasonal	N1	monomer	was	based	on	Colman	8	and	Wei	9,	while	the	location	of	the	HA	structural	sub-domains	in	the	seasonal	H1	monomer	was	established	according	to	Rosenthal	et	al.	10	and	Gamblin	et	al.	11.	The	amino	acid	substitutions	shared	by	two	or	more	UEo	viruses	are	highlighted	in	bold	and	italic,	while	those	occurring	at	residues	belonging	to	 the	 HA	 receptor	 binding	 site	 (based	 on	 Gamblin	 et	 al.	 11)	 are	 underlined.	 Detailed	 information	 on	 the	 NA	 amino	 acid	substitutions	 associated	with	NA	 inhibitor	 resistance	 can	be	 found	 at	 Table	 1.2	 (H275Y)	 or	 section	1.5.2.2	 (potential	 fitness-compensatory	mutations)	of	Literature	Review.			Four	different	combinations	of	specific	amino	acid	substitutions	were	identified	in	the	NA	of	the	seasonal	A(H1N1)	HRI	viruses	from	2008/2009:	(1)	H275Y	+	D354G	(combination	carried	by	those	from	2007/2008);	(2)	H275Y	+	D354G	+	T435R;	(3)	H275Y	+	D354G	+	G41R	 +	 I241L;	 and	 (4)	 H275Y	 +	 D354G	 +	 G41R	 +	 I48M	 +	 I241L.	 These	 different	combinations	were	not,	however,	associated	with	different	fold	increases	in	OS	IC50.	Also,	the	 amino	 acid	 substitutions	 distinguishing	 the	 combinations	 occurred	 at	 residues	located	at	either	some	distance	(I241L)	or	 far	away	(T435R,	G41R,	and	I48M)	 from	the	NA	active	site	and	residue	275.	Residues	241	and	435	are,	respectively,	buried	and	at	the	surface	 of	 the	NA	 globular	 head	 (Figure	 4.7A),	while	 residues	 41	 and	48	 belong	 to	 the	stalk	 domain	 of	 the	 protein	 (Table	 4.4).	 Further	 NA	 specific	 amino	 acid	 substitutions	identified	 in	 single	 HRI	 viruses	 from	 either	 2007/2008	 or	 2008/2009	 also	 lie	 at	 the	surface	of	 the	globular	head	(E259K/E,	S364N;	Figure	4.7A)	or	within	the	stalk	domain	(I54T,	V75F;	Table	4.4).		Seasonal	 A(H1N1)	 UM	 and	 lower	 (LM	 and	 LE)	 outlier	 viruses	 carried	 no	 specific	 NA	amino	 acid	 substitution,	 with	 exception	 of	 the	 virus	 isolate	 A/Lisboa/77/2007	 (LM	outlier)	 that	contained	the	NA	M23T	substitution	 in	 the	 transmembrane	domain	(Table	4.4).			Regarding	 HA	 amino	 acid	 substitutions,	 all	 seasonal	 A(H1N1)	 HRI	 viruses	 from	2008/2009	evaluated	through	HA	sequencing	(n=11)	carried	the	HA	A189T	amino	acid	substitution,	 with	 two	 of	 them	 –	 virus	 isolates	 A/Lisboa/29/2008	 and	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	131		A/Lisboa/03/2009,	 further	 carrying	 HA	 G152E	 amino	 acid	 substitution	 (Table	 4.4).	Residues	189	and	152	are	located	at	or	near	the	190-α-helix	of	the	HA	receptor	binding	site	 (RBS)	 (Figure	 4.7B)	 and	 within	 antigenic	 site	 Sb	 12,13.	 	 All	 other	 HA	 amino	 acid	substitutions	 identified	 in	 single	 HRI	 viruses	 from	 2008/2009	 –	 virus	 isolates	A/Lisboa/40/2008	 (E242G)	 and	 A/Lisboa/20/2009	 (E99G,	 R75K	 (HA2),	 and	 I91F	(HA2)),	 occurred	 away	 from	 the	 RBS.	 But,	 two	 of	 them	 -	 E99G	 and	 R75K	 (HA2),	 are	located	at	or	 in	the	vicinity	of	the	putative	second	sialic	acid	binding	site	on	HA	(Figure	4.7B).	 Two	 seasonal	 A(H1N1)	 HRI	 viruses	 from	 2007/2008	 –	 virus	 isolates	A/Lisboa/27/2008	 and	 A/Lisboa/28/2008,	 carried	 an	 amino	 acid	 substitution	 at	 the	190-α-helix	of	 the	HA	RBS	-	E194K	and	D186G,	respectively	(Figure	4.7B),	with	residue	186	being	directly	involved	in	receptor	binding.	Both	residues	194	and	186	belong	to	the	antigenic	site	Sb.	Virus	isolate	A/Lisboa/28/2008	contained	a	second	specific	amino	acid	substitution	located	at	the	putative	second	sialic	acid	HA	binding	site	-	N71D/N	(Figure	4.7B).	 All	 other	 4	 HRI	 viruses	 from	 2007/2008,	 as	 well	 as	 the	 remaining	 seasonal	A(H1N1)	 outlier	 viruses	 evaluated,	 contained	 either	 no	 specific	 HA	 amino	 acid	substitution	(majority)	or	a	single	HA	amino	acid	substitution	located	away	from	the	RBS	(I116M,	M271I,	V201I	(HA2))	(Table	4.4;	Figure	4.7B).										
	
	
	
	
Figure	4.7	Mapping	of	the	neuraminidase	(A)	and	hemagglutinin	(B)	residues	on	which	were	detected	the	 amino	acid	 substitutions	 specific	 of	 former	 seasonal	A(H1N1)	phenotypic	 outlier	 viruses	 and/or	associated	 with	 neuraminidase	 inhibitor	 resistance,	 onto	 the	 three-dimensional	 structure	 of	 the	protein.	The	 figures	were	generated	 in	PyMOL,	using	 the	protein	structure	 file	previously	retrieved	 from	the	RCSB	Protein	Data	Bank.	
Panel	 A:	 structure	 of	 the	 globular	 head	 of	 the	 neuraminidase	 (NA)	 from	 the	 former	 seasonal	 A(H1N1)	 virus	 A/Brevig	Mission/01/1918	(PDB	ID:	3B3Q;	only	the	globular	head	of	one	of	the	two	monomers	described	in	the	file	is	shown).		
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(Footnotes	Figure	4.7	cont.)	The	residues	forming	the	NA	active	site	(based	on	Colman	et	al.	14)	are	coloured	in	dark	blue	(functional	residues)	or	light	purple	(framework	 residues)	 and	 shown	as	 sticks.	Panel	 B:	 structure	of	 the	hemagglutinin	 (HA)	 from	 the	 former	 seasonal	A(H1N1)	virus	A/South	Carolina/01/1918	(PDB	ID:	1RUZ;	only	one	monomer	of	the	HA	trimer	described	in	the	file	is	shown).	The	HA1	subunit	 is	 displayed	 in	 light	 golden	 and	 the	 HA2	 subunit	 in	 dark	 grey.	 The	 receptor	 binding	 site	 (RBS)	 residues	 (based	 on	Gamblin	et	al.	 11)	are	shown	as	dark	blue	sticks,	while	 the	residues	 forming	the	putative	second	sialic	acid	binding	site	on	HA	(based	on	Sauter	et	al.	15)	are	displayed	as	light	purple	sticks.	Panel	A	and	B:	the	residues	on	which	were	detected	the	amino	acid	 substitutions	 are	 shown	 as	 sticks	 that	 are	 colour-coded	 according	 to	 the	 phenotypic	 outlier	 category	 of	 the	 virus(es)	carrying	 the	 substitution:	 red	 -	 upper	 extreme	 outlier;	 orange	 -	 upper	mild	 outlier;	 turquoise	 blue	 -	 lower	mild	 outlier.	 The	residues	belonging	 to	 the	HA	RBS	or	 second	binding	 site	maintained,	 however,	 the	 colour	 assigned	 to	 the	 functional	 site.	NA	residues	located	outside	the	globular	head	(residues	23,	41,	48,	54	and	75)	could	not	be	displayed	(panel	A).	HA2	residue	201	was	also	missing	in	the	structure	file	used	(HA2	residues	1	to	160)	and	thereby	is	not	displayed	(panel	B).			 4.1.4.2.1.2	Influenza	A(H3N2)	viruses			NA	I222V	amino	acid	substitution	known	to	confer	a	2	or	4-fold	decreased	susceptibility	to	OS	in	A(H3N2)	viruses	(see	Table	1.2,	Literature	Review	for	detail)	was	identified	in	an	UE	outlier	virus	from	2011/2012	with	an	≈4-fold	increase	in	both	OS	and	ZA	IC50	-	virus	isolate	 A/Portugal/43/2012	 (Table	 4.5).	 The	 effect	 of	 this	 substitution	 on	 ZA	susceptibility	 is	 still	 unknown	 for	 A(H3N2)	 subtype	 but	 an	 ≈2-fold	 increase	 in	 IC50	has	been	reported	for	all	other	human	influenza	virus	types	and	subtypes	(detailed	in	Table	1.2,	Literature	Review).	Besides	NA	 I222V,	 the	virus	also	carried	NA	D251G	and	S331N	amino	 acid	 substitutions	 located,	 respectively,	 at	 some	distance	 and	 far	 away	 from	 the	active	 site	 (Figure	 4.8A).	 All	 other	 A(H3N2)	 upper	 outlier	 viruses	 contained	 either	 no	specific	NA	amino	acid	substitution	or	a	single	NA	amino	acid	substitution	located	away		from	the	active	site	(F42L,	T138I/T)	(Table	4.5;	Figure	4.8A).		All	 A(H3N2)	 lower	 outlier	 viruses	 evaluated	 through	NA	 sequencing	 contained	 also	 no	specific	 amino	 acid	 substitution	 in	 their	 NA	 (Table	 4.5).	 The	 NA	 D151N	 amino	 acid	substitution	identified	as	a	mixed	virus	population	in	a	LE	outlier	virus	from	2006/2007	–	virus	isolate	A/Lisboa/08/2007,	is	exceptionally	indicated	in	Table	4.5	as	several	other	substitutions	 at	 this	 same	 residue	 (D151A/E/G/V)	 are	 associated	 with	 (H)RI	 by	 NAI	drugs	 (see	 Table	 1.2,	 Literature	 Review	 for	 detail).	 Also,	 in	 influenza	 B	 viruses,	 this	substitution	 is	 known	 to	 confer	 RI	 by	 PER.	NA	D151N	 substitution	was	 detected	 in	 11	reference	A(H3N2)	viruses	from	2007	to	2012.			
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	133		The	non-outlier	virus	isolate	A/Portugal/56/2013,	recovered	from	a	patient	undergoing	OS	therapy,	carried	NA	I262V	and	D399E	amino	acid	substitutions	located	at	the	surface	of	the	NA	globular	head	(Table	4.5;	Figure	4.8A).	The	clinical	specimen	yielding	this	virus	isolate	contained	both	amino	acid	substitutions	(identical	NA	genetic	background).			
Table	 4.5	 Neuraminidase	 and	 hemagglutinin	 amino	 acid	 substitutions	 specific	 of	 the	 influenza	A(H3N2)	viruses	classified	as	phenotypic	outlier	or	recovered	from	a	patient	under	antiviral	therapy.																					
		E’:	 Vestigial	 esterase;	 LEo:	 Lower	 extreme	outlier;	 LMo:	 Lower	mild	outlier;	OS:	Oseltamivir;	R:	Receptor	binding;	UEo:	Upper	 extreme	outlier;	UMo:	Upper	mild	outlier;	ZA:	Zanamivir	Colour	legend:		 		Associated	with	a	normal	inhibition	≥2-fold	by	OS	in	vitro,	confirmed	by	reverse	genetics	–	influenza	A(H3N2)	viruses	a	 Position	 numbering	 without	 the	 N-terminal	 signal	 sequence	 (amino	 acid	 residues	 1-16);	 b	 LEo	 against	 ZA;	 c	Mixed	 virus	 population;	 d	 Also	identified	 in	11	reference	A(H3N2)	viruses	 from	2007	to	2012;	exceptionally	 indicated	as	 it	occurs	 in	a	residue	widely	associated	with	 (highly)	reduced	inhibition	by	neuraminidase	(NA)	inhibitors	in	vitro	(D151A/E/G/V	amino	acid	substitutions);	e	Not	sequenced.	The	amino	acid	substitutions	were	identified	and	are	displayed	as	described	in	Table	4.4	(N2	and	H3	numbering).	The	analysis	involved	 a	 total	 of	 124	 NA	 and	 hemagglutinin	 (HA)	 sequences	 from	 tested	 (n=60	 NA;	 n=57	 HA	 (+1	 clinical	 specimen))	 and	reference	 (n=63	 NA;	 n=66	 HA)	 A(H3N2)	 viruses	 (detailed	 information	 in	 Tables	 S4.1	 and	 S4.2,	 Supplementary	 data).	 The	location	of	the	NA	structural	domains	in	the	A(H3N2)	N2	monomer	was	based	on	Colman	8,	Colman	and	Ward	16,	and	Air	and	Laver	17;	while	the	location	of	the	HA1	structural	sub-domains	in	the	A(H3N2)	H3	monomer	was	established	according	to	Ha	et	
al.	18.	All	substitutions	occurring	at	residues	belonging	to	the	NA	active	site	(based	on	Colman	et	al.	14)	or	the	HA	receptor	binding	site	 (based	on	Russell	et	al.	 19)	 are	underlined.	Detailed	 information	on	 the	effect	of	NA	 I222V	and	D151A/E/G/V	amino	acid	substitutions	on	A(H3N2)	virus	susceptibility	can	be	found	at	Table	1.2,	Literature	Review.			HA	T135A	amino	acid	substitution	was	 identified	 in	an	A(H3N2)	UM	outlier	virus	 from	2011/2012	–	virus	 isolate	A/Portugal/29/2012	(Table	4.5).	Residue	135	belongs	to	the	HA	 RBS	 and	 is	 directly	 involved	 in	 sialic	 acid	 receptor	 binding.	 It	 also	 belongs	 to	 the	
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																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	134		antigenic	site	A	20,	with	the	threonine	(T)	to	alanine	(A)	substitution	resulting	in	the	loss	of	a	potential	N-linked	glycosylation	site	at	position	133	(N133).	All	other	A(H3N2)	upper	outlier	 viruses,	 as	 well	 as	 all	 lower	 outlier	 viruses	 evaluated	 through	 HA	 sequencing	except	one	(virus	isolate	A/Lisboa/34/2005),	carried	no	specific	amino	acid	substitution.		A/Lisboa/34/2005	carried	HA	S54G	amino	acid	 substitution	 located	 far	 away	 from	 the	RBS	 (Figure	4.8B)	and	within	antigenic	 site	C	 20.	The	single	A(H3N2)	virus	with	known	association	to	antiviral	therapy	(virus	isolate	A/Portugal/56/2013)	contained	HA	R261L	amino	 acid	 substitution	 located	 away	 from	 the	RBS	 (Figure	 4.8B)	 and	within	 antigenic	site	E	20.	This	virus	also	contained,	although	not	specifically	(also	identified	in	8	reference	viruses	from	2006	to	2012/2013),	the	HA	R142G	amino	acid	substitution	that	is	known	to	 occur	 clinically	 under	 OS	 drug	 pressure	 (detailed	 in	 section	 1.5.2.1.2,	 Literature	Review).	 The	 presence	 of	 both	 substitutions	 was	 confirmed	 in	 the	 matching	 clinical	specimen.	 The	 HA	 S262N	 amino	 acid	 substitution	 know	 to	 emerge	 during	 antiviral	therapy	was	identified	in	an	A(H3N2)	non-outlier	virus	from	2004/2005	with	no	known	association	with	drug	use	 (no	 information	available)	–	virus	 isolate	A/Lisboa/90/2005.	The	 impact	 of	 both	 HA	 R142G	 and	 S262N	 substitutions	 on	 A(H3N2)	 virus	 NAI	susceptibility	 is	 still	 unknown.	 But,	 according	 to	 the	 H3	 HA	 structure	 of	A/Victoria/361/2011	 vaccine	 virus,	 these	 substitutions	 occur	 at	 either	 some	 distance	(R142G)	or	far	away	(S262N)	from	the	RBS	(Figure	4.8B).								
	
	
	
	
	
	
	
Figure	4.8	Mapping	of	the	neuraminidase	(A)	and	hemagglutinin	(B)	residues	on	which	were	detected	the	 amino	 acid	 substitutions	 specific	 of	 the	 A(H3N2)	 viruses	 classified	 as	 phenotypic	 outlier	 or	recovered	from	a	patient	under	antiviral	therapy,	onto	the	three-dimensional	structure	of	the	protein.	
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(Footnotes	Figure	4.8)	The	figure	was	generated	and	annotated	as	described	in	Figure	4.7,	using	the	structure	of	the	neuraminidase	(NA)	globular	head	from	 the	 A(H2N2)	 virus	 A/Tokyo/3/1967	 (PDB	 ID:	 1NN2)	 (panel	 A)	 and	 the	 structure	 of	 the	 hemagglutinin	 (HA)	 from	 the	A(H3N2)	 vaccine	 virus	 A/Victoria/361/2011	 (PDB	 ID:	 4WE8)	 (panel	 B).	 The	 residues	 defined	 as	 belonging	 to	 the	 receptor	binding	site	(RBS)	of	H3	HA	are	based	on	Russell	et	al.	19.	Similarly	to	HA	RBS	residues,	NA	active	site	residues	are	not	coloured	according	 to	 the	 phenotypic	 outlier	 category	 of	 the	 virus	 carrying	 the	 substitution,	 maintaining	 the	 colour	 assigned	 to	 the	corresponding	type	of	active	site	residue	(functional	or	framework).	The	additional	residues	on	which	occurred	the	amino	acid	substitutions	specific	of	the	influenza	virus	recovered	from	a	patient	undergoing	antiviral	therapy	are	also	shown	as	sticks	and	are	coloured	in	light	green.	Panel	B:	the	HA	residues	on	which	were	detected	amino	acid	substitutions	known	to	emerge	during	antiviral	therapy	are	indicated	using	dark	green	sticks.		 	4.1.4.2.1.3	Influenza	B	viruses			NA	D197N	 substitution	 known	 to	 confer	 RI	 by	NAIs	 (up	 to	 10-fold	 for	 OS	 and	 ZA;	 see	Table	1.2,	Literature	Review	for	detail)	was	identified	in	a	significant	proportion	(44.1%;	pyrosequencing	data	not	shown)	of	the	virus	population	comprising	the	influenza	B	virus	isolate	 B/Lisboa/34/2008	 that	 exhibited	 an	 ≈3-fold	 increase	 in	 ZA	 IC50	 (UM	 outlier)	(Table	4.6).				
Table	 4.6	 Neuraminidase	 and	 hemagglutinin	 amino	 acid	 substitutions	 specific	 of	 influenza	 B	phenotypic	outlier	viruses.														
	E’:	Vestigial	esterase;	LEo:	Lower	extreme	outlier;	LMo:	Lower	mild	outlier;	OS:	Oseltamivir;	R:	Receptor	binding;	UMo:	Upper	mild	outlier;	VIC:	Victoria;	YAM:	Yamagata;	ZA:	Zanamivir	Colour	legend:		 		Associated	with	reduced	inhibition	by	neuraminidase	(NA)	inhibitors	(NAIs)	in	vitro	-	Influenza	B	viruses	a	Position	numbering	without	the	N-terminal	signal	sequence	(amino	acid	residues	1-15);	b	Also	identified	in	an	reference	influenza	B	virus	from	2009	-	B/Uganda/U514/2009	(no	information	available	regarding	its	susceptibility	to	NAIs);	c	Mixed	virus	population;	d	Not	sequenced.	
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(Footnotes	Table	4.6	cont.)	The	 amino	 acid	 substitutions	 were	 identified	 and	 are	 displayed	 as	 described	 in	 Table	 4.4	 (B/Victoria-lineage	 NA	 and	 HA	numbering).	The	analysis	involved	a	total	of	94	NA	and	108	hemagglutinin	(HA)	sequences	from	tested	(n=38	NA;	n=49	HA)	and	reference	 (n=56	 NA;	 n=59	 HA)	 influenza	 B	 viruses	 (detailed	 information	 in	 Tables	 S4.1	 and	 S4.2,	 Supplementary	 data).	 The	location	of	the	NA	structural	domains	in	the	influenza	B	NA	monomer	was	based	on	Colman	and	Ward	16,	and	Flandorfer	et	al.	21;	while	the	location	of	the	HA1	structural	sub-domains	in	the	influenza	B	HA	monomer	was	established	according	to	Wang	et	al.	22	and	Ni	et	al.	23.	The	amino	acid	substitutions	occurring	at	residues	belonging	to	the	NA	active	site	(based	on	Colman	et	al.	14)	are	underlined.	Detailed	 information	on	the	effect	of	NA	D197N	amino	acid	substitution	on	influenza	B	virus	susceptibility	can	be	found	at	Table	1.2,	Literature	Review.			Further	 evaluation	 of	 virus	 susceptibility	 to	 OS	 by	 chemiluminescent	 assay	 did	 not	confirm	 the	 non-outlier	 status	 of	 this	mixed	 virus	 population	 of	wild-type	 and	mutant	D197N	viruses,	but	rather	identify	the	virus	isolate	as	UM	outlier	(≈2-fold	increase	in	OS	IC50;	data	not	shown).	NA	I240V	amino	acid	substitution	located	closely	to	the	active	site	(Figure	4.9A)	was	 identified	 in	 the	UM	outlier	virus	 isolate	B/Lisboa/12/2005	and	 in	a	reference	 influenza	 B	 virus	 from	 2009	 with	 no	 available	 information	 regarding	 its	susceptibility	 to	 NAIs	 (Table	 4.6).	 All	 further	 NA	 amino	 acid	 substitutions	 specific	 of	influenza	 B	 UM	 outlier	 viruses,	 except	 V63M	 and	 K65L	 (stalk),	 were	 located	 in	 the	globular	 head	 catalytic	 domain	 (Table	 4.6),	 but	 far	 away	 from	 the	 active	 site	 (Figure	4.9A).	Approximately	half	 (6/13)	of	 the	UM	outlier	viruses	contained	no	specific	amino	acid	substitution	in	NA.	This	was	also	the	case	of	the	single	influenza	B	lower	outlier	virus	evaluated	through	NA	sequencing	(Table	4.6).		
											
	
Figure	4.9	Mapping	of	the	neuraminidase	(A)	and	hemagglutinin	(B)	residues	on	which	were	detected	the	 amino	 acid	 substitutions	 specific	 of	 the	 influenza	 B	 phenotypic	 outlier	 viruses,	 onto	 the	 three-dimensional	structure	of	the	protein.	
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(Footnotes	Figure	4.9)	The	figure	was	generated	and	annotated	as	described	in	Figure	4.7,	using	the	structure	of	the	neuraminidase	(NA)	globular	head	(PDB	ID:	4CPL,	only	one	globular	head	of	the	two	described	in	the	file	is	shown)	(panel	A)	and	of	the	hemagglutinin	(HA)	(PDB	ID:	4FQM,	only	one	monomer	of	 the	HA	 trimer	described	 in	 the	 file	 is	 shown)	 (panel	 B)	 from	 the	B/Victoria-lineage	vaccine	virus	B/Brisbane/60/2008.	The	HA	residues	forming	the	influenza	B	RBS	were	defined	according	to	Wang	et	al.	24	and	Wang	25.	NA	 active	 site	 residues	 are	 not	 coloured	 according	 to	 the	 phenotypic	 outlier	 category	 of	 the	 virus	 carrying	 the	 substitution,	maintaining	the	colour	assigned	to	the	corresponding	type	of	active	site	residue	(functional	or	framework).	NA	residue	71	could	not	be	indicated	as	is	missing	in	the	structure	file	used	(include	residues	77	to	466).				All	influenza	B	phenotypic	outlier	viruses	evaluated	through	HA	sequencing	contained	no	specific	 amino	 acid	 substitution,	 with	 exception	 of	 the	 UM	 outlier	 virus	 isolates	B/Lisboa/12/2005	 (2004/2005)	 and	 B/Portugal/02/2009	 (pandemic	 period).	 These	contained,	respectively,	the	HA	K45R	and	T311A	and	HA	A146T	amino	acid	substitutions,	located	far	away	from	the	RBS	(Table	4.6;	Figure	4.9B).			 4.1.4.2.1.4	2009	pandemic	influenza	A(H1N1)	viruses		NA	H275Y	amino	acid	substitution	was	identified	in	the	single	A(H1N1)pdm09	UE	outlier	virus	 showing	 HRI	 by	 OS	 –	 virus	 isolate	 A/Portugal/03/2011	 (Table	 4.7).	 As	 above-mentioned,	NA	H275Y	substitution	is	known	to	confer	HRI	by	OS	and	PER	in	vitro	and	to	cause	clinical	resistance	to	OS,	in	N1	NA	influenza	viruses.	The	clinical	specimen	yielding	this	virus	isolate	also	carried	the	NA	H275Y	substitution,	as	detected	in	the	initial	H275Y	screening	performed	at	HCC	on	 clinical	 specimens	 collected	 from	patients	 suspected	of	having	developed	drug-resistant	influenza	during	antiviral	therapy	(suspected	case	3;	see	Table	 3.2,	 Material	 and	 Methods).	 The	 two	 NA	 amino	 acid	 substitutions	 that	 may	potentially	compensate	 for	 the	 fitness	deficits	of	H275Y	substitution	 in	A(H1N1)pdm09	viruses	–	V241I	and	N369K	substitutions	(detailed	in	section	1.5.2.2,	Literature	Review),	were	 identified	 in	 this	NA	H275Y	variant	virus	and	 in	all	other	A(H1N1)pdm09	viruses	from	2010/2011	onwards	evaluated	through	NA	sequencing	(Table	4.7).	A	proportion	of	the	 virus	 population	 comprising	 the	 isolate	 A/Portugal/03/2011	 also	 carried	 the	 NA	P337S	amino	acid	 substitution	 (P337S/P	mixed	virus	population;	Table	4.7),	 located	at	some	distance	from	either	the	residue	275	or	the	active	site	(Figure	4.10A).		The	two	A(H1N1)pdm09	upper	outlier	viruses	from	the	pandemic	period	sharing	an	≈4-fold	 and	 ≈2-fold	 decreased	 susceptibility	 to,	 respectively,	 OS	 and	 ZA	 –	 virus	 isolates	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	138		A/Portugal/17/2009	 and	 A/Portugal/82/2009,	 carried	 the	 NA	 I223V	 amino	 acid	substitution	 (Table	 4.7).	 This	 substitution	 is	 known	 to	 confer	 slightly	 decreased	susceptibility	 to	 NAIs	 in	 A(H1N1)pdm09	 subtype	 (6-fold	 OS,	 2-fold	 ZA;	 see	 Table	 1.2,	Literature	Review	for	detail).		The	remaining	A(H1N1)pdm09	upper	outlier	viruses	contained	either	a	single	or	two	NA	amino	acid	substitutions	located	within	the	globular	head	but	at	some	distance	(K432E)	or	 far	 away	 (I359M,	 T381N,	 G454S)	 from	 the	 active	 site,	 or	 no	 specific	NA	 amino	 acid	substitution	 (majority)	 (Table	 4.7;	 Figure	 4.10A).	 Most	 A(H1N1)pdm09	 lower	 outlier	viruses	 evaluated	 through	 NA	 sequencing	 contained	 also	 no	 specific	 amino	 acid	substitution.	Only	 two	OS	LM	outlier	viruses	 from	the	pandemic	period	carried	a	single	(virus	 isolate	 A/Portugal/27/2009)	 or	 three	 (virus	 isolate	 A/Portugal/01/2010)	 NA	amino	acid	substitutions,	 located	 in	 the	stalk	(V53A,	T48K)	or	within	 the	globular	head	but	far	away	from	the	active	site	(V267I,	W457G)	(Table	4.7;	Figure	4.10A).	Residue	267	(V267I	substitution)	belongs	to	a	known	antibody	epitope	of	2009	pandemic	N1	NA	(CD6	epitope)	26.			The	NA	Y155H	amino	acid	 substitution	known	 to	 confer	 (H)RI	by	OS	and	ZA	 in	 former	circulating	A(H1N1)	viruses	was	identified	in	A(H1N1)pdm09	viruses	classified	as	either	lower	outlier	 (n=3;	Table	4.7)	 or	non-outlier	 (n=16).	 This	 evidenced	 that	 its	 impact	 on	virus	susceptibility	does	not	extend	to	2009	pandemic	A(H1N1)	subtype.			The	 non-outlier	 virus	 isolate	 A/Portugal/28/2009	 that,	 similarly	 to	 NA	 H275Y	 variant	virus	A/Portugal/03/2011,	was	recovered	from	a	patient	suspected	of	having	developed	drug-resistant	influenza	during	OS	therapy	(suspected	case	1;	see	Table	3.2,	Material	and	Methods),	 contained	 no	 specific	 amino	 acid	 substitution	 in	 NA.	 The	 clinical	 specimen	yielding	this	virus	isolate	presented	an	identical	NA	genetic	background.		NA	 sequencing	of	 the	virus	population	present	 in	 clinical	 specimens	 collected	 from	 the	same	 patient	 before,	 during	 and	 after	 antiviral	 therapy,	 showed	 the	 emergence	 of	 NA	Y66C	 amino	 acid	 substitution	 as	 viral	 quasispecies	 after	 therapy	 (Y66C/Y	mixed	 virus	population).	Residue	66	is	located	in	the	stalk	domain	of	the	protein	(Table	4.7).		
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	139		
Table	4.7	Neuraminidase	and	hemagglutinin	amino	acid	substitutions	specific	of	the	A(H1N1)pdm09	viruses	classified	as	phenotypic	outlier	and/or	recovered	from	a	patient	under	antiviral	therapy,	and	further	substitutions	associated	with	neuraminidase	inhibitor	resistance	or	decreased	susceptibility.			
HRI:	 Highly	 reduced	 inhibition;	 LMo:	 Lower	mild	 outlier;	 OS:	 Oseltamivir;	 R:	 Receptor	 binding;	 UEo:	 Upper	 extreme	 outlier;	 UMo:	 Upper	mild	outlier;	ZA:	Zanamivir	Colour	legend:			Associated	with	HRI	by	OS	and	peramivir	(PER)	in	vitro	and	know	to	cause	clinical	resistance	to	OS	-	influenza	N1	neuraminidase	(NA)	viruses			Associated	with	a	normal	inhibition	≥2-fold	by	NA	inhibitors	(NAIs)	in	vitro,	confirmed	by	reverse	genetics	–	influenza	A(H1N1)pdm09	viruses				Potential	compensatory	substitution	of	the	fitness	deficits	caused	by	NA	H275Y	substitution	in	A(H1N1)pdm09	viruses	a	 Position	 numbering	 without	 the	 N-terminal	 signal	 sequence	 (amino	 acid	 residues	 1-17);	 b	 Recovered	 from	 a	 patient	 suspected	 of	 having	developed	a	drug-resistant	influenza	virus	infection	during	OS	therapy;	c		NA	H275Y	amino	acid	substitution	detected	in	the	entire	virus	population	of	 the	 clinical	 specimen	 (H275Y	 screening	 result	 provided	 by	 the	 Hospital	 Curry	 Cabral);	 	 clinical	 specimen	 collected	 during	 therapy	 but	 not	possible	to	specify	in	which	day	(starting	date	not	available);	d	From	a	case	of	A(H1N1)pdm09	virus	infection	associated	with	antiviral	therapy	but	isolated	 from	 the	 clinical	 specimen	 collected	 before	 OS	 use;	 e	Post-treatment	 clinical	 specimens	 from	 the	 same	 case	 of	 A(H1N1)pdm09	 virus	infection	as	virus	isolate	A/Portugal/55/2013;	f	Is	also	known	to	enhance	the	level	of	reduced	susceptibility	conferred	by	H275Y,	alone	(PER)	or	in	combination	with	N295S	(OS,	ZA)	-	synergistic	amino	acid	substitution	(see	Table	1.2,	Literature	Review);	g	Mixed	virus	population;	h	Identified	in	all	A(H1N1)pdm09	viruses	tested	and	in	most	reference	A(H1N1)pdm09	viruses,	from	2010/2011	onwards;	i	Also	identified	in	approximately	half	(15/32;	including	A/Portugal/28/2009)	of	the	A(H1N1)pdm09	non-outlier	viruses	from	the	pandemic	period	and	in	the	only	A(H1N1)pdm09	non-outlier	virus	from	2012/2013;	exceptionally	indicated	as	it	is	known	to	confer	(H)RI	by	OS	and	ZA	in	former	circulating	A(H1N1)	viruses.	The	 amino	 acid	 substitutions	 were	 identified	 and	 are	 displayed	 as	 described	 in	 Table	 4.4	 (2009	 pandemic	 N1	 and	 H1	numbering).	 The	 analysis	 involved	 a	 total	 of	 253	NA	 and	 243	HA	 sequences	 from	 tested	 (n=214	NA;	 n=205	HA;	 (+4	 clinical	specimens))	 and	 reference	 (n=35	 NA;	 n=34	 HA)	 A(H1N1)pdm09	 viruses	 (detailed	 information	 in	 Tables	 S4.1	 and	 S4.2,	Supplementary	data).	The	location	of	the	NA	structural	domains	in	the	2009	pandemic	N1	monomer	was	based	on	Colman	8	and	da	 Silva	 et	 al.	 27;	 while	 the	 location	 of	 the	 HA	 structural	 sub-domains	 in	 the	 2009	 pandemic	 H1	 monomer	 was	 established	according	to	Gamblin	et	al.	11	and	Yang	et	al.	28.	The	amino	acid	substitutions	occurring	at	residues	belonging	to	the	NA	active	site	(based	 on	 Colman	 et	 al.	 14)	 are	 underlined.	 Detailed	 information	 on	 the	 NA	 amino	 acid	 substitutions	 associated	 with	 NAI	resistance	or	decreased	susceptibility	can	be	found	at	Table	1.2,	Literature	Review.	
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																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	140		The	 upper	 outlier	 virus	 isolate	 A/Portugal/07/2011	 with	 decreased	 susceptibility	 to	both	OS	and	ZA	(2010/2011),	 carried	 the	HA	N129D,	K153E,	N156K	and	G237R	amino	acid	substitutions	in	the	receptor	binding	HA1	sub-domain	(Table	4.7).	All	substitutions	except	G237R	are	located	closely	to	the	HA	RBS	(Figure	4.10B).	According	to	Skowronski	
et	al.	20,	residues	153	and	156	belong	to	the	antigenic	site	Sa,	while	residue	237	is	part	of	the	 antigenic	 site	 Ca1.	 The	 presence	 of	 HA	 K153E	 amino	 acid	 substitution	 as	 viral	quasispecies	 (K153E/K	 mixed	 virus	 population)	 is	 in	 agreement	 with	 its	 known	association	 to	 virus	 adaptation	 to	 cell	 culture	 29.	 HA	 K153E	 substitution	 has	 also	 been	selected	in	vitro	after	serial	passage	under	laninamivir	(LAN)	drug	pressure	(see	section	1.5.2.1.2,	 Literature	 Review	 for	 detail),	 but	 its	 effect	 on	 NAI	 susceptibility	 is	 still	unknown.															
	
	
Figure	 4.10	 Mapping	 of	 the	 neuraminidase	 (A)	 and	 hemagglutinin	 (B)	 residues	 on	 which	 were	detected	the	amino	acid	substitutions	specific	of	the	A(H1N1)pdm09	phenotypic	outlier	viruses,	onto	the	three-dimensional	structure	of	the	protein.	The	figure	was	generated	and	annotated	as	described	in	Figure	4.7,	using	the	structure	of	the	neuraminidase	(NA)	globular	head	(PDB	ID:	3NSS,	only	one	globular	head	of	the	two	described	in	the	file	is	shown)	(panel	A)	and	of	the	hemagglutinin	(HA)	(PDB	ID:	 3LZG,	 only	 one	monomer	 from	 one	 of	 the	 two	 HA	 trimers	 described	 in	 the	 file	 is	 shown)	 (panel	 B)	 from	 the	 reference	A(H1N1)pdm09	virus	A/California/04/2009.	The	residues	forming	the	RBS	in	the	2009	pandemic	H1	HA	are	based	on	Yang	et	
al.	30.	NA	active	site	residues	are	not	coloured	according	to	the	phenotypic	outlier	category	of	the	virus	carrying	the	substitution,	maintaining	 the	colour	assigned	to	 the	corresponding	type	of	active	site	residue	(functional	or	 framework).	Panel	A:	Residue	275	associated	with	clinical	resistance	to	oseltamivir	is	also	indicated.	
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																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	141		NA	 H275Y	 variant	 virus	 A/Portugal/03/2011	 contained	 the	 HA	 N156D	 amino	 acid	substitution	located	closely	to	the	RBS.	All	other	HA	amino	acid	substitutions	identified	in	either	the	remaining	A(H1N1)pdm09	upper	outlier	viruses	or	in	the	lower	outlier	viruses	evaluated	 through	HA	 sequencing,	were	 located	 	 at	 some	distance	 (V199I)	 or	 far	 away	from	the	RBS	(Table	4.7;	Figure	10.B).	The	HA	H51Y	amino	acid	substitution	identified	in	an	 LM	 outlier	 virus	 from	 2010/2011	 -	 virus	 isolate	 A/Portugal/27/2011	 (H51Y/H),	occurred,	however,	near	the	putative	second	sialic	acid	binding	site	on	HA	(Figure	10.B).	Residue	 163	 in	 which	 was	 detected	 the	 single	 HA	 amino	 acid	 substitution	 of	 the	 UE	outlier	virus	isolate	A/Portugal/54/2013	(K163E)	belongs	to	the	antigenic	site	Sa	20.			No	 specific	 HA	 amino	 acid	 substitution	 was	 identified	 in	 the	 non-outlier	 virus	 isolate	A/Portugal/28/2009	with	 known	 association	 to	 antiviral	 drug	 use	 and	 in	 its	matching	clinical	 specimen	 (Table	 4.7).	 Also,	 no	 HA	 amino	 acid	 substitution	 emerged	 during	 or	after	 OS	 therapy	 of	 the	 patient	 from	which	were	 collected	 the	 clinical	 specimens	 from	before,	during	and	after	antiviral	use	(HA	Y167F	amino	acid	substitution	identified	in	all	three	specimens).		HA	 D222G	 amino	 acid	 substitution	 known	 to	 confer	 decreased	 NAI	 susceptibility	 in	former	 circulating	 A(H1N1)	 viruses	 (D221G	 in	 seasonal	 H1	 numbering;	 see	 section	1.5.2.1.2,	Literature	Review)	was	identified	in	an	A(H1N1)pdm09	non-outlier	virus	from	2012/2013	 –	 virus	 isolate	 A/Portugal/53/2013.	 In	 current	 circulating	 2009	 pandemic	A(H1N1)	 viruses,	 this	HA	 substitution	 has	 only	 be	 selected	 in	vitro	after	 serial	 passage	under	LAN	drug	pressure	(detailed	in	section	1.5.2.1.2,	Literature	Review),	with	its	effect	on	NAI	susceptibility	remaining	unknown.					
4.1.4.2.2	Evolutionary	relationships	of	neuraminidase	and	hemagglutinin	genes		 4.1.4.2.2.1	Former	seasonal	influenza	N1	and	H1	genes		Phylogenetic	comparison	of	seasonal	 influenza	N1	genes	showed	that	 the	OS	UE	outlier	viruses	 showing	 HRI	 from	 2007/2008	 were	 closely	 related	 to	 those	 from	 2008/2009,	clustering	 into	 a	 group	 within	 genetic	 clade	 2B	 defined	 by	 the	 NA	 H275Y	 amino	 acid	substitution	 (Figure	 4.11A).	 The	 additional	 presence	 of	 the	 NA	 D354G	 amino	 acid	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	142		substitution	in	all	these	NA	H275Y	variant	viruses	(not	evidenced	in	the	tree;	see	section	4.1.4.2.1.1	 above),	 indicated	 that	 all	 belonged	 to	 the	 Northern	 European	 OS-resistant	lineage	in	clade	2B	31.	The	HRI	NA	H275Y	variant	viruses	from	2008/2009	clustered	into	a	 further	 subgroup	 defined	 at	 only	 nucleotide	 level,	 by	 the	 NA	 T234G/A	 nucleotide	substitution	(Figure	4.11A).	Most	of	these	viruses	were	very	closely	related	to	each	other,	with	 some	 of	 them	 presenting	 100%	 identical	 sequences	 (e.g.	 A/Lisboa/21/2009	 and	A/Lisboa/23/2009).	 Virus	 isolates	 A/Lisboa/07/2009	 and	 A/Lisboa/29/2008	 and	A/Lisboa/03/2009,	 these	two	 latter	grouped	by	the	NA	T435R	amino	acid	substitution,	were	 more	 closely	 related	 to,	 respectively,	 the	 reference	 viruses	 A/Hong	Kong/3192/2008	and	A/England/557/2007.		All	 other	 seasonal	 A(H1N1)	 phenotypic	 outlier	 viruses	 (UM,	 LM	 and	 LE)	 were	 closely	related	to	the	non-outlier	viruses	from	the	same	influenza	season	(Figure	4.11A).		A	 more	 extensive	 phylogenetic	 analysis	 of	 influenza	 virus	 NA	 genes	 was	 further	performed	 in	 seasonal	 A(H1N1)	 subtype,	 including	 all	 NA	 sequences	 of	 worldwide	circulating	 NA	 H275Y	 variant	 viruses	 available	 at	 GISAID	 EpiFlu™	 and	 NCBI	 Influenza	Virus	 Resource	 databases	 (n=585	 by	 January	 2012;	 sequences	 were	 comprised	 in	 the	seasonal	A(H1N1)	dataset	created	during	this	PhD	work	to	study	the	selective	pressure	acting	on	human	influenza	NA;	Chapter	6).	This	more	extensive	analysis	made	clear	the	subtle	 separation	previously	 observed	 for	 the	NA	H275Y	 viruses	 from	2008/2009	 that	now	clustered	within	three	subgroups:	(1)	most	viruses	clustered	with	NA	H275Y	viruses	from	 Europe	 and	 North	 America	 (closest)	 and	 from	 Africa;	 (2)	 virus	 isolate	A/Lisboa/07/2009	 clustered	 with	 NA	 H275Y	 viruses	 from	 particularly	 Eastern	 Asia	(closest)	 but	 also	 from	 Europe	 and	 the	 Americas;	 and	 (3)	 virus	 isolates	A/Lisboa/29/2008	 and	 A/Lisboa/03/2009	 grouped	 with	 NA	 H275Y	 viruses	 from	 the	Americas	 (Figure	4.11B).	 It	 also	 revealed	 a	 similar	 separation	 into	 three	 subgroups	 for	the	NA	H275Y	viruses	 from	2007/2008,	with	 the	virus	 isolates	A/Lisboa/27/2008	and	A/Lisboa/28/2008	 clustering	 together.	 A/Lisboa/02/2008,	 A/Lisboa/11/2008	 and	A/Lisboa/20/2008	 clustered	 with	 NA	 H275Y	 viruses	 from	 all	 worldwide	 continents	except	 Oceania,	 while	 the	 virus	 isolate	 A/Lisboa/03/2008	 grouped	 with	 NA	 H275Y	viruses	from	Europe	and	South	America	(Figure	4.11B).			
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Figure	4.11	Evolutionary	relationships	among	the	neuraminidase	genes	of	 former	seasonal	A(H1N1)	tested	 and	 reference	 viruses	 (A)	 and	 additionally	 of	 all	 worldwide	 NA	 H275Y	 former	 seasonal	A(H1N1)	variant	viruses	with	a	sequence	publicly	available	(B).		nts:	nucleotides;	(a)	Also	present	in	the	reference	virus	A/USSR/90/1977	(outgroup)		Phylogenetic	trees	were	constructed	by	maximum-likelihood	method	in	the	PhyML3.0	platform	available	in	SeaView,	using	the	nucleotide	 substitution	model	GTR+I+Γ4	 (General	Time	Reversible	 (GRT)	model	 assuming	a	proportion	of	 invariable	 sites	 (I)	and	with	a	4-category	gamma	distribution	(Γ4)	for	rate	variation	among	sites),	previously	determined	in	 jModelTest.	SPR	and	NNI	rearrangement	operations	were	used	to	optimise	tree	topology,	while	SH-like	aLRT	method	was	used	to	estimate	branch	support.	Tested	viruses	are	colour-coded	according	 to	 their	phenotypic	outlier	 category	as	 follows:	 red	 -	upper	extreme	(UE)	outlier,	 using	 two	 different	 shades	 of	 red	 to	 distinguish	 the	 viruses	 from	 2007/2008	 (light	 red)	 and	 2008/2009	 (dark	 red);	orange	 -	 upper	 mild	 (UM)	 outlier;	 turquoise	 blue	 -	 lower	 mild	 (LM)	 outlier;	 blue	 -	 lower	 extreme	 (LE)	 outlier.	 If	 the	 virus	belonged	to	different	outlier	categories	in	oseltamivir	and	zanamivir	susceptibility	testing,	it	was	considered	the	category	more	above	in	the	following	order:	UE>UM>LE>LM.	Worldwide	reference	viruses	are	highlighted	in	grey,	including	the	recommended	vaccine	viruses	that	are	further	indicated	in	capital	letters		and	in	bold	and	italic.	Earlier		reference	viruses	were	used	to		root	the		
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A/Argentina/303/2008/1/1410/|/EPI/ISL/25779
CY074173/1/1410/A/California/VRDL215/2009/2009/04/28/6//NA/
A/Brisbane/1/2009/1/1410/|/EPI/ISL/32490
A/El Salvador/468/2008
A/Uganda/0511/2009/1/1410/|/EPI/ISL/66659
A/Washington/01/2008
CY100798/1/1410/A/Texas/WRAIR1115P/2009/2009/03/01/6//NA/
CY080939/1/1410/A/Boston/72/2009/2009/03/24/6//NA/
A/Washington/08/2008/1/1410/|/EPI/ISL/28333
A/Lisboa/19/2008
A/Florida/02/2008/1/1410/|/EPI/ISL/19087
A/Maryland/04/2007
A/Stockholm/6/2009/1/1410/|/EPI/ISL/70806
A/Lisboa/94/2005
A/Kentucky/08/2009
A/Cayman Islands/5082/2009
A/Singapore/88/2009/1/1410/|/EPI/ISL/34737
A/Kazakhstan/2600/2008
A/India/7308/2008/1/1410/|/EPI/ISL/33659
GQ475914/1/1410/A/Hawaii/03/2009/2009/01/29/6//NA/
CY089109/1/1410/A/Boston/59/2009/2009/02/28/6//NA/
CY074125/1/1410/A/California/VRDL194/2009/2009/04/27/6//NA/
A/England/26/2008
A/IBARAKI/68/2008/1/1410/|/EPI/ISL/28175
A/Managua/1985.01/2008/1/1410/|/EPI/ISL/62906
GQ457553/1/1410/A/Saskatchewan/5131/2009/2009/06/19/6//NA/
CY080612/1/1410/A/Boston/95/2009/2009/04/01/6//NA/
CY074485/1/1410/A/California/VRDL292/2009/2009/04/30/6//NA/
A/Idaho/01/2009/1/1410/|/EPI/ISL/61874
A/AOMORI/19/2008/1/1410/|/EPI/ISL/28166
CY053671/1/1410/A/Novosibirsk/7/2009/2009/04//6//NA/
CY100958/1/1410/A/Pucallpa/WRAIR1709P/2009/2009/01/20/6//NA/
A/Georgia/1269/1/1410//36G//2009/|/EPI/ISL/...
A/GWANGJU/4324/2008/1/1410/|/EPI/ISL/28202
GU271968/1/1410/A/Thailand/CU/H565/2009/2009/09/02/6//NA/
A/SHIMANE/1/2009/1/1410/|/EPI/ISL/28187
A/Cameroon/073/2008/1/1410/|/EPI/ISL/65406
A/Rabat/109/2009/1/1410/|/EPI/ISL/65489
GQ475869/1/1410/A/New/York/02/2009/2009/02/14/6//NA/
A/Honduras/100/2008
A/SAMOA/10/2009/1/1410/|/EPI/ISL/65128
CY069551/1/1410/A/Texas/WRAIR1254P/2009/2009/03//6//NA/
A/Brazil/815/2009
CY100934/1/1410/A/Santa/Cruz/WRAIR1706P/2008/2008/12/09/6//NA/
A/WELLINGTON/218/2009/1/1410/|/EPI/ISL/65150
A/Iceland/8599/2009/1/1410/|/EPI/ISL/65514
A/Arizona/13/2008/1/1410/|/EPI/ISL/27639
A/Paraguay/67/2009
A/Moscow/38/2008
A/Buenos/1/1410/Aires/825511/2008/|/EPI/ISL/65471
CY100830/1/1410/A/Japan/WRAIR1226P/2009/2009/02/01/6//NA/
GQ476155/1/1410/A/New/Mexico/01/2009/2009/01/07/6//NA/
A/Michigan/01/2009/1/1410/|/EPI/ISL/33745
A/Singapore/6/1986/EPI/ISL/6905/58244
A/England/594/2006/1/1410/|/EPI/ISL/25708
A/Peru/WRAIR1505P/2007/1/1410/|/EPI/ISL/78572
A/Naypyitaw/M499/2008/1/1410/|/EPI/ISL/33557
A/Thailand/839/2008
GQ476088/1/1410/A/Nebraska/05/2009/2009/03/07/6//NA/
CY050662/1/1410/A/New/York/3150/2009/2009/04/27/6//NA/
A/Ghana/FS/09/718/2009/1/1410/|/EPI/ISL/60087
A/Seychelles/2239/2008/EPI/ISL/60835/A///H1N1/seasonal/NA/WSS964136
GQ475945/1/1410/A/Washington/03/2009/2009/01/21/6//NA/
A/Fukushima/141/2006/EPI/ISL/20229/A///H1N1/seasonal/NA/WSS964101
A/Perth/30/2009
CY074357/1/1410/A/California/VRDL252/2009/2009/04/29/6//NA/
A/Algeria/G825/2008
CY100870/1/1410/A/Nevada/WRAIR1257P/2009/2009/02/01/6//NA/
A/Texas/16/2008/1/1410/|/EPI/ISL/26239
AB521103/1/1410/A/Yamagata/51/2009/2009/01/26/6//NA/
A/KOBE/49/2008
AB521101/1/1410/A/Yamagata/26/2009/2009/01/17/6//NA/
CY074333/1/1410/A/California/VRDL245/2009/2009/04/29/6//NA/
A/Indiana/08/2009
A/Guangdong/Futian/139/2009/1/1410/|/EPI/IS...
AB521111/1/1410/A/Yamagata/77/2009/2009/02/10/6//NA/
A/Lisboa/4/2008
A/Stockholm/7/2009/1/1410/|/EPI/ISL/70800
A/Lisboa/23/2009
A/Sweden/8/2008/1/1410/|/EPI/ISL/70648
CY050478/1/1410/A/New/York/1692/2009/2009/04/27/6//NA/
A/Lisboa/07/2009
A/Fujian/Gulou/1367/2009/1/1410/|/EPI/ISL/3...
A/TAK/334/2009/1/1410/|/EPI/ISL/65129
GQ475877/1/1410/A/New/York/62/2009/2009/03/17/6//NA/
A/Delaware/01/2008/1/1410/|/EPI/ISL/28285
GQ475886/1/1410/A/Nebraska/06/2009/2009/03/22/6//NA/
A/Lisboa/13/2008
A/Lisboa/2/2008
A/Guangdong/Zhuangzuyaozuzizhi/51/200.../1/1410
CY074309/1/1410/A/California/VRDL238/2009/2009/04/29/6//NA/
A/Hong/Kong/3192/2008/EPI/ISL/65482/A///H1N1/seasonal/NA/WSS964139
CY100790/1/1410/A/Oklahoma/WRAIR1110P/2009/2009/03/01/6//NA/
CY073863/1/1410/A/California/VRDL229/2009/2009/04/29/6//NA/
A/KOL/2465/2009
HQ291915/1/1410/A/Taiwan/8949/2008/2008/12/11/6//NA/
A/Quebec/RV3060/2009
A/Arizona/13/2007/1/1410/|/EPI/ISL/15893
CY080795/1/1410/A/Boston/41/2009/2009/02/27/6//NA/
A/Lisboa/16/2009
A/Yamagata/128/2008
GQ476126/1/1410/A/Florida/07/2009/2009/03/25/6//NA/
A/Texas/27/2008/1/1410/|/EPI/ISL/27653
CY074277/1/1410/A/California/VRDL232/2009/2009///6//NA/
A/BEIJING/HUAIROU/185/2008
A/Texas/31/2007/1/1410/|/EPI/ISL/15409
A/Algeria/G864/2008/1/1410/|/EPI/ISL/65468
A/Managua/954.02/2008/1/1410/|/EPI/ISL/33848
A/Quebec/Rv1107/2009/1/1410/|/EPI/ISL/33632
CY080803/1/1410/A/Boston/42/2009/2009/03/01/6//NA/
A/Hawaii/19/2008
GQ476096/1/1410/A/Hawaii/01/2009/2009/01/13/6//NA/
A/Tak/427/2009/1/1410/|/EPI/ISL/66657
A/French/1/1410/Polynesia/2001/2009/|/EPI/I...
GQ475972/1/1410/A/Wisconsin/06/2009/2009/03/03/6//NA/
A/Lisboa/11/2008
CY053655/1/1410/A/Novosibirsk/151/2009/2009/05//6//NA/
HQ256619/1/1410/A/Myanmar/M256/2009/2009/07/16/6//NA/
A/Stockholm/22/2008
A/SAMOA/9/2009/1/1410/|/EPI/ISL/60899
CY069391/1/1410/A/South/Carolina/WRAIR1116P/2009/2009/03/01/6//NA/
A/New/1/1410/Jersey/32/2008/|/EPI/ISL/33750
GQ475874/1/1410/A/Wisconsin/02/2009/2009/01/07/6//NA/
A/Argentina/295/2008/1/1410/|/EPI/ISL/25778
A/Lisboa/9/2008
A/Kenya/0793/2008/1/1410/|/EPI/ISL/33677
GQ476035/1/1410/A/Hawaii/13/2009/2009/04/16/6//NA/
A/Thailand/1577/2007/1/1410/|/EPI/ISL/22372
GQ476143/1/1410/A/Vermont/01/2009/2009/02/09/6//NA/
A/Uganda/0132/2009/1/1410/|/EPI/ISL/66658
CY100974/1/1410/A/Cusco/WRAIR1730P/2008/2008/08/20/6//NA/
A/SHIZUOKA/C/21/2009/1/1410/|/EPI/ISL/28194
CY089783/1/1410/A/Boston/32/2009/2009/02/20/6//NA/
GQ475880/1/1410/A/Tennessee/01/2009/2009/01/12/6//NA/
HQ291910/1/1410/A/Taiwan/3293/2008/2008/05/02/6//NA/
GQ457554/1/1410/A/Saskatchewan/5350/2009/2009/06/18/6//NA/
A/Managua/5007.01/2008/1/1410/|/EPI/ISL/62912
A/Fujian/Gulou/1896/2009/1/1410/|/EPI/ISL/6...
A/Nigeria/0023/2008/1/1410/|/EPI/ISL/25811
A/California/VRDL167/2009
CY089085/1/1410/A/Boston/46/2009/2009/03/01/6//NA/
HQ291909/1/1410/A/Taiwan/2885/2008/2008/11/24/6//NA/
CY100902/1/1410/A/Piura/WRAIR1700P/2009/2009/01/01/6//NA/
A/Johannesburg/45/2008/1/1410/|/EPI/ISL/23112
A/Indiana/06/2009/1/1410/|/EPI/ISL/33812
GQ475894/1/1410/A/California/01/2009/2009/01/07/6//NA/
A/Brisbane/59/2007/EPI/ISL/71838/A///H1N1/seasonal/NA/WSS964111
A/IWATE/40/2008/1/1410/|/EPI/ISL/27996
GQ475847/1/1410/A/New/Mexico/02/2009/2009/01/14/6//NA/
A/Washington/12/2008/1/1410/|/EPI/ISL/33813
A/Pennsylvania/14/2008/1/1410/|/EPI/ISL/33644
A/Samara/46/2008
A/Illinois/16/2007/1/1410/|/EPI/ISL/19084
A/Washington/05/2008/1/1410/|/EPI/ISL/25804
A/Brisbane/10/2009/1/1410/|/EPI/ISL/32493
A/Lisboa/4/2006
A/KwaZulu/1/1410/Natal/272/2008/|/EPI/ISL/65639
A/Denmark/27/2007/1/1410/|/EPI/ISL/25442
A/Maryland/04/2008/1/1410/|/EPI/ISL/28301
CY050550/1/1410/A/New/York/3095/2009/2009/04/29/6//NA/
A/Hong/1/1410/Kong/33597/2009/|/EPI/ISL/68854
A/SAPPORO/90/2008/1/1410/|/EPI/ISL/28010
A/Kenya/1329/2010/1/1410/|/EPI/ISL/98941
A/Georgia/20/2006/1/1410/|/EPI/ISL/21323
A/FUKUI/91/2008
A/USSR/90/77/EPI/ISL/66105/230612
A/Yangon/M195/2008/1/1410/|/EPI/ISL/33555
A/Hong/Kong/1856/2008/EPI/ISL/60838/A///H1N1/seasonal/NA/WSS964138
A/North/1/1410/Carolina/02/2008/|/EPI/ISL/19770
A/Solomon/Islands/3/2006/EPI/ISL/13324/A///H1N1/seasonal/NA/WSS964131
A/Hong/Kong/2652/2006/EPI/ISL/157436/A///H1N1/seasonal/NA/WSS964099
A/St. Petersburg/83/2008
HQ256643/1/1410/A/Myanmar/M428/2009/2009/08/11/6//NA/
A/Lisboa/10/2008
GQ476082/1/1410/A/Arkansas/02/2009/2009/03/01/6//NA/
CY089101/1/1410/A/Boston/54/2009/2009/02/22/6//NA/
A/Jilin/Chaoyang/157/2009/1/1410/|/EPI/ISL/...
CY074117/1/1410/A/California/VRDL193/2009/2009/04/29/6//NA/
A/Pennsylvania/13/2007/1/1410/|/EPI/ISL/23897
A/Marrakech/510/2009
A/Lisboa/15/2008
A/Paris/781/2008/1/1410/|/EPI/ISL/65485
A/Israel/1/2009/1/1410/|/EPI/ISL/65499
A/Boston/06/2009
A/Philippines/1159/2008
A/SHIZUOKA/C/10/2009
A/South/1/1410/Australia/12/2009/|/EPI/ISL/...
A/Argentina/110/2008/1/1410/|/EPI/ISL/25781
A/Niigata/08F093/2009
A/Hong/1/1410/Kong/18106/2009/|/EPI/ISL/65516
A/Nagasaki/07N020/2008/1/1410/|/EPI/ISL/70169
A/Kenya/2743/2009/1/1410/|/EPI/ISL/61877
CY080819/1/1410/A/Boston/45/2009/2009/03/03/6//NA/
A/Perth/1/2009/1/1410/|/EPI/ISL/32484
A/Lisboa/41/2008
A/Texas/36/2008/1/1410/|/EPI/ISL/33733
A/Hong/1/1410/Kong/26552/2009/|/EPI/ISL/66653
HQ256645/1/1410/A/Myanmar/M470/2009/2009/08/20/6//NA/
GQ476053/1/1410/A/New/York/65/2009/2009/03/09/6//NA/
A/BRISBANE/96/2009/1/1410/|/EPI/ISL/65152
A/Lisboa/15/2009
A/Egypt/10/2007/EPI/ISL/106505/A///H1N1/seasonal/NA/WSS964117
A/Hong/1/1410/Kong/852/2008/|/EPI/ISL/65426
CY100814/1/1410/A/Texas/WRAIR1118P/2009/2009/06/01/6//NA/
CY093127/1/1410/A/Boston/47/2009/2009/02/12/6//NA/
A/Belgium/G257/2008
HQ256649/1/1410/A/Myanmar/M533/2009/2009/09/04/6//NA/
A/Oregon/02/2009
A/Yokohama/78/2008
A/NIIGATA/1088/2008/1/1410/|/EPI/ISL/28002
A/Indiana/01/2008/1/1410/|/EPI/ISL/15873
A/Kiev/313/2008
A/India/3414/2009
A/Moscow/02/2009
A/Philippines/3914/2008
A/New/1/1410/Jersey/30/2008/|/EPI/ISL/33747
A/Lisboa/40/2008
A/Chile/1/1983/EPI/ISL/6900/58149
AB465323/1/1410/A/Yokohama/30/2008/2008/01/28/6//NA/
A/Lisboa/12/2008
A/Buenos/1/1410/Aires/R13/2008/|/EPI/ISL/65360
A/Tula/31/2008
A/Guatemala/663/2008
AB521105/1/1410/A/Yamagata/45/2009/2009/01/21/6//NA/
A/Lisboa/06/2009
A/Lisboa/24/2006/A/Lisboa/16/2006
A/Thailand/CU/B42/2009
A/England/557/2007
GQ476149/1/1410/A/New/York/64/2009/2009/04/09/6//NA/
A/St. Petersburg/85/2008
A/Jamaica/2968/2009/1/1410/|/EPI/ISL/33607
A/Cameroon/080/2008
AB521112/1/1410/A/Yamagata/80/2009/2009/02/18/6//NA/
A/Florida/24/2008/1/1410/|/EPI/ISL/28287
A/Lisboa/2/2009
CY100838/1/1410/A/Illinois/WRAIR1233P/2009/2009/03/01/6//NA/
A/Costa Rica/5150/2009
AB465321/1/1410/A/Yokohama/34/2008/2008/01/28/6//NA/
A/England/411/2008/1/1410/|/EPI/ISL/65477
GQ476104/1/1410/A/Pennsylvania/12/2009/2009/01/29/6//NA/
A/Israel/10/2009/1/1410/|/EPI/ISL/65498
A/Lisboa/17/2008
A/Nebraska/WRAIR1247P/2009
GQ475965/1/1410/A/Ohio/06/2009/2009/02/03/6//NA/
GQ476024/1/1410/A/Michigan/07/2009/2009/04/08/6//NA/
CY053657/1/1410/A/Novosibirsk/2/2009/2009/04//6//NA/
A/Belgium/858/2008
A/Lisboa/35/2005
GQ475920/1/1410/A/California/03/2009/2009/02/04/6//NA/
A/SURAT/1/1410/THANI/337/2009/|/EPI/ISL/65130
A/California/VRDL371/2009
GQ475951/1/1410/A/Kentucky/03/2009/2009/02/02/6//NA/
A/Puerto/1/1410/Rico/02/2009/|/EPI/ISL/33708
A/Niigata/08F031/2009
A/Taiwan/693/2009/1/1410/|/EPI/ISL/60130
A/Cameroon/08/235/2008/1/1410/|/EPI/ISL/65497
A/Lisboa/20/2008
A/North/1/1410/Carolina/07/2008/|/EPI/ISL/28372
A/Jilin/Chaoyang1258/2008/1/1410/|/EPI/ISL/28298
A/Bangladesh/9067/2008/1/1410/|/EPI/ISL/33671
A/Lisboa/20/2009
A/Hawaii/41/2008/1/1410/|/EPI/ISL/28376
A/Ireland/744/2008
A/MACAU/3436/2009/1/1410/|/EPI/ISL/65127
HQ533869/1/1410/A/Tianjin/15/2009/2009///6//NA/
CY100918/1/1410/A/Trujillo/WRAIR1702P/2008/2008/12/28/6//NA/
GQ475962/1/1410/A/Montana/01/2009/2009/01/04/6//NA/
GQ475856/1/1410/A/South/Dakota/01/2009/2009/01/22/6//NA/
GU112230/1/1410/A/Tehran/359/2009/2009/01/16/6//NA/
A/HAMAMATU/C/988/2009/1/1410/|/EPI/ISL/65151
A/Ontario/RV0131/2007/1/1410/|/EPI/ISL/22256
A/Minnesota/01/2008/1/1410/|/EPI/ISL/20792
GQ476027/1/1410/A/Maryland/01/2009/2009/01/18/6//NA/
A/Prague/33/2009/1/1410/|/EPI/ISL/65503
A/South/1/1410/Australia/11/2009/|/EPI/ISL/...
A/SAPPORO/66/2008/1/1410/|/EPI/ISL/26396
A/Netherlands/345/2007/EPI/ISL/60837/A///H1N1/seasonal/NA/WSS964114
JN676131/1/1410/A/Thailand/Siriraj/3043/2009/2009/10/06/6//NA/
CY074469/1/1410/A/California/VRDL289/2009/2009/05/01/6//NA/
A/Fujian/Gulou/1292/2009/1/1410/|/EPI/ISL/3...
A/Sichuan/Dongqu/1836/2009/1/1410/|/EPI/ISL...
A/Lisboa/6/2006
JN256687/1/1410/A/Hong/Kong/H090/744/V1/0//2009/2009/07/24/6//NA/
A/Norway/1735/2007/EPI/ISL/106540/A///H1N1/seasonal/NA/WSS964128
A/Michigan/06/2008/1/1410/|/EPI/ISL/27649
A/Pennsylvania/09/2008/1/1410/|/EPI/ISL/26237
A/Hawaii/42/2008/1/1410/|/EPI/ISL/28377
CY100846/1/1410/A/Alabama/WRAIR1235P/2009/2009/04/01/6//NA/
A/Peru/WRAIR1300P/2007/1/1410/|/EPI/ISL/78566
A/Hawaii/28/2007/1/1410/|/EPI/ISL/33820
A/Minnesota/27/2008/1/1410/|/EPI/ISL/27650
EU551821/1/1410/A/Paris/963/2008/2008/01/04/6//NA/
GQ475997/1/1410/A/Minnesota/01/2009/2009/01/16/6//NA/
CY074101/1/1410/A/California/VRDL189/2009/2009/04/29/6//NA/
CY080899/1/1410/A/Boston/65/2009/2009/03/09/6//NA/
CY089045/1/1410/A/Boston/10/2009/2009/02/04/6//NA/
A/Minnesota/34/2008/1/1410/|/EPI/ISL/28371
A/Paris/1157/2008
A/Japan/WRAIR1230P/2009
A/Waikato/1/2009/1/1410/|/EPI/ISL/60125
A/Lisboa/17/2009
A/Salta/2093/2008/1/1410/|/EPI/ISL/65473
A/OSAKA/C/39/2008
CY050774/1/1410/A/New/York/3442/2009/2009/05/09/6//NA/
A/Hong/Kong/2637/2004/EPI/ISL/11833/A///H1N1/seasonal/NA/WSS964097
A/Victoria/214/2009/1/1410/|/EPI/ISL/60131
A/KANAGAWA/68/2008
GQ475931/1/1410/A/Ohio/04/2009/2009/01/28/6//NA/
A/Sri Lanka/13/2009
A/Mexico/2629/2009/1/1410/|/EPI/ISL/33635
A/Austria/404811/2008
A/Lisboa/24/2009
A/INCHEON/4432/2008/1/1410/|/EPI/ISL/28206
A/Johannesburg/21/2008
A/CHANTHABURI/341/2009/1/1410/|/EPI/ISL/65136
A/Annecy/2013/2009/1/1410/|/EPI/ISL/68855
A/St. Petersburg/11/2008
A/Paris/1208/2008
GQ476079/1/1410/A/Hawaii/17/2009/2009/04/13/6//NA/
GU183801/1/1410/A/Thailand/CU/B589/2009/2009/07/10/6//NA/
CY074237/1/1410/A/California/VRDL224/2009/2009/04/29/6//NA/
GU183809/1/1410/A/Thailand/CU/B685/2009/2009/07/12/6//NA/
A/England/40/2004/EPI/ISL/157574/A///H1N1/seasonal/NA/WSS964084
A/California/VRDL283/2009
A/Johannesburg/174/2008/1/1410/|/EPI/ISL/65642
CY089173/1/1410/A/Boston/94/2009/2009/03/13/6//NA/
A/Yamagata/137/2008/1/1410/|/EPI/ISL/71072
A/Lisboa/18/2008
A/Naypyitaw/M783/2008/1/1410/|/EPI/ISL/33559
CY100894/1/1410/A/Piura/WRAIR1699P/2008/2008/12/28/6//NA/
A/Philippines/15/2009/1/1410/|/EPI/ISL/60117
A/Lisboa/7/2008
A/Guatemala/22/2008
CY043539/1/1410/A/Kyoto/08K056/2009/2009/01/07/6//NA/
CY089125/1/1410/A/Boston/70/2009/2009/03/21/6//NA/
A/Dniprodzerzinsk/164/2008
A/St. Petersburg/53/2008
A/Argentina/81/2008
GQ475974/1/1410/A/North/Dakota/01/2009/2009/01/19/6//NA/
A/Alberta/RV2859/2009/1/1410/|/EPI/ISL/66647
A/Luxembourg/116/2008
CY069383/1/1410/A/Alaska/WRAIR1114P/2009/2009/03//6//NA/
A/Ghana/168/2008
CY080691/1/1410/A/Boston/20/2009/2009/02/11/6//NA/
A/Scotland/5/2007/1/1410/|/EPI/ISL/63393
A/Perth/46/2008/1/1410/|/EPI/ISL/28093
A/SHIGA/18/2008/1/1410/|/EPI/ISL/26399
A/Sydney/605/2009/1/1410/|/EPI/ISL/32488
A/Lisboa/18/2009
A/Peru/WRAIR1299P/2007/1/1410/|/EPI/ISL/78565
CY069311/1/1410/A/Bogota/WRAIR0088N/2009/2009/06/10/6//NA/
A/Macau/2517/2009/1/1410/|/EPI/ISL/60135
A/Lisboa/32/2006
A/Georgia/04/2009/1/1410/|/EPI/ISL/60717
CY064841/1/1410/A/California/VRDL141/2009/2009/04/28/6//NA/
A/Kiev/49/2008
A/Lisboa/31/2006
A/India/2757/2009
A/North/1/1410/Carolina/04/2009/|/EPI/ISL/3...
A/Puerto/1/1410/Rico/01/2008/|/EPI/ISL/33657
A/Luxembourg/1344/2008
A/Yamagata/16/2009/2009
A/Marseille/1148/2009/1/1410/|/EPI/ISL/60089
A/British/1/1410/Columbia/RV0035/2009/|/EPI/ISL/66649
A/Virginia/03/2008/1/1410/|/EPI/ISL/28332
A/Belgium/812/2008
A/South Korea/WRAIR1238P/2009
A/Madagascar/6054/2009/1/1410/|/EPI/ISL/68858
A/Illinois/16/2008/1/1410/|/EPI/ISL/28295
CY080652/1/1410/A/Boston/13/2009/2009/02/10/6//NA/
A/VICTORIA/549/2009/1/1410/|/EPI/ISL/66759
CY069375/1/1410/A/South/Dakota/WRAIR1113P/2009/2009/03/01/6//NA/
HQ291918/1/1410/A/Taiwan/11526/2008/2008/12/01/6//NA/
CY100942/1/1410/A/Sullana/WRAIR1707P/2009/2009/02/21/6//NA/
CY100822/1/1410/A/Kuwait/WRAIR1119P/2009/2009/01/01/6//NA/
A/Texas/57/2009/1/1410/|/EPI/ISL/61862
A/Lisboa/25/2009
A/Taiwan/1026/2009
CY074133/1/1410/A/California/VRDL200/2009/2009/04/30/6//NA/
A/Paris/1093/2009/1/1410/|/EPI/ISL/65510
A/Kenya/4225/2009/1/1410/|/EPI/ISL/61868
A/Missouri/05/2009/1/1410/|/EPI/ISL/34733
A/Lisboa/3/2008
A/NEW/1/1410/CALEDONIA/2/2009/|/EPI/ISL/65126
CY070913/1/1410/A/California/VRDL151/2009/2009/04/28/6//NA/
A/Guatemala/866/2009/1/1410/|/EPI/ISL/60716
A/MIYAGI/35/2008
A/Florida/28/2008/1/1410/|/EPI/ISL/28367
A/Matagalpa/179/2009/1/1410/|/EPI/ISL/33648
A/New Jersey/16/2007
A/Bangladesh/3003/2008/1/1410/|/EPI/ISL/33674
A/SHIMANE/117/2008
A/Wisconsin/12/2008/1/1410/|/EPI/ISL/26245
A/Santiago/4689/2008
A/Iceland/8064/2009
A/Mexico/4971/2008/1/1410/|/EPI/ISL/27637
HQ291899/1/1410/A/Taiwan/0045/2006/2006/05/24/6//NA/
CY074141/1/1410/A/California/VRDL202/2009/2009/04/29/6//NA/
A/Guyane/8190/2008
CY070897/1/1410/A/California/VRDL149/2009/2009/04/27/6//NA/
A/Hawaii/58/2008
GQ896377/1/1410/A/Wisconsin/14/2009/2009/05/22/6//NA/
JN582061/1/1410/A/New/York/08/1326/2008/2008/02/13/6//NA/
CY089759/1/1410/A/Boston/87/2009/2009/02/14/6//NA/
A/Lisboa/28/2008
A/CapeTown/124/2008
A/Texas/35/2008/1/1410/|/EPI/ISL/33732
A/yokohama/91/2007/1/1410/|/EPI/ISL/28731
CY074285/1/1410/A/California/VRDL235/2009/2009/04/29/6//NA/
GQ896371/1/1410/A/Utah/12/2009/2009/05/18/6//NA/
A/Lisboa/35/2006
A/NIIGATA/1150/2008/1/1410/|/EPI/ISL/28003
A/Kisii/7541/2008/1/1410/|/EPI/ISL/28471
A/BRISBANE/87/2009/1/1410/|/EPI/ISL/60134
A/Cambodia/21/2007/1/1410/|/EPI/ISL/28585
CY100966/1/1410/A/Maracay/WRAIR1729P/2008/2008/09/03/6//NA/
A/Kenya/4250/2009/1/1410/|/EPI/ISL/70216
A/Lisboa/21/2009
GQ476061/1/1410/A/Illinois/06/2009/2009/03/12/6//NA/
A/Virginia/01/2009/1/1410/|/EPI/ISL/33806
A/Ghana/FS/09/791/2009/1/1410/|/EPI/ISL/60086
A/Marrakech/589/2009
A/Luhansk/18/2008
A/SEOUL/4437/2008/1/1410/|/EPI/ISL/28208
A/Kenya/1432/2008
A/Maryland/07/2008/1/1410/|/EPI/ISL/28383
A/Flanders/G771/2009/1/1410/|/EPI/ISL/65508
A/EHIME/38/2008/1/1410/|/EPI/ISL/28170
A/OKAYAMA/14/2008/1/1410/|/EPI/ISL/28007
A/Honduras/330/2009/1/1410/|/EPI/ISL/33604
CY080987/1/1410/A/Boston/88/2009/2009/02/19/6//NA/
GQ475900/1/1410/A/Indiana/05/2009/2009/01/23/6//NA/
A/Paris/160/2007/EPI/ISL/157392/A///H1N1/seasonal/NA/WSS964105
CY100950/1/1410/A/Piura/WRAIR1708P/2009/2009/03/27/6//NA/
A/North/1/1410/Dakota/01/2008/|/EPI/ISL/28310
A/Massachusetts/08/2008/1/1410/|/EPI/ISL/27647
A/Lisboa/13/2009
HQ256609/1/1410/A/Myanmar/M061/2009/2009/06/27/6//NA/
A/Peru/WRAIR1310P/2007/1/1410/|/EPI/ISL/78567
A/Bratislava/149/2009
A/New/1/1410/Jersey/15/2007/|/EPI/ISL/71839
A/Lisboa/29/2008
A/New/Caledonia/20/1999/EPI/ISL/22626/A///H1N1/seasonal/NA/WSS964089
A/St. Petersburg/62/2008
A/Lisboa/5/2008
A/Vietnam/289/2008
A/Dakar/06/2008
A/Vladivostok/03/2008/1/1410/|/EPI/ISL/33690
A/Hokkaido/08H024/2009
CY073855/1/1410/A/California/VRDL175/2009/2009/04/28/6//NA/
A/Fiji/7/2009/1/1410/|/EPI/ISL/60129
A/Bangladesh/6666/2008/1/1410/|/EPI/ISL/33670
A/Lisboa/1/2008
A/NAIROBI/2/2009/1/1410/|/EPI/ISL/78686
A/Paris/910/2008
A/British/1/1410/Columbia/RV1585/2007/|/EPI/ISL/21859
A/Paris/639/2008/1/1410/|/EPI/ISL/90990
A/Beijing/Chaoyang/11405/2009
A/Lisboa/2/2006
A/Norway/1736/2007/1/1410/|/EPI/ISL/25416
GQ475940/1/1410/A/Montana/03/2009/2009/01/14/6//NA/
A/Pennsylvania/12/2008/1/1410/|/EPI/ISL/28368
CY064873/1/1410/A/California/VRDL146/2009/2009/04/25/6//NA/
CY074661/1/1410/A/California/VRDL380/2009/2009/04/27/6//NA/
A/Lisboa/03/2009
A/Lisboa/16/2008
A/Tottori/08T010/2008
A/Stockholm/28/2008/1/1410/|/EPI/ISL/70666
A/Hong Kong/1975/2009
A/Fujian/Gulou/1581/2009/1/1410/|/EPI/ISL/6...
A/Iceland/4/2008/1/1410/|/EPI/ISL/65389
GQ475908/1/1410/A/Kansas/01/2009/2009/01/29/6//NA/
A/Taiwan/5857/2008
A/Stockholm/5/2009/1/1410/|/EPI/ISL/70668
A/Seychelles/2231/2008/1/1410/|/EPI/ISL/65368
FJ380948/1/1410/A/Finland/11/2008/2008/01/07/6//NA/
A/Thessaloniki/24/2005/EPI/ISL/25428/A///H1N1/seasonal/NA/WSS964095
CY087279/1/1410/A/Hong/Kong/62768/2008/2008///6//NA/
A/Saskatchewan/RV1039/2009/1/1410/|/EPI/ISL...
A/Vladivostok/04/2008/1/1410/|/EPI/ISL/33691
A/New/1/1410/Caledonia/6/2008/|/EPI/ISL/28102
A/Paraguay/61/2009/1/1410/|/EPI/ISL/33621
GQ475948/1/1410/A/Rhode/Island/01/2009/2009/01/27/6//NA/
CY080763/1/1410/A/Boston/36/2009/2009/02/24/6//NA/
GU271952/1/1410/A/Thailand/CU/B97/2009/2009/06/22/6//NA/
A/Massachusetts/05/2007/1/1410/|/EPI/ISL/15455
A/Dakar/14/2008
CY074205/1/1410/A/California/VRDL220/2009/2009/04/29/6//NA/
A/Ghana/FS/205/2008
A/Quebec/RV0984/2009/1/1410/|/EPI/ISL/33649
A/Illinois/12/2009
A/Lisboa/27/2008
GQ476129/1/1410/A/Montana/02/2009/2009/01/02/6//NA/
A/Nebraska/07/2008/1/1410/|/EPI/ISL/28306
CY069343/1/1410/A/Texas/WRAIR1052P/2009/2009/01/09/6//NA/
GQ476012/1/1410/A/North/Dakota/03/2009/2009/03/01/6//NA/
A/Florida/29/2008
A/DAEJEON/4494/2008
A/Martinique/19/2008
A/St. Petersburg/75/2008
A/Buenos/1/1410/Aires/1306/2008/|/EPI/ISL/65472
A/Santiago/5087/2008/1/1410/|/EPI/ISL/23858
CY074341/1/1410/A/California/VRDL249/2009/2009/04/29/6//NA/
A/Ghana/FS/216/2008/1/1410/|/EPI/ISL/65463
A/Johannesburg/279/2008/1/1410/|/EPI/ISL/28096
A/Waikato/2/2009/1/1410/|/EPI/ISL/60126
A/Finland/514/2009/1/1410/|/EPI/ISL/60088
A/Taiwan/639/2008/1/1410/|/EPI/ISL/28323
A/Thailand/778/2008
A/Ukraine/313/2008
CY069487/1/1410/A/Louisiana/WRAIR1170P/2009/2009/02//6//NA/
A/Valparaiso/5366/2008/1/1410/|/EPI/ISL/23865
A/Hong Kong/3195/2008
A/Thailand/874/2008/1/1410/|/EPI/ISL/33664
A/Tottori/52/2008
A/Venezuela/3571/2008/1/1410/|/EPI/ISL/26243
A/PHILIPPINES/3314/2009/1/1410/|/EPI/ISL/60900
A/Nagasaki/07N035/2008
GQ475905/1/1410/A/Kentucky/01/2009/2009///6//NA/
A/Liaoning/Huanggu/1144/2009
CY080971/1/1410/A/Boston/85/2009/2009/02/12/6//NA/
A/Sweden/1/2009/1/1410/|/EPI/ISL/70643
CY089061/1/1410/A/Boston/23/2009/2009/02/18/6//NA/
GQ475980/1/1410/A/Massachusetts/05/2009/2009/02/26/6//NA/
CY100886/1/1410/A/Iraq/WRAIR1683P/2009/2009/03//6//NA/
CY068677/1/1410/A/Singapore/GP101/2009/2009/03/20/6//NA/
A/Belgium/850/2008
A/Boston/67/2009
CY100806/1/1410/A/Nevada/WRAIR1117P/2009/2009/01/01/6//NA/
A/Wyoming/10/2008/1/1410/|/EPI/ISL/19766
A/Lisboa/19/2009
CY053659/1/1410/A/Novosibirsk/3/2009/2009/04//6//NA/
CY100910/1/1410/A/Trujillo/WRAIR1701P/2008/2008/12/26/6//NA/
A/St. Petersburg/12/2008
A/Perth/33/2008/1/1410/|/EPI/ISL/28582
A/Paris/1704/2009/1/1410/|/EPI/ISL/65509
A/Maryland/05/2008/1/1410/|/EPI/ISL/28302
A/CHIBA/86/2008/1/1410/|/EPI/ISL/26386
CY074389/1/1410/A/California/VRDL264/2009/2009/04/25/6//NA/
A/Lisboa/22/2006
A/Washington/25/2009
A/Michigan/14/2009/1/1410/|/EPI/ISL/60719
GU112229/1/1410/A/Tehran/345/2009/2009/01/12/6//NA/
A/Taiwan/01/1986/EPI/ISL/10251/105058
GQ850597/1/1410/A/Shanghai/LWS1/2009/2009/01/03/6//NA/
A/Lisboa/77/2007
GQ475934/1/1410/A/Indiana/07/2009/2009/03/09/6//NA/
A/Austria/404342/2008
A/Vietnam/241/2008
A/Florida/27/2008/1/1410/|/EPI/ISL/60723
A/Michigan/31/2009/1/1410/|/EPI/ISL/77936
A/Pennsylvania/04/2009/1/1410/|/EPI/ISL/33756
CY074637/1/1410/A/California/VRDL377/2009/2009/04/27/6//NA/
A/Minnesota/04/2009
A/Lisboa/05/2009
A/KOCHI/48/2008/1/1410/|/EPI/ISL/27998
A/Tennessee/03/2009/1/1410/|/EPI/ISL/33809
0.02
A/Brisbane/12/2009
A/Minnesota/23/2007/1/1410/|/EPI/ISL/15465
A/Kursk/01/2008
CY080851/1/1410/A/Boston/52/2009/2009/02/14/6//NA/
CY074421/1/1410/A/California/VRDL275/2009/2009/04/30/6//NA/
A/Kericho/7529/2008/1/1410/|/EPI/ISL/28468
A/Kenya/2862/2009/1/1410/|/EPI/ISL/66654
A/Lisboa/39/2008
A/Christchurch/20/2008
A/PERTH/21/2009/1/1410/|/EPI/ISL/66758
A/Vietnam/2036/2009/1/1410/|/EPI/ISL/69711
CY100854/1/1410/A/Washington/WRAIR1237P/2009/2009/02/01/6//NA/
GQ476132/1/1410/A/Oregon/01/2009/2009/01/07/6//NA/
GQ476091/1/1410/A/Pennsylvania/01/2009/2009/01/07/6//NA/
A/Lisboa/6/2008
A/Niigata/08F188/2009
GQ476009/1/1410/A/Virginia/06/2009/2009/05/05/6//NA/
A/Chungbuk/4385/2008/1/1410/|/EPI/ISL/65495
A/Lisboa/14/2009
GQ476118/1/1410/A/Ohio/03/2009/2009/01/15/6//NA/
A/Algeria/G804/2008
GQ476047/1/1410/A/Arkansas/01/2009/2009/02/08/6//NA/
GQ475926/1/1410/A/Virginia/03/2009/2009/02/18/6//NA/
A/Lisboa/25/2006
A/Kyrgyzstan/214/2009/1/1410/|/EPI/ISL/61865
A/Hong Kong/H090/682/V1/0//2009
HQ291908/1/1410/A/Taiwan/2832/2008/2008/10/06/6//NA/
A/Incheon/4532/2008/1/1410/|/EPI/ISL/65492
A/Mauritius/403/2008/1/1410/|/EPI/ISL/65437
A/Sydney/601/2009/1/1410/|/EPI/ISL/60116
GQ475969/1/1410/A/New/York/63/2009/2009/03/31/6//NA/
A/Lisboa/8/2008
A/Berlin/59/2008/1/1410/|/EPI/ISL/65494
CY074597/1/1410/A/California/VRDL358/2009/2009/06/07/6//NA/
A/CHIBA/89/2008/1/1410/|/EPI/ISL/28169
A/Massachusetts/12/2008/1/1410/|/EPI/ISL/28366
A/England/494/2006/1/1410/|/EPI/ISL/25707
A/Algeria/G773/2008/1/1410/|/EPI/ISL/65459
A/Hong Kong/70/2009
A/Perth/33/2009/1/1410/|/EPI/ISL/60123
A/Victoria/501/2008/1/1410/|/EPI/ISL/23119
GQ475883/1/1410/A/West/Virginia/02/2009/2009/03/18/6//NA/
A/Kawasaki/UTK/4/2009
A/Vietnam/1808/2009/1/1410/|/EPI/ISL/69712
A/Hong/Kong/2765/2004/EPI/ISL/157578/A///H1N1/seasonal/NA/WSS964086
A/Norway/1747/07/1/1410/|/EPI/ISL/23298
A/GYEONGGIBUK/4503/2008
A/Lisboa/7/2006
A/WELLINGTON/84/2009/1/1410/|/EPI/ISL/60136
A/Hubei/Wujiagang/133/2009/1/1410/|/EPI/ISL...
A/Victoria/07159220/2007/1/1410/|/EPI/ISL/28584
CY100926/1/1410/A/Pucallpa/WRAIR1704P/2009/2009/01/14/6//NA/
CY080675/1/1410/A/Boston/17/2009/2009/02/10/6//NA/
A/Brazil/146/2009
A/Ghana/172/2008/1/1410/|/EPI/ISL/65441
A/Washington/02/2009/1/1410/|/EPI/ISL/33807
AB521100/1/1410/A/Yamagata/36/2009/2009/01/14/6//NA/
A/Singapore/42/2008/1/1410/|/EPI/ISL/28384
A/Tahiti/3/2009/1/1410/|/EPI/ISL/60132
A/Tennessee/11/2008/1/1410/|/EPI/ISL/28324
A/Slovenia/123/2008
A/Lisboa/14/2008
GQ476072/1/1410/A/Florida/03/2009/2009/02/06/6//NA/
A/Yamagata/125/2008/1/1410/|/EPI/ISL/71068
A/Illinois/05/2009/1/1410/|/EPI/ISL/33728
GQ476109/1/1410/A/New/York/56/2009/2009/02/10/6//NA/
A/Chubut/102197/2008
CY081019/1/1410/A/Boston/93/2009/2009/03/17/6//NA/
GQ476140/1/1410/A/Alaska/01/2009/2009/01/29/6//NA/
CY100774/1/1410/A/Texas/WRAIR1053P/2009/2009/01/01/6//NA/
A/Colorado/08/2008/1/1410/|/EPI/ISL/28378
A/Brazil/5943/2008
A/Gansu/Chengguan1129/2007/1/1410/|/EPI/ISL/20448
A/Belem/241/2008
CY074373/1/1410/A/California/VRDL256/2009/2009/04/29/6//NA/
A/Guatemala/602/2008
A/NAGANO/1204/2008/1/1410/|/EPI/ISL/27999
JN256686/1/1410/A/Hong/Kong/H090/718/V1/0//2009/2009/07/15/6//NA/
A/England/684/2007/1/1410/|/EPI/ISL/25445
A/Ohio/02/2009/1/1410/|/EPI/ISL/33808
A/Yamagata/68/2008/1/1410/|/EPI/ISL/71063
A/Singapore/07/2009/1/1410/|/EPI/ISL/34736
CY080835/1/1410/A/Boston/49/2009/2009/02/13/6//NA/
CY073839/1/1410/A/California/VRDL163/2009/2009/04/29/6//NA/
A/Paris/1154/2008
CY073823/1/1410/A/California/VRDL154/2009/2009/04/28/6//NA/
A/Colorado/17/2008/1/1410/|/EPI/ISL/33652
CY074093/1/1410/A/California/VRDL186/2009/2009/04/29/6//NA/
A/Lisboa/48/2005
A/Kansas/UR06/0104/2007/1/1410/|/EPI/ISL/7867
A/South/1/1410/Australia/1/2008/|/EPI/ISL/22972
A/Paris/445/2008/1/1410/|/EPI/ISL/65483
A/Jilin/Chuanying/1318/2008/1/1410/|/EPI/ISL/33707
A/Florida/21/2008/1/1410/|/EPI/ISL/27641
JF972564/1/1410/A/Mississippi/03/2001/2001/01/25/6//NA/
A/Argentina/303/2008/1/1410/|/EPI/ISL/25779
CY074173/1/1410/A/California/VRDL215/2009/2009/04/28/6//NA/
A/Brisbane/1/2009/1/1410/|/EPI/ISL/32490
A/El Salvador/468/2008
A/Uganda/0511/2009/1/1410/|/EPI/ISL/66659
A/Washington/01/2008
CY100798/1/1410/A/Texas/WRAIR1115P/2009/2009/03/01/6//NA/
CY080939/1/1410/A/Boston/72/2009/2009/03/24/6//NA/
A/Washington/08/2008/1/1410/|/EPI/ISL/28333
A/Lisboa/19/2008
A/Florida/02/2008/1/1410/|/EPI/ISL/19087
A/Maryland/04/2007
A/Stockholm/6/2009/1/1410/|/EPI/ISL/70806
A/Lisboa/94/2005
A/Kentucky/08/2009
A/Cayman Islands/5082/2009
A/Singapore/88/2009/1/1410/|/EPI/ISL/34737
A/Kazakhstan/2600/2008
A/India/7308/2008/1/1410/|/EPI/ISL/33659
GQ475914/1/1410/A/Hawaii/03/2009/2009/01/29/6//NA/
CY089109/1/1410/A/Boston/59/2009/2009/02/28/6//NA/
CY074125/1/1410/A/California/VRDL194/2009/2009/04/27/6//NA/
A/England/26/2008
A/IBARAKI/68/2008/1/1410/|/EPI/ISL/28175
A/Managua/1985.01/2008/1/1410/|/EPI/ISL/62906
GQ457553/1/1410/A/Saskatchewan/5131/2009/2009/06/19/6//NA/
CY080612/1/1410/A/Boston/95/2009/2009/04/01/6//NA/
CY074485/1/1410/A/California/VRDL292/2009/2009/04/30/6//NA/
A/Idaho/01/2009/1/1410/|/EPI/ISL/61874
A/AOMORI/19/2008/1/1410/|/EPI/ISL/28166
CY053671/1/1410/A/Novosibirsk/7/2009/2009/04//6//NA/
CY100958/1/1410/A/Pucallpa/WRAIR1709P/2009/2009/01/20/6//NA/
A/Georgia/1269/1/1410//36G//2009/|/EPI/ISL/...
A/GWANGJU/4324/2008/1/1410/|/EPI/ISL/28202
GU271968/1/1410/A/Thailand/CU/H565/2009/2009/09/02/6//NA/
A/SHIMANE/1/2009/1/1410/|/EPI/ISL/28187
A/Cameroon/073/2008/1/1410/|/EPI/ISL/65406
A/Rabat/109/2009/1/1410/|/EPI/ISL/65489
GQ475869/1/1410/A/New/York/02/2009/2009/02/14/6//NA/
A/Honduras/100/2008
A/SAMOA/10/2009/1/1410/|/EPI/ISL/65128
CY069551/1/1410/A/Texas/WRAIR1254P/2009/2009/03//6//NA/
A/Brazil/815/2009
CY100934/1/1410/A/Santa/Cruz/WRAIR1706P/2008/2008/12/09/6//NA/
A/WELLINGTON/218/2009/1/1410/|/EPI/ISL/65150
A/Iceland/8599/2009/1/1410/|/EPI/ISL/65514
A/Arizona/13/2008/1/1410/|/EPI/ISL/27639
A/Paraguay/67/2009
A/Moscow/38/2008
A/Buenos/1/1410/Aires/825511/2008/|/EPI/ISL/65471
CY100830/1/1410/A/Japan/WRAIR1226P/2009/2009/02/01/6//NA/
GQ476155/1/1410/A/New/Mexico/01/2009/2009/01/07/6//NA/
A/Michigan/01/2009/1/1410/|/EPI/ISL/33745
A/Singapore/6/1986/EPI/ISL/6905/58244
A/England/594/2006/1/1410/|/EPI/ISL/25708
A/Peru/WRAIR1505P/2007/1/1410/|/EPI/ISL/78572
A/Naypyitaw/M499/2008/1/1410/|/EPI/ISL/33557
A/Thailand/839/2008
GQ476088/1/1410/A/Nebraska/05/2009/2009/03/07/6//NA/
CY050662/1/1410/A/New/York/3150/2009/2009/04/27/6//NA/
A/Ghana/FS/09/718/2009/1/1410/|/EPI/ISL/60087
A/Seychelles/2239/2008/EPI/ISL/60835/A///H1N1/seasonal/NA/WSS964136
GQ475945/1/1410/A/Washington/03/2009/2009/01/21/6//NA/
A/Fukushima/141/2006/EPI/ISL/20229/A///H1N1/seasonal/NA/WSS964101
A/Perth/30/2009
CY074357/1/1410/A/California/VRDL252/2009/2009/04/29/6//NA/
A/Algeria/G825/2008
CY100870/1/1410/A/Nevada/WRAIR1257P/2009/2009/02/01/6//NA/
A/Texas/16/2008/1/1410/|/EPI/ISL/26239
AB521103/1/1410/A/Yamagata/51/2009/2009/01/26/6//NA/
A/KOBE/49/2008
AB521101/1/1410/A/Yamagata/26/2009/2009/01/17/6//NA/
CY074333/1/1410/A/California/VRDL245/2009/2009/04/29/6//NA/
A/Indiana/08/2009
A/Guangdong/Futian/139/2009/1/1410/|/EPI/IS...
AB521111/1/1410/A/Yamagata/77/2009/2009/02/10/6//NA/
A/Lisboa/4/2008
A/Stockholm/7/2009/1/1410/|/EPI/ISL/70800
A/Lisboa/23/2009
A/Sweden/8/2008/1/1410/|/EPI/ISL/70648
CY050478/1/1410/A/New/York/1692/2009/2009/04/27/6//NA/
A/Lisboa/07/2009
A/Fujian/Gulou/1367/2009/1/1410/|/EPI/ISL/3...
A/TAK/334/2009/1/1410/|/EPI/ISL/65129
GQ475877/1/1410/A/New/York/62/2009/2009/03/17/6//NA/
A/Delaware/01/2008/1/1410/|/EPI/ISL/28285
GQ475886/1/1410/A/Nebraska/06/2009/2009/03/22/6//NA/
A/Lisboa/13/2008
A/Lisboa/2/2008
A/Guangdong/Zhuangzuyaozuzizhi/51/200.../1/1410
CY074309/1/1410/A/California/VRDL238/2009/2009/04/29/6//NA/
A/Hong/Kong/3192/2008/EPI/ISL/65482/A///H1N1/seasonal/NA/WSS964139
CY100790/1/1410/A/Oklahoma/WRAIR1110P/2009/2009/03/01/6//NA/
CY073863/1/1410/A/California/VRDL229/2009/2009/04/29/6//NA/
A/KOL/2465/2009
HQ291915/1/1410/A/Taiwan/8949/2008/2008/12/11/6//NA/
A/Quebec/RV3060/2009
A/Arizona/13/2007/1/1410/|/EPI/ISL/15893
CY080795/1/1410/A/Boston/41/2009/2009/02/27/6//NA/
A/Lisboa/16/2009
A/Yamagata/128/2008
GQ476126/1/1410/A/Florida/07/2009/2009/03/25/6//NA/
A/Texas/27/2008/1/1410/|/EPI/ISL/27653
CY074277/1/1410/A/California/VRDL232/2009/2009///6//NA/
A/BEIJING/HUAIROU/185/2008
A/Texas/31/2007/1/1410/|/EPI/ISL/15409
A/Algeria/G864/2008/1/1410/|/EPI/ISL/65468
A/Managua/954.02/2008/1/1410/|/EPI/ISL/33848
A/Quebec/Rv1107/2009/1/1410/|/EPI/ISL/33632
CY080803/1/1410/A/Boston/42/2009/2009/03/01/6//NA/
A/Hawaii/19/2008
GQ476096/1/1410/A/Hawaii/01/2009/2009/01/13/6//NA/
A/Tak/427/2009/1/1410/|/EPI/ISL/66657
A/French/1/1410/Polynesia/2001/2009/|/EPI/I...
GQ475972/1/1410/A/Wisconsin/06/2009/2009/03/03/6//NA/
A/Lisboa/11/2008
CY053655/1/1410/A/Novosibirsk/151/2009/2009/05//6//NA/
HQ256619/1/1410/A/Myanmar/M256/2009/2009/07/16/6//NA/
A/Stockholm/22/2008
A/SAMOA/9/2009/1/1410/|/EPI/ISL/60899
CY069391/1/1410/A/South/Carolina/WRAIR1116P/2009/2009/03/01/6//NA/
A/New/1/1410/Jersey/32/2008/|/EPI/ISL/33750
GQ475874/1/1410/A/Wisconsin/02/2009/2009/01/07/6//NA/
A/Argentina/295/2008/1/1410/|/EPI/ISL/25778
A/Lisboa/9/2008
A/Kenya/0793/2008/1/1410/|/EPI/ISL/33677
GQ476035/1/1410/A/Hawaii/13/2009/2009/04/16/6//NA/
A/Thailand/1577/2007/1/1410/|/EPI/ISL/22372
GQ476143/1/1410/A/Vermont/01/2009/2009/02/09/6//NA/
A/Uganda/0132/2009/1/1410/|/EPI/ISL/66658
CY100974/1/1410/A/Cusco/WRAIR1730P/2008/2008/08/20/6//NA/
A/SHIZUOKA/C/21/2009/1/1410/|/EPI/ISL/28194
CY089783/1/1410/A/Boston/32/2009/2009/02/20/6//NA/
GQ475880/1/1410/A/Tennessee/01/2009/2009/01/12/6//NA/
HQ291910/1/1410/A/Taiwan/3293/2008/2008/05/02/6//NA/
GQ457554/1/1410/A/Saskatchewan/5350/2009/2009/06/18/6//NA/
A/Managua/5007.01/2008/1/1410/|/EPI/ISL/62912
A/Fujian/Gulou/1896/2009/1/1410/|/EPI/ISL/6...
A/Nigeria/0023/2008/1/1410/|/EPI/ISL/25811
A/California/VRDL167/2009
CY089085/1/1410/A/Boston/46/2009/2009/03/01/6//NA/
HQ291909/1/1410/A/Taiwan/2885/2008/2008/11/24/6//NA/
CY100902/1/1410/A/Piura/WRAIR1700P/2009/2009/01/01/6//NA/
A/Johannesburg/45/2008/1/1410/|/EPI/ISL/23112
A/Indiana/06/2009/1/1410/|/EPI/ISL/33812
GQ475894/1/1410/A/California/01/2009/2009/01/07/6//NA/
A/Brisbane/59/2007/EPI/ISL/71838/A///H1N1/seasonal/NA/WSS964111
A/IWATE/40/2008/1/1410/|/EPI/ISL/27996
GQ475847/1/1410/A/New/Mexico/02/2009/2009/01/14/6//NA/
A/Washington/12/2008/1/1410/|/EPI/ISL/33813
A/Pennsylvania/14/2008/1/1410/|/EPI/ISL/33644
A/Samara/46/2008
A/Illinois/16/2007/1/1410/|/EPI/ISL/19084
A/Washington/05/2008/1/1410/|/EPI/ISL/25804
A/Brisbane/10/2009/1/1410/|/EPI/ISL/32493
A/Lisboa/4/2006
A/KwaZulu/1/1410/Natal/272/2008/|/EPI/ISL/65639
A/Denmark/27/2007/1/1410/|/EPI/ISL/25442
A/Maryland/04/2008/1/1410/|/EPI/ISL/28301
CY050550/1/1410/A/New/York/3095/2009/2009/04/29/6//NA/
A/Hong/1/1410/Kong/33597/2009/|/EPI/ISL/68854
A/SAPPORO/90/2008/1/1410/|/EPI/ISL/28010
A/Kenya/1329/2010/1/1410/|/EPI/ISL/98941
A/Georgia/20/2006/1/1410/|/EPI/ISL/21323
A/FUKUI/91/2008
A/USSR/90/77/EPI/ISL/66105/230612
A/Yangon/M195/2008/1/1410/|/EPI/ISL/33555
A/Hong/Kong/1856/2008/EPI/ISL/60838/A///H1N1/seasonal/NA/WSS964138
A/North/1/1410/Carolina/02/2008/|/EPI/ISL/19770
A/Solomon/Islands/3/2006/EPI/ISL/13324/A///H1N1/seasonal/NA/WSS964131
A/Hong/Kong/2652/2006/EPI/ISL/157436/A///H1N1/seasonal/NA/WSS964099
A/St. Petersburg/83/2008
HQ256643/1/1410/A/Myanmar/M428/2009/2009/08/11/6//NA/
A/Lisboa/10/2008
GQ476082/1/1410/A/Arkansas/02/2009/2009/03/01/6//NA/
CY089101/1/1410/A/Boston/54/2009/2009/02/22/6//NA/
A/Jilin/Chaoyang/157/2009/1/1410/|/EPI/ISL/...
CY074117/1/1410/A/California/VRDL193/2009/2009/04/29/6//NA/
A/Pennsylvania/13/2007/1/1410/|/EPI/ISL/23897
A/Marrakech/510/2009
A/Lisboa/15/2008
A/Paris/781/2008/1/1410/|/EPI/ISL/65485
A/Israel/1/2009/1/1410/|/EPI/ISL/65499
A/Boston/06/2009
A/Philippines/1159/2008
A/SHIZUOKA/C/10/2009
A/South/1/1410/Australia/12/2009/|/EPI/ISL/...
A/Argentina/110/2008/1/1410/|/EPI/ISL/25781
A/Niigata/08F093/2009
A/Hong/1/1410/Kong/18106/2009/|/EPI/ISL/65516
A/Nagasaki/07N020/2008/1/1410/|/EPI/ISL/70169
A/Kenya/2743/2009/1/1410/|/EPI/ISL/61877
CY080819/1/1410/A/Boston/45/2009/2009/03/03/6//NA/
A/Perth/1/2009/1/1410/|/EPI/ISL/32484
A/Lisboa/41/2008
A/Texas/36/2008/1/1410/|/EPI/ISL/33733
A/Hong/1/1410/Kong/26552/2009/|/EPI/ISL/66653
HQ256645/1/1410/A/Myanmar/M470/2009/2009/08/20/6//NA/
GQ476053/1/1410/A/New/York/65/2009/2009/03/09/6//NA/
A/BRISBANE/96/2009/1/1410/|/EPI/ISL/65152
A/Lisboa/15/2009
A/Egypt/10/2007/EPI/ISL/106505/A///H1N1/seasonal/NA/WSS964117
A/Hong/1/1410/Kong/852/2008/|/EPI/ISL/65426
CY100814/1/1410/A/Texas/WRAIR1118P/2009/2009/06/01/6//NA/
CY093127/1/1410/A/Boston/47/2009/2009/02/12/6//NA/
A/Belgium/G257/2008
HQ256649/1/1410/A/Myanmar/M533/2009/2009/09/04/6//NA/
A/Oregon/02/2009
A/Yokohama/78/2008
A/NIIGATA/1088/2008/1/1410/|/EPI/ISL/28002
A/Indiana/01/2008/1/1410/|/EPI/ISL/15873
A/Kiev/313/2008
A/India/3414/2009
A/Moscow/02/2009
A/Philippines/3914/2008
A/New/1/1410/Jersey/30/2008/|/EPI/ISL/33747
A/Lisboa/40/2008
A/Chile/1/1983/EPI/ISL/6900/58149
AB465323/1/1410/A/Yokohama/30/2008/2008/01/28/6//NA/
A/Lisboa/12/2008
A/Buenos/1/1410/Aires/R13/2008/|/EPI/ISL/65360
A/Tula/31/2008
A/Guatemala/663/2008
AB521105/1/1410/A/Yamagata/45/2009/2009/01/21/6//NA/
A/Lisboa/06/2009
A/Lisboa/24/2006/A/Lisboa/16/2006
A/Thailand/CU/B42/2009
A/England/557/2007
GQ476149/1/1410/A/New/York/64/2009/2009/04/09/6//NA/
A/St. Petersburg/85/2008
A/Jamaica/2968/2009/1/1410/|/EPI/ISL/33607
A/Cameroon/080/2008
AB521112/1/1410/A/Yamagata/80/2009/2009/02/18/6//NA/
A/Florida/24/2008/1/1410/|/EPI/ISL/28287
A/Lisboa/2/2009
CY100838/1/1410/A/Illinois/WRAIR1233P/2009/2009/03/01/6//NA/
A/Costa Rica/5150/2009
AB465321/1/1410/A/Yokohama/34/2008/2008/01/28/6//NA/
A/England/411/2008/1/1410/|/EPI/ISL/65477
GQ476104/1/1410/A/Pennsylvania/12/2009/2009/01/29/6//NA/
A/Israel/10/2009/1/1410/|/EPI/ISL/65498
A/Lisboa/17/2008
A/Nebraska/WRAIR1247P/2009
GQ475965/1/1410/A/Ohio/06/2009/2009/02/03/6//NA/
GQ476024/1/1410/A/Michigan/07/2009/2009/04/08/6//NA/
CY053657/1/1410/A/Novosibirsk/2/2009/2009/04//6//NA/
A/Belgium/858/2008
A/Lisboa/35/2005
GQ475920/1/1410/A/California/03/2009/2009/02/04/6//NA/
A/SURAT/1/1410/THANI/337/2009/|/EPI/ISL/65130
A/California/VRDL371/2009
GQ475951/1/1410/A/Kentucky/03/2009/2009/02/02/6//NA/
A/Puerto/1/1410/Rico/02/2009/|/EPI/ISL/33708
A/Niigata/08F031/2009
A/Taiwan/693/2009/1/1410/|/EPI/ISL/60130
A/Cameroon/08/235/2008/1/1410/|/EPI/ISL/65497
A/Lisboa/20/2008
A/North/1/1410/Carolina/07/2008/|/EPI/ISL/28372
A/Jilin/Chaoyang1258/2008/1/1410/|/EPI/ISL/28298
A/Bangladesh/9067/2008/1/1410/|/EPI/ISL/33671
A/Lisboa/20/2009
A/Hawaii/41/2008/1/1410/|/EPI/ISL/28376
A/Ireland/744/2008
A/MACAU/3436/2009/1/1410/|/EPI/ISL/65127
HQ533869/1/1410/A/Tianjin/15/2009/2009///6//NA/
CY100918/1/1410/A/Trujillo/WRAIR1702P/2008/2008/12/28/6//NA/
GQ475962/1/1410/A/Montana/01/2009/2009/01/04/6//NA/
GQ475856/1/1410/A/South/Dakota/01/2009/2009/01/22/6//NA/
GU112230/1/1410/A/Tehran/359/2009/2009/01/16/6//NA/
A/HAMAMATU/C/988/2009/1/1410/|/EPI/ISL/65151
A/Ontario/RV0131/2007/1/1410/|/EPI/ISL/22256
A/Minnesota/01/2008/1/1410/|/EPI/ISL/20792
GQ476027/1/1410/A/Maryland/01/2009/2009/01/18/6//NA/
A/Prague/33/2009/1/1410/|/EPI/ISL/65503
A/South/1/1410/Australia/11/2009/|/EPI/ISL/...
A/SAPPORO/66/2008/1/1410/|/EPI/ISL/26396
A/Netherlands/345/2007/EPI/ISL/60837/A///H1N1/seasonal/NA/WSS964114
JN676131/1/1410/A/Thailand/Siriraj/3043/2009/2009/10/06/6//NA/
CY074469/1/1410/A/California/VRDL289/2009/2009/05/01/6//NA/
A/Fujian/Gulou/1292/2009/1/1410/|/EPI/ISL/3...
A/Sichuan/Dongqu/1836/2009/1/1410/|/EPI/ISL...
A/Lisboa/6/2006
JN256687/1/1410/A/Hong/Kong/H090/744/V1/0//2009/2009/07/24/6//NA/
A/Norway/1735/2007/EPI/ISL/106540/A///H1N1/seasonal/NA/WSS964128
A/Michigan/06/2008/1/1410/|/EPI/ISL/27649
A/Pennsylvania/09/2008/1/1410/|/EPI/ISL/26237
A/Hawaii/42/2008/1/1410/|/EPI/ISL/28377
CY100846/1/1410/A/Alabama/WRAIR1235P/2009/2009/04/01/6//NA/
A/Peru/WRAIR1300P/2007/1/1410/|/EPI/ISL/78566
A/Hawaii/28/2007/1/1410/|/EPI/ISL/33820
A/Minnesota/27/2008/1/1410/|/EPI/ISL/27650
EU551821/1/1410/A/Paris/963/2008/2008/01/04/6//NA/
GQ475997/1/1410/A/Minnesota/01/2009/2009/01/16/6//NA/
CY074101/1/1410/A/California/VRDL189/2009/2009/04/29/6//NA/
CY080899/1/1410/A/Boston/65/2009/2009/03/09/6//NA/
CY089045/1/1410/A/Boston/10/2009/2009/02/04/6//NA/
A/Minnesota/34/2008/1/1410/|/EPI/ISL/28371
A/Paris/1157/2008
A/Japan/WRAIR1230P/2009
A/Waikato/1/2009/1/1410/|/EPI/ISL/60125
A/Lisboa/17/2009
A/Salta/2093/2008/1/1410/|/EPI/ISL/65473
A/OSAKA/C/39/2008
CY050774/1/1410/A/New/York/3442/2009/2009/05/09/6//NA/
A/Hong/Kong/2637/2004/EPI/ISL/11833/A///H1N1/seasonal/NA/WSS964097
A/Victoria/214/2009/1/1410/|/EPI/ISL/60131
A/KANAGAWA/68/2008
GQ475931/1/1410/A/Ohio/04/2009/2009/01/28/6//NA/
A/Sri Lanka/13/2009
A/Mexico/2629/2009/1/1410/|/EPI/ISL/33635
A/Austria/404811/2008
A/Lisboa/24/2009
A/INCHEON/4432/2008/1/1410/|/EPI/ISL/28206
A/Johannesburg/21/2008
A/CHANTHABURI/341/2009/1/1410/|/EPI/ISL/65136
A/Annecy/2013/2009/1/1410/|/EPI/ISL/68855
A/St. Petersburg/11/2008
A/Paris/1208/2008
GQ476079/1/1410/A/Hawaii/17/2009/2009/04/13/6//NA/
GU183801/1/1410/A/Thailand/CU/B589/2009/2009/07/10/6//NA/
CY074237/1/1410/A/California/VRDL224/2009/2009/04/29/6//NA/
GU183809/1/1410/A/Thailand/CU/B685/2009/2009/07/12/6//NA/
A/England/40/2004/EPI/ISL/157574/A///H1N1/seasonal/NA/WSS964084
A/California/VRDL283/2009
A/Johannesburg/174/2008/1/1410/|/EPI/ISL/65642
CY089173/1/1410/A/Boston/94/2009/2009/03/13/6//NA/
A/Yamagata/137/2008/1/1410/|/EPI/ISL/71072
A/Lisboa/18/2008
A/Naypyitaw/M783/2008/1/1410/|/EPI/ISL/33559
CY100894/1/1410/A/Piura/WRAIR1699P/2008/2008/12/28/6//NA/
A/Philippines/15/2009/1/1410/|/EPI/ISL/60117
A/Lisboa/7/2008
A/Guatemala/22/2008
CY043539/1/1410/A/Kyoto/08K056/2009/2009/01/07/6//NA/
CY089125/1/1410/A/Boston/70/2009/2009/03/21/6//NA/
A/Dniprodzerzinsk/164/2008
A/St. Petersburg/53/2008
A/Argentina/81/2008
GQ475974/1/1410/A/North/Dakota/01/2009/2009/01/19/6//NA/
A/Alberta/RV2859/2009/1/1410/|/EPI/ISL/66647
A/Luxembourg/116/2008
CY069383/1/1410/A/Alaska/WRAIR1114P/2009/2009/03//6//NA/
A/Ghana/168/2008
CY080691/1/1410/A/Boston/20/2009/2009/02/11/6//NA/
A/Scotland/5/2007/1/1410/|/EPI/ISL/63393
A/Perth/46/2008/1/1410/|/EPI/ISL/28093
A/SHIGA/18/2008/1/1410/|/EPI/ISL/26399
A/Sydney/605/2009/1/1410/|/EPI/ISL/32488
A/Lisboa/18/2009
A/Peru/WRAIR1299P/2007/1/1410/|/EPI/ISL/78565
CY069311/1/1410/A/Bogota/WRAIR0088N/2009/2009/06/10/6//NA/
A/Macau/2517/2009/1/1410/|/EPI/ISL/60135
A/Lisboa/32/2006
A/Georgia/04/2009/1/1410/|/EPI/ISL/60717
CY064841/1/1410/A/California/VRDL141/2009/2009/04/28/6//NA/
A/Kiev/49/2008
A/Lisboa/31/2006
A/India/2757/2009
A/North/1/1410/Carolina/04/2009/|/EPI/ISL/3...
A/Puerto/1/1410/Rico/01/2008/|/EPI/ISL/33657
A/Luxembourg/1344/2008
A/Yamagata/16/2009/2009
A/Marseille/1148/2009/1/1410/|/EPI/ISL/60089
A/British/1/1410/Columbia/RV0035/2009/|/EPI/ISL/66649
A/Virginia/03/2008/1/1410/|/EPI/ISL/28332
A/Belgium/812/2008
A/South Korea/WRAIR1238P/2009
A/Madagascar/6054/2009/1/1410/|/EPI/ISL/68858
A/Illinois/16/2008/1/1410/|/EPI/ISL/28295
CY080652/1/1410/A/Boston/13/2009/2009/02/10/6//NA/
A/VICTORIA/549/2009/1/1410/|/EPI/ISL/66759
CY069375/1/1410/A/South/Dakota/WRAIR1113P/2009/2009/03/01/6//NA/
HQ291918/1/1410/A/Taiwan/11526/2008/2008/12/01/6//NA/
CY100942/1/1410/A/Sullana/WRAIR1707P/2009/2009/02/21/6//NA/
CY100822/1/1410/A/Kuwait/WRAIR1119P/2009/2009/01/01/6//NA/
A/Texas/57/2009/1/1410/|/EPI/ISL/61862
A/Lisboa/25/2009
A/Taiwan/1026/2009
CY074133/1/1410/A/California/VRDL200/2009/2009/04/30/6//NA/
A/Paris/1093/2009/1/1410/|/EPI/ISL/65510
A/Kenya/4225/2009/1/1410/|/EPI/ISL/61868
A/Missouri/05/2009/1/1410/|/EPI/ISL/34733
A/Lisboa/3/2008
A/NEW/1/1410/CALEDONIA/2/2009/|/EPI/ISL/65126
CY070913/1/1410/A/California/VRDL151/2009/2009/04/28/6//NA/
A/Guatemala/866/2009/1/1410/|/EPI/ISL/60716
A/MIYAGI/35/2008
A/Florida/28/2008/1/1410/|/EPI/ISL/28367
A/Matagalpa/179/2009/1/1410/|/EPI/ISL/33648
A/New Jersey/16/2007
A/Bangladesh/3003/2008/1/1410/|/EPI/ISL/33674
A/SHIMANE/117/2008
A/Wisconsin/12/2008/1/1410/|/EPI/ISL/26245
A/Santiago/4689/2008
A/Iceland/8064/2009
A/Mexico/4971/2008/1/1410/|/EPI/ISL/27637
HQ291899/1/1410/A/Taiwan/0045/2006/2006/05/24/6//NA/
CY074141/1/1410/A/California/VRDL202/2009/2009/04/29/6//NA/
A/Guyane/8190/2008
CY070897/1/1410/A/California/VRDL149/2009/2009/04/27/6//NA/
A/Hawaii/58/2008
GQ896377/1/1410/A/Wisconsin/14/2009/2009/05/22/6//NA/
JN582061/1/1410/A/New/York/08/1326/2008/2008/02/13/6//NA/
CY089759/1/1410/A/Boston/87/2009/2009/02/14/6//NA/
A/Lisboa/28/2008
A/CapeTown/124/2008
A/Texas/35/2008/1/1410/|/EPI/ISL/33732
A/yokohama/91/2007/1/1410/|/EPI/ISL/28731
CY074285/1/1410/A/California/VRDL235/2009/2009/04/29/6//NA/
GQ896371/1/1410/A/Utah/12/2009/2009/05/18/6//NA/
A/Lisboa/35/2006
A/NIIGATA/1150/2008/1/1410/|/EPI/ISL/28003
A/Kisii/7541/2008/1/1410/|/EPI/ISL/28471
A/BRISBANE/87/2009/1/1410/|/EPI/ISL/60134
A/Cambodia/21/2007/1/1410/|/EPI/ISL/28585
CY100966/1/1410/A/Maracay/WRAIR1729P/2008/2008/09/03/6//NA/
A/Kenya/4250/2009/1/1410/|/EPI/ISL/70216
A/Lisboa/21/2009
GQ476061/1/1410/A/Illinois/06/2009/2009/03/12/6//NA/
A/Virginia/01/2009/1/1410/|/EPI/ISL/33806
A/Ghana/FS/09/791/2009/1/1410/|/EPI/ISL/60086
A/Marrakech/589/2009
A/Luhansk/18/2008
A/SEOUL/4437/2008/1/1410/|/EPI/ISL/28208
A/Kenya/1432/2008
A/Maryland/07/2008/1/1410/|/EPI/ISL/28383
A/Flanders/G771/2009/1/1410/|/EPI/ISL/65508
A/EHIME/38/2008/1/1410/|/EPI/ISL/28170
A/OKAYAMA/14/2008/1/1410/|/EPI/ISL/28007
A/Honduras/330/2009/1/1410/|/EPI/ISL/33604
CY080987/1/1410/A/Boston/88/2009/2009/02/19/6//NA/
GQ475900/1/1410/A/Indiana/05/2009/2009/01/23/6//NA/
A/Paris/160/2007/EPI/ISL/157392/A///H1N1/seasonal/NA/WSS964105
CY100950/1/1410/A/Piura/WRAIR1708P/2009/2009/03/27/6//NA/
A/North/1/1410/Dakota/01/2008/|/EPI/ISL/28310
A/Massachusetts/08/2008/1/1410/|/EPI/ISL/27647
A/Lisboa/13/2009
HQ256609/1/1410/A/Myanmar/M061/2009/2009/06/27/6//NA/
A/Peru/WRAIR1310P/2007/1/1410/|/EPI/ISL/78567
A/Bratislava/149/2009
A/New/1/1410/Jersey/15/2007/|/EPI/ISL/71839
A/Lisboa/29/2008
A/New/Caledonia/20/1999/EPI/ISL/22626/A///H1N1/seasonal/NA/WSS964089
A/St. Petersburg/62/2008
A/Lisboa/5/2008
A/Vietnam/289/2008
A/Dakar/06/2008
A/Vladivostok/03/2008/1/1410/|/EPI/ISL/33690
A/Hokkaido/08H024/2009
CY073855/1/1410/A/California/VRDL175/2009/2009/04/28/6//NA/
A/Fiji/7/2009/1/1410/|/EPI/ISL/60129
A/Bangladesh/6666/2008/1/1410/|/EPI/ISL/33670
A/Lisboa/1/2008
A/NAIROBI/2/2009/1/1410/|/EPI/ISL/78686
A/Paris/910/2008
A/British/1/1410/Columbia/RV1585/2007/|/EPI/ISL/21859
A/Paris/639/2008/1/1410/|/EPI/ISL/90990
A/Beijing/Chaoyang/11405/2009
A/Lisboa/2/2006
A/Norway/1736/2007/1/1410/|/EPI/ISL/25416
GQ475940/1/1410/A/Montana/03/2009/2009/01/14/6//NA/
A/Pennsylvania/12/2008/1/1410/|/EPI/ISL/28368
CY064873/1/1410/A/California/VRDL146/2009/2009/04/25/6//NA/
CY074661/1/1410/A/California/VRDL380/2009/2009/04/27/6//NA/
A/Lisboa/03/2009
A/Lisboa/16/2008
A/Tottori/08T010/2008
A/Stockholm/28/2008/1/1410/|/EPI/ISL/70666
A/Hong Kong/1975/2009
A/Fujian/Gulou/1581/2009/1/1410/|/EPI/ISL/6...
A/Iceland/4/2008/1/1410/|/EPI/ISL/65389
GQ475908/1/1410/A/Kansas/01/2009/2009/01/29/6//NA/
A/Taiwan/5857/2008
A/Stockholm/5/2009/1/1410/|/EPI/ISL/70668
A/Seychelles/2231/2008/1/1410/|/EPI/ISL/65368
FJ380948/1/1410/A/Finland/11/2008/2008/01/07/6//NA/
A/Thessaloniki/24/2005/EPI/ISL/25428/A///H1N1/seasonal/NA/WSS964095
CY087279/1/1410/A/Hong/Kong/62768/2008/2008///6//NA/
A/Saskatchewan/RV1039/2009/1/1410/|/EPI/ISL...
A/Vladivostok/04/2008/1/1410/|/EPI/ISL/33691
A/New/1/1410/Caledonia/6/2008/|/EPI/ISL/28102
A/Paraguay/61/2009/1/1410/|/EPI/ISL/33621
GQ475948/1/1410/A/Rhode/Island/01/2009/2009/01/27/6//NA/
CY080763/1/1410/A/Boston/36/2009/2009/02/24/6//NA/
GU271952/1/1410/A/Thailand/CU/B97/2009/2009/06/22/6//NA/
A/Massachusetts/05/2007/1/1410/|/EPI/ISL/15455
A/Dakar/14/2008
CY074205/1/1410/A/California/VRDL220/2009/2009/04/29/6//NA/
A/Ghana/FS/205/2008
A/Quebec/RV0984/2009/1/1410/|/EPI/ISL/33649
A/Illinois/12/2009
A/Lisboa/27/2008
GQ476129/1/1410/A/Montana/02/2009/2009/01/02/6//NA/
A/Nebraska/07/2008/1/1410/|/EPI/ISL/28306
CY069343/1/1410/A/Texas/WRAIR1052P/2009/2009/01/09/6//NA/
GQ476012/1/1410/A/North/Dakota/03/2009/2009/03/01/6//NA/
A/Florida/29/2008
A/DAEJEON/4494/2008
A/Martinique/19/2008
A/St. Petersburg/75/2008
A/Buenos/1/1410/Aires/1306/2008/|/EPI/ISL/65472
A/Santiago/5087/2008/1/1410/|/EPI/ISL/23858
CY074341/1/1410/A/California/VRDL249/2009/2009/04/29/6//NA/
A/Ghana/FS/216/2008/1/1410/|/EPI/ISL/65463
A/Johannesburg/279/2008/1/1410/|/EPI/ISL/28096
A/Waikato/2/2009/1/1410/|/EPI/ISL/60126
A/Finland/514/2009/1/1410/|/EPI/ISL/60088
A/Taiwan/639/2008/1/1410/|/EPI/ISL/28323
A/Thailand/778/2008
A/Ukraine/313/2008
CY069487/1/1410/A/Louisiana/WRAIR1170P/2009/2009/02//6//NA/
A/Valparaiso/5366/2008/1/1410/|/EPI/ISL/23865
A/Hong Kong/3195/2008
A/Thailand/874/2008/1/1410/|/EPI/ISL/33664
A/Tottori/52/2008
A/Venezuela/3571/2008/1/1410/|/EPI/ISL/26243
A/PHILIPPINES/3314/2009/1/1410/|/EPI/ISL/60900
A/Nagasaki/07N035/2008
GQ475905/1/1410/A/Kentucky/01/2009/2009///6//NA/
A/Liaoning/Huanggu/1144/2009
CY080971/1/1410/A/Boston/85/2009/2009/02/12/6//NA/
A/Sweden/1/2009/1/1410/|/EPI/ISL/70643
CY089061/1/1410/A/Boston/23/2009/2009/02/18/6//NA/
GQ475980/1/1410/A/Massachusetts/05/2009/2009/02/26/6//NA/
CY100886/1/1410/A/Iraq/WRAIR1683P/2009/2009/03//6//NA/
CY068677/1/1410/A/Singapore/GP101/2009/2009/03/20/6//NA/
A/Belgium/850/2008
A/Boston/67/2009
CY100806/1/1410/A/Nevada/WRAIR1117P/2009/2009/01/01/6//NA/
A/Wyoming/10/2008/1/1410/|/EPI/ISL/19766
A/Lisboa/19/2009
CY053659/1/1410/A/Novosibirsk/3/2009/2009/04//6//NA/
CY100910/1/1410/A/Trujillo/WRAIR1701P/2008/2008/12/26/6//NA/
A/St. Petersburg/12/2008
A/Perth/33/2008/1/1410/|/EPI/ISL/28582
A/Paris/1704/2009/1/1410/|/EPI/ISL/65509
A/Maryland/05/2008/1/1410/|/EPI/ISL/28302
A/CHIBA/86/2008/1/1410/|/EPI/ISL/26386
CY074389/1/1410/A/California/VRDL264/2009/2009/04/25/6//NA/
A/Lisboa/22/2006
A/Washington/25/2009
A/Michigan/14/2009/1/1410/|/EPI/ISL/60719
GU112229/1/1410/A/Tehran/345/2009/2009/01/12/6//NA/
A/Taiwan/01/1986/EPI/ISL/10251/105058
GQ850597/1/1410/A/Shanghai/LWS1/2009/2009/01/03/6//NA/
A/Lisboa/77/2007
GQ475934/1/1410/A/Indiana/07/2009/2009/03/09/6//NA/
A/Austria/404342/2008
A/Vietnam/241/2008
A/Florida/27/2008/1/1410/|/EPI/ISL/60723
A/Michigan/31/2009/1/1410/|/EPI/ISL/77936
A/Pennsylvania/04/2009/1/1410/|/EPI/ISL/33756
CY074637/1/1410/A/California/VRDL377/2009/2009/04/27/6//NA/
A/Minnesota/04/2009
A/Lisboa/05/2009
A/KOCHI/48/2008/1/1410/|/EPI/ISL/27998
A/Tennessee/03/2009/1/1410/|/EPI/ISL/33809
0.02
A/Brisbane/12/2009
A/Minnesota/23/2007/1/1410/|/EPI/ISL/15465
A/Kursk/01/2008
CY080851/1/1410/A/Boston/52/2009/2009/02/14/6//NA/
CY074421/1/1410/A/California/VRDL275/2009/2009/04/30/6//NA/
A/Kericho/7529/2008/1/1410/|/EPI/ISL/28468
A/Kenya/2862/2009/1/1410/|/EPI/ISL/66654
A/Lisboa/39/2008
A/Christchurch/20/2008
A/PERTH/21/2009/1/1410/|/EPI/ISL/66758
A/Vietnam/2036/2009/1/1410/|/EPI/ISL/69711
CY100854/1/1410/A/Washington/WRAIR1237P/2009/2009/02/01/6//NA/
GQ476132/1/1410/A/Oregon/01/2009/2009/01/07/6//NA/
GQ476091/1/1410/A/Pennsylvania/01/2009/2009/ / 7/6//NA/
A/Lisboa/6/2008
A/Niigata/08F188/2009
GQ476009/1/1410/A/Virginia/06/2009/2009/05/05/6//NA/
A/Chungbuk/4385/2008/1/1410/|/EPI/ISL/65495
A Lisboa/14/2009
GQ476118/1/1410/A/Ohio/03/2009/2009/01/15/6//NA/
A/Algeria/G804/2008
GQ476047/1/1410/A/Arkansas/01/2009/2009/02/08/6//NA/
GQ475926/1/1410/A/Virginia/03/2009/2009/ 2/18/6//NA/
A/Lisboa/25/2006
A/Kyrgyzstan/214/2009/1/1410/|/EPI/ISL/61865
A/Hong Kong/H090/682/V1/0//2009
HQ291908/1/1410/A/Taiwan/2832/2008/2008/10/06/6//NA/
A/Incheon/4532/2008/1/1410/|/EPI/ISL/65492
A/Mauritius/403/2008/1/1410/|/EPI/ISL/65437
A/Sydney/601/2009/1/1410/|/EPI/ISL/60116
GQ475969/1/1410/A/New/York/63/2009/2009 03/31/6//NA/
A/Lisboa/8/2008
A/Berlin/59/2008/1/1410/|/EPI/ISL/65494
CY074597/1/1410/A/California/VRDL358/2009/2 09 06/ 7 6//NA/
A/CHIBA/89/2008/1/1410/|/EPI/ISL/28169
A/Massachusetts/12/2008/1/1410/|/EPI/ISL/28366
A/England/494/2006/1/1410/|/EPI/ISL/25707
A/Algeria/G773/2008/1/1410/|/EPI/ISL/65459
A/Hong Kong/70/2009
A/Perth/33/2009/1/1410/|/EPI/ISL/60123
A/Victoria/501/2008/1/1410/|/EPI/ISL/23119
GQ475883/1/1410/A/West/Virginia/02/2009/2009/03/18/6//NA/
A/Kawasaki/UTK/4/2009
A/Vietnam/1808/2009/1/1410/|/EPI/ISL/69712
A/Hong/Kong/2765/2004/EPI/ISL/157578/A///H1N1/seasonal/NA/WSS964086
A/Norway/1747/07/1/1410/|/EPI/ISL/23298
A/GYEONGGIBUK/4503/2008
A/Lisboa/7/2006
A/WELLINGTON/84/2009/1/1410/|/EPI/ISL/60136
A/Hubei/Wujiagang/133/2009/1/1410/|/EPI/ISL...
A/Victoria/07159220/2007/1/1410/|/EPI/ISL/28584
CY100926/1/1410/A/Pucallpa/WRAIR1704P/2009/2009/01/14/6//NA/
CY080675/1/1410/A/Boston/17/2009/2009/02/1 6 NA/
A/Brazil/146/2009
A/Ghana/172/2008/1/1410/|/EPI/ISL/65441
A/Washington/02/2009/1/1410/|/EPI/ISL/33807
AB521100/1/1410/A/Yamagata/36/2009/2009/01/14/6//NA/
A/Singapore/42/2008/1/1410/|/EPI/ISL/28384
A/Tahiti/3/2009/1/1410/|/EPI/ISL/60132
A/Tennessee/11/2008/1/1410/|/EPI/ISL/28324
A/Slovenia/123/2008
A/Lisboa/14/2008
GQ476072/1/1410/A/Florida/03/2009/2009/02/06/6//NA/
A/Yamagata/125/2008/1/1410/|/EPI/ISL/71068
A/Illinois/05/2009/1/1410/|/EPI/ISL/33728
GQ476109/1/1410/A/New/York/56/2009/2009/02/1 /6//NA/
A/Chubut/102197/2008
CY081019/1/1410/A/Boston/93/2009/2009/03/17/6//NA/
GQ476140/1/1410/A/Alaska/01/2009/2009/01/29/6//NA/
CY100774/1/1410/A/Texas/WRAIR1053P/2009/2009/01/01/6//NA/
A/Colorado/08/2008/1/1410/|/EPI/ISL/28378
A/Brazil/5943/2008
A/Gansu/Chengguan1129/2007/1/1410/|/EPI/ISL/20448
A/Belem/241/2008
CY074373/1/1410/A/California/VRDL256/2009/2 9 4/29 6//NA/
A/Guatemala/602/2008
A/NAGANO/1204/2008/1/1410/|/EPI/ISL/27999
JN256686/1 1410/A/Hong/Kong/H090/718/V1/0//2009/2009/07/15/6//NA/
A/England/684/2007/1/1410/|/EPI/ISL/25445
A/Ohio/ 2 2009/1/1410/|/EPI/ISL/33808
A/Yamagata/68/2008/1/1410/|/EPI/ISL/71063
A/Singapore/07/2009/1/1410/|/EPI/ISL/34736
CY080835/1/1410/A/Boston/49/2009/2009/02/13/6//NA/
CY073839/1/1410/A/California/VRDL163/2009/2009/04/29/6//NA/
A/Paris/1154/2008
CY073823/1/1410/A/California/VRDL154/2009/2009/04/28/6//NA/
A/Colorado/17/2008/1/1410/|/EPI/ISL/33652
CY074093/1/1410/A/California/VRDL186/2009/2009/04/29/6//NA/
A/Lisboa/48/2005
A/Kansas/UR06/0104/2007/1/1410/|/EPI/ISL/7867
A/South/1/1410/Australia/1/2008/|/EPI/ISL/22972
A/Paris/445/2008/1/1410/|/EPI/ISL/65483
A/Jilin/Chuanying/1318/2008/1/1410/|/EPI/ISL/33707
A/Florida/21/2008/1/1410/|/EPI/ISL/27641
JF972564/1/1410/A/Mississippi/03/2001/2001/01/25/6//NA/
A/Argentina/303/2008/1/1410/|/EPI/ISL/25779
CY074173/1/1410/A/California/VRDL215/2009/2009/04/28/6//NA/
A/Brisbane/1/2009/1/1410/|/EPI/ISL/32490
A/El Salvador/468/2008
A/Uganda/0511/2009/1/1410/|/EPI/ISL/66659
A/Washington/01/2008
CY100798/1/1410/A/Texas/WRAIR1115P/2009/2009/03/01/6//NA/
CY080939/1 1410/A/Boston/72/2009/2009/03/24 6 /NA
A/Washington/08/2008/1/1410/|/EPI/ISL/28333
A/Lisboa/19/2008
A/Florida/02/2008/1/1410/|/EPI/ISL/19087
A/Maryland/04/2007
A/Stockholm/6/2009/1/1410/|/EPI/ISL/70806
A/Lisboa/94/2005
A/Kentucky/08/2009
A/Cayman Islands/5082/2009
A/Singapore/88/2009/1/1410/|/EPI/ISL/34737
A/Kazakhstan/2600/2008
A/India/7308/2008/1/1410/|/EPI/ISL/33659
GQ475914/1/1410/A/Hawaii/03/2009/2009/01/29/6//NA/
CY089109/1/1410/A/Boston/59/2009/2009/02/28/6//NA/
CY 74125/1/1410/A/California/VRDL194/2009/2 09/04/27/6//NA/
A/England/26/2008
A/IBARAKI/68/2008/1/1410/|/EPI/ISL/28175
A/Managua/1985.01/2008/1/1410/|/EPI/ISL/62906
GQ457553/1/1410/A/Saskatchewan/5131/2009/2009/06/19/6//NA/
CY080612/1/1410/A/Boston/95/2009/2009/04/0 /6//NA/
CY074485/1/1410/A/California/VRDL292/2009/2009/04/30/6//NA/
A/Idaho/01/2009/1/1410/|/EPI/ISL/61874
A/AOMORI/19/2008/1/1410/|/EPI/ISL/28166
CY053671/1/1410/A/Novosibirsk/7/2009/2009/04//6//NA/
CY100958/1/1410/A/Pucallpa/WRAIR1709P/2009/2009/01/20/6//NA/
A/Georgia/1269/1/1410//36G//2009/|/EPI/ISL/...
A/GWANGJU/4324/2008/1/1410/|/EPI/ISL/28202
GU271968/1/1410/A/Thailand/CU/H565/2009/2009/09/02/6//NA/
A/SHIMANE/1/2009/1/1410/|/EPI/ISL/28187
A/Cameroon/073/2008/1/1410/|/EPI/ISL/65406
A Rabat/109/2009/1/1410/|/EPI/ISL/65489
GQ475869/1/1410/A/New/York/02/2009/2009/02/14/6//NA/
A/Honduras/100/2008
A/SAMOA/10/2009/1/1410/|/EPI/ISL/65128
CY069551/1/1410/A/Texas/WRAIR1254P/2009/2009/03//6//NA/
A/Brazil/815/2009
CY100934/1/1410/A/Santa/Cruz/WRAIR1706P/2008/2008/12/09/6//NA/
A/WELLINGTON/218/2009/1/1410/|/EPI/ISL/65150
A/Iceland/8599/2009/1/1410/|/EPI/ISL/65514
A/Arizona/13/2008/1/1410/|/EPI/ISL/27639
A/Paraguay/67/2009
A/Moscow/38/2008
A/Buenos/1/1410/Aires/825511/2008/|/EPI/ISL/65471
CY100830/1/1410/A/Japan/WRAIR1226P/2009/2 09/02/0 /6//NA
GQ476155/1/1410/A/New/Mexico/01/2009/2009/01/07/6//NA/
A/Michigan/01/2009/1/1410/|/EPI/ISL/33745
A/Singapore/6/1986/EPI/ISL/6905/58244
A/England/594/2006/1/1410/|/EPI/ISL/25708
A/Peru/WRAIR1505P/2007/1/1410/|/EPI/ISL/78572
A/Naypyitaw/M499/2008/1/1410/|/EPI/ISL/33557
A/Thailand/839/2008
GQ476088/1/1410/A/Nebraska/05/2009/2009/03/07/6//NA/
CY 5 662/1/1410/A/New/York/3150/2009/2009/04/27/6//NA/
A/Ghana/FS/09/718/2009/1/1410/|/EPI/ISL/60 7
A/Seychelles/2239/2008/EPI/ISL/60835/A///H1N1/seasonal/NA/WSS964136
GQ475945/1/1410/A/Washington/03/2009/2009/01/21/6//NA/
A/Fukushima/141/2006/EPI/ISL/20229/A///H1N1/seasonal/NA/WSS964101
A/Perth/30/2009
CY074357/1/1410/A/California/VRDL252/2009/2009/04/29/6//NA/
A/Algeria/G825/2008
CY100870/1/1410/A/Nevada/WRAIR1257P/2009/2009/02/01/6//NA/
A/Texas/16/2008/1/1410/|/EPI/ISL/26239
AB521103/1/1410/A/Yamagata/51/2009/2009/01/26/6//NA/
A/KOBE/49/2008
AB521101/1/1410/A/Yamagata/26/2009/2009/01/17/6//NA/
CY074333/1/1410/A/California/VRDL245/2009/2009/04/29/6//NA/
A/Indiana/08/2009
A/Guangdong/Futian/139/2009/1/1410/|/EPI/IS...
AB521111/1/1410/A/Yamagata/77/2009/2009/02/10/6//NA/
A/Lisboa/4/2008
A/Stockholm/7/2009/1/1410/|/EPI/ISL/70800
A/Lisboa/23/2009
A/Sweden/8/2008/1/1410/|/EPI/ISL/70648
CY050478/1/1410/A/New/York/1692/2009/20 9/04/27/6//NA/
A/Lisboa/07/2009
A/Fujian/Gulou/1367/2009/1/1410/|/EPI/ISL/3...
A/TAK/334/2009/1/1410/|/EPI/ISL/65129
GQ475877/1/1410/A/New/York/62/2009/2009/03 7 6//NA/
A/Delaware/01/2008/1/1410/|/EPI/ISL/2828
GQ475886/1/1410/A/Nebraska/06/2009/2009/03/22/6//NA/
A/Lisboa/13/2008
A/Lisboa/2/2008
A/Guangdong/Zhuangzuyaozuzizhi/51/200.../1/1410
CY 74309/1 1410/A/California/VRDL238/2009/2009/04/29/6//NA/
A/Hong/Kong/3192/2008/EPI/ISL/65482/A///H1N /seasonal/NA/WSS964139
CY100790/1/1410/A/Oklahoma/WRAIR1110P/2009/2009/03/01/6//NA/
CY073863/1/1410/A/California/VRDL229/2009 2009/04/29/6//NA/
/KOL/2 65/2009
HQ291915/1/1410/A/Taiwan/8949/2008/2008/12/11/6//NA/
A/Quebec/RV3060/2009
A/Arizona/13/2007/1/1410/|/EPI/ISL/15893
CY080795/1/1410/A/Boston/41/2009/2009/0 /27/6//NA/
A/Lisboa/16/2009
A/Yamagata/128/2008
GQ476126/1/1410/A/Florida/07/2009/2009/03/25/6//NA/
A/Texas/27/2008/1/1410/|/EPI/ISL/27653
CY074277/1/1410/A/California/VRDL232/2009/2009///6//NA/
A/BEIJING/HUAIROU/185/2008
A/Texas/31/2007/1/1410/|/EPI/ISL/15409
A/Algeria/G864/2008/1/1410/|/EPI/ISL/65468
A/Managua/954.02/2008/1/1410/|/EPI/ISL/33848
A/Quebec/Rv1107/2009/1/1410/|/EPI/ISL/33632
CY 80803/1/1410/A/Boston/42/2009/2009/03/01/6/ N /
A/Hawaii/19/2008
GQ476096/1/1410/A/Hawaii/01/2009/2009/01/13/6//NA/
A/Tak/427/2009/1/1410/|/EPI/ISL/66657
A/French/1/1410/Polynesia/2001/2009/|/EPI/I...
GQ475972/1/1410/A/Wisconsin/06/2009/2009/03/03/6//NA/
A/Lisboa/11/2008
CY053655/1/1410/A/Novosibirsk/151/2009/2009/05//6//NA/
HQ256619/1/1410/A/Myanmar/M256/2009/2009/07/16/6//NA/
A/Stockholm/22/2008
A/SAMOA/9/2009/1/1410/|/EPI/ISL/60899
CY069391/1/1410/A/South/Carolina/WRAIR1116P/2009/2009/03/01/6//NA/
A/New/1/1410/Jersey/32/2008/|/EPI/ISL/33750
GQ475874/1/1410/A/Wisconsin/02/2009/2009/01/07/6//NA/
A/Argentina/295/2008/1/1410/|/EPI/ISL/25778
A/Lisboa/9/2008
A/Kenya/0793/2008/1/1410/|/EPI/ISL/33677
GQ476035/1/1410/A/Hawaii/13/2009/2009/04/16/6//NA/
A/Thailand/1577/2007/1/1410/|/EPI/ISL/22372
GQ476143/1/1410/A/Vermont/01/2009 2009/02/09/6// A/
A/Uganda/0132/2009/1/1410/|/EPI/ISL/66658
CY100974/1/1410/A/Cusco/WRAIR1730P/2008/2008/08/20/6//NA/
A/SHIZUOKA/C/21/2009/1/1410/|/EPI/ISL/28194
CY089783/1/1410/A/Boston/32/2009/2009 02 20/6 /NA/
GQ475880/1/1410/A/Tennessee/01/2009/2009/01/12/6//NA/
HQ291910/1/1410/A/Taiwan/3293/2008/2008/05/02/6//NA/
GQ457554/1/1410/A/Saskatchewan/5350/2009/2009/06/18/6//NA/
A/Managua/5007.01/2008/1/1410/|/EPI/ISL/62912
A/Fujian/Gulou/1896/2009/1/1410/|/EPI/ISL/6...
A/Nigeria/0023/2008/1/1410/|/EPI/ISL/25811
A/California/VRDL167/2009
CY089085/1/1410/A/Boston/46/2009/2009/03/01/6//NA/
HQ291909/1/1410/A/Taiwan/2885/2008/2008/11/24/6//NA/
CY100902/1/1410/A/Piura/WRAIR1700P/2009/2009/01/01/6//NA/
A/Johannesburg/45/2008/1/1410/|/EPI/ISL/23112
A/Indiana/06/2009/1/1410/|/EPI/ISL/33812
GQ475894/1/1410/A/California/01/2009/2009/01/07/6//NA/
A/Brisbane/59/2007/EPI/ISL/71838/A///H1N1/seasonal/NA/WSS964111
A/IWATE/40/2008/1/1410/|/EPI/ISL/27996
GQ475847/1/1410/A/New/Mexico/02/2009/2009/01/14/6//NA/
A/Washington/12/2008/1/1410/|/EPI/ISL/33813
A/Pennsylvania/14/2008/1/1410/|/EPI/ISL/33644
A/Samara/46/2008
A/Illinois/16/2007/1/1410/|/EPI/ISL/19084
A/Washington/05/2008/1/1410/|/EPI/ISL/25804
A/Brisbane/10/2009/1/1410/|/EPI/ISL/32493
A/Lisboa/4/2006
A/KwaZulu/1/1410/Natal/272/2008/|/EPI/ISL/65639
A/Denmark/27/2007/1/1410/|/EPI/ISL/25442
A/Maryland/04/2008/1/1410/|/EPI/ISL/28301
CY050550/1/1410/A/New/York/3095/2009/2009/04/29/6//NA/
A/Hong/1/1410/Kong/33597/2009/|/EPI/ISL/6 854
A/SAPPORO/90/2008/1/1410/|/EPI/ISL/28010
A/Kenya/1329/2010/1/1410/|/EPI/ISL/98941
A/Georgia/20/2006/1/1410/|/EPI/ISL/21323
A/FUKUI/91/2008
A/USSR/90/77/EPI/ISL/66105/230612
A/Yangon/M195/2008/1/1410/|/EPI/ISL/33555
A/Hong/Kong/1856/2008/EPI/ISL/60838/A///H1N1/seasonal/NA/WSS964138
A/North/1/1410/Carolina/02/2008/|/EPI/ISL/19770
A/Solomon/Islands/3/2006/EPI/ISL/13324/A///H1N1/seasonal/NA/WSS964131
A/Hong/Kong/2652/2006/EPI/ISL/157436/A///H1N1/seasonal/NA/WSS964099
A/St. Petersburg/83/2008
HQ256643/1/1410/A/Myanmar/M428/2009/2009/ 8/11/6//NA/
A/Lisboa/10/2008
GQ476082/1/1410/A/Arkansas/02/2009/2009/03/01/6//NA/
CY089101/1/1410/A/Boston/54/2009/2009 02 2/6//NA/
A/Jilin/Chaoyang/157/2009/1/1410/|/EPI/ISL/...
CY0741 7/1 1410/A/California/VRDL193/2009/2009/04/29/6//NA/
A/Pennsylvania/13/2007/1/1410/|/EPI/ISL/23897
A/Marrakech/510/2009
A/Lisboa/15/2008
A/Paris/781/2008/1/1410/|/EPI/ISL/65485
A/Israel/1/2009/1/1410/|/EPI/ISL/65499
A/Boston/06/2009
A/Philippines/1159/2008
A/SHIZUOKA/C/10/2009
A/South/1/1410/Australia/12/2009/|/EPI/ISL/...
A/Argentina/110/2008/1/1410/|/EPI/ISL/25781
A/Niigata/08F093/2009
A/Hong/1/1410/Kong/18106/2009/|/EPI/ISL/655 6
A/Nagasaki/07N020/2008/1/1410/|/EPI/ISL/70169
A/Kenya/2743/2009/1/1410/|/EPI/ISL/61877
CY080819/1/1410/A/Boston/45/2009/2009/03/03/6//NA/
A/Perth/1/2009/1/1410/|/EPI/ISL/32484
A/Lisboa/41/2008
A/Texas/36/2008/1/1410/|/EPI/ISL/33733
A/Hong/1/1410/Kong/26552/2009/|/EPI/ISL/66653
HQ256645/1/1410/A/Myanmar/M470/2009/2009/ 8/20/6//NA/
GQ476053/1/1410/A/New/York/65/2009/2009/03/09/6//NA/
A/BRISBANE/96/2009/1/1410/|/EPI/ISL/65152
A/Lisboa/15/2009
A/Egypt/10/2007/EPI/ISL/106505/A///H1N1/seasonal/NA/WSS964117
A/Hong/1/1410/Kong/852/2008/|/EPI/ISL/65426
CY100814/1/1410/A/Texas/WRAIR1118P/2009/2009/06/01/6//NA/
CY093127/1/1410/A/Boston/47/2009/2009/02/12/6//NA/
A/Belgium/G257/2008
HQ256649/1/1410/A/Myanmar/M533/2009/2009/0 /04/6//NA/
A/Oregon/02/2009
A/Yokohama/78/2008
A/NIIGATA/1088/2008/1/1410/|/EPI/ISL/28002
A/Indiana/01/2008/1/1410/|/EPI/ISL/15873
A/Kiev/313/2008
A/India/3414/2009
A/Moscow/02/2009
/Philippines/3914/2008
A/New/1/1410/Jersey/30/2008/|/EPI/ISL/33747
A/Lisboa/40/2008
A/Chile/1/1983/EPI/ISL/6900/58149
AB465323/1/1410/A/Yokohama/30/2008/2008/01/28/6//NA/
A/Lisboa/12/2008
A/Buenos/1/1410/Aires/R13/2008/|/EPI/ISL/65360
A/Tula/31/2008
A/Guatemala/663/2008
AB521105/1/1410/A/Yamagata/45/2009/2009/01/21/6//NA/
A/Lisboa/06/2009
A/Lisboa/24/2006/A/Lisboa/16/2006
A/Thailand/CU/B42/2009
A/England/557/2007
GQ476149/1/1410/A/New/York/64/2009/2009/04/09/6//NA/
A/St. Petersburg/85/2008
A/Jamaica/2968/2009/1/1410/|/EPI/ISL/33607
A/Cameroon/080/2008
AB521112/1/1410/A/Yamagata/80/2009/2009/02/18/6//NA/
A/Florida/24/2008/1/1410/|/EPI/ISL/28287
A/Lisboa/2/2009
CY100838/1/1410/A/Illinois/WRAIR1233P/2009/2009/03/01/6//NA/
A/Costa Rica/5150/2009
AB465321/1/1410/A/Yokohama/34/2008/2008/01/28/6//NA/
A/England/411/2008/1/1410/|/EPI/ISL/65477
GQ476104/1/1410/A/Pennsylvania/12/2009/2009/01/29/6//NA/
A/Israel/10/2009/1/1410/|/EPI/ISL/65498
A/Lisboa/17/2008
A/Nebraska/WRAIR1247P/2009
GQ475965/1/1410/A/Ohio/06/2009/2009/02/03/6//NA/
GQ476024/1/1410/A/Michigan/07/2009/2009/04/08/6//NA/
CY053657/1/1410/A/Novosibirsk/2/2009/2009/0 //6//NA/
A/Belgium/858/2008
A/Lisboa/35/2005
GQ475920/1/1410/A/California/03/2009/2009/02/04/6//NA/
A/SURAT/1/1410/THANI/337/2009/|/EPI/ISL/6513
A/California/VRDL371/2009
GQ475951/1/1410/A/Kentucky/03/2009/2009/02/02/6//NA/
A/Puerto/1/1410/Rico/02/2009/|/EPI/ISL/33708
A/Niigata/08F031/2009
A/Taiwan/693/2009/1/1410/|/EPI/ISL/60130
A/Cameroon/08/235/2008/1/1410/|/EPI/ISL/65497
A/Lisboa/20/2008
A/North/1/1410/Carolina/07/2008/|/EPI/ISL/28372
A/Jilin/Chaoyang1258/2008/1/1410/|/EPI/ISL/28298
A/Bangladesh/9067/2008/1/1410/|/EPI/ISL/33671
A/Lisboa/20/2009
A/Hawaii/41/2008/1/1410/|/EPI/ISL/28376
A/Ireland/744/2008
A/MACAU/3436/2009/1/1410/|/EPI/ISL/65127
HQ533869/1/1410/A/Tianjin/15/2009/2009///6//NA/
CY100918/1/1410/A/Trujillo/WRAIR1702P/2008/2008/12/28/6//NA/
GQ475962/1/1410/A/Montana/01/2009/2009/01/04/6//NA/
GQ475856/1/1410/A/South/Dakota/01/2009/2009/ /22/6//NA/
GU112230/1/1410/A/Tehran/359/2009/2009/01/16/6//NA/
A/HAMAMATU/C/988/2009/1/1410/|/EPI/ISL/65151
A/Ontario/RV0131/2007/1/1410/|/EPI/ISL/22256
A/Minnesota/01/2008/1/1410/|/EPI/ISL/20792
GQ476027/1/1410/A/Maryland/01/2009/2009/01/18/6//NA/
A/Prague/33/2009/1/1410/|/EPI/ISL/65503
A/South/1/1410/Australia/11/2009/|/EPI/ISL/...
A/SAPPORO 66/2008/1/1410/|/EPI/ISL/26396
A/Netherlands/345/2007/EPI/ISL/60837/A///H1N1/seasonal/NA/WSS964114
JN676131/1/1410/A/Thailand/Siriraj/3043/2009/2009/10/06/6//NA/
CY074469/1/1410/A/California/VRDL289/2009/2009/05/01/6//NA/
A/Fujian/Gulou/1292/2009/1/1410/|/EPI/ISL/3...
A/Sichuan/Dongqu/1836/2009/1/1410/|/EPI/ISL...
A/Lisboa/6/2006
JN256687/1/1410/A/Hong/Kong/H090/744/V /0//2009/ 0 9/07/24/6//NA/
A/Norway/1735/2007/EPI/ISL/106540/A///H1N1/seasonal/NA/WSS964128
A/Michigan/06 2008/1/1410/|/EPI/ISL/27649
A/Pennsylvania/09/2008/1/1410/|/EPI/ISL/26237
A/Hawaii/42/2008/1/1410/|/EPI/ISL/28377
CY100846/1/1410/A/Alabama/WRAIR1235P/2009/2009/04/01/6//NA/
A/Peru/WRAIR1300P/2007/1/1410/|/EPI/ISL/78566
A/Hawaii/28/2007/1/1410/|/EPI/ISL/33820
A/Minnesota/27/2008/1/1410/|/EPI/ISL/27650
EU551821/1/1410/A/Paris/963/2008/2008/01/04/6//NA/
GQ475997/1/1410/A/Minnesota/01/2009/2009/01/16/6//NA/
CY074101/1/1410/A/California/VRDL189/2009/2009/04/29/6//NA/
CY080899/1/1410/A/Boston/65/2009/2009/03/ 9/6//NA/
CY089045/1/1410/A/Boston/10/2009/2009/02/04/6//NA/
A/Minnesota/34/2008/1/1410/|/EPI/ISL/28371
A/Paris/1157/2008
A/Japan/WRAIR1230P/2009
A/Waikato/1/2009/1/1410/|/EPI/ISL/60125
A/Lisboa/17/2009
A/Salta/2093/2008/1/1410/|/EPI/ISL/65473
A/OSAKA/C/39/2008
CY050774/1/1410/A/New/York/3442/2009/2009/05 09/6//NA
A/Hong/Kong/2637/2004/EPI/ISL/11833/A///H1N1/seasonal/NA/WSS964097
A/Victoria/214/2009/1/1410/|/EPI/ISL/60131
A/KANAGAWA/68/2008
GQ475931/1/1410/A/Ohio/04/2009/2009/01/28/6//NA/
A/Sri Lanka/13/2009
A/Mexico/2629/2009/1/1410/|/EPI/ISL/33635
A/Austria/404811/2008
A/Lisboa/24/2009
A/INCHEON/4432/2008/1/1410/|/EPI/ISL/28206
A/Johannesburg/21/2008
A/CHANTHABURI/341/2009/1/1410/|/EPI/ISL/65136
A/Annecy/2013/2009/1/1410/|/EPI/ISL/68855
A/St. Petersburg/11/2008
A/Paris/1208/2008
GQ476079/1/1410/A/Hawaii/17/2009/2009/04/13/6//NA/
GU183801/1/1410/A/Thailand/CU/B589/2009 2009/07/10/6//NA/
CY074237/1/1410/A/California/VRDL224/2009/2009/04/29/6//NA/
GU183809/1/1410/A/Thailand/CU/B685/2009/2009/ 7 12/6//NA/
A/England/40/2004/EPI/ISL/157574/A///H1N1/seasonal/NA/WSS964084
A/California/VRDL283/2009
A/Johannesburg/174/2008/1/1410/|/EPI/ISL/65642
CY089173/1/1410/A/Boston/94/2009/2009/03/13 6 NA/
A/Yamagata/137/2008/1/1410/|/EPI/ISL/71072
A/Lisboa/18/2008
A/Naypyitaw/M783/2008/1/1410/|/EPI/ISL/33559
CY100894/1/1410/A/Piura/WRAIR1699P/2008/2008/12/28/6//NA/
A/Philippines/15/2009/1/1410/|/EPI/ISL/60117
A/Lisboa/7/2008
A/Guatemala/22/2008
CY043539/1/1410/A/Kyoto/08K056/2009/2009/01/07/6//NA/
CY089125/1/1410/A/Boston/70/2009/2009/03/21/6//NA/
A/Dniprodzerzinsk/164/2008
A/St. Petersburg/53/2008
A/Argentina/81/2008
GQ47597 /1/1410/A/North/Dakota/01/2009/2009/01/19/6//NA/
A/Alberta/RV2859/2009/1/1410/|/EPI/ISL/66647
A/Luxembourg/116/2008
CY069383/1/1410/A/Alaska/WRAIR1114P/2009/2009/03//6//NA/
A/Ghana/168/2008
CY080691/1/1410/A/Boston/20/2009/2009/02/11/6//NA/
A/Scotland/5/2007/1/1410/|/EPI/ISL/63393
A/Perth/46/2008/1/1410/|/EPI/ISL/28093
A/SHIGA/18/2008/1/1410/|/EPI/ISL/26399
A/Sydney/605/2009/1/1410/|/EPI/ISL/32488
A/Lisboa/18/2009
A/Peru/WRAIR1299P/2007/1/1410/|/EPI/ISL/78565
CY069311/1/1410/A/Bogota/WRAIR0088N/2009/2 09/06/10/6//NA/
A/Macau/2517/2009/1/1410/|/EPI/ISL/60135
A/Lisboa/32/2006
A/Georgia/04/2009/1/1410/|/EPI/ISL/60717
CY064841/1/1410/A/California/VRDL141/2009/2009/04/28/6//NA/
A/Kiev/49/2008
A/Lisboa/31/2006
A/India/2757/2009
A/North/1/1410/Carolina/04/2009/|/EPI/ISL/3...
A/Puerto/1/1410/Rico/01/2008/|/EPI/ISL/33657
A/Luxembourg/1344/2008
A/Yamagata/16/2009/2009
A/Marseille/1148/2009/1/1410/|/EPI/ISL/60089
A/British/1/1410/Columbia/RV0035/2009/|/EPI/ISL/66649
A/Virginia/03/2008/1/1410/|/EPI/ISL/28332
A Belgium/812/2008
A/South Korea/WRAIR1238P/2009
A/Madagascar/6054/2009/1/1410/|/EPI/ISL/68858
A/Illinois/16/2008/1/1410/|/EPI/ISL/28295
CY080652/1/1410/A/Boston/13/2009/2009/02/10 6//NA
A/VICTORIA/549/2009/1/1410/|/EPI/ISL/66759
CY069375/1/1410/A/South/Dakota/WRAIR1113P/2009/2009/03/01/6//NA/
HQ291918/1/1410/A/Taiwan/11526/2008/2008/12/01/6//NA/
CY100942/1/1410/A/Sullana/WRAIR1707P/2009/2009/02/21/6//NA/
CY100822/1/1410/A/Kuwait/WRAIR1119P/2009/2009/01/01/6//NA/
A/Texas/57/2009/1/1410/|/EPI/ISL/61862
A/Lisboa/25/2009
A/Taiwan/1026/2009
CY074133/1/1410/A/California/VRDL200/2009/ 09/04/30/6//NA/
A/Paris/1093/2009/1/1410/|/EPI/ISL/65510
A/Kenya/4225/2009/1/1410/|/EPI/ISL/61868
A/Missouri/05/2009/1/1410/|/EPI/ISL/34733
A/Lisboa/3/2008
A/NEW/1/1410/CALEDONIA/2/2009/|/EPI/ISL/65126
CY070913/1/1410/A/California/VRDL151/2009/2009/04/28/6//NA/
A/Guatemala/866/2009/1/1410/|/EPI/ISL/60716
A/MIYAGI/35/2008
A/Florida 28/2008/1/1410/|/EPI/ISL/28367
A/Matagalpa/179/2009/1/1410/|/EPI/ISL/33648
A/New Jersey/16/2007
A/Bangladesh/3003/2008/1/1410/|/EPI/ISL/33674
A/SHIMANE/117/2008
A/Wisconsin/12/2008/1/1410/|/EPI/ISL/26245
A/Santiago/4689/2008
A/Iceland/8064/2009
A Mexico/4971/2008/1/1410/|/EPI/ISL/27637
HQ291899/1/1410/A/Taiwan/0045/2006/2006/05/24/6//NA/
CY074141/1/1410/A/California/VRDL202/2009/2009/04/29/6//NA/
A/Guyane/8190/2008
CY070897/1/1410/A/California/VRDL149/2009/2009/04/27/6//NA/
A/Hawaii/58/2008
GQ896377/1/1410/A/Wisconsin/14/2009/2009/05/22/6//NA/
JN582061/1/1410/A/New/York/08/1326/2008/2008 2/13/6//NA/
CY089759/1/1410/A/Boston/87/2009/2009/02/14/6//NA/
A/Lisboa/28/2008
A/CapeTown/124/2008
A/Texas/35/2008/1/1410/|/EPI/ISL/33732
A/yokohama/91/2007/1/1410/|/EPI/ISL/28731
CY074285/1/1410/A/California/VRDL235/2009/2009/04/29/6//NA/
GQ896371/1/1410/A/Utah/12/2009/2009/05/18/6//NA/
A/Lisboa/35/2006
A/NIIGATA/1150/2008/1/1410/|/EPI/ISL/28003
A/Kisii/7541/2008/1/1410/|/EPI/ISL/28471
A/BRISBANE/87/2009/1/1410/|/EPI/ISL/60134
A/Cambodia/21/2007/1/1410/|/EPI/ISL/28585
CY100966/1/1410/A/Maracay/WRAIR1729P/2008/2008/09/03/6//NA/
A/Kenya/4250/2009/1/1410/|/EPI/ISL/70216
A/Lisboa/21/2009
GQ476061/1/1410/A/Illinois/06/2009/2009/03/12/6//NA/
A/Virginia/01/2009/1/1410/|/EPI/ISL/33806
A/Ghana/FS/09/791/2009/1/1410/|/EPI/ISL/60086
A/Marrakech/589/2009
A/Luhansk/18/2 08
A/SEOUL/4437/2008/1/1410/|/EPI/ISL/28208
A/Kenya/1432/2008
A/Maryland/07/2008/1/1410/|/EPI/ISL/28383
A/Flanders/G771/2009/1/1410/|/EPI/ISL/65508
A/EHIME/38/2008/1/1410/|/EPI/ISL/28170
A/OKAYAMA/14/2008/1/1410/|/EPI/ISL/28007
A/Honduras/330/2009/1/1410/|/EPI/ISL/33604
CY080987/1/1410/A/Boston/88/2009/2009/02/19/6//NA/
GQ475900/1/1410/A/Indiana/05/2009/2009/01/23/6//NA/
A/Paris/160/2007/EPI/ISL/157392/A///H1N1/seasonal/NA/WSS964105
CY100950/1/1410/A/Piura/WRAIR1708P/2009/2009/03/27/6//NA/
A/North/1/1410/Dakota/01/2008/|/EPI/ISL/28310
A/Massachusetts/08/2008/1/1410/|/EPI/ISL/27647
A Lisboa/13/2009
HQ256609/1/1410/A/Myanmar/M061/2009/20 9/06/27/6//NA/
A/Peru/WRAIR1310P/2007/1/1410/|/EPI/ISL/78567
A/Bratislava/149/2009
A/New/1/1410/Jersey/15/2007/|/EPI/ISL/71839
A/Lisboa/29/2008
A/New/Caledonia/20/1999/EPI/ISL/22626/A///H1N1/seasonal/NA/WSS964089
A St. Petersburg/62/2008
A/Lisboa/5/2008
A/Vietnam/289/2008
A/Dakar/06/2008
A/Vladivostok/03/2008/1/1410/|/EPI/ISL/33690
A/Hokkaido/08H024/2009
CY073855/1/1410/A/California/VRDL175/2009/2009/04/28/6//NA/
A/Fiji/7/2009/1/1410/|/EPI/ISL/60129
A/Bangladesh/6666/2008/1/1410/|/EPI/ISL/33670
A/Lisboa/1/2008
A/NAIROBI/2/2009/1/1410/|/EPI/ISL/78686
A/Paris/910/2008
A/British/1/1410/Columbia/RV1585/2007/|/EPI/ISL/21859
A/Paris/639/2008/1/1410/|/EPI/ISL/90990
A/Beijing/Chaoyang/11405/2009
A/Lisboa/2/2006
A/Norway/1736/2007/1/1410/|/EPI/ISL/25416
GQ475940/1/1410/A/Montana/03/2009/2009/01/14/6//NA/
A/Pennsylvania/12/2008/1/1410/|/EPI/ISL/28368
CY064873/1/1410/A/California/VRDL146/2009/2009/04/25/6//NA/
CY074661/1/1410/A/California/VRDL380/2009/2 9/04/27/6//NA/
A/Lisboa/03/2009
A/Lisboa/16/2008
A/Tottori/08T010/2008
A/Stockholm/28/2008/1/1410/|/EPI/ISL/70666
A/Hong Kong/1975/2009
A/Fujian/Gulou/1581/2009/1/1410/|/EPI/ISL/6...
A/Iceland/4/2008/1/1410/|/EPI/ISL/65389
GQ475908/1/1410/A/Kansas/01/2009/2009/01/29/6//NA/
A/Taiwan/5857/2008
A/Stockholm/5/2009/1/1410/|/EPI/ISL/70668
A/Seychelles/2231/2008/1/1410/|/EPI/ISL/65368
FJ380948/1/1410/A/Finland/11/2008/2008/01/07/6//NA/
A/Thessaloniki/24/2005/EPI/ISL/25428/A///H1N1/seasonal/NA/WSS964095
CY087279/1/1410/A/Hong/Kong/62768/2008/2008///6//NA/
A/Saskatchewan/RV1039/2009/1/1410/|/EPI/ISL...
A/Vladivostok/04/2008/1/1410/|/EPI/ISL/33691
A/New/1/1410/Caledonia/6/2008/|/EPI/ISL/28102
A/Paraguay/61/2009/1/1410/|/EPI/ISL/33621
GQ475948/1/1410/A/Rhode/Island/01/2009/2009/01/27/6//NA/
CY080763/1/1410/A/Boston/36/2009/2009/02/2 6 /NA
GU271952/1/1410/A/Thailand/CU/B97/2009/2009/06/22/6//NA/
A/Massachusetts/05/2007/1/1410/|/EPI/ISL/15455
A/Dakar/14/2008
CY074205/1/1410/A/California/VRDL220/2009/2009/04/29/6//NA/
A/Ghana/FS/205/2008
A/Quebec/RV0984/2009/1/1410/|/EPI/ISL/33649
A/Illinois/12/2009
A/Lisboa/27/2008
GQ476129/1/1410/A/Montana/02/2009/2009/01/02/6//NA/
A/Nebraska/07/2008/1/1410/|/EPI/ISL/28306
CY069343/1/1410/A/Texas/WRAIR1052P/2009/2009/01/09/6//NA/
GQ476012/1/1410/A/North/Dakota/03/2009/2009/03/01/6//NA/
A/Florida/29/2008
A/DAEJEON/4494/2008
A/Martinique/19/2008
A/St. Petersburg/75/2008
A/Buenos/1/1410/Aires/1306/2008/|/EPI/ISL/65472
A/Santiago/5087/2008/1/1410/|/EPI/ISL/23858
CY074341/1/1410/A/California/VRDL249/2009/2009/04/29/6//NA/
A/Ghana/FS/216/2008/1/1410/|/EPI/ISL/65463
A/Johannesburg/279/2008/1/1410/|/EPI/ISL/28096
A/Waikato/2/2009/1/1410/|/EPI/ISL/60126
A/Finland/514/2009/1/1410/|/EPI/ISL/60088
A/Taiwan/639/2008/1/1410/|/EPI/ISL/28323
A/Thailand/778/2008
A/Ukraine/313/2008
CY069487/1/1410/A/Louisiana/WRAIR1170P/2009/2009/02//6//NA/
A/Valparaiso/5366/2008/1/1410/|/EPI/ISL/23865
A/Hong Kong/3195/2008
A/Thailand/874/2008/1/1410/|/EPI/ISL/33664
A/Tottori/52/2008
A/Venezuela/3571/2008/1/1410/|/EPI/ISL/26243
A/PHILIPPINES/3314/2009/1/1410/|/EPI/ISL 60900
A/Nagasaki/07N035/2008
GQ475905/1/1410/A/Kentucky/01/2009/2009///6//NA/
A/Liaoning/Huanggu/1144/2009
CY080971/1/1410/A/Boston/85/2009/2009/02/12/6//NA/
A/Sweden/1/2009/1/1410/|/EPI/ISL/70643
CY089061/1/1410/A/Boston/23/2009/2009/02/18/6//NA/
GQ475980/1/14 0/A/Massachusetts/05/2009/ 09/02/26/6//NA/
CY10 886/1/1410/A/Iraq/WRAIR1683P/2009/2009/03//6//NA/
CY068677/1/1410/A/Singapore/GP101/2009/2009/03/20/6//NA/
A/Belgium/850/2008
A/Boston/67/2009
CY100806/1/1410/A/Nevada/WRAIR1117P/2009/2009/01/01/6//NA/
A/Wyoming/10/2008/1/1410/|/EPI/ISL/19766
A/Lisboa/19/2009
CY053659/1/1410/A/Novosibirsk/3/2009/2009/04//6//NA/
CY100 10/1/1410/A/Trujillo/WRAIR1701P/2008/2008/12/26/6//NA/
A/St. Petersburg/12/2008
A/Perth/33/2008/1/1410/|/EPI/ISL/28582
A/Paris/1704/2009/1/1410/|/EPI/ISL/65509
A/Maryland/05/2008/1/1410/|/EPI/ISL/28302
A/CHIBA/86/2008/1/1410/|/EPI/ISL/26386
CY074389/1 1410/A/California/VRDL264/2009/2009/04/25/6//NA/
A/Lisboa/22/2006
A/Washington/25/2009
A/Michigan/14/2009/1/1410/|/EPI/ISL/60719
GU112229/1/1410/A/Tehran/345/2009/2009/01/12/6//NA/
A/Taiwan/01/1986/EPI/ISL/10251/105058
GQ850597/1/1410/A/Shanghai/LWS1/2009/2009/01/03/6//NA/
A/Lisboa/77/2007
GQ475934/1/1410/A/Indiana/07/2009/2009/03/09/6//NA/
A/Austria/404342/2008
A/Vietnam/241/2008
A/Florida/27/2008/1/1410/|/EPI/ISL/60723
A/Michigan/31/2009/1/1410/|/EPI/ISL/77936
A/Pennsylvania/04/2009/1/1410/|/EPI/ISL/33756
CY074637/1/1410/A/California/VRDL377/2009/2009/04/27/6//NA/
A/Minnesota/04/2009
A/Lisboa/05/2009
A/KOCHI/48/2008/1/1410/|/EPI/ISL/27998
A/Tennessee/03/2009/1/1410/|/EPI/ISL/33809
0.02
A/Brisbane/12/2009
A/Minnesota/23/2007/1/1410/|/EPI/ISL/15465
A/Kursk/01/2008
CY080851/1/1410/A/Boston/52/2009/2009/02/14/6//NA/
CY074421/1/1410/A/California/VRDL275/2009/2009/04/30/6//NA/
A/Kericho/7529/2008/1/1410/|/EPI/ISL/28468
A/Kenya/2862/2009/1/1410/|/EPI/ISL/66654
A Lisboa/39/2008
A/Christchurch/20 2008
A/PERTH/21/2009/1/1410/|/EPI/ISL/66758
A/Vietnam/2036/2009/1/ 41 /|/EPI/ISL/69711
CY100854/1/1410/A/Washington/WRAIR1237P/2009/2009/02/01/6//NA/
GQ476132/1/1410/A/Oregon/01/2009/20 9/ 1/07/6//NA/
GQ476091/1/1410/A/Pennsylvania/01/2009/2009/01/07/6//NA/
A/Lisboa/6/2008
A/Niigata/08F188/2009
GQ476009/1/1410/A/Virginia/06/2009/2009/05/05/6//NA/
A/Chungbuk/4385/2008/1/1410/|/EPI/ISL/65495
A/Lisboa/14/2009
GQ476118/ / /A/Ohio/03/20 9/2009/01/15/6//NA/
A/Algeria/G804/2008
GQ476047/1/1410/A/Arkansas/01/2009/ 009/02/08/6//NA/
GQ475926/1/1410/A/Virginia/03/2009/2009/ 2/18/6//NA/
A/Lisboa/25/2006
/Kyrgyzstan/2 4/2009/1/1410/|/EPI/ISL/61865
A/Hong Kong/H090/682/V1/0//2009
HQ291908/1/1410/A/Taiwan/2832/2008/2008/10/06/6//NA/
A/Incheon/4532/2008/1/1410/|/EPI/ISL/65492
A/Mauritius/403/2008/1/1410/|/EPI/ISL/65437
A/Sydney/601/2009/1/1410/|/EPI/ISL/60116
GQ475969/1/1410/A/New/York/63/2009/2009/ 3/3 /6//NA/
A/Lisboa/8/2008
A/Berlin 59/2008/1/1410/|/EPI ISL/65494
CY074597/1/1410/A/California/VRDL358/2 09/2009/06/07/6//NA/
A/CHIBA/89/2008/1/1410/|/EPI/ISL/28169
A/Massachusetts/12/2008/1/1410/|/EPI/ISL/28366
A/England/494/2006/1/1410/|/EPI/ISL/25707
A/Algeria/G773/2008/1/1410/|/EPI/ISL/65459
A/Hong Kong/70/2009
A/Perth/33/2009/1/1410/|/EPI/ISL/6 123
A/Victoria/501/2008/1/1410/|/EPI/ISL/23119
GQ475883/1/1410/A/West/Virginia/02/2009/2009/ 3/ 8/ //NA/
A/Kawasaki/UTK/4/2009
A/Vietnam/1808/2009/1/1410/|/EPI/ISL/69712
A/Hong/Kong/2765/ 4/EPI/ISL/157578/A///H1N1/seasonal/NA/WSS964086
A/Norway/1747/07/1/1410/|/EPI/ISL/23298
A/GYEONGGIBUK/4503/2008
A/Lisboa/7/2006
A/WELLINGTON/84/2009/1/1410/|/EPI/ISL/ 136
A/Hubei/Wujiagang/133/2009/1/1410/|/EPI/ISL...
A/Victoria/071592 /2007/1/1410/|/EPI/ISL/28584
CY100926/1/1410/A/Pucallpa/WRAIR1704P/2009/2009/01/14/6//NA/
CY 80675/1/1410/A/Boston/17/2009/20 9/02 10/6//NA/
A/Brazil/146/2009
A/Ghana/ 72/2008/1/1410/|/EPI/ISL/65441
A/Washington/02/2009/ 1410/|/EPI ISL/33807
AB521100/1/1410/A/Yamagata/36/2009/2009/01/14/6//NA/
A/Singapore/42/2008/1/1410/|/EPI/ISL/28384
A/Tahiti/3/2009/1/1410/|/EPI/ISL/60132
A/Tennessee/11/2008/1/1410/|/EPI/ISL/2 24
A/Slovenia/123/2008
Lisb a/ 4/2008
GQ476072/1/1410/A/Florida/03/2009/2009/02/06/6//NA/
A/Yamagata/125/2008/1/1410/|/EPI/ISL/71068
A/Illinois/ 5/2009/1/1410/|/EPI/ISL/33728
GQ476109/1/1410/A/New/York/56/2009/2009 02 1 /6//NA/
A/Chubut/102 97/2008
CY081019/1/1410/A/Boston/93/2009/2009/03/17/6//NA/
GQ476140/1/1410/A/Alaska/01/2009/2009/01/29/6//NA/
CY100774/1/1410/A/Texas/WRAIR1053P/2009/2009/01/01/6//NA/
A/Colorado/08/2008/1/1410/|/EPI/ISL/28378
A/Brazil/5943/20 8
A/Gansu/Chengguan1129/2007/1/1410/|/EPI/ISL/20448
A/Belem/241/2008
CY074373/1/1410/A/California/VRDL256/2009/2 9/04/29/6//NA/
A/Guatemala/602/2008
A/NAGANO/1204/2008/1/1410/|/EPI/ISL/27999
JN256686/1/1410/A/Hong/Kong/H090/718/V1/0//2009/2009/07/15/6//NA/
A/England/684/2007/1/1410/|/EPI/ISL/25445
A/Ohio/02/2009/1/1410/|/EPI/ISL/33808
A/Yamagata/68/2008/1/1410/|/EPI/ISL/71063
A/Singapore/07/2009/1/1410/|/EPI/ISL/34736
CY080835/1/1410/A/Boston/49/2009/2009/02/13/6//NA/
CY073839/1/1410/A/California/VRDL163/20 9/2 /04/29/6//NA/
A/Paris/1154/2008
CY073823/1/1410/A/California/VRDL15 / 0 9/2009/04/28/6//NA/
A Colorado/17/2008/1/1410/|/EPI/ISL/33652
CY074093/1/1410/A/California/VRDL186/2009/2009/04/29/6//NA/
A/Lisboa/48/2005
A/Kansas/UR06/0104/2007/1/1410/|/EPI/ISL/7867
A/South/1/1410/Australia/1/2008/|/EPI/ISL/22972
A/Paris/445/2008/1/1410/|/EPI/ISL/65483
A/Jilin/Chuanying/1318/2008/1/1410/|/EPI/ISL/33707
A/Florida/21/2008/1/1410/|/EPI/ISL/27641
JF972564/1/1410/A/Mississippi/03/2001/2001/01/25/6//NA/
A/Argentina/303 2008/1/1410/|/EPI/ISL/25779
CY074173/1/1410/A/California/VRDL215/2009/2009/04/28/6//NA/
A/Brisbane/1/2009/1/1410/|/EPI/ISL/32490
A/El Salvador/468/2008
A/Uganda/ 511/2009/1/1410/|/EPI/ISL/66659
A/Washington/01/2008
CY100798/1/1410/A/Texas/WRAIR1115P/2009/2009/03/01/6//NA/
CY08093 1/1410/A/Boston/72/2009/2 9/ 3/24/6//NA/
A/Washington/08/2008/1/1410/|/EPI/ISL/28333
A/Lisboa/19/2008
A/Florida/02/2008/1/1410/|/EPI/ISL/19087
A/Maryland/04/2007
A/Stockholm/6/2009/1/1410/|/EPI/ISL/70806
A/Lisboa/94/2005
A/Kentucky/08/2009
A/Cayman Islands/5082/2009
A/Singapore/88/2009/1/1410/|/EPI/ISL/34737
A/Kazakhstan/2600/2008
A/India/7308/2008/1/1410/|/EPI/ISL/33659
GQ475914/1/1410/A/Hawaii/03/20 9/2009/01/29/ // /
CY089109/1/1410/A/Boston/59/2009/20 9 02/28/6//NA/
CY074125/1/1410/A/California/VRDL19 /2009/ 009/04/27/6//NA/
A/England/26/2008
A/IBARAKI/68/2008/1/1410/|/EPI/ISL/28175
A/Managua/1985.01/2008/1/1410/|/EPI/ISL/629 6
GQ457553/1/1410/A/Saskatchewan/5131/2009/2009/06/19/6//NA/
CY080612/1/1410/A/Boston/95/2009/200 /0 01/6//NA/
CY074485/1/1410/A/California/VRDL292/20 9/2 09/04/30/6//NA/
A/Idaho/01/2009/1/1410/|/EPI/ISL/61874
A/AOMORI/19/2008/1/1410/|/EPI/ISL/28166
CY053671/1/1410/A/Novosibirsk/7/2009/2009/04//6//NA/
CY100958/1/1410/A/Pucallpa/WRAIR1709P/2009/2009/01/20/6//NA/
A/Georgia/1269/1/1410//36G//2009/|/E I/ISL/...
A/GWANGJU/4324/2008/1/1410/|/EPI/ISL/28202
GU271968/1/1410/A/Thailand/CU/H565/2009/2009/09/02/6//NA/
A/SHIMANE/1/2009/1/1410/|/EPI/ISL/28187
A/Cameroon/073/2008/1/1410/|/EPI/ISL/65406
A/Rabat/109/2009/1/1410/|/EPI/ISL/65489
GQ475869/1/1410/A/New/York/ 2/2009/2 9/ 2/14/6//NA/
A/Honduras/100/2008
A/SAMOA/10/2009/1/1410/|/EPI/ISL/651 8
CY069551/1/1410/A/Texas/WRAIR1254P 2 09/2009/03//6//NA/
A/Brazil/815/2009
CY100934/1/1410/A/Santa/Cruz/WRAIR1706P/2008/2008/12/09/6//NA/
A/WELLINGTON/218/2009/1/1410/|/EPI/ISL 65150
A/Iceland/8599/2009/1/1410/|/EPI/ISL 65514
A/Arizona/13 2008 1/1410/| EPI/ISL/27639
A/Paraguay/67/2009
A/Moscow/38/2008
A/Buenos/1/ 410/Aires/825511/2008/|/EPI/ISL/65471
CY100830/1/1410/A/Japan/WRAIR1226P/2 09/2009/ 2/01/6//NA/
GQ476155/1/1410/A/New/Mexico/01/2009/2009/01/07/6//NA/
A/Michigan/01/2009/1/1410/|/EPI/ISL/33745
A/Singapore/6/1986/EPI/ISL/6905/58244
A/England/594/2006/1/1410/|/EPI/ISL/25708
A/Peru/WRAIR1505P/2007/1/1410/|/EPI/ISL/78572
A/Naypyitaw/M499/2008/1/1410/|/EPI/ISL/33557
A/Thailand/839/2008
GQ476088/1/1410/A/Nebraska/05/20 9/2009/03/07/6//NA/
CY050662/1/1410/A/New/York/3150/2009/ 0 9/04/27/6//NA/
A/Ghana/FS/09/718/2009/1/1410/|/EPI/ISL 60087
A/Seychelles/2239/2008/EPI/ISL/60835/A///H1N1/seasonal/NA/WSS964136
GQ475945/1/1410/A/Washington/03/2009/2009/01/21/6//NA/
A/Fukushima/14 /2006 EPI/ISL/202 9/A///H1N1/seasonal NA/WSS964101
A/Perth/30/2009
CY074357/1/1410/A/California/VRDL252/2009/2009/04/29/6//NA/
A/Algeria/G825/2008
CY100870/1/1410/A/Nevada/WRAIR1257P/2009/2009/02/01/6//NA/
A/Texas/16/2008/1/1410/|/EPI/ISL/26239
AB521103/1/1410/A/Yamagata/51/2009/2009/01/26/6//NA/
A/KOBE/49/2008
AB521101/1/1410/A/Yamagata/26/2009/2009/01/17/6//NA/
CY074333/1/1410/A/California/VRDL245/2009/2009/04/29/6//NA/
A/Indiana/08/2009
A/Guangdong/Futian/139/2009/1/1410/|/EPI/IS...
AB521111/1/1410/A/Yamagata/77/2009/2009/02/10/6//NA/
A/Lisboa/4/2008
A/Stockholm 7 2009/1/1410/| EPI/ISL/70800
A/Lisboa/23/2009
A/Sweden 8 2008/1 1410/|/EPI/ISL/70648
CY050478/1/1410/A/New/York/1692/20 /2009/ 4 27/6//NA/
A/Lisboa/07/2009
A/Fujian/Gulou/1367/2009/1/1410/|/EPI/ISL/3...
A/TAK/334/2009/ /1410/|/EPI/ISL/65129
GQ475877/1/1410/A/New/York/62/2009/2009/03/17/6//NA/
A/Delaware/01/2008/1/1410/|/EPI/ISL/2828
GQ475886/1/1410/A/Nebraska/06/2009/ 09/0 /22/6//NA/
A/Lisboa/13/2008
A/Lisboa/2/2008
A/Guangdong/Zhuangzuyaozuzizhi/51/200.../1/1410
CY074309/1/14 0/A California/VRDL238/2 09 20 9/04/29/6//NA/
A/Hong/Kong/3192/2008/EPI/ISL/65482/A///H1N1/sea onal/NA/WSS964139
CY100790/1/1410/A/Oklahoma/WRAIR1110P/2009/2009/03/01/6//NA/
CY073863/1/1410/A/California/VRDL229/2009/ 9/04/29/6//NA/
A/KOL/2465/20 9
HQ291915/1/1410/A/Taiwan/8949/2008/2008/12/11/6//NA/
A/Quebec/RV3060/20 9
A/Arizona/13/2007/1/1410/|/EPI/ISL/15893
CY080795/1/1410/A/Boston/41/2009/20 / 2 27/6//NA/
A/Lisboa/ 6/20 9
A/Yamagata/128/2008
GQ476126/1/1410/A/Florida/07/2009/2009/03/25/6//NA/
A/Texas/27/2008/1/1410/|/EPI/ISL/27653
CY074277/1/1410/A/California/VRDL232/2009/2009///6//NA/
A/BEIJING/HUAIROU/185/2008
A/Texas/31/2007/1/1410/|/EPI/ISL/15409
A/Algeria/G864/2008/1/1410/|/EPI/ISL/65468
A/Managua/954.02/2008/1/1410/|/EPI/ISL/33848
A/Quebec/Rv 07/2009/1/1410/|/EPI/ISL/33632
CY080803/1/1410/A/Boston/42/2009/20 9 3/ 1/6//NA/
A/Hawaii/19/2008
GQ476096/1/1410/A/Hawaii/01/2009/2009/0 /13/6/ NA/
A/Tak/427/2009/1/1410/|/EPI/ISL/66657
A/French/1/1410/Polynesia/2001/2009 |/EPI/I...
GQ475972/1/1410/A/Wisconsin/06/2009/200 / 3/03/6//NA/
A/Lisboa/11/2008
CY053655/1/14 0/A/Novosibirsk/151/2009/2009/05//6//NA/
HQ256619/1/1410/A/Myanmar/M256/2009/2009/07/16/6//NA/
A/Stockholm/22/2008
A/SAMOA/9/2009/1/1410/|/EPI/ISL/60899
CY 6 391/ /1410/A/South/Carolina/WRAIR1116P/2009/2009/03/01/6//NA/
A/New/1/1410/Jersey/32/2008/|/EPI/ISL/33750
GQ475874/1/1410/A/Wisconsin/02/2009/2009/01/07/6//NA/
A/Argentina 295/2008 1/1410/|/EPI/ISL/25778
A/Lisb a/9/200
A/Kenya/0793/2008/1/1410/|/EPI/ISL/33677
GQ476035/1/1410/A/Hawaii/13/2009/ 09/04/16/6//NA/
A/Thailand/1577/2007/1/1410/|/EPI/ISL/22372
GQ476143/1/1410/A/Vermont/01/2009/2009/02/09/6//NA/
A/Uganda/0132/2009/1/ 41 /|/EPI/ISL/66658
CY100974/1/1410/A/Cusco/WRAIR1730P/2008/2008/08/20/6//NA/
A/SHIZUOKA/C/21/2009/1/1410/|/EPI/ISL/28194
CY089783/1/1410/A/Boston/32/2009/2 09/02/20/6//NA/
GQ475880/1/1410/A/Tennessee/01/2009/2009/01/12/6//NA/
HQ291910/1/1410/A/Taiwan/3293/2008/2008/05/02/6//NA/
GQ457554/1/1410/A/Saskatchewan/5350/2009/2009/06/18/6//NA/
A/Managua/5007.01/2008/1/1410/|/EPI/ISL/6 12
A Fujian/Gulou/1896/2009/1/1410/|/EPI/ISL/6...
A/Nigeria/0023/2008/1 410/|/EPI/ SL/2581
A/California/VRDL167/2009
CY089085/1/1410/A/Boston/46/2009/2009/03/01/6//NA/
HQ291909/1/1410/A/Taiwan/2885/2008/2008/11/24/6//NA/
CY100902/1/1410/A/Piura/WRAIR1700P/2009/2009/01/01/6//NA/
A/Johannesburg/45/2008/1/1410/|/EPI/ISL/23112
A/Indiana/06/2009/1/1410/|/EPI/ISL/33812
GQ475894/1/1410/A/California/01/2009/2009/01/07/6//NA/
/Brisbane/59/2007/EPI/ISL/71838/A///H1N1/seasonal/NA/WSS964111
A/IWATE/40/2008/1/1410/|/EPI/ISL/27996
GQ475847/1/1410/A/New/Mexico/02/20 9/2009/01/14/6//NA/
A/Washington/12/2008/1/1410/|/EPI/ISL/ 3813
A/Pennsylvania/14/2008/1/1410/|/EPI/ISL/33644
A/Samara/46/2008
A/Illinois/16/2007/1/1410/|/EPI/ISL/19084
A/Washington/05/2008/1/1410/|/EPI/ISL/25804
A/Brisbane/10/2009/1/1410/|/EPI/ISL 32493
A/Lisboa/4/2006
A/KwaZulu 1/1410/Natal/272/2008/|/EPI/ISL/65639
/Denmark/27/2007/1/1410/|/EPI/ISL/25442
A/Maryland/04/2008/1/1410/|/EPI/ISL/28301
CY05055 /1/1410/A/New/York/3095/2009/2009/04/29/6//NA/
A/Hong/1/1410 Kong/3359 /2009/|/EPI/ISL/68854
A/SAPPORO/90/2008/1/1410/|/EPI/ISL/28010
A/Kenya/ 329/2010/1/1410/|/EPI/ISL/98941
A/Georgia/20/2006/1/1410/|/EPI/ISL/21323
A/FUKUI/91/2008
A/USSR/90/77/EPI/ISL/66105/230612
A/Yangon/M195/2008/1/1410/|/EPI/ISL/33555
A/Hong/Kong/1856/2008/EPI/ISL/60838/A///H1N1/seasonal/NA/WSS964138
A North/1/14 0/Carolina/0 /2008/|/EPI/ISL 19770
A/Solomon/Islands/3/2006/EPI/ISL/13324/A// H1N1/seasonal/NA/WSS964131
A/Hong/Kong/2652/2006/EPI/ISL/157436/A///H1N1/seasonal/NA/WSS964099
A/St. Petersburg/83/2008
HQ256643/1/1410/A/Myanmar/M428/2009/2009/08/11/6//NA/
A/Li oa/10/2 08
GQ476082/1/1410/A/Arkansas/02/2009/ 009/03/01/6//NA/
CY089101/1/1410/A/Boston/54/2009/2 9/02/ 2/6//NA/
A/Jilin/Chaoyang/157/2009/1/1410/|/EPI/ISL/...
CY074117/1/1410/A/California/VRDL193/2009/2009/04/29/6//NA/
A/Pennsylvania/13/2007/1/1410/|/EPI/ISL/23897
A/Marrakech/510/2009
/Lisboa/15/20 8
A/Paris/781/2008/1/1410/|/EPI/ISL/65485
A/Israel/ /2009/1/ 410/|/EPI/ISL/65499
A/Boston/06/
A/Philippines/1159/2008
A/SHIZUOKA/C/10/2009
A/South/1/1410/Australia/12/2009/|/EPI/ISL/...
A/Argentina/110/2008/1/1410/|/EPI/ISL/25781
A/Niigata/08F093/2009
A/Hong 1 1410/Kong/18106/2009/|/EPI/ISL/65516
A/Nagasaki/07N020/2008/1/1410/|/EPI/ISL/70169
A/Kenya/2743/2009/1/1410/|/EPI/ISL/61877
CY080819/1/1410/A/Boston/45/2009/20 9 03/03/6//NA/
A/Perth/1/2009/1/1410/|/EPI/ISL/32484
A/Lisboa/41/2008
A/Texas/36/2008/1/1410/|/EPI/ISL/33733
A/Hong/1/1410/Kong/26552/2009/|/EPI/ISL/66653
HQ256645/ / 410/A/Myanmar/M470/2009/2009/08/20/6//NA/
GQ476053/1/1410/A/New/York/6 /2009/2009/03/09/6//NA/
A/BRISBANE/96/2009/1/1410/|/EPI/ISL/ 5 52
A/Lisboa 15/2009
A/Egypt/10/2007/EPI/ISL/106505/A///H1N1/seasonal/NA/WSS964117
A/Hong/1/1410/Kong/852/2008/|/EPI/ISL/65426
CY100814/1/1410/A/Texas/WRAIR1118P/2009/2009/06/01/6//NA/
CY093127/1/1410/A/Boston/47/2009/20 2 12/6//NA/
A/Belgium/G257/2008
HQ256649/1/1410/A/Myanmar/M533/2009/2009/09/04/6//NA/
/Oregon/02 9
A/Yokohama/78/2008
A/NIIGATA/1088/2008/1/1410/|/EPI/ISL/28002
A/Indiana/01/2008/1/1410/|/EPI/ISL/15873
A/Kiev/313/2008
A/India/3414/2009
A/Moscow/02/2009
A/Philippines/3914/2008
A/New/1/1410/Jersey/30/2008/|/EPI/ISL/337 7
A/Lisboa/40/2008
A/Chile/1/1983/EPI/ISL/6900/58149
B465323/1/ 410/A/Yokohama/30/2008/2008/01/28/6//NA/
A/Lisboa/12/2008
A/Buenos/1/1410/Aires/R13/2008/|/EPI/ISL/65360
A/Tula/31/2008
A/Guatemala/663/2008
AB521105/1/1410/A/Yamagata/45/2009/2009/01/21/6//NA/
A/Lisboa/ 6/2009
A/Lisboa/24/2006/A/Lisboa/16/2006
A/Th iland/CU/B42/2009
A/England/557/2007
GQ476149/1/1410/A/New/York/64/2009/2009/04/09/6//NA/
A/St. Petersburg/85/2008
A/Jamaica/2968/2009/1/1410/|/EPI/ISL/336 7
A/Cameroon/080/2008
AB521112/1/1410/A/Yamagata/80/2009/2009/02/18/6//NA/
A/Florida/24/2008/1/141 /|/EPI/ISL/28287
A/Lisboa/2/2009
CY100838/1/1410/A/Illinois/WRAIR1233P/20 9 2009/03/01/6//NA/
A/Costa Rica/5150/2 09
B465321/1/1410/A/Yokohama/34/2008/2008/01/28/6//NA/
A/England/411/2008/1/1410/|/EPI/ISL/65477
GQ476104/1/1410/A/Pennsylvania/12/2009/2009/01/29/6//NA/
A/Israel/10/2009/1/1410/|/EPI/ISL/65498
A/Lisboa/17 2008
A/Nebraska/WRAIR1247P/2009
GQ475965/ /1410/A/Oh o 06/2009/2009/02/ 3/6/ NA/
GQ476024/1/1410/A/Michigan/07/2009/2009/04/08/6//NA/
CY053657/1/1410/A/Novosibirsk/2/2009/2009/04//6// A/
A/Belgium/858/2008
A/Lisboa/35/2005
GQ475920/1/1410/A/California/03/2009/2009/02/04/6//NA/
A/SURAT/1/1410/THANI/337/2009/|/EPI/ISL/65130
A/California/VRDL371/2009
GQ47595 /1/1410/A/Kentucky/03/ 09/2009/02/02/6//NA/
A/Puerto/1/1410/Rico/02/2009/|/EPI/ISL/337 8
A/Niigata/08F031/2009
A/Taiwan/693/2009/1/1410/|/EPI/ISL/60130
A/Cameroon 08/235/2008/1/1410/|/EPI/ISL/65497
A/Lisboa/20/2008
A/North/ /1410 Caro in 07/2008/|/E I/ISL/28372
A/Jilin/Chaoyang1258/20 8/1/1410/|/EPI/ISL/28298
A/Bangladesh/9067/2008/1/1410/|/EPI/ISL/33671
A/Lisboa/20/2009
/Hawaii/41/2008/1/1410/|/EPI/ISL/28376
A/Ireland/744/2008
A/MACAU/3436/2009/1/1410/|/EPI/ISL/65127
HQ533869/1/1410/A/Tianjin/15/2009/2009///6//NA/
CY100918/1 1410/A/Trujillo/W AIR1702P/20 8/2008/12/28/6//NA/
GQ475962/1/1410/A/Montana/01/2009/20 9/01/04/6//NA/
GQ475856/1/1410/A/South/Dakota/01/2009/2009/01/22/6//NA/
GU11223 /1/1410/A/Tehran/359/2009/2009/01/16/6//NA/
A/HAMAMATU/C/988/2009/1/1410/|/EPI/ISL/65151
A/Ontario/RV0131/2007/1/1410/|/EPI/ISL/22256
A/Minnesota/01/2008/1/1410/|/EPI/ISL/20792
GQ476027/1/1410 A/Maryland/01/2009/2009/01/18/6//NA/
A/Prague/33/2009/1/1410/|/EPI/ISL/65503
A/South/1/1410/Australia/11/2009/|/EPI/ISL/...
A/SAPPORO/66/2008/1/1410/|/EPI/ISL/26396
A/Netherlands/345/2007/EPI/ISL/60837/A///H1N1/seasonal/NA/WSS964114
JN676131/1/1410/A/Thailand/Siriraj/3043/2009/2009/10/06/6//NA/
CY074469/1/1410/A/California/VRDL289/2009/2009/05/01/6//NA/
A/Fujian/Gulou/1292/2009/1/14 0/|/EPI/ISL/3...
A/Sichuan/Dongqu/1836/2009/1/1410/|/EPI/ISL...
A/Lisboa/6/2006
JN256687/1/1410/A/Hong/Kong/H090/744/V1/0//2009/2009/07/24/6//NA/
A/Norway/1735/2007/EPI/ISL/106540/A///H1N1/seasonal/NA/WSS964128
A/Michig n/06/2008/1/141 /|/EPI/ISL/27649
A/Pennsylvania/09/2008/1/141 /| EPI/ISL/26237
A/Hawaii/42/2008/1/1410/|/EPI/ISL/28377
CY100846/1/1410/A/Alabama/WRAIR1235P/ 9/2009/04/01/6//NA/
A/Peru/WRAIR 30 P/2007/1 1410/|/EPI/ISL/78566
/Hawaii/28/2007/1/1410/|/EPI/ISL/33820
A/Minnesota/27/2008/1/1410/|/EPI/ISL/27650
EU551821/1/1410/A/Paris/963/2008/2008/01/04/6//NA/
GQ475997/1/1410/A/Minnesota/01/2009/2009/01/16/6//NA/
CY074101/1/1410/A/California/VRDL189/2009/2009/04/29/6//NA/
CY080899/1/1410/A/Boston/65/2009/2 9/ 3/0 /6// A/
CY089045/1/1410/A/Boston/10/2009/2009/02/04/6//NA/
A/Minnesota/34/2008/1/1410/|/EPI/ISL/28371
A/Paris/1 57/2008
A/Japan/WRAIR1230P/2009
A/Waikato/1/2009/1/1410/|/EPI/ISL/60125
/Lisboa/17/2009
A/Salta/2093/2008/1/1410/| EPI/ISL/65473
A/OSAKA/C/39/2008
CY050774/1/1410/A/New/York/3442/2009/2009/05/09/6//NA/
A/Hong/Kong/2637/200 /EPI/ISL/11833/A///H1N1/seasonal/NA/WSS964097
A/Victoria/214/2009/1/1410/|/EPI/ISL/60131
A/KANAGAW /68/2008
GQ475931/1/1410/A/Ohio/04/2009/2009 28/ //NA/
A/Sri Lanka/13/2009
A/Mexico/2629 2 9/ 1410/|/EPI/ISL/33635
A/Austria/4 4811/2008
A/Lisboa/24/2009
A/INCHEON/4432/2008/1/1410/|/EPI/ISL/28206
A/Johannesburg/21/2008
A/CHANTHABURI/341/2009/1/1410/|/EPI/ISL/65136
A/Annecy/2013/2009/1/1410/|/EPI/ISL/68855
A/St. Petersburg/11/2008
A/Paris/1208/2008
GQ476079/1/1410 A/Hawaii/17/2009/2009/04/13/6//NA/
GU1838 1/ /A/Thailand/CU/B589/2009/2009/07/10/6//NA/
CY074237/1/1410/A/California/VRDL224/2009/2009/04/29/6//NA/
GU183809/1/1410/A/Thailand/CU/B685/2009/2009/07/12/6//NA/
A/England/40/2004/EPI/ISL/157574/A///H1N1/seasonal/NA/WSS964084
A/California/VRDL283/2009
A/Johannesburg/174/2008/1/1410/|/EPI/ISL/65642
CY089173/1/1410/A/Boston/94/2009/2 9/03/13/6//NA/
A/Yamagata/137/2008/1/1410/|/EPI/ISL/71072
A/Lisboa 18/20 8
A/Naypyitaw/M783/2008/1/1410/|/EPI/ISL/33559
CY100894/1/1410/A/Piura/WRAIR1699P/2008/2008/12/28/6//NA/
A/Philippines/15/2009/1/1410/|/EPI/ISL/60117
A/Lisboa/7/2008
A/Guatemala/22/2008
CY043 39/1/1410/A/Kyoto 08K056/2009/2009/01/07/6//NA/
CY089125/1/1410/A/Boston/70/2009/200 /03 21/6//NA/
A/Dniprodzerzinsk/164/2008
A/St. Petersburg/53/2008
A/Arg ntina/81/2 08
GQ475974/1/1410/A/North/Dakota/01/ 09/2009/01/19/6//NA/
A/Alberta/RV2859/2009/1/1410/|/EPI/ISL/66647
A/Luxembourg/116/2 08
CY069383/1/1410/A/Alaska/WRAIR1114P/2009/2009/03//6//NA/
A/Ghana/168/2008
CY080691/1/1410/A/Boston/20/2009/2 9/02/ 1/6//NA/
A/Scotland/5/2007/1/1410/|/EPI/ISL/63393
A/Perth/46/ 8/ /1410/|/EPI/ISL/28093
A/SHIGA/ 8/2008/1/1410/|/EPI/ISL 63 9
A/Sydney/605/2009/1/1410/|/EPI/ISL/32488
A/Lisboa/1 /20 9
A/Peru/WRAIR1299P/2007/1/1410/|/EPI/ISL/78565
CY069311/ /1410/A/Bogota/WRAIR0088 /2009/ 9/06/10/6//NA/
A/Macau/2517/2009/1/1410/|/EPI/ISL/6 135
A/Lisboa/32/2006
A/Georgia/04/2009/1/1410/|/EPI/ISL/60717
CY064841/1/1410/A/California/VRDL141/2009/2009/04/28/6//NA/
A/Kiev/49/2008
A/Lisboa/31/2006
A/India/2757/2009
A/North/1/1410/Carolina/04/2009/|/EPI/ISL/3...
A/Puerto/1/1410/Rico/01/2008/|/EPI/ISL/336 7
A/Luxembourg/1344/2008
A/Yamagata/16/2009/2009
A/Marseille/1148/2009/1/1410/|/EPI/ISL/60089
A/British/1/1410/Columbia/RV0035/2009/|/EPI/ISL/66649
A/Virginia/03/2008/1/1410/|/EPI/ISL/2833
A/Belgium/812/2008
A/South Korea/WRAIR1238P/2009
A/Madagascar/6054/2009/1/1410/|/EPI/ISL/68858
A/Illinois/16/2008/1/1410/|/EPI/ISL/282 5
CY080652/1/1410/A/Boston/13/2009/2009/ 2/10 //NA/
A/VICTORIA/549/2009/1/1410/|/EPI/ISL/66759
CY069375/1/1410/A/South/Dakota/WRAIR1113P/2009/2009/03/01/6//NA/
HQ291918/1/1410/A/Taiwan/11526/2008/2008/12/01/6//NA/
CY100942/1/1410/A/Sullana/WRAIR1707P/2009/2009/02/21/6//NA/
CY100822/1/1410/A/Kuwait/WRAIR1 9P 2 9/2009/01/01/6//NA/
A/Texas/57/2009/1/1410/|/EPI/ISL/61862
A/Lisboa/25/2009
A/Taiwan/1026/20 9
CY074133/1/1410/A/California/VRDL20 2009/ 09/04/30/6//NA/
A/Paris/1093/2009/1/1410/|/EPI/ISL/65510
A/Kenya/4225/2009/1/1410/|/EPI/ISL/61868
A/Missouri/05/2009/1/1410/|/EPI/ISL/34733
A/Lisboa/3/2008
A/NEW/1/1410/CALEDONIA/2/2009/|/EPI/ISL 651 6
CY0709 3/1 1410/A/California/VRDL151 9/2009 04/28/6//NA/
A/Guatemala/866/2009/1/1410/|/EPI/ISL/60716
A/MIYAGI/35/2008
A/Florida/28/2008/1/1410/|/EPI/ISL/28367
A/Matagalpa/179/2009/1/1410/|/EPI/ISL/336 8
/New Jersey/16/2007
A/Bangladesh/3003/2008/1/1410/|/EPI/ISL/33 74
A/SHIMANE/117/2008
A/Wisconsin/12/2008/1/1410/|/EPI/ISL/26245
A/Santiago/4689/2008
/Iceland/8064/2009
A/Mexico/4971/2008/1/141 /|/EPI/ISL/2763
HQ291899/1/1410/A/Taiwan/0045/2006/2006/05/24/6//NA/
CY074141/1/1410/A/California/VRDL202/2009/2009/04/29/6//NA/
A/Guyane/8190/2008
CY070897/1/1410/A/California/VRDL149/2 09/2009/04/27/6//NA/
A/Hawaii/58/2008
GQ896377/1/1410/A/Wisconsin/14/2009/2009/05/22/6//NA/
JN582061/1/1410/A/New/York/08/1326/2008 20 8/ 2 13/6//NA/
CY089759/1/1410/A/Boston/87/2009/2009/02/14/6//NA/
A/Lisboa/28/2008
A/CapeTown/124/2008
A/Texas 35/2008/1/1410/|/EPI/ISL/33732
A/yokohama/91/2007/1/1410/|/EPI/ISL/28731
CY074 85/1/1410/A/California/VRDL235/2 09/2009/04/29/6//NA/
GQ896371/1/1410/A/Utah/12/2009/2009/05/ 8/6//N /
A/Lisboa/35/2006
A/NIIGATA/1150/2008/1/1410/|/EPI/ISL/28003
A/Kisii/7541/2008/1/1410/|/EPI/ISL/28471
/BRISBANE/87/20 9/1/1410/|/EPI/ISL/60 34
A/Cambodia/21/2007/1/1410/|/EPI/ISL/28585
CY100966/1/1410/A/Maracay/WRAIR1729P/2008/2008/09/03/6//NA/
A/Kenya/4250/2009/1/1410/|/EPI/ISL/70216
A/Lisboa/21/2009
GQ476061/1/1410/A/Illinois/06/2009/2009/03/12/6//NA/
A/Virginia/01/2009/1/1410/|/EPI/ISL/338
A/Ghana/FS/09/791/2009/1/1410/|/EPI/ISL/60086
A/Marrakech/589/2009
A/Luhansk/18/2008
A/SEOUL/ 437/2008/1/1410/|/EPI/ISL/28208
A/Kenya/1432/2008
A/Maryland/07/2008/1/1410/|/EPI/ISL/28383
A/Flanders/G771/2009/1/1410/|/EPI/ISL/65508
A/EHIME/38/2008/1/1410/|/EPI/ISL/28170
A/OKAYAMA/14/2008/1/1410/|/EPI/ISL/28007
A/Honduras/330/2009/1/1410/|/EPI/ISL/33604
CY080987/1/1410/A/Boston/88/2009/2009/02/19/6//NA/
GQ475900/1/1410/A/Indiana/05/2009/ 9 01/23/6//NA/
A/Paris/160/2007/EPI/ISL/157392/A///H1N1/seasonal/NA/WSS964105
CY100950/1/1410/A/Piura/WRAIR1708P/2009/2009/03/27/6//NA/
A/North/1/1410/Dakota/01/2008/|/EPI/ISL/28310
/Mass chusetts/08/2008/1/1410/|/EPI/ISL/ 647
A/Lisboa/13/2009
HQ 56609/1/1410/A/Myanmar/M061/2009/2009/06/27/6//NA/
A/Peru/WRAIR1310P/2007/1/1410/|/EPI/ISL/78567
A/Bratislava/149/2009
A/New/1/1410/Jersey/15/2007/|/EPI/ISL/71839
A/Lisboa 9/2008
A/New/Caledonia/20/1999/EPI/ISL/22626/A///H1N1/seasonal/NA/WSS964089
A/St. Petersburg/62/2 08
A/Lisboa/5/2008
A/Viet am/289/2008
A/Dakar/06/2008
A/Vladivostok/03/2008/1/1410/|/EPI/ISL/33690
A/Hokkaido/08H024/2009
CY073855/1/1410/A/California/VRDL175/2009/2009/04/28/6//NA/
A/Fiji/7/2009/1/1410/|/EPI/ISL/60129
A/Bangladesh/6666/2008/1/1410/|/EPI/ISL/33670
A/Lisbo 1/2008
A/NAI OBI/2/2009/1/1410/|/EPI/ISL/78686
A/Paris/ 10/2008
A/British/1/1410/Columbia/RV1585/2007/|/EPI/ISL/21859
A/Paris/639/2008/1/1410/|/EPI/ISL/90990
A/Beijing/Chaoyang/11405/2009
A/Lisboa/2/2006
A/Norway/1736/2007/1/1410/|/EPI/ISL/25416
GQ475940/1/1410/A/Montana/03/2009/2009/01/14/6//NA/
A/Pennsylvania/12/2008/1/1410/|/EPI/ISL/28368
CY064873/1/1410/A/California/VRDL146/2009/2009/04/25/6//NA/
CY074661/1/141 /A California/VRDL38 2009/ 09/04/27/6//NA/
A/Lisboa 03/2009
A/Lisboa/16/2008
A/Tottori/08T010/2008
A/Stockholm/28/2008/1/1410/|/EPI/ISL/70666
A/Hong Kong/1975/2009
A/Fujian/Gulou/1581/2009/1/1410/|/EPI/ISL/6...
A/Ic land/4/2008/1/1410/|/EPI/ISL/65389
GQ475908/1/1410/A/Kansas/01/2009/2 09/01/29/6//NA/
A/Taiwan/5857/2008
A/Stockholm/5/2009/1/1410/|/EPI/ISL/70668
A/Seychelles/2231/2008/1/1410/|/EPI/ISL/65368
FJ380948/1/1410/A/Finland/11/2008/2008/01/07/6//NA/
A/Thessaloniki/24/2005/EPI/ISL/25428/A///H1N1/seasonal/NA/WSS964095
CY087279/1/1410/A/Hong/Kong/62768/2008/2008///6//NA/
A/Saskatchewan/RV1039/2009/1/1410/|/EPI/ISL...
A/Vladivostok/04/2008/1/1410/|/EPI/ISL/33691
A/New/1/1410/Caledonia/6/2008/|/EPI/ISL/ 8102
A/Paraguay/61/2009/1/1410/|/EPI/ISL/33621
GQ475948/1/1410/A/Rhode/Island/01/2009/2009/01/27/6//NA/
CY080763/1/1410/A/Boston/36/2009/2009/02/ 4/6//NA/
GU271952/1/1410/A/Thailand/CU/B97/2009/2009/06/22/6//NA/
A/Massachusetts/05/2007/1/1410/|/EPI/ISL/15455
A/Dakar/14/2008
CY074205/1/1410/A/California/VRDL220/2009/2009/04/29/6//NA/
A/Ghana/FS/205/2008
A/Quebec/RV0984/2009/1/1410/|/EPI/ISL/33649
A/Illinois/12/2009
A/Lisboa/27/2008
GQ476129/1/1410/A/Montana/02/2009/2009/01/02/6//NA/
A/Nebraska/07/2008/1/1410/|/EPI/ISL/28306
CY069343/1/1410/A/Texas/WRAIR1052P 20 9 2009/01/09/6//NA/
GQ476012/1/1410/A/North/Dakota/03/2009/2009/03/01/6//NA/
A/Florida/29/2008
A/DAEJEON/4494/2008
A/Martinique/ 9/2008
A/St. Petersburg/75/2008
A/Buenos/1/1410/Aires/1306/2008/|/EPI/ISL/65472
A/Santiago/5087/2008/1/1410/|/EPI/ISL/23858
CY074341/1/1410/A/California/VRDL249/2009/2009/04/29/6//NA/
A/Ghana/FS/2 6 2008/1/1410/|/EPI/ISL/65463
A/Johannesburg/279/2008/1/1410/|/EPI/ISL/28096
A/Waikato/2/2009/1/1410/|/EPI/ISL/60126
A/Finland/514/2009/1/141 /|/EPI/ISL 60088
A/Taiwan/639/2008/1/1410/|/EPI/ISL/28323
A/Thailand/778/2008
A/Ukraine/313/2008
CY069487/1/1410/A/Louisiana/WRAIR1 7 P/2009/2009/02//6//NA/
A/Valparaiso/5366/2008/1/1410/|/EPI/ISL/23865
A/Hong Kong/3195/2008
A/Thailand/874/2008/1/1410/|/EPI/ISL/33664
A/Tottori/52/2008
A/Venezuela/3571/2008/1/1410/|/EPI/ISL/26243
A/PHILIPPINES/3314/2009/1/1410/|/EPI ISL/6 900
A/Nagasaki/07N 35/2008
GQ 75905/1/1410/A/Kentucky 01/2009/2009///6//NA/
A/Liaoning/Huanggu/1144/2009
CY080971/1/1410/A/Boston/85/2009/2009/ 2/ /6// A/
A/Sweden/1/2009/1/1410/|/EPI/ISL/70643
CY0890 1/1/1410/A/Boston/23/2009/2009/ 2/18/6//NA/
GQ475980 1/1410/A/Massachusetts/05/20 9/2009/02/26/6//NA/
CY100886/1/1410/A/Iraq/WRAIR1683P/2009/2009/03//6//NA/
CY068677/1/1410/A/Singapore/GP101/2009/2009/03/20/6//NA/
A/Belgium/850/2008
A/Boston/67/2009
CY100806 /A/Nevada/WRAIR1117P/2009/2009/01/01/6//NA/
A/Wyoming/10/2008/1/1410/|/EPI/ISL/19766
A/Lisboa/19/2009
CY 53659/1/1410/A/Novosibirsk/3/2009/2009/04//6//NA/
CY1009 0/1/1410/A/Trujillo/WRAIR1701P/2008/2008/12/26/6//NA/
A/St. Petersburg/12/2008
A/Perth/33/2008/1/1410/|/EPI/ISL/28582
A/Paris/ 704/2009/1/1410/|/EPI/ISL/65509
A/Maryland/05/2008/1/ 410/|/EPI/ISL/28302
A/CHIBA/86/2008/1/1410/|/EPI/ISL/26386
CY074389/1/1410/A/California/VRDL264/2009/2009/04/25/6//NA/
A/Lisboa/22/2006
A/Washington/25/2009
A/Michigan/14/2009/1/1410/|/EPI/ISL/60719
GU 12229/1/1410/A/Tehran/345/ /20 9/01/12/6//NA/
A/Taiwan/01/1986/EPI/ISL/10251/105058
GQ850597/1/1410/A/Shanghai/LWS1/2009/2009/01/03/6//NA/
A/Lisboa/77/2007
GQ475 34/1/1410/A/Indiana/07/2009/2009/03/09/6//NA/
A/Austria/404342/2008
A/Vietnam/241/2008
A/Florida/27/2008/1/1410/|/EPI/ISL/6072
A/Michigan/31/2009/1/1410/|/EPI/ISL/77936
A/Pennsylvania/04/2009/1/1410/|/EPI/ISL/33756
CY074637/1/1410/A/California/VRDL3 /2 09/2009/04/27/6//NA/
/Minnesota/04/2009
A/Lisboa/05/2 09
A/KOCHI/48/2008/1/1410/|/EPI/ISL/27998
A/Tennessee/03/2009/1/1410/|/EPI/ISL/33809
A 
0.02
A/Brisbane/12/2009
A/Minnesota/23/2 07/1/1410/|/EPI/ISL/15465
A/Kursk/01/2008
CY080851/1/1410/A/Boston/52/2009/2009/02/14/6//NA/
CY074421/1/1410/A/California/VRDL275/2009/2009/04/30/6//NA/
/K richo/7529/2008/1/ 410/|/EPI/ISL/28468
A/Kenya/2862/2009/1/1410/|/E I ISL/66654
A/Lisboa/39/2008
A/Christchurch/20/2008
A/PERTH/21/2009/1/1410/|/EPI/ISL/66758
A/Vietnam/2036/2009/1/1410/|/EPI/ISL/69711
CY100854/1/1410/A/Washington/WRAIR1237P/2009/2009/02/01/6//NA/
GQ476132/1/1410/A/Oregon/01/2009/2009/01/07/6//NA/
GQ476091/1/1410/A/Pennsylvania/01/2009/2009/01/07/6//NA/
A/Lisboa/6/2008
A/Niigata/08F188/2009
GQ476009/1/1410/A/Virginia/06/2009/2 09/05/05/6//NA/
A/Chungbuk/4385/2008/1/1410/|/EPI/ISL 65495
A/Lisboa/14/2009
GQ476118/1/1410/A/Ohio/03/2009/2009/01/15/6//NA/
A/Algeria/G804/2008
GQ476047/1/1410/A/Arkansas/01/2009/2009/02/08/6//NA/
GQ475926/1/1410/A/Virginia/03/2009/2009/02/18/6//NA/
A/Lisboa/25/2006
A/Kyrgyzstan/214/2009/1/1410/|/EPI/ISL/61865
A/Hong Kong/H090/682/V1/0//2009
HQ 91908/1/1410/A/Taiwan/2832/2008/2008/10/06/6//NA/
A/Incheon/4532/2008/1/1410/|/EPI/ISL/65492
A/Mauritius/403/2008/1/1410/|/EPI/ISL/65437
A/Sydney/601/2009/1/1410/|/EPI/ISL/60116
GQ475969/1/1410/A/New/York/63/2009/2009/03/31/6//NA/
A/Lisboa/8/2008
A/Berlin/59/2008/1/1410/|/EPI/ISL/65494
CY074597/1/1410/A/California/VRDL358/2009/2009/06/07/6//NA/
A/CHIBA/89/2008/1/1410/|/EPI/ISL/28169
A/Massachusetts/12/2008/1/1410/|/EPI/ISL/28366
A/England/494/20 6/1/1410/|/EPI/ISL/25707
A/Algeria/G773/2008/1/1410/|/EPI/ISL/65459
A/Hong Kong/70/2009
A/Perth/33/2009/1/1410/|/EPI/ISL/60123
A/Victoria/501/2008/1/1410/|/EPI/ISL/23 19
GQ475883/1/1410/A/West/Virginia/02/2009/2009/03/18/6//NA/
A/Kawasaki/UTK/4/2009
A/Vietnam/1808/2009/1/1410/|/EPI/ISL/69712
A/Hong/Kong/2765/2004/EPI/ISL/157578/A///H1N1/seasonal/NA/WSS964086
A/Norway/1747/07/1/1410/|/EPI/ISL/23298
A/GYEONGGIBUK/4503/2008
A/Lisboa/7/2006
A/WELLINGTON/84/2009/1/1410/|/EPI/ISL/60136
A/Hubei/Wujiagang/133/2009/1/1410/|/EPI/ISL...
A/Victoria/07159220/2007/1/1410/|/EPI/ISL/28584
CY100926/1/1410/A/Pucallpa/WRAIR1704P/2009/2009/01/14/6//NA/
CY080675/1/1410/A/Boston/17/2009/2009/02/10/6//NA/
A/Brazil/146/2009
A/Ghana/17 /2008/1/ 410/|/EPI/ISL/65441
A/Washington/02/2009/1/1410/|/EPI/ISL/33807
AB521100/1/1410/A/Yamagata/36/2009/2009/01/14/6//NA/
/Singapore/42/2008/1/1410/|/EPI/ISL/28384
A/Tahiti/3/2009/1/1410/|/EPI/ISL/60132
A/Tennessee/11/2008/1/1410/|/EPI/ISL/28324
A/Slovenia/123/2008
A/Lisboa/14/2 08
GQ476072/1/1410/A/Florida/03/2009/2 09/ 2/ 6 6//NA/
A/Yamagata/125/2008/1/1410/|/EPI/ISL/71068
A/Illinois/05/2009 1/1410 |/EPI/ISL/33728
GQ476109/1/1410/A/New/York/56/2009/2009/02/10/6//NA/
A/Chubut/102197/20 8
CY081019/1/1410/A/Boston/93/2009/2009/03/ 7/6 A/
GQ476140/1/1410/A/Alaska/01/2009/2009/01/29/6//NA/
CY100774/1/1410/ /Texas/WRAIR105 P/200 /2009/01/01/6//NA/
A/Colorado/0 /2008/ / /|/ I/ISL/28378
A/Brazil/5943/2008
A/Gansu/Chengguan 129/2007/1/1410/|/EPI/ISL/20448
A/Belem/241/2008
CY074373/1/1410/A/California/VRDL256/2009/2009/04/29/6//NA/
A/Guatemala/602/2008
A/NAGANO/1204/2008/1/1410/|/EPI/ISL/27999
JN256686/1/1410/A/Hong/Kong/H090/718/V1/0//2009/2009/07/15/6//NA/
A/England/684/2007/1/1410/|/EPI/ISL 254 5
A/Ohio/02/2009/1/1410/|/EPI/ISL/33808
A/Yamagata/68/2008/1/1410/|/EPI/ISL/71063
A/Singapore/07/2009/1/1410/|/EPI/ISL/34736
CY080835/1/ 410/A/Boston/49/2009/ /02/13/6//NA/
CY073839/1/1410/A/California/VRDL163/2009/2009/04/29/6//NA/
/ ris/1154/2008
CY073823/1/1410/A/California/VRDL154/2009/2009/04/28/6//NA/
A/Colorado/17/2008/1/1410/|/EPI/ISL/33652
CY074093/1/ 41 /A/California/VRDL186/ 09/2009/04/29/6//NA/
A/Lisboa/48/2005
A/Kansas/UR06/0 04/2007/ /1410/|/EPI/ISL/7867
A/South/1/1410/Australia/1/2008/|/EPI/ISL/22972
A/Paris/445/2008/1/1410/|/EPI/ISL/65483
A/Jilin/Chuanying/1318/2008/1/1410/|/EPI/ISL/33707
A/Florida/2 /2 08/1/1410/|/EPI ISL/27641
JF972564/1/1410/A/Mississippi/03/2001/2001/01/2 /6//NA/
A/Argentina/303/2008/1/1410/|/EPI/ISL/25779
CY074173/1/1410/A/California/VRDL215/2009/2009/04/28/6//NA/
A/Brisbane/1/2009/1/1410/|/EPI/ISL/32 90
A/El Salvador/468/2 08
A/Uganda/ 511/2009/1/1410/|/EPI ISL/66659
A/Washington/01/2008
CY1 0798/1/1410/A/Texas/WRAIR1115P/2009/2009/03/01/6//NA/
CY080939/1/1410/A/Boston/72/2009/2009/03/24/6//NA/
A/Washington/08/2008/1/1410/|/EPI/ISL/28333
A/Lisboa/19/2008
A/Florida/02/2 08/1/1410/|/EPI/ISL/19 87
A/Maryland/04/2007
A/Stockholm/6/2009/1/1410/| EPI ISL/70806
A/Lisboa/94/2005
A/Kentucky/08/2009
A/Cayman Islands/5082/2009
A/Singapore/88/2009/1/1410/|/EPI/ISL/34737
A/Kazakhstan/2600
A/India/7308/2008/1/1410/|/EPI/ISL/ 3659
GQ475914/1/1410/A/Hawaii/03/2009/2009/01/29/6//NA/
CY089109/1/1410/A/Boston/59/2009/2009/02/28/6//NA/
CY074125/1/1410/A/California/VRDL194/2009/2009/04/27/6//NA/
A/England/26 2008
A/IBARAKI/68/2008/1/1410/|/EPI/ISL/28175
A/Managua/1985.01/2008/1/1410/|/EPI/ISL/62906
GQ457553/1/1410/A/Saskatchewan/5131/2009/2009/06/19/6//NA/
CY080612/1/1410/A/Boston/95/2009/2009/04/01/6//NA/
CY074485/1/1410/A/California/VRDL292/2009/2009/04/30/6//NA/
A/Idaho/01/2009/1/1410/|/EPI/ISL/61874
A/AOMORI/19/2008/1/1410/|/EPI/ISL/28166
CY05367 /1/1410/A/Novosibirsk/7 9/20 9 04//6 /NA/
CY100958/1/1410/A/Pucallpa/WRAIR1709P/2009/2009/01/20/6//NA/
A/Georgia/1269/1/1410//36G//2009/|/EPI/ISL/...
A/GWANGJU/4324/2008/1/1410/|/EPI/ISL/28202
GU271968/1/1410/A/Thailand/CU/H565/2009/2009/09/02/6//NA/
A/SHIMANE/1/2009/1/1410/|/EPI/ISL/28187
A/Cameroon/073/2008/1/1410/|/EPI/ISL/65406
A/Rabat/109/2009/1/1410/|/EPI/ISL/65489
GQ475869/1/1410/A/New/York/02/2009/2009/02/14/6//NA/
A Honduras 100/2008
A/SAMOA/10/2009/1/1410/|/EPI/ISL/65128
CY069551/1/1410/A/Texas/WRAIR1254P/2009/2009/03//6//NA/
A/Brazil/815/2009
CY10 934/1/1410/A/Santa/Cruz/WRAIR1706P/20 8/2 08/12/09/6//NA/
A/WELLINGTON/218/2009/1/1410/|/EPI/ISL/65150
A/Iceland/8599/2009/1/1410/|/EPI/ISL 65514
A/Arizona/13/2008/1/1410/|/EPI/ISL/27639
A/Paraguay/67/2009
A/Moscow/38/2008
A/Buenos/1/1410/Aires/825511/2008/|/EPI/ISL/65471
CY100830/1/1410/A/Japan/WRAIR1226P/2009/2009/02/01/6//NA/
GQ476155/1/1410/A/New/Mexico/01/2009/2009/01/07/6//NA/
A/Michigan/01/2 09/1/1410/|/EPI/ISL/ 745
A/Singapore/6/1986/EPI/ISL/6905/58244
A/England/594/2006/1/1410/|/EPI/ISL/25708
A/Pe u/WRAIR1505P/2007/1/1410/|/EPI/ISL/78572
A/Naypyitaw/M499 200 /1/141 /|/EPI/ISL/33557
A/Thailand/839/2008
GQ476088/1/14 0/A/Nebraska 05/2 09/2009/03/07/6//NA/
CY050662/1/1410/A/New/York/3150/2009/2009/04/27/6//NA/
A/Ghana/FS/09/718/2009/1/1410/|/EPI/ISL/60087
A/Seychelles/2239/2008/EPI/ISL/60835/A///H1N1/seasonal/NA/WSS964136
GQ475945/1/1410/A/Washington/03/2009/2009/01/21/6//NA/
A/Fukushima/141/20 6/EPI/ISL/20229/A///H1N1/seasonal/NA/WSS964101
A/Perth/30/2009
CY074357/1/1410/A/California/VRDL252/2009/2009/04/29/6//NA/
A/Algeria/G825/2008
CY100870/1/1410/A/Nevada/WRAIR1257P/2009/2009/02/01/6//NA/
A/Texas/16/2008/1/1410/|/EPI/ISL/26239
AB521103/1/1410/A/Yamagata/51/2009/2009/01/26/6//NA/
A/KOBE/49/2008
AB521101/1/1410/A/Yamagata/26/2009/2009/01/17/6//NA/
CY074333/1/1410/A/California/VRDL245/2009/2009/04/29/6//NA/
A/Indiana/08/2009
A/Guangdong/Futian/139/2009/1/1410/|/EPI/IS...
AB521111/1/1410/A/Yamagata/77/2009/2009/02/10/6//NA/
A/Lisboa 4/2 08
A/Stockholm/7/2009/1/ 410/|/EPI ISL/70800
A/Lisboa/23/2009
A/Sweden/8/2008/1/1410/|/EPI/ISL/70648
CY050478/1/1410/A/New/York/1692/2009/2009/04/27/6//NA/
A/Lisboa/07/2009
A/Fujian/Gulou/1367/2009/1/1410/|/EPI/ISL/3...
A/TAK/334/2009/1/1410/|/EPI/ISL/65129
GQ475877/1/1410/A/New/York/62/2009/2009/03/17/6//NA/
A/Delaware/01/2008/1/1410/|/EPI/ISL/28285
GQ475886/1/1410/A/Nebraska/06/2009/2009/03/22/6//NA/
A/Lisboa/13/2008
A/Lisboa/2/2008
A/Guangdong/Zhuangzuyaozuzizhi/51/200.../1/1410
CY074309/1/1410/A/California/VRDL238/2009/2009/04/29/6//NA/
A/Hong/Kong/3192/2008/EPI/ISL/65482/A///H1N1/seasonal/NA/WSS964139
CY100790/1/1410/A/Oklahoma/WRAIR 10 2 09/2009/03/01/6//NA/
CY073863/1/1410/A/California/VRDL229/2009/2009/04/29/6//NA/
A/KOL/2465/2009
HQ291915/1/1410/A/Taiwan/8949/2008/2008/12/11/6//NA/
A/Quebec/RV3060/2009
A/Arizona 3/2007/1/1410/|/EPI/ISL/15893
CY080795/1/1410/A/Boston/41/2009/2009/02/27/6//NA/
A/Lisboa/16/2009
A/Yamagata/128/2008
GQ4761 6/1/1410/A/Florida/07/2009/20 9/03/25/6//NA/
A/Texas/27/2008/1/1410/|/EPI/ISL/27653
CY074277/1/1410/A/California/VRDL232/2009/2009///6//NA/
A/BEIJING/HUAIROU/185/2008
A/Texas/31/2007/1 141 /|/EPI/ISL/15409
A/Algeria/G864/2008/1/1410/|/EPI/ISL/65468
A/Managua/954.02/2008/1/1410/|/EPI/ISL/33848
A/Quebec/Rv1107/2009/1/1410/|/EPI/ISL/33632
CY080803/1/1410/A/Boston/42/2009/2009/03/01/6//NA/
A/Hawaii/19/2008
GQ476096/1/1410/A/Hawaii/01/2009/2009/01/13/6//NA/
A/Tak/427/2009/1/1410/|/EPI/ISL/66657
A/French/1/1410/Polynesia/2001/2009/|/EPI/I...
GQ475972/1/1410/A/Wisconsin/06/2009/2009/03/03/6//NA/
A/Lisboa/11/2008
CY053655/1/1410/A/Novosibirsk/151/2 09/2009/05//6//NA/
HQ256619/1/1410/A/Myanmar/M256/2009/2009/07/16/6//NA/
A/Stockholm/22/2008
A/SAMOA/9/2009/1/1410/|/EPI/ISL/60899
CY069391/1/1410/A/South/Carolina/WRAIR1 16P/ 009/2009/03/01/6//NA/
A/New/1/1410/Jersey/32/2008/|/EPI/ISL/33750
GQ475874/ /1410/A/Wisconsin/02/2009 200 / 1/07/6//NA/
A/Argentina/295/2008/1/1410/|/EPI/ISL/25778
/Lisboa 9/20 8
A/Kenya/0793/2008/1/1410/|/EPI/ISL/33677
GQ476035/1/14 0/A/Hawaii/13/20 9/2009/04/16/6//NA/
Thailand 1577/2007/1/14 0/|/EPI/ISL/ 2372
GQ476143/1/1410/A/Vermont/01/2009/2009/02/09/6//NA/
A/Uganda/ 132/2009/1/1410/|/EPI/ISL/66658
CY100974/1/ 410/A/Cusco/WRAIR1730P/2008/2008/08/20/6//NA/
A/SHIZUOKA/C/21/2009/1/1410/|/EPI/ISL/28194
CY089783/1/1410/A/Boston/32/2009/2009/02/20/6//NA/
GQ475880/1/1410/A/Tennessee/01/2 09/2009/01/12/6//NA/
HQ291910/1/1410/A/Taiwan/3293/2008/2008/05/02/6//NA/
GQ457554/1/1410/A/Saskatchewan/5350/2009/2009/06/18/6//NA/
A/Managua/5007.01/2008/1/1410/|/EPI/ISL/62912
A/Fujian/Gulou/1896/2009/1/1410/|/EPI/ISL/6...
A/Nigeria/0023/2008/1/1410/|/EPI/ISL/25811
A/California/VRDL167/2009
CY 89085/1/ 410/A/Boston/46/20 9/20 9/03/01/6/ N /
HQ29 909 1 1410/A/Taiwan/ 885 20 8 2008 11/24/6//NA/
CY100902/1/1410/A/Piura/WRAIR1700P/2009/2009/01/01/6//NA/
A/Johannesburg/45/2008/1/1410/|/EPI/ISL/ 3 1
A/Indiana/06/2009/1/1410/|/EPI/ISL/33812
GQ475894/1/1410/A/California/01 2009/2 09/01/07/6/ NA/
A/Brisbane/59/2007/EPI/ISL/71838/A///H1N1/seasonal/NA/WSS964111
A/IWATE/40/2008/1/1410/|/EPI/ISL/27996
GQ475847/1/1410/A/New/Mexico/02/2009/2009/01/14/6//NA/
A/Washington/12/2008/1/1410/|/EPI/ISL/33813
A/Pennsylvania/14/2008/1/1410/|/EPI/ISL/33644
A/Samara/46/2008
A/Illin is/16/2007/1/14 0/|/EPI/ISL/19084
A/Washington/ 5/2008/1/14 0 |/EPI/ISL/25804
A/Brisbane/10/2009/1/1410/|/EPI/ISL/324 3
A/Lisboa/4/2006
/KwaZulu/1/1410/Natal/272/2008/|/EPI/ISL/6 63
A/Denmark/27 2007 1/1410/|/EPI/ISL/25442
A/Maryland/04/2008/1/1410/|/EPI/ISL/28301
CY050550/1/1410/A/New/York/3095/2009/2009/04/29/6//NA/
A/Hong/1/1410/Kong/33597/2009/|/EPI/ISL/68854
A/SAPPORO/90/2008/1/1410/|/EPI/ISL/28010
A/Kenya/1329/2010/1/1410/|/EPI/ISL/98941
A/Georgia/20/2006/1 1410/|/EPI/ISL/21323
A/FUKUI/91/2008
A/USSR/90/77/EPI/ISL/66105/230612
A/Yangon/M195/2008/1/1410/|/EPI/ISL/33555
A/Hong/Kong/1856/2008/EPI/ISL/60838/A///H1N1/seasonal/NA/WSS964138
A/North/1/1410/Carolina/02/2008/|/EPI/ISL/19770
A/Solomon/Islands/3/2006/EPI/ISL/13324/A///H1 1/seasonal/NA/WSS964131
A/Hong/Kong/2652/2006/EPI/ISL/157436/A///H1N1/seasonal/NA/WSS964099
A/St. Petersburg/83/2008
HQ256643/1/1410/A/Myanmar/M428/2009/2009/08/11/6//NA/
A/Lisboa/10/2008
GQ476082/1/1410/A/Arkansas/02/2009/2009/03/01/6//NA/
CY089101/1/1410/A/Boston/54/2009/2009/02/22/6//NA/
A/Jilin/Chaoyang/157/2009/1/1410/|/EPI/ISL ...
CY074117/1/1410/A/California/VRDL193/2009/2009/04/29/6//NA/
A/Pennsylvania/13/2 07/1/14 0/|/EPI/ISL/23897
A/Marrakech/510/2009
A/Lisboa/15/2008
A/Paris/781 2008/1/1410/|/EPI/ISL/65485
A/Israel/1/ 09/1/1410/|/EPI/ISL/65499
A/Boston/06/2009
A/Philippines/1159/2008
A/SHIZUOKA/C/10/2009
A/South/1/1410/Australia/12/2009/|/EPI/ISL/...
A/Argentina/110 2008/1/1410/|/EPI/ISL/25781
A/Niigata/08F093/2009
A/Hong/1/1410/Kong/18106/2009/|/EPI/ISL/65516
A/Nagasaki/ 7N020/2008/1/1410/|/EPI/ISL/7 169
A/Kenya/2743/2009/1/1410/|/EPI/ISL/61877
CY080819/1/1410/A/Boston/45/2009/2009/03/03/6//NA/
A/Perth/1/2009/1/ 410/|/EPI/ISL/32484
A/Lisboa/41/2008
A/Texas/36/2008/1/1410 |/EPI/ISL/33733
A/Hong/1/1410/Kong/26552/2009/|/EPI/ISL/66653
HQ256645/1/1410/A/Myanmar/M470/2009/2009/08/20/6//NA/
GQ476053/ / 410/A/New/York/65/2009/2009/03/09/6//NA/
A/BRISBANE/96/2009/1/1410/|/EPI/ISL/65152
A/Lisboa/15/2009
A/Egypt/10/2007/EPI/ISL/106505/A///H1N1/seasonal/NA/WSS964117
A/Hong/1/1410/Kong/852/2008/|/EPI/ISL/65426
CY100814/1/1410/A/Texas/WRAIR1 8P 0 9 2009/06/01/6//NA/
CY093127/1/1410/A/Boston/47/2009/2009/02/12/6//NA/
A/Belgium/G257/2008
HQ256649/1/1410/A/Myanmar/M533/2009/2009/09/04/6//NA/
A/Oregon/02/2009
A/Yokohama/78/2008
A/NIIGATA/1088/2008/1/1410/|/EPI/ISL/28002
A/Indiana/01/2008/1/ 410/|/EPI/ISL/15873
A/Kiev/313/2008
A/India/3414/2009
A/Moscow/02/2009
A/Philippines/3914/2008
A/New/1/1410/Jersey/30/2008/|/EPI/ISL/33747
A/Lisboa/40/2008
A/Chile/1/1983/EPI/ISL/6900/58149
AB465323/1/1410/A/Yokohama/30/2008/2008/01/28/6//NA/
A/Lisboa/12/2008
A/Buen s/1/1410/Aires/R13/2008/|/EPI/ISL/65360
A/Tula/31/2008
A/Guatemala/663/2 08
AB521105/1/1410/A/Yamagata/45/2009/2009/01/21/6//NA/
A/Lisboa/06/2009
A/Lisboa/24 2006/A/Lisboa/ / 6
A/Thailand/CU/B42/2009
A/England/557/2007
GQ476149/1/1410/A/New/York/64/2009/2009/04/09/6//NA/
A/St. Petersburg/85/2008
A/Jamaica/2968/2009/1/1410/|/EPI/ISL/33607
A/Cameroon/080/2008
AB521112/1/1410/A/Yamagata/80/2009 2009/0 18 6//NA/
A/Florida/24/2008/1/1410/|/EPI/ISL/28287
A/Lisboa/2/2009
CY100838/1/1410/A/Illinois/WRAIR1233P/2009/2009/03/01/6//NA/
A/Costa Rica/5150/2009
AB4 5321/1/14 0/A/Yokohama/34/20 8/ 8/ 1/28/6//NA/
A/England/4 1/20 8/1/1410/|/EPI/ISL/65 77
GQ4761 4/1/1410/A/Pennsylvania/12/2009/2009/01/29/6//NA/
A/Israel/10/2009/1/1410/|/EPI/ISL/65498
A/Lisboa/17/2008
A/Nebraska/WRAIR1247P/2009
GQ475965/ /1410/A/Ohio/06/2009/2009/02/03/6//NA/
GQ476 24/1/1410/A/Michigan/07 2009/2 0 /04/08/6//NA/
CY053657/1/1410/A/Novosibirsk/2/2009/2009/04//6//NA/
A/Belgium/858/2008
A/Lisboa/35/2005
GQ475920/1/1410/A/California/03/2009/2009/02/04/6//NA/
A/SURAT/1/1410/THANI/337/2009/|/EPI/ISL/65130
A/California/VRDL371/2009
GQ475951/1/1410/A/Kentucky/03/2009 2009/ 2 02/6//NA/
A/Puerto/1/1410/Rico/02/2009/|/EPI/ISL/33708
A/Niigata/08F031/2009
A/Taiwan/693/2009/1/1410/|/EPI/ISL/60130
A/Cam roon/08/ 35/2008/1/1410/|/EPI/ISL/65497
A/Lisboa/20/2 08
A/North/ /1410/Carolina/07/2 08/|/EPI ISL 28372
A/Jilin/Chaoyang1258/2008/1/1410/|/EPI/ISL/28298
A/Bangladesh/9067/2008/1/1410/|/EPI/ISL/33 71
A/Lisboa/20/2009
A/Hawaii/41/2008/1/1410/|/EPI/ISL/28376
A/Ireland/744/2008
A/MACAU/3436/2009/1/1410/|/EPI/ISL/65127
HQ533869/1 1410/A/Tianjin/15/2009/ ///6//NA
CY100918 1/1410/A/Trujillo/WRAIR1702P/2008/2008/12/28/6//NA/
GQ475962/1/1410/A/Montana/01/2009/2009/01/04/6//NA/
GQ475856/1/1410/A/South/Dakota/01/2009/2009/01/22/6//NA/
GU112230/ /1410/A/Tehran/359/ 009/2009/0 /16/6//NA/
A/HAMAMATU/C/988/2009/1/1410/|/EPI/ISL/65151
A/Ontario/RV0131/2007/1/1410/|/EPI/ISL/22256
A/Minnesota/0 /2008/1/1410/|/EPI/ISL/20792
GQ476027/ / 410/A Maryland/01/2009/2009/01/18/6//NA/
A/Prague/33/2009/1/1410/|/EPI/ISL/65503
A/South/1/1410/Australia/11/2009/|/EPI/ISL/...
A/SAPPORO/66/2008/1/1410/|/EPI/ISL/26396
A/Netherlands/345/2007/EPI/ISL/60837/A///H1N1/seasonal/NA/WSS964114
JN676131/1/1410/A/Thailand/Siriraj/3043/2009/2009/10/06/6//NA/
CY074469/1/1410/A/California/VRDL289/2009/2009/05/01/6//NA/
A/Fujian/Gulou/1292/2009/1/1410/|/EPI/ISL/3...
A/Sichuan/Dongqu/1836/2009/1/1410/|/EPI/ISL...
A/Lisboa/6/2006
JN256687/1/1410/A/Hong/Kong/H090/744/V1/0//2009/2009/07/24/6//NA/
A/Norway/1735/2007/EPI/ISL/106540/A///H1N1/seasonal/NA/WSS964128
A/Michigan/06/2008/1/1410/|/EPI/ISL/27649
A/Pennsylvania/09/2008/1/1410/|/EPI/ISL/26237
A/Hawaii/42/20 8/1/141 /|/ I/I /28377
CY100846/1/1410/A/Alab ma/WRAIR1235P/20 9 009/04 01/6//NA/
A/Peru/WRAIR1300P/2007/1/1410/|/EPI/ISL 78566
A/Hawaii/28/2007/1/1410/|/EPI/ISL/33820
A/Minnesota/27/2008/1/1410/|/EPI/ISL/27650
EU 51 21/1/1410/A/Paris/963/20 8/2008/01/04 6//NA/
GQ475997/1/1410/A/Minnesota/01/2009 20 9/01/16/6//NA/
CY074 0 /1/1410/A/California/VRDL1 9 2 09/2009/04/29/6//NA/
CY080899/1/1410/A/Boston/65/2009/2009/03/09/6//NA/
CY089045/1/1410/A/Boston/10/2009/2009/02/04/6//NA/
A/Min esota/34/2 08/1/1410/|/EPI/ISL 28371
A/Paris/ 157/2 08
A/Japan/WRAIR1230P/2009
A/Waikato/1/2009/1/1410/|/EPI/ISL/60125
A/Lisboa/17/2009
A/Salta/2093/20 8/1/1410/|/EPI/ISL/65473
A/OSAKA/C/39/2008
CY050774/1/1410/A/New/York/3442/2009/2009/05/09/6//NA/
A/Hong/Kong/2637/2004/EPI/ISL/11833/A///H1N1/seasonal/NA/WSS964097
A/Victoria/214/2009/1/1410/|/EPI/ISL/60131
A/KANAGAWA/68/2008
GQ475931/1/1410/A/Ohio/04/2009/2009/01/28/6//NA/
A/Sri Lanka/13/2009
A/Mexico/2629/2009/1/1410/|/EPI/ISL/33635
A/ ustri /404811/2008
A/Lisboa/24/2009
A/INCHEON/4432/2008/1/1410/|/EPI/ISL/28206
A/Johannesburg/21/2008
A/CHANTHABURI/341/2009/1/1410/|/EPI/ISL/65136
A/Annecy/2013/2009/1/1410/|/EPI/ISL/68855
A/St. Petersburg/11/2008
A/Paris/1208/2008
GQ476079/ /1410/A/Hawaii/17/2009/2009/04/13/6//NA/
GU183801/1/1410/A/Thailand/CU/B589/2009/2009/07/10/6//NA/
CY074237/1/1410/A/California/VRDL224/2009/2009/04/29/6//NA/
GU183809/1/1410/A/Thailand/CU/B685/2009/2009/07/12/6//NA/
A/England/40/2004/EPI/ISL/15757 A///H1N1/seasonal/NA/WSS964084
A/California/VRDL283/2009
A/Johannesburg/174/2008/1/1410/|/EPI/ISL 6564
CY089173/1/1410/A/Boston/94/2009/2009/03/13/6//NA/
A/Yamagata/137/ /1/1410/|/EPI/ISL 71072
A/Lisboa/18/2008
A/Naypyitaw/M783/2008/1/1410/|/EPI/ISL/33559
CY100894/1/141 /A/Piura/WRAIR1699P/2008/2008/12/28/6//NA/
A/Philippines/15/2009/1/1410/|/EPI/ISL/60117
A/Lisboa 7/20 8
A/Guatemala/22/2008
CY043539/1 1410/A/Kyoto/08K05 /2009/2009/01/07/6//NA/
CY089125/1/1410/A/Boston/70/2009/2009/03/21/6//NA/
Dn prodzerzinsk/ 64/2008
A/St. Petersburg/53/2008
A/Argent na/81/2008
GQ475 74/1/ 410/A/North/Dakota/01/2009/2009/01/19/6//NA/
A/Alberta/RV2859/2009/1/1410/|/EPI/ISL/66647
/Luxembourg/116/2008
CY069383/1/1410/A/Alaska/WRAIR1114P/2009/2009/03//6//NA/
A/Ghana/168/2008
CY080691/1/1410/A/Boston/20/2009/2009/02/11/6//NA/
A/Scotland/ / 7/ /1410/|/EPI/ISL/6 93
A/Perth/46/2 08/1/1410/|/EPI/ISL/28 93
A/SHIGA/18/2008/1/1410/|/EPI/ISL/26399
A/Sydney/605/2009/1/1410/|/EPI/ISL/32488
A/Lisboa/18/2009
A/Peru/WRAIR1 99P/2007/1/1410/|/EPI/ISL/78565
CY069311/1/1410/A/Bogota/WRAIR0088N/2009/2009/06/10/6//NA/
A/Macau/2517/2009/1/1410/|/EPI/ISL/60135
A/Lisboa/32/2006
A/Georgia/04/2009/1/1410/|/EPI/ISL/60717
CY 64841/1/1410/A/California/VRDL14 2009/2009/04/28/6//NA/
A/Kiev/49/2008
A/Lisboa/31/2006
A/India/2757/2009
A/North/1/1410/Carolina/04/2009/|/EPI/ISL/3...
A/Puerto/1/1410/Rico/01/2008/|/EPI/ISL/33657
A/Luxembourg/1344/2008
A/Yamagata/16/2009/2009
A/Marseille/1148/2009/1/1410/|/EPI/ISL/60089
A/British/1/1410/Columbia/RV0035/ 9/|/EPI/ISL/66649
A/Virginia/03/2008/1/1410/|/EPI/ISL/28332
A/Belgium/812/2008
A/South Korea/WRAIR1238P/2009
A/Madagascar/6054/2009/1/1410/|/EPI/ISL/68858
A/Illinois/16/2008/1/1410/|/EPI/ISL/28295
CY080652/1/1410/A/Boston/13/2009/2009/02/10/6//NA/
A/VICTORIA/549/2009/1/1410/|/EPI/ISL/6675
CY069375/1/1410/A/South/Dakota/WRAIR1113P/2009/2009/03/01/6//NA/
HQ291918/1/1410/A/Taiwan/11526/2008/2008/12/01/6//NA/
CY100942/1/ 410/A/Sullana/WRAIR1707P/2009/2009/02/21/6//NA/
CY100822/1/1410/A/Kuwait/WRAIR1119P/2009/2009/01/01/6//NA/
A/Texas/57/2009/1/1410/|/EPI/ISL/61862
A/Lisboa/25/2009
A/Taiwan/1026/2009
CY074133/1/1410/A/California/VRDL200/2009/2009/04/30/6//NA/
A/Paris/1093/2009/1/1410/|/EPI/ISL/655 0
A/Kenya/4225/2009/1/1410/|/EPI/ISL/6 68
A/Missouri/05/2009/1/1410/|/EPI/ISL/34733
A/Lisboa/3/2008
A/NEW/1/1410/CALEDONIA/2/2009/|/EPI/ISL/65126
CY070913/1/1410/A/California/VRDL 51/20 009/04/28/6//NA/
A/Guatemala/866/2009/1/1410/|/EPI/ISL/60716
A/MIYAGI/35/2008
A/Florida/28/2008/1/1410/|/EPI/ISL/28367
A/Matagalpa/179/2009/1/1410/|/EPI/ISL/33648
A/New Jersey/16/2007
A/Bangl desh/3 03/2008/1/1410/|/EPI/ISL/33674
A/SHIMANE/117/2008
A/Wisconsin/12/2008/1/1410/|/EPI/ISL/26245
A/Santiago/4689/2008
A/Iceland/8064/2009
A/Mexico/4971/2008/1/1410/|/EPI/ISL/27637
HQ291899/1/1410/A/Taiwan/0045/2006/2006/05/24/6//NA/
CY074141/1/1410/A/California/VRDL202/2009/2009/04/29/6//NA/
A/Guyane/8190/2008
CY070897/1/1410/A/California/VRDL149/2009/2009/04/27/6//NA/
A/Hawaii/58/2008
GQ896377/1/1410/A/Wisconsin/14/2009/2009/05/22/6//NA/
JN582061/1/1410/A/New/York/08/1326/2008/2008/02/13/6//NA/
CY089759/ /1410/A/Boston 87/2009/2009/02/14/ //NA/
A/Lisboa/28/2008
A/CapeTown/124/2008
A/Texas/35/2008/1/14 0/|/EPI/ISL/33732
A yokohama/91/2007/1/1410/|/EPI/ISL/28731
CY074285/1/1410/A/California/VRDL235/2009/2009/04/29/6//NA/
GQ896371/1 410/A/Utah/12/200 /2009/05/18/6//NA/
A/Lisboa/35/2006
A/NIIGATA/1150/2008/1/1410/|/EPI/ISL/28003
A/Kisii/7541/2008/1/1410/|/EPI/ISL 2847
A/BRISBANE/87/2009/1/1410/|/EPI/ISL/60134
A/Cambodia/21/2007/1/1410/|/EPI/ISL/28585
CY100966/1/1410/A/Maracay/WRAIR1729P/2008/2008/09/03/6//NA/
A/Kenya/4250/2009/1/1410/|/EPI/ISL/70 6
A/Lisboa/21/2009
GQ476061/1 410/A/Illinois/06/2009 2 09 03/12/6//NA/
A/Virginia/01/2009/1/1410/|/EPI/ISL/33806
A/Ghana/FS/09/791/2009/1/1410/|/EPI/ISL/60086
A/Marrakech/589/2009
A/Luhansk/ 8/2008
A/SEOUL/4437/2008/1/1410/|/EPI/ISL/28208
A/Kenya/1432/2008
A/Maryland/07/2008/1/1410/|/EPI/ISL/28383
A/Flanders/G771/2009/1/1410/|/EPI/ISL 65508
A/EHIME/38/2008/1/1410/|/EPI/ISL/28170
A/OKAYAMA/14/2008/1/1410/|/EPI/ISL/28007
A/Honduras/330/2009/1/1410/|/EPI/ISL/33604
CY080987/1/1410/A/Boston/88/2009/2009/02/19/6//NA/
GQ475900/1/1410/A/Indiana/ 5/2009/2009/01/23/6//NA/
A/Paris/160/2007/EPI/ISL/157392/A///H1N1/seasonal/NA/WSS964105
CY100950/1/1410/A/Piura/WRAIR1708P/2009/2009/03/27/6//NA/
A/North/1/1410/Dakota/01/2008/|/EPI/ISL/2831
A/Massachusetts/08/2008/1/1410/|/EPI/ISL/27647
A/Lisboa/13/2009
HQ256609/1/1410/A/Myanmar/M061/2009/2009/06/27/6//NA/
A/Peru/WRAIR1310P/2007/1/1410/|/EPI/ISL/78567
A/Bratislava/149/2009
A/New/1 1410/Jersey/15/2007/|/EPI/ISL/71839
A/Lisboa/29/2008
A/New/Caledonia/20/1999/EPI/ISL/22626/A// H1N1/seasonal/NA WSS964089
A/St. Petersburg/62/2008
/Lisboa/5/2008
A/Vietnam/289/2008
A/Dakar/06/2008
A/Vladivostok/03/2008/1/1410/|/EPI/ISL/33690
A/Hokkaido/08H024/2009
CY073855/1/1410/A/California/VRDL 75/ 0 9/2009/04/28/6//NA/
A/Fiji/7/20 9/1 410/|/EPI/ISL/60129
A/Bangladesh/6666/2008/1/1410/|/EPI/ISL/33670
A/Lisbo / 0 8
A/NAIROBI/2/20 9/1/14 /|/ I/ISL/78686
A/Paris/910/2 08
A/British/ / C lumbia/RV1585/2007/|/EPI/ISL/21859
A/Paris/639/2008/1/1410/|/EPI/ISL/90990
A/Beijing/Chaoyang/11405/2009
A/Lisboa/2/2006
A/Norway/1736/2007/1/1410/|/EPI/ISL/25416
GQ475940/1/1410/A/Montana/03/2009/2009/01/14/6//NA/
A/Pennsylvania/1 /2008/1/1410/|/EPI/ISL/28368
CY064873/1/1410/A/California/VRDL146/2009/2009/04/25/6//NA/
CY074661/1/1410/A/California/VRDL380/2009/2009/04/27/6//NA/
A/Lisboa/03/2009
A/Lisboa/16/2008
A/Tottori/08T010/2008
A/Stockholm/28/2008/1/1410/|/EPI/ISL 70 66
A/Hong Kong/1975/2009
A/Fujian/Gulou/1581/2009/1/1410/|/EPI/ISL/6...
A/Iceland/4 2 08/1/1410/|/EPI/ISL/65389
GQ475908/1/1410/A/Kansas/01/2009/2009/01/29/6//NA/
A/Taiwan/5857/2 08
A/Stockholm/5/2009/1/1410/|/EPI ISL/70668
A/Seychelles/2231/2008/1/1410/|/EPI/ISL/6 368
FJ380948/1/1410/A/Finland/11/2008/2008/01/07/6//NA/
A/Thessaloniki/24/2005/EPI/ISL/25428/A///H1N1/seasonal/NA/WSS964095
CY087279/1/1410/A/Hong/Kong/62768/2008/2008///6//NA/
A/Saskatchewan/RV1039/2009/1/1410/|/EPI/ISL...
A/Vladivostok/04/2008/1/1410/|/EPI/ISL/33691
New/1/ 4 /Caledonia/6/2008/|/EPI/ISL/28102
A/Paraguay/61/2009/1/1410/|/EPI/ISL/33621
GQ475948 /1410 A/Rhode Island/ 1/20 9/2 09/01 27/6//NA/
CY080763/1/1410/A/Boston/36/2009/2009/02/24/6//NA/
GU271952/1/1410/A/Thailand/CU/B97/2009/2009/06/22/6//NA/
A/Massachusetts/05/2007/1/1410/|/EPI/ISL/15455
A/Dakar/14/2008
CY074205/1/1410/A/California/VRDL220/2009/2009/04/29/6//NA/
A/Ghana/FS/205/2008
A/Quebec/RV0984/2009/1/1410/|/EPI/ISL/33649
Illinois/12/2009
A/Lisboa/27/2008
GQ476129/1/1410/A/Montana/02 2009 2009/01/02/6//NA/
A/Nebrask 07/ 08/1/1410/|/EPI/ISL/28306
CY069343/1/1410/A/Texas/WRAIR1052P/2009/2009/01/09/6//NA/
GQ476012/1 410/A/North/Dakota/03 09/2009/03/01/6//NA/
A/Florida/29/2008
A/DAEJEON/4494/2008
A/Martinique/19/2008
A/St. Petersburg/75/2008
A/Bu nos/ /1410/Aires/1306 2008/|/EPI/ISL/65472
A/Santiago/5087/2008/1/1410/|/EPI/ISL/23858
CY074341/1/1410/A/California/VRDL249/2009/2009/04/29/6//NA/
A/Ghana/FS/2 6 2008/1/1410/|/EPI/ISL/65463
A/Johannesburg/279/2008/1/1410 |/EPI IS 28096
A/Waikato/2/2009/1/1410/|/EPI/ISL/60126
A inland/514/2009/1/1410/| EPI/ISL/60088
A/Taiwan/639/2008/1/1410/|/EPI/ISL/28323
A/Thailand/778/2008
A/Ukraine/313/2008
CY069487/1/1410/A/Louisiana/WRAIR1170P/2009/2009/02//6//NA/
A/Valparaiso/5366/20 8/1/1 10/|/EPI/ISL/23865
A/Hong Kong/3195/2008
A/Thailand 874/2008/1/1410/|/EPI/ISL/33664
A/Tottori/52/2008
A/Venezuela/3571/2008/1/1410/|/EPI/ISL/26243
A/PHILIPPINES/3314/2009/1/1410/|/EPI/ISL/60900
A/Nagasaki/07N035/2008
GQ475905/1/1410/A/Kentucky/01/2009/2009///6//NA/
/Liao ing/Huanggu/ 144/2009
CY080971/1/1410/A/Boston/85/2009/2009/02/12/6//NA/
A Sweden/1/2009/1/1410/|/EPI/ISL 70643
CY089061/1/1410/A/Boston/23/2009/2009/02/18/6//NA/
GQ475980/1/1410/A/Massachusetts/05/2009/2009/02/26/6//NA/
CY100886/1/141 /A/Iraq/WRAIR1683P/2009/2009/03//6//NA/
CY068677/1/1410/A/Singapore/GP101/2009/2009/03/20/6//NA/
A/Belgium/850/2008
A/Boston/67/2009
CY100806/1 1410/A/Nevada/WRAIR1117P/2009/2009/01/01/6//NA/
A/Wyoming/10/2008/1/1410/|/EPI/ISL/19 66
A/Lisboa/19/2009
CY053659/1/1410/A/Novosibirsk/3/2009/2009/04//6//NA/
CY1009 0/1/1410/A/Trujillo/WRAIR1701P/2008/2008/12/26/6//NA/
A/St. Petersburg/12/2008
A/Perth/33/2 08 / 410/|/EPI/ISL/28582
A/Paris/1704/2009/1/1410/|/EPI/ISL/65509
A/Maryland 05/2008/1 1410/|/EPI/ISL/28302
A/CHIBA/86/2008/1/1410/|/EPI/ISL/ 6386
CY074389/1/1410/A/California/VRDL264 2 09/2009/04/25/6//NA/
A/Lisboa/22/2006
A/Washington/25/2009
A/Michigan/14/2009/1/1410/|/EPI/ISL/60719
GU 12229/1/1410/A/Tehran/ 45/20 9 009 01 12/6//NA/
A/Taiwan/01/1986/EPI/ISL/10251 105058
GQ850597/1/1410/A/Shanghai/LWS1/2009/2009/01/03/6//NA/
A/Lisboa/77/2007
GQ475934/1/1410/A/Indiana/07/20 9/2009/ 3/09/6//NA/
A/Austria/4 4342/2008
A/Vietnam/241/2008
A/Florida/27/2008/1/1410/|/EPI/ISL/60723
A/Michigan/31/2009/1/1410/|/EPI/ISL/7 36
A/Pennsylvania/ 4/2009/1/1410/|/EPI/ISL/33756
CY074637/1/1410/A/California/VRDL377/2009/2009/04/27/6//NA/
A/Minnesota/04/2009
A/Lisboa/05/2009
A/KOCHI/48/2008/1/1410/|/EPI/ISL/27998
A/Tennessee/03/2009/1/1410/|/EPI/ISL 3 809
0.02
A/Brisbane/12/2009
A/Minnesota/23/2007/1/1410/|/EPI/ISL/15465
/Kursk/01/2 08
CY080851/1/1410/A/Boston/52 2009 2 09/02/14/6//NA/
CY074421/1/141 /A/California/VRDL275/2009/2009/04/30/6//NA/
A/Kericho/7529/2008/1/1410/|/EPI/ISL/28468
A/K nya/2862/2009/1/1410/|/EPI/ISL/66654
A/Lisboa/39/2 08
A/Christchurch/20/2008
A/PERTH/21/2009/1/1410/|/EPI/ISL/66758
A/Vietnam/2036/2009/1/1410/|/EPI/ISL/69711
CY100854/1/1410/A/Washington/WRAIR1237P/2009/2009/02/01/6//NA/
GQ476132/1/1410/A/Oregon/01/2009/2009/01/07/6//NA/
GQ476091/1/1410/A/Pennsylvania/01/2009/2009/01/07/6//NA/
A/Lisboa/6/ 008
A/Niigata/08F18 /2009
009/1/1410/A/Virginia/ 6/ 9/20 9/ 5/ 5/6/ NA/
A/Chungbuk/4385/2008/1/1410/|/EPI/ISL/65495
A/Lisboa/14/2009
GQ476118/1/1410/A/Ohio/03/2009/2009/01/15/6//NA/
A/Algeria/G804/2008
GQ476047/1/1410/A/Arkansas/01/2009/2009/02/08/6//NA/
GQ475926/1/1410/A/Virginia/03/2009/2009/02/18/6//NA/
A/Lisboa/25/2006
A/Kyrgyzstan/214/2009/1/1410/|/EPI/ISL/61865
A/Hong Kong/H090/682/V1/0//2009
HQ291908/1/1410/A/Taiwan/2832/2008/2008/10/06/6//NA/
/Inche n/453 /2 08/1/1410/|/EPI/ISL/65492
A/Mauritius/403/2008/ /141 /|/EPI/ISL/65437
A/Sydney/601/2009/ /1410/|/EPI/ISL/6 116
GQ475969/1/1410/A/New/York/63/ 009/2009/03/31/6/ NA/
A/Lisboa/8/2008
A/Berlin/59/2008/1/1410/|/EPI/ISL/65494
CY074597/1/1410/A/California/VRDL358/2009/2009/06/07/6//NA/
A/CHIBA/89/2008/1/1410/|/EPI/ISL/28169
A/Massachusetts/12/2008/1/1410/|/EPI/ISL/28366
A/England/ 94/2006/1/1410/|/EPI/ISL/25707
A/Algeria/G773/2008/ /1410/|/EPI/ISL/65 59
A/Hong Kong/70/2009
A/Perth/33/2009/1/1410/|/EPI/ISL/60123
A/Victoria/501/2008/1/ 410/|/EPI/ISL/23 19
GQ475883/1/1410/A/West/Virginia/02/2009/2009/03/18/6//NA/
A/Kawasaki/UTK/4/2009
A/Vietnam/1808/2009/1/1410/|/EPI/ISL/69712
A/Hong/Kong/2765/2004/EPI/ISL/ 5757 /A///H1N1/seasonal/NA/WSS964086
A/Norway/1747/07/1/1410/|/EPI/ISL/23298
A/GYEONGGIBUK/4503/2008
A/Lisboa/7/2006
A/WELLINGTON/84/2009/1/1410/|/EPI/ISL/60136
A/Hubei/Wujiagang/133/2009/1/1410/|/EPI/ISL...
A/Victoria/07159220/2007/1/1410/|/EPI/ISL/28584
CY100926/1/14 / /Pucallpa/WRAIR1 0 P/2 0 2 09/01/14/6//NA/
CY080 75 B ston/17/20 /2009 02 10/6//NA/
A/Brazil/146/2009
A/Ghana/172/2008/1/1410/|/EPI/ISL/65441
A/Washington/02/2009/1/1410/|/EPI/ISL/ 38 7
AB521100/1/1410/A/Yamagata/36/2009/2009/01/14/6//NA/
Singapore 42/2008/1 1410/|/EPI/ISL/2838
/Tahiti/3/2009/1/1410/|/EPI/ISL/60132
A/Tennessee/11/2008/1/1410/|/EPI/ISL/28324
A/Slovenia/123/2008
A/Lisboa/14/2 08
GQ476072/1/1410/A/Florida/03/2009/200 /02/ 6/6// A/
A/Yamagat /125/2008/1/1410/|/EPI/ISL/71068
A/Illinois/05/2009/1/ 410/|/EPI/ISL/ 3728
GQ476109/1/1410/A/New/York/56/2009/2009/02/10/6//NA/
A/Chubut/102 97/2 08
CY081019/1/1410/A/Boston/93/2009/2009/0 / 7/6//NA/
GQ476140/1/ 41 /A/Alaska/01/2009/2009/01/29/6//NA/
CY100774/1/1410/A/Texas/WRAIR1053P/2009/2009/01/01/6//NA/
A/Colorado 08/2008 1/1410/|/EPI/ISL/283 8
A/Brazil/5943/2008
A/Gansu/Chengguan1129/2007/1/1410/|/EPI/ISL/20448
A/Belem/241/2008
CY074373/1/1410/A/California/VRDL256/2009/2009/04/29/6//NA/
A/Guatemala/602/2008
A/NAGANO 1204/2008/1/1410/|/EPI/ISL/27999
JN256686/1/1410/A/Hong/Kong/H090/718/V1/0//2009/2009/07/15/6//NA/
A/England/684/2007/1/1410/|/EPI/ISL/25445
Ohio 02 /1/141 /| 33 08
A/Yamagata/68/2008/1/1410/|/EPI/ISL/71063
A/Singapore/07/2009/1/1410/|/EPI/ISL/ 4736
CY080835/1/1410/A/Boston/49/2009/20 9/ 2/1 /6//NA/
CY073839/1/1410/A/California/VRDL163/2009/2009/04/29/6//NA/
A/Paris 1154/ 008
CY073823/1 14 /A/California VRDL154/2009/2009/04/28/6//NA/
A/Colorado/17/2008/1/1410/|/EPI/ISL/33652
CY074093/1/1410/A California/VRDL186/20 9 2 0 / 4/29/6//NA/
A/Lisboa/48/2005
A/Kansas/UR06/0104/2007/1/1410/|/EPI/ISL/7867
A/South 1/1 10/Australia/1/2008 |/EPI/ISL/22972
A/Paris/445/2008/ /1410 |/EPI/ISL/65483
A/Jilin/Chuanying/1318/2008/1/141 /|/EPI/ISL/33707
A/Florida/21 008/1/1410/|/EPI/ISL 2764
JF972564/1/1410/A/Mississippi/03/2001/2001/01/25/6//NA/
A/Argentina/3 3/2008/1/1410/|/EPI ISL/2577
CY074173/1/141 /A/California/VRDL215/2009/2009/04/28/6//NA/
A/Bri bane/1/2009/1/1410/|/EPI ISL/32490
A/El Salvador/468/2008
A/Uganda/0511/2009/1/1410/|/EPI/ISL/66659
A/Washington/01/2008
CY1 0798/1/1410/A/Texas/WRAI 1115P/ / / 3 01
CY080939/1/1410/A/Boston/72/2009/2009/03/24/6// /
A/Washington/08/2008/1/1410/|/EPI/ISL/28333
A/Lisboa/19/2008
A/Florida/02/2008/1/1410/|/EPI/ISL/19087
A/Maryland/04/2 07
/Stockholm/6/2009/1/1410/|/EPI/ISL/70806
A/Lisboa/94/2005
A/Kentucky/08/2009
A/ ayman Islands/5082/2009
A/Singapore/88/2009/1/1410/|/EPI/ISL/34737
A/Kazakhstan/2600/2008
A/India/7308/2008/1/1410/|/EPI ISL/33659
GQ475914/1/1410/A/Hawaii/03/2009/20 9/01/29/6//NA/
CY089109/1/1410/A/Boston/59/2009/2009/ 2/28/6//NA/
CY074125/1/1410/A/California/VRDL194/2009/2009/04/27/6//NA/
/England 26/2008
A/IBARAKI/68/2008/ /1410/|/EPI/ISL/28175
A/ anagua/1985. 1 2008/1/1410/|/EPI/ISL/62906
GQ457553 /Saskatchewan/5131/2009/2009/06/19/6//NA/
80612/1/1410/A/Boston/95/2 09/ /04/01/6//NA/
CY074485/ /141 /A California/VRDL292/2009/2009/04/30/6//NA/
A/I aho/01/2009/1/1410/|/EPI/ISL/61874
A/AOMORI/19/2 08/1/141 /|/EPI/ISL/28166
CY053671 / / /Novosibirsk/7/ 009/2009/04//6//NA
CY100 58/1/1410/ /Pucallpa/WRAIR1 P/2009/2009/01/20/6//NA/
A/Georgia/1269/1/1410//36G//2009/|/EPI/ISL/...
A/GWANGJU/4324/2008/1/1410/|/EPI/ISL/28202
GU271968/1/ 410/A/Thailand/CU/H565/ /2009/09/02/6//NA/
/SHIMANE/1/20 /1/1410/|/EPI/ISL/28187
A/Cameroon/073/2008/1/1410/|/EPI/ISL/65406
A/Rabat/109/2009/1/1410/|/EPI/ISL/65489
GQ475869/1/141 /A/New/York/02/2009/2009/02/14/6//NA/
A/Honduras/100/2008
A/SAMOA/10/2 09/1/1410/|/EPI/ISL/65128
CY069551/1/1410/A/Texas/WRAIR 254P/20 9/2 09/03//6//NA/
A/Brazil/815/2009
CY100934/1/1410/A/Santa/Cruz/WRAIR1706P/2008/2008/12/09/6//NA/
/WELLINGTON 218/2 09/1/1410/|/EPI/ISL/65150
A/Iceland/8599/2 09/1/1410/|/EPI/ISL 65514
A/Arizona/13/2008/1/1410/|/EPI/ISL/27639
A/Paraguay/67/20 9
A/Moscow/38 2008
A/Buenos/ / 410/Aires/825511/2008/|/EPI ISL/65471
CY100830/1/1410/A/Japan/WRAIR1226P/2009/2009/02/01/6//NA/
GQ476155/1/1410/A/New/Mexico/01/20 9 9/01/07/6//NA/
A/Michigan/0 2009/1/1410/|/EPI/ISL/33745
A/Singapore/6/1986/EPI/ISL/6905/58244
A/England 59 /2 06 /1410/|/EPI/ISL/25708
A/Peru WRAIR1505P/2007/1/1410/|/EPI ISL/785
A/Naypyitaw/M499/2008/1/1410/|/EPI/ISL/33557
/Thailand/839/2008
GQ476 8/1/14 0/A/Nebraska 05/2009/2009/03/07/6//NA/
CY050662/1/1410/A/New/York/3150/2009/2009/ 4 27 6//NA/
A/Ghana/FS/09/718/2009/1/1410/|/EPI/ISL/60087
A/Seychelles/ 239/2008/EPI/ISL/60835/A///H1N1/seasonal/NA/WSS964136
GQ47594 /1/14 0/A/Washington/03/2009/2009/ 1/21/6//NA/
A/Fukushima/141/20 6/EPI/ISL 20229/A// H1N1/seasonal/NA/WSS964101
A/Perth/30/2009
CY074357/ /141 /A/California/VRDL 52/2 09/ 09/04/29/6//NA/
A/Algeria/G 25/20 8
CY100 70/1/1410/A/Nevada/WRAIR1257P 2009/ 9/02/01/6//NA/
A/Texas/16/2008/1/1410/|/EPI/ISL/26239
AB521103/1/1410/A/Yamagata/51/2009/2009/01/26/6//NA/
A/KOBE/49/2008
AB521101/1/1410/A/Yamagata/26/2009/2009/01/17/6//NA/
CY074333/1/14 0/A/California/VRDL245/2009/2 9/04/29/6//NA/
A/Indiana/ /2009
A/Guangdong/Futian/139/2009/1/1410/|/EPI/IS...
AB521111/1/1410/A/Yamagata/77/2009/2009/02/10/6//NA/
A/Lisboa/4/ 8
A/Stockholm/7/2009/1/1410/|/EPI/ISL/70800
/Lisboa/23/2009
A/Sweden/8/2008/1/1410/|/EPI ISL/70648
CY050478/1/1410/A/New/York/1692/2009/2009/04/27/6//NA/
A/Lisboa/07/2009
A/Fujian/Gulou/1367/2009/1/1410/|/EPI/ISL/3...
A/TAK/334/2009/1/1410/|/EPI/ISL/65129
GQ475877/1/1410/A/New/York/62/2009/2009/03/17/6//NA/
A/Del ware/0 / 8/1/1410/|/EPI/ISL/28285
GQ475886/1/1 /A/Nebraska/06/2009/2009/03/22/6//NA/
/Lisboa/1 8
A/Lisboa/2/2008
A/Guangdong/Zhuangzuyaozuzizhi/51/ 0 .../1/1410
CY074309/1/1410/A/California/VRDL238/2009/2009/04/29/6// /
A/Hong/K ng/3192/2008/EPI/ISL/65482/A///H1N1/seasonal/NA/WSS964139
10 790/ / 0/ /Oklahoma/WRAIR1110P/2009/2009/03/01/6//NA/
CY073863/1/1410/A/California/VRDL229/2009/2009/04/29/6//NA/
A/KOL/2465/2009
HQ291915/1/1410/A/Taiwan/8949/2008/2008/12/11/6//NA/
A/Quebec/RV3060/2009
A/Arizona/13/2007/1/1410/|/EPI/ISL/15893
080795/1/1410/A/Boston/41/2009/2009/02/27/6//NA/
A/Lisboa/16 2009
A/Yamagata/128/2008
GQ476126/1/1410/A/Florida/07/2009/2 09 03/25/6 NA/
A/Texas/27/2008/1/1410/|/EPI/ISL/2765
CY074277/1/ 410/A/California/VRDL232/2009/2009///6//NA/
A/BEIJING/HUAIROU/185/20
A/Texas/31/2007/1/1410 |/EPI ISL/15409
A/Algeria/G864/2008/1/1410/|/EPI/ISL/65 68
A/Managua/954.02/2008/1/1410/|/EPI/ISL/33848
A/Quebec/Rv1107/2009/1/1410/|/EPI/ISL/3363
CY080803/1 1410/A/Boston/42/2009/2009/03/01/6//NA/
A/Hawaii/19/2008
GQ476096/1/1410/A/Hawaii/01/2009/2009/01/13/6//NA/
A/T k/427/2009/1/1410/|/EPI/ISL/66657
A/French/1/1410/Polynesia/2001/2009/|/EPI/I...
GQ475972/1/1410/A/Wisconsin/06/2009/2009/03/03/6//NA/
A/Lisboa/11/2008
CY0536 5/ /1410/A/Novosibirsk/151/2 09/2009/05//6//NA/
HQ256619/1/1410/A/Myanmar/M256/2009/2009/07/16/6//NA/
A/Stockholm/22/2008
A/SAMOA/9/2009/1/1410/|/EPI/ISL/6 899
CY069391/1/1410/A/South/Carolina/WRAIR1116P/2009/2009/03/01/6//NA/
A/New/1/1410 Jersey/32/2008/|/EPI/ISL/33750
GQ475874/1/1410/A/Wisconsin/02/2009/2009/01/07/6//NA/
A/Argenti a/295/ 0 8/ /|/ PI/ SL/25778
A/Lisboa/9/20 8
A/Kenya/0793/2008/1/1410/|/E I/ISL/33677
GQ476 35/1/1410/A Hawaii/13/2009/2009 04/16/6//NA/
A/Thailand/1577/2007/1/1410/|/EPI/ISL/22372
GQ476143/1/1410/A/Vermont/01/2009/2009/02/09/6//NA/
A/Uganda/0132/2009/1/1410/|/EPI/ISL 66658
CY100974/1/ 4 0/A/Cusco/WRAIR1730P/2008 2008/ 8/20/6//NA/
A/SHIZUOKA/C/21/2009/1/1410/|/EPI/ISL/28194
CY089783/1/1410/A/Boston/32/2009/2009/02/20/6//NA/
GQ475880/1/1410/A/Tennessee/01/2009/2009/01/12/6//NA/
HQ291910/1/1410/A/Taiwan/3293/2008/2008/05/02/6//NA/
GQ457554/1/1410/A/Saskatchewan/5350/2009/2009/06/18/6//NA/
A/Managua/5 07.01/2008/1 1410/|/EPI/ISL/62912
A/Fujian/Gulou/1896/2009/1/1410/|/EPI/ISL/6...
A/Nigeria/0023/2008/1/1410/|/EPI/ISL/2581
A/California/VRDL 6 /2009
CY089085/1/1410/A/Boston/46/2009 2 09 03/01/6//NA/
HQ 91909/1/1410/A/Taiwan/2885/2008/2008/11/24/6//NA/
CY100902 /141 /A/Piura/WRAIR170 P/2009/ 9 01/01/6//NA/
A/Johanne burg/45/2008 /1410/|/EPI/ISL/23112
A/Indiana/06/2009/1/141 /|/EPI/ISL/338 2
GQ475894/1/1410/A/Ca ifornia/01/2009/20 9/ 1/07
A/Brisbane/59/2007/EPI/ISL/71838/A///H1N1/seasonal/NA/WSS964111
A/IWATE/40/2008/1/1410/|/EPI/ISL 79 6
GQ475847/1/1410/A/New/Mexico/02/2009/2009/01/14/6//NA/
A/Washington/12/2008/1/1410/|/EPI/ISL/33813
A/Pennsylvania/14/2008/1/1410/|/EPI/ISL/33644
A/Samara 46/2008
A/Illinois/16/2007/1/141 /| EPI/ISL/19084
A/Washington/05/2008/1/1410/|/EPI/ISL/25804
A/Brisbane/10 2009/1/1410/|/EPI/ISL/3 493
A/Lisboa/4/ 6
A/KwaZulu/1/1410/Natal/27 /2008/|/EPI/ISL/65639
A/Denmark/27/2007/1/1410/|/EPI/ISL/25442
A/Maryland/04/2008/1/1410/|/EPI/ISL/28301
CY050550/1/1 10 A/New/York/3095/2009/2 09/04/29/6//NA/
A/Hong/1/1410/Kong/33597/2009/|/EPI/ISL/68854
A/SAPPORO/90/2008/1/1410/|/EPI/ISL/28010
A/Kenya/1329/2010/1/1410/|/EPI/IS / 8941
A/Georgia/20/2006/1/1410/|/EPI/ISL/21323
A/FUKUI/91/2008
A/USSR/90/77/EPI/ISL/66105/230612
A Yangon/M195/2008/1/1410/|/EPI/ISL/33555
A/Hong/Kong/1856/2008/EPI/ISL/60838/A///H1N1/seasonal/NA/WSS964138
A/North/1/1410/Carolina/02/2008/|/EPI/ISL/19770
A/Solomon Islands/ /2006/EPI/ISL/ 3324/A///H1N1/seasonal/NA/WSS964131
A/Hong/Kong/2652/2006/EPI/ISL/157436/A///H1N1/seasonal/NA/WSS964099
A/St. Petersburg/83/2008
HQ256643/1/1410/A/Myanmar/M428/2009/2009/08/11/6//NA/
/Lisboa/10/2008
GQ476082/1/1410/A/Arkansas/02/2009/2009/03/01/6//NA/
CY089101/1/1410/A/Boston/54/2009/2009/02/22/6//NA/
A/Jilin/Chaoyang/ 57/2009/1/1410/|/EPI/ISL/...
CY074117/1/1410/A/California/VRDL193/2009/2009/04/29/6//NA/
A/Pennsylvania/13/2007/1/141 /|/EPI/ISL/23897
A/Marrakech/510/2009
A/Lisboa/15/2008
A/Paris/781/20 8/1/1410/|/EPI/ISL/65485
A/Israel/1/2009/1/141 /|/EPI/ISL/65499
A/Boston/06/20 9
A/Philippines/1159/2008
A/SHIZUOKA/C/10/2009
A/South/1/1410/Australia/12/2009/|/EPI/ISL/...
A/Argentina/11 /2008/ /1410/|/EPI/ISL/25781
A/Niigata/08F093/2009
A/Hong/1/1410/Kong/18106/2009/|/EPI/ISL/65516
A/Nagasaki/ 7N020/2008/1/1410/|/EPI/ISL/70169
A/Kenya/2743/2009/1/ 410/|/EPI/ISL/6187
CY080819/1/ 410/A/Boston/45 2009/2009/03/03/6/ NA/
/Pe th/1/2 09/1/1410/|/EPI/ISL/32484
A/Lisboa/41/2008
A/Texas/36/200 /1/1410/|/EPI/ISL/33733
A/Hong/1/1410/Kong/26552/2009/|/EPI/ISL/66653
HQ256645/1/1410/A/Myanmar/M470/2009/2009/08/20/6//NA/
GQ476053/1 1410 A/New/York/65/20 9/200 / 3/ 9/6//NA/
/BRISBANE/96/2009/1/1410/|/EPI/ISL/65152
A/L sboa/15/2009
A/Egypt/10/2007/EPI/ISL/106505/A///H1N1/seasonal/NA/WSS964117
A/Hong/1/1410/Kong/852/2008/|/EPI/ISL/65426
CY 00814/1/1410/A/Texas/WRAIR1118P/2009/2009/06/01/6//NA/
CY093127/1/1410/A/Boston/47/2009/2009/02/12/6//NA/
A Belgium/G257/2 08
HQ256649/1/1410/A/Myanmar/M533/2009/2009/09/04/6//NA/
A/Oregon/02/2009
A/Yokohama/78/2008
A/NIIGATA/1088/2008/1/1410/|/EPI/ISL/28002
A/I diana/01/2008/1/1410/|/EPI/ISL/15873
A/Kiev/313/2008
A/India/3414/2009
A/Moscow/ 2/2009
A/Philippines/3914/2008
A/New/1/1410/Jersey/30/2008/|/EPI/ISL/33 47
A/Lisboa/40/2008
A/Chile/1/1983/EPI/ISL/6900/58149
AB4653 3/1/1410/A/Yokohama/30/2008/2008/01/28/6//NA/
A/Lisboa/12/2008
A/Bu nos/1/1410/Aires/R 3 2008 |/EPI/ISL/65360
A/Tula/31 2008
A/Guatemala/663/2008
AB521 5/ /1410 A/Yamagata/45/2009 2009 1 21 6//NA/
A/Lisboa/06/2009
A/Lisboa/24/2006/A/Lisboa/16/2006
A/Thailand/CU/B42/2009
A/England/557/2007
GQ476149/1/1410/A/New/York/64/2009/2009/04/09/6//NA/
A/St. Petersburg/85/2 08
A/Jamaica/2968/2 09/1/141 /| EPI/ISL/33607
A/Cameroon/080/2008
AB521112/1/ 10/A/Y magat /8 /20 9/20 9/02/18/6//NA/
A/Florida/24/2 08/1/14 0/|/EPI/ISL/28287
A/Lisboa/2/2009
CY100838/1/141 /A/Illinois/WRAIR1233P/2009/2009/03/01/6//NA/
A/Costa Rica/5150/ 09
AB465321/1/1410/A/Yokohama/34/2008/2008/01/28/6//NA/
A/England 41 / /|/ I/ISL/65477
GQ476104/1/ 410/A/Pennsylvania/12/ 0 9/2 9/01/29/6//NA/
A/Israel/10/2009/1/1410/|/EPI/ISL/65498
A/Lisboa/17 2008
A/Nebraska/WRAIR1247P/2009
GQ475965/1/ 410/A/Ohi /06/2009/2 9/ 2/03/6 /NA/
GQ476024/1/1410/A/Michigan/07 09/2009/04/08/6//NA/
CY053657/1/1410/A/Novosibirsk/2/2009/2009/04//6//NA/
A/Belgium/858/2008
A/Lisboa/35/2005
GQ475920/1/1410/A California/03/2009/2009/02/04/6//NA/
A/SURAT/1/1410/THANI/337/2009/|/EPI/ISL/65130
A/California/VRDL371/2009
GQ475951/1/1410/A/Kentucky/03/2009/2 9/02/ 2/6//NA/
A/Puerto/1/1410/Rico/02/2009/|/EPI/ISL/33708
A/Niigata/08F031/2009
A/Taiwan/693/2009/1/1410/|/EPI/ISL/60130
A/Cameroon/08/235/2008/1/1410/|/EPI ISL/65497
A/Lisboa/ /2008
A/North/1/1410/Carolina/07/2008/|/EPI ISL/28372
A/Jilin/Chaoyang1258/2008/1/1410/|/EPI/ISL/28298
A/Bangladesh/9067/2008/1/1410/|/EPI/ISL/33671
A/Lisboa/20/2009
A/Hawaii/41/2008/1/1410/|/EPI/ISL/28376
A/Ireland/744/2008
A/MACAU/3436/2009/1/1410/|/EPI/ISL/65127
HQ533869/1/141 /A/Tianjin/15/2 09/ 009// 6 /NA/
CY1009 8/1/1410/A/Trujillo/WRAIR17 2P 20 8/ 08/12 28/6//NA/
GQ475962/1/14 0/A/Montana/01/2009/2009/01/ 4/6//NA/
GQ475856/1/1410/A/South/Dakota/01/2009/2009/01/22/6//NA/
GU112230/1/1410/A/Tehran/359/2009/2009/01/16/6//NA/
A/HAMAMATU/C/988/2009/1/1410/|/EPI/ISL/65151
A/Ontario/RV0131/2007/1/1410/|/EPI/ISL/22256
A/Minnesota/01/2008/1/1410/| EPI/ISL 7 2
GQ476027/1/141 /A/Maryland/01/2009/ 0 9/01/18/6//NA/
A/Prague/33/2009 1/1410 |/EPI/ISL/65503
A/South/1/1410/Australia/11/2009/|/EPI/ISL/...
A/SAPPORO/66/2008/1/1410/|/EPI/ISL/26396
A/Netherlands/345/20 7/EPI/ISL/60837/A///H1N1/seasonal/NA/WSS964114
JN676131/1/1410/A/Thailand/Siriraj/3043/2009/2009/10/06/6//NA/
CY074469/1/1410/A/California/VRDL289/2009/2009/05/01/6//NA/
A/Fujian/Gulou/1292/2009/1/1410/|/EPI/ISL/3...
A/Sichuan/Dongqu/1836/2009/1/1410/|/EPI/ISL...
A/Lisboa/6/2006
JN256687/1/1410/A/Hong/Kong/H090/744/V1/0//2009/2009/07/24/6//NA/
A/Norway/1735/2007/EPI/ISL/106540/A///H N /seasonal/NA/WSS964128
A/Michigan/06/2008/1/1410/|/EPI/ISL/27649
A/Pennsylvania/09/2008/1/1410/|/EPI/ISL/26237
A/H waii/42 2008/1/1410/|/EPI/ISL/28377
CY100846/1/ 4 0/A/Alabama/WRAIR1 35 / 009/2009/04/01/6//NA/
A/Peru/WRAIR1300P/2007/1/1410/|/EPI/ISL/78566
A/Hawaii/28/2007/1/1410/|/EPI/ISL/33820
A/Minnesota/2 2008/1 1410/|/EPI/ISL 765
EU551821/1/14 0/A/Paris/963/ 008/2008/01/04/6//NA/
GQ475997/1/141 /A/Minnesota/01/2009/2009/01/16/6//NA/
CY074101/1/1410/A/California/VRDL189/2 09/20 9/04/29/6//NA/
CY080899/ /1410/A/Boston/65/2009/2009/ 3/09/6//NA/
CY0 9045/1/ 410/A/Boston/10/2009/2009/ 2/04/6//NA/
A/Minnesota/34/2008/1/1410/|/EPI/ISL/28371
A/Paris/115 /2 08
A/Japan/WRAIR1230P/2009
A/Waikato/1/2009/1/1410/|/EPI/ISL/6 25
A/Lisboa/17/2009
A/Salta/2093/2008/1/1410/|/EPI/ISL/65473
A/OSAKA/C/39/2008
CY050774/1/1410/A/New/York/3442/2009/2009/05/09/6//NA/
A/Hong/Kong/2637/2004/EPI/ISL/11833/A///H1N1/seasonal/NA/WSS964097
A/Victoria/214/2009/1/1410/|/EPI/ISL/60131
A/KANAGAWA/68/2008
GQ475931/1/1410/A/Ohio/04/2009/2009/01/28/6//NA/
A/Sri Lanka/13/2009
A/Mexic /2629/2009/1/1410/|/EPI/ISL/3 635
/Austria/404811/2008
A/Lisboa/24/2009
A/INCHEON/4432/2008/1/1410/|/EPI/ISL/28206
A/Johannesburg/21/2008
A/CHANTHABURI/341/2009/1/1410/|/EPI/ISL/65136
A/Annecy/2013/2009/1/1410/|/EPI/ISL/68855
A/St. Petersburg/11/2008
A/Paris/1208/2008
GQ476079/1/1410/A/Hawaii/17/2009/2 09 4/13 6//NA/
GU183801/1/1410/A/Thailand/CU/B589/2009/2009/07/10/6//NA/
CY074237/1/1410/A/California/VRDL224/2009/2009/04/29/6//NA/
GU183809/1/1410/A/Thailand/CU/B685/2009/2009/07/12/6//NA/
A/England/40/2004/EPI/ISL/157574/A///H1N1/seasonal NA/WSS964084
A/California/VRDL283/2009
A/Johannesburg/174/2008/1/1410/|/EPI/ISL/65642
CY089173/1/1410/A/Boston/94 2009 2009 03/13/6//NA/
A/Yamagata/137/2008/1/141 /|/EPI/ISL/71072
A/Lisboa/18/2008
A/Naypyitaw/M783/2008/1/1410/|/EPI/ISL/33559
CY100894/1/ 410/A Piura/WRAIR1699P 2008 8 12/28/6//NA/
A/Philippines/15/2009/1/1410/|/EPI/ISL/60117
A/Lisbo /7/20 8
A/Guatemala/22/2008
CY043539/1/1410/A/Kyoto/08K056/2009/ 009/01/07/6//NA/
CY089125/1/1410/A/Boston/70/2009/2009/03/21/6//NA/
A/Dniprodzerzinsk/ 64/2008
A/St. Petersburg/53/2008
A/Argentina/81/20 8
GQ475974/1/1410/A/North/Dakota/01/20 9/ 009/01/19/6//NA/
/Alberta/RV 85 2009/1/1410/|/EPI/ISL/66647
/Luxembourg/116/2008
CY069 83/1/14 0/A Alaska/WRAIR1114P/2 09/2009/03//6//NA/
A/Ghana/168/2008
CY080691/1/1410/A/Boston/20/2009/2009/02/11/6//NA/
A/Scotland/5/2007/1/1410/| EPI/ISL/63393
A/Perth/46/2008/1/1410/|/EPI/ISL/28093
A/SHIGA/18/2008 1/1410/|/EPI/ISL/26399
A/Sydney/605/2009/1/1410/|/EPI/ISL/32488
A/Lisboa/18/2009
A/Peru/WRAIR1299P/2007/1/1410/|/EPI/ISL/78565
CY069311/1/1410/A/Bogota/WRAIR0088N/2009/2009/06/10/6//NA/
A/Macau/2517/2009/1/1410/|/EPI/ISL/60135
A/Lisboa/32/2006
A/Georgia/04/2009/1/1410/|/EPI/ISL/60717
CY064841/1/1410/A/California/VRDL141/2 09/2 09/04/28/6//NA/
A/Kiev/4 /2008
A/Lisboa/31/2006
A/India/2757 2009
A/North/1/1410/Carolina/04/2009/|/EPI/ISL/3...
A/Puerto/1/1410/Rico/01/2008/|/EPI/ISL/33657
A/Luxembourg/1344/2008
A/Yamagata/16/2009/2009
A Marseille/1148/2009/1/1410/|/EPI/IS /6 089
A/British/1/1 10/Columbia RV0035/2 09/|/EPI/ISL/66649
A/Virginia/03/2008/1/1410/|/EPI/ISL/28332
A/Belgium/812/2008
A/South Korea/WRAIR 238P/2009
A/Madagascar/6054/2009/1/1 10/|/EPI/ISL/68858
/Illinois/16/2008/1/1410/|/EPI/ISL/28295
CY080652/1/1 1 /A/Boston/13/2009/ 009/02/10/6//NA/
A/VICTORIA/5 9/2009/1/1410/|/EPI/ISL/66759
CY069375/1/1410/A/South/Dakota/WRAIR1113P/2009/2009/03/01/6//NA/
HQ291918/1/1410/A/Taiwan/11526/2008/2008/12/01/6//NA/
CY100942/1/1410/A/Sullana/WRAIR 7 7P/2 9/2009/02/21/6//NA/
CY100822/1/1410/A/Kuwait/WRAIR1119P/20 9/2009/01/01/6//NA/
A/Texas/57/2009/1/1410/|/EPI/ISL/61862
A/Lisboa/25/2009
A/Taiwan/1026/2009
CY074133/1/1410/A/California/VRDL200/20 9/2009/04/30/6//NA/
Paris/1093/2009/1/ /65510
A/Kenya/4225/2009 1/141 /|/EPI/ISL/61868
A/Missouri/05/2009/1/ 410/|/EPI/ISL/34733
A/Lisboa/3/2008
A/NEW/1/1410/CALEDONIA/ /2009/|/EPI/ISL/6512
CY070913/1/14 0/A/California/VRDL151/ 0 9/2009/04/28/6//NA/
A/Guatemala/866/2009/1/1410/|/EPI/ISL/60716
A/MIYAGI/35/2008
A/Florida/28/2008/1/ 4 0/|/EPI/ISL/28 7
A/Matagalpa 179/2009/ /1410/|/EPI/ISL/33648
A/New Jersey/16/2007
A/Bangladesh/3003/2008/1/ 41 /| EPI/ISL 3367
A/SHIMANE/117/2008
A/Wisconsin/12/2008/1/1410/|/EPI/ISL/26 45
A/Santiago/4689/2008
A/Iceland/8064/2009
A/Mexico/4971/2008/1/1410/|/EPI/ISL/27637
HQ291899/1/1410/A/Taiwan/0045/2006/2006/05/24/6//NA/
CY074141/1/1410/A/California/VRDL202/2009/2009/04/29/6//NA/
A Guyane/8190/2008
CY07089 /1/1410/A/California/VRDL149/2 09/2009/04/27/6//NA/
A/Hawaii/58/2008
GQ896377/1/141 /A Wisconsin/14/2009/2009/05/22/6//NA/
JN582061/1/1410/A/New/York/08/1326/2008/2008/02/13/6//NA/
CY089759/1/1410/A/Boston/87/2009 2 09 2/14/6//NA/
A/Lisboa/28/2008
A/CapeTown/124/2008
A/T xas/35/2008/1/1410/|/EPI/ISL/33732
A/yokohama/91/20 7/1/1410/|/EPI/ISL/28731
CY074285/1/1410/A/California/VRDL235/2009/2009/04/29/6//NA/
GQ896371/1/1410/A/Utah/12/2009/2009 05/1 /6//NA/
A/Lisboa/35/2006
A/NIIGATA/1150 2008/1/1410/| EPI/ISL/28003
A/Kisii/7541/2008/1/1410/|/EPI/ISL/28471
A/BRISB NE/87/20 9/1/1410/|/EPI/ISL/60134
A/Cambodia/21/2007/1/1410/|/ I/I L/28585
CY100966/1/1410/A/Maracay/WRAIR1729P 20 8/2008/09/03/6//NA/
A/Kenya/4250/2009/1/1410/|/EPI/ISL/702 6
A/Lisboa/21/2009
GQ476061/1/1410/A/Illinois/06/2009/2009/ 3/ 2
A/Virginia/01/2009/1/1410/|/EPI/ISL/33806
A/Ghana/FS/09/791/2009/1/141 /| EPI/ SL/60086
A/Marrakech/589/2009
A/Luhansk/18/2008
A/SEOUL/4437/2008/1/1410/|/EPI/ISL/28208
A/Kenya/1432/2008
A/Maryland/07/2008/1/1410/|/EPI/ISL/28383
A/Flanders/G771/20 9/1/1410/|/EPI/ISL 65508
A/EHIME/38/2008/1/1410/|/EPI/ISL/28170
A/OKAYAMA/14/2008/1/1410/|/EPI/ISL/28007
A/Honduras/330/2009/1/1410/|/EPI/ISL/33604
CY080987/1/1410/A/Boston/88 2009/20 9/02/1 /6// A/
GQ475900/1/1410/A/Indiana/05/2009/2009/01/23/6//NA/
A/Paris/160/20 7/EPI/ISL/157392/ /seasonal/NA/W S964105
CY10 950/1/14 0/A Piura/WRAIR1708P/ 009/2009/03/27/6//NA/
A/North/1/1410/Dakota 01/2008/|/EPI/ISL/28310
A/Massachusetts/ 8/2008/ /1410/|/EPI/ISL/ 7647
A/Lisboa/13/2009
HQ256609/1/1410/A/Myanmar/M061/2009/2009/06/27/6//NA/
A/Peru/WRAIR1310P/2007/1/1410/|/EPI/ISL/78567
A/Bratislava/149/2009
A/New/1/14 0/Jersey/15/ 7/|/EPI/ISL/71839
A/Lisboa/29 2008
A/New/Caledonia/20/1999/EPI/ISL/22626/A///H1N1/seasonal/NA/WSS964089
A/St. Petersburg/62/2008
/Lisboa/5/20 8
A/Vietnam/289/20 8
A/Dakar/06/2008
A/Vladivostok/03/2008/1/1410/|/EPI/ISL/33690
A/Hokkaido/08H024/2009
CY073855/1/1410/A/California/VRDL175/2009/2009/04/28/6//NA/
A/Fiji/7/2009 / /|/EPI/ISL/6 2
A/Bangladesh/6666/2008/1/1410/|/EPI/ISL/3 67
L sboa/1/2 8
A/NAIROBI/2/2009/1/1410/|/EPI/ISL/78686
A/Paris/910/2008
A/B itish/1/141 /Columbia/RV1585/2007/|/EPI/ISL/21859
A/Paris/639/2008/1/1410/|/EPI/ISL/90990
A/Beijing/Chaoyang/11405/2009
A/Lisboa/2/2006
A/Norway/1736/2007/1/1410/|/EPI/ISL/254 6
GQ475940/1/14 0/A/Montana/03/2009/2009/01/14/6//NA/
/Pennsylvania/12/2008/1/1410/|/EPI/ISL/28368
CY064873/1/1410/A/California/VRDL146/2009/2009/04/25/6//NA/
CY074661/1/1410/A/California/VRDL380/2009/2009/04/27/6//NA/
A/Lisboa/03 2009
A/Lisboa/16/2008
A/Tottori/08T010/2008
A/Stockholm/28 2008/1/1410/|/EPI ISL/70666
A/Hong Kong/1975/2009
A/Fujian/Gulou/1581/2009/1/1410/|/EPI/ISL/6...
A/Iceland/4/2008/1/1410/|/EPI/ISL/65389
GQ475908/1/1410/A/Kansas/01/2009/20 9/ 1/29 6//NA/
A/Taiwan/5857/2008
A/Stockholm/5/2009/1/1410/|/EPI/ISL/70668
A/Seychelles 2231 2008/1/1410/|/EPI/ISL/653 8
FJ380948/1/1410/A/Finland/11/2008/2008/ 1/ 7/6//NA/
A/Thessaloniki/24/2005/EPI ISL/2542 /A //H N1/seasonal/NA/WSS964095
CY087279/1/1410/A/Hong/Kong/62768/2008/2008 //6//NA/
A/Saskatchewan/RV1039/2009/1/1410/|/EPI I L...
A/Vladivostok/04/2008/1/1410/|/EPI/ISL/33691
A/New/1/1410/Caledonia/6/2008/|/EPI/ISL/28102
A/Paraguay/61/2009/1/1410/|/EPI/ISL/33621
GQ475948/1/1410/A/Rhode/Island/ 1 2009/ /01/27/6//NA/
CY080763/1/1410/A/Boston/36/2009/2009/02/24/6//NA/
GU271952/1/1410/A/Thailand/CU/B97/2009/2009/06/22/6//NA/
A/Massachusetts/05/20 7 1/1410 |/EPI ISL/15455
A/Dakar/14/2008
CY074205/1/1410/A/California/VRDL220/2009/2009/04/29/6//NA/
A/Ghana FS/205/2008
A/Qu bec/RV0984/2009/1/14 0/|/EPI/ISL 33649
A/Illin is/12/2009
A/Lisboa/27/2008
GQ476129/1/1410/A/Montana/02/2009/2009/01/02/6//NA/
/Nebraska/ 7 2008/1/1410/|/EPI/ISL/283 6
CY069343 1/1410/A/Texas/WRAIR1052P 2009/2009/01/09/6//NA/
GQ476012/1/14 0/A North/Dakota/ 3/20 9/2 09/03 01/6//NA/
A/Florida/29/2008
/DAEJEON/4494/2008
A/M rtinique/19/2 08
A/St. Petersburg/75/2008
A/Buenos/1/1410/Aires/1306/2008/|/EPI/ISL/65472
A/Santiago/5087/2008/1/1410/|/EPI/ISL/23858
CY074341/1/1410/A/California/VRDL249/2009/2009/04/29/6//NA/
A/Ghana/FS/216/2008/1/1410/|/EPI/ISL/65463
A/Johannesburg/279/2008/1/1410/|/EPI/ISL/28096
A/Waikato/2/2009/1/1410/|/EPI/ISL/60126
A/Finland/514/2009/1/1410/|/EPI/ISL/60088
A/Taiwan/639/2008/1/1410/|/EPI/ISL/28323
A/Thail nd/ 78/2008
A/Ukraine/31 / 8
CY069487/1/1410/A/Louisiana/WRAIR1170P/2009/2009/02//6//NA/
A/Valparaiso/5366/2008/1/1410/|/EPI/ISL/23865
A/Hong Kong/3195/2008
A/Th iland/874/20 8/ /1410/|/ I/I /33664
A/Tottori/52/2008
A/Venezuela/3571/2008/1/1410/|/EPI/ISL/26243
A/PHILIPPINES/3314/2009/1/1410/|/EPI/ISL/6090
A/Nagasaki/07N035/2008
GQ475905/1/1410/A/Kentucky/01/20 9/2009///6//NA/
A/Liaoning/Huanggu/1144/20 9
CY080971/ /1410/A/Boston/85/2009/2009/02/12/6//NA/
A/Sweden/1/2009 1/1410/|/EPI/ISL/70643
CY089061/1/1410/A/Boston/23/2009/2009/02/18/6//NA/
GQ475980/1/1410/A Massachusetts/05/2009/2009/02/26/6//NA/
1008 6/1/1410/A/Iraq/WRAIR1683P/ 09/2 09/ 3//6//NA/
CY068677/1/1410/A/Singapore/GP101/2009/2009/03/20/6//NA/
A/Belgium/850/2008
A/Boston/67/2009
CY100806/1/141 /A/Nevada/WRAIR1117P/2009/2009/01/01/6//NA/
A Wyoming/10/2008/1/1410/|/EPI/ISL/19766
A/Lisboa/19/2009
CY053659/1/1410/A/Novosibirsk/3/20 / /04//6//NA/
CY100910/1/ 1 /A/Trujillo/WRAIR170 P/2 8/2008/12/26/6//NA/
A/St. Petersburg/ 2/2008
/Perth/33/20 8/1/1410/|/EPI/ISL/28582
A/Paris/1704/2009/1/1410/|/EPI/ISL/65509
A/Maryland/05/2008/1/1410/|/EPI/ISL 28302
A/CHIBA/86/2008/1/1410/|/EPI/ISL/26386
CY074389/1/1410/A/California/VRDL264/2009/2009/04/25/6//NA/
A/Lisboa/22/2006
A/Washington/25/2009
A/Michigan/14/2009/1/1410/|/EPI/ISL/6 719
GU112229/1/1410/A/Tehran/345/2009/2009/01/12/6//NA/
A/Taiwan/01/1986/EPI/ISL/10251/105058
GQ850597/1/1410/A/Shanghai/LWS1/2009/2009/01/03/6//NA/
A/Lisboa/77/2007
GQ475934/1/1410/A/Indiana/07/2009/2009/03/09/6//NA/
A/Austria/404342/2008
A/Vietnam/241/2008
A/Florida/27/2008/1/1410/|/EPI/ISL/60723
A/Michigan/31/2009/1/1410/|/EPI/ISL/77 36
/Pennsylvania/04/2009 1/1410/|/EPI/ISL 337 6
CY074637/1/1410/A/California/VRDL377/ 009/2009/04/27/6//NA/
A/Minnesota/04/2 09
A/Lisboa/05/2009
A/KOCHI/48/2008/1/1410/|/EPI/ISL/27998
A/Tennesse /03/20 9/1/1410/|/EPI/ISL/33809
B 
0.02
A/Brisbane/12/2009
A/Minnesota/23/2007/1/1410/|/EPI/ISL/15465
A/Kursk/01/2008
CY080851/1/1410/A/Boston/52/2009/2009/02/14/6//NA/
CY074421/1/1410/A/California/VRDL275/2009/2009/04/30/6//NA
A/Kericho/ 529/20 8/1/1410/|/EPI/ISL/28468
A/Kenya/2862/20 9/1/1410/|/EPI/ISL/66654
A/Lisboa/39/2008
A/Christchurch/20/2008
A/PERTH/21/2009/1/1410/|/EPI/ISL/66758
A/Vietnam/2036/2009/1/1410/|/EPI/ISL/69711
CY100854/1/1410/A/Washington/WRAIR1237P/2009/2009/02/01/6/ NA/
GQ476132/1/1410/A/Oregon/01/2009/2009/01/07/6//NA/
GQ476091/1/1410/A/Pennsylvania/01/2009/2009/01/07/6//NA/
A/Lisboa/6/2008
A/Niigata/08F188/2009
GQ476009/1/14 0/A/Virginia/06/ 0 9/200 / 5 05/6//NA/
/Chu gbuk 4385/2008/1/1410/|/EPI/ISL/65495
A/Lisboa/14/2009
GQ476118/1/1410/A/Ohio/03/2009/2009/01/15/6//NA/
A/Algeria/G804/2008
GQ476047/1/1410/A/Arkansas/01/2009/2009/02/08/6//NA/
GQ475926/1/1410/A/Virginia/03/2009/2009/02/18/6//NA/
A/Lisboa/25/2006
A/Kyrgyzstan/214/2009/1/1410/|/EPI/ISL/61865
A/Hong Kong/H090/682/V1/0//2009
HQ291908/1/1410/A/Taiwan/2832/2008/2008/10/06/6//NA/
A/Incheon/4532/2008/1/1410/|/EPI/ISL/65492
A/Mauritiu /403/ 8/1/1410/|/EPI/ISL/65437
A/Sydney/601/2009/1/1410/|/EPI/ISL/60116
GQ475969/1/1410/A/New/York/63/2009/2009/03/31/6//NA/
A/Lisboa 8/2008
A/Berlin/59/2008/1/141 /|/EPI/ISL/65494
CY074597/1/1410/A/California/VRDL358/2009/2009/06/07/6//NA
A/CHIBA/89/2008/1/1410/|/EPI/ISL/28169
A/Massachusetts/12/2008/1/1410/|/EPI/ISL/28366
A/England/494/2006/1/1410/|/EPI/ISL/25707
A/Algeria/G773/2008/1/1410/|/EPI/ISL/65459
A/Hong Kong/70/2009
A/Perth/33/2009/1/1410/|/EPI/ISL/60123
A/Victoria/501/2008/1/1410/|/EPI/ISL/23119
GQ475883/1/1410/A/West/Virginia/02/2009/2009/03/18/6//NA/
A/Kawasaki/UTK/4/2009
A/Vietnam/1808/2009/1/1410/|/EPI/ISL/69712
A/Hong/Kong/2765/2004/EPI/ISL/ 57578/A///H1N1/seasonal NA/WSS964086
A/Norway/1747/07/1/1410/|/EPI/ISL/23298
A/GYEONGGIBUK/4503/2008
A/Lisboa/7/2006
A/WELLINGTON/84/2009/1/1410/|/EPI/ISL/60136
A/Hubei/Wujiagang/133/2009/1/1410/|/EPI/ISL...
A/Victoria/07159220/2007/1/1410/|/EPI/ISL/28584
CY100926/1/1410/A/Pucallpa/WRAIR1704P/2009/2009/01/14/6/ NA
CY080675/1/1410/A/Boston/17/2009/2009/02/10/6//NA/
A/Brazil/146/2009
A/Ghan /172/2008/1/14 0/|/EPI/ SL/65441
A/Washington/02/2009/1/1410/|/EPI/ISL/33807
AB521100/1/1410/A/Yamagata/36/2009/2009/01/14/6//NA/
A/Singapore/42/2008/1/1410/|/EPI/ISL/28384
A/Tahiti/3/2009/1/1410/|/EPI/ISL/60132
A/Tennessee/11/2008/1/1410/|/EPI/ISL/28324
A/Slovenia/123/2008
A/Lisboa/14/2008
GQ476072/1/1410/A/Florida/03/2009/2009/02/06/6//N /
A/Yamagata/125/2008/1/1410/|/EPI/ISL/71068
A/Illinois/05/2009/1/1410/|/EPI/ISL/33728
GQ476109/1/1410/A/New/York/56/2009/2009/02/10/6//NA/
A/Chubut/102197/2008
CY081019/1/1410/A Boston/93/2009/2009/03/17/6//NA/
GQ476140/1/1410/A/Alaska/01/2009/2009/01/29/6//NA/
CY100774/1/1410/A/Texas/WRAIR1053P/2009/2009/01/01/6//NA
A/Colorado/08/2008/1/1410/|/EPI/ISL/28378
A/Brazil/5943/2008
A/Gansu/Ch ngguan1129/2007/1/1410/|/EPI/ISL/20448
A/Belem/241/2008
CY074373/1/1410/A/California/VRDL256/2009/2009/04 29/6//NA/
A/Guatemala/602/2008
A/NAGANO/1204/2008/1/1410/|/EPI/ISL/27999
JN256686/1/1410/A/Hong/Kong/H090/718/V1/0//2009/2009/07/15/6//NA/
A/England/684/2007/1/1410/|/EPI/ISL/254 5
A/Ohio/02/2009/1/1410/|/EPI/ISL/33808
A/Yamagata/68/2008/1/1410/|/EPI/ISL/71063
A/Singapore/07/2009/1/1410/|/EPI/ISL/34736
CY080835/1/1410/A/Boston/49/2009/2009/02/13/6//NA/
CY073839/1/1410/A/California/VRDL163/2009/2009/04/29/ //NA/
A/Paris/1154/2008
CY073823/1/1410/A/California/VRDL154/2009/2009/04/28/6//NA/
A/Colorado/17/2008/1/1410/|/EPI/ISL/33652
CY074093/1/1410/A/California/VRDL186/2009/2009/04/29/6//NA/
A/Lisboa/48/2005
A/Kansas/UR06/0104/2007/1/1410/|/EPI/ISL/7867
A/South/ /14 0/Australi /1/2008/|/EPI/ISL/22972
A/Paris/445/2008/1/1410/|/EPI/ISL/65483
A/Jilin/Chuanying/1318/2008/1/1410/|/EPI/ISL/33707
A/Florida/21/2008/1/1410/|/EPI/ISL/27641
JF972564/1/1410/A/Mississippi/03/2001/2001/01/25/6//NA/
A/Argentina/303/2008/1/1410/|/EPI/ISL/25779
CY074173/1/1410/A/California/VRDL215/2009/2009/04/28/6//NA/
A/Brisbane/1/2009/1/1410/|/EPI/ISL/32490
A/El Salvador/468/2008
A/Uganda/0511/2009/1/1410/|/EPI/ISL/66659
A/Washington/01/2008
CY100798/1/1410/A/Texas/WRAIR1115P/2009/2009/03/01/6//NA/
CY080939/1/1410/A/Boston/72/2009/2009/03/24/6//NA/
A/Washington/08/2008/1/1410/|/EPI/ISL/28333
A/Lisboa/19/2008
A/Florida/02/2008/1/1410/|/EPI/ISL/19087
A/Maryland/04/2007
A/Stockh lm/6/ 009/1/1410/|/EPI/ISL/70806
A/Lisboa/94/2005
A/Kentucky/08/2009
A/Cayman Islands/5082/2009
A/Singapore/88/2009/1/1410/|/EPI/ISL/34737
A/Kazakhstan/2600/2008
A/India/7308/2008/1/1410/|/EPI/ISL/33659
GQ475914/1/1410/A/Hawaii/03/2009/2009/01/29/6//NA/
CY089109/1/1410/A/Boston/59/2009/2009/02/28/6//NA/
CY074125/1/1410/A/California/VRDL194/2009/2009/04/27/6//NA/
A/England/26/2008
A/IBARAKI/68/2008/1/1410/|/EPI/ISL/28175
A/Managua/1985.01/2008/1/1410/|/EPI/ISL/62906
GQ457553/1/1410/A/Saskatchewan/5131/2009/2009/06/19/6//NA/
CY080612/1/1410/A/Boston/95/2009/2009/04/01/6//NA/
CY074485/1/1410/A/California/VRDL292/2009/2009/04/30/6//NA/
A/Idaho/01/2009/1/1410/|/EPI/ISL/61874
A/AOMORI/19/2008/1/1410/|/EPI/ISL/28166
CY053671/1/1410/A Novosibirsk 7/2009 009/04//6 /NA/
CY100958/1/1410/A/Puc llpa/WRAIR1709P/2 09/2009/01/20/6//NA/
A/Georgia/1269/1/1410//36G//2009/|/EPI/ISL/...
A/GWANGJU/4324/2008/1/1410/|/EPI/ISL/28202
GU271968/1/1410/A/Thailand/CU/H565/2009/2009/09/02/6//NA/
A/SHIMANE/1/2009/1/1410/|/EPI/ISL/28187
A/Cameroon/073/2008/1/1410/|/EPI/ISL/65406
A/Rabat/109/2009/1/1410/|/EPI/ISL/65489
GQ475869/1/1410/A/New/York/02/2009/2009/02/14/6//NA/
A/Honduras/100/2008
A/SAMOA/10/2009/1/1410/|/EPI/ISL/65128
CY069551/1/1410/A/Texas/WRAIR1254P/2009/2009/03//6//NA/
A/Brazil/815/2009
CY100934/1/1410/A/Santa/Cruz/WRAIR1706P/2008/2 08/12/09/6 /NA/
A/WELLINGTON/218/2009/1/1410/|/EPI/ISL/65150
A/Iceland/8599/200 410/|/EPI/ISL/65514
A/Arizona/13/2008/1/1410/|/EPI/ISL/27639
A/Paraguay/67/2009
A/Moscow/38/2008
A/Buenos/1/1410/Aires/825511/2008/|/EPI/ISL/65471
CY100830/1/1410/A/Japan/WRAIR1226P/2009/2009/02/01/6//NA/
GQ476155/1/1410/A/New/Mexico/01/2 9/2009/01/07/6//NA/
A/Michigan/01/2009/1/1410/|/EPI/ISL/33745
A/Singapore/6/1986/EPI/ISL/6905/58244
A/England/594/2006/1/1410/|/EPI/ISL/25708
A/Peru/WRAIR1505P/2007/1/1410/|/EPI/ISL/78572
A/Naypyitaw M499/2008/1/14 0/|/EPI/ISL/33557
A/Thailand/839/2008
GQ476088/1/1410/A/Nebraska/05/2009/2009/03/07/6//NA/
CY050662/1/1410/A/New/York/3150/2009/2009/04/27/6//NA/
A/Ghana/FS/09/718/2009/1/1410/|/EPI/ISL/60087
A/Seychelles/2239/2008/EPI/ISL/60835/A///H1N1/seasonal/NA/WSS964136
GQ475945/1/1410/A/Washington/03/2009/2009/01/21/6//NA/
A/Fukushima/141/2006/EPI/ISL/20229/A///H1N1/seasonal/NA/WSS964101
A/Perth/30/2009
CY074357/1/1410/A/California/VRDL252/2009/2009/04/29/6//NA/
A/Algeria/G825/2008
CY100870/1/1410/A/Nevada/WRAIR1257P/2009/2009/02/01/6//NA
A/Texas/16/2008/1/1410/|/EPI/ISL/26239
AB521103/1/1410/A/Yamagata/51/2009/2009/01/26/6//NA/
A/KOBE/49/2008
AB521101/1/1410/A/Yamagata/26/2009/2009/01/17/6//NA/
CY074333/1/1410/A/California/VRDL245/2009/2009/04/29/6//NA/
A/Indiana/08/2009
A/Guangdong/Futian/139/2009/1/1410/|/EPI/IS...
AB521111/1/1410/A/Yamagata/77/2009/2009/02/10/6//NA/
A/Lisboa/4/2008
/Stockholm/7/2009/1/1410/|/EPI/ISL/70800
A/Lisboa/23/2009
A/Sweden/8/2008/1/141 /|/EPI/ISL/70648
CY050478/1/1410/A/New/York/1692/2009/2009/04/27/6//NA/
A/Lisboa/07/2009
A/Fujian/Gulou/1367/2009/1/1410/|/EPI/ISL/3...
A/TAK/334/2009/1/1410/|/EPI/ISL/65129
GQ475877/1/1410/A/New/York/62/2009/2009/03/17/6//NA/
A/Delaware/01/2008/1/1410/|/EPI/ISL/28285
GQ475886/1/1410/A/Nebraska/06/2009/2009/03/22/6//NA/
A/Lisboa/13/2008
A/Lisboa/2/2008
A/Guangdong/Zhuangzuyaozuzizhi/51/200.../1/1410
CY074309/1/1410/A/California/VRDL238/2009/2009/04/29/6//NA/
A/Hong/Kong/3192/2008/EPI/ISL/65482/A///H1N1/seasonal/NA/WSS964139
CY100790/1/1410/A/Oklahoma/WRAIR1110P/2009 2009/03/01/6 /NA/
CY073863/1/1410/A/California/VRDL229/2009/2009/04/29/6//NA/
A/KOL/2465/2009
HQ291915/1/1410/A/Taiwan/8949/2008/2008/12/11/6//NA/
A/Quebec/RV3060 9
A/Arizona/13/2007/1/1410/|/EPI/ISL/15893
CY080795/1/1410/A/Boston/41/2009/2009/02/27/6//NA/
A/Lisboa/16/2009
A/Yamagata/128/2008
GQ476126/1/1410/A/Florida/07/2009/2009/03/25/6//N /
A/Texas/27/2008/1/1410/|/EPI/ISL/27653
CY074277/1/1410/A/California/VRDL232/2009/2009///6//NA/
A/BEIJING/HUAIROU/185/2008
A/Texas/31/2007/1/1410/|/EPI/ISL/15409
A/Algeria/G864/2008/1/1410/|/EPI/ISL/65468
A/Managua/954.02/2008/1/1410/|/EPI/ISL/33848
A/Quebec/Rv1107/2009/1/1410/|/EPI/ISL/33632
CY080803/1/1410/A/Boston/42/2009/2009/03/01/6//NA/
A/Hawaii/19/2008
GQ476096/1/1410/A/Hawaii/01/2009/2009/01/13/6//NA/
A/Tak/427/2009/1/1410/|/EPI/ISL/66657
A/French/1/1410/Polynesia/2001/2009/|/EPI/I...
GQ475972/1/1410/A/Wisconsin/06/2009/2009/03/03/6//NA/
A/Lisboa/11/2008
CY053655/1/1410/A/Novosibirsk/151/2009/2009/05//6//NA/
HQ256619/1/1410/A/Myanmar/M256/2009/2009/07/16/6//NA/
A/Stockholm/22/2008
A/SAMOA/9/2009/1/1410/|/EPI/ISL/60899
CY069391/1/1410/A South/Carolina/WRAIR1116P/2009/2009/03/01 6//NA/
A/New/1/1410/Jersey/32/2008/|/EPI/ISL/33750
GQ475874/1/1410/A/Wisconsin/02/2009/2009/01/07/6//NA/
A/Argentina/295/2008/1/1410/|/EPI/ISL/25778
A/Lisboa/9/2008
A/Kenya/0793/2008/1/1410/|/EPI/ISL/33677
GQ476035/1/1410/A/Hawaii/13/2009/2009/04/16/6//NA/
A/Thailand/1577/2007/1/14 0/|/EPI/ SL/22372
GQ476143/1/1410/A/Vermont/01/2009/2009/02/09/6//NA/
A/Uganda/0132/2009/1/1410/|/EPI/ISL/66658
CY100974/1/1410/A/Cusco/WRAIR1730P/2008/2008/08/20/6//NA/
A/SHIZUOKA/C/21/2009/1/1410/|/EPI/ISL/28194
CY089783/1/1410/A/Boston/32/2009/2009/02/20/6//NA/
GQ475880/1/1410/A/Tennessee/01/2009/2009/01/12/6//NA/
HQ291910/1/1410/A/Taiwan/3293/2008/2008/05/02/6//N /
GQ457554/1/1410/A/Saskatchewan/5350/2009/2009/06/18/6//NA/
A/Managua/5007.01/2008/1/1410/|/EPI/ISL/62912
A/Fujian/Gulou/1896/2009/1/1410/|/EPI/ISL/6...
A/Nigeria/0023/2008/1/1410/|/EPI/ISL/25811
A/California/VRDL167/2009
CY089085/ 410/A/Bost n/46/2009/2009/03/01/6//NA/
HQ291909/1/1410/A/Taiwan/2885/2008/2008/11/24/6//NA/
CY100902/1/1410/A/Piura/WRAIR1700P/2009/2009/01/01 6 /NA
A/Johannesburg/45/2008/1/1410/|/EPI/ISL/ 3112
A/Indiana/06/2009/1/1410/|/EPI/ISL/33812
GQ475894/1/1410/A/California/01/2009/2009/01/07/6//NA/
A/Brisbane/59/2007/EPI/ISL/71838/A///H1N1/seasonal/NA/WSS964111
A/IWATE/40/2008/1/1410/|/EPI/ISL/27996
GQ475847/1/1410/A/New/Mexico/02/2009/2009/01/14/6//NA/
A/Washington/12/2008/1/1410/|/EPI/ISL/33813
A/Pennsylvania/14/2008/1/1410/|/EPI/ISL/33644
A/Samara/46/2008
A/Illinois/16/2007/1/1410/|/EPI/ISL/19084
A/Washington/05/2 08/1/1410/|/EPI/ISL/25804
A/Brisbane/10/2009/1/1410/|/EPI/ISL/32493
A/Lisboa/4/2006
A/KwaZulu/1/ 410/Natal/272/2008/|/EPI/ISL/65639
A/Denmark/27/2007/1/1410/|/EPI/ISL/25442
A/Maryland/04/2008/1/1410/|/EPI/ISL/28301
CY050550/1/1410/A/New/York/3095/2009/2009/04/29/6//NA/
A/Hong/1/1410/Kong/33597/2009/|/EPI/ISL/68854
A/SAPPORO/90/2008/1/1410/|/EPI/ISL/28010
A/Kenya/1329/2010/1/1410/|/EPI/ISL/98941
A/Georgia/20/2006/1/1410/|/EPI/ISL/21323
A/FUKUI/91/2008
A/USSR/90/77/EPI/ISL/66105/230612
A/Yangon/M195/2008/1/1410/|/EPI/ISL/33555
A/Hong/Kong/1856/2008/EPI/ISL/60838/A///H1N1/seasonal/NA/WSS964138
A/North/1/1410/Carolina/02/2008/|/EPI/ISL/19770
A/Solomon/Islands/3/2006/EPI/ISL/13324/A///H1N1/seasonal/NA/WSS964131
A/Hong/Kong/2652/20 6/EPI/ISL/157436/A/ /H1N1/seasonal/NA/WSS964099
A/St. Petersburg/83/2008
HQ256643/1/1410/A/Myanmar/M428/2009/2009/08/11/6//NA/
A/Lisboa/10/2008
GQ476082/1/1410/A/Arkansas/02/2009/2009/03/01/6//NA/
CY089101/1/1410/A/Boston/54/2009/2009/02/22/6//NA/
A/Jilin/Chaoyang/157/2009/1/1410/|/EPI/ISL/...
CY074117/1/1410/A/California/VRDL193/2009/2009/04/29/6//NA/
A/Pennsylvania/13/2007/ /1410/|/EPI/ISL/23897
A/Marrakech/510/2009
A/Lisboa/15/2008
A/Paris/781/2008/1/1410 |/EPI/ISL 65485
A/Isr el/1/2009/1/1410/|/EPI/ISL/65499
A/Boston/06/2009
A/Philippines/1159/2008
A/SHIZUOKA/C/10/2009
A/South/1/1410/Australia/12/2009/|/EPI/ISL/...
A/Argentina/110/2008/1/1410/|/EPI/ISL/25781
A/Niigata/08F093/2009
A/Hong/1/1410/Kong/18106/2009/|/EPI/ISL/65516
A/Nagasaki/07N020/2008/1/1410/|/EPI/ISL/70169
A/Kenya/2743/2009/1/1410/|/EPI/ISL/61877
CY080819/1/1410/A/Boston/45/2009/2009/03/03/6//NA/
A/Perth/1/2009/1/1410/|/EPI/ISL/32484
A/Lisboa/41/2008
A/Texas/36/2008/1/1410/|/EPI/ISL/33733
A/Hong/1/1410/Kong/26552/2009/|/EPI/ISL/66653
HQ256645/1/1410/A/Myanmar/M470/2009/2009/08/20/6//NA/
GQ476053/1/141 /A/New/York/65/2009/2009/03/09/6//NA/
A/BRISBANE/96/2009/1/1410/|/EPI/ISL/65152
A/Lisboa/15/2009
A/Egypt/10/2007/EPI/ISL/106505/A///H1N1/seasonal/NA/WSS964117
A/Hong/1/1410/Kong/852/2008/|/EPI/ISL/65426
CY100814/1/14 0/A/Texas/WRAIR1118P/2 09/2009/06/01/6 /NA/
CY093127/1/1410/A/Boston/47/2009/2009/02/12/6//NA/
A/Belgium/G257/2008
HQ256649/1/1410/A/Myanmar/M533/2009/2009/09/04/6//NA/
A/Oregon/02/2009
A/Yokohama/78/2008
A/NIIGATA/1088/2008/1/1410/|/EPI/ISL/28002
A/Indiana/01/2008/1/1410/|/EPI/ISL/15873
A/Kiev/313/2008
A/India/3414/2009
A/Moscow/02/2009
A/Philippines/3914/2008
A/New/1/1410/Jersey/30/2008/|/EPI/ISL/33747
A/Lisboa/40/2008
A/Chile/1/1983/EPI/ISL/6900/58149
AB465323/1/141 /A/Yokohama/30/2008/2008/01/28/6//NA/
A/Lisboa/12/2008
A/Buenos/1/1410/Aires/R13/2008/|/EPI/ISL/65360
A/Tula/31/2008
A/Guatemala/663/2008
AB521105/1/1410/A/Yamagata/45/2009/2009/01/21/6//NA/
A/Lisboa/06/2009
A/Lisboa/24/2006/A/Lisboa/16/2006
A/Thailand/CU/B42/2009
A/England/557/2007
GQ476149/1/1410/A/New/York/64/2009/2009/04/09/6//NA/
A/St. Petersburg/85/2 08
A/Jamaica/2968/2009/1/1410/|/EPI/ISL/33607
A/Cameroon/080/2008
AB521112/1/1410/A/Yamagata/80/2009/2009/02/18 6//NA/
A/Florida/24/2008/1/1410/|/EPI/ISL/28287
A/Lisboa/2/2009
CY100838/1/1410/A/Illinois/WRAIR1233P/2009/2009/03/01/6//NA/
A/Costa Rica/5150/2009
AB465321/1/1410/A/Yokohama/34/2008/2008/01/28/6//NA/
A/England/411/ /1/1410/|/EPI/ISL/65477
GQ47610 /1/1410/A/Pennsylv nia/12/2009/2009/01/29 6//NA/
A/Israel/10/2009/1/1410/|/EPI/ISL/65498
A/Lisboa/17/2008
A/Nebraska/WRAIR1247P/2009
GQ475965/1/1410/A/Ohio/06/2009/2009/02/03/6//NA/
GQ476024/1/1410/A/Michigan/07/2009/2009/04/08/6//NA/
CY053657/1/1410/A/Novosibirsk/2/2009/2009/04//6//NA/
A/Belgium/858/2008
A/Lisboa/35/2005
GQ475920/1/1410/A/California/03/2009/2009/02/04/6//NA/
A/SURAT/1/1410/THANI/337/2009/|/EPI/ISL/65130
A/California/VRDL371/2009
GQ475951/1/1410/A/Kentucky/03/2009/2009/02/02/6//NA/
A/Puerto/1/1410/Rico/02/2009/|/EPI/ISL/33708
A/Niigata/08F031/2009
A/Taiwan/693/2009/1/1410/|/EPI/ISL/60130
A/Cameroon/08/235/2008/1 410/|/E I /65497
A/Lisboa/20/2008
A/North/1/1410/Carolina/07/2008/|/EPI/ISL/28372
A/Jilin/Chaoyang1258/2008/1/1410/|/EPI/ISL/28298
A/Bangladesh/9067/2008/1/141 /|/EPI/ISL/33671
A/Lisboa/20/2009
A/Hawaii/41/2008/1/1410/|/EPI/ISL/28376
A/Ireland/744/2008
A/MACAU/3436/2009/1/1410/|/EPI/ISL/65127
HQ533869/1/1410/A/Tianjin/15/2009/2009///6//NA/
CY100918/1/14 0/A/Trujill /WRAIR170 P/2008/2008/12/28/6//NA
GQ475962/1/1410/A/Montana/01/2009/2009/01/04/6//NA/
GQ475856/1/1410/A/South/Dakota/01/2009/2009/01/22/6//NA/
GU112230/1/1410/A/Tehran/359/2009/2009/01/16/6//NA/
A/HAMAMATU/C/988/2009/1/1410/|/EPI/ISL/65151
A/Ontario/RV0131/2007/1/1410/|/EPI/ISL/22256
A/Minnesota/01/2 08/1/ 410/|/EPI/ISL/2 792
GQ4760 /1/14 0/A/Maryland/01/2009/2009/01/18/6//N /
A/Prague/33/2009/1/1410/|/EPI/ISL/65503
A/South/1/1410/Australia/11/2009/|/EPI/ISL/...
A/SAPPORO/66/2008/1/1410/|/EPI/ISL/26396
A/Netherlands/345/2007/EPI/ISL/60837/A///H1N1/seasonal/NA/WSS964114
JN676131/1/1410/A/Thailand/Siriraj/3043/2009/2009/10/06/6//NA/
CY074469/1/1410/A/California/VRDL289/2009/2009/05/01/6//NA/
A/Fujian/Gulou/1292/2009/1/1410/|/EPI/ISL/3...
A/Sichuan/Dongqu/1836/2009/1/1410/|/EPI/ISL...
A/Lisboa/6/2006
JN256687/1/1410/A/Hong/Kong/H090/744/V1/0//2009/2009/07/24/6//NA/
A/Norway/1735/2007/EPI/ISL/106540/A///H1N1/seasonal/NA/WSS964128
A/Michigan/06/2008/1/1410/|/EPI/ISL/27649
A/Pennsylvania/09/2008/1/1410/|/EPI/ISL/26237
A/Hawaii/42/2008/1/1410/|/EPI/ISL/28377
CY100846/1/1410/A/Alabama/WRAIR1235P/2009/2009/04/ 1/6//NA/
A/Peru/WRAIR1300P/2007/1/1410/|/EPI/ISL/78566
A/Hawaii/28/2007/1/1410/|/EPI/ISL/33820
A/Minnesota/27/2008/1/1410/|/EPI/ISL/27650
EU551821/1/1410/A/Paris/963/2008/2008/01/04/6//NA/
GQ475997/1/ 410/A/Minnesota/01/ 09/2 09/01/1 /6//NA/
CY074101/1/1410/A/California/VRDL189/2009/2009/04/29/6//NA/
CY080899/1/1410/A/Boston/65/2009/2009/03/09/6//NA/
CY089045/1/1410/A/Boston/10/2009/2009/02/04/6//NA/
A/Minnesota/34/2008/1/1410/|/EPI/ISL/28371
A/Paris/1157/2008
A/Japan/WRAIR1230P/2009
A/Waikato/1/2009/1/1410/|/EPI/ISL/60125
A/Lisboa/17/2009
A/Salta/2093/2008/1/1410/|/EPI/ISL/65473
A/OSAKA/C/39/2008
CY050774/1/1410/A/New/York/3442/2009/2009/05/09/6//NA/
A/Hong/Kong/2637/2004/EPI/ISL/1 833/A///H1N1/seasonal/NA/WSS964097
A/Victoria/214/2009/1/1410/|/EPI/ISL/60131
A/KANAGAWA/68/2008
GQ475931/1/1410/A/Ohio/04/2009/2009/01/28/6//NA/
A/Sri Lanka/13/20 9
A/Mexico/2629/2009/1/1410/|/EPI/ISL/33635
A/Austria/404811/2008
A/Lisboa/24/2009
A/INCHEON/4432/2008/1/1410/|/EPI/ISL/28206
A/Johannesburg/21/2008
A/CHANTHABURI/341/2009/1/1410/|/EPI/ISL/65136
A/Annecy/2013/2009/1/1410/|/EPI/ISL/68855
A/St. Petersburg/11/2008
A/Paris/1208/2008
GQ476079/1/1410/A/Hawaii/17/2009/2009/04/13/6//NA/
GU183801/1/1410/A/Thailand/CU/B589/2009/2009/07/10/6//NA/
CY074237/1/1410/A/California/VRDL224/2009/2009/04/29/6//NA/
GU183809/1/1410/A/Thailand/CU/B685/2009/2009/07/12/6//NA/
A/England/40/2004/EPI/ISL/157574/A///H N1/seasonal/NA/WSS 64084
A/California/VRDL283/2009
A/Johannesburg/174/2008/1/1410/|/EPI/ISL/65642
CY089173/1/1410/A/Boston/94/2009/2009/03/13/6//NA/
A/Yamagata/137/2008/1/1410/|/EPI/ISL/71072
A/Lisboa/18/2008
A/Naypyitaw/M783/2008/1/1410/|/EPI/ISL/33559
CY100894/1/1410/A/Piu a/WRAIR1699P/2008/2008/12/28/6//NA/
A/Philippines/15/2009/1/1410/|/EPI/ISL/60117
A/Lisboa/7/2008
A/Guatemala/22/2008
CY043539/1/1410/A/Kyoto/08K056/2009/2009/01/07/6//NA/
CY089125/1/1410/A/Boston/70/2009/2009/03/21/6//NA/
A/Dniprodzerzinsk/164/2008
A/St. Petersburg/53/2008
A/Argentina/81/2008
GQ475974/1/1410/A/North/Dakota/01/2009/2009/01/19/6//NA/
A/Alberta/RV2859/2009/1/1410/|/EPI/ISL/66647
A/Luxembourg/116/2008
CY069383/1/1410/A/Alaska/WRAIR1114P/2009/2009/03//6//NA/
A/Ghana/168/2008
CY080691/1/1410/A/Boston/20/2009/2009/02/11/6//NA/
A/Scotland/5/2007/1/1410/|/EPI/ISL/63393
A/Perth/46/2008/1/1410/|/EPI/ISL/28093
A/SHIGA/18/2008/1/1410/|/EPI/ISL/26399
A/Sydney/605/2009/1/1410/|/EPI/ISL/32488
A/Lisboa/18/2009
A/Peru/WRAIR1299P/2007/1/1410/|/EPI/ISL/78565
CY069311/1/1410/A/Bogota/WRAIR0088N/2009/2009/06/10/6//NA/
A/Macau/2517/2009/1/1410/|/EPI/ISL/60135
A/Lisboa/32/2006
A/Georgia/04/2009/1/1410/|/EPI/ISL/60717
CY064841/1/1410/A/California/VRDL141/2009/2009/04/28/6 /NA/
A/Kiev/49/2008
A/Lisboa/31/2006
A/India/2757/2009
A/North/1/1410/Carolina/04/2009/|/EPI/ISL/3...
A/Puerto/1/1410/Rico/01/2008/|/EPI/ISL/33657
A/Luxembourg/1344/2008
A/Yamagata/16/2009/2009
A/Marseille/1148/2009/1/1410/|/EPI/ISL/60089
A/British/1/1410/Columbia/RV0035/2009/|/EPI/ISL/66649
A/Virginia/03/2008/1/1410/|/EPI/ISL/28332
A/Belgium/812/2008
A/South Korea/WRAIR1238P/2009
A/Madagascar/6054/2009/1/1410/|/EPI/ISL/68858
A/Illinois/16/2008/1/1410/|/EPI/ISL/28295
CY080652/1/1410/A/Boston/13/2009/2009/02/10/6//NA/
A/VICTORIA/549/2009/1/1410/|/EPI/ISL/66759
CY069375/1/1410/A/South/Dakota/WRAIR1113P/2009/2009/03/01/6//NA/
HQ291918/1/1410/A/Taiwan/11526/2008/2008/12/01/6//NA/
CY100942/1/1410/A/Sullana/WRAIR1707P/2009/2009/02/21/6//NA/
CY100822/1/1410/A/Kuwait/WRAIR1119P/2009/2009/01/01/6//NA/
A/Texas/57/2009/1/1410/|/EPI/ISL/61862
A/Lisboa/25/2009
A/Taiwan/ 026/2 09
CY074133/1/1410/A/California/VRDL200/2009/2009/04/30/6//NA/
A/Paris/1093/2009/1/1410/|/EPI/ISL/65510
A/Kenya/4225/2009/1/1410/|/EPI/ISL/61868
A/Missouri/05/2009/1/1410/|/EPI/ISL/34733
A/Lisboa/3/2008
A/NEW/1/1410/CALEDONIA/2/2009/|/EPI/ISL/65126
CY070913/1/1410/A/California/VRDL151/2009/2009/04/28/6//NA/
A/Guatemala/866/2009/1/1410/|/EPI/ISL/60716
A/MIYAGI/35/2008
A/Florida/28/2008/ /1410/|/EPI/ISL/ 8367
A/Matagalpa/179/2009/1/1410/|/EPI/ISL/33648
A/New Jersey/16/2007
A/Bangladesh/3003/2008/1/1410/|/EPI/ISL/33674
A/SHIMANE/117/2008
A/Wisconsin/12/2008/1/1410/|/EPI/ISL/26245
A/Santiago/4689/2008
A/Iceland/8064/2009
A/Mexico/4971/2008/1/1410/|/EPI/ISL/27637
HQ291899/1/1410/A/Taiwan/0045/2006/2006/05/24/6//NA/
CY074141/1/1410/A/California/VRDL202/2009/2009/04/29/6//NA/
A/Guyane/819 /20 8
CY070897/1/1410/A/California/VRDL149/2009/2009/04/27/6//NA/
A/Hawaii/58/2008
GQ896377/1/1410/A/Wisconsin/14/2009/2009/05/22 6//NA/
JN582061/1/1410/A/New/York/08/1326/2008/2008/02/13/6//NA/
CY089759/1/1410/A/Boston/87/2009/2009/02/14/6//N /
A/Lisboa/28/2008
A/CapeTown/124/2008
A/Texas/35/2008/1/1410/|/EPI/ISL/33732
A/yokohama/91/2007/1/1410/|/EPI/ISL/28731
CY074285/1/1410/A/California/VRDL235/2009/2009/04/29/6//NA/
GQ896371/1/1410/A/Utah/12/2009/2009/05/18/6//NA/
A/Lisboa/35/2006
A/NIIGATA/1150/2008/1/1410/|/EPI/ISL/28003
A/Kisii/7541/2008/1/1410/|/EPI/ISL/28471
A/BRISBANE/87/2009/1/1410/|/EPI/ISL/60134
A/Cambodia/21/2007/1/1410/|/EPI/ISL/28585
CY100966/1/1410/A/Maracay/WRAIR1729P/2008/2008/09/03/6//NA/
A/Kenya/4250/2009/1/1410/|/EPI/ISL/70216
A/Lisboa/21/2009
GQ476061/1/1410/A/Illinois/06/2009/2009/03/12/6//NA/
A/Virginia/01/2009/1/1410/|/EPI/ISL/33806
A/Ghana/FS/09/791/2009/1/1410/|/EPI/ISL/60086
A/Marrakech/589/2009
A/Luhansk/18/2008
A/SEOUL/4437/2008/1/1410/|/EPI/ISL/28208
A/Kenya/1432/2008
A/Maryland/07/2008/1/1410/|/EPI/ISL/28383
A/Flanders/G771/2009/1/1410/|/EPI/ISL/65508
A/EHIME/38/2008/1/1410/|/EPI/ISL/28170
A/OKAYAMA/14/2008/1/1410/|/EPI/ISL/28007
A/Honduras/330/2009/1/1410/|/EPI/ISL/33604
CY080987/1/1410/A/Boston/88/2009/2009/02/19/6//NA/
GQ475900/1/1410/A/Indiana/05/2009/2009/01/23/6//NA/
A/Paris/160/2007/EPI/ISL/157392/A///H1N1/seasonal/NA/WSS964105
CY100950/1/1410/A/Piura/WRAIR1708P/2009/2009/03/27/6//NA
A/North/1/1410/Dakota/ 1/2008/|/EPI/ISL/28310
A/Massachusetts/08/2008/1/1410/|/EPI/ISL/27647
A/Lisboa/13/2009
HQ256609/1/1410/A/Myanmar/M061/2009/2009/06/27/6//NA/
A/Peru/WRAIR1310P/2007/1/1410/|/EPI/ISL/78567
A/Bratislava/149/2009
A/New/1/1410/Jersey/15/2007/|/EPI/ISL/71839
A/Lisboa/29/2008
A/New/Caledonia/20/1999/EPI/ISL/22626/A///H1N1/seasonal/NA/WSS964089
A/St. Petersburg/62/2008
A/Lisboa/5/2008
A/Vietnam/289/2008
A/Dakar/06/2008
A/Vladivostok/03/2008/1/1410/|/EPI/ISL/33690
A/Hokkaido/08H024/2009
CY073855/1/1410/A/California/VRDL175/2009/2009/04/28/6//NA/
A/Fiji/7/2009/1/1410/|/EPI/ISL/60129
A/Bangladesh 6666/2 08 /1410/|/EPI/ISL/33670
A/Lisboa/1/2008
A/NAIROBI/2/2009/1/1410/|/EPI/ISL/78686
A/Paris/910/2008
A/British/1/1 10/Columbia/RV1585/2007/|/EPI/ISL/21859
A/Paris/639/2008/1/1410/|/ I/I L/90990
A/Beijing/Chaoyang/11405/2009
A/Lisboa/2/2006
A/Norway/173 /2007/1/ 410/|/EPI/ISL/25416
GQ475940/1/1410/A/Montana/03/2009/2009/01/14/6//NA/
A/Pennsylvania/12/2008/1/1410/|/EPI/ISL/28368
CY064873/1/1410/A/California/VRDL146/2009/2009/04/25/6//NA/
CY074661/1/1410/A/California/VRDL380/2009/2009/04/27/6//NA/
A/Lisboa/03/2009
A/Lisboa/16/2008
A/Tottori/08T010/2008
A/Stockholm/28/2008/1/1410/|/EPI/ISL/70666
A/Hong Kong/1975/2009
A/Fujian/Gulou/1581/2009/1/1410/|/EPI/ISL/6...
A/Iceland/4/2008/1/1410/|/EPI/ISL/6 389
GQ475908/1/1410/A/Kansas/01/2009/2009/01/29/6//NA/
A/Taiwan/5857/2008
A/Stockholm/5/2009/1/1410/|/EPI/ISL/70668
A/Seychelles/2231/2008/1/1410/|/EPI/ISL/65368
FJ380948/1/1410/A/Finland/11/2008/20 8/01/ 7 6//NA/
A/Thessaloniki/24/2005/EPI/ISL/25428/A///H1N1/seasonal/NA/WSS964095
CY087279/1/1410/A/Hong/Kong/62768/2008/2008///6//NA/
A/Saskatchewan/RV1 3 /2009/1 1410/|/EPI/ISL...
A/Vladivostok/04/2008/1/1410/|/EPI/ISL/33691
A/New/1/1410/Caledonia/6/2008/|/EPI/ISL/28102
A/Paraguay/61/2009/1/1410/|/EPI/ISL/33621
GQ475948/1/1410/A/Rhode/Island/01/2009/2009/01/27/6//NA
CY080763/1/1410/A/Boston/36/2009/2009/02/24/6//NA/
GU271952/1/1410/A/Thailand/CU/B97/2009/2009/06/22/6//NA/
A/Massachusetts/05/2 07/1/14 0/|/EPI/ISL/15455
A/Dakar/14/2008
CY074205/1/1410/A/California/VRDL220/2009/2009/04/29/6//NA/
A/Ghana/FS/205/2008
A/Quebec/RV0984/2009/1/1410/|/EPI/ISL/33649
A/Illinois/12/2009
A/Lisboa/27/2008
GQ476129/1/1410/A/Montana/02/2009/2009/01/02/6 /NA/
A/Nebraska/07/2008/1/1410/|/EPI/ISL/28306
CY069343/1/1410/A/Texas/WRAIR1052P/2009/2009/01/09/6//NA/
GQ476012/1/ 410/A/North/Dakota/ 3/2009/ 009/03 01/6//NA/
A/Florida/29/2008
A/DAEJEON/4494/2008
A/Martinique/19/2008
A/St. Petersburg/75/2008
A/Buenos/1/1410/Aires/1306/2008/|/EPI/ISL/65472
A/Santiago/5087/2008/1/1410/|/EPI/ISL/23858
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(Footnotes	Figure	4.11	cont.)	phylogenetic	 trees	 (outgroup)	 and	provide	directionality	 to	 the	evolutionary	histories.	Detailed	 information	on	 the	 reference	nucleotide	sequences	used	can	be	found	at	Table	S4.2,	Supplementary	data.	The	accession	number	of	the	nucleotide	sequences	of	the	viruses	tested	shared	through	public-access	databases	is	also	available	in	Supplementary	data	(Table	S4.1).	Panel	A:	SH-like	aLRT	branch	support	values	equal	or	higher	than	0.90	are	indicated	in	the	tree.	The	genetic	clades	to	which	the	different	viruses	belong	are	also	 indicated	on	 the	 right	 side.	Four	genetic	 clades	are	defined	 for	 former	circulating	A(H1N1)	viruses	 (based	on	hemagglutinin	gene),	designated	as	1,	2A,	2B	and	2C	and	represented	by,	respectively,	A/New	Caledonia/20/1999,	A/Solomon	Islands/03/2006,	A/Brisbane/59/2007	and	A/Hong	Kong/2652/2006	reference	viruses	 32.	Only	 the	amino	acid	 substitutions	relevant	for	the	interpretation	of	phenotypic	susceptibility	data	are	indicated	in	the	tree.	All	substitutions	were	identified	against	the	seasonal	N1	consensus	sequence,	except	those	highlighted	with	an	asterisk	(*)	that	were	identified	against	the	sequences	of	the	viruses	not	comprised	 in	 that	 specific	evolutionary	clade	or	group.	Panel	 B:	 included	585	additional	neuraminidase	 (NA)	gene	 sequences	 from	 NA	 H275Y	 former	 seasonal	 A(H1N1)	 variant	 viruses	 circulating	 worldwide.	 These	 sequences	 were	available	at	GISAID	EpiFlu™	and	NCBI	Influenza	Virus	Resource	databases	by	January	2012	and	were	comprised	in	the	former	seasonal	A(H1N1)	dataset	created	during	this	PhD	work	to	study	the	selective	pressure	acting	on	influenza	NA	(Chapter	6).			Of	note,	the	change	in	the	natural	in	vitro	susceptibility	of	seasonal	A(H1N1)	viruses	to	OS	(decrease)	and	ZA	(increase)	between	2005/2006	and	2007/2008	matched	a	change	in	the	genetic	clade	to	which	the	circulating	viruses	belonged.	As	shown	in	Figure	4.11A,	all	non-outlier	 viruses	 from	 2004/2005	 and	 2005/2006	 belonged	 to	 the	 genetic	 clade	 1,	represented	 by	 the	 reference	 virus	 A/New	 Caledonia/20/1999	 (NC/99),	 while	 those	from	 2007/2008	 onwards	 fell	 into	 the	 genetic	 clade	 2B,	 represented	 by	A/Brisbane/59/2007	(BR/07).	Six	NA	amino	acid	substitutions	distinguished	the	BR/07-like	from	previous	NC/99-like	viruses:	E214G,	R222Q,	V234M,	G249K,	T287I	and	D382N.	According	to	the	1918	N1	NA	structure,	all	these	amino	acid	substitutions	occurred	at	the	surface	of	the	globular	head,	except	R222Q	and	G249K	substitutions	that	occurred	closely	to	the	active	site	(Figure	4.12A).	Residue	222	lies	adjacently	to	the	framework	active	site	residue	223,	while	 residue	249	belongs	 to	 the	 243-251	 surface	 loop	 that	 is	 a	 potential	antigenic	 site	of	 seasonal	N1	NA	 33.	Moreover,	 the	 arginine	 (R)	 to	 glutamine	 (Q)	 amino	acid	substitution	at	residue	222	is	known	to	significantly	increase	NA	binding	affinity	to	its	 substrate	 34,35	 (potential	 fitness-compensatory	 substitution).	 The	 NA	 D344N	 amino	acid	substitution	also	known	to	significantly	increase	NA	binding	affinity	to	its	substrate	34-36	 and,	 additionally,	 to	 OS	 and	 ZA	 37,	 was	 present	 in	 all	 BR/07-like	 viruses	 except	A/Paris/160/2006	(Figure	4.11A),	occurring	closely	to	the	active	site	(Figure	4.12A).			Regarding	the	evolutionary	relationships	of	seasonal	 influenza	H1	genes	(HA1	subunit),	all	 phenotypic	 outlier	 viruses	 were	 closely	 related	 to	 the	 non-outlier	 viruses	 from	 the	same	 influenza	 season	 (Figure	 S4.1A,	 Supplementary	 data).	 The	 OS	 UE	 outlier	 viruses	showing	HRI	(NA	H275Y	variant	viruses)	 fell	 into	the	genetic	clade	2B,	with	those	from	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	145		2008/2009	 continuing	 to	 cluster	 together	 like	 in	 NA,	 but	 with	 no	 amino	 acid	 or	nucleotide	substitution	defining	the	subgroup.	The	virus	isolates	A/Lisboa/29/2008	and	A/Lisboa/03/2009	remained	also	grouped	(HA	G152E)	and	positioned	more	apart	from	the	 other	 UE	 outlier	 viruses	 comprising	 the	 subgroup.	 Among	 these	 was	 included	 the	virus	 isolate	 A/Lisboa/07/2009,	 with	 all	 sharing	 HA	 S141N	 and	 G185A	 amino	 acid	substitutions	(Figure	S4.1A,	Supplementary	data).			
	
	
Figure	4.12	Mapping	of	 the	neuraminidase	residues	on	which	occurred	the	amino	acid	substitutions	differentiating	 former	 seasonal	 influenza	A(H1N1)	 (A)	 or	 influenza	A(H3N2)	 (B)	 genetic	 clades	 and		influenza	B	co-circulating	lineages	(C),	onto	the	three-dimensional	structure	of	the	protein.	The	 figures	were	 generated	 and	 annotated	 as	 described	 in	 Figure	 4.7,	 except	 the	 residues	 under	 study	 that	 are	 coloured	 in	yellow.	 Panel	 A:	 amino	 acid	 substitutions	 differentiating	 clade	 2B	 A/Brisbane/59/2007-like	 viruses	 from	 clade	 1	 A/New	Caledonia/20/1999-like	 viruses.	 Residue	 344	 is	 also	 indicated,	 as	 NA	 D344N	 amino	 acid	 substitution	 was	 present	 in	 all	A/Brisbane/59/2007-like	viruses	except	A/Paris/160/2006.	The	 former	seasonal	N1	neuraminidase	(NA)	structure	used	was	the	 same	 as	 in	 Figure	 4.7A.	 Panel	 B:	 amino	 acid	 substitutions	 differentiating	 Victoria/208	 clade	 viruses	 from	 previously	circulating	Brisbane/10,	Wisconsin/67	and	California/07	clade	viruses.		It	was	used	the	same	N2	NA	structure	as	in	Figure	4.8A.	
Panel	 C:	 amino	 acid	 substitutions	 characteristic	 of	 B/Victoria-lineage	 viruses,	 compared	 to	 the	 B/Yamagata-lineage	 NA	consensus	sequence.	The	influenza	B/Victoria-lineage	NA	structure	used	was	the	same	as	in	Figure	4.9A.			 4.1.4.2.2.2	Influenza	A(H3N2),	B	and	A(H1N1)pdm09	virus	neuraminidase	and	hemagglutinin	genes			Phylogenetic	comparison	of	 influenza	A(H3N2),	B	and	A(H1N1)pdm09	virus	NA	(Figure	4.13)	 and	HA	 (Figure	 S4.1B-D,	 Supplementary	data)	 genes	 showed	 that	 the	phenotypic	outlier	 viruses	were	 closely	 related	 to	 the	 non-outlier	 viruses	 from	 the	 same	 influenza	season	or	period	 and,	 for	 type	B	 influenza,	 also	 lineage.	The	A(H3N2)	UM	outlier	 virus	A/Portugal/29/2012	clustered	within	a	different	group	(group	3B)	than	the	non-outlier	viruses	 from	 2011/2012	 (group	 6),	 but	 probably	 due	 to	 the	 high	 diversity	 of	 genetic	groups	within	Victoria/208	clade.		
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Figure	4.13	Phylogenetic	comparison	of	influenza	A(H3N2)	(A),	B	(B)	and	A(H1N1)pdm09	virus	(C)	neuraminidase	genes.		0.0060
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(Footnotes	Figure	4.13)	
Panel	B:	(a)	also	present	in	all	or	nearly	all	outgroup	viruses;	(b)	only	not	present	in	one	or	two	(T389A)	reference	B/Victoria-lineage	viruses.		Neuraminidase	(NA)	phylogenetic	trees	were	constructed	and	annotated	as	described	in	Figure	4.11	(panel	A),	with	the	upper	extreme	outlier	viruses	being	just	coloured	in	light	red.	The	relevant	N2	(panel	A)	and	2009	pandemic	N1	(panel	C)	amino	acid	substitutions	 indicated	 in	 the	 tree	 were	 identified	 against	 the	 corresponding	 consensus	 sequence,	 while	 the	 amino	 acid	substitutions	characteristic	of	B/Victoria	(VIC)	-	lineage	viruses	indicated	in	the	influenza	B	NA	tree	(panel	B)	were	identified	against	the	consensus	sequence	of	B/Yamagata	(YAM)	-	lineage	viruses.	Panel	A:	the	six	genetic	clades	considered	for	circulating	A(H3N2)	 viruses	 include	 three	 earlier	 clades	 -	 Fujian/411,	 California/07	 and	Wisconsin/67,	 defined	 by	 the	 vaccine	 viruses	A/Fujian/411/2002,	A/California/07/2004	and	A/Wisconsin/67/2005;	and	the	three	recent	clades	defined	by	WHO	(based	on	hemagglutinin	 (HA)	 gene)	 -	 Brisbane/10,	 Perth/16	 and	 Victoria/208,	 represented	 by	 the	 reference	 viruses	A/Brisbane/10/2007,	 A/Perth/16/2009	 and	 A/Victoria/208/2009	 (the	 first	 two	 also	 vaccine	 viruses)	 38.	 Perth/16	 and	Victoria/208	genetic	clades	are	further	divided	according	to	the	established	genetic	groups:	1	and	2	(Perth/16);	3A,	3B,	3C,	4,	5,	6	and	7	(Victoria/208)	39.	Panel	B:	the	HA	genetic	clades	defined	by	WHO	40		for	each	influenza	B	virus	lineage	are	indicated	in	the	 tree,	 including:	 clades	 1	 (or	 Brisbane/60,	 represented	 by	 the	 vaccine	 virus	 B/Brisbane/60/2008),	 4,	 5	 and	 6	 for	 B/VIC	lineage,	in	which	clade	1	is	further	divided	into	the	established	genetic	groups	1A	and	1B	41;	and	the	Florida/4,	Brisbane/3	(or	clade	2)	and	Bangladesh/3333	(or	clade	3)	clades	for	B/YAM	lineage,	represented	by	the	reference	viruses	B/Florida/04/2006	(vaccine	 virus),	 B/Brisbane/3/2007	 and	 B/Bangladesh/3333/2007.	Panel	 C:	 the	 HA	 genetic	 groups	 defined	 by	WHO	 41	 for	circulating	A(H1N1)pdm09	viruses	are	indicated	in	the	tree,	including	8	genetic	groups	designated	from	1	to	8	and	represented	by	 the	 reference	 viruses	A/California/07/2009	 (vaccine	 virus;	 1),	 A/Czech	Republic/32/2011	 (2),	 A/Hong	Kong/3934/2011	(3),	 A/Christchurch/16/2010	 (4),	 A/Astrakhan/01/2011	 (5),	 A/St	 Petersburg/27/2011	 (6),	 A/St	 Petersburg/100/2011	 (7),	and	A/Norway/2552/2012	(8).			Influenza	A(H3N2)	virus	NA	phylogenetic	tree	also	showed	that	a	change	to	a	new	drift	variant	 may	 have	 been	 at	 the	 origin	 of	 the	 decrease	 observed	 in	 the	 natural	 in	 vitro	susceptibility	of	 circulating	viruses	 to	OS	and	ZA,	between	2008/2009	and	2011/2012.	All	A(H3N2)	non-outlier	viruses	from	2011/2012	onwards	belonged	to	the	Victoria/208	genetic	 clade,	 while	 those	 circulating	 previously	 belonged	 to	 either	 Brisbane/10,	Wisconsin/67	 or	 California/07	 genetic	 clades	 (Figure	 4.13A).	 Two	 NA	 amino	 acid	substitutions	 located	 closely	 to	 the	 active	 site	 -	 S367N	 and	 K369T,	 distinguished	 the	A/Victoria/208/2009-like	 viruses	 from	 the	 viruses	 belonging	 to	 these	 three	 previous	clades	(Figure	4.13A;	Figure	4.12B).		The	 influenza	 B	 UM	 outlier	 virus	 B/Lisboa/12/2005	 revealed	 to	 be	 an	 inter-lineage	reassortant,	 possessing	 a	NA	 gene	 from	 the	B/VIC-lineage	 (Figure	 4.13B)	 and	having	 a	B/YAM-like	 HA	 gene	 (Figure	 S4.1C,	 Supplementary	 data).	 As	 influenza	 B	 lineage	differentiation	was	based	on	the	antigenic	and/or	genetic	characteristics	of	HA,	this	virus	isolate	 was	 mistakenly	 analysed	 as	 a	 B/YAM-lineage	 virus	 in	 NA	 inhibition	 assay.	 No	genetic	 support	 was	 found	 for	 the	 decrease	 observed	 in	 the	 natural	 in	 vitro	 OS	susceptibility	of	circulating	influenza	B	viruses	after	2004/2005	and	then	further	in	the	pandemic	 period.	 However,	 8	 NA	 amino	 acid	 substitutions	 distinguished	 the	 B/VIC-
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	148		lineage	viruses	 that	overall	exhibited	a	 lower	natural	 susceptibility	 to	ZA	and,	although	less	evidently,	to	OS,	compared	to	B/YAM-lineage	viruses.	Specifically:	NA	E148G,	K219N,	D235N,	 P244S,	 K373E,	 T389A,	 E392D	 and	T436E	 substitutions	 (Figure	 4.13B).	 Four	 of	these	substitutions	-	E148G,	K219N,	P244S,	K373E,	are	closely	to	the	active	site	(Figure	4.12C).			The	 two	NA	 I223V	A(H1N1)pdm09	OS	UE/ZA	UM	outlier	 viruses	 A/Portugal/17/2009	and	 A/Portugal/82/2009	 presented	 100%	 identical	 NA	 (Figure	 4.13C)	 and	HA	 (Figure	S4.1D,	 Supplementary	 data)	 gene	 sequences.	 Based	 on	 patient	 epidemiological	 and	clinical	 data,	 these	 two	outlier	 viruses	were	 also	 geographically	 and	 temporally	 closely	related.	 No	 genetic	 support	 was	 found	 for	 the	 slight	 decrease	 in	 the	 natural	 in	 vitro	susceptibility	of	circulating	A(H1N1)pdm09	viruses	to	OS	between	the	pandemic	period	and	2010/2011.	A(H1N1)pdm09	non-outlier	viruses	 from	2010/2011	belonged	 to	new	genetic	 groups	 (groups	 5,	 6	 and	 7),	 but	 only	 NA	 N369K	 amino	 acid	 substitution	differentiated	 these	 non-outlier	 viruses	 from	 those	 circulating	 during	 the	 pandemic	period	(genetic	group	1)	(Figure	4.13C).	NA	N369K	variant	viruses	are	known	to	exhibit	increased	(and	not	decreased)	affinity	for	the	substrate	(potential	fitness-compensatory	substitution)	42.			
4.1.5	 Influenza	 Antiviral	 Prescription	 on	 Influenza-like	 Illness	 Patients	
(complementary	study)			Between	 2005/2006	 and	 2008/2009,	 influenza	 antivirals	were	 prescribed	 at	 very	 low	frequencies	 to	 the	 influenza-like	 illness	 (ILI)	 patients	 presenting	 to	 healthcare	 systems	covered	by	the	National	Influenza	Surveillance	Programme.	The	frequencies	varied	from	1.0%	(6/600)	 in	2008/2009	to	3.1%	(7/226)	 in	2007/2008	(Figure	4.14),	not	differing	significantly	 over	 time	 (Pearson	Chi-Square	Test,	 p	 =	0.191).	Antiviral	 information	was	missing	for	more	than	650	of	the	total	2290	ILI	cases	notified	during	the	period	studied,	which	were	excluded	from	the	analysis.		Virtually	 all	 cases	 of	 ILI	 reporting	 antiviral	 prescription	 were	 received	 through	 the	network	 of	 emergency	 units	 (27/30;	 90.0%).	 	 Influenza	 antivirals	 were	 mainly	prescribed	 to	 patients	 within	 the	 15–44	 years	 age	 group	 (22/30;	 73.3%),	 with	 no	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	149		underlying	 risk	 condition.	 Four	 (13.3%)	 of	 the	 patients	 to	 whom	 antivirals	 were	prescribed	had	previously	been	vaccinated	for	influenza	but	no	information	was	available	regarding	vaccination	date.	OS	was	the	antiviral	most	prescribed,	having	been	identified	in	 19	 (90.5%)	 of	 the	 21	 notifications	 on	 which	 the	 antiviral	 was	 specified.	 However,	approximately	 half	 (14;	 46.7%)	 of	 the	 ILI	 patients	 to	whom	antivirals	were	 prescribed	tested	negative	for	influenza	virus	infection.													
	
	
Figure	 4.14	 Distribution	 of	 the	 cases	 of	 influenza-like	 illness	 notified	 between	 2005/2006	 and	2008/2009	 in	 the	 context	 of	 the	 National	 Influenza	 Surveillance	 Programme,	 according	 to	 antiviral	prescription.	ILI:	Influenza-like	illness	The	number	of	ILI	cases	notified	with	information	on	antiviral	prescription	is	displayed	at	the	top	of	each	stacked	column.	At	the	left	side	are	specified	the	frequencies	of	antiviral	prescription	and	no	antiviral	prescription,	using	the	same	colour	as	the	section	in	the	column.	The	corresponding	number	of	cases	is	shown	below	under	brackets.				
4.2	DISCUSSION		This	PhD	work	established	the	capacity	and	capability	to	comprehensively	evaluate	and	monitor	 influenza	 antiviral	 susceptibility	 at	 national	 level.	 Human	 influenza	 viruses	circulating	in	Portugal	were	for	the	first	time	characterized	regarding	their	susceptibility	to	the	three	antivirals	approved	nationally	for	clinical	use	-	AMA	(M2	inhibitor),	and	OS	and	ZA	 (NAIs).	Antiviral	 susceptibility	 testing	of	 circulating	viruses	 started	 in	2008	but	
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																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	150		went	 back	 3	 influenza	 seasons	 (until	 2004/2005;	 retrospective	 study)	 to	 match	 the	beginning	 of	 influenza	 antiviral	 susceptibility	 surveillance	 in	 Europe	 (2004;	 VIRGIL	network).	 At	 this	 time,	 only	 a	 very	 limited	 number	 of	 European	 countries	 were	 fully	testing	 and	 reporting	 influenza	 antiviral	 susceptibility,	 contributing	 to	 the	 overall	 data	generated	 by	 the	 VIRGIL	 network	 43.	 Also,	 only	 a	 small	 proportion	 of	 the	 viruses	circulating	 globally	 was	 being	 tested	 for	 antiviral	 susceptibility	 7.	 The	 first	 national	antiviral	 susceptibility	 data	 generated	 through	 this	 study	 was	 therefore	 extremely	valuable	 for	 the	 surveillance	 carried	 out	 at	 both	 European	 and	 global	 level.	 Antiviral	susceptibility	testing	activities	continued	until	2012/2013,	covering	a	total	of	8	influenza	seasons	plus	the	2009	pandemic	period.	Influenza	viruses	circulating	in	both	community	and	hospitalized	settings	were	tested,	with	these	later	including	viruses	recovered	from	patients	undergoing	antiviral	therapy	either	or	not	suspected	of	having	developed	drug-resistant	influenza.						
4.2.1	Influenza	Antiviral	Susceptibility	Testing	Platform	
	The	 technological	 platform	 established	 for	 influenza	 antiviral	 susceptibility	 testing	comprises	 a	 genotypic	 platform	 for	 evaluation	 of	M2	 inhibitor	 susceptibility	 (complete	cross-resistance	between	AMA	and	RIM6);	and	a	twofold	phenotypic-genotypic	platform	combined,	whenever	possible,	with	patient	clinical	data,	for	evaluating	the	susceptibility	to	OS	and/or	ZA.	Notably,	 the	 two	phenotypic	NA	 inhibition	assays	 implemented	 in	 the	platform	are	suitable	to	any	novel	NAI	targeting	the	NA	active	site,	as	it	is	the	case	of	the	two	 recently	 available	 drugs	 PER	 and	 LAN,	 for	 now	 only	 approved	 in	 very	 limited	markets	 44-46,	 and	 of	 the	 investigational	 tamiphosphor	 (pre-clinical	 stage)	 47.	 Genotypic	testing	through	full-length	sequencing	of	NA	and	HA	genes	can	also	extend	to	any	novel	NAI,	 independently	of	 its	target.	The	different	complexity	of	the	platforms	implemented	for	 M2	 inhibitor	 drug	 class	 and	 OS	 and	 ZA	 reflects	 the	 different	 knowledge	 on	 the	mechanisms	 underlying	 the	 development	 of	 clinical	 resistance.	 The	 genetic	 basis	 for	clinical	 resistance	 to	 M2	 inhibitors	 is	 well	 characterized	 (7	 molecular	 markers	 of	resistance	 established),	while	 NA	H275Y	 is	 the	 only	 amino	 acid	 substitution	 known	 to	confer	clinical	resistance	to	NAIs,	specifically	to	OS	and	solely	in	N1	NA	influenza	viruses	(seasonal	A(H1N1),	A(H1N1)pdm09	and	A(H5N1))	48.	Several	amino	acid	substitutions	in	NA,	 as	 well	 as	 two	 amino	 acid	 substitutions	 at	 position	 221	 of	 the	 HA1	 subunit	 of	
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vitro,	but	its	clinical	impact	is	less	clear	or	completely	unknown	5,49.	Also,	the	relationship	between	 reduced	 NAI	 susceptibility	 in	 vitro	 (phenotype)	 and	 genotypic	 background	(genotype)	is	not	always	predictable,	remaining	one	of	the	major	challenges	in	influenza	antiviral	 susceptibility	 testing	 50.	An	 influenza	virus	exhibiting	 reduced	 susceptibility	 in	
vitro	 may	 retain	 the	 genetic	 characteristics	 of	 a	 fully	 susceptible	 virus	 or	 carry	 a	 still	unknown	amino	acid	substitution	conferring	RI	or	HRI	by	the	drug.	Phenotypic	 methodologies	 accounting	 for	 HA-mediated	 changes	 in	 susceptibility	 were	not	 implemented,	 as	 those	 available	were	 either	 not	 recommended	 (cell-culture	 based	assays)	or	even	not	yet	standardized	(red	blood	cell	elution	assays)	51,52.	In	the	absence	of	phenotypic	data,	the	genetic	analysis	of	virus	HA	to	evaluate	NAI	susceptibility	is	limited	to	 the	 screening	 of	 the	 two	 HA	 amino	 acid	 substitutions	 known	 to	 confer	 reduced	susceptibility	 and,	 when	 applicable,	 the	 comparison	 of	 the	 HA	 of	 the	 virus	 population	present	before	and	after	treatment.			
4.2.2	Influenza	A	Virus	Resistance	to	M2	Protein	Inhibitors		Influenza	 A(H3N2)	 viruses	 resistant	 to	M2	 inhibitors	 began	 to	 circulate	 in	 Portugal	 in	2005/2006.	 M2	 inhibitor	 resistance	 was	 initially	 estimated	 in	 100%	 (single	 virus	isolated),	 changing	 to	 74.5%	 in	 2006/2007	 and	 then	 settling	 at	 100%	 during	 the	following	 influenza	 seasons	 analysed	 (2008/2009,	 2011/2012	 and	 2012/2013).	 All	resistant	viruses	carried	the	S31N	amino	acid	substitution	in	the	M2	protein,	with	three	viruses	 from	 2008/2009	 further	 carrying	 the	 V27A	 substitution	 (double	 V27A/S31N	mutant	 viruses).	 The	 beginning	 of	 M2	 inhibitor	 resistance	 in	 Portugal	 matched	 the	emergence	 and	 global	 spread	 of	 a	 new	 lineage	 of	 drug-resistant	 S31N	 variant	 viruses,	designated	as	N-lineage	53.	In	the	origin	of	this	new	lineage	is	a	4+4	genome	reassortment	event	in	early	2005,	involving	the	drug-resistant	viruses	circulating	in	South-East	Asia	in	the	 presence	 of	 drug-selective	 pressure,	 specifically	 those	 circulating	 in	 Hong	 Kong	 as	recently	evidenced	by	Nelson	et	al.	54.	The	presence	of	beneficial	amino	acid	substitutions	in	 the	 novel	 HA	 acquired	 by	 reassortment	 (A/Wisconsin/67/2005-like	 HA),	 with	 a	hitchhiking	effect	on	M2	S31N	amino	acid	substitution,	has	been	considered	as	the	most	probable	 explanation	 for	 the	 global	 spread	 of	 M2	 inhibitor-resistant	 N-lineage	 viruses	53,54.	 Drug-selective	 pressure	 had	 apparently	 no	 role	 in	 this	 global	 spread,	 with	 S31N	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	152		resistant	viruses	spreading	around	the	world	independently	of	 the	presence	or	absence	of	selective	pressure	from	drug	use.	Portugal	belongs	to	this	latter	group.	The	use	of	AMA	(only	 M2	 inhibitor	 licensed;	 Parkadina®)	 has	 been	 essentially	 for	 the	 treatment	 of	Parkinson´s	disease	and	not	 influenza	A	virus	 infections,	with	the	drug	belonging	to	the	pharmacotherapeutic	 group	 of	 anti-Parkinson	 drugs,	 dopamine	 agonists	(www.infarmed.pt).		The	 frequency	 at	 which	 A(H3N2)	 M2	 inhibitor-resistant	 viruses	 were	 detected	 in	Portugal	was	 in	accordance	with	 the	 frequencies	 reported	by	other	national	and	global	influenza	antiviral	susceptibility	surveillance	studies.	These	ranged	from	42.7%	to	100%	in	2005/2006	55-57	and	from	78%	to	89.6%	between	2007	and	2007/2008	58,59,	settling	at	100%	from	2008	onwards	59,60.	The	M2	V27A/S31N	combination	found	in	three	resistant	viruses	has	been	identified	worldwide,	representing	the	second	most	 frequent	resistant	genotype	(after	S31N)	of	influenza	H3	HA	viruses	circulating	between	1968	and	2013	61.	Moreover,	the	frequency	at	which	was	detected	at	national	level	(5.7%)	was	very	similar	to	 that	 at	 which	 was	 detected	 globally	 among	 these	 H3	 HA	 viruses	 (5.4%)	 61.	 The	mechanisms	underlying	 the	 emergence	of	 this	 double	M2	S31N/V27A	 resistant	 variant	remain,	however,	unknown.		The	 natural	 resistance	 exhibited	 by	 recently	 emerging	 A(H1N1)pdm09	 viruses	 to	 M2	inhibitors	(M2	S31N)	was	inherited	from	the	parental	Eurasian	avian-like	swine	A(H1N1)	virus	that	since	1989	is	characterized	for	being	resistant	to	this	antiviral	drug	class	62,63.		No	M2	inhibitor	resistance	was	observed	in	seasonal	influenza	A(H1N1)	subtype.	Further	analysis	of	the	evolutionary	relationships	among	seasonal	H1	HA	genes,	carried	out	in	the	context	 of	 NAI	 genotypic	 susceptibility	 testing,	 confirmed	 that	 none	 of	 the	 viruses	evaluated	through	HA	sequencing	belonged	to	the	M2	drug-resistant	HA	clades	2A	and	2C	59.	The	viruses	from	2004/2005	and	2005/2006	clustered	into	clade	1,	while	those	from	2007/2008	and	2008/2009	belonged	to	the	clade	2B.			M2	 inhibitor	 susceptibility	 testing	 is	 no	 longer	 considered	 a	 priority	 64.	 Naturally	resistant	 2009	 A(H1N1)	 pandemic	 viruses	 replaced	 seasonal	 A(H1N1)	 viruses	 during	2009/2010	 and	 2010/2011,	 resulting	 in	 an	 overall	 M2	 inhibitor	 resistance	 among	circulating	 influenza	A	viruses	65.	The	rapid	and	unpredictable	nature	of	 influenza	virus	evolution	makes	 however	 important	 to	 continue	monitoring	 virus	 susceptibility	 to	M2	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	153		inhibitors,	 even	more	 in	 a	 context	 of	 no	drug-selective	 pressure	 for	more	 than	5	 years	(M2	 inhibitor	 use	 not	 recommend	 by	 WHO	 since	 2010	 66).	 Given	 the	 very	 limited	repertoire	of	influenza	antivirals	effective	against	currently	circulating	viruses,	it	is	very	important	to	timely	detect	any	change	in	the	susceptibility	to	M2	inhibitors.			
4.2.3	Influenza	Virus	Susceptibility	to	Oseltamivir	and	Zanamivir			Virtually	 all	 human	 influenza	 viruses	 circulating	 in	 Portugal	 from	 2004/2005	 to	2012/2013,	except	those	belonging	to	seasonal	A(H1N1)	subtype,	were	sensitive	to	both	NAIs	OS	 and	 ZA.	 Overall	 frequencies	 ranged	 from	91.2%	 to	 98.6%	 across	 the	 different	influenza	virus	types	and	subtypes	and	NAI	drug,	including	both	phenotypic	non-outlier	and	lower	outlier	viruses.	The	frequency	of	seasonal	A(H1N1)	viruses	sensitive	to	OS	was	lower	but	still	high	(68.8%),	while	an	overall	susceptibility	was	observed	to	ZA.	Similar	results	were	obtained	in	other	antiviral	susceptibility	surveillance	studies	carried	out	at	national	 67-70	 and	 worldwide	 level	 71-73	 during	 the	 time	 period	 covered	 by	 this	 study.	According	 to	 these,	 88.3%	 to	 99.9%	 of	 the	 circulating	 human	 influenza	 viruses	 were	sensitive	to	OS	and/or	ZA,	with	the	lower	limit	decreasing	to	76.4%	when	including	the	OS-sensitive	seasonal	A(H1N1)	viruses.	Two	of	the	studies	were	conducted	in	Japan	69,70,	which	alongside	with	USA	is	distinguished	by	a	high	use	of	NAIs,	specifically	OS.	All	other	worldwide	 countries	 have	 been	 characterized	 by	 a	 relatively	 low	 use	 of	 NAIs,	 with	 an	exceptional	higher	use	during	the	2009	influenza	pandemic	50.	This	was	well	evidenced	in	the	 antiviral	 prescription	 data	 obtained	 in	 this	 study,	 according	 to	 which	 influenza	antivirals	 (90%	 OS)	 were	 only	 prescribed	 to	 ≈2%	 of	 the	 ILI	 patients	 presenting	 to	healthcare	 systems	 covered	 by	 the	 National	 Influenza	 Surveillance	 Programme	 in	Portugal,	from	2005/2006	to	2008/2009.	This	extremely	low	prescription	rate	reflected	the	national	public	health	policy	 for	antiviral	 therapy	 in	seasonal	 influenza	 that,	at	 that	time,	 was	 even	 more	 restrictive	 than	 now.	 Antiviral	 use	 was	 only	 recommended	 for	patients	 with	 underlying	 risk	 conditions	 or	 in	 very	 particular	 situations	 that	 included	clusters	 of	 influenza	 virus	 infection,	 cases	 of	 infection	 with	 highly	 pathogenic	 avian	influenza	A(H5N1)	viruses	and	circulation	of	vaccine-mismatched	influenza	viruses	74,75.	Now,	it	is	further	recommended	to	all	cases	of	severe	or	progressive	disease,	hospitalized	patients	and	health	care	professionals	infected	with	influenza	76.		
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4.2.3.1	 NA	 H275Y	 Oseltamivir-Resistant	 Former	 Seasonal	 and	 2009	 Pandemic	 A(H1N1)	
Viruses		Resistance	 to	OS	was	detected	 in	both	 former	 and	 current	 circulating	A(H1N1)	 viruses	(HRI	 phenotype,	 NA	 H275Y	 substitution),	 but	 at	 two	 completely	 different	 scales.	Approximately	 21%	 of	 the	 seasonal	 A(H1N1)	 viruses	 circulating	 during	 2007/2008	showed	to	be	resistant,	with	the	frequency	increasing	to	100%	in	the	following	influenza	season	 (2008/2009).	 	 Only	 a	 single	 A(H1N1)pdm09	 virus	 from	 2010/2011,	 recovered	from	 an	 immunocompromised	 pregnant	 women	 hospitalized	 with	 severe	 influenza	illness	 and	 suspected	 of	 having	 developed	 drug-resistant	 influenza	 during	 OS	 therapy,	exhibited	resistance	to	the	drug	-	virus	isolate	A/Portugal/03/2011.		Similar	 frequencies	 of	 OS-resistant	 seasonal	 A(H1N1)	 viruses	were	 obtained	 in	 several	other	worldwide	countries,	resulting	from	the	emergence	and	worldwide	spread	of	a	fit	and	 transmissible	NA	H275Y	OS-resistant	 A(H1N1)	 variant	 during	 2007/2008	with	 no	relation	 to	 the	 country	 OS	 usage	 72,77,78.	 This	 OS-resistant	 variant	 continued	 to	 spread	globally	from	2008	onwards,	rapidly	outcompeting	the	drug-sensitive	counterparts	from	circulation,	 so	 that,	 by	 the	 end	 of	 2008/2009	 virtually	 all	 seasonal	 A(H1N1)	 viruses	circulating	worldwide	were	resistant	to	OS	(93%	global	resistance)	72.	The	initial	rate	at	which	 NA	 H275Y	 OS-resistant	 seasonal	 A(H1N1)	 viruses	 were	 detected	 in	 Portugal	(2007/2008)	was	very	close	to	the	average	rate	reported	for	Europe	(24.2%).	During	this	season,	 the	 proportion	 of	 OS-resistant	 viruses	 in	 Europe	 varied	 widely	 by	 country,	ranging	 from	0.9%	 in	 Italy	 to	68%	 in	Norway,	with	 this	 latter	 representing	 the	highest	frequency	 of	 OS	 resistance	 reported	 globally	 79.	 NA	 H275Y	 OS-resistant	 viruses	 from	2007/2008	and	2008/2009	exhibited	similar	IC50	fold-change	values	that	overall	ranged	from	≈160	 to	 615-fold.	 Also,	 no	 difference	was	 observed	 in	 the	 IC50	 fold-change	 of	 the	resistant	 viruses	 from	 the	 same	 influenza	 season	 that	 exhibited	 different	 overall	 NA	genetic	 backgrounds	 (4	 different	 backgrounds;	 2008/2009)	 and/or	 specific	 NA	 amino	acid	changes.	This	 lack	of	difference	was	supported	by	 the	 fact	 that	none	of	 the	genetic	differences	occurred	closely	to	either	residue	275	or	NA	active	site.	Most	IC50	fold-change	values	 were	 below	 the	 reference	 range	 considered	 by	 the	WHO	 AVWG	 for	 NA	 H275Y	substitution	in	a	seasonal	N1	background	(321	to	2597-fold)	80,	and	those	located	within	the	 range	 were	 positioned	 at	 or	 near	 its	 lower	 limit.	 This	 is	 probably	 related	 with	technical	 issues,	 associated	 with	 the	 use	 of	 a	 different	 fluorescence	 reader	 and/or	 a	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	155		different	assay	protocol	compared	to	those	used	in	the	studies	on	which	these	reference	values	were	based	(inter-laboratory	variability).	Supporting	this	are	the	lower	IC50	fold-change	estimates	also	 reported	 in	other	national	NAI	susceptibility	 surveillance	studies	(from	 ≈260-fold	 on)	 31,81,82.	 All	 NA	 H275Y	 OS-resistant	 seasonal	 A(H1N1)	 viruses	circulating	in	Portugal	belonged	to	the	genetic	clade	2B	and	specifically	to	the	Northern	European	 lineage,	as	evidenced	by	 the	presence	of	 the	NA	D354G	reversion	amino	acid	substitution.	 	The	clustering	of	all	resistant	viruses	 in	an	evolutionary	group	defined	by	the	 NA	 H275Y	 mutation	 confirmed	 that	 none,	 particularly	 those	 from	 2007/2008,	emerged	 locally	 as	 a	 result	 of	 drug	 use.	 The	 more	 extensive	 phylogenetic	 analysis	performed	with	seasonal	N1	NA	genes,	including	a	large	number	of	additional	sequences	from	worldwide	NA	H275Y	variant	viruses,	 suggested	 the	occurrence	of	 three	different	introductions	 for	 the	OS-resistant	 viruses	 circulating	 in	 Portugal	 during	 each	 influenza	season.	 	 This	 was	 evidenced	 by	 the	 clear	 separation	 of	 the	 OS-resistant	 viruses	 from	either	2007/2008	or	2008/2009	in	three	evolutionary	subgroups,	with	the	viruses	from	each	subgroup	being	closely	related	to	other	resistant	viruses	from	different	worldwide	regions.	 The	 emergence	 of	 a	 fit	 and	 transmissible	 NA	 H275Y	 OS-resistant	 seasonal	A(H1N1)	 variant	 has	 been	 explained	 by	 the	 presence	 of	 additional	 NA	 amino	 acid	substitutions	that	compensated	for	the	detrimental	effect	of	H275Y	substitution	on	virus	fitness	 83.	 This	 compensatory	 role	 is	 currently	 attributed	 to	NA	R222Q,	V234M,	D344N	and	 D354G	 amino	 acid	 substitutions	 48,	 which	 were	 identified	 in	 all	 NA	 H275Y	 OS-resistant	viruses	characterized	genotypically.	It	is	however	still	puzzling	why	NA	H275Y	A(H1N1)	variant	viruses	spread	over	their	OS-sensitive	counterparts,	outcompeting	them	from	 circulation,	 even	 more	 in	 a	 context	 of	 overall	 low	 drug	 use.	 Two	 evolutionary	mechanisms	 have	 been	 proposed,	 specifically:	 (1)	 HA-NA	 functional	 balance	 (better	balance	 between	 HA	 receptor-binding	 and	 NA	 receptor-destroying	 activities)	 36,79,84-86;	and	 (2)	 genetic	 hitchhiking	 (physical	 linkage	 of	 NA	 H275Y	 substitution	 to	 beneficial	amino	 acid	 substitutions)	 37,87,88.	 But,	 both	 mechanisms	 involve	 the	 potential	 fitness-compensatory	substitutions	above	referred	or	the	HA	A189T	amino	acid	substitution,	all	also	 characteristic	 of	 the	 clade	 2C	 OS-resistant	 viruses	 that	 did	 not	 spread	 worldwide	37,87.	As	evidenced	in	this	study,	the	HA	A189T	substitution	implied	an	amino	acid	change	in	the	RBS	of	the	protein	that	is	the	major	determinant	of	both	receptor-binding	affinity	and	specificity	 89.	Also,	 it	was	 the	only	amino	acid	substitution	differentiating	 the	 latter	clade	 2B	 OS-resistant	 viruses	 that	 fixed	 NA	 H275Y	 in	 A(H1N1)	 virus	 population	(2008/2009	 viruses)	 from	 those	 initially	 circulating	 (2007/2008	 viruses)(NA	 and	 HA	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	156		genes).	 Considering	 that	 amino	 acid	 substitutions	 in	 PB1-F2	 and	 PB2	 were	 found	 to	distinguish	 clade	 2B	 and	 2C	 OS-resistant	 viruses	 36,87,	 it	 is	 possible	 that	 genetic	hitchhiking	may	have	in	alternative	involved	other	genetic	changes	located	elsewhere	in	the	viral	genome,	particularly	 in	 the	polymerase	complex	genes	37,87.	 It	has	been	 in	 fact	suggested	 that	 the	 key	 to	 completely	 understand	why	NA	H275Y	OS-resistant	 seasonal	A(H1N1)	viruses	became	dominant	is	to	look	for	the	virus	as	a	whole	and	to	investigate	all	 other	 segments	 of	 influenza	 virus	 genome	 34,35,90.	 This	will	 be	 addressed	 in	 the	next	chapter	of	this	PhD	thesis	(genome-wide	study;	Chapter	5).	HA	D186G	and	G152E	amino	acid	 substitutions	were	 found	 in,	 respectively,	 a	 single	and	 two	NA	H275Y	OS-resistant	seasonal	 A(H1N1)	 viruses	 from	 2007/2008	 and	 2008/2009.	 Besides	 the	 structural	evidence	 that	 both	 substitutions	may	 affect	 NAI	 susceptibility	 (location	 at	 or	 near	 the	RBS),	residue	186	is	know	to	play	a	key	role	in	the	effective	binding	to	human-like	α(2,6)	receptors	91,	while	residue	152	is	associated	with	in	vitro	selection	of	an	influenza	variant	after	 serial	 passage	 under	 LAN	 drug	 pressure	 in	 2009	 pandemic	 A(H1N1)	 subtype	(K153E	variant;	2009	pandemic	H1	numbering)	92.			The	single	NA	H275Y	OS-resistant	A(H1N1)pdm09	virus	detected	exhibited	an	≈250-fold	decrease	 in	 OS	 susceptibility,	which	was	within	 the	 reference	 range	 considered	 by	 the	WHO	 AVWG	 for	 NA	 H275Y	 substitution	 in	 a	 2009	 pandemic	 N1	 background	 (221	 to	1637-fold)	 80.	The	virus	also	exhibited	an	amino	acid	substitution	near	 the	RBS	 in	HA	 -	N156D	 substitution,	 but	 probably	 as	 an	 artefact	 of	 cell	 culture.	 Several	 amino	 acid	substitutions	 at	 residue	 156	 of	 H1	 HA,	 including	 the	 one	 identified	 in	 this	 virus	(N156D/S/K/T),	have	been	described	as	 commonly	but	not	exclusively	associated	with	virus	 propagation	 in	 cell	 culture	 93,94.	 NA	 H275Y	 substitution	was	 also	 detected	 in	 the	clinical	 specimen	 from	 another	 case	 of	 A(H1N1)pdm09	 virus	 infection	 received	 in	2010/2011	with	a	high	level	of	suspicion	of	clinical	resistance	to	OS,	but	in	only	26.2%	of	the	virus	population.	The	patient	was	also	hospitalized	with	severe	influenza	illness	but	had	 no	 underlying	 risk	 condition.	 However,	 it	 was	 not	 possible	 to	 analyse	 this	 mixed	population	of	H275Y/H	virus	through	phenotypic	assay,	as	not	enough	volume	of	clinical	specimen	was	available	 for	 viral	 isolation.	According	 to	 the	WHO	 laboratory	guidelines	for	interpretation	of	NA	H275Y/H	mixed	virus	populations,	this	case	should	be	defined	as	ambiguous	and	not	as	resistant	(H275Y	variant	≥50%)	95.	Patient	clinical	data	suggested,	however,	 that	 this	minor	 viral	 sub-population	 of	NA	H275Y	OS-resistant	 viruses	might	have	been	sufficient	to	reduce	treatment	efficacy	(clinical	suspicion	of	resistance).	Since	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	157		no	 information	was	available	about	 the	 timing	between	 the	onset	of	symptoms	and	 the	beginning	 of	 antiviral	 therapy,	which	 is	 critical	 for	 treatment	 efficacy	 (<48h)	 96,	 it	was	decided	 to	 more	 accurately	 define	 the	 case	 as	 ambiguous.	 Mixed	 populations	 of	 NA	H275Y/H	 A(H1N1)pdm09	 viruses	 have	 been	 identified	 worldwide	 in	 either	 clinical	specimens	or	virus	isolates,	creating	additional	challenges	in	the	laboratory	diagnosis	of	resistance	95,97.	The	two	NA	H275Y	A(H1N1)pdm09	variant	viruses	detected	in	Portugal	emerged	 under	 drug-selective	 pressure	 (OS	 therapy),	 which	 is	 in	 agreement	 with	 the	major	 role	 that	 drug	 use	 has	 been	 playing	 in	 the	 emergence	 of	 OS	 resistance	 in	 2009	A(H1N1)	 pandemic	 subtype.	 Most	 NA	 H275Y	 OS-resistant	 A(H1N1)pdm09	 viruses	detected	 worldwide	 were	 recovered	 from	 patients	 undergoing	 OS	 therapy,	 many	 of	whom	also	shared	an	immunocompromised	condition	59.			
4.2.3.2	Influenza	Viruses	with	Decreased	Susceptibility	to	Oseltamivir	and/or	Zanamivir			Decreased	 susceptibility	 to	OS	 and/or	ZA	was	detected	 in	 all	 influenza	 virus	 types	 and	subtypes,	in	a	limited	number	of	viruses	with	no	known	association	to	drug	use	–	natural	decreased	susceptibility.	No	predominance	for	decreased	susceptibility	to	either	OS	or	ZA	was	observed,	with	the	total	number	of	viruses	exhibiting	decreased	susceptibility	to	OS	(n=12;	 2	 seasonal	 A(H1N1),	 3	 A(H3N2),	 3	 B	 and	 4	 A(H1N1)pdm09),	 ZA	 (n=13;	 1	A(H3N2),	 8	 B	 and	 4	 A(H1N1)pdm09),	 or	 to	 both	 NAIs	 (n=10;	 1	 A(H3N2),	 2	 B	 and	 7	A(H1N1)pdm09)	being	very	similar.	Also,	all	viruses	exhibited	only	a	slight	decrease	 in	susceptibility,	 sharing	 an	 upper	 outlier	 status	 and	 a	 NI	 phenotype.	 The	 decrease	 in	susceptibility	was	 predominantly	 ≤2-fold,	 extending	 to	 3	 and	 4-fold	 in	 few	 exceptional	cases.	The	 increasing	trend	observed	 in	the	 fold-change	decrease	 in	ZA	susceptibility	of	influenza	B	upper	outlier	viruses	over	time,	from	≤2-fold	in	2004/2005	to	≈3-fold	during	2006/2007	 to	 2008/2009	 and	 then	 to	 ≈4-fold	 in	 both	 the	 pandemic	 period	 and	2010/2011,	 was	 most	 probably	 an	 artefact	 of	 the	 combined	 analysis	 of	 B/VIC	 and	B/YAM-lineage	 viruses	 and/or	 the	 use	 of	 wide-ranging	 combined	 cut-offs	 (pandemic	period	–	2012/2013).	Both	were	needed	due	to	constraints	in	the	number	of	influenza	B	viruses	analysed,	from	either	the	non-predominant	or	both	lineages.			The	 three	 influenza	 A	 viruses	 with	 an	 ≈4-fold	 decrease	 in	 OS	 and	 ZA	(A/Portugal/43/2012,	 A(H3N2))	 or	 just	 OS	 (A/Portugal/17/2009	 and	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	158		A/Portugal/82/2009,	 A(H1N1)pdm09)	 susceptibility,	 contained	 the	 NA	 I222V	 amino	acid	substitution	(N2	numbering;	I223V	in	N1	numbering).	This	substitution	is	known	to	reduce	 OS	 susceptibility	 by	 2	 to	 4-fold	 in	 A(H3N2)	 viruses	 and	 by	 6-fold	 in	A(H1N1)pdm09	 viruses	 80,98,99,	 explaining	 therefore	 the	 decreases	 observed.	 It	 is	 also	known	 to	 reduce	 ZA	 susceptibility	 by	 2-fold	 in	 A(H1N1)pdm09	 viruses	 80,	 which	 was	precisely	 the	decrease	observed	 for	both	virus	 isolates.	 Its	effect	on	ZA	susceptibility	 is	still	 unknown	 for	 A(H3N2)	 subtype,	 but	 the	 previous	 study	 of	 Baz	 and	 colleagues	suggests	no	impact	99.	They	identified	the	NA	I222V	substitution	together	with	NA	E119V	amino	acid	substitution	in	an	A(H3N2)	virus	with	an	≈2-fold	decreased	susceptibility	to	ZA	and	 it	 is	known	that	E119V	alone	reduces	the	susceptibility	by	1	to	7-fold	80.	The	4-fold	decreased	susceptibility	of	A/Portugal/43/2012	to	ZA	may	therefore	be	a	result	of	the	 presence	 of	 NA	 D251G	 amino	 acid	 substitution.	 This	 substitution	 was	 previously	reported	in	an	A(H3N2)	virus	with	an	≈5-fold	decrease	in	ZA	susceptibility	71,	but	it	was	not	 considered	 for	 the	 list	 of	 amino	 acid	 substitutions	 in	 NA	 causing	 decreased	susceptibility	(see	Table	1.2,	Literature	Review),	as	its	minor	effect	on	susceptibility	was	not	 yet	 confirmed	by	 reverse	 genetics	 (RG).	 This	was	 the	 first	 time	 that	 both	A(H3N2)	and	A(H1N1)pdm09	viruses	carrying	NA	I222V	substitution	were	reported	in	untreated	patients.	 Previously,	 it	 had	 only	 been	 described	 in	 viruses	 recovered	 from	 patients	undergoing	 OS	 therapy,	 in	 association	 with	 NA	 E119V	 (A(H3N2))	 or	 H274Y	(A(H1N1)pdm09;	 N2	 numbering)	 substitution,	 or	 in	 reverse	 engineered	 viruses	(A(H1N1)pdm09)	 92,99-102.	Moreover,	 the	 two	NA	 I222V	A(H1N1)pdm09	variant	 viruses	were	probably	linked	through	a	transmission	event,	as	evidenced	by	the	100%	similarity	of	both	NA	and	HA	gene	sequences	and	the	close	geographic	and	temporal	relationship	of	the	cases.	NA	I222V	substitution	is	known	to	have	no	detrimental	effect	on	the	biological	fitness	of	A(H1N1)pdm09	viruses	102.		The	 presence	 of	 NA	 D197N	 amino	 acid	 substitution	 in	 44%	 of	 the	 virus	 population	comprising	the	isolate	B/Lisboa/34/2008	(D197N/D	mixed	virus	population),	explained	the	 3	 and	 ≈2-fold	 decrease	 in,	 respectively,	 ZA	 and	 OS	 susceptibility,	 this	 latter	 only	evidenced	by	chemiluminescent	assay.	NA	D197N	substitution	is	known	to	reduce	ZA	and	OS	 susceptibility	 in	 influenza	 B	 viruses	 by,	 respectively,	 2	 to	 17-fold	 and	 4	 to	 10-fold,	when	present	in	the	entire	virus	population	80.	The	chemiluminescent	assay	revealed	to	be	 better	 at	 detecting	 the	 mixture	 of	 wild-type	 virus	 and	 D197N	 mutant	 virus	 with	decreased	susceptibility,	which	 is	 in	agreement	with	 its	higher	sensitivity	 in	measuring	NA	activity,	 compared	 to	 fluorescent	MUNANA-based	assays	 103.	NA	D197N	variant	has	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	159		been	 sporadically	 detected	 in	 circulating	 influenza	 B	 viruses	 with	 no	 or	 unknown	association	to	drug	use,	particularly	in	China	and	Japan	48,104-108.	The	B/YAM-lineage	HA:	B/VIC-lineage	 NA	 reassortant	 exhibiting	 a	 2-fold	 decrease	 in	 OS	 susceptibility	 –	 virus	isolate	B/Lisboa/12/2005,	carried	the	NA	I240V	amino	acid	substitution	near	the	active	site.	The	 impact	 of	 this	 substitution	on	NAI	 susceptibility	 is	 unknown,	but	based	on	 its	location	into	the	protein	structure,	it	may	play	a	role	in	the	slight	decrease	observed.	It	is	also	 possible	 that	 this	 decrease	was	 just	 an	 artefact	 of	 the	 joint	 analysis	 of	 B/VIC	 and	B/YAM-lineage	viruses,	as	it	was	identified	against	statistical	cut-offs	based	on	essentially	IC50	values	of	B/YAM-lineage	viruses	 that	over	 the	10-year	period	studied	(2004-2013)	tended	to	be	lower	than	those	of	B/VIC	lineage.	Further	RG	studies	will	be	important	to	clarify	 the	 effect	 of	 NA	 I240V	 substitution	 on	 influenza	 B	 virus	 NAI	 susceptibility.	Phylogenetic	analysis	of	influenza	B	NA	and	HA	genes	revealed	to	be	essential	to	identify	B/Lisboa/12/2005	as	an	inter-lineage	reassortant	and	to	accurately	interpret	IC50	data.		All	other	 influenza	A	and	B	viruses	exhibiting	decreased	susceptibility	 to	OS	and/or	ZA	(≤3-fold	influenza	A;	≤4-fold	influenza	B)	contained	no	specific	amino	acid	substitution	in	NA	or	only	specific	substitutions	located	away	from	the	NA	active	site,	which	are	unlikely	to	affect	virus	susceptibility.	This	 lack	of	genetic	evidence	suggests	that	≤3-fold	and	≤4-fold	 decreases	 in	 phenotypic	 susceptibility	 can	 be	 an	 inherent	 characteristic	 of,	respectively,	influenza	A	and	B	viruses.	It	is	therefore	questionable	whether	it	would	be	more	appropriate	to	consider	these	viruses	as	sensitive,	particularly	those	containing	no	specific	NA	amino	acid	substitution.	The	A(H3N2)	virus	isolate	A/Portugal/29/2012	with	a	2-fold	decreased	susceptibility	to	OS	contained	an	amino	acid	substitution	at	the	HA	RBS	-	T135A	substitution.	Moreover,	it	is	 known	 that	 the	 amino	 acid	 change	 to	 alanine	 (A)	 at	 residue	 135	 in	 seasonal	 H1	HA	(G135A;	 G132A	 in	 H1	 numbering)	 reduces	 the	 virus’s	 binding	 affinity	 for	 cellular	receptors,	having	emerged	in	a	reassortant	virus	lacking	sialidase	activity	(compensatory	change	 for	 the	 loss	 of	 viral	 sialidase)	 109.	 Since	 HA	 amino	 acid	 changes	 with	 these	characteristics	 are	 expected	 to	 reduce	 NAI	 susceptibility	 110,	 it	 is	 possible	 that	 this	A(H3N2)	virus	isolate	presents	in	fact	a	different	susceptibility	to	NAIs	than	that	detected	
in	 vitro	 through	 NA	 inhibition	 assay	 (NA-mediated	 susceptibility).	 Further	 in	 vitro	antiviral	susceptibility	testing	accounting	for	HA-mediated	changes	is	required	to	clarify	the	 effect	 of	 H3	 HA	 T135A	 substitution.	 HA	 N129D,	 K153E	 and	 N156K	 amino	 acid	substitutions	 near	 the	 RBS	 were	 detected	 in	 the	 A(H1N1)pdm09	 virus	 isolate	A/Portugal/07/2011	 with	 an	 ≈2-fold	 decreased	 susceptibility	 to	 both	 OS	 and	 ZA.	 All	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	160		three	 substitutions	 have	 been	 reported	 among	 circulating	 A(H1N1)pdm09	 viruses,	particularly	 the	 two	 latter	 ones	 29,111,112.	 	 HA	 K153E	 substitution	 is	 known	 to	 be	 cell	culture-selected	29	and	its	presence	as	a	mixed	virus	population	(K153E/K)	supports	this	association	 to	 cell	 culture.	 Amino	 acid	 substitutions	 at	 residue	 156	 have	 also	 been	associated	with	virus	propagation	in	cell	culture,	as	above-mentioned	for	NA	H275Y	OS-resistant	 A(H1N1)pdm09	 virus,	 but	 N156K	 substitution	was	 found	more	 commonly	 in	clinical	 specimens	 than	 in	 cell	 culture	 isolates	 29.	 Also,	 HA	 N156K	 may	 play	 a	 role	 in	enhancing	viral	 fitness,	as	evidenced	 in	a	previous	 in	vivo	study	conducted	 in	 ferrets,	 in	which	 the	HA	N156K	mutant	 virus	 showed	 to	 be	 fitter	 than	 the	wild-type	 counterpart	(potential	 fitness-enhancing	 mutation)	 29.	 The	 authors	 suggested	 that	 the	 N156K	substitution	 increases	 the	 receptor-binding	 affinity	 of	 virus	 HA,	 based	 on	 the	 altered	receptor-binding	 preferences	 of	 the	mutant	 virus	 and	 on	 its	 computationally	 predicted	effect	 on	 HA	 binding,	 stability	 and	 receptor	 specificity.	 All	 other	 influenza	 viruses	exhibiting	decreased	susceptibility	contained	no	specific	HA	amino	acid	substitutions	or	only	specific	substitutions	located	away	from	the	RBS.			
4.2.3.3	Drug-Sensitive	Viruses	and	Relevant	Amino	Acid	Changes		All	 influenza	 viruses	with	known	association	 to	 antiviral	 use	 except	 the	NA	H275Y	OS-resistant	 A(H1N1)pdm09	 virus	 A/Portugal/03/2011,	 were	 sensitive	 to	 OS	 and/or	 ZA.	This	 included	 the	A(H1N1)pdm09	 virus	 isolate	A/Portugal/28/2009,	 recovered	 from	 a	patient	 suspected	 of	 having	 developed	 drug-resistant	 influenza.	 An	 alternative	explanation	 for	 the	 reduced	 treatment	efficacy	observed	may	be	a	delay	>48h	between	the	onset	of	symptoms	and	the	beginning	of	antiviral	therapy	(starting	date	not	available)	that	is	known	to	compromise	drug	efficacy	96.		The	increased	susceptibility	to	OS	and/or	ZA	exhibited	by	several	influenza	viruses	from	all	 different	 types	 and	 subtypes	 (phenotypic	 lower	 outlier	 viruses)	 appear	 to	 be	 an	inherent	characteristic	of	these	viruses,	as	no	genetic	evidence	for	the	increase	observed	was	 found.	 The	 viruses	 contained	 either	 no	 specific	 amino	 acid	 substitution	 in	 NA	(majority)	or	only	specific	substitutions	located	far	away	from	the	active	site.		
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	161		Both	 D151N	 and	 Y155H	 amino	 acid	 substitutions	 in	 N2	 and	 2009	 pandemic	 N1	 NA,	respectively,	revealed	to	have	no	effect	on	NAI	susceptibility.	NA	D151N	substitution	was	detected	as	a	mixed	virus	population	in	an	A(H3N2)	virus	sensitive	to	both	OS	and	ZA.	Its	presence	as	viral	quasispecies	supports	 the	association	 to	virus	culturing	 that	has	been	evidenced	 in	 several	 previous	 studies	 31,113,114.	 McKimm-Breschkin	 and	 colleagues	 had	previously	described	 the	effect	of	NA	D151N	on	NAI	susceptibility	but	 the	results	were	unclear	115.	Two	of	the	D151N	A(H3N2)	variant	viruses	were	sensitive	to	both	NAIs,	while	a	 third	one	exhibited	an	≈7-fold	decreased	susceptibility	to	OS	(fluorescent	assay	data).	The	results	here	obtained	support	 the	 lack	of	effect	on	NAI	susceptibility,	but	 it	will	be	important	 to	 confirm	 this	 phenotype	 in	 more	 specific	 studies,	 using	 RG.	 Amino	 acid	substitutions	at	residue	151	in	N2	NA	are	usually	associated	with	high	decreases	in	NAI	susceptibility,	 conferring	RI	by	OS	 (D151E)	or	 (H)RI	by	ZA	 (D151A/G/V)	 80.	NA	Y155H	substitution	was	detected	in	several	A(H1N1)pdm09	viruses	sensitive	to	both	NAIs.	This	substitution	conferred	(H)RI	by	NAIs	in	former	circulating	A(H1N1)	viruses	but	its	effect	in	A(H1N1)pdm09	viruses	was	still	unknown.	These	results	were	the	first	evidence	that	NA	Y155H	substitution	has	no	effect	on	the	NAI	susceptibility	of	current	circulating	2009	pandemic	 A(H1N1)	 viruses,	 as	 timely	 reported	 in	 Giria	 et	 al.	 116.	 Similar	 results	 were	recently	obtained	in	an	influenza	antiviral	susceptibility	surveillance	study	carried	out	in	Spain,	 confirming	 the	 lack	 of	 effect	 of	 NA	 Y155H	 117.	 Structural	 differences	 between	seasonal	and	2009	pandemic	N1	NA	may	explain	the	virus-specific	nature	of	the	effect	of	this	 substitution	 on	 susceptibility.	 The	 lack	 of	 the	 150-cavity	 characteristic	 of	 group	 1	NAs	 in	2009	pandemic	N1	NA	 is	 the	main	 feature	distinguishing	 the	 structure	of	 these	two	N1	NAs.	But,	it	probably	does	not	explain	the	difference	observed,	as	avian	influenza	A(H5N1)	 viruses	 carrying	 NA	 Y155H	 substitution	 were	 also	 sensitive	 to	 NAIs	 and	 the	150-cavity	is	present	in	their	NA	98.		The	R142G	and	S262N	amino	acid	substitutions	in	H3	HA	known	to	occur	clinically	under	OS	 drug-selective	 pressure	 118,119,	 were	 detected	 in	 single	 sensitive	 viruses	 with,	respectively,	 known	 and	 unknown	 association	 to	 drug	 use.	 The	 D222G	 amino	 acid	substitution	in	2009	pandemic	H1	HA	was	also	detected	in	a	single	virus	sensitive	to	both	NAIs	 in	 NA	 inhibition	 assay.	 This	 amino	 acid	 substitution	 is	 known	 to	 cause	 a	 high	decrease	 (≤100-fold)	 in	 the	 NAI	 susceptibility	 of	 former	 circulating	 A(H1N1)	 viruses	(D221G;	seasonal	H1	numbering)	49,	but	in	2009	pandemic	A(H1N1)	subtype	it	was	only	selected	 in	vitro	after	serial	passages	under	drug-selective	pressure	(LAN)	92.	Further	 in	
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vitro	 susceptibility	 testing	 is	 essential	 to	 determine	 how	 these	 three	 HA	 amino	 acid	substitutions	 affect	NAI	 susceptibility	 in	 the	 specific	 influenza	 virus	 subtypes	on	which	were	detected	 (HA-mediated	susceptibility).	Based	on	both	epidemiological	and	clinical	data,	 it	 is	 not,	 however,	 expected	 a	 significant	 impact	 for	 HA	 D222G	 substitution.	 HA	D222G	 variant	 has	 been	 detected	 at	 low	 to	 medium-low	 rates	 (5%	 to	 24%)	 in	A(H1N1)pdm09	viruses	recovered	from	patients	with	severe	disease	and	admitted	in	ICU	facilities	120,121.	Since	the	use	of	NAIs	is	highly	recommended	for	such	patients,	these	were	most	probably	under	antiviral	therapy	and	no	report	of	suspected	clinical	resistance	was	found	in	the	literature.			
4.2.3.4	Natural	In	Vitro	Susceptibility	of	Circulating	Viruses			The	natural	in	vitro	susceptibility	of	human	influenza	viruses	circulating	in	Portugal	from	2004/2005	to	2012/2013	to	NAIs	varied	over	time,	but	with	no	particular	trend	and	in	essentially	 different	 ways	 to	 OS	 and	 ZA.	 Given	 the	 very	 low	 prescription	 of	 NAIs	 in	Portugal	 (National	 Influenza	 Surveillance	Programme	data;	 2005/2006	 to	2008/2009),	the	variations	in	the	baseline	phenotypic	drug	susceptibility	were	unlikely	to	be	related	to	drug	use,	reflecting	most	probably	natural	evolutionary	changes	in	influenza	virus	NA.			The	marked	decrease	in	the	natural	in	vitro	susceptibility	of	circulating	seasonal	A(H1N1)	viruses	 to	 OS	 between	 2007/2008	 and	 2008/2009	 was	 driven	 by	 the	 worldwide	emergence	of	a	NA	H275Y	OS-resistant	variant	that,	as	above-mentioned,	resulted	in	an	overall	global	resistance	to	OS.	The	slight	(≤2-fold)	but	significant	change	in	their	natural	susceptibility	 to	 both	 NAIs	 between	 2005/2006	 and	 2007/2008	 also	 matched	 the	evolutionary	 drift	 from	 NC/99-like	 to	 BR/07-like	 viruses.	 The	 susceptibility	 changed,	however,	 in	 opposite	 ways	 for	 the	 two	 NAIs,	 decreasing	 for	 OS	 and	 increasing	 for	 ZA.	Previous	studies	showed	that	the	NA	of	BR/07-like	viruses	had	a	higher	affinity	for	sialic	acid	 (natural	 substrate)	 and	 OS	 and	 ZA,	 compared	 to	 NC/99-like	 viruses	 35,82,84,	supporting	 the	 role	 of	 evolutionary	 drift	 in	 the	 increased	 natural	 susceptibility	 of	 the	viruses	to	ZA.	This	role	may	have	been	played	by	NA	R222Q	and/or	D344N	amino	acid	substitutions	(D344N	only	not	present	in	one	reference	BR/07-like	virus)	that	are	known	to	significantly	increase	NA	binding	affinity	for	the	substrate	(fitness-compensatory	role	in	NA	H275Y	variant)	34-37.	All	other	NA	amino	acid	substitutions	characteristic	of	BR/07-
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	163		like	 viruses	 except	 G249K	 are	 located	 distantly	 from	 the	 active	 site	 and	 thereby	 are	unlikely	 to	 affect	 NA	 binding	 affinity.	 The	 lower	 natural	 susceptibility	 of	 BR/07-like	viruses	to	OS	is	puzzling	and	difficult	to	understand	as	it	goes	against	the	known	higher	affinity	of	the	virus	NA	for	drug	binding.		The	change	to	a	new	drift	variant	may	also	explain	the	2-fold	decrease	in	the	natural	 in	
vitro	susceptibility	of	circulating	A(H3N2)	viruses	to	OS	and	ZA	between	2008/2009	and	2011/2012.	 A(H3N2)	 viruses	 from	 2011/2012	 onwards	 belonged	 to	 the	 Victoria/208	genetic	 clade,	 while	 those	 circulating	 previously	 belonged	 to	 either	 Brisbane/10,	Wisconsin/67	 or	 California/07	 genetic	 clades.	 Based	 on	 its	 occurrence	 near	 the	 active	site,	both	NA	amino	acid	 substitutions	 characterizing	A/Victoria/208/2009-like	viruses	(S367N	and	K369T)	could	have	played	a	role	in	this	decrease.		The	slightly	lower	natural	in	vitro	susceptibility	of	influenza	B	viruses	circulating	during	the	pandemic	period	to	OS	(2	to	3-fold)	and	of	those	circulating	during	2005/2006	to	ZA	(2	to	≈4-fold)	were	probably	artefacts	of,	respectively,	the	use	of	wide-ranging	combined	cut-offs	 and	 joint	 analysis	 of	 B/VIC	 and	B/YAM-lineage	 viruses.	 The	potential	 role	 that	influenza	B	 lineage	 plays	 in	NAI	 susceptibility,	 particularly	 to	 ZA,	 evidenced	 by	 overall	comparative	analysis	of	the	non-outlier	IC50	values	of	B/VIC	and	B/YAM-lineage	viruses,	supports	 this	 latter.	 A	 decrease	 in	 influenza	B	 virus	 natural	 susceptibility	 to	NAIs,	 less	evident	 for	 OS,	 was	 also	 observed	 between	 2004/2005	 and	 2005/2006	 in	 a	 previous	susceptibility	surveillance	study	covering	the	period	from	1998/1999	to	2005/2006	122.	However,	the	authors	attributed	the	decrease	to	the	evolutionary	drift	 in	NA	and	not	to	virus	 lineage,	 considering	 that	 the	 NAs	 of	 the	 B/VIC-lineage	 viruses	 circulating	 in	2005/2006	were	 still	 from	 the	 B/YAM	 lineage	 (origin	 in	 a	 B/VIC-lineage	 HA:	 B/YAM-lineage	NA	reassortant	 from	2001/2002).	Two	of	 the	NA	amino	acid	substitutions	here	identified	as	specific	of	B/VIC-lineage	viruses	-	NA	K219N	and	K373E,	were	also	reported	in	this	previous	study	for	the	B/VIC-lineage	viruses	from	2005/2006.	Both	substitutions	occurred	 near	 the	 active	 site	 and	 thereby	 may	 have	 played	 a	 role	 in	 the	 decrease	observed.	 Large-scale	 in	 vitro	 NAI	 susceptibility	 testing	 of	 B/VIC	 and	 B/YAM-lineage	viruses	is	essential	to	clarify	the	effect	of	influenza	B	lineage	on	NAI	susceptibility,	even	more	when	 the	 recent	worldwide	 study	of	Okomo-Adhiambo	 and	 colleagues	 suggested	its	impact	on	exclusively	OS	susceptibility	(no	impact	on	ZA,	PER	and	LAN	susceptibility)	73.	
																																																													Antiviral	susceptibility	profile	of	circulating	influenza	viruses	|	164		No	 genetic	 evidence	 in	 NA	 was	 found	 for	 the	 slight	 decrease	 in	 the	 natural	 in	 vitro	susceptibility	 of	 A(H1N1)pdm09	 viruses	 to	 OS	 between	 the	 pandemic	 period	 and	2010/2011.	 Only	 the	NA	N369K	 amino	 acid	 substitution	 that	 is	 known	 to	 significantly	increase	NA	 binding	 affinity	 for	 the	 substrate	 (fitness-compensatory	 role	 in	NA	H275Y	variant)	 42,	 distinguished	 the	 A(H1N1)pdm09	 viruses	 from	 these	 two	 time	 periods.	 If	affecting	NAI	susceptibility,	 this	substitution	would	 increase	and	not	decrease	 the	virus	natural	 susceptibility	 to	 the	 drug.	 It	 is	 important	 to	 note	 that	 this	 decrease	 in	susceptibility	occurred	after	the	higher	use	of	OS	during	2009	influenza	pandemic	123.			Further	RG	 studies	will	 be	 essential	 to	 confirm	 the	 role	 of	 seasonal	N1	NA	R222Q	 and	D344N,	 N2	 NA	 S367N	 and	 K369T,	 and	 influenza	 B	 NA	 K219N	 and	 K373E	 amino	 acid	substitutions	in	NAI	susceptibility.		Both	former	and	current	circulating	A(H1N1)	viruses,	as	well	as	influenza	B	viruses,	were	more	susceptible	to	ZA	than	to	OS,	while	the	inverse	was	observed	in	A(H3N2)	subtype.	These	 drug-specific	 differences	 have	 been	 reported	 in	 other	 worldwide	 98,115,124	 and	national	NAI	susceptibility	surveillance	studies	67,68,125-128,	and	are	known	to	be	related	to	differences	in	the	chemical	structure	of	the	drugs	129.	OS	and	ZA	have	different	core	ring	structures	and	active	moieties,	binding	differently	at	the	enzyme	catalytic	site	36,130.	Drug-specific	differences	up	 to	5-fold	were	here	observed	 in	 type	B	 influenza,	while	 those	 in	influenza	A	subtypes	varied	up	to	3-fold	except	in	seasonal	A(H1N1)	viruses	(≤2-fold).			Influenza	 virus	 natural	 susceptibility	 to	 OS	 and	 ZA	 also	 differed	 according	 to	 the	 virus	type	and	subtype,	in	a	similar	way	to	both	drugs.	The	only	exception	were	the	A(H3N2)	and	A(H1N1)pdm09	viruses	that	exhibited	a	similar	overall	susceptibility	to	ZA.	Overall,	the	 differences	 observed	 were	 ordered	 as	 follows:	 B	 <	 seasonal	 A(H1N1)	 <	A(H1N1)pdm09	<oseltamivir/~zanamivir	A(H3N2).	The	same	order	has	been	reported	for	OS	in	other	worldwide	71,115,124	and	national	NAI	susceptibility	surveillance	studies	67,126-128,131.	But,	 in	 all	 of	 them	 except	 one	 67,	 A(H3N2)	 viruses	 were	 less	 susceptible	 to	 ZA	 than	seasonal	A(H1N1)	viruses.	Influenza	type	and	subtype-specific	differences	are	likely	to	be	related	to	differences	in	the	structure	of	the	virus	NAs	that	can	result	in	different	binding	affinities	 for	 the	 drug	 125.	 Based	 on	 the	 lesser	 therapeutic	 response	 to	 OS	 observed	 in	patients	with	influenza	B	illness	compared	to	those	with	influenza	A	72,132,133,	it	has	been	
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4.3	CONCLUSIONS		This	 study	 marked	 the	 beginning	 of	 influenza	 antiviral	 susceptibility	 testing	 and	monitoring	activities	in	Portugal.	As	the	activities	were	extended	over	a	wide	time	period	(10	years;	2004-2013),	it	also	generated	comprehensive	information	on	the	susceptibility	of	 circulating	 human	 influenza	 viruses	 to	 the	 three	 antivirals	 approved	 nationally	 for	clinical	use	(AMA,	OS,	and	ZA).	This	information	contributed	to	the	global	and	European	influenza	surveillance	on	antiviral	susceptibility	and	allowed	to	 improve	the	knowledge	on	 the	 relationship	between	virus	NAI	 susceptibility	phenotype	and	genotype,	which	 is	one	of	 the	major	 current	 challenges	 in	 the	 field,	 and	on	 the	natural	 variations	 in	 the	 in	
vitro	 susceptibility	 of	 circulating	 viruses	 over	 time.	 In	 a	 broader-sense,	 this	 study	 also	provided	a	better	understanding	of	the	evolutionary	dynamics	of	influenza	virus	NA	and	HA	genes.		
BOX	4.2	-	MAIN	FINDINGS	
Specific	objective	1(b)	
	 M2	inhibitor	resistance	
• M2	 inhibitor	 resistance	 was	 detected	 in	 A(H3N2)	 subtype	 since	 2005/2006	 (S31N,	 except	 3	S31N/V27A	double	mutants)	and	 in	A(H1N1)pdm09	subtype	 since	 its	 emergence	 (S31N;	naturally-occurring	resistance).		
• The	frequency	of	A(H3N2)	drug-resistant	viruses	varied	 initially	between	100%	and	74.5%,	settling		at	100%	from	2008/2009	onwards.	
OS	and	ZA	susceptibility	
• Virtually	 all	human	 influenza	viruses	circulating	 in	Portugal	 from	2004/2005	 to	2012/2013,	 except	those	from	seasonal	A(H1N1)	subtype,	were	sensitive	to	OS	and	ZA.	
• OS	 resistance	 in	 seasonal	 A(H1N1)	 subtype	 increased	 from	 20.7%	 in	 2007/2008	 to	 100%	 in	2008/2009.	All	cases	were	associated	with	the	worldwide	spread	of	a	fit	and	transmissible	NA	H275Y	OS-resistant	variant.	
• NA	 H275Y	OS-resistant	 viruses	 belonged	 to	 the	 genetic	 clade	 2B	 (Northern	 European	 lineage)	 and	apparently	 resulted	 from	 three	 different	 introductions	 of	 the	NA	H275Y	 variant	 in	 Portugal	 during	2007/2008	and	2008/2009.	
• OS	resistance	 in	A(H1N1)pdm09	subtype	was	detected	 in	a	 single	virus	 from	2010/2011	 recovered	from	 an	 immunocompromised	 and	 pregnant	 patient	 under	 antiviral	 therapy	 (suspected	 case	 of	clinical	resistance).	
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• A	patient	 clinically	 suspected	of	having	developed	drug-resistant	 influenza	harboured	a	minor	 viral	sub-population	of	NA	H275Y	OS-resistant	A(H1N1)pdm09	virus	(<30%).			
• Few	influenza	viruses	from	all	different	types	and	subtypes	exhibited	a	natural	≤2	to	4-fold	decreased	susceptibility	to	OS	and/or	ZA	(NI	phenotype;	no	known	association	to	drug	use).		
• NA	I222V	amino	acid	substitution	(N2	numbering)	conferred	the	≈4-fold	decrease	in	OS	susceptibility	observed	 in	a	 single	A(H3N2)	virus	and	 in	 two	A(H1N1)pdm09	viruses.	 It	 also	 conferred	 the	2-fold	decreased	susceptibility	to	ZA	exhibited	by	both	A(H1N1)pdm09	viruses.	
• NA	 I222V	 A(H3N2)	 and	A(H1N1)pdm09	 variants	were	 for	 the	 first	 time	 recovered	 from	untreated	patients.	
• NA	 D251G	 amino	 acid	 substitution	may	 confer	 a	 4-fold	 decreased	 susceptibility	 to	 ZA	 in	 A(H3N2)	subtype	(novel	amino	acid	change).	
• A	 sub-population	 of	 NA	 D197N	 influenza	 B	 virus	 (44%)	 exhibited	 a	 3	 and	 ≈2-fold	 decreased	susceptibility	to	ZA	and	OS,	respectively.	
• NA	D151N	(N2	numbering)	and	NA	Y155H	(N1	numbering)	amino	acid	substitutions	have	no	effect	on	NAI	susceptibility	in,	respectively,	A(H3N2)	and	A(H1N1)pdm09	subtypes.	
• An	A(H1N1)pdm09	virus	with	≈2-fold	decreased	susceptibility	to	OS	and	ZA	harboured	the	potential	fitness-enhancing	HA	N156K	mutation.		
Specific	objective	1(c)	
• Fold	decreases	≤3	and	≤4	in	in	vitro	NAI	susceptibility	(phenotype)	can	be	an	inherent	characteristic	of,	 respectively,	 influenza	 A	 and	 B	 viruses,	 having	 no	 amino	 acid	 genetic	 change	 underlying	 it	(genotype).		
Specific	objective	1(d)	
• Natural	in	vitro	NAI	susceptibility	of	circulating	human	influenza	viruses	varied	over	time	but	with	no	particular	trend	and	in	essentially	different	ways	to	OS	and	ZA.	
• Marked	 decrease	 in	 the	 natural	 in	 vitro	 susceptibility	 of	 seasonal	 A(H1N1)	 viruses	 to	 OS	 between	2007/2008	and	2008/2009	as	a	result	of	the	worldwide	spread	of	a	 fit	and	transmissible	NA	H275Y	OS-resistant	variant	(only	drug-resistant	viruses	circulated	in	2008/2009	–	IC50	outlier	median).		
• Evolutionary	 drift	 to	 A/Brisbane/59/2007-like	 viruses	 in	 seasonal	 A(H1N1)	 subtype	 and	 to	A/Victoria/208/2009-like	viruses	in	A(H3N2)	subtype	might	have	had	a	minor	(≤2-fold	change)	but	significant	impact	on	virus	natural	susceptibility	to	OS	and/or	ZA.	
• Influenza	B	lineage	may	play	a	role	in	virus	susceptibility	to	OS	and	particularly	ZA.	
• Natural	in	vitro	 susceptibility	of	A(H1N1)pdm09	viruses	 to	OS	decreased	slightly	 (<2-fold)	after	the	higher	use	of	the	drug	during	2009	influenza	pandemic	but	no	genetic	support	was	found.	
Complementary	study	on	influenza	antiviral	prescription		
• Antivirals	were	rarely	prescribed	to	patients	presenting	with	ILI	to	healthcare	systems	covered	by	the	National	Influenza	Surveillance	Programme	in	Portugal	from	2005/2006	to	2008/2009,	reflecting	the	national	 public	 health	 policy	 for	 antiviral	 therapy	 in	 seasonal	 influenza	 that,	 at	 that	 time,	 was	essentially	restricted	to	patients	with	underlying	risk	conditions.		
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Table	S4.1	List	of	the	accession	number	of	the	hemagglutinin	and	neuraminidase	nucleotide	sequences	of	influenza	viruses	circulating	in	Portugal	used	in	this	study	and	shared	in	public-access	databases.																																			 																													
Influenza)virus)type/subtype Influenza)season/)Pandemic)perioda Sequence)database Accession)number Segment Virus)isolateEU128342 HA A/Lisboa/04/2004EU128343 HA A/Lisboa/05/2004EU128344 HA A/Lisboa/06/2005EU128346 HA A/Lisboa/10/2005EU128345 HA A/Lisboa/12/2005EU128347 HA A/Lisboa/15/2005EU128348 HA A/Lisboa/23/2005EU128350 HA A/Lisboa/33/2005EU128351 HA A/Lisboa/34/2005EU128352 HA A/Lisboa/40/2005EU128353 HA A/Lisboa/41/2005EU128354 HA A/Lisboa/50/2005EU128355 HA A/Lisboa/51/2005EU128357 HA A/Lisboa/53/2005EU128358 HA A/Lisboa/82/2005EU128359 HA A/Lisboa/87/2005EU128361 HA A/Lisboa/90/2005EU128362 HA A/Lisboa/91/2005EU370378 HA B/Lisboa/01/2004EU370381 HA B/Lisboa/03/2005EU370386 HA B/Lisboa/11/2005EU370387 HA B/Lisboa/12/2005EU370388 HA B/Lisboa/13/2005EU370389 HA B/Lisboa/19/2005EU370390 HA B/Lisboa/22/2005EU370379 HA B/Lisboa/32/2005EPI500665 HA A/Portugal/01/2009EPI500664 NA A/Portugal/01/2009EPI500667 HA A/Portugal/02/2009EPI500666 NA A/Portugal/02/2009EPI500669 HA A/Portugal/03/2009EPI500668 NA A/Portugal/03/2009EPI500671 HA A/Portugal/04/2009EPI500670 NA A/Portugal/04/2009EPI500673 HA A/Portugal/05/2009EPI500672 NA A/Portugal/05/2009EPI500675 HA A/Portugal/06/2009EPI500674 NA A/Portugal/06/2009EPI500677 HA A/Portugal/07/2009EPI500676 NA A/Portugal/07/2009EPI500679 HA A/Portugal/08/2009EPI500678 NA A/Portugal/08/2009EPI500681 HA A/Portugal/09/2009EPI500680 NA A/Portugal/09/2009EPI500683 HA A/Portugal/10/2009EPI500682 NA A/Portugal/10/2009EPI500685 HA A/Portugal/11/2009EPI500684 NA A/Portugal/11/2009EPI500687 HA A/Portugal/12/2009EPI500686 NA A/Portugal/12/2009EPI500689 HA A/Portugal/13/2009EPI500688 NA A/Portugal/13/2009EPI500691 HA A/Portugal/14/2009EPI500690 NA A/Portugal/14/2009EPI500693 HA A/Portugal/15/2009EPI500692 NA A/Portugal/15/2009EPI500696 HA A/Portugal/17/2009EPI500695 NA A/Portugal/17/2009EPI500698 HA A/Portugal/18/2009EPI500697 NA A/Portugal/18/2009EPI500700 HA A/Portugal/19/2009EPI500699 NA A/Portugal/19/2009EPI500702 HA A/Portugal/23/2009EPI500701 NA A/Portugal/23/2009
Pandemic)period GISAID)EPIFLUTM)
A(H3N2) 2004/2005 NCBI)Influenza)Virus)Resource)
B 2004/2005 NCBI)Influenza)Virus)Resource)
A(H1N1)pdm09
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(Table	S4.1	cont.)																																
	a	2009	pandemic	period	–	from	11th	June	2009	to	9th	August	2010;	NA:	Neuraminidase;	HA:	Hemagglutinin	NCBI	Influenza	Virus	Resource	database:	http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html	GISAID	EpiFlu™	database:	http://platform.gisaid.org.	The	sequences	were	either	generated	in	this	study	or	were	already	available	at	the	laboratory	sequence	database,	having	been	obtained	in	the	context	of	the	study	on	the	evolutionary	dynamics	of	the	two	major	antigens	of	influenza	viruses.		
Influenza)virus)type/subtype Influenza)season/)Pandemic)perioda Sequence)database Accession)number Segment Virus)isolateEPI500704 HA A/Portugal/25/2009EPI500703 NA A/Portugal/25/2009EPI500706 HA A/Portugal/26/2009EPI500705 NA A/Portugal/26/2009EPI500708 HA A/Portugal/27/2009EPI500707 NA A/Portugal/27/2009EPI500710 HA A/Portugal/28/2009EPI500709 NA A/Portugal/28/2009EPI500712 HA A/Portugal/30/2009EPI500711 NA A/Portugal/30/2009EPI500714 HA A/Portugal/31/2009EPI500713 NA A/Portugal/31/2009EPI500716 HA A/Portugal/33/2009EPI500715 NA A/Portugal/33/2009EPI500718 HA A/Portugal/41/2009EPI500717 NA A/Portugal/41/2009EPI500720 HA A/Portugal/45/2009EPI500719 NA A/Portugal/45/2009EPI500722 HA A/Portugal/46/2009EPI500721 NA A/Portugal/46/2009EPI500724 HA A/Portugal/47/2009EPI500723 NA A/Portugal/47/2009EPI500727 HA A/Portugal/52/2009EPI500726 NA A/Portugal/52/2009EPI500729 HA A/Portugal/53/2009EPI500728 NA A/Portugal/53/2009EPI500731 HA A/Portugal/63/2009EPI500730 NA A/Portugal/63/2009EPI500733 HA A/Portugal/64/2009EPI500732 NA A/Portugal/64/2009EPI500735 HA A/Portugal/66/2009EPI500734 NA A/Portugal/66/2009EPI500737 HA A/Portugal/77/2009EPI500736 NA A/Portugal/77/2009EPI500739 HA A/Portugal/78/2009EPI500738 NA A/Portugal/78/2009EPI500741 HA A/Portugal/80/2009EPI500740 NA A/Portugal/80/2009EPI500743 HA A/Portugal/82/2009EPI500742 NA A/Portugal/82/2009EPI500745 HA A/Portugal/90/2009EPI500744 NA A/Portugal/90/2009EPI500747 HA A/Portugal/101/2009EPI500746 NA A/Portugal/101/2009EPI500749 HA A/Portugal/114/2009EPI500748 NA A/Portugal/114/2009EPI500752 HA A/Portugal/01/2010EPI500751 NA A/Portugal/01/2010EPI500755 HA A/Portugal/02/2010EPI500754 NA A/Portugal/02/2010EPI500757 HA A/Portugal/03/2011EPI500756 NA A/Portugal/03/2011EPI500759 HA A/Portugal/07/2011EPI500758 NA A/Portugal/07/2011EPI500761 HA A/Portugal/10/2011EPI500760 NA A/Portugal/10/2011EPI500764 HA A/Portugal/21/2011EPI500763 NA A/Portugal/21/2011EPI500766 HA A/Portugal/22/2011EPI500765 NA A/Portugal/22/2011EPI500769 HA A/Portugal/28/2011EPI500768 NA A/Portugal/28/2011
2010/2011 GISAID)EPIFLUTM)
A(H1N1)pdm09
Pandemic)period GISAID)EPIFLUTM)
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I	acknowledge	the	authors,	originating	and	submitting	laboratories	of	the	HA	and	NA	nucleotide	sequences	of	worldwide	reference	influenza	viruses	retrieved	from	GISAID	EpiFlu™	and	NCBI	Influenza	Virus	Resource	databases	that	were	used	in	this	study.				
Table	 S4.2	 Detailed	 information	 on	 the	 hemagglutinin	 and	 neuraminidase	 nucleotide	 sequences	 of	 worldwide	 reference	 influenza	 viruses	 used	 in	 this	 study,	retrieved	from	GISAID	EpiFluTM	and	NCBI	Influenza	Virus	Resource	databases.		
		
Influenza)(sub)type Accession)number Segment Country Collection)date)(year;month;day) Reference)virus Originating)Lab Submitting)Lab AuthorsEPI249530 HA Australia 2007;Jan;01 A/Brisbane/59/2007 ; Other)Database)Import Webby,R.;)Webster,R.G.;)Govorkova,E.;)Duan,S.EPI249532 NA Australia 2007;Jan;01 A/Brisbane/59/2007 ; Other)Database)Import Webby,R.;)Webster,R.G.;)Govorkova,E.;)Duan,S.EPI58144 HA Chile 1983;Jan;01 A/Chile/01/1983 ; Other)Database)Import ;EPI58149 NA Chile 1983;Jan;01 A/Chile/01/1983 ; Other)Database)Import ;EPI357133 HA Egypt 2007;Oct;31 A/Egypt/10/2007 VACSERA National)Institute)for)Medical)Research ;EPI357134 NA Egypt 2007;Oct;31 A/Egypt/10/2007 VACSERA National)Institute)for)Medical)Research ;EPI509645 HA United)Kingdom 2004;May;20 A/England/40/2004 Health)Protection)Agency National)Institute)for)Medical)Research ;EPI509646 NA United)Kingdom 2004;May;20 A/England/40/2004 Health)Protection)Agency National)Institute)for)Medical)Research ;EPI141301 NA United)Kingdom 2007;Nov;15 A/England/557/2007 ; Other)Database)Import ;EPI168135 HA United)Kingdom 2007;Nov;15 A/England/557/2007 ; Other)Database)Import ;EPI155237 HA Japan 2006;Jan;17 A/Fukushima/141/2006 ; Centers)for)Disease)Control)and)Prevention ;EPI155235 NA Japan 2006;Jan;17 A/Fukushima/141/2006 ; Centers)for)Disease)Control)and)Prevention ;EPI211553 HA Hong)Kong)(SAR) 2008;Jul;24 A/Hong)Kong/1856/2008 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI211567 NA Hong)Kong)(SAR) 2008;Jul;24 A/Hong)Kong/1856/2008 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI509649 HA Hong)Kong)(SAR) 2004;Jun;24 A/Hong)Kong/2637/2004 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI116196 NA China 2004;Jan;01 A/Hong)Kong/2637/2004 ; Other)Database)Import ;EPI509368 HA Hong)Kong)(SAR) 2006;Jul;17 A/Hong)Kong/2652/2006 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI509369 NA Hong)Kong)(SAR) 2006;Jul;17 A/Hong)Kong/2652/2006 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI509650 HA Hong)Kong)(SAR) 2004;Jun;29 A/Hong)Kong/2765/2004 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI509651 NA Hong)Kong)(SAR) 2004;Jun;29 A/Hong)Kong/2765/2004 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI229176 HA Hong)Kong)(SAR) 2008;Nov;24 A/Hong)Kong/3192/2008 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI229175 NA Hong)Kong)(SAR) 2008;Nov;24 A/Hong)Kong/3192/2008 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI211552 HA Netherlands 2007;Oct;12 A/Netherlands/345/2007 Erasmus)University)of)Rotterdam National)Institute)for)Medical)Research ;EPI211551 NA Netherlands 2007;Oct;12 A/Netherlands/345/2007 Erasmus)University)of)Rotterdam National)Institute)for)Medical)Research ;EPI159392 HA New)Caledonia 1999;Jan;01 A/New8Caledonia/20/1999 ; Other)Database)Import ;EPI159394 NA New)Caledonia 1999;Jan;01 A/New8Caledonia/20/1999 ; Other)Database)Import ;EPI357156 HA Norway 2007;Dec;08 A/Norway/1735/2007 Norwegian)Institute)of)Public)Health National)Institute)for)Medical)Research ;EPI357157 NA Norway 2007;Dec;08 A/Norway/1735/2007 Norwegian)Institute)of)Public)Health National)Institute)for)Medical)Research ;EPI509308 HA France 2006;Nov;30 A/Paris/160/2007 Institut)Pasteur National)Institute)for)Medical)Research ;EPI509309 NA France 2006;Nov;30 A/Paris/160/2007 Institut)Pasteur National)Institute)for)Medical)Research ;EPI211539 HA Seychelles 2008;Mar;06 A/Seychelles/2239/2008 Institut)Pasteur)de)Madagascar National)Institute)for)Medical)Research ;EPI211540 NA Seychelles 2008;Mar;06 A/Seychelles/2239/2008 Institut)Pasteur)de)Madagascar National)Institute)for)Medical)Research ;EPI58239 HA Singapore 1986;Jan;01 A/Singapore/06/1986 ; Other)Database)Import ;EPI58244 NA Singapore 1986;Jan;01 A/Singapore/06/1986 ; Other)Database)Import ;EPI123778 HA Solomon)Islands 2006;Aug;21 A/Solomon8Islands/03/2006 ; Other)Database)Import ;EPI123696 NA Solomon)Islands 2006;Aug;21 A/Solomon8Islands/03/2006 ; Other)Database)Import ;EPI168229 HA Russian)Federation 2008;Feb;13 A/St.)Petersburg/12/2008 ; Centers)for)Disease)Control)and)Prevention ;EPI172726 NA Russian)Federation 2008;Feb;13 A/St.)Petersburg/12/2008 ; Centers)for)Disease)Control)and)Prevention ;EPI117358 HA Australia 2005;Oct;07 A/Sydney/550/2005 ; Other)Database)Import ;EPI105054 HA Taiwan 1986;Jan;01 A/Taiwan/01/1986 ; Other)Database)Import ;EPI105058 NA Taiwan 1986;Jan;01 A/Taiwan/01/1986 ; Other)Database)Import ;EPI347370 HA Greece 2005;Feb;03 A/Thessaloniki/24/2005 Aristotelian)University)of)Thessaloniki National)Institute)for)Medical)Research ;EPI166680 NA Greece 2005;Feb;03 A/Thessaloniki/24/2005 ; Other)Database)Import ;EPI230610 HA Russian)Federation 1977;Jan;01 A/USSR/90/1977 ; Other)Database)Import NIAID)Influenza)Genome)Sequencing)ConsortiumEPI230612 NA Russian)Federation 1977;Jan;01 A/USSR/90/1977 ; Other)Database)Import NIAID)Influenza)Genome)Sequencing)Consortium
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Influenza)(sub)type Accession)number Segment Country Collection)date)(year;month;day) Reference)virus Originating)Lab Submitting)Lab AuthorsEPI349374 HA United)States 2011;Dec;07 A/Alabama/04/2011 ADPH)Bureau)of)Clinical)Laboratories Centers)for)Disease)Control)and)Prevention ;EPI349373 NA United)States 2011;Dec;07 A/Alabama/04/2011 ADPH)Bureau)of)Clinical)Laboratories Centers)for)Disease)Control)and)Prevention ;EPI278805 HA United)States 2010;Jul;13 A/Alabama/05/2010 U.S.)Air)Force)School)of)Aerospace)Medicine Centers)for)Disease)Control)and)Prevention ;EPI278804 NA United)States 2010;Jul;13 A/Alabama/05/2010 U.S.)Air)Force)School)of)Aerospace)Medicine Centers)for)Disease)Control)and)Prevention ;EPI365898 HA China 1992;Jan;01 A/Beijing/32/1992 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI365900 NA China 1992;Jan;01 A/Beijing/32/1992 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI367190 HA China 1989;Jan;01 A/Beijing/353/1989 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI367192 NA China 1989;Jan;01 A/Beijing/353/1989 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI347409 HA Germany 2006;Feb;06 A/Berlin/02/2006 Robert;Koch;Institute National)Institute)for)Medical)Research ;EPI353304 HA Australia 2007;Feb;06 A/Brisbane/10/2007 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Iannello,P;)Komadina,NEPI353303 NA Australia 2007;Feb;06 A/Brisbane/10/2007 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Iannello,P;)Komadina,NEPI168615 HA Australia 2008;Jun;23 A/Brisbane/24/2008 ; Centers)for)Disease)Control)and)Prevention ;EPI168614 NA Australia 2008;Jun;23 A/Brisbane/24/2008 ; Centers)for)Disease)Control)and)Prevention ;EPI228963 HA United)States 2004;Jan;01 A/California/07/2004 ; Other)Database)Import Bragstad,K.;)Nielsen,L.P.;)Fomsgaard,A.EPI228966 NA United)States 2004;Jan;01 A/California/07/2004 ; Other)Database)Import Bragstad,K.;)Nielsen,L.P.;)Fomsgaard,A.EPI302283 HA United)States 2010;Dec;08 A/California/28/2010 California)Department)of)Health)Services Centers)for)Disease)Control)and)Prevention ;EPI302282 NA United)States 2010;Dec;08 A/California/28/2010 California)Department)of)Health)Services Centers)for)Disease)Control)and)Prevention ;EPI417021 HA Senegal 2012;Oct;11 A/Dakar/15/2012 Institut)Pasteur)de)Dakar National)Institute)for)Medical)Research ;EPI417022 NA Senegal 2012;Oct;11 A/Dakar/15/2012 Institut)Pasteur)de)Dakar National)Institute)for)Medical)Research ;EPI417237 HA United)States 2012;Nov;12 A/Delaware/15/2012 Delaware)Public)Health)Lab Centers)for)Disease)Control)and)Prevention ;EPI417236 NA United)States 2012;Nov;12 A/Delaware/15/2012 Delaware)Public)Health)Lab Centers)for)Disease)Control)and)Prevention ;EPI346607 HA United)Kingdom 2011;Nov;16 A/England/259/2011 Health)Protection)Agency National)Institute)for)Medical)Research ;EPI346608 NA United)Kingdom 2011;Nov;16 A/England/259/2011 Health)Protection)Agency National)Institute)for)Medical)Research ;EPI301362 HA United)Kingdom 2010;Nov;26 A/England/4820166/2010 Health)Protection)Agency National)Institute)for)Medical)Research ;EPI301361 NA United)Kingdom 2010;Nov;26 A/England/4820166/2010 Health)Protection)Agency National)Institute)for)Medical)Research ;EPI358866 HA United)Kingdom 2006;Nov;22 A/England/560/2006 ; Other)Database)Import Galiano,M.;)Johnson,B.F.;)Myers,R.;)Ellis,J.;)Daniels,R.;)et#al.EPI315043 NA United)Kingdom 2006;Nov;22 A/England/560/2006 ; Other)Database)Import Galiano,M.;)Johnson,B.F.;)Myers,R.;)Ellis,J.;)Daniels,R.;)et#al.EPI215006 HA United)Kingdom 2008;Dec;30 A/England/687/2008 Health)Protection)Agency National)Institute)for)Medical)Research ;EPI215005 NA United)Kingdom 2008;Dec;30 A/England/687/2008 Health)Protection)Agency National)Institute)for)Medical)Research ;EPI358784 HA China 2002;Jan;01 A/Fujian/411/2002 ; Other)Database)Import Galiano,M.;)Johnson,B.F.;)Myers,R.;)Ellis,J.;)Daniels,R.;)et#al.EPI358786 NA China 2002;Jan;01 A/Fujian/411/2002 ; Other)Database)Import Galiano,M.;)Johnson,B.F.;)Myers,R.;)Ellis,J.;)Daniels,R.;)et#al.EPI123249 HA United)States 2006;Dec;28 A/Hawaii/06/2006 ; Centers)for)Disease)Control)and)Prevention ;EPI123136 NA United)States 2006;Dec;28 A/Hawaii/06/2006 ; Centers)for)Disease)Control)and)Prevention ;EPI342130 HA United)States 2009;Mar;30 A/Hawaii/07/2009 State)of)Hawaii)Department)of)Health Centers)for)Disease)Control)and)Prevention ;EPI342129 NA United)States 2009;Mar;30 A/Hawaii/07/2009 State)of)Hawaii)Department)of)Health Centers)for)Disease)Control)and)Prevention ;EPI126805 HA Japan 2005;Oct;24 A/Hiroshima/52/2005 ; Other)Database)Import Krammer,F.;)Grabherr,R.EPI126807 NA Japan 2005;Oct;24 A/Hiroshima/52/2005 ; Other)Database)Import Krammer,F.;)Grabherr,R.EPI211537 HA Hong)Kong)(SAR) 2009;Mar;24 A/Hong)Kong/1952/2009 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI211538 NA Hong)Kong)(SAR) 2009;Mar;24 A/Hong)Kong/1952/2009 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI211541 HA Hong)Kong)(SAR) 2009;Apr;04 A/Hong)Kong/1985/2009 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI211542 NA Hong)Kong)(SAR) 2009;Apr;04 A/Hong)Kong/1985/2009 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI353512 HA Hong)Kong)(SAR) 2009;Apr;07 A/Hong)Kong/2000/2009 Government)Virus)Unit Centers)for)Disease)Control)and)Prevention ;EPI353511 NA Hong)Kong)(SAR) 2009;Apr;07 A/Hong)Kong/2000/2009 Government)Virus)Unit Centers)for)Disease)Control)and)Prevention ;EPI397688 HA Hong)Kong)(SAR) 2005;Jun;24 A/Hong)Kong/4443/2005 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI335923 HA United)States 2010;Dec;30 A/Iowa/19/2010 Iowa)State)Hygienic)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI335922 NA United)States 2010;Dec;30 A/Iowa/19/2010 Iowa)State)Hygienic)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI211546 HA South)Africa 2008;Jun;26 A/Johannesburg/15/2008 National)Institute)for)Communicable)Disease National)Institute)for)Medical)Research ;EPI211545 NA South)Africa 2008;Jun;26 A/Johannesburg/15/2008 National)Institute)for)Communicable)Disease National)Institute)for)Medical)Research ;EPI405934 HA South)Africa 2012;Jun;04 A/Johannesburg/3224/2012 Sandringham,)National)Institute)for)Communicable)D National)Institute)for)Medical)Research ;EPI405935 NA South)Africa 2012;Jun;04 A/Johannesburg/3224/2012 Sandringham,)National)Institute)for)Communicable)D National)Institute)for)Medical)Research ;EPI210086 HA South)Africa 2009;Jun;08 A/Johannesburg/385/2009 National)Institute)for)Communicable)Disease National)Institute)for)Medical)Research ;EPI210175 NA South)Africa 2009;Jun;08 A/Johannesburg/385/2009 National)Institute)for)Communicable)Disease National)Institute)for)Medical)Research ;EPI232568 HA Kenya 2009;Sep;15 A/Kenya/4408/2009 CDC;Kenya Centers)for)Disease)Control)and)Prevention ;EPI232567 NA Kenya 2009;Sep;15 A/Kenya/4408/2009 CDC;Kenya Centers)for)Disease)Control)and)Prevention ;EPI606852 HA Japan 2002;Dec;25 A/Kumamoto/102/2002 ; Other)Database)Import Bedford,T.;)Riley,S.;)Barr,I.G.;)Broor,S.;)Chadha,M.;)et#al.#EPI319276 HA Madagascar 2011;Feb;21 A/Madagascar/0648/2011 Institut)Pasteur)de)Madagascar National)Institute)for)Medical)Research ;EPI319277 NA Madagascar 2011;Feb;21 A/Madagascar/0648/2011 Institut)Pasteur)de)Madagascar National)Institute)for)Medical)Research ;EPI408608 HA United)States 2012;Nov;13 A/Maryland/43/2012 Maryland)Department)of)Health)and)Mental)Hygiene Centers)for)Disease)Control)and)Prevention ;EPI408607 NA United)States 2012;Nov;13 A/Maryland/43/2012 Maryland)Department)of)Health)and)Mental)Hygiene Centers)for)Disease)Control)and)Prevention ;EPI390181 HA Nepal 2006;Aug;01 A/Nepal/921/2006 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI390183 NA Nepal 2006;Aug;01 A/Nepal/921/2006 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI381971 HA United)States 2004;Jan;01 A/New)York/55/2004 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI381973 NA United)States 2004;Jan;01 A/New)York/55/2004 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI326137 HA Norway 2011;Mar;16 A/Norway/1186/2011 Norwegian)Institute)of)Public)Health National)Institute)for)Medical)Research ;EPI326138 NA Norway 2011;Mar;16 A/Norway/1186/2011 Norwegian)Institute)of)Public)Health National)Institute)for)Medical)Research ;EPI302231 HA Norway 2010;Dec;03 A/Norway/1330/2010 WHO)National)Influenza)Centre National)Institute)for)Medical)Research ;EPI302230 NA Norway 2010;Dec;03 A/Norway/1330/2010 WHO)National)Influenza)Centre National)Institute)for)Medical)Research ;
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(Table	S4.2	cont.)	
		
Influenza)(sub)type Accession)number Segment Country Collection)date)(year;month;day) Reference)virus Originating)Lab Submitting)Lab AuthorsEPI384820 HA United)States 2012;Mar;08 A/Ohio/02/2012 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)Prevention ;EPI387810 NA United)States 2012;Mar;08 A/Ohio/02/2012 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)Prevention ;EPI417031 HA France 2012;Oct;29 A/Paris/1651/2012 Institut)Pasteur National)Institute)for)Medical)Research ;EPI417032 NA France 2012;Oct;29 A/Paris/1651/2012 Institut)Pasteur National)Institute)for)Medical)Research ;EPI215031 HA France 2008;Dec;15 A/Paris/777/2008 Institut)Pasteur National)Institute)for)Medical)Research ;EPI215030 NA France 2008;Dec;15 A/Paris/777/2008 Institut)Pasteur National)Institute)for)Medical)Research ;EPI390117 HA Australia 2010;Aug;01 A/Perth/10/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI390119 NA Australia 2010;Aug;01 A/Perth/10/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI182941 HA Australia 2009;Apr;07 A/Perth/16/2009 Pathwest)QE)II)Medical)Centre WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Deng,Y;M;)Iannello,P;)Erneste,J;)Komadina,N.EPI182942 NA Australia 2009;Apr;07 A/Perth/16/2009 Pathwest)QE)II)Medical)Centre WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Deng,Y;M;)Iannello,P;)Erneste,J;)Komadina,N.EPI390310 HA United)States 2010;Aug;01 A/Rhode)Island/01/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI390379 NA United)States 2010;Aug;01 A/Rhode)Island/01/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI326115 HA Serbia 2011;Jan;06 A/Serbia/71/2011 Institute)of)Immunology)and)Virology)Torlak National)Institute)for)Medical)Research ;EPI326116 NA Serbia 2011;Jan;06 A/Serbia/71/2011 Institute)of)Immunology)and)Virology)Torlak National)Institute)for)Medical)Research ;EPI155916 HA Greece 2007;Jan;01 A/Serres/77/2007 ; Centers)for)Disease)Control)and)Prevention ;EPI155915 NA Greece 2007;Jan;01 A/Serres/77/2007 ; Centers)for)Disease)Control)and)Prevention ;EPI545334 HA Singapore 2004;Nov;01 A/Singapore/37/2004 ; Other)Database)Import Fonville,J.M.;)Wilks,S.H.;)James,S.L.;)Fox,A.;)Ventresca,M.;)et#al.EPI117105 NA Singapore 2004;Jun;07 A/Singapore/37/2004 ; Other)Database)Import ;EPI215043 HA Singapore 2008;Sep;15 A/Singapore/N593/2008 Tan)Tock)Seng)Hospital National)Institute)for)Medical)Research ;EPI215042 NA Singapore 2008;Sep;15 A/Singapore/N593/2008 Tan)Tock)Seng)Hospital National)Institute)for)Medical)Research ;EPI155918 HA Bulgaria 2007;Jan;01 A/Sofia/319/2007 ; Centers)for)Disease)Control)and)Prevention ;EPI155917 NA Bulgaria 2007;Jan;01 A/Sofia/319/2007 ; Centers)for)Disease)Control)and)Prevention ;EPI326139 HA Sweden 2011;Mar;28 A/Stockholm/18/2011 Swedish)Institute)for)Infectious)Disease)Control National)Institute)for)Medical)Research ;EPI326140 NA Sweden 2011;Mar;28 A/Stockholm/18/2011 Swedish)Institute)for)Infectious)Disease)Control National)Institute)for)Medical)Research ;EPI238690 HA Sweden 2009;Aug;01 A/Stockholm/90/2009 Swedish)Institute)for)Infectious)Disease)Control Swedish)Institute)for)Infectious)Disease)Control ;EPI238691 NA Sweden 2009;Aug;01 A/Stockholm/90/2009 Swedish)Institute)for)Infectious)Disease)Control Swedish)Institute)for)Infectious)Disease)Control ;EPI176951 HA Australia 1997;Jan;01 A/Sydney/05/1997 ; Other)Database)Import ;EPI176953 NA Australia 1997;Jan;01 A/Sydney/05/1997 ; Other)Database)Import ;EPI556816 HA United)States 2012;Apr;15 A/Texas/50/2012 Texas)Department)of)State)Health)Services;Laboratory)Services Centers)for)Disease)Control)and)Prevention ;EPI556815 NA United)States 2012;Apr;15 A/Texas/50/2012 Texas)Department)of)State)Health)Services;Laboratory)Services Centers)for)Disease)Control)and)Prevention ;EPI152544 HA Uruguay 2007;Jan;01 A/Uruguay/716/2007 ; Centers)for)Disease)Control)and)Prevention ;EPI152546 NA Uruguay 2007;Jan;01 A/Uruguay/716/2007 ; Centers)for)Disease)Control)and)Prevention ;EPI232629 HA United)States 2009;Sep;30 A/Vermont/22/2009 Vermont)Department)of)Health)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI232628 NA United)States 2009;Sep;30 A/Vermont/22/2009 Vermont)Department)of)Health)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI190148 HA Australia 2009;Jun;02 A/Victoria/210/2009 Victorian)Infectious)Diseases)Reference)Laboratory) WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI190149 NA Australia 2009;Jun;02 A/Victoria/210/2009 Victorian)Infectious)Diseases)Reference)Laboratory) WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI418017 HA Australia 2011;Oct;24 A/Victoria/361/2011 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)Prevention ;EPI438985 NA Australia 2011;Oct;24 A/Victoria/361/2011 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)Prevention ;EPI40980 HA New)Zealand 2005;Sep;13 A/Waikato/12/2005 ; Other)Database)Import ;EPI40985 NA New)Zealand 2005;Sep;13 A/Waikato/12/2005 ; Other)Database)Import ;EPI185937 HA United)States 2009;Apr;06 A/Washington/15/2009 Washington)State)Public)Health)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI185935 NA United)States 2009;Apr;06 A/Washington/15/2009 Washington)State)Public)Health)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI416181 HA United)States 2012;Dec;05 A/Washington/60/2012 Spokane)Regional)Health)District Centers)for)Disease)Control)and)Prevention ;EPI416180 NA United)States 2012;Dec;05 A/Washington/60/2012 Spokane)Regional)Health)District Centers)for)Disease)Control)and)Prevention ;EPI390109 HA New)Zealand 2004;Aug;01 A/Wellington/01/2004 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI390111 NA New)Zealand 2004;Aug;01 A/Wellington/01/2004 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI390189 HA United)States 2007;Aug;01 A/Wisconsin/03/2007 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI390191 NA United)States 2007;Aug;01 A/Wisconsin/03/2007 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI381901 HA United)States 2009;Aug;01 A/Wisconsin/15/2009 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI211309 NA United)States 2009;Jun;07 A/Wisconsin/15/2009 Wisconsin)State)Laboratory)of)Hygiene Centers)for)Disease)Control)and)Prevention ;EPI123261 HA United)States 2006;Dec;12 A/Wisconsin/42/2006 ; Centers)for)Disease)Control)and)Prevention ;EPI123152 NA United)States 2006;Dec;12 A/Wisconsin/42/2006 ; Centers)for)Disease)Control)and)Prevention ;EPI367110 HA United)States 2005;Jan;01 A/Wisconsin/67/2005 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI367112 NA United)States 2005;Jan;01 A/Wisconsin/67/2005 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI609838 HA China 2004;Aug;23 A/Wuhan/269/2004 ; Other)Database)Import Bedford,T.;)Riley,S.;)Barr,I.G.;)Broor,S.;)Chadha,M.;)et#al.EPI158311 NA China 2004;Aug;23 A/Wuhan/269/2004 ; Centers)for)Disease)Control)and)Prevention ;EPI397298 HA China 1995;Oct;01 A/Wuhan/359/1995 ; Other)Database)Import Hoschler,K.;)Thomson,C.;)Casas,I.;)Ellis,J.;)Galiano,M.;)et#al.EPI362822 NA China 1995;Jan;01 A/Wuhan/359/1995 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.#EPI499365 HA United)States 2003;Feb;13 A/Wyoming/03/2003 Iowa)State)Hygienic)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI499364 NA United)States 2003;Feb;13 A/Wyoming/03/2003 Iowa)State)Hygienic)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI155914 HA Croatia 2007;Jan;01 A/Zagreb/1216/2007 ; Centers)for)Disease)Control)and)Prevention ;EPI155913 NA Croatia 2007;Jan;01 A/Zagreb/1216/2007 ; Centers)for)Disease)Control)and)Prevention ;
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Influenza)(sub)type Accession)number Segment Country Collection)date)(year;month;day) Reference)virus Originating)Lab Submitting)Lab AuthorsEPI279851 HA Algeria 2010;Jun;06 B/Algeria/G486/2010 Institut)Pasteur)d'Algerie National)Institute)for)Medical)Research ;EPI279850 NA Algeria 2010;Jun;06 B/Algeria/G486/2010 Institut)Pasteur)d'Algerie National)Institute)for)Medical)Research ;EPI352447 HA Cote)d'Ivoire 2011;Sep;22 B/Attecoube/GR887/2011 Pasteur)Institut)of)Côte)d'Ivoire National)Institute)for)Medical)Research ;EPI352448 NA Cote)d'Ivoire 2011;Sep;22 B/Attecoube/GR887/2011 Pasteur)Institut)of)Côte)d'Ivoire National)Institute)for)Medical)Research ;EPI416443 HA Germany 2012;Nov;26 B/Baden)Wurttemberg/41/2012 Robert;Koch;Institute National)Institute)for)Medical)Research ;EPI416444 NA Germany 2012;Nov;26 B/Baden)Wurttemberg/41/2012 Robert;Koch;Institute National)Institute)for)Medical)Research ;EPI366548 HA Bangladesh 2007;Jan;01 B/Bangladesh/3333/2007 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366549 NA Bangladesh 2007;Jan;01 B/Bangladesh/3333/2007 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI352417 HA Germany 2011;Oct;19 B/Berlin/146/2011 Robert;Koch;Institute National)Institute)for)Medical)Research ;EPI352418 NA Germany 2011;Oct;19 B/Berlin/146/2011 Robert;Koch;Institute National)Institute)for)Medical)Research ;EPI294717 HA Bolivia,)Plurinationial)State)of 2010;Jan;01 B/Bolivia/1526/2010 ; Centers)for)Disease)Control)and)Prevention ;EPI294716 NA Bolivia,)Plurinationial)State)of 2010;Jan;01 B/Bolivia/1526/2010 ; Centers)for)Disease)Control)and)Prevention ;EPI168165 HA Brazil 2008;Jul;28 B/Brazil/2937/2008 ; Centers)for)Disease)Control)and)Prevention ;EPI168274 NA Brazil 2008;Jul;28 B/Brazil/2937/2008 ; Centers)for)Disease)Control)and)Prevention ;EPI155964 HA Australia 2007;Mar;09 B/Brisbane/03/2007 ; Centers)for)Disease)Control)and)Prevention ;EPI155963 NA Australia 2007;Mar;09 B/Brisbane/03/2007 ; Centers)for)Disease)Control)and)Prevention ;EPI163726 HA Australia 2008;Jul;13 B/Brisbane/33/2008 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI186302 NA Australia 2008;Jul;13 B/Brisbane/33/2008 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI163725 HA Australia 2008;Aug;04 B/Brisbane/60/2008 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI173276 NA Australia 2008;Aug;04 B/Brisbane/60/2008 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI348438 HA Cambodia 2011;Oct;10 B/Cambodia/1412/2011 National)Public)Health)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI348437 NA Cambodia 2011;Oct;10 B/Cambodia/1412/2011 National)Public)Health)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI366564 HA United)Kingdom 2008;Jan;01 B/England/145/2008 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366566 NA United)Kingdom 2008;Jan;01 B/England/145/2008 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI211559 HA United)Kingdom 2008;Aug;29 B/England/393/2008 Health)Protection)Agency National)Institute)for)Medical)Research ;EPI211560 NA United)Kingdom 2008;Aug;29 B/England/393/2008 Health)Protection)Agency National)Institute)for)Medical)Research ;EPI315675 HA United)Kingdom 2007;Oct;03 B/England/552/2007 ; Other)Database)Import Ellis,J.EPI279859 HA United)Kingdom 2010;May;02 B/England/63/2010 Microbiology)Services)Colindale,)Public)Health)England National)Institute)for)Medical)Research ;EPI279858 NA United)Kingdom 2010;May;02 B/England/63/2010 Microbiology)Services)Colindale,)Public)Health)England National)Institute)for)Medical)Research ;EPI406983 HA Estonia 2011;Mar;14 B/Estonia/55669/2011 National)Institute)for)Medical)Research Centers)for)Disease)Control)and)Prevention ;EPI406982 NA Estonia 2011;Mar;14 B/Estonia/55669/2011 National)Institute)for)Medical)Research Centers)for)Disease)Control)and)Prevention ;EPI294743 HA United)States 2010;Oct;18 B/Florida/04/2010 Florida)Department)of)Health;Jacksonville Centers)for)Disease)Control)and)Prevention ;EPI294742 NA United)States 2010;Oct;18 B/Florida/04/2010 Florida)Department)of)Health;Jacksonville Centers)for)Disease)Control)and)Prevention ;EPI159978 HA United)States 2006;Jan;01 B/Florida/04/2006 ; Other)Database)Import ;EPI159980 NA United)States 2006;Jan;01 B/Florida/04/2006 ; Other)Database)Import ;EPI406250 HA Argentina 2012;Aug;06 B/Formosa/V2367/2012 Instituto)Nacional)de)Enfermedades)Infecciosas National)Institute)for)Medical)Research ;EPI406251 NA Argentina 2012;Aug;06 B/Formosa/V2367/2012 Instituto)Nacional)de)Enfermedades)Infecciosas National)Institute)for)Medical)Research ;EPI366580 HA China 2008;Jan;01 B/Fujian;Gulou/1272/2008 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366582 NA China 2008;Jan;01 B/Fujian;Gulou/1272/2008 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI51231 HA United)States 2004;Jun;21 B/Hawaii/13/2004 ; Other)Database)Import ;EPI51236 NA United)States 2004;Jun;21 B/Hawaii/13/2004 ; Other)Database)Import ;EPI156987 HA Honduras 2005;Dec;20 B/Honduras/1465/2005 ; Centers)for)Disease)Control)and)Prevention ;EPI301202 HA Honduras 2010;Oct;11 B/Honduras/6927/2010 Laboratorio)Nacional)de)Virologia Centers)for)Disease)Control)and)Prevention ;EPI301201 NA Honduras 2010;Oct;11 B/Honduras/6927/2010 Laboratorio)Nacional)de)Virologia Centers)for)Disease)Control)and)Prevention ;EPI105163 HA Hong)Kong)(SAR) 1972;Jan;01 B/Hong5Kong/05/1972 ; Other)Database)Import ;EPI105167 NA Hong)Kong)(SAR) 1972;Jan;01 B/Hong5Kong/05/1972 ; Other)Database)Import ;EPI392575 HA Hong)Kong)(SAR) 2012;Apr;30 B/Hong)Kong/3496/2012 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI392576 NA Hong)Kong)(SAR) 2012;Apr;30 B/Hong)Kong/3496/2012 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI392589 HA Hong)Kong)(SAR) 2012;Jun;13 B/Hong)Kong/3577/2012 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI392590 NA Hong)Kong)(SAR) 2012;Jun;13 B/Hong)Kong/3577/2012 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI211555 HA Hong)Kong)(SAR) 2005;Feb;07 B/Hong)Kong/45/2005 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI211556 NA Hong)Kong)(SAR) 2005;Feb;07 B/Hong)Kong/45/2005 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI377713 HA Ireland 2012;Feb;29 B/Ireland/12M17522/2012 National)Virus)Reference)Laboratory National)Institute)for)Medical)Research ;EPI377714 NA Ireland 2012;Feb;29 B/Ireland/12M17522/2012 National)Virus)Reference)Laboratory National)Institute)for)Medical)Research ;EPI352840 HA Israel 2011;Dec;13 B/Israel/15/2011 Central)Virology)Laboratory)Israel)(NIC) National)Institute)for)Medical)Research ;EPI352841 NA Israel 2011;Dec;13 B/Israel/15/2011 Central)Virology)Laboratory)Israel)(NIC) National)Institute)for)Medical)Research ;EPI187537 HA China 2009;Feb;23 B/Jiangsu;Gulou/125/2009 WHO)Chinese)National)Influenza)Center Centers)for)Disease)Control)and)Prevention ;EPI187538 NA China 2009;Feb;23 B/Jiangsu;Gulou/125/2009 WHO)Chinese)National)Influenza)Center Centers)for)Disease)Control)and)Prevention ;CY033844* HA China 2003 B/Jiangsu/10/2003 ; ; Spiro,D.,)Halpin,R.,)Boyne,A.,)Bera,J.,)Ghedin,E., #et#al.CY033846* NA China 2003 B/Jiangsu/10/2003 ; ; ;EPI159930 HA China 2003;Jan;01 B/Jilin/20/2003 ; Other)Database)Import ;EPI159932 NA China 2003;Jan;01 B/Jilin/20/2003 ; Other)Database)Import ;EPI406272 HA South)Africa 2012;Aug;03 B/Johannesburg/3964/2012 Sandringham,)National)Institute)for)Communicable)D National)Institute)for)Medical)Research ;EPI406273 NA South)Africa 2012;Aug;03 B/Johannesburg/3964/2012 Sandringham,)National)Institute)for)Communicable)D National)Institute)for)Medical)Research ;EPI294801 HA Lao,)People's)Democratic)Republic 2010;Sep;14 B/Laos/833/2010 National)Center)for)Laboratory)and)Epidemiology Centers)for)Disease)Control)and)Prevention ;EPI294800 NA Lao,)People's)Democratic)Republic 2010;Sep;14 B/Laos/833/2010 National)Center)for)Laboratory)and)Epidemiology Centers)for)Disease)Control)and)Prevention ;
B
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Influenza)(sub)type Accession)number Segment Country Collection)date)(year;month;day) Reference)virus Originating)Lab Submitting)Lab AuthorsEPI334664 HA France 2011;Mar;01 B/Lyon/1179/2011 CRR)virus)Influenza)region)Sud National)Institute)for)Medical)Research ;EPI334665 NA France 2011;Mar;01 B/Lyon/1179/2011 CRR)virus)Influenza)region)Sud National)Institute)for)Medical)Research ;EPI175755 HA Malaysia 2004;Jan;01 B/Malaysia/2506/2004 ; Other)Database)Import ;EPI175757 NA Malaysia 2004;Jan;01 B/Malaysia/2506/2004 ; Other)Database)Import ;EPI346734 HA Malta 2011;Mar;07 B/Malta/MV636714/2011 Mater)Dei)Hospital National)Institute)for)Medical)Research ;EPI346735 NA Malta 2011;Mar;07 B/Malta/MV636714/2011 Mater)Dei)Hospital National)Institute)for)Medical)Research ;EPI376344 HA United)States 2012;Mar;13 B/Massachusetts/02/2012 Massachusetts)Department)of)Public)Health Centers)for)Disease)Control)and)Prevention ;EPI376343 NA United)States 2012;Mar;13 B/Massachusetts/02/2012 Massachusetts)Department)of)Public)Health Centers)for)Disease)Control)and)Prevention ;EPI406961 HA United)States 2012;Oct;28 B/Montana/06/2012 Montana)Laboratory)Services)Bureau Centers)for)Disease)Control)and)Prevention ;EPI406960 NA United)States 2012;Oct;28 B/Montana/06/2012 Montana)Laboratory)Services)Bureau Centers)for)Disease)Control)and)Prevention ;EPI407195 HA United)States 2012;Nov;26 B/New)Mexico/04/2012 New)Mexico)Department)of)Health Centers)for)Disease)Control)and)Prevention ;EPI407194 NA United)States 2012;Nov;26 B/New)Mexico/04/2012 New)Mexico)Department)of)Health Centers)for)Disease)Control)and)Prevention ;EPI368752 HA Russian)Federation 2012;Feb;14 B/Novosibirsk/01/2012 Russian)Academy)of)Medical)Sciences Centers)for)Disease)Control)and)Prevention ;EPI368751 NA Russian)Federation 2012;Feb;14 B/Novosibirsk/01/2012 Russian)Academy)of)Medical)Sciences Centers)for)Disease)Control)and)Prevention ;EPI346478 HA United)States 2005;Feb;23 B/Ohio/01/2005 Cincinnati)Children's)Hospital Centers)for)Disease)Control)and)Prevention ;EPI346479 NA United)States 2005;Feb;23 B/Ohio/01/2005 Cincinnati)Children's)Hospital Centers)for)Disease)Control)and)Prevention ;AJ784057* HA Norway 2004 B/Oslo/71/2004 ; ; ;AJ784101* NA Norway 2004 B/Oslo/71/2004 ; ; ;EPI211562 HA France 2009;Feb;09 B/Paris/1762/2009 Institut)Pasteur National)Institute)for)Medical)Research ;EPI211561 NA France 2009;Feb;09 B/Paris/1762/2009 Institut)Pasteur National)Institute)for)Medical)Research ;EPI326171 HA Serbia 2011;Mar;08 B/Serbia/1894/2011 Institute)of)Immunology)and)Virology)Torlak National)Institute)for)Medical)Research ;EPI326172 NA Serbia 2011;Mar;08 B/Serbia/1894/2011 Institute)of)Immunology)and)Virology)Torlak National)Institute)for)Medical)Research ;EPI347893 HA China 2011;Nov;12 B/Shanghai;Chongming/1458/2011 WHO)Chinese)National)Influenza)Center WHO)Chinese)National)Influenza)Center Lan,)Y.;)Li,)X.;Zhao,)X.;)Cheng,Y.;)Tan,M.;)et#al.EPI347892 NA China 2011;Nov;12 B/Shanghai;Chongming/1458/2011 WHO)Chinese)National)Influenza)Center WHO)Chinese)National)Influenza)Center Lan,)Y.;)Li,)X.;Zhao,)X.;)Cheng,Y.;)Tan,M.;)et#al.EPI13603 HA China 2002;Jun;12 B/Shanghai/361/2002 ; Other)Database)Import ;EPI116668 NA China 2002;Jun;12 B/Shanghai/361/2002 ; Other)Database)Import ;EPI131322 HA Singapore 1979;Jan;01 B/Singapore/222/1979 ; Other)Database)Import ;EPI129892 NA Singapore 1979;Jan;01 B/Singapore/222/1979 ; Other)Database)Import ;EPI301320 HA Slovakia 2010;Jul;27 B/Slovakia/1731/2010 National)Public)Health)Institute)of)Slovakia National)Institute)for)Medical)Research ;EPI301319 NA Slovakia 2010;Jul;27 B/Slovakia/1731/2010 National)Public)Health)Institute)of)Slovakia National)Institute)for)Medical)Research ;EPI340834 HA Sweden 2011;Feb;28 B/Stockholm/12/2011 National)Institute)for)Medical)Research Centers)for)Disease)Control)and)Prevention ;EPI340833 NA Sweden 2011;Feb;28 B/Stockholm/12/2011 National)Institute)for)Medical)Research Centers)for)Disease)Control)and)Prevention ;EPI438791 HA Germany 2013;Jan;07 B/Thuringen/01/2013 Robert;Koch;Institute National)Institute)for)Medical)Research ;EPI438792 NA Germany 2013;Jan;07 B/Thuringen/01/2013 Robert;Koch;Institute National)Institute)for)Medical)Research ;EPI233234 HA Uganda 2009;Oct;21 B/Uganda/0514/2009 Uganda)Virus)Research)Institute)(UVRI),)National)Influenza)Center Centers)for)Disease)Control)and)Prevention ;EPI233233 NA Uganda 2009;Oct;21 B/Uganda/0514/2009 Uganda)Virus)Research)Institute)(UVRI),)National)Influenza)Center Centers)for)Disease)Control)and)Prevention ;EPI211563 HA Spain 2008;Feb;18 B/Valladolid/18/2008 Universidad)de)Valladolid National)Institute)for)Medical)Research ;EPI211564 NA Spain 2008;Feb;18 B/Valladolid/18/2008 Universidad)de)Valladolid National)Institute)for)Medical)Research ;EPI51801 HA Canada 1987;Jan;01 B/Victoria/02/1987 ; Other)Database)Import ;EPI51806 NA Canada 1987;Jan;01 B/Victoria/02/1987 ; Other)Database)Import ;EPI502811 HA Australia 2006;Jun;06 B/Victoria/304/2006 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI502813 NA Australia 2006;Jun;06 B/Victoria/304/2006 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI483004 HA Australia 2005;Oct;16 B/Victoria/530/2005 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI483006 NA Australia 2005;Oct;16 B/Victoria/530/2005 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI271600 HA United)States 2010;Feb;20 B/Wisconsin/01/2010 Wisconsin)State)Laboratory)of)Hygiene Centers)for)Disease)Control)and)Prevention ;EPI271599 NA United)States 2010;Feb;20 B/Wisconsin/01/2010 Wisconsin)State)Laboratory)of)Hygiene Centers)for)Disease)Control)and)Prevention ;EPI43948 HA United)States 2006;Apr;02 B/Wisconsin/10/2006 ; Other)Database)Import ;EPI51820 HA Japan 1988;Jan;01 B/Yamagata/16/1988 ; Other)Database)Import ;EPI51825 NA Japan 1988;Jan;01 B/Yamagata/16/1988 ; Other)Database)Import ;EPI319590 HA Russian)Federation 2011;Feb;28 A/Astrakhan/01/2011 WHO)National)Influenza)Centre)Russian)Federation National)Institute)for)Medical)Research ;EPI319591 NA Russian)Federation 2011;Feb;28 A/Astrakhan/01/2011 WHO)National)Influenza)Centre)Russian)Federation National)Institute)for)Medical)Research ;EPI177661 HA New)Zealand 2009;Apr;25 A/Auckland/03/2009 Auckland)Hospital WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI177280 NA New)Zealand 2009;Apr;25 A/Auckland/03/2009 Auckland)Hospital WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI239631 HA Germany 2009;Jan;01 A/Bayern/69/2009 ; Centers)for)Disease)Control)and)Prevention ;EPI239630 NA Germany 2009;Jan;01 A/Bayern/69/2009 ; Centers)for)Disease)Control)and)Prevention ;EPI177294 HA United)States 2009;Apr;09 A/California/07/2009 Naval)Health)Research)Center Centers)for)Disease)Control)and)Prevention ;EPI185379 NA United)States 2009;Apr;09 A/California/07/2009 Naval)Health)Research)Center Centers)for)Disease)Control)and)Prevention ;EPI280344 HA New)Zealand 2010;Jul;12 A/Christchurch/16/2010 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)Prevention ;EPI280343 NA New)Zealand 2010;Jul;12 A/Christchurch/16/2010 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)Prevention ;EPI319447 HA Czech)Republic 2011;Jan;18 A/Czech)Republic/32/2011 National)Institute)of)Public)Health National)Institute)for)Medical)Research ;EPI319448 NA Czech)Republic 2011;Jan;18 A/Czech)Republic/32/2011 National)Institute)of)Public)Health National)Institute)for)Medical)Research ;EPI417122 HA Senegal 2012;Dec;09 A/Dakar/20/2012 Institut)Pasteur)de)Dakar National)Institute)for)Medical)Research ;EPI417123 NA Senegal 2012;Dec;09 A/Dakar/20/2012 Institut)Pasteur)de)Dakar National)Institute)for)Medical)Research ;EPI190214 HA Denmark 2009;Jun;09 A/Denmark/528/2009 ; Other)Database)Import ;EPI190216 NA Denmark 2009;Jun;09 A/Denmark/528/2009 ; Other)Database)Import ;EPI294674 HA United)Kingdom 2010;Nov;01 A/England/4880374/2010 Microbiology)Services)Colindale,)Public)Health)England Microbiology)Services)Colindale,)Public)Health)England Galiano,M.EPI294673 NA United)Kingdom 2010;Nov;01 A/England/4880374/2010 Microbiology)Services)Colindale,)Public)Health)England Microbiology)Services)Colindale,)Public)Health)England Galiano,M.
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	NA:	Neuraminidase;	HA:	Hemagglutinin	Virtually	all	sequences	were	retrieved	from	GISAID	EpiFluTM	database.		The	four	influenza	B	virus	sequences	(2	HA+2NA)	retrieved	from	NCBI	Influenza	Virus	Resource	database	are	marked	with	an	asterisk	(*)	after	the	accession	number	(2nd	column).	Reference	viruses	included	in	the	Northern	Hemisphere´s	seasonal	influenza	vaccines	are	highlighted	in	bold	and	italic.	The	dash	(-)	represents	no	information.
Influenza)(sub)type Accession)number Segment Country Collection)date)(year;month;day) Reference)virus Originating)Lab Submitting)Lab AuthorsEPI348185 HA United)States 2011;Dec;07 A/Florida/35/2011 Florida)Department)of)Health;Tampa Centers)for)Disease)Control)and)Prevention ;EPI348184 NA United)States 2011;Dec;07 A/Florida/35/2011 Florida)Department)of)Health;Tampa Centers)for)Disease)Control)and)Prevention ;EPI331061 HA Ghana 2011;May;13 A/Ghana/763/2011 University)of)Ghana National)Institute)for)Medical)Research ;EPI331062 NA Ghana 2011;May;13 A/Ghana/763/2011 University)of)Ghana National)Institute)for)Medical)Research ;EPI279895 HA Hong)Kong)(SAR) 2010;Jul;16 A/Hong)Kong/2212/2010 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI279894 NA Hong)Kong)(SAR) 2010;Jul;16 A/Hong)Kong/2212/2010 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI326206 HA Hong)Kong)(SAR) 2011;Mar;29 A/Hong)Kong/3934/2011 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI326207 NA Hong)Kong)(SAR) 2011;Mar;29 A/Hong)Kong/3934/2011 Government)Virus)Unit National)Institute)for)Medical)Research ;EPI382424 HA Hong)Kong)(SAR) 2012;May;21 A/Hong)Kong/5659/2012 Public)Health)Laboratory)Services)Branch,)Centre)for)Health)Protection Public)Health)Laboratory)Services)Branch,)Centre)for)Health)Protection Mak,G.C.;Lo,J.Y.C.EPI382425 NA Hong)Kong)(SAR) 2012;May;21 A/Hong)Kong/5659/2012 Public)Health)Laboratory)Services)Branch,)Centre)for)Health)Protection Public)Health)Laboratory)Services)Branch,)Centre)for)Health)Protection Mak,G.C.;Lo,J.Y.C.EPI178946 HA United)States 2006;Nov;08 A/Iowa/01/2006 Iowa)State)Hygienic)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI342434 HA United)States 2010;Nov;01 A/Kentucky/09/2010 Kentucky)Division)of)Laboratory)Services Centers)for)Disease)Control)and)Prevention ;EPI342433 NA United)States 2010;Nov;01 A/Kentucky/09/2010 Kentucky)Division)of)Laboratory)Services Centers)for)Disease)Control)and)Prevention ;EPI346699 HA France 2011;Feb;23 A/Lorraine/1176/2011 CRR)virus)Influenza)region)Sud National)Institute)for)Medical)Research ;EPI346700 NA France 2011;Feb;23 A/Lorraine/1176/2011 CRR)virus)Influenza)region)Sud National)Institute)for)Medical)Research ;EPI215957 HA Ukraine 2009;Oct;27 A/Lviv/N6/2009 Ministry)of)Health)of)Ukraine National)Institute)for)Medical)Research ;EPI215956 NA Ukraine 2009;Oct;27 A/Lviv/N6/2009 Ministry)of)Health)of)Ukraine National)Institute)for)Medical)Research ;EPI416401 HA France 2012;Dec;28 A/Lyon/02/2013 CRR)virus)Influenza)region)Sud National)Institute)for)Medical)Research ;EPI416402 NA France 2012;Dec;28 A/Lyon/02/2013 CRR)virus)Influenza)region)Sud National)Institute)for)Medical)Research ;EPI408003 HA United)States 1976;Jan;01 A/New)Jersey/8/1976 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Wester,E.;)et#al.EPI233202 HA United)States 2009;Oct;16 A/North)Carolina/49/2009 North)Carolina)State)Laboratory)of)Public)Health Centers)for)Disease)Control)and)Prevention ;EPI233201 NA United)States 2009;Oct;16 A/North)Carolina/49/2009 North)Carolina)State)Laboratory)of)Public)Health Centers)for)Disease)Control)and)Prevention ;EPI416419 HA Norway 2012;Dec;17 A/Norway/2552/2012 WHO)National)Influenza)Centre National)Institute)for)Medical)Research ;EPI416420 NA Norway 2012;Dec;17 A/Norway/2552/2012 WHO)National)Influenza)Centre National)Institute)for)Medical)Research ;EPI189161 HA Singapore 2009;May;30 A/Singapore/57/2009 Singapore)General)Hospital Centers)for)Disease)Control)and)Prevention ;EPI189162 NA Singapore 2009;May;30 A/Singapore/57/2009 Singapore)General)Hospital Centers)for)Disease)Control)and)Prevention ;EPI346513 HA Thailand 2011;Sep;12 A/Song)Khla/270/2011 WHO)National)Influenza)Centre,)National)Institute)of)Medical)Research)(NIMR) Centers)for)Disease)Control)and)Prevention ;EPI346512 NA Thailand 2011;Sep;12 A/Song)Khla/270/2011 WHO)National)Influenza)Centre,)National)Institute)of)Medical)Research)(NIMR) Centers)for)Disease)Control)and)Prevention ;EPI316435 HA Russian)Federation 2011;Mar;14 A/St.)Petersburg/100/2011 Russian)Academy)of)Medical)Sciences Centers)for)Disease)Control)and)Prevention ;EPI316434 NA Russian)Federation 2011;Mar;14 A/St.)Petersburg/100/2011 Russian)Academy)of)Medical)Sciences Centers)for)Disease)Control)and)Prevention ;EPI319527 HA Russian)Federation 2011;Feb;14 A/St.)Petersburg/27/2011 WHO)National)Influenza)Centre)Russian)Federation National)Institute)for)Medical)Research ;EPI319528 NA Russian)Federation 2011;Feb;14 A/St.)Petersburg/27/2011 WHO)National)Influenza)Centre)Russian)Federation National)Institute)for)Medical)Research ;EPI301380 HA Sweden 2010;Dec;02 A/Stockholm/12/2010 Swedish)Institute)for)Infectious)Disease)Control Swedish)Institute)for)Infectious)Disease)Control ;EPI301381 NA Sweden 2010;Dec;02 A/Stockholm/12/2010 Swedish)Institute)for)Infectious)Disease)Control Swedish)Institute)for)Infectious)Disease)Control ;EPI301779 HA Sweden 2010;Dec;12 A/Stockholm/14/2010 Swedish)Institute)for)Infectious)Disease)Control Swedish)Institute)for)Infectious)Disease)Control ;EPI301780 NA Sweden 2010;Dec;12 A/Stockholm/14/2010 Swedish)Institute)for)Infectious)Disease)Control Swedish)Institute)for)Infectious)Disease)Control ;EPI347564 HA Sweden 2011;Nov;22 A/Stockholm/35/2011 ; Swedish)Institute)for)Infectious)Disease)Control ;EPI347565 NA Sweden 2011;Nov;22 A/Stockholm/35/2011 ; Swedish)Institute)for)Infectious)Disease)Control ;EPI396874 NA France 1982;Oct;01 A/swine/Finnistere/2899/1982 ; Other)Database)Import Lycett,S.J.;)Baillie,G.;)Coulter,E.;)Bhatt,S.;)Kellam,P.;)et#al.EPI396914 NA France 1999;Oct;01 A/swine/Ille)et)Vilaine/1455/1999 ; Other)Database)Import Lycett,S.J.;)Baillie,G.;)Coulter,E.;)Bhatt,S.;)Kellam,P.;)et#al.EPI12290 NA Italy 1995;Jan;01 A/swine/Italy/1424;4/1995 ; Other)Database)Import ;EPI396960 NA Italy 1998;Oct;01 A/swine/Italy/1513;1/1998 ; Other)Database)Import Lycett,S.J.;)Baillie,G.;)Coulter,E.;)Bhatt,S.;)Kellam,P.;)et#al.EPI173655 HA United)States 2007;Jan;01 A/swine/OH/511445/2007 ; Other)Database)Import ;EPI406026 HA United)States 2012;Oct;31 A/Tennessee/09/2012 Tennessee)Department)of)Health)Laboratory;Nashville Centers)for)Disease)Control)and)Prevention ;EPI406025 NA United)States 2012;Oct;31 A/Tennessee/09/2012 Tennessee)Department)of)Health)Laboratory;Nashville Centers)for)Disease)Control)and)Prevention ;EPI335840 HA Chile 2011;Aug;10 A/Valparaiso/17275/2011 Instituto)de)Salud)Publica)de)Chile) Centers)for)Disease)Control)and)Prevention ;EPI335839 NA Chile 2011;Aug;10 A/Valparaiso/17275/2011 Instituto)de)Salud)Publica)de)Chile) Centers)for)Disease)Control)and)Prevention ;EPI239643 HA Vietnam 2009;Dec;01 A/Vietnam/2043/2009 National)Institute)of)Hygiene)and)Epidemiology Centers)for)Disease)Control)and)Prevention ;EPI239642 NA Vietnam 2009;Dec;01 A/Vietnam/2043/2009 National)Institute)of)Hygiene)and)Epidemiology Centers)for)Disease)Control)and)Prevention ;EPI247506 HA United)States 2010;Feb;08 A/Wyoming/01/2010 Wyoming)Public)Health)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI247505 NA United)States 2010;Feb;08 A/Wyoming/01/2010 Wyoming)Public)Health)Laboratory Centers)for)Disease)Control)and)Prevention ;
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Figure	S4.1	Phylogenetic	comparison	of	former	seasonal	A(H1N1)	(A),	A(H3N2)	(B),	influenza	B	(C)	and	A(H1N1)pdm09	virus	(D)	hemagglutinin	genes.		Hemagglutinin	(HA)	phylogenetic	trees	were	constructed	and	annotated	as	described	in	Figure	4.11	A,	with	influenza	A(H3N2)	(panel	B)	and	A(H1N1)pdm09	(panel	D)	upper	extreme	outlier	viruses	being	just	coloured	in	light	red.	Influenza	A(H3N2)	(panel	B),	B	(panel	C)	and	A(H1N1)pdm09	(panel	D)	HA	genetic	clades	are	described	in	Figure	4.13.
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A/Alabama/05/2010
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A/Lisboa/33/2005
A/Lisboa/37/2008
A/Paris/777/2008
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A/Wisconsin/42/2006
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A/Wisconsin/03/2007
A/Portugal/29/2012
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A/Washington/60/2012
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A/Lisboa/10/2007
A/Vermont/22/2009
A/Lisboa/10/2006
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A/Wisconsin/15/2009
A/Lisboa/18/2007
0.99
1
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CHAPTER	5	
	 WHOLE-GENOME	MUTATIONAL	LANDSCAPE	OF	INFLUENZA	VIRUSES	RESISTANT	OR	WITH	DECREASED	SUSCEPTIBILITY	TO	OSELTAMIVIR	AND/OR	ZANAMIVIR						Some	results	published	in:			Gíria	M,	Rebelo-de-Andrade	H,	Santos	LA,	Correia	V,	Pedro	S,	Santos	MM,	2012.	Genomic	signatures	and	antiviral	drug	susceptibility	profile	of	A(H1N1)pdm09.	J	Clin	Virol	53(2),	140-144.		Santos	LA,	Correia	V,	Giria	M,	Pedro	S,	Santos	MM,	Silvestre	MJ,	Rebelo-de-Andrade	H,	2011.	Genetic	and	Antiviral	Drug	 Susceptibility	 Profiles	 of	 Pandemic	 A(H1N1)v	 Influenza	 Virus	 Circulating	 in	 Portugal.	 Influenza	 Other	Respi	Viruses	5	(Suppl.	1),	294–300.							I	carried	out	all	activities,	methodologies	and	data	analysis	underlying	the	results	presented	in	this	chapter.	Gene	sequences	of	A(H1N1)pdm09	viruses	sensitive	 to	oseltamivir	and	zanamivir	were	 included	as	were	available	at	the	laboratory	sequence	database,	having	been	obtained	by	two	team	colleagues	to	study	the	molecular	dynamics	underlying	the	evolution	of	the	newly	emergent	A(H1N1)	pandemic	virus.				 FCG-funding	research	project		“Avaliação	e	Caracterização	da	Emergência	das	Resistências	aos	Antivirais	Específicos	para	a	Gripe	no	Contexto	da	
Infecção	Respiratória	Aguda”	(SDH49;	ACSS	reinforcement	grant)
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5	WHOLE-GENOME	MUTATIONAL	 LANDSCAPE	 OF	 INLUENZA	 VIRUSES	 RESISTANT	
OR	WITH	DECREASED	SUSCEPTIBILITY	TO	OSELTAMIVIR	AND/OR	ZANAMIVIR				
“Evolution	will	outsmart	intelligent	design	every	time.”	Steitz	T.	Lunchtime	science.	Nature	2011;	478:S2–S3.			This	 is	 a	 short-completing	 chapter	 of	 the	 previous	 one	 (Chapter	 4).	 It	 presents	 and	discusses	the	results	of	the	genome-wide	mutational	analysis	performed	on	the	influenza	viruses	identified	as	resistant	or	with	decreased	susceptibility	to	oseltamivir	(OS)	and/or	zanamivir	 (ZA)	 (2nd	 general	 objective;	 see	2.2,	 Study	Description).	Neuraminidase	 (NA)	and	hemagglutinin	(HA)	virus	genome	segments	(segments	6	and	4,	respectively)	are	not	presented	as	were	already	covered	in	the	previous	chapter.					The	main	activities	carried	out	during	this	study	are	summarized	below.									
5.1	RESULTS		Thirty-eight	human	influenza	viruses	exhibiting	resistance	or	decreased	susceptibility	to	OS	 and/or	 ZA	 (14	 former	 seasonal	 A(H1N1),	 3	 A(H3N2),	 8	 B,	 and	 13	A(H1N1)pdm09)	were	 evaluated	 through	 whole-genome	 sequencing	 (PB2,	 PB1,	 PA,	 NP,	 M	 and	 NS	segments).	This	 included	most	 (38/63)	 influenza	viruses	 identified	as	 resistant	or	with	decreased	susceptibility	in	previous	antiviral	susceptibility	testing	surveillance	activities	(see	Chapter	4).	Due	to	the	overall	OS	resistance	observed	for	former	seasonal	A(H1N1)	subtype	 (herein	designated	 as	 seasonal	A(H1N1))	 in	 2008/2009,	 only	~25%	 (6/21)	 of	the	 NA	 H275Y	 OS-resistant	 viruses	 from	 that	 season,	 	 distributed	 over	 time,	 were	
BOX	5.1	-	MAIN	ACTIVITIES	
• Implementation	and	optimization	of	a	Sanger	sequencing	protocol	for	former	seasonal	A(H1N1),	A(H3N2)	and	influenza	B	virus	whole-genome.	
• Whole-genome	sequencing	of	influenza	viruses	exhibiting	resistance	or	decreased	susceptibility	to	OS	and/or	ZA	-	PB2,	PB1,	PA,	NP,	M	and	NS	segments.	
• Mutational	analysis	against	the	influenza	virus	type-	or	subtype-matched	consensus	sequence.		
Mutational	landscape	of	influenza	virus	genomes	|	188		selected	 for	 whole-genome	 characterization.	 Also,	 for	 10	 of	 the	 viruses	 of	 the	 other	influenza	types	or	subtypes	exhibiting	decreased	susceptibility	to	the	drug(s),	it	was	not	available	enough	volume	of	viral	isolate	to	perform	the	characterization	(2	A(H3N2),	5	B,	and	3	A(H1N1)pdm09).			Table	 5.1	 presents	 the	 amino	 acid	 substitutions	 found	 specifically	 in	 the	 PB2	 (PB2	protein),	PB1	(PB1,	PB1-N40,	and	PB1-F2	proteins),	PA	(PA,	PA-N155,	PA-N182,	and	PA-X	 proteins),	NP	 (NP	protein),	M	 (M1,	 and	M2	 or	BM2	proteins),	 and	NS	 (NS1	 and	NEP	proteins)	 genome	 segments	 of	 the	 influenza	 viruses	 resistant	 or	 with	 decreased	susceptibility	 to	 OS	 and/or	 ZA,	 compared	 to	 the	 virus	 type	 or	 subtype-matched	consensus	sequence.		NA	 H275Y	 OS-resistant	 seasonal	 A(H1N1)	 viruses	 from	 2007/2008	 and	 2008/2009	shared	 two	 amino	 acid	 substitutions	 located	 in	 two	 different	 genome	 segments	 -	 PB2	P453S	 and	 PB1-F2	 H3P.	 Both	 substitutions	 were	 exceptionally	 identified	 against	 the	sequence	 of	 the	 clade	 2B	 OS-sensitive	 reference	 virus	 A/Brisbane/59/2007.	 The	 NA	H275Y	viruses	 from	2008/2009	 shared	 also	 the	N642S	amino	 acid	 substitution	 in	PB1	protein	 (N603S	 in	PB1-N40	protein).	 Structurally,	 residue	453	belongs	 to	 the	PB2	 cap-binding	domainA	but	is	located	distantly	from	the	residues	involved	in	the	binding	to	the	5´cap	of	host	messenger	RNAs	 (mRNAs)	 (cap-binding	 residues),	 as	 evidenced	 in	Figure	5.1A.	Residue	642	is	located	outside	of	all	functional	domains	described	to	date	for	PB1B,	and	 the	 PB1-F2	 protein	 of	 former	 circulating	 A(H1N1)	 viruses	 is	 present	 in	 the	 C-terminally	truncated	form	of	19	amino	acids	that	is	thought	to	be	non-functional	(known	functions	of	PB1-F2	are	mostly	associated	with	the	C-terminal	end	of	the	protein)	3.	The	NA	H275Y	OS-resistant	seasonal	A(H1N1)	virus	A/Lisboa/24/2009	contained	two	amino	acid	substitutions	 in	or	close	 to	residues	 functionally	 important.	Specifically,	 the	F254V	substitution	 in	 the	 PB1	 3´vRNA	 binding	 RNP1	 motif	 (residues	 251-254)B,	 and	 the	 PA	I596V	substitution	adjacently	to	residue	M595	involved	in	PB1	binding	(PA	PB1-binding	domainC;	Figure	5.1F).	It	also	contained	the	Y89P	amino	acid	substitution	in	the	region	of	the	non-structural	protein	1	(NS1)	that	interacts	with	the	host-cell	factor	eIF4GI	involved	in	viral	mRNA	translation	(residues	81-113)	4.	The	PA	I596V	amino	acid	substitution	was																																																									A	Domain	structure	of	influenza	A	virus	PB2	protein	based	on	Mehle	and	McCullers	1.										B	Domain	structure	and	critical	residues	of	influenza	A	virus	PB1	protein	based	on	Mehle	and	McCullers	1	and	Chu	et	al.	2.	C	Domain	structure	and	critical	residues	of	influenza	A	virus	PA	protein	based	on	Mehle	and	McCullers	1.	
Mutational	landscape	of	influenza	virus	genomes	|	189		also	 identified	 in	 another	 OS-resistant	 virus	 from	 the	 same	 season	 –	 virus	 isolate	A/Lisboa/15/2009.	The	OS-resistant	virus	 isolate	A/Lisboa/40/2008	also	contained	an	amino	acid	change	 in	PA	close	to	a	residue	functionally	 important	 -	 I129M	substitution,	close	 to	 the	 catalytic	 residue	 K134	 involved	 in	 PA	 endonuclease	 activity	 (PA	endonuclease	domainC;	Figure	5.1E).	Also	of	notice,	 the	virus	 isolate	A/Lisboa/20/2009	carried	 the	NS1	N143D	amino	 acid	 substitution	 located	both	within	 the	nuclear	 export	signal	 (NES)	 (residues	 138-147;	 C-terminal	 effector	 domainD)	 and	 the	 region	 that	interacts	with	the	host-cell	protein	hGBP1	involved	in	the	host	immune	response	to	viral	infection	(antiviral	activity;	residues	123-144)	4.			The	 single	 NA	 H275Y	 OS-resistant	 A(H1N1)pdm09	 virus	 –	 virus	 isolate	A/Portugal/03/2011,	only	contained	the	K52R	amino	acid	substitution	in	PB1	(K13R	in	PB1-N40)	(Table	5.1).	Structurally,	residue	52	is	located	outside	of	all	functional	domains	described	to	date	for	PB1B.		The	seasonal	A(H1N1)	virus	 isolate	A/Lisboa/25/2006	with	decreased	susceptibility	 to	OS	 presented	 the	 most	 distinctive	 genome,	 carrying	 a	 total	 of	 16	 specific	 amino	 acid	substitutions	(Table	5.1).	Of	note,	it	contained	the	PB2	R375K	and	S453H	substitutions	in	the	cap-binding	domain,	with	the	former	occurring	adjacently	to	residue	K376	involved	in	capped	mRNA	binding	 (Figure	5.1A);	and	 the	PB2	N556T	and	V667I	substitutions	 in	the	627	functional	domainA.	It	also	contained	an	amino	acid	substitution	in	the	PB1	PB2-binding	domainB	-	M744I	substitution,	but	at	some	distance	or	far	away	from	the	residues	known	to	be	critical	for	stable	PB2	binding	(residues	695,	699,	and	750;	Figure	5.1C);	and	two	 further	amino	acid	substitutions	 located	closely	 to	 residues	 functionally	 important.	Specifically,	 the	 PA	 K626E	 substitution	 located	 closely	 to	 residues	 involved	 in	 PB1	binding,	particularly	residue	E623	(PA	PB1-binding	domainC;	Figure	5.1F);	and	the	F71Y	substitution	in	the	nucleocapsid	protein	(NP),	located	closely	to	the	residues	forming	the	putative	RNA-binding	site,	particularly	residue	R175	(Figure	5.1G).	The	second	seasonal	A(H1N1)	 virus	 with	 decrease	 susceptibility	 to	 OS	 –	 virus	 isolate	 A/Lisboa/08/2008,	carried	 the	 NS1	 V230I	 amino	 acid	 substitution	 (Table	 5.1).	 Residue	 230	 has	 the	particularity	of	belonging	to	the	target	region	of	either	PABII	(residues	223-end)	or	PDZ	domain-containing	 (residues	 227-230)	 host-cell	 proteins,	 which	 are	 involved	 in,	respectively,	host	pre-mRNA	processing	and	viral	pathogenesis	4,6.																																																										D	Domain	structure	and	critical	residues	of	influenza	A	virus	NS1	protein	based	on	Krug	and	García-Sastre	5.	
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Table	5.1	Genome-wide	amino	acid	substitutions	specific	of	influenza	viruses	resistant	or	with	decreased	susceptibility	to	oseltamivir	and/or	zanamivir	(PB2,	PB1,	PA,	NP,	M	and	NS	virus	genome	segments)	
	
PB1$F2 M1 M2/BM2d2005/2006 A/Lisboa/25/2006 !S+OS/(≈22fold) S107N D309G R375K S453H M535L N556T V667I F94S/(F55S) M744I/(M705I) 2 None I387V/(I233V;/I206V) V505I/(V351I;/V324I) K626E/(K472E;/K445E) T216I L236S F71Y S430I None NoneA/Lisboa/08/2008 !S+OS/(≈22fold) None P332S/(P178S;/P515S) 2 2 None None V230I 2A/Lisboa/02/2008 ® /OS/(HRI;/NA/H275Y) K121R P453S*e 2 2 2 2 2 H3P*e R400K 2 None NoneA/Lisboa/03/2008 ® /OS/(HRI;/NA/H275Y) P453S*e 2 2 2 2 2 2 H3P*e None None K64R 2 2A/Lisboa/11/2008 ® /OS/(HRI;/NA/H275Y) K121R P453S*e 2 2 2 2 2 L473I/L/(L434I/L)/f 2 2 H3P*e R400K 2 None NoneA/Lisboa/20/2008 ® /OS/(HRI;/NA/H275Y) K121R P453S*e 2 2 2 2 2 H3P*e R400K 2 None NoneA/Lisboa/27/2008 ® /OS/(HRI;/NA/H275Y) P453S*e 2 2 2 2 2 2 H3P*e R490G/(R336G;/R309G) 2 2 None NoneA/Lisboa/28/2008 ® /OS/(HRI;/NA/H275Y) P453S*e 2 2 2 2 2 2 H3P*e None NoneA/Lisboa/29/2008 ® /OS/(HRI;/NA/H275Y)A/Lisboa/39/2008 ® /OS/(HRI;/NA/H275Y)A/Lisboa/40/2008 ® /OS/(HRI;/NA/H275Y) P453S*e 2 2 2 2 2 2 N642S*(N603S)*g 2 2 H3P*e I129M 2 2 I129M 2 None NoneA/Lisboa/41/2008 ® /OS/(HRI;/NA/H275Y)A/Lisboa/02/2009 ® /OS/(HRI;/NA/H275Y)A/Lisboa/03/2009 ® /OS/(HRI;/NA/H275Y)A/Lisboa/05/2009 ® /OS/(HRI;/NA/H275Y) P453S*e 2 2 2 2 2 2 N642S*(N603S)*g 2 2 H3P*e S450N 2 None None D74N 2A/Lisboa/06/2009 ® /OS/(HRI;/NA/H275Y)A/Lisboa/07/2009 ® /OS/(HRI;/NA/H275Y) P453S*e 2 2 2 2 2 2 N642S*(N603S)*g 2 2 H3P*e H535P/H/(H381P/H;/H345P/H)/f M561L/(M407L;/M380L) 2 2/h 2/hA/Lisboa/13/2009 ® /OS/(HRI;/NA/H275Y)A/Lisboa/14/2009 ® /OS/(HRI;/NA/H275Y)A/Lisboa/15/2009 ® /OS/(HRI;/NA/H275Y) T108A/T/f P453S*e 2 2 2 2 2 I156M/(I117M) N642S*(N603S)*g 2 H3P*e I596V*(I442V;*I415V) 2 2 None NoneA/Lisboa/16/2009 ® /OS/(HRI;/NA/H275Y)A/Lisboa/17/2009 ® /OS/(HRI;/NA/H275Y)A/Lisboa/18/2009 ® /OS/(HRI;/NA/H275Y)A/Lisboa/19/2009 ® /OS/(HRI;/NA/H275Y)A/Lisboa/20/2009 ® /OS/(HRI;/NA/H275Y) P453S*e 2 2 2 2 2 2 N642S*(N603S)*g 2 2 H3P*e None None C59Y N143DA/Lisboa/21/2009 ® /OS/(HRI;/NA/H275Y)A/Lisboa/23/2009 ® /OS/(HRI;/NA/H275Y)A/Lisboa/24/2009 ® /OS/(HRI;/NA/H275Y) P453S*e 2 2 2 2 2 2 F254V/(F215V) Q567E/(Q528E) N642S*(N603S)*g H3P*e I596V*(I442V;*I415V) 2 2 None None Y89P 2A/Lisboa/25/2009 ® /OS/(HRI;/NA/H275Y)A/Lisboa/01/2007 !S+OS/(<22fold)A/Lisboa/54/2007 !S+OS/(<22fold)A/Portugal/29/2012 !S+OS/(≈22fold) S375G/(S336G) R602P/(R563P) 2 S25F M441T/(M287T;/M260T) 2 2 V97I None L214P 2A/Portugal/43/2012 !S+OS;/ZA////////////////////////(42fold;/NA/I222V) None L403P/(L249P;/L222P) P534S/(P380S;/P353S) A618T/(A464T;/A437T) None NoneA/Portugal/53/2012 !S /ZA/(≈22fold) D152G 2 2 2 2 2 2 None None NoneB/Lisboa/01/2005/(YAM) !S /ZA/(<22fold) V62A 2 None NoneB/Lisboa/12/2005/(VIC) !S+OS/(≈22fold)B/Lisboa/31/2005/(YAM) !S /ZA/(≈22fold) V62A 2 None None Y43H/Y/f/ 2B/Lisboa/05/2006/(VIC) !S+OS/(<22fold) I331T Y729C K741R None NoneB/Lisboa/11/2006/(VIC) !S+OS/(<22fold) I331T D553Y 2 None None2006/2007 B/Lisboa/02/2007/(VIC) !S /ZA/(32fold)2007/2008 B/Lisboa/34/2008/(YAM) !S //OS/(≈22fold);/ZA//////////////////(32fold)/(NA/D197N) N16S R686K/R/f 2 2 2 2 2 I594V 2 2 K142R 2 None None V67A 2 22008/2009 B/Lisboa/01/2009/(VIC) !S+OS;/ZA/(2;/≈32fold) V140I 2 2 2 2 2 2 M95I 2 2 S415N/S/f 2 2 None NoneB/Portugal/01/2009/(VIC) !S /ZA/(≈42fold)B/Portugal/02/2009/(VIC) !S /ZA/(≈42fold) None S82DB/Portugal/03/2009/(YAM) !S /ZA/(42fold)B/Portugal/01/2011/(YAM) !S /ZA/(32fold)B/Portugal/02/2011/(VIC) !S+OS;/ZA/(≈2;/42fold) V485I M529I/M/f 2 2 2 2 2 None None V140G 2 S47Y E69D N81T
None
2010/2011 None None None
None
None None NonePandemic/period None None None None None
2005/2006 None None None None NoneNone None 2/h None
None
NOT/EN
CODED
None None
None None None None
None
None
None None None None None
B
2004/2005 None None
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None None NoneNone None None None None NoneA(H3N
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2006/2007
2011/2012 None None
None None
None None None
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(Table	5.1	cont.)	
	HRI:	 Highly	 Reduced	 Inhibition;	M1:	Matrix	 protein;	 NA:	 Neuraminidase;	 NAI:	 Neuraminidase	 inhibitor;	 NEP:	 Nuclear	 export	 protein;	 NP:	 Nucleocapsid	 protein;	 NS1:	 Non-structural	 protein	 1;	 NS2:	 Non-structural	 protein	 2;	 OS:	Oseltamivir;	VIC:	Victoria	lineage;	YAM:	Yamagata	lineage;	ZA:	Zanamivir	Symbol	legend:	êS	-	Decreased	Susceptibility;	®	-	Resistance	a	2009	pandemic	period	-	period	between	11th	June	2009	and	9th	August	2010	(WHO	pandemic	alert	Phase	6);	b	Produced	from	the	same	reading	frame	as	PB1	but	lacks	the	first	39	amino	acids	-	N-terminally	truncated	variant	of	PB1;	not	encoded	 in	 influenza	B	virus	PB1	segment;	 c	Produced	 from	the	same	reading	 frame	as	PA	but	 lack,	respectively,	 the	 first	154	and	181	amino	acids	 -	N-terminally	 truncated	variants	of	PA;	not	encoded	 in	 influenza	B	virus	PA	segment;	d	M	segment	encodes	M2	protein	in	influenza	A	viruses	and	BM2	protein	in	influenza	B	viruses;	e	Shared	by	all	NA	H275Y	OS-resistant	former	seasonal	A(H1N1)	viruses	(tested	+	reference)	-	exceptionally	identified	against	the	sequence	of	the	clade	2B	OS-sensitive	reference	virus	A/Brisbane/59/2007;	f	Mixed	virus	population;	g	Shared	by	all	tested	NA	H275Y	OS-resistant	former	seasonal	A(H1N1)	viruses	from	2008/2009;	also	yielded	by	the	NA	H275Y	OS-resistant	reference	virus	A/England/557/2007;	h	Not	successfully	sequenced.			Nucleotide	 sequences	 of	 influenza	 virus	 genome	 segments	were	 aligned	 by	 Clustal	W	method,	 edited	 and	 translated	 into	 the	 amino	 acid	 sequence	 of	 the	 protein(s)	 encoded	 in	MEGA5	 software.	 The	alignment	included	the	sequences	from	the	viruses	under	study	(n=14	former	seasonal	A(H1N1),	except	for	NP	and	M	(n=13);	n=3	A(H3N2);	n=8	B,	except	for	NP	(n=7);	n=13	A(H1N1)pdm09),	sequences	from	drug-sensitive	counterparts	(only	A(H1N1)pdm09,	n=20	(PB2,	PB1,	PA	and	NP)	or	38	(M	and	NS)	-	available	at	the	laboratory	sequence	database),	and	sequences	from	worldwide	reference	viruses	available	at	GISAID	EpiFlu™	and	NCBI	Influenza	Virus	Resource	databases	(n=	3	former	seasonal	A(H1N1),	except	for	M	(n=6);	n=20	to	39	A(H3N2);	n=16	to	29	B;	n=5	to	24	A(H1N1)pdm09).	The	accession	number	of	 the	sequences	of	 the	viruses	circulating	 in	Portugal,	either	obtained	in	this	study	or	already	available	(drug-sensitive),	shared	in	public-access	databases	can	be	found	in	Supplementary	data	(Table	S5.1).	Detailed	 information	on	 the	nucleotide	sequences	of	 the	worldwide	reference	viruses	 is	also	presented	 in	Supplementary	data	(see	Table	S5.2).	Recently	discovered	PB2-S1,	M42	and	NS3	auxiliary	proteins,	encoded	in,	respectively,	influenza	A	virus	PB2,	M	and	NS	segments,	were	not	considered	as	were	either	only	express	in	former	seasonal	A(H1N1)	viruses	(PB2-S1)	or	only	found	in	a	limited	number	of	 influenza	A	viruses	(M42	and	NS3).	Amino	acid	substitutions	were	 identified	against	 the	virus	 type-	or	subtype-matched	consensus	sequence	using	MEGA5	(only	 two	exceptions;	see	footnote	e)	and	are	indicated	using	influenza	A	or	B	numbering	scheme.	The	amino	acid	substitutions	shared	by	two	or	more	viruses	are	highlighted	in	bold	and	italic.	The	influenza	viruses	resistant	or	with	decreased	susceptibility	that	were	not	evaluated	through	whole-genome	sequencing,	either	by	choice	(NA	H275Y	OS-resistant	former	seasonal	A(H1N1)	viruses	from	2008/2009	–	overall	resistance	lead	to	the	selection	of		≈25%	(6/21)	of	the	viruses,	distributed	throughout	the	season)	or	by	not	enough	volume	of	viral	isolate	to	performed	the	analysis,	are	shaded	in	grey.		
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Mutational	landscape	of	influenza	virus	genomes	|	192		Regarding	the	A(H3N2)	viruses	with	decreased	susceptibility	to	NA	inhibitors	(NAIs),	the	NA	I222V	variant	virus	A/Portugal/43/2012	contained	three	amino	acid	substitutions	in	the	PA	PB1-binding	domainC,	two	of	which	located	closely	to	the	residues	involved	in	PB1	binding	 –	 L403P	 and	 A618T	 substitutions	 (Figure	 5.1F).	 And,	 the	 virus	 isolate	A/Portugal/29/2012	 yielded	 the	NS1	 L214P	 amino	 acid	 substitution	within	 the	 region	that	 interacts	with	 the	host-cell	proteins	Crk	and	CrkL	 involved	 in	 the	activation	of	 the	PI3K	signalling	pathway	(residues	212-217)	4,6.			The	 NA	 D197N	 influenza	 B	 variant	 virus	 B/Lisboa/34/2008	 with	 decreased	susceptibility	 to	both	NAIs	 carried	 two	amino	acid	 substitutions	 in	PB2,	 located	within	two	different	functional	domains.	Specifically,	the	N16S	substitution	within	the	PB2	PB1-binding	domain	(residues	1-39,	adapted	from	A);	and	the	R686K	substitution	within	the	NLS	domain	(residues	682-770,	adapted	from	A)	but	outside	the	NLS	motif	(residues	740-759).	 Other	 influenza	 B	 virus	 with	 dual	 decreased	 susceptibility	 –	 virus	 isolate	B/Portugal/02/2011,	 contained	an	amino	acid	 substitution	within	 the	PB2	 cap-binding	domain	 (residues	 320-484,	 adapted	 from	 A)	 –	 V485I	 substitution.	 Structural	 mapping	showed,	however,	that	residue	485	is	located	distantly	from	any	of	the	residues	involved	in	 capped	 mRNA	 binding	 (Figure	 5.1B).	 The	 virus	 isolate	 B/Lisboa/05/2006	 with	decreased	 susceptibility	 to	 OS	 yielded	 two	 amino	 acid	 substitutions	 in	 the	 PB1	 PB2-binding	 domain	 (residues	 677-752,	 adapted	 from	 B)	 –	 Y729C	 and	K741R	 substitutions.		Both	residues	are	located	at	some	distance	(residue	741)	or	far	away	(residue	729)	from	the	 residues	 known	 to	 be	 critical	 for	 stable	 PB2	 binding	 (residues	 694,	 698,	 and	 749;	Figure	 5.1D).	 Also	 of	 notice,	 the	 virus	 isolate	 B/Lisboa/31/2005	 with	 decreased	susceptibility	to	ZA	contained	the	NS1	Y43H	substitution	within	the	RNA-binding	domain	(residues	 15-93)7,	 lying	 adjacently	 to	 residue	 P44	 involved	 in	 the	 interactions	 with	double-stranded	RNA	(dsRNA)	(Figure	5.1I).	Regarding	NP	genome	segment,	 it	was	not	possible	to	structurally	analyse	the	location	of	the	two	residues	on	which	were	detected	specific	 amino	 acid	 substitutions	 -	 residues	 62	 and	 142.	 Both	 residues	 were	 not	comprised	 in	 any	 of	 the	 influenza	 B	 NP	 structures	 available	 at	 the	 RCSB	 Protein	 Data	Bank	(http://www.rcsb.org/pdb).		The	 two	NA	 I223V	A(H1N1)pdm09	 variant	 viruses	with	 decreased	 susceptibility	 to	OS	and	 ZA	 –	 virus	 isolates	A/Portugal/17/2009	 and	A/Portugal/82/2009,	 shared	 the	 PB2	V480I	amino	acid	substitution	(Table	5.1).		
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Figure	5.1	Mapping	of	the	genome-wide	residues	on	which	were	detected	the	amino	acid	substitutions	specific	of	influenza	viruses	resistant	or	with	decreased	susceptibility	to	oseltamivir	and/or	zanamivir,	onto	the	three-dimensional	structure	of	the	corresponding	protein	or	protein	domain	(A-I).	The	 figures	were	 generated	 in	PyMOL,	 using	 protein	 or	 protein	domain	 structure	 files	 retrieved	 from	 the	RCSB	Protein	Data	Bank	(PDB)	(http://www.rcsb.org/pdb).	The	residues	on	which	occurred	the	amino	acid	substitutions	are	shown	as	sticks	that	are	colour-coded	according	to	the	susceptibility	profile	of	the	virus(es)	carrying	the	substitution:	red	-	resistant;	orange	–	with	decreased	 susceptibility.	 When	 viruses	 from	 both	 categories	 carried	 amino	 acid	 substitutions	 at	 the	 same	 residue,	 this	 was	coloured	in	red	(prevalence	of	resistant	profile).	The	residues	known	to	be	functionally	important	are	shown	as	dark	blue	sticks,	maintaining	the	colour	assigned	to	functional	relevance	when	also	associated	with	the	occurrence	of	an	amino	acid	substitution.	The	residues	are	numbered	according	to	the	influenza	type	specific	numbering	scheme	(influenza	A	or	B).	(A)	Structure	of	the	PB2	cap-binding	domain	from	an	influenza	A	virus	(PDB	ID:	4U6O;	residues	318-483).	The	PDB	file	also	includes	the	cap-binding	domain	of	a	second	PB2	monomer	that	is	shown	in	light	grey.	(B)	Structure	of	the	PB2	cap-binding	domain	from	the	influenza	B	virus	B/Lee/1940	(PDB	ID:	5EF9;	residues	420-484).	Panel	A	and	B:	the	residues	known	to	be	functionally	relevant	are	those	involved	in	the	binding	to	the	5´cap	of	host	mRNAs	(cap-binding	residues;	based	on	Mehle	and	McCullers	1).		(C)	Structure	of	the	PB1	PB2-binding	domain	from	the	former	seasonal	A(H1N1)	virus	A/Puerto	Rico/08/1934	(PDB	ID:	3A1G;	residues	678-757).	The	PDB	file	also	includes	the	PB1-binding	domain	of	PB2	(shown	in	dark	grey)	and	the	PB1-PB2	interface	of	a	second	monomer	(shown	in	 light	grey).	(D)	Structure	of	 the	PB1	protein	 from	the	 influenza	B	virus	B/Memphis/13/2003	(PDB	ID:	5FMZ).	The	PDB	file	also	includes	the	PB2	(shown	in	dark	grey)	and	PA	(shown	in	black)	proteins	-	RNA	polymerase	complex.			
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Panel	 C	 and	D:	 the	PB1	residues	 indicated	as	 functionally	 important	are	those	known	to	be	critical	 for	stable	binding	to	PB2	(residues	695,	699,	750	(influenza	A	numbering);	based	on	Mehle	and	McCullers	1).	(E)	Structure	of	the	PA	endonuclease	domain	from	 the	 reference	 A(H1N1)pdm09	 virus	 A/California/04/2009	 (PDB	 ID:	 5DES;	 residues	 1-196).	 	 Functionally	 important	residues	include	those	coordinating	the	binding	to	the	2	Mn2+	metal	ions	(metal-dependent	endonuclease)	and	residue	K143	that	interacts	directly	with	host	mRNAs	during	the	cleavage	of	its	5’	cap	(cap-snatching	endonuclease;	residue	exceptionally	coloured	in	light	purple)	1.	(F)	Structure	of	the	PA	PB1-binding	domain	from	the	former	seasonal	A(H1N1)	virus	A/Puerto	Rico/08/1934	(PDB	 ID:	2ZNL;	 residues	239-716).	The	PDB	 file	 also	 includes	 the	PA-binding	domain	of	PB1	 (shown	 in	dark	grey)	–	PA-PB1	interface.	PA	residue	387	on	which	was	detected	the	I387V	amino	acid	substitution	could	not	be	indicated	as	is	missing	in	the	structure	 file	 used.	 The	 PA	 residues	 known	 to	 be	 functionally	 important	 are	 those	 involved	 in	 the	 binding	 to	 PB1	 (based	 on	Mehle	and	McCullers	1).	(G)	Structure	of	the	nucleocapsid	protein	(NP)	from	the	former	seasonal	A(H1N1)	virus	A/WSN/1933	(PDB	ID:	2IQH).	The	PDB	 file	also	describes	 the	 two	other	monomers	comprising	 the	crystallized	NP	(homotrimer),	 shown	 in	light	grey.	Functionally	 important	 residues	 include	 those	comprising	 the	putative	RNA-binding	 site	 (based	on	Ye	et	al.	 8).	(H)	Structure	 of	 the	 NS1	 RNA-binding	 domain	 from	 the	 A(H3N2)	 virus	 A/Udorn/307/1972	 (PDB	 ID:	 1AIL;	 residues	 1-73).	 (I)	Structure	of	the	NS1	RNA-binding	domain	from	the	influenza	B	virus	B/Lee/40	(PDB	ID:	1XEQ;	residues	15-93).	Panel	H	and	I:	the	 residues	 indicated	 as	 functionally	 important	 are	 those	mediating	 the	 interaction	with	dsRNA	 (based	on	Krug	 and	García-Sastre	5	and	Hale	et	al.	6).				Structurally,	residue	480	belongs	to	the	PB2	cap-binding	domain	but	is	located	distantly	from	 the	 residues	 involved	 in	 capped	 mRNA	 binding,	 as	 shown	 in	 Figure	 5.1A.	A/Portugal/82/2009	contained	a	second	specific	PB2	amino	acid	substitution	in	the	NLS	domainA,	 located	 outside	 the	 NLS	 motif	 (residues	 736-755)	 –	 D680E	 substitution.	Additional	PB2	amino	acid	substitutions	located	within	functional	domains	included:	PB2	R368K	 substitution	 in	 A/Portugal/78/2009	 (cap-binding	 domain,	 but	 located	 distantly	from	 cap-binding	 residues	 (Figure	 5.1A));	 and	 PB2	 A707T	 substitution	 in	A/Portugal/66/2009	(NLS	domain,	outside	NLS	motif).	This	latter	also	contained	the	NS1	L43S	substitution	at	the	RNA-binding	domainD,	located	closely	to	the	residues	mediating	the	 interactions	 with	 dsRNA	 (Figure	 5.1H).	 A(H1N1)pdm09	 virus	 isolates	A/Portugal/101/2009	 and	 A/Portugal/07/2011	 with	 decreased	 susceptibility	 to	 OS	and/or	ZA	carried	an	amino	acid	substitution	in	the	PA	PB1-binding	domain	-	V407A	and	M595I	 substitutions,	 respectively.	 Structural	 mapping	 showed	 that	 residue	 407	 lies	adjacently	 to	 residue	Q408	 involved	 in	PB1	binding	 (Figure	5.1F),	while	 residue	595	 is	directly	involved	in	the	binding	to	this	other	polymerase	subunit.	Also	of	note,	the	virus	isolate	A/Portugal/114/2009	with	decreased	susceptibility	to	OS	contained	the	NP	L47I	amino	acid	substitution	located	within	the	sequence	of	the	NES	1	(residues	29-49);	and	the	 virus	 isolates	 A/Portugal/22/2011	 and	 A/Portugal/54/2013	 with	 decreased	susceptibility	to	OS	and/or	ZA	contained	an	amino	acid	change	within	the	region	of	 the	NS1	 that	 interacts	 with	 the	 host-cell	 factor	 CPSF30	 involved	 in	 pre-mRNA	 processing	(residues	103,	106,	and	144-188)	4,6	–	L185H	and	D173N	substitutions,	respectively.	
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5.2	DISCUSSION		Genetic	characterization	of	influenza	viruses	resistant	or	with	decreased	susceptibility	to	NAIs	usually	 stays	 limited	 to	 the	 two	genome	 segments	 in	which	 can	occur	 amino	acid	substitutions	affecting	virus	susceptibility	 -	NA	and	HA	segments	 9.	The	emergence	and	worldwide	 spread	 of	 a	 fit	 and	 transmissible	 drug-resistant	 variant	 in	 late	 2007	 (NA	H275Y	 seasonal	 A(H1N1))	 showed,	 however,	 the	 importance	 of	 expanding	 genetic	characterization	to	all	other	6	segments	of	influenza	virus	genome	(PB2,	PB1,	PA,	NP,	M	and	 NS	 segments).	 Amino	 acid	 changes	 at	 all	 genome	 segments	 can	 affect	 the	 overall	virus	fitnessE	and	compensate	for	the	expected	fitness	deficit	of	drug-resistant	variants	or	even	 result	 in	 an	 enhanced	 virus	 fitness	 compared	 to	 drug-sensitive	 counterparts.	Transmissible	drug	resistance	poses	a	serious	threat	to	public	health,	as	it	could	render	NAIs	useless	against	circulating	human	influenza	viruses	and	left	us	without	any	options	for	 antiviral	 therapy.	Elucidating	 the	molecular	mechanisms	underlying	 fitness	gains	 in	drug-resistant	viruses	is	therefore	a	priority	in	influenza.		NA	H275Y	OS-resistant	seasonal	A(H1N1)	viruses	shared	the	PB2	P453S	and	PB1-F2	H3P	amino	 acid	 substitutions,	 with	 those	 from	 2008/2009	 further	 sharing	 the	 PB1	 N642S	amino	acid	substitution.	However,	 the	PB1-F2	protein	of	seasonal	A(H1N1)	viruses	was	present	in	a	C-terminally	truncated	non-functional	form	and	structural	analysis	of	either	PB2	P453S	or	PB1	N642S	substitutions	suggested	no	role	in	the	enhanced	viral	fitness	of	these	 drug-resistant	 viruses.	 PB2	 P453S	 occurred	 within	 the	 cap-binding	 functional	domain	 but	 distantly	 from	 the	 residues	 directly	 involved	 in	 the	 binding	 to	 the	 host	mRNAs;	 while	 PB1	 N642S	 occurred	 outside	 of	 all	 known	 functional	 domains.	Notwithstanding,	 it	 has	 to	 be	 taken	 into	 consideration	 that,	 contrary	 to	 the	 other	 two	polymerase	 subunits	 (PB2	 and	 PA),	 only	 limited	 structural	 information	 is	 available	 for	PB1	 1.	 Both	 PB2	 P453S	 and	 PB1	 N642S	 substitutions	 were	 identified	 in	 a	 previous	genome-wide	study	targeting	seasonal	A(H1N1)	viruses	circulating	in	Taiwan	from	2005	to	 2009,	 distinguishing	 clade	 2B	 OS-resistant	 and	 OS-sensitive	 viruses	 12.	 But,	 no	information	 is	 available	 about	 its	 effect	 on	 overall	 virus	 fitness.	 Further	 in	vitro	 and	 in	
vivo	 studies	are	 still	 required	 to	 clarify	 the	 role	of	both	amino	acid	 substitutions	 in	 the	enhanced	 viral	 fitness	 of	 NA	 H275Y	 OS-resistant	 viruses.	 Particularly	 of	 PB1	 N642S,																																																									E	Considered	 as	 the	 ability	 of	 the	 virus	 to	 replicate	 efficiently	 (replicative	 fitness)	 and	 transmit	 readily	 between	 hosts	(transmission	fitness)	10.	This	takes	into	consideration	both	standard	(‘‘the	capacity	of	a	virus	to	produce	infectious	progeny	in	a	
given	 environment’’)	 and	 Darwinian	 (“the	 amount	 of	 genetic	material	 passed	 on	 to	 the	 next	 generation”)	 definitions	 of	 overall	fitness	11.		
Mutational	landscape	of	influenza	virus	genomes	|	196		which	was	 the	 only	 amino	 acid	 substitution	 shared	by	 the	 latter	drug-resistant	 viruses	(2008/2009)	 that	 spread	 over	 their	 sensitive	 counterparts	 and	 fixed	 NA	 H275Y	 in	A(H1N1)	virus	population	(100%	resistance).			Amino	 acid	 changes	 in	 or	 close	 to	 residues	 known	 to	 be	 functionally	 important	 were	detected	 individually	 in	 either	 NA	 H275Y	 OS-resistant	 seasonal	 A(H1N1)	 viruses	 from	2008/2009	or	 influenza	viruses	with	decreased	susceptibility	 to	OS	and/or	ZA	 from	all	different	 types	 and	 subtypes.	 Based	 on	 its	 structural	 location,	 these	 amino	 acid	substitutions	 may	 play	 a	 role	 in	 the	 overall	 fitness	 of	 the	 virus.	 In	 fact,	 PB2	 V667I	substitution	 is	 known	 to	 be	 associated	 with	 an	 enhanced	 transmission	 to	 humans	(molecular	marker	of	enhanced	transmission)	13,	but	no	information	was	found	about	any	of	 the	 other	 substitutions	 in	 the	 literature.	 It	 is	 also	 important	 to	 note	 that	 previous	genetic	 characterization	 of	 HA	 gene	 (genotypic	 susceptibility	 testing;	 Chapter	 4)	identified	 the	 potential	 fitness-enhancing	 mutation	 HA	 N156K	 in	 the	 A(H1N1)pdm09	virus	A/Portugal/07/2011	with	decreased	susceptibility	to	both	NAIs.			The	NA	H275Y	OS-resistant	A(H1N1)pdm09	virus	isolate	A/Portugal/03/2011	carried	a	single	 amino	acid	 substitution	 in	PB1	 (PB1	K52R)	 that,	 based	on	 its	 structural	 location	outside	 of	 all	 known	 functional	 domains,	 had	 probably	 no	 impact	 on	 viral	 fitness.	Nonetheless,	 only	 limited	 structural	 information	 is	 available	 for	 PB1,	 as	 above-mentioned.		Previous	 in	 vitro	 studies	 showed	 that	 the	 PB2	 T108A,	 D195N	 and	 M535L	 amino	 acid	substitutions	 found	 in	 influenza	N1	NA	viruses	resistant	or	with	decrease	susceptibility	to	 OS	 and/or	 ZA	 (A/Lisboa/15/2009	 (seasonal	 N1),	 A/Portugal/22/2011	 and	A/Portugal/54/2013	 (N1pdm09),	 and	 A/Lisboa/25/2006	 (seasonal	 N1),	 respectively),	increase	the	activity	of	the	viral	ribonucleoprotein	(RNP)	complex	14-16.	Considering	that	the	 RNP	 complex	 mediates	 both	 transcription	 and	 replication	 of	 viral	 RNA	 (vRNA)	genome	 1,	 the	 enhanced	 activity	 associated	 with	 the	 presence	 of	 such	 amino	 acid	substitutions	 may	 be	 linked	 to	 an	 increase	 in	 viral	 transcription	 and/or	 replication	efficiency.	 The	 T48A	 amino	 acid	 substitution	 additionally	 found	 in	 the	 nuclear	 export	protein	 (NEP)	 of	 A/Portugal/54/2013	 is	 know	 to	 increase	 the	 binding	 to	 the	 host-cell	protein	CRM1	that	mediates	the	export	of	viral	RNP	complexes	from	the	nucleus	(nuclear	transport	 receptor)	 17.	 	 This	 increased	 interaction	 with	 CMR1	may	 result	 in	 enhanced	
Mutational	landscape	of	influenza	virus	genomes	|	197		nuclear	export	of	viral	RNP	complexes	and	consequently	enhanced	viral	replication.	The	NS1	D74N	 amino	 acid	 substitution	 identified	 in	 an	 additional	OS-resistant	 seasonal	N1	virus	 –	 virus	 isolate	 A/Lisboa/05/2009,	 is	 known	 to	 significantly	 increase	 viral	replication	 in	 vitro	 in	 influenza	 A(H1N1)pdm09	 and	 A(H5N1)	 backgrounds	 18.	 The	substitution	was	studied	in	more	detailed	in	A(H5N1)	avian	viruses,	in	which	showed	to	alter	 the	 viral	 RNP	 complex	 export	 dynamics	 and	 increase	 its	 activity,	 enhance	 viral	genome	and	protein	synthesis,	and	improve	replication	and	transcription	activities.	Also,	given	its	location	in	the	linker	region,	it	was	proposed	to	alter	the	structural	flexibility	of	NS1,	 affecting	 how	 the	 specific	 protein-RNA	 or	 protein-protein	 interactions	 occur	 in	either	RNA-binding	or	effector	functional	domains	18.			
5.3	CONCLUSIONS		This	 study	 enabled	 the	 complete	 characterization	 of	 the	 genome	 of	 influenza	 viruses	resistant	 or	 with	 decreased	 susceptibility	 to	 OS	 and/or	 ZA.	 It	 contributed	 at	 finding	potential	 determinants	 of	 viral	 fitness	 in	 other	 segments	 of	 influenza	 virus	 genome	beyond	NA	and	HA;	and	at	elucidating	the	potential	lack	of	role	of	these	other	segments	in	 the	 enhanced	 viral	 fitness	 of	 NA	H275Y	OS-resistant	 seasonal	 A(H1N1)	 viruses	 that	spread	worldwide.	In	a	broader	sense,	it	also	contributed	at	a	better	understanding	of	the	genetic	changes	underlying	the	evolution	of	influenza	virus	genomes.												
	
	
	
BOX	5.2	-	MAIN	FINDINGS	
• Structural	location	of	PB2	P453S	and	PB1	N642S	amino	acid	substitutions	shared	by	NA	H275Y	OS-resistant	 seasonal	 A(H1N1)	 viruses	 suggests	 no	 role	 in	 their	 fitness	 advantage	 over	 OS-sensitive	counterparts.	
• Additional	 PB1-F2	 H3P	 amino	 acid	 substitution	 specific	 of	 NA	 H275Y	 OS-resistant	 seasonal	A(H1N1)	viruses	occurred	in	a	C-terminally	truncated	non-functional	protein.	
• NA	H275Y	OS-resistant	A(H1N1)pdm09	virus	with	only	a	single	amino	acid	substitution	in	PB1,	outside	of	all	known	functional	domains	(PB1	K52R).	
• PB2	T108A,	D195N,	M535L	and	V667I	amino	acid	substitutions,	as	well	as	NEP	T48A	and	NS1	D74N	 amino	 acid	 substitutions,	 detected	 in	 A(H1N1)	 viruses	 from	 either	 former	 or	 current	circulating	subtypes	resistant	or	with	decreased	susceptibility	to	OS	and/or	ZA,	are	known	to	or	may	play	a	role	in	enhance	overall	virus	fitness.	
Mutational	landscape	of	influenza	virus	genomes	|	198		
5.4	REFERENCES		1	 Mehle	A,	McCullers	 JA,	 2013.	 Structure	 and	 function	 of	 the	 influenza	 virus	 replication	machinery	 and	PB1-F2.	 In:	Webster	R,	Monto	A,	Braciale	T,	Lamb	R	(Eds.),	Textbook	of	Influenza,	 	2nd	ed.	 John	Wiley	&	Sons,	Ltd,	West	Sussex,	United	Kingdom,	pp.	133-145.	2	 Chu	C,	Fan	S,	Li	C,	Macken	C,	Kim	JH,	Hatta	M,	Neumann	G,	Kawaoka	Y,	2012.	Functional	analysis	of	conserved	motifs	in	influenza	virus	PB1	protein.	PLoS	One	7(5),	e36113.	3	 Wei	P,	Li	W,	Zi	H,	Cunningham	M,	Guo	Y,	Xuan	Y,	Musa	TH,	Luo	P,	2015.	Epidemiological	and	molecular	characteristics	of	 the	PB1-F2	proteins	in	H7N9	influenza	viruses,	Jiangsu.	Biomed	Res	Int	2015,	804731.	4	 Engel	DA,	2013.	The	influenza	virus	NS1	protein	as	a	therapeutic	target.	Antiviral	Res	99(3),	409-416.	5	 Krug	R,	García-Sastre	A,	2013.	The	NS1	protein:	A	master	regulator	of	host	and	viral	functions.	In:	Webster	R,	Monto	A,	Braciale	T,	Lamb	R	(Eds.),	Textbook	of	Influenza,		2nd	ed.	John	Wiley	&	Sons,	Ltd,	West	Sussex,	United	Kingdom,	pp.	114-132.	6	 Hale	BG,	Randall	RE,	Ortin	J,	Jackson	D,	2008.	The	multifunctional	NS1	protein	of	influenza	A	viruses.	J	Gen	Virol	89(Pt	10),	2359-2376.	7	 Yin	 C,	 Khan	 JA,	 Swapna	 GV,	 Ertekin	 A,	 Krug	 RM,	 Tong	 L,	Montelione	 GT,	 2007.	 Conserved	 surface	 features	 form	 the	 double-stranded	RNA	binding	site	of	non-structural	protein	1	(NS1)	from	influenza	A	and	B	viruses.	J	Biol	Chem	282(28),	20584-20592.	8	 Ye	Q,	Krug	RM,	Tao	YJ,	2006.	The	mechanism	by	which	influenza	A	virus	nucleoprotein	forms	oligomers	and	binds	RNA.	Nature	444(7122),	1078-1082.	9	 Zambon	 M,	 Hayden	 FG,	 Global	 Neuraminidase	 Inhibitor	 Susceptibility	 N,	 2001.	 Position	 statement:	 global	 neuraminidase	inhibitor	susceptibility	network.	Antiviral	Res	49(3),	147-156.	10	 Hurt	AC,	2014.	The	epidemiology	and	spread	of	drug	resistant	human	influenza	viruses.	Curr	Opin	Virol	8,	22-29.	11	 Wargo	AR,	Kurath	G,	2012.	Viral	fitness:	definitions,	measurement,	and	current	insights.	Curr	Opin	Virol	2(5),	538-545.	12	 Yang	JR,	Lin	YC,	Huang	YP,	Su	CH,	Lo	J,	Ho	YL,	Yao	CY,	Hsu	LC,	Wu	HS,	Liu	MT,	2011.	Reassortment	and	mutations	associated	with	emergence	and	spread	of	oseltamivir-resistant	seasonal	influenza	A/H1N1	viruses	in	2005-2009.	PLoS	One	6(3),	e18177.	13	 Mertens	E,	Dugan	VG,	Stockwell	TB,	Lindsay	LL,	Plancarte	M,	Boyce	WM,	2013.	Evaluation	of	phenotypic	markers	in	full	genome	sequences	of	avian	influenza	isolates	from	California.	Comp	Immunol	Microbiol	Infect	Dis	36(5),	521-536.	14	 Nakazono	 Y,	 Hara	 K,	 Kashiwagi	 T,	 Hamada	 N,	 Watanabe	 H,	 2012.	 The	 RNA	 polymerase	 PB2	 subunit	 of	 influenza	A/HongKong/156/1997	(H5N1)	restricts	the	replication	of	reassortant	ribonucleoprotein	complexes.	PLoS	One	7(2),	e32634.	15	 Sang	X,	Wang	A,	Ding	J,	Kong	H,	Gao	X,	Li	L,	Chai	T,	Li	Y,	Zhang	K,	Wang	C,	Wan	Z,	Huang	G,	Wang	T,	Feng	N,	Zheng	X,	Wang	H,	Zhao	Y,	Yang	S,	Qian	J,	Hu	G,	Gao	Y,	Xia	X,	2015.	Adaptation	of	H9N2	AIV	in	guinea	pigs	enables	efficient	transmission	by	direct	contact	and	inefficient	transmission	by	respiratory	droplets.	Sci	Rep	5,	15928.	16	 Chen	GW,	Kuo	SM,	Yang	SL,	Gong	YN,	Hsiao	MR,	Liu	YC,	Shih	SR,	Tsao	KC,	2016.	Genomic	Signatures	 for	Avian	H7N9	Viruses	Adapting	to	Humans.	PLoS	One	11(2),	e0148432.	17	 Gao	S,	Wang	S,	Cao	S,	Sun	L,	Li	J,	Bi	Y,	Gao	GF,	Liu	W,	2014.	Characteristics	of	nucleocytoplasmic	transport	of	H1N1	influenza	A	virus	nuclear	export	protein.	J	Virol	88(13),	7455-7463.	18	 Kanrai	 P,	 2015.	 Identification	 and	 characterization	 of	 specific	 amino	 acid	 residues	 in	 the	 NS1	 protein	 that	 facilitated	 viral	replication	of	avian	influenza	viruses	in	mammalian	host.	PhD	Thesis,	Justus	Liebig	University	Giessen,	Giessen,	Hesse,	Germany.	Available	 at:	 http://geb.uni-giessen.de/geb/volltexte/2015/11455/pdf/KanraiPumaree_2015_04_21.pdf	 (Accessed	 November	10,	2015)					
					
SUPPLEMENTARY		
DATA																							
								 	
Mutational	landscape	of	influenza	virus	genomes	-	Supplementary	data			|	201	
	
Table	S5.1	List	of	the	accession	number	of	the	genome-wide	nucleotide	sequences	of	influenza	viruses	circulating	in	Portugal	used	in	this	study	and	shared	in	public-access	databases.									NA:	Neuraminidase;	NAI:	Neuraminidase	inhibitor;	OS:	Oseltamivir;	ZA:	Zanamivir	Symbol	legend:	êS	-	Decreased	Susceptibility	a	Period	from	11th	June	2009	to	9th	August	2010	GISAID	EpiFlu™	database:	http://platform.gisaid.org.	The	sequences	were	either	generated	in	this	study	(A/Portugal/17/2009)	or	were	already	available	at	the	laboratory	sequence	database	(drug-sensitive	viruses),	having	been	obtained	in	the	context	of	the	study	on	the	evolutionary	dynamics	of	the	newly	emerging	A(H1N1)	pandemic	virus.									
Influenza)virus)subtype )2009)pandemic)perioda)/)Influenza)season Sequence)database Accession)number Segment Virus)isolate NAI)susceptibility)profileEPI500694 PB1 A/Portugal/17/2009 !S )OS)(3Kfold);)ZA))))))))))))))(≈2Kfold))(NA)I223V)EPI500725 PB1 A/Portugal/52/2009 SensitiveEPI500750 PB1 A/Portugal/01/2010 SensitiveEPI500753 PB1 A/Portugal/02/2010 SensitiveEPI500762 PB1 A/Portugal/21/2011 SensitiveEPI500767 PB1 A/Portugal/28/2011 Sensitive
A(H1N1)pdm09 Pandemic)period GISAID)EPIFLUTM)
2010/2011
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I	 acknowledge	 the	 authors,	 originating	 and	 submitting	 laboratories	 of	 the	 genome-wide	 nucleotide	 sequences	 of	 worldwide	 reference	influenza	viruses	retrieved	from	GISAID	EpiFlu™	and	NCBI	Influenza	Virus	Resource	databases	that	were	used	in	this	study.			
Table	S5.2	Detailed	information	on	the	genome-wide	nucleotide	sequences	of	worldwide	reference	influenza	viruses	used	in	this	study	(PB2,	PB1,	PA,	NP,	M	and	NS	segments),	retrieved	from	GISAID	EpiFluTM	and	NCBI	Influenza	Virus	Resource	databases.		
		
Influenza)(sub)type Segment)ID Segment Country Collection)date)(year;month;day) Reference)virus Originating)Lab Submitting)Lab AuthorsEPI249527 PB2 Australia 2007;Jan;01 A/Brisbane/59/2007 ; Other)Database)Import Webby,R.;)Webster,R.G.;)Govorkova,E.;)Duan,S.EPI249528 PB1 Australia 2007;Jan;01 A/Brisbane/59/2007 ; Other)Database)Import Webby,R.;)Webster,R.G.;)Govorkova,E.;)Duan,S.EPI249529 PA Australia 2007;Jan;01 A/Brisbane/59/2007 ; Other)Database)Import Webby,R.;)Webster,R.G.;)Govorkova,E.;)Duan,S.EPI249531 NP Australia 2007;Jan;01 A/Brisbane/59/2007 ; Other)Database)Import Webby,R.;)Webster,R.G.;)Govorkova,E.;)Duan,S.EPI249533 M Australia 2007;Jan;01 A/Brisbane/59/2007 ; Other)Database)Import Webby,R.;)Webster,R.G.;)Govorkova,E.;)Duan,S.EPI249534 NS Australia 2007;Jan;01 A/Brisbane/59/2007 ; Other)Database)Import Webby,R.;)Webster,R.G.;)Govorkova,E.;)Duan,S.EPI168128 PB1 United)Kingdom 2007;Nov;15 A/England/557/2007 ; Other)Database)Import ;EPI168130 PA United)Kingdom 2007;Nov;15 A/England/557/2007 ; Other)Database)Import ;EPI168131 PB2 United)Kingdom 2007;Nov;15 A/England/557/2007 ; Other)Database)Import ;EPI168132 NP United)Kingdom 2007;Nov;15 A/England/557/2007 ; Other)Database)Import ;EPI168133 M United)Kingdom 2007;Nov;15 A/England/557/2007 ; Other)Database)Import ;EPI168134 NS United)Kingdom 2007;Nov;15 A/England/557/2007 ; Other)Database)Import ;EPI155236 M Japan 2006;Jan;17 A/Fukushima/141/2006 ; Centers)for)Disease)Control)and)Prevention ;EPI159399 PB2 New)Caledonia 1999;Jan;01 A/New2Caledonia/20/1999 ; Other)Database)Import ;EPI159398 PB1 New)Caledonia 1999;Jan;01 A/New2Caledonia/20/1999 ; Other)Database)Import ;EPI159397 PA New)Caledonia 1999;Jan;01 A/New2Caledonia/20/1999 ; Other)Database)Import ;EPI159395 NP New)Caledonia 1999;Jan;01 A/New2Caledonia/20/1999 ; Other)Database)Import ;EPI159393 M New)Caledonia 1999;Jan;01 A/New2Caledonia/20/1999 ; Other)Database)Import ;EPI159396 NS New)Caledonia 1999;Jan;01 A/New2Caledonia/20/1999 ; Other)Database)Import ;EPI152158 M Solomon)Islands 2006;Aug;21 A/Solomon2Islands/03/2006 ; Other)Database)Import ;EPI189429 M Russian)Federation 2008;Feb;13 A/St.)Petersburg/12/2008 ; Centers)for)Disease)Control)and)Prevention ;EPI349372 M United)States 2011;Dec;07 A/Alabama/04/2011 ADPH)Bureau)of)Clinical)Laboratories Centers)for)Disease)Control)and)Prevention ;EPI341641 PB2 United)States 2010;Jul;13 A/Alabama/05/2010 U.S.)Air)Force)School)of)Aerospace)Medicine Centers)for)Disease)Control)and)Prevention ;EPI341642 PB1 United)States 2010;Jul;13 A/Alabama/05/2010 U.S.)Air)Force)School)of)Aerospace)Medicine Centers)for)Disease)Control)and)Prevention ;EPI341640 PA United)States 2010;Jul;13 A/Alabama/05/2010 U.S.)Air)Force)School)of)Aerospace)Medicine Centers)for)Disease)Control)and)Prevention ;EPI341638 NP United)States 2010;Jul;13 A/Alabama/05/2010 U.S.)Air)Force)School)of)Aerospace)Medicine Centers)for)Disease)Control)and)Prevention ;EPI278803 M United)States 2010;Jul;13 A/Alabama/05/2010 U.S.)Air)Force)School)of)Aerospace)Medicine Centers)for)Disease)Control)and)Prevention ;EPI341639 NS United)States 2010;Jul;13 A/Alabama/05/2010 U.S.)Air)Force)School)of)Aerospace)Medicine Centers)for)Disease)Control)and)Prevention ;EPI353310 PB2 Australia 2007;Feb;06 A/Brisbane/10/2007 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Iannello,P;)Komadina,NEPI353309 PB1 Australia 2007;Feb;06 A/Brisbane/10/2007 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Iannello,P;)Komadina,NEPI353308 PA Australia 2007;Feb;06 A/Brisbane/10/2007 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Iannello,P;)Komadina,NEPI353307 NP Australia 2007;Feb;06 A/Brisbane/10/2007 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Iannello,P;)Komadina,NEPI353305 M Australia 2007;Feb;06 A/Brisbane/10/2007 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Iannello,P;)Komadina,NEPI353306 NS Australia 2007;Feb;06 A/Brisbane/10/2007 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Iannello,P;)Komadina,NEPI175105 M Australia 2008;Jun;23 A/Brisbane/24/2008 ; Centers)for)Disease)Control)and)Prevention ;EPI228932 PB2 United)States 2004;Jan;01 A/California/07/2004 ; Other)Database)Import Bragstad,K.;)Nielsen,L.P.;)Fomsgaard,A.EPI228943 PA United)States 2004;Jan;01 A/California/07/2004 ; Other)Database)Import Bragstad,K.;)Nielsen,L.P.;)Fomsgaard,A.EPI228945 M United)States 2004;Jan;01 A/California/07/2004 ; Other)Database)Import Bragstad,K.;)Nielsen,L.P.;)Fomsgaard,A.EPI228949 NS United)States 2004;Jan;01 A/California/07/2004 ; Other)Database)Import Bragstad,K.;)Nielsen,L.P.;)Fomsgaard,A.EPI302281 M United)States 2010;Dec;08 A/California/28/2010 California)Department)of)Health)Services Centers)for)Disease)Control)and)Prevention ;EPI500570 M Senegal 2012;Oct;11 A/Dakar/15/2012 Institut)Pasteur)de)Dakar National)Institute)for)Medical)Research ;EPI490084 PB2 United)States 2012;Nov;12 A/Delaware/15/2012 Delaware)Public)Health)Lab Centers)for)Disease)Control)and)Prevention ;EPI490085 PB1 United)States 2012;Nov;12 A/Delaware/15/2012 Delaware)Public)Health)Lab Centers)for)Disease)Control)and)Prevention ;EPI490083 PA United)States 2012;Nov;12 A/Delaware/15/2012 Delaware)Public)Health)Lab Centers)for)Disease)Control)and)Prevention ;EPI417235 M United)States 2012;Nov;12 A/Delaware/15/2012 Delaware)Public)Health)Lab Centers)for)Disease)Control)and)Prevention ;EPI490081 NP United)States 2012;Nov;12 A/Delaware/15/2012 Delaware)Public)Health)Lab Centers)for)Disease)Control)and)Prevention ;EPI490082 NS United)States 2012;Nov;12 A/Delaware/15/2012 Delaware)Public)Health)Lab Centers)for)Disease)Control)and)Prevention ;
Forme
r)seaso
nal)A(H
1N1)
A(H3N
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(Table	S5.2	cont.)	
		
Influenza)(sub)type Segment)ID Segment Country Collection)date)(year;month;day) Reference)virus Originating)Lab Submitting)Lab AuthorsEPI508354 M United)Kingdom 2010;Nov;26 A/England/4820166/2010 Health)Protection)Agency National)Institute)for)Medical)Research ;EPI358781 PB2 China 2002;Jan;01 A/Fujian/411/2002 ; Other)Database)Import Galiano,M.;)Johnson,B.F.;)Myers,R.;)Ellis,J.;)Daniels,R.;)et#al.EPI358782 PB1 China 2002;Jan;01 A/Fujian/411/2002 ; Other)Database)Import Galiano,M.;)Johnson,B.F.;)Myers,R.;)Ellis,J.;)Daniels,R.;)et#al.EPI358783 PA China 2002;Jan;01 A/Fujian/411/2002 ; Other)Database)Import Galiano,M.;)Johnson,B.F.;)Myers,R.;)Ellis,J.;)Daniels,R.;)et#al.EPI358785 NP China 2002;Jan;01 A/Fujian/411/2002 ; Other)Database)Import Galiano,M.;)Johnson,B.F.;)Myers,R.;)Ellis,J.;)Daniels,R.;)et#al.EPI358787 M China 2002;Jan;01 A/Fujian/411/2002 ; Other)Database)Import Galiano,M.;)Johnson,B.F.;)Myers,R.;)Ellis,J.;)Daniels,R.;)et#al.EPI358788 NS China 2002;Jan;01 A/Fujian/411/2002 ; Other)Database)Import Galiano,M.;)Johnson,B.F.;)Myers,R.;)Ellis,J.;)Daniels,R.;)et#al.EPI342128 M United)States 2009;Mar;30 A/Hawaii/07/2009 State)of)Hawaii)Department)of)Health Centers)for)Disease)Control)and)PreventionEPI142344 PB2 Japan 2005;Oct;24 A/Hiroshima/52/2005 ; Other)Database)Import Krammer,F.;)Grabherr,R.EPI142345 PB1 Japan 2005;Oct;24 A/Hiroshima/52/2005 ; Other)Database)Import Krammer,F.;)Grabherr,R.EPI142346 PA Japan 2005;Oct;24 A/Hiroshima/52/2005 ; Other)Database)Import Krammer,F.;)Grabherr,R.EPI142347 NP Japan 2005;Oct;24 A/Hiroshima/52/2005 ; Other)Database)Import Krammer,F.;)Grabherr,R.EPI142349 M Japan 2005;Oct;24 A/Hiroshima/52/2005 ; Other)Database)Import Krammer,F.;)Grabherr,R.EPI142348 NS Japan 2005;Oct;24 A/Hiroshima/52/2005 ; Other)Database)Import Krammer,F.;)Grabherr,R.EPI353509 PB2 Hong)Kong)(SAR) 2009;Apr;07 A/Hong)Kong/2000/2009 Government)Virus)Unit Centers)for)Disease)Control)and)PreventionEPI353510 PB1 Hong)Kong)(SAR) 2009;Apr;07 A/Hong)Kong/2000/2009 Government)Virus)Unit Centers)for)Disease)Control)and)PreventionEPI353508 PA Hong)Kong)(SAR) 2009;Apr;07 A/Hong)Kong/2000/2009 Government)Virus)Unit Centers)for)Disease)Control)and)PreventionEPI353505 NP Hong)Kong)(SAR) 2009;Apr;07 A/Hong)Kong/2000/2009 Government)Virus)Unit Centers)for)Disease)Control)and)PreventionEPI353507 M Hong)Kong)(SAR) 2009;Apr;07 A/Hong)Kong/2000/2009 Government)Virus)Unit Centers)for)Disease)Control)and)PreventionEPI353506 NS Hong)Kong)(SAR) 2009;Apr;07 A/Hong)Kong/2000/2009 Government)Virus)Unit Centers)for)Disease)Control)and)PreventionEPI335920 PB2 United)States 2010;Dec;30 A/Iowa/19/2010 Iowa)State)Hygienic)Laboratory Centers)for)Disease)Control)and)PreventionEPI335921 PB1 United)States 2010;Dec;30 A/Iowa/19/2010 Iowa)State)Hygienic)Laboratory Centers)for)Disease)Control)and)PreventionEPI335919 PA United)States 2010;Dec;30 A/Iowa/19/2010 Iowa)State)Hygienic)Laboratory Centers)for)Disease)Control)and)PreventionEPI335916 NP United)States 2010;Dec;30 A/Iowa/19/2010 Iowa)State)Hygienic)Laboratory Centers)for)Disease)Control)and)PreventionEPI335918 M United)States 2010;Dec;30 A/Iowa/19/2010 Iowa)State)Hygienic)Laboratory Centers)for)Disease)Control)and)PreventionEPI335917 NS United)States 2010;Dec;30 A/Iowa/19/2010 Iowa)State)Hygienic)Laboratory Centers)for)Disease)Control)and)PreventionEPI232566 M Kenya 2009;Sep;15 A/Kenya/4408/2009 CDC;Kenya Centers)for)Disease)Control)and)PreventionEPI417175 M United)States 2012;Nov;13 A/Maryland/43/2012 Maryland)Department)of)Health)and)Mental)Hygiene Centers)for)Disease)Control)and)PreventionEPI390187 PB1 Nepal 2006;Aug;01 A/Nepal/921/2006 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390188 PB2 Nepal 2006;Aug;01 A/Nepal/921/2006 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390186 PA Nepal 2006;Aug;01 A/Nepal/921/2006 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390184 NP Nepal 2006;Aug;01 A/Nepal/921/2006 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390182 M Nepal 2006;Aug;01 A/Nepal/921/2006 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390185 NS Nepal 2006;Aug;01 A/Nepal/921/2006 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI381978 PB2 United)States 2004;Jan;01 A/New)York/55/2004 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI381977 PB1 United)States 2004;Jan;01 A/New)York/55/2004 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI381976 PA United)States 2004;Jan;01 A/New)York/55/2004 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI381975 NP United)States 2004;Jan;01 A/New)York/55/2004 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI381972 M United)States 2004;Jan;01 A/New)York/55/2004 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI381974 NS United)States 2004;Jan;01 A/New)York/55/2004 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI508321 M Norway 2010;Dec;03 A/Norway/1330/2010 WHO)National)Influenza)Centre National)Institute)for)Medical)ResearchEPI397576 PB2 United)States 2012;Mar;08 A/Ohio/02/2012 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)PreventionEPI397577 PB1 United)States 2012;Mar;08 A/Ohio/02/2012 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)PreventionEPI397638 PA United)States 2012;Mar;08 A/Ohio/02/2012 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)PreventionEPI397637 NP United)States 2012;Mar;08 A/Ohio/02/2012 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)PreventionEPI384819 M United)States 2012;Mar;08 A/Ohio/02/2012 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)PreventionEPI397575 NS United)States 2012;Mar;08 A/Ohio/02/2012 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)PreventionEPI500625 M France 2012;Oct;29 A/Paris/1651/2012 Institut)Pasteur National)Institute)for)Medical)ResearchEPI390180 PB2 Australia 2010;Aug;01 A/Perth/10/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390179 PB1 Australia 2010;Aug;01 A/Perth/10/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390178 PA Australia 2010;Aug;01 A/Perth/10/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390120 NP Australia 2010;Aug;01 A/Perth/10/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390118 M Australia 2010;Aug;01 A/Perth/10/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390121 NS Australia 2010;Aug;01 A/Perth/10/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI272741 PB2 Australia 2009;Apr;07 A/Perth/16/2009 Pathwest)QE)II)Medical)Centre WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Deng,Y.M.;)Iannello,P;)Erneste,J;)Komadina,N.EPI272742 PB1 Australia 2009;Apr;07 A/Perth/16/2009 Pathwest)QE)II)Medical)Centre WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Deng,Y.M.;)Iannello,P;)Erneste,J;)Komadina,N.EPI272743 PA Australia 2009;Apr;07 A/Perth/16/2009 Pathwest)QE)II)Medical)Centre WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Deng,Y.M.;)Iannello,P;)Erneste,J;)Komadina,N.EPI272744 NP Australia 2009;Apr;07 A/Perth/16/2009 Pathwest)QE)II)Medical)Centre WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Deng,Y.M.;)Iannello,P;)Erneste,J;)Komadina,N.EPI272746 M Australia 2009;Apr;07 A/Perth/16/2009 Pathwest)QE)II)Medical)Centre WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Deng,Y.M.;)Iannello,P;)Erneste,J;)Komadina,N.EPI272745 NS Australia 2009;Apr;07 A/Perth/16/2009 Pathwest)QE)II)Medical)Centre WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Deng,Y.M.;)Iannello,P;)Erneste,J;)Komadina,N.
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Influenza)(sub)type Segment)ID Segment Country Collection)date)(year;month;day) Reference)virus Originating)Lab Submitting)Lab AuthorsEPI390384 PB2 United)States 2010;Aug;01 A/Rhode)Island/01/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390383 PB1 United)States 2010;Aug;01 A/Rhode)Island/01/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390382 PA United)States 2010;Aug;01 A/Rhode)Island/01/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390380 NP United)States 2010;Aug;01 A/Rhode)Island/01/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390378 M United)States 2010;Aug;01 A/Rhode)Island/01/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390381 NS United)States 2010;Aug;01 A/Rhode)Island/01/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI507964 M Sweden 2011;Mar;28 A/Stockholm/18/2011 Swedish)Institute)for)Infectious)Disease)Control National)Institute)for)Medical)ResearchEPI238692 M Sweden 2009;Aug;01 A/Stockholm/90/2009 Swedish)Institute)for)Infectious)Disease)Control Swedish)Institute)for)Infectious)Disease)ControlEPI556813 PB2 United)States 2012;Apr;15 A/Texas/50/2012 Texas)Department)of)State)Health)Services;Laboratory)Services Centers)for)Disease)Control)and)PreventionEPI556814 PB1 United)States 2012;Apr;15 A/Texas/50/2012 Texas)Department)of)State)Health)Services;Laboratory)Services Centers)for)Disease)Control)and)PreventionEPI556812 PA United)States 2012;Apr;15 A/Texas/50/2012 Texas)Department)of)State)Health)Services;Laboratory)Services Centers)for)Disease)Control)and)PreventionEPI556809 NP United)States 2012;Apr;15 A/Texas/50/2012 Texas)Department)of)State)Health)Services;Laboratory)Services Centers)for)Disease)Control)and)PreventionEPI556811 M United)States 2012;Apr;15 A/Texas/50/2012 Texas)Department)of)State)Health)Services;Laboratory)Services Centers)for)Disease)Control)and)PreventionEPI556810 NS United)States 2012;Apr;15 A/Texas/50/2012 Texas)Department)of)State)Health)Services;Laboratory)Services Centers)for)Disease)Control)and)PreventionEPI152549 M Uruguay 2007;Jan;01 A/Uruguay/716/2007 ; Centers)for)Disease)Control)and)PreventionEPI232627 M United)States 2009;Sep;30 A/Vermont/22/2009 Vermont)Department)of)Health)Laboratory Centers)for)Disease)Control)and)PreventionEPI381911 NP Australia 2009;Aug;01 A/Victoria/210/2009 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI381909 M Australia 2009;Aug;01 A/Victoria/210/2009 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI381912 NS Australia 2009;Aug;01 A/Victoria/210/2009 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI417234 PB2 Australia 2011;Oct;24 A/Victoria/361/2011 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)PreventionEPI418016 PB1 Australia 2011;Oct;24 A/Victoria/361/2011 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)PreventionEPI418015 PA Australia 2011;Oct;24 A/Victoria/361/2011 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)PreventionEPI440094 NP Australia 2011;Oct;24 A/Victoria/361/2011 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)PreventionEPI417233 M Australia 2011;Oct;24 A/Victoria/361/2011 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)PreventionEPI417232 NS Australia 2011;Oct;24 A/Victoria/361/2011 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)PreventionEPI40997 PB2 New)Zealand 2005;Sep;13 A/Waikato/12/2005 ; Other)Database)ImportEPI40994 PB1 New)Zealand 2005;Sep;13 A/Waikato/12/2005 ; Other)Database)ImportEPI40992 PA New)Zealand 2005;Sep;13 A/Waikato/12/2005 ; Other)Database)ImportEPI40987 NP New)Zealand 2005;Sep;13 A/Waikato/12/2005 ; Other)Database)ImportEPI40982 M New)Zealand 2005;Sep;13 A/Waikato/12/2005 ; Other)Database)ImportEPI40989 NS New)Zealand 2005;Sep;13 A/Waikato/12/2005 ; Other)Database)ImportEPI185936 M United)States 2009;Apr;06 A/Washington/15/2009 Washington)State)Public)Health)Laboratory Centers)for)Disease)Control)and)PreventionEPI416179 M United)States 2012;Dec;05 A/Washington/60/2012 Spokane)Regional)Health)District Centers)for)Disease)Control)and)PreventionEPI390116 PB2 New)Zealand 2004;Aug;01 A/Wellington/01/2004 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390115 PB1 New)Zealand 2004;Aug;01 A/Wellington/01/2004 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390114 PA New)Zealand 2004;Aug;01 A/Wellington/01/2004 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390112 NP New)Zealand 2004;Aug;01 A/Wellington/01/2004 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390110 M New)Zealand 2004;Aug;01 A/Wellington/01/2004 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390113 NS New)Zealand 2004;Aug;01 A/Wellington/01/2004 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390196 PB2 United)States 2007;Aug;01 A/Wisconsin/03/2007 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390195 PB1 United)States 2007;Aug;01 A/Wisconsin/03/2007 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390194 PA United)States 2007;Aug;01 A/Wisconsin/03/2007 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390192 NP United)States 2007;Aug;01 A/Wisconsin/03/2007 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390190 M United)States 2007;Aug;01 A/Wisconsin/03/2007 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI390193 NS United)States 2007;Aug;01 A/Wisconsin/03/2007 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI381903 NP United)States 2009;Aug;01 A/Wisconsin/15/2009 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI381902 M United)States 2009;Aug;01 A/Wisconsin/15/2009 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI381904 NS United)States 2009;Aug;01 A/Wisconsin/15/2009 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI367117 PB2 United)States 2005;Jan;01 A/Wisconsin/67/2005 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI367116 PB1 United)States 2005;Jan;01 A/Wisconsin/67/2005 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI367115 PA United)States 2005;Jan;01 A/Wisconsin/67/2005 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI367113 NP United)States 2005;Jan;01 A/Wisconsin/67/2005 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI367111 M United)States 2005;Jan;01 A/Wisconsin/67/2005 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI367114 NS United)States 2005;Jan;01 A/Wisconsin/67/2005 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI504828 PB2 United)States 2003;Feb;13 A/Wyoming/03/2003 Iowa)State)Hygienic)Laboratory Centers)for)Disease)Control)and)PreventionEPI503943 PB1 United)States 2003;Feb;13 A/Wyoming/03/2003 Iowa)State)Hygienic)Laboratory Centers)for)Disease)Control)and)PreventionEPI503942 PA United)States 2003;Feb;13 A/Wyoming/03/2003 Iowa)State)Hygienic)Laboratory Centers)for)Disease)Control)and)PreventionEPI499391 NP United)States 2003;Feb;13 A/Wyoming/03/2003 Iowa)State)Hygienic)Laboratory Centers)for)Disease)Control)and)PreventionEPI499392 M United)States 2003;Feb;13 A/Wyoming/03/2003 Iowa)State)Hygienic)Laboratory Centers)for)Disease)Control)and)PreventionEPI499393 NS United)States 2003;Feb;13 A/Wyoming/03/2003 Iowa)State)Hygienic)Laboratory Centers)for)Disease)Control)and)Prevention
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Influenza)(sub)type Segment)ID Segment Country Collection)date)(year;month;day) Reference)virus Originating)Lab Submitting)Lab AuthorsEPI366555 PB2 Bangladesh 2007;Jan;01 B/Bangladesh/3333/2007 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366554 PB1 Bangladesh 2007;Jan;01 B/Bangladesh/3333/2007 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366553 PA Bangladesh 2007;Jan;01 B/Bangladesh/3333/2007 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366551 NP Bangladesh 2007;Jan;01 B/Bangladesh/3333/2007 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366550 M Bangladesh 2007;Jan;01 B/Bangladesh/3333/2007 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366552 NS Bangladesh 2007;Jan;01 B/Bangladesh/3333/2007 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI294715 NS Bolivia,)Plurinationial)State)of 2010;Jan;01 B/Bolivia/1526/2010 ; Centers)for)Disease)Control)and)Prevention ;EPI370453 PB2 Australia 2008;Jul;13 B/Brisbane/33/2008 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI370452 PB1 Australia 2008;Jul;13 B/Brisbane/33/2008 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI370451 PA Australia 2008;Jul;13 B/Brisbane/33/2008 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI370450 NP Australia 2008;Jul;13 B/Brisbane/33/2008 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI370449 M Australia 2008;Jul;13 B/Brisbane/33/2008 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI370448 NS Australia 2008;Jul;13 B/Brisbane/33/2008 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI556423 PB2 Australia 2008;Aug;04 B/Brisbane/60/2008 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI556424 PB1 Australia 2008;Aug;04 B/Brisbane/60/2008 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI556425 PA Australia 2008;Aug;04 B/Brisbane/60/2008 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI309756 NP Australia 2008;Aug;04 B/Brisbane/60/2008 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI217339 M Australia 2008;Aug;04 B/Brisbane/60/2008 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI309757 NS Australia 2008;Aug;04 B/Brisbane/60/2008 Queensland)Health)Scientific)Services WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI348436 NS Cambodia 2011;Oct;10 B/Cambodia/1412/2011 National)Public)Health)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI366571 PB2 United)Kingdom 2008;Jan;01 B/England/145/2008 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366570 PB1 United)Kingdom 2008;Jan;01 B/England/145/2008 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366569 PA United)Kingdom 2008;Jan;01 B/England/145/2008 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366567 NP United)Kingdom 2008;Jan;01 B/England/145/2008 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366565 M United)Kingdom 2008;Jan;01 B/England/145/2008 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366568 NS United)Kingdom 2008;Jan;01 B/England/145/2008 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI406981 NS Estonia 2011;Mar;14 B/Estonia/55669/2011 National)Institute)for)Medical)Research Centers)for)Disease)Control)and)Prevention ;EPI294741 NS United)States 2010;Oct;18 B/Florida/04/2010 Florida)Department)of)Health;Jacksonville Centers)for)Disease)Control)and)Prevention ;EPI159985 PB2 United)States 2006;Jan;01 B/Florida/04/2006 ; Other)Database)Import ;EPI159984 PB1 United)States 2006;Jan;01 B/Florida/04/2006 ; Other)Database)Import ;EPI159983 PA United)States 2006;Jan;01 B/Florida/04/2006 ; Other)Database)Import ;EPI159981 NP United)States 2006;Jan;01 B/Florida/04/2006 ; Other)Database)Import ;EPI159979 M United)States 2006;Jan;01 B/Florida/04/2006 ; Other)Database)Import ;EPI159982 NS United)States 2006;Jan;01 B/Florida/04/2006 ; Other)Database)Import ;EPI366587 PB2 China 2008;Jan;01 B/Fujian;Gulou/1272/2008 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366586 PB1 China 2008;Jan;01 B/Fujian;Gulou/1272/2008 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366585 PA China 2008;Jan;01 B/Fujian;Gulou/1272/2008 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366583 NP China 2008;Jan;01 B/Fujian;Gulou/1272/2008 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366581 M China 2008;Jan;01 B/Fujian;Gulou/1272/2008 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366584 NS China 2008;Jan;01 B/Fujian;Gulou/1272/2008 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI51248 PB2 United)States 2004;Jun;21 B/Hawaii/13/2004 ; Other)Database)Import ;EPI51246 PB1 United)States 2004;Jun;21 B/Hawaii/13/2004 ; Other)Database)Import ;EPI51244 PA United)States 2004;Jun;21 B/Hawaii/13/2004 ; Other)Database)Import ;EPI51239 NP United)States 2004;Jun;21 B/Hawaii/13/2004 ; Other)Database)Import ;EPI51233 M United)States 2004;Jun;21 B/Hawaii/13/2004 ; Other)Database)Import ;EPI51241 NS United)States 2004;Jun;21 B/Hawaii/13/2004 ; Other)Database)Import ;EPI301200 NS Honduras 2010;Oct;11 B/Honduras/6927/2010 Laboratorio)Nacional)de)Virologia Centers)for)Disease)Control)and)Prevention ;EPI232752 NS China 2009;Feb;23 B/Jiangsu;Gulou/125/2009 WHO)Chinese)National)Influenza)Center Centers)for)Disease)Control)and)Prevention ;CY033851* PB2 China 2003 B/Jiangsu/10/2003 ; ; Spiro,D.;)Halpin,R.;)Boyne,A.;)Bera,J.;)Ghedin,E.;)et#al.CY033850* PB1 China 2003 B/Jiangsu/10/2003 ; ; Spiro,D.;)Halpin,R.;)Boyne,A.;)Bera,J.;)Ghedin,E.;)et#al.CY033849* PA China 2003 B/Jiangsu/10/2003 ; ; Spiro,D.;)Halpin,R.;)Boyne,A.;)Bera,J.;)Ghedin,E.;)et#al.CY033847* NP China 2003 B/Jiangsu/10/2003 ; ; Spiro,D.;)Halpin,R.;)Boyne,A.;)Bera,J.;)Ghedin,E.;)et#al.CY033845* M China 2003 B/Jiangsu/10/2003 ; ; Spiro,D.;)Halpin,R.;)Boyne,A.;)Bera,J.;)Ghedin,E.;)et#al.CY033848* NS China 2003 B/Jiangsu/10/2003 ; ; Spiro,D.;)Halpin,R.;)Boyne,A.;)Bera,J.;)Ghedin,E.;)et#al.EPI159937 PB2 China 2003;Jan;01 B/Jilin/20/2003 ; Other)Database)Import ;EPI159936 PB1 China 2003;Jan;01 B/Jilin/20/2003 ; Other)Database)Import ;EPI159935 PA China 2003;Jan;01 B/Jilin/20/2003 ; Other)Database)Import ;EPI159933 NP China 2003;Jan;01 B/Jilin/20/2003 ; Other)Database)Import ;EPI159931 M China 2003;Jan;01 B/Jilin/20/2003 ; Other)Database)Import ;EPI159934 NS China 2003;Jan;01 B/Jilin/20/2003 ; Other)Database)Import ;
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Influenza)(sub)type Segment)ID Segment Country Collection)date)(year;month;day) Reference)virus Originating)Lab Submitting)Lab AuthorsEPI294799 NS Lao,)People's)Democratic)Republic 2010;Sep;14 B/Laos/833/2010 National)Center)for)Laboratory)and)Epidemiology Centers)for)Disease)Control)and)Prevention ;EPI175762 PB2 Malaysia 2004;Jan;01 B/Malaysia/2506/2004 ; Other)Database)Import ;EPI175761 PB1 Malaysia 2004;Jan;01 B/Malaysia/2506/2004 ; Other)Database)Import ;EPI175760 PA Malaysia 2004;Jan;01 B/Malaysia/2506/2004 ; Other)Database)Import ;EPI175758 NP Malaysia 2004;Jan;01 B/Malaysia/2506/2004 ; Other)Database)Import ;EPI175756 M Malaysia 2004;Jan;01 B/Malaysia/2506/2004 ; Other)Database)Import ;EPI175759 NS Malaysia 2004;Jan;01 B/Malaysia/2506/2004 ; Other)Database)Import ;EPI397596 PB2 United)States 2012;Mar;13 B/Massachusetts/02/2012 Massachusetts)Department)of)Public)Health Centers)for)Disease)Control)and)Prevention ;EPI395218 PB1 United)States 2012;Mar;13 B/Massachusetts/02/2012 Massachusetts)Department)of)Public)Health Centers)for)Disease)Control)and)Prevention ;EPI395217 PA United)States 2012;Mar;13 B/Massachusetts/02/2012 Massachusetts)Department)of)Public)Health Centers)for)Disease)Control)and)Prevention ;EPI395214 NP United)States 2012;Mar;13 B/Massachusetts/02/2012 Massachusetts)Department)of)Public)Health Centers)for)Disease)Control)and)Prevention ;EPI395216 M United)States 2012;Mar;13 B/Massachusetts/02/2012 Massachusetts)Department)of)Public)Health Centers)for)Disease)Control)and)Prevention ;EPI395215 NS United)States 2012;Mar;13 B/Massachusetts/02/2012 Massachusetts)Department)of)Public)Health Centers)for)Disease)Control)and)Prevention ;EPI406959 NS United)States 2012;Oct;28 B/Montana/06/2012 Montana)Laboratory)Services)Bureau Centers)for)Disease)Control)and)Prevention ;EPI407350 NS United)States 2012;Nov;26 B/New)Mexico/04/2012 New)Mexico)Department)of)Health Centers)for)Disease)Control)and)Prevention ;EPI368750 NS Russian)Federation 2012;Feb;14 B/Novosibirsk/01/2012 Russian)Academy)of)Medical)Sciences Centers)for)Disease)Control)and)Prevention ;EPI346476 PB2 United)States 2005;Feb;23 B/Ohio/01/2005 Cincinnati)Children's)Hospital Centers)for)Disease)Control)and)Prevention ;EPI346475 PB1 United)States 2005;Feb;23 B/Ohio/01/2005 Cincinnati)Children's)Hospital Centers)for)Disease)Control)and)Prevention ;EPI346477 PA United)States 2005;Feb;23 B/Ohio/01/2005 Cincinnati)Children's)Hospital Centers)for)Disease)Control)and)Prevention ;EPI346469 NP United)States 2005;Feb;23 B/Ohio/01/2005 Cincinnati)Children's)Hospital Centers)for)Disease)Control)and)Prevention ;EPI346471 M United)States 2005;Feb;23 B/Ohio/01/2005 Cincinnati)Children's)Hospital Centers)for)Disease)Control)and)Prevention ;EPI346520 NS United)States 2005;Feb;23 B/Ohio/01/2005 Cincinnati)Children's)Hospital Centers)for)Disease)Control)and)Prevention ;AJ781208* PB2 Norway 2004 B/Oslo/71/2004 ; National)Institute)for)Medical)Research Wright,H.G.,)Gregory,V.,)Lin,Y.,)Bennett,M.)and)Hay,A.J.AJ781187* PB1 Norway 2004 B/Oslo/71/2004 ; National)Institute)for)Medical)Research Wright,H.G.,)Gregory,V.,)Lin,Y.,)Bennett,M.)and)Hay,A.J.AJ716222* PA Norway 2004 B/Oslo/71/2004 ; National)Institute)for)Medical)Research Wright,H.G.,)Gregory,V.,)Lin,Y.,)Bennett,M.)and)Hay,A.J.AJ784079* NP Norway 2004 B/Oslo/71/2004 ; National)Institute)for)Medical)Research Wright,H.G.,)Gregory,V.,)Lin,Y.,)Bennett,M.)and)Hay,A.J.AJ783391* M Norway 2004 B/Oslo/71/2004 ; National)Institute)for)Medical)Research Wright,H.G.,)Gregory,V.,)Lin,Y.,)Bennett,M.)and)Hay,A.J.AJ781288* NS Norway 2004 B/Oslo/71/2004 ; National)Institute)for)Medical)Research Wright,H.G.,)Gregory,V.,)Lin,Y.,)Bennett,M.)and)Hay,A.J.EPI13407 PB2 China 2002;Jun;12 B/Shanghai/361/2002 ; Other)Database)Import ;EPI13365 PB1 China 2002;Jun;12 B/Shanghai/361/2002 ; Other)Database)Import ;EPI13647 NP China 2002;Jun;12 B/Shanghai/361/2002 ; Other)Database)Import ;EPI13553 M China 2002;Jun;12 B/Shanghai/361/2002 ; Other)Database)Import ;EPI13467 NS China 2002;Jun;12 B/Shanghai/361/2002 ; Other)Database)Import ;EPI340832 NS Sweden 2011;Feb;28 B/Stockholm/12/2011 National)Institute)for)Medical)Research Centers)for)Disease)Control)and)Prevention ;EPI241184 NS Uganda 2009;Oct;21 B/Uganda/0514/2009 Uganda)Virus)Research)Institute)(UVRI),)National)Influenza)Center Centers)for)Disease)Control)and)Prevention ;EPI502818 PB2 Australia 2006;Jun;06 B/Victoria/304/2006 ; Other)Database)Import Wentworth,D.E.;)Halpin,R.A.;)Lin,X.;)Zhou,B.;)Bera,J.;)et#al.EPI502817 PB1 Australia 2006;Jun;06 B/Victoria/304/2006 ; Other)Database)Import Wentworth,D.E.;)Halpin,R.A.;)Lin,X.;)Zhou,B.;)Bera,J.;)et#al.EPI502816 PA Australia 2006;Jun;06 B/Victoria/304/2006 ; Other)Database)Import Wentworth,D.E.;)Halpin,R.A.;)Lin,X.;)Zhou,B.;)Bera,J.;)et#al.EPI502814 NP Australia 2006;Jun;06 B/Victoria/304/2006 ; Other)Database)Import Wentworth,D.E.;)Halpin,R.A.;)Lin,X.;)Zhou,B.;)Bera,J.;)et#al.EPI502812 M Australia 2006;Jun;06 B/Victoria/304/2006 ; Other)Database)Import Wentworth,D.E.;)Halpin,R.A.;)Lin,X.;)Zhou,B.;)Bera,J.;)et#al.EPI502815 NS Australia 2006;Jun;06 B/Victoria/304/2006 ; Other)Database)Import Wentworth,D.E.;)Halpin,R.A.;)Lin,X.;)Zhou,B.;)Bera,J.;)et#al.EPI483011 PB2 Australia 2005;Oct;16 B/Victoria/530/2005 ; Other)Database)Import Wentworth,D.E.;)Halpin,R.A.;)Lin,X.;)Zhou,B.;)Bera,J.;)et#al.EPI483010 PB1 Australia 2005;Oct;16 B/Victoria/530/2005 ; Other)Database)Import Wentworth,D.E.;)Halpin,R.A.;)Lin,X.;)Zhou,B.;)Bera,J.;)et#al.EPI483009 PA Australia 2005;Oct;16 B/Victoria/530/2005 ; Other)Database)Import Wentworth,D.E.;)Halpin,R.A.;)Lin,X.;)Zhou,B.;)Bera,J.;)et#al.EPI483007 NP Australia 2005;Oct;16 B/Victoria/530/2005 ; Other)Database)Import Wentworth,D.E.;)Halpin,R.A.;)Lin,X.;)Zhou,B.;)Bera,J.;)et#al.EPI483005 M Australia 2005;Oct;16 B/Victoria/530/2005 ; Other)Database)Import Wentworth,D.E.;)Halpin,R.A.;)Lin,X.;)Zhou,B.;)Bera,J.;)et#al.EPI483008 NS Australia 2005;Oct;16 B/Victoria/530/2005 ; Other)Database)Import Wentworth,D.E.;)Halpin,R.A.;)Lin,X.;)Zhou,B.;)Bera,J.;)et#al.EPI366487 PB2 United)States 2010;Jan;01 B/Wisconsin/01/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366486 PB1 United)States 2010;Jan;01 B/Wisconsin/01/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366485 PA United)States 2010;Jan;01 B/Wisconsin/01/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366483 NP United)States 2010;Jan;01 B/Wisconsin/01/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI366481 M United)States 2010;Jan;01 B/Wisconsin/01/2010 ; Other)Database)Import Wentworth,D.E.;)Dugan,V.;)Halpin,R.;)Lin,X.;)Bera,J.;)et#al.EPI271598 NS United)States 2010;Feb;20 B/Wisconsin/01/2010 Wisconsin)State)Laboratory)of)Hygiene Centers)for)Disease)Control)and)Prevention ;EPI176616 PB2 United)States 2009;Apr;09 A/California/07/2009 Naval)Health)Research)Center Centers)for)Disease)Control)and)Prevention ;EPI176615 PB1 United)States 2009;Apr;09 A/California/07/2009 Naval)Health)Research)Center Centers)for)Disease)Control)and)Prevention ;EPI176617 PA United)States 2009;Apr;09 A/California/07/2009 Naval)Health)Research)Center Centers)for)Disease)Control)and)Prevention ;EPI184298 NP United)States 2009;Apr;09 A/California/07/2009 Naval)Health)Research)Center Centers)for)Disease)Control)and)Prevention ;EPI176619 M United)States 2009;Apr;09 A/California/07/2009 Naval)Health)Research)Center Centers)for)Disease)Control)and)Prevention ;EPI176618 NS United)States 2009;Apr;09 A/California/07/2009 Naval)Health)Research)Center Centers)for)Disease)Control)and)Prevention ;EPI190211 PB2 Denmark 2009;Jun;09 A/Denmark/528/2009 ; Other)Database)Import ;EPI190212 PB1 Denmark 2009;Jun;09 A/Denmark/528/2009 ; Other)Database)Import ;
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(Table	S4.2	cont.)	
	Virtually	all	sequences	were	retrieved	from	GISAID	EpiFluTM	database.		The	sequences	exceptionally	retrieved	from	NCBI	Influenza	Virus	Resource	database	are	marked	with	an	asterisk	(*)	after	the	 accession	 number	 (2nd	 column).	 Reference	 viruses	 included	 in	 the	 Northern	 Hemisphere´s	 seasonal	 influenza	 vaccines	 are	 highlighted	 in	 bold	 and	 italic.	 The	 dash	 (-)	 represents	 no	information.	
Influenza)(sub)type Segment)ID Segment Country Collection)date)(year;month;day) Reference)virus Originating)Lab Submitting)Lab AuthorsEPI190213 PA Denmark 2009;Jun;09 A/Denmark/528/2009 ; Other)Database)Import ;EPI190215 NP Denmark 2009;Jun;09 A/Denmark/528/2009 ; Other)Database)Import ;EPI190217 M Denmark 2009;Jun;09 A/Denmark/528/2009 ; Other)Database)Import ;EPI190218 NS Denmark 2009;Jun;09 A/Denmark/528/2009 ; Other)Database)Import ;EPI189163 M Singapore 2009;May;30 A/Singapore/57/2009 Singapore)General)Hospital Centers)for)Disease)Control)and)Prevention ;EPI177279 M New)Zealand 2009;Apr;25 A/Auckland/03/2009 Auckland)Hospital WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza ;EPI239629 M Germany 2009;Jan;01 A/Bayern/69/2009 ; Centers)for)Disease)Control)and)Prevention ;EPI215955 PB2 Ukraine 2009;Oct;27 A/Lviv/N6/2009 Ministry)of)Health)of)Ukraine National)Institute)for)Medical)Research ;EPI215952 NP Ukraine 2009;Oct;27 A/Lviv/N6/2009 Ministry)of)Health)of)Ukraine National)Institute)for)Medical)Research ;EPI215954 M Ukraine 2009;Oct;27 A/Lviv/N6/2009 Ministry)of)Health)of)Ukraine National)Institute)for)Medical)Research ;EPI215953 NS Ukraine 2009;Oct;27 A/Lviv/N6/2009 Ministry)of)Health)of)Ukraine National)Institute)for)Medical)Research ;EPI233200 M United)States 2009;Oct;16 A/North)Carolina/49/2009 North)Carolina)State)Laboratory)of)Public)Health Centers)for)Disease)Control)and)Prevention ;EPI239641 M Vietnam 2009;Dec;01 A/Vietnam/2043/2009 National)Institute)of)Hygiene)and)Epidemiology Centers)for)Disease)Control)and)Prevention ;EPI280342 M New)Zealand 2010;Jul;12 A/Christchurch/16/2010 WHO)Collaborating)Centre)for)Reference)and)Research)on)Influenza Centers)for)Disease)Control)and)Prevention ;EPI294672 PB2 United)Kingdom 2010;Nov;01 A/England/4880374/2010 Microbiology)Services)Colindale,)Public)Health)England Microbiology)Services)Colindale,)Public)Health)England Galiano,M.EPI294671 PA United)Kingdom 2010;Nov;01 A/England/4880374/2010 Microbiology)Services)Colindale,)Public)Health)England Microbiology)Services)Colindale,)Public)Health)England Galiano,M.EPI294668 NP United)Kingdom 2010;Nov;01 A/England/4880374/2010 Microbiology)Services)Colindale,)Public)Health)England Microbiology)Services)Colindale,)Public)Health)England Galiano,M.EPI294670 M United)Kingdom 2010;Nov;01 A/England/4880374/2010 Microbiology)Services)Colindale,)Public)Health)England Microbiology)Services)Colindale,)Public)Health)England Galiano,M.EPI294669 NS United)Kingdom 2010;Nov;01 A/England/4880374/2010 Microbiology)Services)Colindale,)Public)Health)England Microbiology)Services)Colindale,)Public)Health)England ;EPI342431 PB2 United)States 2010;Nov;01 A/Kentucky/09/2010 Kentucky)Division)of)Laboratory)Services Centers)for)Disease)Control)and)Prevention ;EPI342432 PB1 United)States 2010;Nov;01 A/Kentucky/09/2010 Kentucky)Division)of)Laboratory)Services Centers)for)Disease)Control)and)Prevention ;EPI342430 PA United)States 2010;Nov;01 A/Kentucky/09/2010 Kentucky)Division)of)Laboratory)Services Centers)for)Disease)Control)and)Prevention ;EPI342427 NP United)States 2010;Nov;01 A/Kentucky/09/2010 Kentucky)Division)of)Laboratory)Services Centers)for)Disease)Control)and)Prevention ;EPI342429 M United)States 2010;Nov;01 A/Kentucky/09/2010 Kentucky)Division)of)Laboratory)Services Centers)for)Disease)Control)and)Prevention ;EPI342428 NS United)States 2010;Nov;01 A/Kentucky/09/2010 Kentucky)Division)of)Laboratory)Services Centers)for)Disease)Control)and)Prevention ;EPI301382 M Sweden 2010;Dec;02 A/Stockholm/12/2010 Swedish)Institute)for)Infectious)Disease)Control Swedish)Institute)for)Infectious)Disease)Control ;EPI301781 M Sweden 2010;Dec;12 A/Stockholm/14/2010 Swedish)Institute)for)Infectious)Disease)Control Swedish)Institute)for)Infectious)Disease)Control ;EPI252104 PB2 United)States 2010;Feb;08 A/Wyoming/01/2010 Wyoming)Public)Health)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI252105 PB1 United)States 2010;Feb;08 A/Wyoming/01/2010 Wyoming)Public)Health)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI252103 PA United)States 2010;Feb;08 A/Wyoming/01/2010 Wyoming)Public)Health)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI252101 NP United)States 2010;Feb;08 A/Wyoming/01/2010 Wyoming)Public)Health)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI247504 M United)States 2010;Feb;08 A/Wyoming/01/2010 Wyoming)Public)Health)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI252102 NS United)States 2010;Feb;08 A/Wyoming/01/2010 Wyoming)Public)Health)Laboratory Centers)for)Disease)Control)and)Prevention ;EPI348183 M United)States 2011;Dec;07 A/Florida/35/2011 Florida)Department)of)Health;Tampa Centers)for)Disease)Control)and)Prevention ;EPI346511 M Thailand 2011;Sep;12 A/Song)Khla/270/2011 WHO)National)Influenza)Centre,)National)Institute)of)Medical)Research Centers)for)Disease)Control)and)Prevention ;EPI316432 PB2 Russian)Federation 2011;Mar;14 A/St.)Petersburg/100/2011 Russian)Academy)of)Medical)Sciences Centers)for)Disease)Control)and)Prevention ;EPI316433 PB1 Russian)Federation 2011;Mar;14 A/St.)Petersburg/100/2011 Russian)Academy)of)Medical)Sciences Centers)for)Disease)Control)and)Prevention ;EPI316431 PA Russian)Federation 2011;Mar;14 A/St.)Petersburg/100/2011 Russian)Academy)of)Medical)Sciences Centers)for)Disease)Control)and)Prevention ;EPI316428 NP Russian)Federation 2011;Mar;14 A/St.)Petersburg/100/2011 Russian)Academy)of)Medical)Sciences Centers)for)Disease)Control)and)Prevention ;EPI316430 M Russian)Federation 2011;Mar;14 A/St.)Petersburg/100/2011 Russian)Academy)of)Medical)Sciences Centers)for)Disease)Control)and)Prevention ;EPI316429 NS Russian)Federation 2011;Mar;14 A/St.)Petersburg/100/2011 Russian)Academy)of)Medical)Sciences Centers)for)Disease)Control)and)Prevention ;EPI335838 M Chile 2011;Aug;10 A/Valparaiso/17275/2011 Instituto)de)Salud)Publica)de)Chile) Centers)for)Disease)Control)and)Prevention ;EPI500464 M Senegal 2012;Dec;09 A/Dakar/20/2012 Institut)Pasteur)de)Dakar National)Institute)for)Medical)Research ;EPI382426 M Hong)Kong)(SAR) 2012;May;21 A/Hong)Kong/5659/2012 Public)Health)Laboratory)Services)Branch,)Centre)for)Health)Protection Public)Health)Laboratory)Services)Branch,)Centre)for)Health)Protection Mak,G.C.;Lo,J.Y.C.EPI500493 M France 2012;Dec;28 A/Lyon/02/2013 CRR)virus)Influenza)region)Sud National)Institute)for)Medical)Research ;EPI500516 M Norway 2012;Dec;17 A/Norway/2552/2012 WHO)National)Influenza)Centre National)Institute)for)Medical)Research ;EPI347566 M Sweden 2011;Nov;22 A/Stockholm/35/2011 ; Swedish)Institute)for)Infectious)Disease)Control ;EPI406024 M United)States 2012;Oct;31 A/Tennessee/09/2012 Tennessee)Department)of)Health)Laboratory;Nashville Centers)for)Disease)Control)and)Prevention ;
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		CHAPTER	6	
	UNCOVERING	THE	MOLECULAR	FOOTPRINTS	OF	SELECTIVE	PRESSURE	IN	INFLUENZA	A	AND	B	VIRUS	NEURAMINIDASE	GENE							 Results	partially	presented	at:			
Correia	V,	Abecasis	AB,	Rebelo-de-Andrade	H,	2016.	Uncovering	the	role	of	positive	selection	in	the	evolutionary	pathways	to	influenza	virus	resistance	or	reduced	inhibition	by	neuraminidase	inhibitors.	Poster	presentation	at	the	Options	IX	for	the	Control	of	Influenza,	Chicago,	USA,	26th	August.	
Correia	V,	Abecasis	AB,	Rebelo-de-Andrade	H,	2014.	Selective	pressure	acting	on	influenza	neuraminidase	gene:	a	complementary	approach	for	studying	the	emergence	and	evolution	of	antiviral	drug	resistance	and	reduced	susceptibility.	Oral	presentation	at	the	International	Meeting	on	Emerging	Diseases	and	Surveillance,	Vienna,	Austria,	3rd	November.	
Correia	V,	Abecasis	AB,	Rebelo-de-Andrade	H,	2014.	Large-scale	differential	selection	analysis	on	influenza	A	and	B	neuraminidase	gene:	a	new	approach	for	studying	antiviral	drug	resistance	and	reduced	susceptibility.	Oral	presentation	at	the	III	International	Conference	on	Antimicrobial	Research,	Madrid,	Spain,	3rd	October.					I	carried	out	all	activities,	methodologies	and	data	analysis	underlying	the	results	presented	in	this	chapter.	The	phylogenetic	trees	and	both	site-specific	and	differential	selective	pressure	analysis	of	NA	sequence	(sub-)datasets	with	more	 than	3000	 sequences	were	 exceptionally	 constructed/executed	 at	more	powerful	 computer	 systems	available	at	the	laboratory	of	Ana	Abecasis	at	the	Instituto	de	Higiene	e	Medicina	Tropical,	Universidade	NOVA	de	Lisboa.	Ana	Abecasis	also	provided	key	guidance	and	support	during	the	entire	work.	
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BOX	6.1	-	MAIN	ACTIVITIES	
• Collection	 of	 all	 potentially	 complete	 NA	 coding	 sequences	 available	 at	 GISAID	 EpiFlu™	 and	NCBI	 Influenza	Virus	Resource	databases,	 for	each	 time	period	 (temporal	 split)	 and	 influenza	virus	subtype	or	lineage.	Addition	of	unpublished	sequences	of	viruses	circulating	in	Portugal.	
• Five-step	sequence	treatment	of	temporal	sub-datasets,	followed	by	merging	into	total	datasets.		
• Inference	 of	 the	 maximum-likelihood	 phylogenetic	 tree	 from	 each	 total	 and	 temporal	 NA	sequence	(sub-)dataset,	after	determining	the	best-fit	codon	model	for	human	influenza	NA.		
• Estimate	the	global	and	site-specific	(SLAC	and	FEL	analysis)	ratios	between	non-synonymous	(dN)	and	 synonymous	 (dS)	 substitution	rates	 	 (dN/dS	 ratios),	 for	 each	 total	 and	 temporal	NA	sequence	(sub-)dataset.	
• Identification	and	mapping	of	the	positively	selected	sites	onto	the	three-dimensional	structure	of	the	corresponding	NA	protein.		
• Differential	 selection	analysis	 to	 identify	which	 sites	within	each	 influenza	 subtype	or	 lineage	NA	evolved	under	different	SP	among	the	different	contexts	of	NAI	global	use	(temporal	split).		
• Determination	of	 the	frequency	of	amino	acid	substitutions	conferring	or	enhancing	resistance	or	(H)RI	by	NAIs	in	vitro.	
6	 UNCOVERING	 THE	 MOLECULAR	 FOOTPRINTS	 OF	 SELECTIVE	 PRESSURE	 IN	
INFLUENZA	A	AND	B	VIRUS	NEURAMINIDASE	GENE	 		
“One	general	law,	leading	to	the	advancement	of	all	organic	beings,	namely,	multiply,	vary,	let	the	
strongest	live	and	the	weakest	die.”		Charles	Darwin,	On	The	Origin	of	Species,	1859			This	 chapter	 presents	 and	 discusses	 the	 results	 of	 the	 large-scale	 study	 conducted	 to	analyse	 the	 selective	 pressure	 (SP)	 acting	 on	 the	 influenza	 neuraminidase	 (NA)	 of	worldwide	 circulating	 viruses	 from	 all	 human	 influenza	 subtypes	 and	 lineages	 (former	seasonal	 A(H1N1),	 A(H3N2),	 B/Victoria	 and	B/Yamagata-lineage,	 and	A(H1N1)pdm09)	(3rd	general	objective;	see	section	2.2,	Study	Description).	A	higher	focus	was	given	to	the	SP	 acting	 on	 the	 codon	 sites	 (herein	 designated	 as	 sites)	 associated	with	 NA	 inhibitor	(NAI)	 resistance	 or	 (highly)	 reduced	 inhibition	 ((H)RI)	 in	 vitro,	 and	 on	 further	 sites	contacting	directly	or	indirectly	with	the	drug	(NA	active	site).			An	overview	of	the	main	activities	carried	out	during	this	study	is	presented	below	for	a	better	understanding	of	the	underlying	work.															
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6.1	RESULTS		The	results	are	organized	in	5	main	sub-sections	as	follows:	(1)	study	sample;	(2)	overall	analysis	 of	 selective	 pressure;	 (3)	 site-by-site	 analysis	 of	 selective	 pressure;	 (4)	differential	 analysis	 of	 site-by-site	 selective	 pressures	 among	 different	 contexts	 of	neuraminidase	 inhibitor	drug	use	 (temporal	 sub-datasets);	 (5)	 frequency	of	amino	acid	substitutions	 conferring	 or	 enhancing	 neuraminidase	 inhibitor	 resistance	 or	 (highly)	reduced	inhibition	in	vitro	in	sequence	databases	(complementary	study).			
6.1.1	Study	Sample		Following	 sequence	 treatment	 (detailed	 in	 section	 3.2.3.2,	 Material	 and	 Methods),	temporal	sub-datasets	contained	between	34	and	3122	NA	gene	sequences	of	 influenza	viruses	 circulating	worldwide	 (Table	 6.1).	 The	 number	 of	 sequences	 varied	widely	 not	only	among	human	influenza	virus	subtypes	or	lineages	but	also	time	periods,	as	already	evidenced	 in	 the	original	 sequence	 sub-datasets	 (see	Table	3.3,	Material	 and	Methods).	Only	 the	 two	 later	 A(H3N2)	 NA	 sequence	 sub-datasets	 were	 comprised	 by	 a	 similar	number	 of	 sequences.	 The	 first	 temporal	 sub-dataset	 (before	 1999)	 contained	 a	much	smaller	 number	 of	 sequences	 for	 all	 virus	 subtypes	 and	 lineages	 (not	 applied	 to	A(H1N1)pdm09	 subtype)	 (Table	 6.1).	 It	 included	 sequences	 from	 1943	 onwards	 for	former	seasonal	A(H1N1)	subtype	(herein	designated	as	seasonal	A(H1N1));	from	1968	onwards	 for	 A(H3N2)	 subtype,	 matching	 the	 beginning	 of	 virus	 circulation;	 and	 from	1972	and	1973	onwards	for,	respectively,	influenza	B/Victoria	(B/VIC)	and	B/Yamagata	(B/YAM)	 lineages,	 covering	 the	 beginning	 of	 lineage	 differentiation.	 A(H3N2)	 temporal	sub-datasets	 contained	 a	 higher	 number	 of	 sequences	 compared	 to	 seasonal	 A(H1N1)	and	both	influenza	B/VIC	and	B/YAM-lineage	sub-datasets	(Table	6.1).	Seasonal	A(H1N1)	viruses	ended	to	be	completely	replaced	by	the	novel	A(H1N1)pdm09	viruses,	explaining	why	 the	 latest	 sequences	 dated	 from	 2010	 (from	 2009	 onwards	 sub-dataset).	 The	A(H1N1)pdm09	(pre-)pandemicA	sub-dataset	enclosed	the	highest	number	of	sequences	(3122	NA	gene	sequences).	Total	NA	sequence	datasets	were	obtained	by	merging	the	treated	temporal	sub-datasets.	An	 additional	 99.99%	 redundancy	 threshold	 had	 to	 be	 applied	 to	 both	 A(H3N2)	 and																																																									A	Pre-pandemic	(late	March	to	10th	June	2009)	or	pandemic	(11th	June	2009	to	9th	August	2010)	period.																																					
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A(H1N1)pdm09	datasets	to	reduce	the	total	number	of	sequences	to	below	4000	due	to	posterior	 software	 constraints	 (detailed	 in	 section	 3.2.3.2,	 Material	 and	 Methods).	A(H3N2)	and	A(H1N1)pdm09	total	datasets	were	comprised	by	more	than	3400	NA	gene	sequences,	while	the	number	of	sequences	within	seasonal	A(H1N1)	and	influenza	B/VIC	and	 B/YAM-lineage	 total	 datasets	 varied	 between	 approximately	 1450	 to	 2000	sequences	(Table	6.1).		
	
Table	6.1	Characterization	of	the	temporal	sub-datasets	of	human	influenza	virus	neuraminidase	gene	sequences	after	sequence	treatment	and	of	the	resultant	total	sequence	datasets,	regarding	number	of	sequences	enclosed	and	time	period	covered.			
	N:	Number	of	sequences;	T:	Time	period	a	Pre-pandemic	or	pandemic	period;	b	Do	not	correspond	to	the	sum	of	temporal	sub-dataset	sequences	as	a	further	99.99%	redundancy	threshold	had	to	be	applied	to	reduce	the	number	of	sequences	to	below	4000	(software	constraints	in	posterior	selective	pressure	analysis).	The	temporal	split	that	defined	the	different	temporal	sub-datasets	was	based	on	differences	on	neuraminidase	inhibitor	drug	use	(detailed	in	section	2.1,	Study	Description).			
6.1.1.1	Distribution	Over	Time		A(H3N2)	NA	sequence	(sub-)datasets	contained	sequences	from	all	years	within	the	time	period	covered	(Figure	6.1B).	The	same	was	verified	for	the	two	later	seasonal	A(H1N1)	and	influenza	B/VIC	and	B/YAM	temporal	sub-datasets	(1999-2008,	from	2009	onwards),	but	 not	 for	 the	 first	 one	 (before	 1999)	 and	 in	 consequence	 for	 total	 dataset.	 Very	 few	seasonal	A(H1N1)	NA	sequences	were	from	1943	to	1956	(no	circulation	between	1957	and	1976),	distributing	sporadically	across	years,	with	the	same	occurring	for	B/VIC	and	B/YAM-lineage	NA	sequences	from	1972	to	1992	and	1973	to	1991,	respectively	(Figure	6.1A,C).	 Sequences	 from	 most	 or	 all	 remaining	 years	 within	 the	 sub-dataset	 (before	1999)	were	present.	Due	to	the	smaller	time	period	covered	(≈2	to	5	years),	the	temporal	
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distribution	 of	 A(H1N1)pdm09	NA	 sequences	was	 instead	 analysed	 by	 epidemiological	week	 (Sunday	 to	 Saturday1)	 (Figure	 6.1D).	 Sequences	 from	 all	 epidemiological	 weeks	were	present	in	A(H1N1)pdm09	(sub-)datasets.		
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Figure	6.1	Temporal	distribution	of	 the	neuraminidase	gene	sequences	of	 former	seasonal	A(H1N1)	
(A),	 A(H3N2)	 (B),	 B/Victoria	 and	B/Yamagata-lineage	 (C)	 and	A(H1N1)pdm09	 (D)	 sequence	 (sub-)	datasets.		All	 sequences	 were	 analysed	 by	 year	 of	 virus	 collection	 except	 those	 belonging	 to	 A(H1N1)pdm09	 subtype,	 for	 which	 the	analysis	was	 performed	 by	 epidemiological	week	 (Sunday	 to	 Saturday1).	 Supplementary	 information	 on	 the	 number	 of	 virus	globally	detected	 is	 shown	on	 the	 secondary	y-axis	 for	 the	 time	period	 for	which	 this	 information	was	available	 (since	1995;	Source:	 FluNet,	 World	 Health	 Organization	 (WHO)	 Global	 Influenza	 Surveillance	 and	 Response	 System	 (GISRS)	(http://www.who.int/influenza/	gisrs_laboratory/flunet/en/)).	Panel	 A-C:	 the	different	background	colours	 indicate	 the	 time	period	 covered	 the	 different	 temporal	 sub-datasets	 -	 white	 (before	 1999);	 beige	 (1999-2008);	 golden	 brown	 (from	 2009	onwards).		Panel	D:	the	time	period	covered	by	each	temporal	sub-dataset	is	indicated	with	arrows	at	the	top	of	the	plot.				The	NA	 gene	 sequences	 of	 all	 human	 influenza	 virus	 subtype	 or	 lineage	 (sub-)datasets	were	not	uniformly	distributed	over	time	(Figure	6.1A-D).	This	was,	in	part,	related	with	the	specific	circulation	dynamics	of	influenza	viruses	in	human	population,	as	evidenced	by	 the	 overall	 overlapping	 variation	 in	 number	 of	 sequences	 and	 viruses	 globally	detected	 (information	 available	 since	 1995;	 Source:	 FluNet,	World	Health	Organization	(WHO)	Global	 Influenza	Surveillance	and	Response	System	B).	Only	 for	B/VIC	 lineage	 it	seemed	to	exist	since	2007	an	one	to	two-year	delay	in	the	variation	of	both	parameters	(Figure	 6.1C).	 The	 shift	 to	 right	 in	 the	 distribution	 of	 seasonal	 A(H1N1),	 A(H3N2)	 and	influenza	B/VIC	and	B/YAM-lineage	NA	sequences	(Figure	6.1A-C),	was	already	expected	given	 the	much	 smaller	 size	of	 the	 earlier	 sub-dataset	 (before	1999).	The	 fact	 that	 this	earlier	 period	 was	 considerably	 longer	 than	 the	 two	 latter	 ones	 (26	 to	 56	 years,	compared	to	10	and	2	to	5	years),	made	this	shift	even	more	evident.																																																											B	http://www.who.int/influenza/gisrs_laboratory/flunet/en/		
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6.1.1.2	Geographic	Distribution	(Continents	and	Influenza	Transmission	Zones)	
	All	 NA	 sequence	 (sub-)datasets	 contained	 sequences	 from	 the	 5	worldwide	 continents	(Americas,	 Europe,	 Africa,	 Asia	 and	 Oceania).	 The	 only	 exception	 was	 the	 earliest	influenza	 B/VIC	 temporal	 sub-dataset	 (before	 1999)	 that	 did	 not	 contained	 sequences	from	either	Africa	or	Oceania	(Figure	6.2).	The	distribution	of	 the	sequences	across	 the	different	 worldwide	 continents	 was	 not,	 however,	 uniform.	 	 Most	 (sub-)datasets	 were	essentially	 comprised	by	 sequences	 	 from	 the	Americas,	Asia	 and	Europe,	while	 others	contained	 sequences	 from	mainly	 the	 two	 former	 continents	 (seasonal	A(H1N1)	 (sub-)	datasets	except	1999-2008,	and	influenza	B/VIC	and	B/YAM	before	1999	and	1999-2008	sub-datasets).	Only	very	few	of	the	sequences	within	each	(sub-)dataset	were	from	Africa	(1%	to	10%).			
		
	
	
	
Figure	6.2	Geographic	distribution	of	the	neuraminidase	gene	sequences	of	former	seasonal	A(H1N1),	A(H3N2),	 B/Victoria	 and	 B/Yamagata-lineage,	 and	 A(H1N1)pdm09	 (sub-)datasets,	 by	 continent	 or	influenza	transmission	zone.	The	 18	 influenza	 transmission	 zones	 established	 by	 the	World	 Health	 Organization	 join	 geographically	 related	 countries	 or	territories	in	larger	areas	with	similar	influenza	transmission	patterns	2.	
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A	more	detailed	analysis	showed	that	most	(sub-)datasets	contained	sequences	from	all	18	 influenza	 transmission	 zones	 established	 by	 WHO	 (Figure	 6.2).	 An	 influenza	transmission	zone	represents	a	geographical	area	with	a	similar	 influenza	 transmission	pattern	2.	Most	sequences	within	the	(sub-)datasets	belonged	to	the	North	America	and	Eastern	Asia	 influenza	 transmission	zones,	with	 the	 third	 top	position	varying	between	South	 West	 Europe	 and	 South	 East	 Asia	 (Figure	 6.2).	 As	 expected,	 given	 the	 lower	number	 of	 sequences	 enclosed,	 the	 before	 1999	 sub-datasets	were	 the	 less	 diversified,	not	comprising	sequences	from	most	influenza	transmission	zones	in	Africa.		
	
6.1.1.3	Nucleotide	Diversity			Nucleotide	 diversityC	of	 NA	 sequence	 (sub-)datasets	 varied	 not	 only	 among	 human	influenza	virus	 subtypes	or	 lineages	but	 also	over	 time	 (Figure	6.3).	 Similar	degrees	of	polymorphism	 were	 exceptionally	 found	 for	 the	 influenza	 B/VIC	 and	 B/YAM	 total	sequence	datasets	and	also	for	the	different	temporal	sub-datasets	of	B/YAM	lineage.				
					
Figure	 6.3	 Mean	 nucleotide	 diversity	 of	 former	 seasonal	 A(H1N1),	 A(H3N2),	 B/Victoria	 and	B/Yamagata-lineage,	 and	 A(H1N1)pdm09	 neuraminidase	 sequence	 (sub-)datasets,	 with	 standard	error	estimates.																																																									C	Average	 number	 of	 nucleotide	 substitutions	 per	 site	 for	 all	 pairwise	 comparisons	 among	 the	n	 sequences	within	 the	 (sub-)	dataset	3.	
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(Footnotes	Figure	6.3)	Sequence	diversity	was	estimated	in	MEGA5	software	by	Maximum	Composite	Likelihood	method.	 	Rate	variation	among	sites	was	modelled	with	a	gamma	distribution	(shape	parameter	=	1.327)	and	500	bootstrap	replications	were	used	to	estimate	the	associated	standard	error,	represented	in	the	figure	by	the	error	bars.			A(H3N2)	 sequence	 dataset	 was	 the	 most	 diverse	 of	 all	 human	 influenza	 subtype	 or	lineage	 total	 datasets	 (3.7x10-2	 nucleotide	 substitutions	 per	 site),	 followed	 by	 seasonal	A(H1N1)	 dataset	 (3.0x10-2)	 and	 then	 by	 both	 influenza	 B/VIC	 and	 B/YAM	 datasets	(2.1x10-2	and	2.0x10-2,	respectively).	A(H1N1)pdm09	total	sequence	dataset	was	the	less	polymorphic,	 with	 a	 mean	 diversity	 of	 0.7x10-2	 nucleotide	 substitutions	 per	 site.	 The	nucleotide	 sequence	 diversity	 of	 seasonal	 A(H1N1),	 A(H3N2)	 and,	 in	 a	 lesser	 extent,	B/VIC-lineage	 temporal	 sub-datasets	 was	 increasingly	 lower,	 while	 the	 converse	 was	observed	 for	A(H1N1)pdm09	 subtype.	 A(H1N1)pdm09	post-pandemic	 sub-dataset	was	approximately	 two	 times	more	 diverse	 (0.9x10-2)	 than	 the	 (pre-)pandemic	 sub-dataset	(0.4x10-2).			No	 evidence	 of	 recombination	 was	 found	 in	 total	 NA	 sequence	 datasets	 (results	 not	shown).	Based	on	 this,	 it	was	assumed	 that	 all	 sites	 in	 the	NA	sequences	of	 the	human	influenza	 virus	 subtype	 or	 lineage	 datasets	 shared	 a	 common	 evolutionary	 history,	allowing	them	to	be	directly	used	in	following	SP	analyses.			
6.1.2	Overall	Analysis	of	Selective	Pressure			Global	dN/dS	values	express	the	ratio	of	the	rate	of	non-synonymous	substitutions	(dN)	to	 the	rate	of	synonymous	substitutions	(dS)	over	 the	entire	coding	region,	providing	a	measure	of	the	overall	strength	of	selection	acting	on	protein-coding	genes	4.	Global	dN/dS	ratios	 for	 influenza	NA	gene	 in	 total	 time	periods	were	similar	across	 the	different	virus	subtypes	or	lineages	circulating	among	humans,	ranging	from	0.21	to	0.26	(Figure	6.4).	Considering	that	a	dN/dS	ratio	significantly	less	than	1	indicates	negative	SP	(NSP)	4,	these	results	evidenced	that	the	different	human	influenza	virus	NA	genes	have	been	evolving	under	NSP	of	 similar	magnitude.	The	global	dN/dS	ratio	 for	each	human	influenza	virus	NA	gene	was	also	very	similar	across	 the	different	 time	periods	studied	(temporal	 sub-datasets)	 (Figure	 6.4),	 suggesting	 that	 neither	 the	 introduction	 of	 NAIs	
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into	 clinic	 (1999)	 and/or	 its	 increased	 use	 during	 2009	 A(H1N1)	 pandemic	 had	 an	impact	on	the	overall	SP	acting	on	NA	gene.			
			
	
	
	
	
Figure	6.4	Global	estimates	of	the	dN/dS	ratio	in	the	neuraminidase	gene	of	former	seasonal	A(H1N1),	A(H3N2),	 B/Victoria	 and	 B/Yamagata-lineage,	 and	 A(H1N1)pdm09	 viruses	 with	 95%	 confidence	intervals,	in	total	and	temporal	sequence	(sub-)datasets.		dN:	rate	of	non-synonymous	substitutions;	dS:	rate	of	synonymous	substitutions	Analyses	were	 conducted	 in	 HyPhy	 using	 the	Muse-Gaut	 94	model	 crossed	with	 the	model	 described	 as	 012340,	 previously	determined	by	Akaike’s	Information	Criterion	as	the	best	time	reversible	model	for	influenza	neuraminidase.	Error	bars	show	the	95%	confidence	interval.				
6.1.3	Site-by-Site	Analysis	of	Selective	Pressure			
6.1.3.1	Summary	Results	(SLAC	and	FEL	consensus-based	inference)		Table	 6.2	 summarizes	 the	 site-specific	 SP	 results	 obtained	 through	 consensus-based	inference	 of	 Single-Likelihood	 Ancestor	 Counting	 (SLAC)	 and	 Fixed	 Effects	 Likelihood	(FEL)	 individual	 results.	When	no	 consensus	was	 verified,	 it	was	 considered	 the	 result	got	 by	 FEL	method,	 except	 in	 the	 case	 of	 positively	 or	 negatively	 selected	 sites.	 These	were	only	accepted	under	consensus.				
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Most	 sites	 (93.3%	 to	 98.5%)	 on	 the	 NA	 gene	 of	 the	 different	 human	 influenza	 virus	subtypes	 or	 lineages	 varied	 in	 their	 composition	 in	 total	 sequence	 dataset.	 From	 these	variable	sites,	the	majority	(82.6%	to	86.1%)	was	found	to	be	experiencing	a	dN/dS	ratio	less	than	1	that	was	statistically	significant	for	approximately	or	slightly	more	than	half	of	them	–	negatively	selected	sites	(41.6%	to	52.3%).	For	A(H3N2)	subtype,	the	percentage	of	sites	under	significant	purifying	selection	was	exceptionally	higher,	reaching	67.3%	of	all	variable	sites.	Approximately	13%	to	17%	of	all	variable	sites,	according	to	the	virus	subtype	 or	 lineage,	 were	 estimated	 to	 be	 experiencing	 a	 dN/dS	 ratio	 greater	 than	 1.	However,	 only	 for	 a	 very	 few	 of	 them,	 varying	 from	 0.2%	 to	 1.8%,	 this	 ratio	 was	statistically	significant	-	positive	selection.	A	minor	percentage	of	all	variable	sites	within	each	human	 influenza	virus	NA	were	 found	under	neutral	evolution	(dN/dS≈1;	0.7%	to	2.0%).			
Table	 6.2	 Summary	 characterization	 of	 the	 site-by-site	 selective	 pressure	 results	 obtained	 for	 the	neuraminidase	gene	of	 former	 seasonal	A(H1N1),	A(H3N2),	B/Victoria	and	B/Yamagata-lineage,	and	A(H1N1)pdm09	viruses,	in	total	and	temporal	sequence	(sub-)datasets.			
	dN:	rate	of	non-synonymous	substitutions;	dS:	 rate	of	synonymous	substitutions;	SLAC:	Single-Likelihood	Ancestor	Counting;	FEL:	Fixed	Effects	Likelihood.	 	a	Stop	codon	not	included;	b	Percentage	relative	to	all	codon	sites;	c	Percentage	relative	to	variable	codon	sites;	d	Percentage	of	codon	sites	with	the	same	result	for	SLAC	and	FEL	methods	among	all	codon	sites.	 	 	 	 	SLAC	and	FEL	analyses	were	conducted	in	HyPhy	using	the	Muse-Gaut	94	model	crossed	with	the	model	described	as	012340,	previously	determined	by	Akaike’s	Information	Criterion	as	the	best	time	reversible	model	for	influenza	neuraminidase.		
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(Footnotes	Table	6.2	cont.)	The	results	were	obtained	throughout	consensus-based	inference	of	SLAC	and	FEL	individual	results.	When	no	consensus	was	verified,	it	was	considered	the	result	got	by	FEL	analysis,	except	in	the	case	of	positively	or	negatively	selected	sites	that	were	only	validated	under	consensus.					The	splitting	into	different	time	periods	revealed	some	differences	in	the	distribution	of	the	sites	across	the	different	SP	profiles.	However,	these	have	to	be	interpreted	carefully	as	most	of	them	appear	to	be	artefacts	of	the	different	size	of	temporal	sub-datasets	(see	Table	 6.1	 above).	 This	 is	 clearly	 the	 case	 of	 the	 differences	 in	 the	 percentage	 of	 sites	experiencing	 a	 dN/dS	 ratio	 less	 than	 1	 or	 under	 NSP	 observed	 for	most	 or	 all	 human	influenza	virus	subtypes	or	lineages	(Table	6.2),	as	evidenced	by	the	direct	correlation	of	the	variation	and	the	number	of	sequences	enclosed	in	the	sub-datasets.	The	fact	that	the	differences	 were	 more	 pronounced	 when	 the	 number	 of	 sequences	 was	 also	 more	divergent	further	supports	this.	The	increase	in	the	percentage	of	positively	selected	sites	in	 B/VIC	 lineage	 NA	 over	 the	 different	 time	 periods	 might	 also	 be	 an	 artefact	 of	 the	increasingly	 larger	 size	 of	 sequence	 sub-datasets.	 However,	 this	 was	 the	 only	 virus	subtype/lineage	for	which	this	increase	was	observed	(Table	6.2).					
6.1.3.2	Positively	Selected	Sites			
6.1.3.2.1	Former	seasonal	influenza	A(H1N1)	virus	neuraminidase		Site	275	was	the	only	amino	acid	site	in	seasonal	A(H1N1)	virus	NA	under	PSP	during	the	total	 time	period	analysed	 (total	 sequence	dataset)	 (Table	6.3).	 Structurally,	 site	275	 is	well-know	to	lie	close	to	the	enzymatic	active	site	of	N1	NA	6.	Moreover,	it	is	the	only	NA	site	associated	with	clinical	resistance	to	NAIs,	specifically	to	oseltamivir	(OS),	and	is	also	associated	 with	 highly	 reduced	 inhibition	 (HRI)	 by	 OS	 and	 peramivir	 (PER)	 in	 vitro	(H275Y	 amino	 acid	 substitution)	 7,8.	 The	 detection	 of	 275H/Y	 as	 the	 only	 amino	 acid	polymorphism	occurring	at	this	site	(Table	6.3),	showed	that	PSP	favoured	the	concerted	substitution	 towards	 the	 amino	 acid	 residue	 conferring	 resistance	 or	 HRI	 -	 directional	PSP.	
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Table	6.3	Codon	sites	under	positive	selective	pressure	in	the	neuraminidase	gene	of	former	seasonal	A(H1N1),	A(H3N2),	B/Victoria	and	B/Yamagata-lineage,	and	A(H1N1)pdm09	viruses,	in	total	and	temporal	sequence	(sub-)datasets.			
		
p"value dN"*"dS"scaled dN" dS p"value dN/dS dN" dS1 275"(274) GH"catalytic"domain;"Clinical"R"OS"+"HRI"by"OS"and"PER"in#vitro"(NA"H275Y) 0.0047 15.11 3.61 3.80 0.0057 2.25 0.56 4.02 61.6%"H;"38.4%&YBefore"1999 0 * * * * * * * * * * *1999"*"2008 1 275"(274) (see"above) 0.00046 14.08 1.20 6.30 0.00014 3.38 0.27 12.60 76.1%"H;"23.9%&YFrom"2009"onwards 0 * * * * * * * * * * *44 Stalk"domain 0.013 2.11 31.50 17.01 0.00020 2.56 2.48 0.97 97.7%"S;"1.8%"P;"0.3%"F;"0.1%"Y;"0.03%"L"
148 GH"catalytic"domain,"150*cavity"loop;"Enhancement"of"the"reduced"NAI"susceptibility"conferred" in#vitro"by"E119V"(NA"T148I;"synergy);"N*glycosilation"motif"(N146) 2.45E*15 7.87 59.09 5.07 6.99E*12 9.02 4.17 0.46 96.0%"T;"2.7%&I;"1.0%"K;"0.2%"P;"0.05%"A;"0.05%"R
151 GH"catalytic"domain,"functional"active"site"residue,"150*cavity"loop;"RI"by"OS"(NA"D151E)"+"(H)RI"by"ZA"(NA"D151A/G/V) #in#vitro 5.58E*15 8.88 67.01 6.09 6.33E*15 10.90 4.74 0.44 95.4%"D;"1.9%&G;"1.6%"N;"0.8%&E;"0.2%&V;"0.08%&A435 GH"catalytic"domain 0.011 1.33 11.63 2.47 0.051 3.35 0.82 0.24 93.1%"E;"4.1%"R;"2.2%"K;"0.4%"D;"0.2%"G;"0.03%"A468 GH"catalytic"domain 0.0083 1.31 12.00 3.00 0.017 3.50 0.74 0.21 99.2%"P;"0.4%"S;"0.2%"H;"0.1%"L;"0.03%"R;"0.03%"T120 GH"catalytic"domain 0.0033 6.08 9.50 1.00 0.0027 9.02 3.25 0.36 95.9%"P;"3.5%"L;"0.6%"H370 GH"catalytic"domain 0.0062 4.52 7.02 0.71 0.015 7.24 2.59 0.36 68.1%"L;"19.1%"S;"12.8%"F432 GH"catalytic"domain,"430*cavity"loop 0.055 3.18 4.44 0.00 0.016 3.24E+08 1.62 0.00 98.9%"Q;"0.3%"E;"0.3%"K;"0.2%"P;"0.3%"L434 GH"catalytic"domain 0.039 2.86 4.00 0.00 0.013 inf 1.36 0.00 97.9%"T;"1.5%N;"0.2%"I;"0.5%"A44 (see"above) 0.022 3.06 15.00 6.00 0.0023 3.36 2.70 0.80 97.8%"S;"1.9%"P;"0.2%"F;"0.05%"Y
147 GH"catalytic"domain,"150*cavity"loop;"Epitope"contacting"residue"(Mem5"antibody)"with"potential"effect"on"antibody"binding 0.018 2.41 8.30 1.20 0.0021 9.44 1.44 0.15 87.8%"D;"11.8%"N;"0.3%"Y;"0.1%"G
148 (see"above) 1.60E*05 6.39 21.85 3.04 0.00042 5.22 3.61 0.69 97.0%"T;"2.1%&I;"0.8%"K;"0.05%"P;"0.05%"A
151 (see"above) 5.25E*09 11.96 38.87 3.69 4.56E*10 11.62 6.82 0.59 94.4%"D;&2.3%&G;"1.8%"N;"1.2%&E;"0.3%&V;"0.05%&A435 (see"above) 0.022 1.96 5.76 0.00 0.020 inf 0.98 0.00 98.8%"E;"0.6%"D;"0.5%"K;"0.05%"G40 Stalk"domain 0.043 2.13 8.95 2.43 0.012 4.71 1.73 0.37 94.6%"Y;"3.1%"C;"2.1%"H;"0.1%"F;"0.05%"D;"0.05%"S
148 (see"above) 1.65E*11 11.95 38.55 2.05 3.90E*09 14.68 5.91 0.40 95.0%"T;"3.4%&I;"1.2%"K;"0.2%"P;"0.05%"A;"0.1%"R
151 (see"above) 6.00E*08 10.10 34.48 3.64 3.55E*08 9.60 5.31 0.55 95.8%"D;"1.8%"N;"1.7%&G;"0.4%&E;"0.1%&V;"0.1%&A468 (see"above) 0.0034 2.29 7.00 0.00 0.00095 1.02E+06 1.02 0.00 99.0%"P;"0.6%"S;"0.2%"H;"0.1%"L;"0.05%"T
Sequence"""""""""""""""""""""""(sub*)dataset POSITIVELY.SELECTED.SITESTotal"number Codon"site"a Structural"domain"and"site"particularities SLAC""" FEL Amino"acid"polymorphism(s)"
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	(Table	6.3	cont.)		
	
p"value dN"*"dS"scaled dN" dS p"value dN/dS dN" dS46"(47) Stalk"domain 0.0070 2.31 8.48 1.00 0.010 7.12 1.11 0.16 96.4%"T;"3.3%"I;"0.2%"N;"0.05%"S;"0.05%"A;"0.05%"P48"(49) Stalk"domain 0.0023 2.32 7.51 0.00 0.0055 inf 0.99 0.00 99.1%"P;"0.6%"S;"0.1%"Q;"0.1%"T;"0.05%"R;"0.05%"L65"(66) Stalk"domain;"N*glycosilation"motif"(N64) 0.018 3.58 22.81 11.19 0.052 1.86 3.27 1.76 90.8%"R;"7.7%"H;"0.7%"L;"0.3%"C;"0.3%"S;"0.2%"Y68"(69) Stalk"domain 0.017 1.54 5.00 0.00 0.024 inf 0.65 0.00 98.8%"T;"1.2%"A;"0.05%"K72"(73) GH"catalytic"domain 0.00057 3.38 11.96 1.01 0.0091 6.96 1.57 0.23 98.3%"T;"1.3%"I;"0.3%"A;"0.2%K;"0.05%"S73"(74) GH"catalytic"domain 6.46E*05 5.64 22.48 4.19 0.00025 4.72 3.09 0.65 67.7%"L;"32.0%"F;"0.2%"P;"0.1%"S;"0.05%"R;"0.05%"I395"(390) GH"catalytic"domain;"RI"by"OS"and"PER"in#vitro"(NA"A395E) 3.16E*06 7.55 30.48 6.01 4.70E*05 4.26 4.03 0.95 88.7%"A;"5.7%"T;"4.1%"V;"1.3%"D;"0.2%"I;"0.1%%E465"(465) GH"catalytic"domain 0.019 1.85 7.00 1.00 0.028 5.82 0.90 0.15 94.8%"A;"5.0%"T;"0.05%"D;"0.05%"G;"0.05%"VBefore"1999 0 * * * * * * * * * * *42"(43) Stalk"domain 0.036 4.89 4.15 0.00 0.039 inf 2.15 0.00 80.5%"P;"16.4%"S;"1.6%"Q;"1.0%"R;"0.5%"L65"(66) (see"above) 0.031 6.37 6.42 1.02 0.029 5.91 3.53 0.60 88.3%"R;"10.9%"H;"0.5%"L;"0.3%"C
395$(390) (see"above) 0.0077 7.08 6.00 0.00 0.0031 inf 3.11 0.00 92.2%"A;"5.7%"T;"1.8%"V;"0.3%"D46"(47) (see"above) 0.012 2.39 5.50 0.00 0.0058 1.79E+16 1.00 5.55E*17 99.0%"T;"0.8%"I;"0.1%"N;"0.06%"A;"0.06%"P48"(49) (see"above) 0.039 1.74 4.00 0.00 0.042 inf 0.74 0.00 99.4%"P;"0.4%"S;"0.1%"T54"(55) Stalk"domain 0.016 2.50 5.75 0.00 0.0039 inf 1.28 0.00 99.0%"C;"0.9%"Y;"0.06%"R;"0.06%"F68"(69) (see"above) 0.039 1.74 4.00 0.00 0.044 inf 0.72 0.00 98.8%"T;"1.1%"A;"0.06%"K72"(73) (see"above) 0.00085 4.53 11.45 1.01 0.012 6.66 2.09 0.31 97.9%"T;"1.6%"I;"0.3%"A;"0.06%K;"0.06%"S73"(74) (see"above) 0.00016 6.31 16.63 2.09 0.00036 6.96 3.20 0.46 63.8%"L;"35.8%"F;"0.1%"S;"0.06%"P;"0.06%"R;"0.06%"I199"(200) GH"catalytic"domain 0.017 2.44 5.62 0.00 0.0057 inf 1.16 0.00 82.2%"N;"17.4%"D;"0.2%"K;"0.06%"S;"0.06%"G
395$(390) (see"above) 0.00010 7.80 22.98 5.01 0.00082 3.79 4.18 1.10 87.8%"A;"5.6%"T;"4.8%"V;"1.5%"D;"0.2%"I;"0.1%%E42"(43) Stalk"domain 0.0058 5.35 15.28 4.01 0.014 3.32 3.31 1.00 46.8%"Q;"41.9%"R;"9.2%"P;"1.4%"T;"0.3%"S;"0.2%"L;"0.2%"K65"(66) Stalk"domain;"N*glycosilation"motif"(N64) 0.0015 5.18 12.92 2.03 0.0032 5.47 2.71 0.50 88.5%"R;"10.8%"H;"0.4%"L;"0.1%"S;"0.1%"C73"(74) GH"catalytic"domain 0.0070 4.03 10.48 2.01 0.018 4.23 2.07 0.49 90.4%"L;"8.0%"P;"1.6%"F106"(110*111b) GH"catalytic"domain 0.028 2.60 6.49 1.00 0.012 7.26 1.25 0.17 65.9%"T;"32.3%"I;"1.6%"N;"0.2%"A;"0.07%"V198"(199) GH"catalytic"domain 0.00036 6.13 14.05 1.16 0.00091 9.93 2.86 0.29 93.8%"S;"6.2%"N465"(465) GH"catalytic"domain 0.010 3.33 8.00 1.00 0.020 6.18 1.51 0.24 58.6%"A;"41.0%"T;"0.1%"N;"0.1%"V;"0.07%"D;"0.07%"SBefore"1999 0 * * * * * * * * * * *
65$(66) (see"above) 0.014 9.14 7.48 1.01 0.018 6.47 4.78 0.74 93.5%"R;"5.3%"H;"0.5%"L;"0.5%"S;"0.2%"C
198$(199) (see"above) 0.025 8.94 7.49 1.16 0.039 5.29 4.62 0.87 94.7%"S;"5.3%"N395"(390) GH"catalytic"domain;"RI"by"OS"and"PER#in#vitro "(NA"A395E) 0.039 5.65 4.00 0.00 0.022 inf 2.28 0.00 94.7%"A;"3.9%"T;"1.0%"S;"0.5%"V
65$(66) (see"above) 0.019 4.05 4.96 0.00 0.016 2.91E+14 1.52 5.23E*15 85.8%"R;"14.0%"H;"0.1%"L;"0.1%"C106"(110*111b) (see"above) 0.0080 4.89 5.98 0.00 0.0010 inf 2.06 0.00 49.2%"I;"48.0%"T;"2.4%"N;"0.3%"A;"0.1%"V
198$(199) (see"above) 0.0060 5.75 7.03 0.00 0.0046 inf 2.41 0.00 93.0%"S;"7.0%"N465"(465) (see"above) 0.017 4.09 5.00 0.00 0.011 inf 1.69 0.00 50.4%"T;"49.2%"A;"0.2%"N;"0.1%"V;"0.1%"S
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	(Table	6.3	cont.)	
	SLAC:	Single-Likelihood	Ancestor	Counting;	FEL:	Fixed	Effects	Likelihood;	dN:	rate	of	non-synonymous	substitutions;	dS:	rate	of	synonymous	substitutions;	GH:	Globular	head;	R:	Resistance;	HRI:	Highly	reduced	inhibition;	RI:	Reduced	inhibition;	(H)RI:	HRI	or	RI;	OS:	Oseltamivir;	PER:	Peramivir;	ZA:	Zanamivir;	NAI:	Neuraminidase	inhibitor;	inf:	infinity	(dS=0.00)	 	a	Standard	N2	numbering	is	indicated	in	brackets	after	the	type	or	subtype-specific	numbering;	b	Precise	N2	numbering	cannot	be	given	as	influenza	B	NA	carries	a	deletion	in	the	alignment	compared	to	A(H3N2)	NA	Positive	 selection	was	only	 considered	when	detected	by	both	 SLAC	and	FEL	methods	 (consensus-based	 criterion).	 	 Sites	under	positive	 selective	pressure	 in	more	 than	one	 temporal	 sub-dataset	 are	highlighted	 in	bold	and	 italic,	as	well	as	 the	amino	acid	residues	associated	with	NAI	resistance	or	(H)RI	among	the	amino	acid	polymorphism(s)	 identified	 in	the	site.	The	 location	of	 the	NA	structural	domains	was	based	on	Colman	9	and	Wei	10	(former	seasonal	N1);	Colman	9,	Colman	and	Ward	11	and	Air	and	Laver	12	(N2);	Colman	and	Ward	11	and	Flandorfer	et	al.	13	(influenza	B	NA);	and	Colman	9	and	da	Silva	et	al.	14	(2009	pandemic	N1).	Site	particularities	were	defined	according	to	the	information	found	at	Li	et	al.	15	(cavity	loops);	Colman	9	(N-glycosylation	motifs);	WHO	8	and	WHO	16	(association	with	NAI	resistance	or	(H)RI);	and	Venkatramani	et	al.	17	and	Wan	et	al.	18	(epitope	contacting	residues).				
p"value dN"*"dS"scaled dN" dS p"value dN/dS dN" dS46"(44) Stalk"domain 0.014 1.75 11.99 3.28 0.0047 4.24 1.27 0.30 98.5%"I;"1.1%"T;"0.4%"V;"0.03%"M74"(72) Stalk"domain 0.013 1.52 8.78 1.20 0.0026 9.03 1.00 0.11 99.2%"F;"0.5%"L;"0.3%"V;"0.03%"I;"0.03%"S95"(95) GH"catalytic"domain;"Epitope"contacting"residue"(CD6"antibody)"crucial"for"antibody"binding 0.054 1.32 10.16 3.60 0.031 3.19 1.06 0.33 98.7%"S;"0.8%"N;"0.4%"G;"0.06%"R;"0.06%"I
247"(246) GH"catalytic"domain;"RI"by"OS" in#vitro"(NA"S247G);"Enhancement"of"the"(H)RI"by"OS"and"PER"conferred"in#
vitro#by"H275Y"(NA"S247N;"synergy) 0.0075 1.93 12.00 2.40 0.0026 5.65 1.26 0.22 99.0%"S;"0.9%%N ;"0.03%%G;"0.03%"I275"(274) GH"catalytic"domain;"Clinical"R"OS"+"(H)RI"by"OS"and"PER#in#vitro"(NA"H275Y) 0.00016 5.42 44.43 17.49 7.25E*06 3.01 3.97 1.32 95.7%"H;"4.3%%Y450"(451) GH"catalytic"domain;"Epitope"contacting"residue"(CD6"antibody) 0.053 0.84 4.15 0.00 0.011 inf 0.43 0.00 99.7%"S;"0.2%"G;"0.03%"I46"(44) (see"above) 0.013 2.12 8.14 1.10 0.0038 8.59 1.22 0.14 98.9%"I;"0.9%"T;"0.2%"V74"(72) (see"above) 0.040 1.38 4.60 0.00 0.0052 inf 0.75 0.00 99.5%"F;"0.4%"L;"0.1%"V;"0.03%"I
275$(274) (see"above) 1.50E*06 8.33 33.58 5.86 1.61E*09 7.95 4.88 0.61 96.9%"H;"3.1%%Y ;"0.03%"R247"(246) (see"above) 0.0035 3.63 7.90 0.00 0.00022 inf 2.06 0.00 98.3%"S;"1.6%%N ;"0.1%"I
275$(274) (see"above) 0.0038 6.96 24.42 9.24 5.44E*05 3.77 5.82 1.55 94.2%"H;"5.8%%Y454"(455) GH"catalytic"domain 0.018 3.21 8.99 2.00 0.0097 4.83 2.05 0.42 98.5%"G;"0.7%"S;"0.7%"D;"0.1%"V
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Temporal	splitting	revealed	 that	site	275	was	only	under	PSP	between	1999	and	2008,	corresponding	to	the	period	after	NAI	introduction	into	clinic	but	before	its	increased	use	during	2009	pandemic.	 In	 fact,	 the	H275Y	amino	acid	substitution	 favoured	by	positive	selection	was	not	detected	 in	any	of	 the	 sequences	 from	before	1999,	when	NAIs	were	not	available	in	the	market	(100%	H275),	and,	from	2009	onwards	was	already	fixed	in	the	seasonal	A(H1N1)	virus	population	(3.6%	H275;	96.4%	275Y).	No	other	site	besides	275	was	found	under	PSP	in	the	different	time	periods	studied.		Given	 the	 emergence	 and	worldwide	 spread	of	 a	H275Y	OS-resistant	 variant	 since	 late	2007,	two	additional	time	periods	were	studied	for	seasonal	A(H1N1)	subtype	to	further	investigate	the	PSP	acting	on	site	275	between	1999	and	2008.	Specifically,	(1)	1999	to	2006,	 and	 (2)	 1999	 to	 2007.	 Evidence	 for	 positive	 selection	 was	 only	 obtained	 in	 the	latter	 period	 (SLAC:	 p	 =0.0028;	 dN-dS	 scaled=8.33;	 dN=8.33;	 dS=0.00;	 FEL:	 p=0.0014;	dN/dS=infinite;	dN=2.82;	dS=0.00),	suggesting	that	it	may	have	only	started	in	2007	and	thereby	may	be	simply	an	artefact	of	the	worldwide	spread	of	the	drug-resistant	variant.				
6.1.3.2.2	Influenza	A(H3N2)	virus	neuraminidase			Sites	44,	148,	151,	435	and	468	 in	human	 influenza	N2	NA	were	under	PSP	during	 the	total	time	period	analysed.	Sites	148	and	151	were	both	under	strong	PSP,	as	evidenced	by	the	extremely	low	p-values	calculated	by	SLAC	and	FEL	methods	(10-12	to	10-15)	(Table	6.3).	 Structurally,	 these	 sites	 are	 known	 to	 be	 located	 very	 near	 (site	 148	 -	 150-cavity	loop)	15	or	at	the	NA	active	site	(site	151	-	functional	residue)	19.	Moreover,	they	are	both	associated	with	(H)RI	by	NAI	drugs	in	vitro.	Several	amino	acid	substitutions	at	site	151	are	known	to	confer	(H)RI	(D151E/V/A/G)	8,	while	the	T148I	amino	acid	substitution	at	site	 148	 has	 a	 synergistic	 effect	 on	 the	 reduced	 susceptibility	 caused	 by	 NA	 E119V	substitution	16.		Site	148	is	additionally	involved	in	the	potential	N-linked	glycosylation	of	Asn146	9.	Two	other	positively	selected	sites	–	sites	435	and	468,	belong	to	the	globular	head	catalytic	domain,	but	are	located	distantly	from	the	active	site	(Figure	6.5).		All	five	positively	selected	sites	presented	an	amino	acid	profile	highly	polymorphic,	with	the	different	variants	occurring	at	very	low	frequency	(0.03%	to	4.1%)	(Table	6.3).	This	indicated	that	positive	selection	favoured	the	maintenance	of	several	amino	acid	variants	
																																																																										Footprints	of	selective	pressure	in	influenza	neuraminidase	|	226																																																	
	
at	these	sites	in	virus	population,	prompting	diversity	–	diversifying	PSP.	All	amino	acid	substitutions	 at	 site	 151	 known	 to	 confer	 (H)RI	 were	 among	 the	 polymorphisms	identified	(D151E/V/A/G),	as	well	as	the	synergistic	T148I	amino	acid	substitution	at	site	148	(Table	6.3).	However,	only	 in	one	sequence	 from	2011	this	synergistic	substitution	was	found	together	with	the	NA	E119V	amino	acid	substitution	conferring	(H)RI.			
	
	
	
	
	
Figure	6.5	Mapping	of	the	human	influenza	N2	neuraminidase	sites	under	positive	selective	pressure	onto	the	three-dimensional	structure	of	the	protein	globular	head	domain.	The	 figures	 were	 generated	 in	 PyMOL,	 using	 the	 structure	 file	 of	 the	 neuraminidase	 (NA)	 globular	 head	 domain	 from	 the	A(H2N2)	 virus	A/Tokyo/3/1967,	 previously	 retrieved	 from	 the	RCSB	Protein	Data	Bank	 (PDB	 ID:	 1NN2).	 The	 globular	 head	domain	is	presented	in	the	same	orientation	for	all	different	time	periods.	The	amino	acid	residues	forming	the	NA	active	site	(based	on	Colman	et	al.	 19)	are	coloured	in	dark	blue	(functional	residues)	or	light	purple	(framework	residues)	and	shown	as	sticks,	while	positively	selected	sites	are	highlighted	as	red	sticks.			Temporal	splitting	showed	that	sites	148	and	151	were	continually	under	PSP	after	the	introduction	 of	 NAI	 drug	 class	 into	 clinic	 (between	 1999	 and	 2008,	 and	 from	 2009	onwards)	(Table	6.3).	It	also	showed	that	PSP	at	site	148	was	stronger	during	the	period	of	 increased	NAI	drug	use	 (from	2009	onwards),	 as	 evidenced	by	 the	notably	 lower	p-value	and	greater	dN-dS	scaled	(SLAC)	or	dN/dS	(FEL)	value,	compared	to	1999	to	2008	(Table	6.3).	At	amino	acid	 level,	 this	 stronger	PSP	 translated	 into	a	new	polymorphism	(T148R)	 and	 a	 slight	 increase	 in	 frequency	 for	 three	 variants	 (T148I/K/P).	 Other	positively	selected	sites	 located	near	or	at	 the	NA	active	site	 included	site	120	but	only	during	the	period	before	1999	(no	NAI	drug	available),	and	site	147	between	1999	and	2008	 (Figure	 6.5).	 Site	 147	 is	 a	 known	 epitope	 contacting	 residue	 17,	 being	 under	selection	of	the	host´s	antibody-mediated	immune	response.		
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6.1.3.2.3	Influenza	B/Victoria-lineage	neuraminidase		Positively	selected	sites	 in	 influenza	B/VIC-lineage	NA	 included	sites	46,	48,	65,	68,	72,	73,	 395	 and	465,	 in	 the	 total	 time	period.	 The	 first	 4	 sites	 are	 located	within	 the	 stalk	domain	 of	 the	 protein,	 while	 the	 last	 4	 belong	 to	 the	 catalytic	 globular	 head	 domain	(Table	6.3).	None	of	these	latter	sites	lie	near	the	enzymatic	active	site,	as	evidenced	by	structural	 mapping	 (sites	 395	 and	 465;	 Figure	 6.6)	 or	 based	 on	 its	 location	 at	 the	beginning	of	the	domain	(sites	72	and	73;	not	included	in	the	NA	structure	files	available	for	use).	Positively	selected	site	395	is	associated	with	reduced	inhibition	(RI)	by	OS	and	PER	in	vitro	(NA	A395E	amino	acid	substitution)	8.				
		
Figure	6.6	Mapping	of	 the	 influenza	B/Victoria-lineage	neuraminidase	 sites	under	positive	 selective	pressure	onto	the	three-dimensional	structure	of	the	protein	globular	head	domain.	The	figures	were	generated	and	annotated	as	described	in	Figure	6.5,	using	the	structure	file	of	the	neuraminidase	globular	head	domain	 from	 the	 B/Victoria-lineage	 vaccine	 virus	 B/Brisbane/60/2008	 (PDB	 ID:	 4CPL;	 only	 one	 globular	 head	 of	 the	 two	described	 in	 the	 file	 is	 shown).	 	 Positively	 selected	 sites	72	 and	73	 (total	 time	period	 and	 from	2009	onwards)	 could	not	be	indicated	as	are	missing	in	the	structure	file	used	(amino	acid	residues	77	to	466).				All	 positively	 selected	 sites	 except	 site	 68	were	 highly	 polymorphic,	 presenting	 4	 to	 5	different	 amino	 acid	 variants	 (Table	 6.3).	 Site	 68	 presented	 two	 different	 variants.	Moreover,	 all	 amino	 acid	 polymorphisms	 occurred	 at	 very	 low	 frequency	 (0.05%	 to	7.7%),	suggesting	that	PSP	prompted	the	maintenance	of	amino	acid	diversity	-	positive	diversifying	 selection.	 The	 only	 exception	 was	 site	 73,	 in	 which	 the	 L73F	 amino	 acid	substitution	occurred	at	a	much	higher	frequency	(32.0%)	than	all	other	variants	(Table	6.3),	indicating	that	PSP	favoured	the	substitution	towards	the	phenylalanine	(F)	residue	
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–	positive	directional	 selection.	The	A395E	amino	acid	 substitution	known	 to	 confer	RI	was	one	of	the	polymorphisms	found	at	site	395.		None	 of	 the	 sites	 under	 PSP	 between	 1999	 and	 2008	 and	 from	 2009	 onwards	 is	 also	located	 near	 or	 at	 the	NA	 active	 site,	 lying	 in	 the	 stalk	 domain	 or	 in	 the	 globular	 head	domain	but	at	either	its	beginning	(sites	72	and	73)	or	surface	region	(sites	199	and	395;	Figure	6.6)	(Table	6.3).	Site	395	associated	with	NAI	RI	was	continually	under	PSP	during	these	 two	 time	 periods,	 with	 the	 site-specific	 values	 calculated	 by	 both	 SLAC	 and	 FEL	methods	 suggesting	 similar	PSP	 in	 the	 two	periods	 (Table	6.3).	The	amino	acid	variant	conferring	RI	only	 emerged	during	 the	period	of	 increased	NAI	drug	use	 (A395E;	 from	2009	 onwards).	 It	 is	 important	 to	 note	 that	 the	 lack	 of	 positively	 selected	 sites	 before	1999	might	be	due	to	the	extremely	low	number	of	sequences	comprising	the	sub-dataset	(N=34;	see	Table	6.1	above).		 	
6.1.3.2.4	Influenza	B/Yamagata-lineage	neuraminidase			Six	 sites	 in	 influenza	 B/YAM-lineage	 NA	 were	 under	 PSP	 during	 the	 total	 time	 period	analysed.	Specifically,	sites	42,	65,	73,	106,	198	and	465	(Table	6.3).	Most	of	these	sites	are	 located	 within	 the	 globular	 head	 catalytic	 domain,	 but	 only	 site	 198	 lies	 near	 the	enzymatic	active	site,	as	evidenced	in	Figure	6.7	(site	73	not	shown	as	 is	missing	in	the	structure	file	used,	but	lies	at	the	beginning	of	the	domain).	 	Site	198	was	also	the	most	strongly	 selected	 site,	 based	 on	 the	 simultaneously	 lowest	 p-value	 and	 greatest	 dN-dS	scaled	(SLAC)	or	dN/dS	(FEL)	value	(Table	6.3).			Most	positively	selected	sites	were	highly	polymorphic,	presenting	4	to	6	different	amino	acid	 variants.	 Sites	 73	 and	 198	were	 the	 only	 exceptions,	 presenting	 two	 and	 a	 single	amino	 acid	 variant,	 respectively	 (Table	 6.3).	 However,	 all	 sites	 appeared	 to	 be	 under	positive	directional	 selection,	 based	on	 the	much	higher	 frequency	 at	which	one	of	 the	variants	within	each	polymorphic	site	was	detected	(Q42R;	R65H;	L73P;	T106I;	A465T).	Only	for	site	73,	the	frequency	at	which	the	different	variants	were	detected	was	not	so	distinct,	making	the	situation	less	clear.	
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Figure	6.7	Mapping	of	the	influenza	B/Yamagata-lineage	neuraminidase	sites	under	positive	selective	pressure	onto	the	three-dimensional	structure	of	the	protein	globular	head	domain.	The	figures	were	generated	and	annotated	as	described	in	Figure	6.5,	using	the	structure	file	of	the	neuraminidase	globular	head	domain	 from	 the	 B/Yamagata-lineage	 reference	 virus	 B/Perth/211/2001	 (PDB	 ID:	 3K36;	 only	 one	 globular	 head	 of	 the	 two	described	in	the	file	is	shown).	Positively	selected	site	73	(total	time	period)	could	not	be	indicated	as	is	missing	in	the	structure	file	used	(amino	acid	residues	77	to	466).					Temporal	 splitting	 showed	 that	 sites	 65	 and	198	were	 continually	 under	PSP	 after	 the	licensing	of	NAI	drugs	 (between	1999	 and	2008,	 and	 from	2009	onwards)	 (Table	6.3).	Only	 site	 198	 lies,	 however,	 near	 the	 active	 site	 of	 the	 protein	 (drug	 target),	 as	 above-mentioned.	 	Also,	there	was	no	consensus	for	a	particular	change	in	the	strength	of	PSP	acting	at	these	sites	between	the	two	time	periods	(SLAC	–	decrease;	FEL	–	increase).	Site	395	associated	with	NAI	RI,	as	already	mentioned	for	B/VIC	lineage,	but	located	distantly	from	the	NA	active	site,	was	under	PSP	between	1999	and	2008.	Nevertheless,	the	A395E	amino	 substitution	 known	 to	 confer	 RI	 was	 not	 among	 the	 polymorphisms	 identified	(Table	6.3).	Similarly	to	B/VIC	 lineage,	 it	 is	 important	to	note	that	the	 lack	of	positively	selected	sites	before	1999	might	be	due	to	the	low	number	of	sequences	comprising	the	sub-dataset	(N=83;	see	Table	6.1	above).			
6.1.3.2.5	2009	pandemic	influenza	A(H1N1)	virus	neuraminidase		Sites	46,	74,	95,	247,	275	and	450	in	2009	pandemic	N1	NA	were	under	PSP	during	the	total	 time	 period	 analysed.	 Most	 of	 these	 sites	 are	 located	 within	 the	 globular	 head	catalytic	domain	(Table	6.3),	but	only	sites	247	and	275	lie	close	to	the	enzymatic	active	site	(Figure	6.8).	As	above-mentioned	for	seasonal	A(H1N1)	subtype,	site	275	is	the	only	NA	site	associated	with	clinical	resistance	to	OS.	Moreover,	in	A(H1N1)pdm09	subtype,	it	
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NO POSITIVELY 
SELECTED SITES 
198 
106 
465 
198 
395 
198 
106 
465 
																																																																										Footprints	of	selective	pressure	in	influenza	neuraminidase	|	230																																																	
	
is	associated	with	 (H)RI	by	OS	and	PER	 in	vitro	 (H275Y	amino	acid	substitution)	 8.	 Site	247	is	also	associated	with	NAI	(H)RI,	specifically	with	RI	by	OS	in	vitro	(NA	S247G	amino	acid	 substitution)	 and	 with	 an	 enhancement	 of	 the	 H(RI)	 conferred	 by	 H275Y	substitution	(NA	S247N	amino	acid	substitution;	synergistic	effect)	16.	Positively	selected	sites	95	and	450	lie	at	the	surface	of	the	globular	head	(Figure	6.8),	which	is	in	agreement	with	 their	 known	 role	 of	 epitope	 contacting	 residue	 18.	 Antibody-mediated	 immune	selection	contributed	therefore	for	the	PSP	acting	at	both	sites.										
		
Figure	6.8	Mapping	of	the	influenza	2009	pandemic	N1	neuraminidase	sites	under	positive	selective	pressure	onto	the	three-dimensional	structure	of	the	protein	globular	head	domain.	The	figures	were	generated	and	annotated	as	described	in	Figure	6.5,	using	the	structure	file	of	the	neuraminidase	globular	head	domain	 from	 the	 A(H1N1)pdm09	 reference	 virus	 A/California/04/2009	 (PDB	 ID:	 3NSS;	 only	 one	 globular	 head	 of	 the	 two	described	in	the	file	is	shown).				The	 275H/Y	 was	 the	 only	 amino	 acid	 polymorphism	 detected	 at	 site	 275	 (Table	 6.3),	evidencing	 that	 positive	 directional	 selection	 was	 operating	 at	 the	 site,	 favouring	 the	substitution	 towards	 the	 amino	 acid	 residue	 conferring	 resistance	 or	 (H)RI.	 All	 other	positively	 selected	 sites	 presented	 2	 to	 4	 different	 amino	 acid	 variants	 at	 very	 low	frequencies	 (0.03%	 to	 1.1%),	 suggesting	 positive	 diversifying	 selection.	 The	 RI-conferring	 S247G	 and	 the	 synergistic	 S247N	 amino	 acid	 substitutions	were	 among	 the	polymorphisms	detected	at	site	247.	However,	this	latter	was	never	found	in	combination	with	NA	H275Y.			Site	 275	was	 under	 PSP	 in	 both	 (pre-)pandemic	 and	 post-pandemic	 period,	with	 SLAC	and	FEL	site-specific	values	suggesting	a	stronger	PSP	in	the	former	period,	during	which	NAI	drugs	were	more	widely	used	(lower	p-value;	greater	dN-dS	scaled	or	dN/dS	value)	
TOTAL DATASET 
(Pre-)Pandemic period Post-pandemic period 
TEMPORAL SUB-DATASETS 
275 
247 
450 
95 
275 275 
247 
454 
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(Table	 6.3).	 Site	 247	was	 otherwise	 only	 positively	 selected	 during	 the	 post-pandemic	period.	 None	 of	 the	 other	 sites	 under	 PSP	 in	 the	 two	 time	 periods	 is	 located	 near	 the	active	 site,	 lying	 either	 at	 the	 stalk	 domain	 (sites	 46	 and	 74)	 or	 at	 the	 surface	 of	 the	globular	head	domain	(site	454;	Figure	6.8).			
6.1.3.3	Selective	Pressure	Profile	of	the	Sites	Associated	with	Resistance	or	(Highly)	Reduced	
Inhibition	by	Neuraminidase	Inhibitors	and/or	Contacting	with	the	Drug	(Active	Site)	
	Most	 amino	acid	 substitutions	 conferring	 resistance	or	 (H)RI	by	NAI	drugs	or	having	 a	synergistic	effect	on	the	level	of	inhibition	caused	are	influenza	type-	or	subtype-specific.	The	 SP	 profile	 of	 the	 sites	 at	 which	 these	 substitutions	 occur	 and	 of	 further	 sites	contacting	 directly	 or	 indirectly	 with	 the	 drug	 (NA	 active	 site),	 are	 therefore	 showed	separately	by	influenza	NA	type	or	subtype	(N1,	N2,	and	influenza	B)	in	Figure	6.9	(A,	B,	and	C,	respectively).		N1	NA	sites	from	either	former	or	current	circulating	A(H1N1)	subtypes	associated	with	NAI	resistance	or	(H)RI	and/or	contacting	with	the	drug	were	essentially	under	negative	selection	(majority)	or	experiencing	a	not	significant	(n.s.)	dN/dS<1	during	the	total	time	period.	 In	 fact,	 several	 sites	 presented	 the	 same	 profile	 in	 both	 subtypes,	 particularly	those	under	NSP	(Figure	6.9A).	Site	275	was	also	under	PSP	in	both	subtypes,	as	detailed	above	in	sections	6.1.3.2.1	(seasonal	A(H1N1))	and	6.1.3.2.5	(A(H1N1)pdm09).	Site	247	associated	 with	 NAI	 (H)RI	 in	 exclusively	 A(H1N1)pdm09	 subtype	 was	 also	 under	 PSP	(detailed	in	section	6.1.3.2.5).	Few	sites	were	found	to	be	experiencing	an	n.s.	dN/dS>1,	including	sites	70,	117	and	155	in	seasonal	N1	NA,	and	site	199	in	2009	pandemic	N1	NA	(Figure	 6.9A).	 The	 single	 or	 at	 least	 one	 of	 the	 amino	 acid	 substitutions	 at	 these	 sites	known	 to	 confer	 or	 enhance	 (H)RI	were	 among	 the	polymorphism(s)	 identified	 (N70S,	I117M,	Y155H;	D199G/N)(presented	below	in	Figure	6.11A).	Temporal	splitting	revealed	that	 seasonal	 N1	 NA	 sites	 119	 and	 228	 maintained	 the	 same	 SP	 profile	 across	 the	different	time	periods.	All	other	sites	in	seasonal	N1	NA	experienced	varied	profiles	but	with	no	similar	or	particular	 trend	 that	could	be	associated	with	 the	differences	 in	NAI	drug	 use	 defined	 by	 the	 different	 time	 periods	 (Figure	 6.9A).	 It	 is	 possible	 that	 the	different	 size	 of	 sequence	 sub-datasets	may	 be	 contributing	 for	 some	 of	 the	 variations	observed,	as	evidenced	by	 the	higher	number	of	 conserved	sites	before	1999	and	 from	
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2009	onwards	(smaller	sub-datasets),	and	the	higher	similarity	of	the	1999	to	2008	and	total	time	period	SP	profiles	(Figure	6.9A).		Also,	the	very	short	time	period	covered	from	2009	onwards	(2	years),	due	to	the	rapid	replacement	by	the	new	pandemic	virus,	may	have	 contributed	 for	 the	 conserved	 status	 of	 several	 sites.	 In	 A(H1N1)pdm09	 subtype,	most	 sites	maintained	 the	 same	 SP	profile	 in	both	 (pre-)	 pandemic	 and	post-pandemic	periods	 (Figure	 6.9A).	 Also,	 the	 variations	 observed	 involved	 essentially	 a	 change	between	significant	and	n.s.	dN/dS<1.	Only	 for	sites	136	and	151	 the	change	was	more	pronounced,	from	significant	or	n.s.	dN/dS<1	to	n.s.	dN/dS>1.			 	
	 	
Before&1999 1999&)&2008 From&2009&onwards (Pre))pandemic&period Post)pandemic&period70 !&RI&ZA&(N1) ! ! !117 !&E119V&ZA;&N295S+H275Y&OS+ZA&(N1) ! ! !118 "119  !&(H)RI&OS+ZA+PER&(N1+N1pdm09)&/&(H)RI&LAN&(N1pdm09)&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&
!&H275Y&PER&(N1pdm09) * * *136 !&(H)RI&ZA+PER&(N1+N1pdm09)&/&RI&LAN&(N1pdm09) * *151 " !&RI&ZA+PER&(N1pdm09)&&!&H275Y&OS+ZA+PER&(N1) *152 " *155 !&(H)RI&OS+ZA+PER&(N1) ! ! !156 179 180 199  !&RI&OS&(N1pdm09)&&!&H275Y&OS&(N1pdm09) *223  !&RI&OS+ZA+PER&(N1pdm09)&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&
!&H275Y&PER;&N295S+H275Y&OS+ZA&(N1)&/&H275Y&ZA+PER&(N1pdm09) *225 "228  *247 !&RI&OS&(N1pdm09)&&!&H275Y&OS+ZA+PER&(N1pdm09) ! ! ! !275 &&&&&&&&&R&OS;&(H)RI&OS+PER&(N1+N1pdm09) *277 " *278 293 " !&RI&ZA&(N1) *295  !&(H)RI&OS+PER&(N1)&/&HRI&OS;&RI&PER&(N1pdm09)313&a !&RI&OS+ZA&(N1pdm09) ! ! ! ! *325 !&RI&OS&(N1pdm09) ! ! ! ! *368 " *402 " *425 427&a !&RI&OS+ZA&(N1pdm09) ! ! ! !
A#!"N1"NEURAMINIDASE
Codon&site Characteristics FORMER(SEASONAL(A(H1N1) A(H1N1)pdm09TOTAL&DATASET TEMPORAL&SUB)DATASETS TOTAL&DATASET TEMPORAL&SUB)DATASETS
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B"(cont.)"!"N2"NEURAMINIDASE"(A(H3N2))
Codon&site Characteristics TOTAL&DATASET TEMPORAL&SUB)DATASETSBefore&1999 1999&)&2008 From&2009&onwards41 !&RI&OS * *118 "119  !&(H)RI&OS;&RI&ZA * *136 !&(H)RI&ZA148 !&E119V&OS+ZA+PER+LAN151 " !&RI&OS;&(H)RI&ZA *152 "156 178 179 198 
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Figure	6.9	Selective	pressure	profile	of	the	sites	associated	with	neuraminidase	inhibitor	resistance	or	(highly)	reduced	 inhibition	and/or	contacting	with	 the	drug	(active	site)	 in	human	 influenza	N1	(A),	N2	(B)	and	B	(C)	neuraminidase,	in	total	and	temporal	sequence	(sub-)datasets.	NA:	Neuraminidase;	NAI:	NA	inhibitor;	RI:	Reduced	inhibition;	HRI:	Highly	reduced	inhibition;	(H)RI:	RI	or	HRI;	OS:	Oseltamivir;	ZA:	Zanamivir;	PER:	Peramivir;	LAN:	Laninamivir		
Before	1999 1999	-	2008 From	2009	onwards Before	1999 1999	-	2008 From	2009	onwards71a ê	RI	PER+LAN *105 ê	RI	OS+ZA+LAN;	(H)RI	PER *114 ê	RI	PER116 n117  ê	(H)RI	OS+ZA;	HRI	PER+LAN134 ê	RI	PER138 ê	RI	ZA+LAN;	(H)RI	PER * *139 ê	(H)RI	OS+ZA+PER+LAN *140 ê	(H)RI	OS+ZA+PER+LAN142 ê	RI	PER * *145	b ê	RI	OS;	HRI	PER * * *148c ê	RI	PER149 n ê	RI	PER150 n ê	HRI	OS+PER;	(H)RI	ZA *151 ê	RI	ZA *154  * *177 178  *197  ê	(H)RI	OS+PER;	RI	ZA200 ê	RI	OS+ZA221  ê	(H)RI	OS+PER;	RI	ZA+LAN *223 n226  * *245 ê	RI	OS+ZA+PER *264 ê	RI	PER *273 ê	RI	OS;	(H)RI	PER * * *275 n *276  *292 n ê	HRI	OS+PER;	RI	ZA294  ê	(H)RI	OS;	RI	PER343c ê	RI	PER * *360 ê	HRI	PER * *374 n ê	HRI	OS+PER;	(H)RI	ZA * *395 ê	RI	OS+PER *407 ê	RI	PER * * *409 n * * *428  * *432 ê	RI	PER439a ê	RI	PER+LAN *440 ê	RI	PER449 ê	RI	PER * *
C	-	INFLUENZA	B	NEURAMINIDASE
Codon	site Characteristics B/VICTORIA B/YAMAGATATOTAL	DATASET TEMPORAL	SUB-DATASETS TOTAL	DATASET TEMPORAL	SUB-DATASETS
! Functional*residue*NA*active*site  Framework*residue*NA*active*site Associated*with*NAI*clinical*resistance*and*(H)RI*in#vitro!
! Associated*with*(H)RI*by*NAIs*in#vitro ! Associated*with*a*synergistic*effect*on*NAI*(H)RI Conserved)(dN=0;)dS=0)
Positively*selected Not*significant*dN/dS>1 dN/dS*≈1 Negatively*selected* Not*significant*dN/dS<1
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	(Footnotes	Figure	6.9	cont.)	Site-specific	 selective	 pressure	 profiles	 were	 determined	 through	 consensus-based	 inference	 of	 Single-Likelihood	 Ancestor	Counting	(SLAC)	and	Fixed	Effects	Likelihood	(FEL)	individual	results.	When	no	consensus	was	verified,	 it	was	considered	the	result	got	by	FEL	method,	except	in	the	case	of	positively	or	negatively	selected	sites	that	were	only	validated	under	consensus.	Individual	results	are	indicated	with	an	asterisk	(*).	Functional	and	framework	NA	active	site	residues	were	defined	according	to	Colman	 et	 al.	 19,	 while	 the	 association	 to	 NAI	 resistance	 or	 (H)RI	 was	 based	 on	WHO	 8	 and	WHO	 16.	Panel	 A:	 a	 Only	 when	combined	with	each	other	(Q313K+I427T),	 individual	phenotype	not	known;	Panel	C:	 a	Only	when	combined	with	each	other	(V71A+H439R),	individual	phenotype	not	known;	b	Only	in	combination	with	site	142	(Y142H+G145R),	individual	phenotype	of	G145R	amino	acid	substitution	not	known;	 c	Only	when	combined	with	each	other	(G148R+K343E),	 individual	phenotype	not	known.			Most	 N2	 NA	 sites	 associated	 with	 NAI	 resistance	 or	 (H)RI	 and/or	 contacting	 with	 the	drug	were	 under	 negative	 selection	 in	 both	 total	 and	 at	 least	 one	 of	 the	 different	 time	periods	analysed	(temporal	splitting)	(Figure	6.9B).	When	not	negatively	selected,	these	sites	were	 found	 to	be	experiencing	an	n.s.	dN/dS<1.	The	positive	selection	detected	at	sites	148	 and	151	 contrasted	with	 this	 overall	 scenario.	As	detailed	 above	 (see	 section	6.1.3.2.2),	both	sites	were	under	PSP	in	the	total	time	period	and,	specifically,	since	NAI	introduction	 into	clinic	 (1999	 -	2008,	and	 from	2009	onwards).	 Site	148	experienced	a	greater	change,	as	was	initially	under	n.s.	dN/dS<1	(before	1999;	Figure	6.9B).		Influenza	B	NA	sites	associated	with	NAI	resistance	or	(H)RI	and/or	contacting	with	the	drug	 were	 essentially	 under	 negative	 selection	 for	 B/VIC	 lineage	 and	 either	 under	negative	selection	or	experiencing	an	n.s.	dN/dS<1	 for	B/YAM	lineage,	 in	 the	 total	 time	period	analysed	(Figure	6.9C).	Site	395	was	the	only	under	PSP	and	in	exclusively	B/VIC-lineage,	as	detailed	above	in	section	6.1.3.2.3.	Few	sites	were	found	to	be	experiencing	an	n.s.	dN/dS>1,	including	sites	71	and	149	in	B/VIC-lineage	NA,	and	sites	71,	395	and	449	in	B/YAM-lineage	NA.	Only	V71A	and	D149N	amino	acid	substitutions	known	to	confer	RI	 were,	 however,	 among	 the	 polymorphisms	 identified	 (presented	 below	 in	 Figure	6.11C).	 Temporal	 splitting	 revealed	 an	 overall	 variation	 in	 the	 SP	 profile	 of	 the	 sites	across	 the	 different	 time	periods	 (Figure	 6.9C),	 but	with	 no	 similar	 or	 particular	 trend	that	 could	 be	 explained	 by	 the	 underlying	 differences	 on	 NAI	 drug	 use.	 The	 only	exception	was	site	395	that,	although	already	experiencing	an	n.s.	dN/dS>1	before	1999,	started	to	be	positively	selected	after	the	licensing	of	NAI	drugs	(see	section	6.1.3.2.3	for	detail).	The	higher	number	of	conserved	sites	before	1999	for	both	influenza	B	lineages	was	most	probably	a	result	of	the	much	smaller	size	of	the	sequence	sub-dataset.		
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6.1.3.4	 Overall	 Profiling	 of	 Site-Specific	 Selective	 Pressures	 in	 Human	 Influenza	 Virus	
Neuraminidase			The	site-specific	SP	profiles	obtained	for	the	entire	coding	region	of	the	different	human	influenza	 NA	 subtypes	 or	 lineages	 during	 the	 total	 time	 period	 (total	 datasets),	 were	aligned	 using	 N2	 codon	 coordinates	 (standard	 numbering	 scheme)	 (Figure	 6.10).	 This	not	only	allowed	to	have	an	overall	picture	of	the	site-specific	SP	acting	on	influenza	NA	but	also	to	compare	SP	profiles	of	particular	sites	or	regions	across	the	different	subtypes	or	lineages	of	human	influenza	NA.	Seven	regions	within	the	NA	catalytic	globular	head	domain	were	found	to	be	comprised	by	 6	 or	more	 sites	 experiencing	 significant	 (negatively	 selected)	 or	 n.s.	 dN/dS<1	 in	 all	different	virus	subtypes	or	lineages.	Specifically,	regions	(1)	87-92;	(2)	164-171;	(3)	177-186;	(4)	227-233;	(5)	254-261;	(6)	275-284;	and	(7)	297-307	(N2	coordinates)	(Figure	6.10).	Considering	that	many	of	the	amino	acid	substitutions	at	these	sites	are	likely	to	be	intolerable,	 particularly	 those	 at	 negatively	 selected	 sites	 20,	 these	 regions	 may	 be	suitable	for	drug	targeting.	In	fact,	region	227-233	(region	4)	is	partially	included	in	the	only	 universally	 conserved	 region	 among	 influenza	 A	 and	 B	 viruses	 (region	 222-230).	This	conserved	region	has	been	pinpoint	as	a	potential	new	target	for	NAI	drugs	21.		The	150-cavity	 loop	has	also	been	considered	as	an	attractive	 target	 for	antiviral	 therapy	22	but	 all	 sites	 within	 this	 region	 except	 one	 (site	 152)	 were	 found	 to	 be	 under	 positive	selection	or	experiencing	an	n.s.	dN/dS>1	for	at	least	one	virus	subtype	or	lineage.			
	
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47
A(H3N2) * * * − − − * * * *
A(H1N1) * * * − * * * * *
A(H1N1)pdm09 * * * * − * * * * * * *
B/Victoria * − − − − * * * * * * * * * *
B/Yamagata − − − − * * * * * * * * * *
!
48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97
A(H3N2) * * * * * *
A(H1N1) * * * * * − − *
A(H1N1)pdm09 * * * * * * * * * * * − − * *
B/Victoria * * * − − − −
B/Yamagata * * − − − − * * *
! !
98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144
A(H3N2) − − − * * *
A(H1N1) * * * − − − * * * * * * *
A(H1N1)pdm09 − − − * * * * *
B/Victoria * * * * * * * *
B/Yamagata * * * * * * * *
!
145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193
A(H3N2) − *
A(H1N1) * * * * * * * *
A(H1N1)pdm09 * * * * * * *
B/Victoria * * *
B/Yamagata * * * * * * * *
! ! !
194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243
A(H3N2) * * * *
A(H1N1) * * * * *
A(H1N1)pdm09 * * * * * * *
B/Victoria * * * * * * * * * *
B/Yamagata * * * * * * *
Influenza A and B highly conserved region 
150-cavity loop 
1"
2" 3"
4"
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Figure	6.10	Overall	mapping	of	site-specific	selective	pressure	profiles	across	the	different	subtypes	or	lineages	of	human	influenza	virus	neuraminidase.	The	 different	 human	 influenza	 virus	 neuraminidase	 (NA)	 site-specific	 selective	 pressure	 (SP)	 profiles	were	 aligned	 using	N2	codon	 coordinates	 (standard	 numbering	 scheme).	 The	 profiles	 were	 determined	 as	 described	 in	 Figure	 6.9,	 using	 total	 NA	sequence	datasets	(total	time	period).	Similarly,	individual	results	are	indicated	with	an	asterisk	(*).	Functional	and	framework	NA	 active	 site	 residues	 were	 defined	 according	 to	 Colman	 et	 al.	 19;	 while	 calcium	 binding	 site	 and	 disulfide	 bound	 cysteine	residues	were	 based	 on	 Air	 23,	 and	 on	 Colman	 and	Ward	 11	 and	 Colman	 9,	 respectively.	 	 The	 blue	 rectangles	 highlight	 the	 7	regions	 that,	 based	on	 their	 site-specific	 SP	profiles	 ((not)	 significant	dN/dS<1),	may	 constitute	potential	 new	 targets	 for	NA	inhibitor	drugs.					
6.1.4	 Differential	 Analysis	 of	 Site-by-Site	 Selective	 Pressures	 Among	 Different	
Contexts	of	Neuraminidase	Inhibitor	Drug	Use	(temporal	sub-datasets)		
	Differential	 site-by-site	 SP	 analysis	 allowed	 to	 identify	which	 sites	within	 the	 different	human	 influenza	 NA	 subtypes	 or	 lineages	 experienced	 distinct	 SP	 among	 the	 different	time	 periods	 analysed	 (temporal	 sub-datasets).	 Considering	 that	 the	 different	 time	periods	 represented	different	 contexts	of	 global	NAI	drug	use,	 it	were	only	analysed	 in	detail	 the	 differentially	 selected	 sites	 associated	 with	 NAI	 resistance	 or	 (H)RI	 and/or	contacting	directly	or	 indirectly	with	the	drug	(NA	active	site).	A	 list	of	all	differentially	selected	sites	can	be	found	at	Supplementary	data,	Tables	S6.1	to	S6.5.		
Positively*selected Not*significant*dN/dS>1 dN/dS*≈1 Negatively*selected* Not*significant*dN/dS<1 Conserved*(dN=0;*dS=0)
! Functional*residue*NA*active*site  Framework*residue*NA*active*site " Calcium*binding*site*residue # Dissulfide*bond*cysteine*residue
! ! ! !
244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292
A(H3N2) * − *
A(H1N1) * * − *
A(H1N1)pdm09 * * * * * * −
B/Victoria * * * * *
B/Yamagata * * * * * *
" " ! " !
293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342
A(H3N2) * *
A(H1N1) * − * * * − − − *
A(H1N1)pdm09 − * * * − − * − * *
B/Victoria * * * * * * * * − *
B/Yamagata * * * * * * −
" "
343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385
A(H3N2) * − − − − − * * * − − *
A(H1N1) * * * − − − − − − − *
A(H1N1)pdm09 * * * − − − − − * * − −
B/Victoria * − * * *
B/Yamagata * * − * * * * *
! !
386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431
A(H3N2) * * * − − − − *
A(H1N1) − * * * *
A(H1N1)pdm09 − * * * * * *
B/Victoria * − − * − − − − * *
B/Yamagata * * * * * − − − − − − * * *
!
432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469
A(H3N2) * * * * −
A(H1N1) * * * * * * * * *
A(H1N1)pdm09 * * − * * * * * * * * * *
B/Victoria * − − − * * − − − −
B/Yamagata * * − − − * * * * * * * * − − − −
430-cavity loop 
5" 6"
7"
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Site	275	of	seasonal	N1	NA	was	found	to	be	experiencing	stronger	SP	(S_SP)	in	both	1999	to	2008	and	from	2009	onwards	time	periods,	compared	to	before	1999	(Table	6.4).		This	was	 in	agreement	with	the	variation	observed	 in	 its	SP	profile	across	the	different	time	periods,	 from	n.s.	dN/dS<1	 to	positively	 selected	and	 then	 to	n.s.	 	dN/dS>1	(see	Figure	6.9A).	However,	as	above-mentioned,	it	 is	possible	that	differences	in	the	strength	of	SP	acting	at	this	site	may	be	just	an	artefact	of	the	worldwide	spread	of	a	NA	H275Y	drug-resistant	seasonal	A(H1N1)	variant	since	late	2007.			
Table	 6.4	 Differentially	 selected	 sites	 in	 former	 seasonal	 A(H1N1),	 A(H3N2),	 B/Victoria	 and	B/Yamagata-lineage	 virus	 neuraminidase	 associated	 with	 neuraminidase	 inhibitor	 resistance	 or	(highly)	reduced	inhibition	and/or	contacting	with	the	drug	(active	site).		
	vs:	versus;	dN:	rate	of	non-synonymous	substitutions;	dS:	rate	of	synonymous	substitutions;	DIF:	Difference;	R:	Resistance;	HRI:	Highly	reduced	inhibition;	RI:	Reduced	 inhibition;	 (H)RI:	HRI	or	RI;	OS:	Oseltamivir;	ZA:	Zanamivir;	PER:	Peramivir;	LAN:	Laninamivir;	S_SP:	Stronger	Selective	Pressure;	W_SP:	Weaker	Selective	Pressure;	inf:	infinite	(dS=0)	Symbol	legend:		
		Site-by-site	 selective	 pressures	 (SP)	 acting	 on	 influenza	 neuraminidase	 (NA)	 gene	 from	 two	 different	 time	 periods	 were	compared	in	HyPhy,	using	the	Muse-Gaut	94	model	crossed	with	the	model	described	as	012340	and	previously	determined	by	Akaike’s	Information	Criterion	as	the	best	time	reversible	model	for	NA	gene.	The	dash	(-)	represents	no	significant	difference	in	the	SP	between	that	specific	time	periods,	while	significant	differences	involving	stronger	SP	are	highlighted	in	bold	and	italic.	A	list	 of	 all	 differentially	 selected	 sites	 within	 the	 different	 human	 influenza	 NA	 subtypes	 and	 lineages	 can	 be	 found	 at	Supplementary	data,	Tables	S6.1	to	S6.4.			N2	NA	site	148	was	also	 found	to	be	experiencing	S_SP	 in	both	1999	to	2008	and	 from	2009	onwards	time	periods,	compared	to	before	1999.	A	S_SP	was	also	detected	at	site	41	of	N2	NA	but	only	in	the	period	of	increased	NAI	drug	use	(from	2009	onwards)	(Table	6.4).	 The	 significant	 differences	 at	 site	 148	 were	 in	 complete	 agreement	 with	 the	variation	 previously	 observed	 in	 its	 SP	 profile,	 from	 n.s.	 dN/dS<1	 before	 1999	 to	positively	 selected	 in	 both	 1999	 to	 2008	 and	 from	 2009	 onwards	 time	 periods	 (see	Figure	6.9B	above).	
p"value dN/dS_1" dN/dS_2 DIF p"value dN/dS_2" dN/dS_3 DIF p"value dN/dS_1" dN/dS_3 DIFFormer"seasonal"A(H1N1) 275 !!!! """""""""R"OS;"HRI"OS+PER 0.00061 1.02EG09 12.65 S_SP − − − − 0.012 0.00 inf S_SP41 !!! ""RI"ZA − − − − − − − − 0.042 0.14 0.79 S_SP148 !!!! ""E119V"OS+ZA+PER+LAN 0.012 0.18 5.22 S_SP − − − − 0.0019 0.18 14.64 S_SPB/Victoria 294 !!!!  ""(H)RI"OS;"RI"PER − − − − 0.053 0.50 0.00 W_SP − − − −154 !!!!  − − − − 0.050 0.00 inf S_SP − − − −197 !!!!  ""(H)RI"OS+PER;"RI"ZA − − − − 0.050 inf 0.32 W_SP − − − −
From"2009"onwards"(3) From"2009"onwards"(3)
A(H3N2)
B/Yamagata
Influenza"virus"subtype"or"lineage Codon"site Site"characteristics
Before"1999"(1) 1999G2008"(2) Before"1999"(1)
vs vs vs1999G2008"(2)
!
!!! Stalk&domain !!!! Catalytic&globular&head&domain Associated&with&NAI&clinical&resistance&and&(H)RI&in#vitro!
! Associated*with*(H)RI*by*NAIs*in#vitro ! Associated*with*a*synergistic*effect*on*NAI*(H)RI
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Influenza	 B	 NA	 sites	 associated	with	 NAI	 (H)RI	 and/or	 contacting	with	 the	 drug	were	only	differentially	selected	between	1999	to	2008	and	from	2009	onwards,	in	both	B/VIC	and	 B/YAM	 lineages.	 Sites	 294	 and	 197	 in,	 respectively,	 B/VIC	 and	 B/YAM-lineage	NA	were	found	to	be	experiencing	weaker	SP	(W_SP)	in	the	period	of	increased	NAI	drug	use	(from	2009	onwards),	while	 the	 converse	was	observed	 for	 site	 154	 in	B/YAM-lineage	NA	(S_SP)	(Table	6.4).		Regarding	 A(H1N1)pdm09	 virus	 NA,	 sites	 136,	 247	 and	 295	 were	 identified	 as	differentially	 selected	 between	 the	 (pre-)pandemic	 and	 post-pandemic	 periods	 (Table	6.5).	All	three	sites	experienced	S_SP	in	the	latter	period,	during	which	NAI	drug	use	was	lower.	 Also,	 evidence	 for	 differential	 selection	 was	 considerably	 stronger	 for	 site	 136	(lower	p	value).	These	significant	differences	were	noted	in	the	SP	profile	of	the	sites	in	each	 time	 period	 (see	 Figure	 6.9A),	 except	 for	 site	 295	 that	 was	 continually	 under	negative	selection.			
Table	 6.5	 Differentially	 selected	 sites	 in	 2009	 pandemic	 N1	 NA	 associated	 with	 neuraminidase	inhibitor	resistance	or	(highly)	reduced	inhibition	and/or	contacting	with	the	drug	(active	site).						
	dN:	 rate	 of	 non-synonymous	 substitutions;	 dS:	 rate	 of	 synonymous	 substitutions;	 DIF:	 Difference;	HRI:	 Highly	 reduced	 inhibition;	 RI:	 Reduced	inhibition;	OS:	Oseltamivir;	ZA:	Zanamivir;	PER:	Peramivir;	LAN:	Laninamivir;	S_SP:	Stronger	Selective	Pressure;	W_SP:	Weaker	Selective	Pressure;	inf:	infinite	(dS=0)	Symbol	legend:					 	
	Site-by-site	 selective	 pressures	 (SP)	 in	 the	 two	 different	 time	 periods	 were	 compared	 as	 described	 in	 Table	 6.5.	 Significant	differences	involving	stronger	SP	are	highlighted	in	bold	and	italic.	A	list	of	all	differentially	selected	sites	within	2009	pandemic	N1	NA	is	presented	in	Table	S6.5,	Supplementary	data.			
6.1.5	Frequency	of	amino	acid	substitutions	conferring	or	enhancing	neuraminidase	
inhibitor	 resistance	 or	 (highly)	 reduced	 inhibition	 in	 vitro	 in	 sequence	 databases	
(complementary	study)	
	As	an	 important	complement	 to	all	data	generated	 throughout	 this	PhD	study,	 total	NA	sequence	datasets	were	further	examined	to	determine	the	frequency	of	the	amino	acid	
(Pre%)Pandemic-period Post%pandemic-period136 !!!! -"-HRI-ZA+PER;-RI-LAN 0.00090 0.00 2.30 S_SP247 !!!! "-RI-OS-- -"-H275Y-ZA+PER 0.047 2.26 inf S_SP295 !!!!  "-HRI-OS;-RI-PER 0.019 0.00 0.22 S_SP
Codon-site Site-characteristics p-value dN/dS DIF
!!!! Catalytic(globular(head(domain " Associated(with((H)RI(by(NAIs(in#vitro " Associated(with(a(synergistic(effect(on(NAI((H)RI
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substitutions	 known	 to	 confer	 or	 enhance	 NAI	 resistance	 or	 (H)RI	 in	 each	 human	influenza	 virus	 type	 or	 subtype	 (based	 on	 WHO	 8	 and	 WHO	 16).	 Total	 NA	 sequence	datasets	 were	 obtained	 by	 merging	 the	 temporal	 sub-datasets	 constructed	 with	 all	potentially	 complete	 NA	 coding	 sequences	 available	 at	 GISAID	 EpiFlu™	 and	 NCBI	Influenza	Virus	Resource	databases	(detailed	in	section	3.1.6,	Material	and	Methods).	The	frequency	 at	 which	 the	 amino	 acid	 substitutions	 were	 detected	 is	 presented	 in	 Figure	6.11,	separately	by	NA	type	and	subtype	(N1	(A);	N2	(B);	and	influenza	B	(C)).	Only	the	substitutions	identified	in	at	least	one	sequence	are	indicated.			Most	 amino	 acid	 substitutions	 conferring	 or	 enhancing	 NAI	 resistance	 or	 (H)RI	 in	seasonal	 A(H1N1)	 subtype	 were	 identified	 at	 a	 frequency	 lower	 than	 0.5%	 (0.1%	 to	0.4%;	1	to	7	sequences)	(Figure	6.11A).	The	only	exceptions	were	the	N70S	and	H275Y	substitutions	 that	were	present	 in,	 respectively,	27	(1.8%)	and	585	(38.4%)	sequences.	The	 much	 higher	 frequency	 of	 H275Y	 substitution	 was	 already	 expected,	 giving	 the	worldwide	 spread	 of	 an	 NA	 H275Y	 drug-resistant	 variant.	 	 NA	 D151G	 and	 I223V	substitutions	were	identified	together	with	H275Y	in	one	sequence,	constituting	the	only	synergistic	 combinations	 identified.	The	synergistic	 I117V	substitution	and	both	E119V	and	R293K	substitutions	conferring	(H)RI	were	not	identified	in	any	of	the	sequences.		The	amino	acid	substitutions	conferring	or	enhancing	NAI	resistance	or	(H)RI	in	current	circulating	A(H1N1)	viruses	(A(H1N1)pdm09)	were	essentially	identified	at	a	frequency	of	0.1%	or	 less	 (5	or	 less	sequences)	 (Figure	6.11A).	Exceptions	 include	 the	synergistic	D199N	 and	 S247N	 substitutions	 that	 were	 present	 in,	 respectively,	 18	 (0.5%)	 and	 31	(0.9%)	sequences;	and	the	H275Y	substitution	that	was	found	in	146	sequences	(4.3%).	However,	 neither	 D199N	 nor	 S247N,	 as	 well	 as	 none	 of	 the	 remaining	 synergistic	substitutions,	were	identified	together	with	the	mutation	conferring	the	(H)RI	phenotype	(H275Y;	 N295S+H275Y).	 Similarly,	 Q313K	 substitution	was	 identified	 in	 22	 sequences	(0.6%)	 but	 in	 none	 existed	 together	 with	 I427T	 (not	 detected;	 0.0%),	 being	 the	combination	of	both	amino	acid	changes	that	is	known	to	confer	RI.	In	addition	to	I427T,	the	E119V/D	and	D199E	substitutions	conferring	(H)RI	were	not	detected	in	any	of	the	sequences.		
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Figure	 6.11	 Frequency	 of	N1	 (A),	 N2	 (B)	 and	 influenza	B	 (C)	 neuraminidase	 amino	 acid	 substitutions	 conferring	 or	 enhancing	 neuraminidase	 inhibitor	 resistance	 or	(highly)	reduced	inhibition	in	vitro	in	sequence	databases.		NAI:	Neuraminidase	inhibitor;	RI:	Reduced	inhibition;	HRI:	Highly	reduced	inhibition;	(H)RI:	RI	or	HRI;	OS:	Oseltamivir;	ZA:	Zanamivir;	PER:	Peramivir;	LAN:	Laninamivir	Symbol	legend:		 	Associated*with*NAI*clinical*resistance*and*(H)RI*in#vitro ! Associated*with*(H)RI*by*NAIs*in#vitro ! Associated*with*a*synergistic*effect*on*NAI*(H)RI!
Codon%site Amino%acid%substitution NAI%susceptibility%profile A(H3N2)((((((((((((((((((((((((((((((((((((((((((((((N=3712;%1968A2013)41 E41G !%RI%OS 0.05%(2)E119D !%RI%ZA 0.05%(2)E119V !%(H)RI%OS 0.2%(8)136 Q136K !%(H)RI%ZA 0.2%(7)148 T148I !%E119V%OS+ZA+PER+LAN 2.7%(102)D151E !%RI%OS 0.8%(30)D151V !%HRI%ZA 0.2%(8)D151A !%RI%ZA 0.08%(3)D151G !%HRI%ZA 1.9%(70)222 I222T !%RI%OS 0.1%(5)226 Q226H !%RI%OS 0.05%(2)292 R292K !%(H)RI%OS+ZA+PER 0.08%(3)
119
151
B"!"N2"NEURAMINIDASE Codon%site Amino%acid%substitution NAI%susceptibility%profile B/VICTORIA%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%(N=1978;%1972?2013) B/YAMAGATA----------------------------(N=1441;%1973?2013)71 V71Aa !%RI%PER+LAN 0.0%(0) 0.1%(2)%(0.0*%(0))105 E105K !%RI%OS+ZA+LAN;%(H)RI%PER 0.2%(4) 0.0%(0)117 E117A !%HRI%OS+ZA+PER+LAN 0.0%(0) 0.07%(1)134 H134Y !%RI%PER 0.05%(1) 0.0%(0)Q138R !%RI%ZA+LAN;%(H)RI%PER 0.05%(1) 0.0%(0)Q138K !%RI%PER 0.05%(1) 0.0%(0)139 P139S !%(H)RI%OS+ZA+PER+LAN 0.05%(1) 0.0%(0)140 G140R !%(H)RI%OS+ZA+PER+LAN 0.05%(1) 0.0%(0)142 Y142H !%RI%PER 0.05%(1) 0.0%(0)145 G145Rb !%RI%OS;%HRI%PER 0.2%(4)%(0.05*%(1)) 0.0%(0)148 G148Rc !%RI%PER 0.1%(2)%(0.05*%(1)) 0.0%(0)149 D149N !%RI%PER 0.3%(5) 0.0%(0)151 N151S !%RI%ZA 0.0%(0) 0.07%(1)D197E !%RI%OS+ZA+PER 0.0%(0) 0.07%(1)D197N !%RI%OS+ZA+PER 0.05%(1) 0.3%(4)200 A200T !%RI%OS+ZA 0.05%(1) 0.07%(1)I221L !%HRI%OS;%RI%ZA+PER+LAN 0.05%(1) 0.0%(0)I221T !%RI%OS+ZA+PER 0.1%(2) 0.2%(3)I221V !%RI%OS+PER 0.3%(6) 0.0%(0)I221N !%HRI%OS+PER;%RI%ZA 0.05%(1) 0.07%(1)245 A245T !%RI%OS+ZA+PER 0.05%(1) 0.0%(0)264 E264V !%RI%PER 0.05%(1) 0.0%(0)273 H273Y !%RI%OS;%(H)RI%PER 0.0%(0) 0.07%(1)294 N294S !%(H)RI%OS;%RI%PER 0.05%(1) 0.0%(0)343 K343E%c !%RI%PER 2.0%(39)%(0.05*%(1)) 7.1%(102)%(0.0*%(0))360 K360E !%HRI%PER 0.1%(2) 0.0%(0)374 R374K !%HRI%OS+PER;%(H)RI%ZA 0.05%(1) 0.0%(0)395 A395E !%RI%OS+ZA 0.1%(2) 0.0%(0)432 D432G !%RI%PER 0.2%(3) 0.0%(0)439 H439R%a !%RI%PER+LAN 0.1%(2)%(0.0*%(0)) 0.0%(0)
138
197
221
C"!"INFLUENZA"B"NEURAMINIDASECodon%site Amino%acid%substitution NAI%susceptibility%profile FORMER&SEASONAL&A(H1N1)&&&&&&&&&&&&&&&&&&&&&&&&&&&%%(N=1523;%1943@2010) A(H1N1)pdm09&&&&&&&&&&&&&&(N=3428;%2009@2013)70 N70S !%RI%ZA%(N1) 1.8%(27) @117 I117M !%N295S+H275Y%ZA%(N1) 0.3%(5) @E119A !%RI%OS+ZA+PER+LAN%(N1pdm09) @ 0.03%(1)E119G !%HRI%ZA+LAN;%RI%PER%(N1pdm09)%%%!%H275Y%PER%(N1pdm09) @ 0.03%(1)Q136K !%(H)RI%ZA+PER%(N1+N1pdm09);%RI%LAN%(N1pdm09) 0.4%(7) 0.03%(1)Q136R !%HRI%ZA+PER;%RI%LAN%(N1pdm09) @ 0.1%(5)D151E !%RI%ZA+PER%(N1pdm09) @ 0.06%(2)D151N !%H275Y%OS%(N1) 0.3%(4) @D151G !%H275Y%OS+ZA+PER%(N1) 0.1%(2) @155 Y155H !%(H)RI%OS+ZA+PER%(N1) 0.1%(1) @D199G !%RI%OS%(N1pdm09) @ 0.06%(2)D199N !%H275Y%OS%(N1pdm09) @ 0.5%(18)I223K !%RI%OS%(N1pdm09)%%%!%H275Y%ZA%(N1pdm09) @ 0.03%(1)I223R !%RI%OS+ZA+PER%(N1pdm09)%%%!%H275Y%ZA+PER%(N1pdm09) @ 0.1%(5)I223V !%H275Y%PER%(N1+N1pdm09);%N295S+H275Y%OS+ZA%(N1) 0.1%(2) 0.03%(1)S247G !%RI%OS%(N1pdm09) @ 0.03%(1)S247N !%H275Y%OS+ZA+PER%(N1pdm09) @ 0.9%(31)275 H275Y %%%%%%%%%R%OS;%(H)RI%OS+PER%(N1+N1pdm09) 38.4%(585) 4.3%(146)295 N295S !%(H)RI%OS+PER%(N1)%/%HRI%OS;%RI%PER%(N1pdm09) 0.1%(1) 0.03%(1)313 Q313K%a !%RI%OS+ZA%(N1pdm09) @ 0.6%(22)%(0.0*%(0))325 N325K !%RI%OS%(N1pdm09) @ 0.03%(1)
247
A"!"N1"NEURAMINIDASE
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(Footnotes	Figure	6.11	cont.)	The	 frequency	 of	 the	 amino	 acid	 substitutions	 was	 determined	 in	 total	 neuraminidase	 (NA)	 sequence	 datasets,	 which	 were	obtained	by	merging	the	different	 temporal	sequence	datasets	constructed	with	all	potentially	complete	NA	coding	sequences	available	at	GISAID	EpiFlu™	and	NCBI	Influenza	Virus	Resource	databases	(see	Material	and	Methods,	section	3.1.6	for	detail).	The	specific	number	of	sequences	containing	the	substitution	is	indicated	under	brackets	after	its	frequency.	Both	total	number	of	sequences	enclosed	 in	 the	dataset	and	time	period	covered	are	also	 indicated	under	brackets,	below	the	designation	of	 the	human	influenza	virus	subtype	or	lineage.	NAI	susceptibility	profiles	conferred	by	the	amino	acid	substitutions	were	based	on	WHO	8	and	WHO	16.	Panel	A:	a	RI	when	combined	with	I427T	substitution;	Panel	C:	a	RI	when	combined	with	each	other;	b	(H)RI	when	combined	with	Y142H	substitution;	 c	RI	when	combined	with	each	other.	 In	 the	cases	wherein	 is	a	 combination	of	 two	amino	acid	substitutions	that	confers	 the	(H)RI	phenotype,	 it	 is	 first	 indicated	the	overall	 frequency	at	which	the	substitution	was	detected	and	only	then,	under	brackets	and	highlighted	with	an	asterisk	(*),	the	frequency	at	which	was	identified	with	the	other	substitution.	Amino	acid	substitutions	are	indicated	using	the	influenza	NA	type	or	subtype-specific	numbering	scheme.				Regarding	A(H3N2)	subtype,	most	amino	acid	substitutions	were	present	at	frequencies	that	 varied	 between	 0.05%	 and	 0.2%	 (2	 to	 8	 sequences)	 (Figure	 6.11B).	 NA	 D151E/G	substitutions	 were	 exceptionally	 identified	 in	 30	 (0.8%)	 and	 70	 (1.9%)	 sequences,	respectively.	The	synergistic	T148I	substitution	was	also	identified	in	a	higher	number	of	sequences	 (102	 sequences;	 2.7%),	 but	 only	 in	 one	 existed	 together	 with	 the	 E119V	substitution	conferring	(H)RI	 .	Six	amino	acid	substitutions	known	to	confer	(H)RI	were	not	identify	in	any	of	the	sequences	-	E119I,	I222L,	R224K,	E276D,	N294S,	and	R371K.			Influenza	 B	 NA	 amino	 acid	 substitutions	 conferring	 (H)RI	 were	 identified	 at	 very	 low	frequencies	that	varied	from	0.05%	to	0.3%	(1	to	6	sequences)	for	B/VIC	and	from	0.07%	to	0.3%	(1	to	4	sequences)	 for	B/YAM	lineage	(Figure	6.11C).	Additionally,	many	of	the	substitutions	 were	 only	 present	 in	 B/VIC-lineage	 virus	 sequences.	 The	 K343E	substitution	 was	 identified	 at	 a	 higher	 frequency	 in	 both	 lineages	 (2.0%	 B/VIC;	 7.1%	B/YAM),	 but	 only	 in	 a	 single	 B/VIC-lineage	 virus	 sequence	 (0.05%)	 was	 detected	together	 with	 G148R,	 resulting	 in	 the	 combination	 that	 is	 know	 to	 confer	 RI.	 Several	amino	 acid	 substitutions	 known	 to	 confer	 (H)RI	 were	 not	 detected	 in	 any	 of	 the	sequences	 from	 both	 lineages,	 including	 I114R,	 E117D/G/V,	 R150K,	 D197Y,	 R292K,	G407S,	S440L,	and	M449V	substitutions.	
	
	
6.2	DISCUSSION	
	Global	and	site-specific	SP	acting	on	influenza	NA	were	for	the	first	time	estimated	for	all	virus	 subtypes	 and	 lineages	 circulating	 among	 humans.	 Moreover,	 it	 was	 not	 only	
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considered	a	total	time	period	but	also	different	sub-time	periods	defined	by	differences	on	NAI	global	use.	Total	NA	sequence	datasets	enclosed	a	very	large	number	of	sequences	of	 worldwide	 circulating	 viruses	 that	 exceeded	 3400	 sequences	 for	 A(H3N2)	 and	A(H1N1)pdm09	subtypes	and	varied	between	approximately	1450	and	2000	sequences	for	 seasonal	 A(H1N1)	 and	 influenza	 B/VIC	 and	 B/YAM	 subtype/lineages.	 These	differences	were	in	agreement	with	the	greater	 incidence	rates	and	higher	frequency	of	A(H3N2)	 seasonal	 epidemics,	 comparing	 to	 A(H1N1)	 and	 type	 B	 epidemics,	 and	 the	pandemic	nature	of	A(H1N1)pdm09	viruses	24,25.	All	sequence	datasets	with	exception	of	A(H1N1)pdm09	dataset	also	covered	an	extensive	time	period	that	varied	from	41	to	68	years,	 according	 to	 the	 virus	 subtype	 or	 lineage.	 Such	 large	 number	 of	 sequences	 and	extensive	 time	 period	 were	 only	 analysed	 in	 a	 previous	 study	 conducted	 with	 N1	 NA	sequences	of	A(H1N1)	viruses	 from	different	hosts	and	 for	exclusively	 seasonal	human	influenza	A(H1N1)	subtype	(1735	sequences;	until	2010)	26.	Temporal	NA	sequence	sub-datasets	 varied	widely	 in	 their	 size	 and/or	 time	 period	 covered.	 As	 expected,	 the	 first	temporal	sub-dataset	(before	1999)	contained	a	much	smaller	number	of	sequences	for	all	 virus	 subtypes	 or	 lineages	 (not	 applied	 to	 A(H1N1)pdm09).	 Both	 polymerase	 chain	reaction	 (PCR)	 and	 automated	 Sanger	 sequencing	 technologies	were	only	developed	 in	the	 1980s	 27,28,	 meaning	 that	 all	 sequences	 from	 previously	 circulating	 viruses	 were	obtained	 through	 specific	 retrospective	 studies.	 The	 larger	 size	 of	 A(H3N2)	 and,	particularly,	 influenza	 B/VIC	 and	 B/YAM-lineage	 from	 2009	 onwards	 sub-datasets,	compared	to	1999	to	2008	sub-datasets,	may	be	related	with	the	efforts	that	have	been	made	 since	 the	 2009	 A(H1N1)	 pandemic	 to	 improve	 global	 influenza	 surveillance	 29.	Although	not	uniformly	distributed,	 sequences	 from	all	 years	or	epidemiological	weeks	(A(H1N1)pdm09)	within	 the	 time	period	 covered	and	 from	all	 5	worldwide	 continents	were	 present	 in	 the	 different	 (sub-)datasets.	 Only	 for	 seasonal	 A(H1N1)	 and	 influenza	B/VIC	 and	 B/YAM-lineage	 before	 1999	 sub-datasets	 this	 was	 not	 observed.	 A	 more	detailed	 geographic	 analysis	 showed	 also	 that	most	 (sub-)datasets	 included	 sequences	from	all	18	 influenza	 transmission	zones	established	by	WHO.	Genetic	diversity	of	 total	sequence	 datasets	 ordered	 as	 follows:	 	 A(H3N2)	 >	 seasonal	 A(H1N1)	 >	 B/Victoria	 ≈	B/Yamagata	 >	 A(H1N1)pdm09.	 This	 was	 in	 agreement	 with	 the	 differences	 in	 the	evolutionary	antigenic	drift	of	the	different	human	influenza	NA	types	or	subtypes.	N2	NA	gene	is	known	to	evolve	rapidly	as	a	single	lineage,	followed	by	seasonal	N1	NA	gene	that,	although	 mutating	 at	 a	 similar	 rate,	 has	 been	 experiencing	 weaker	 antigenic	 drift	 30.	Influenza	 B	 NA	 gene	 usually	 evolves	 at	 a	 two	 to	 three	 times	 lower	 rate	 than	 N2	 and	
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seasonal	N1	NA	genes	30;	while	2009	pandemic	N1	NA	gene	has	been	evolving	at	a	very	slow	 rate,	mainly	 as	 a	 result	 of	 a	 relatively	 low	 immunological	 pressure	 (new	 virus	 to	which	 many	 people	 had	 no	 pre-existing	 immunity)	 31.	 	 The	 decreasing	 nucleotide	diversity	of	seasonal	A(H1N1),	A(H3N2)	and,	 in	a	 lesser	extent,	B/VIC-lineage	 temporal	sub-datasets	 was	 probably	 an	 artefact	 of	 their	 different	 size	 and/or	 time	 length.	 The	approximate	two-fold	increase	in	the	genetic	diversity	of	A(H1N1)pdm09	temporal	sub-datasets	may	be	associated	with	an	increase	in	the	human	population	immunity	against	the	virus,	probably	as	a	result	of	infection	or	vaccination.			
6.2.1	Global	Selective	Pressure	on	Human	Influenza	Virus	Neuraminidase	Gene		Global	dN/dS	ratios	 for	 influenza	NA	gene	were	similar	and	 less	 than	1	not	only	across	the	different	virus	subtypes	or	lineages	in	total	time	period	but	also	across	the	different	time	periods	 in	each	virus	 subtype	or	 lineage.	This	 indicated	 that	NSP	 forces	of	 similar	magnitude	 have	 been	 acting	 on	 the	 NA	 gene	 of	 all	 human	 influenza	 viruses,	 and	 that	neither	 the	 introduction	 of	 NAIs	 into	 clinic	 and/or	 its	 increased	 use	 during	 2009	A(H1N1)	 pandemic	 had	 an	 impact	 on	 the	 overall	 strength	 of	 NSP.	 Global	 dN/dS	 ratio	estimates	 in	 total	 time	 period	 (0.21	 -	 0.26)	were	 similar	 to	 those	 obtained	 in	 previous	studies	(0.19	-	0.30)	20,26,32-39.			
6.2.2	Site-by-Site	Selective	Pressures	on	Human	Influenza	Virus	Neuraminidase	Gene		Most	variable	sites	within	the	NA	gene	of	all	human	influenza	virus	subtypes	or	lineages	were	 found	 to	 be	 experiencing	 a	 dN/dS<1	 that	 was	 statistically	 significant	 for	approximately	or	slightly	more	than	half	of	them	in	total	time	period	-	41.6%	to	52.3%	of	all	variable	sites	under	negative	selection.	Only	in	A(H3N2)	virus	NA	gene	this	percentage	was	even	higher,	reaching	67.3%.	The	high	percentage	of	negatively	selected	sites	 in	all	virus	subtypes	or	 lineages	may	be	a	result	of	the	 intensive	sequence	sampling	that	may	have	allowed	for	sequences	representing	transitory	sub-optimal	viral	sub-populations	to	be	 present.	 Nevertheless,	 it	 was	 in	 agreement	 with	 the	 significant	 dN/dS<1	 value	obtained	for	the	entire	gene	(global	dN/dS	ratio).	Very	few	NA	sites	were	under	positive	
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selection,	 varying	 from	1	 to	 8	 (0.2%	 to	 1.8%	 of	 all	 variable	 sites)	 in	 total	 time	 period,	according	to	the	virus	subtype	or	lineage.		The	 differences	 in	 the	 distribution	 of	 the	 variable	 sites	 across	 the	 different	 SP	 profiles	over	 the	different	 time	periods	were	probably	 just	 artefacts	 of	 the	different	 size	 of	 the	sequence	sub-datasets.			
6.2.2.1	Positively	Selected	Sites			Site	275	was	 the	only	positively	 selected	 site	 in	 seasonal	 influenza	N1	NA	 in	either	 the	total	time	period	or	the	different	time	periods	analysed	(only	between	1999	and	2008).	Moreover,	the	H275Y	substitution	known	to	confer	clinical	resistance	to	OS	and	(H)RI	by	OS	 and	 PER	 in	 vitro	 was	 the	 only	 amino	 acid	 polymorphism	 detected	 at	 this	 site,	evidencing	the	occurrence	of	directional	PSP.	In	fact,	from	2009	onwards	the	site	was	no	longer	under	PSP	and	H275Y	was	already	fixed	in	the	virus	population	(96.4%	H275Y).	Previous	studies	have	also	identified	site	275	as	the	only	40,41	or	as	one	of	the	positively	selected	 sites	 26	 in	 seasonal	 N1	 NA,	 with	 two	 of	 them	 suggesting	 a	 significant	 role	 for	positive	selection	in	the	rapid	and	global	spread	of	a	NA	H275Y	OS-resistant	variant	since	late	 2007	 26,40.	 Further	 investigation	 of	 the	 PSP	 acting	 on	 site	 275	 between	 1999	 and	2008	did	not,	however,	support	 that.	The	site	was	 found	under	PSP	 from	1999	to	2007	but	 not	 from	1999	 to	 2006,	 indicating	 that	 positive	 selection	may	have	 only	 started	 in	2007.	Based	on	this,	 it	may	be	just	an	artefact	of	the	global	spread	of	the	drug-resistant	variant	 that	 may	 otherwise	 have	 resulted	 from	 genetic	 hitchhiking	 to	 advantageous	mutations	located	in	any	other	segment	of	viral	genome,	as	has	been	suggested	in	several	studies	 42-44.	 This	 can	 be	 the	 case	 of	 PB2	 P453S	 and/or	 PB1	 N642S	 amino	 acid	substitutions	 identified	 in	this	PhD	study	as	specific	of	NA	H275Y	OS-resistant	seasonal	A(H1N1)	 viruses	 (see	 Chapter	 5	 for	 detail),	 but	 which	 effect	 on	 virus	 fitness	 is	 still	unknown.	 It	 will	 be	 interesting	 to	 investigate	 if	 positive	 selection	 has	 been	 acting	 on	theses	sites	and	if	so,	if	it	has	favoured	those	particular	amino	acid	changes.		Sites	 44,	 148,	 151,	 435	 and	 468	 in	 human	 influenza	N2	NA	were	 found	 to	 be	 evolving	under	diversifying	PSP	in	total	time	period.	PSP	revealed	to	be	particularly	strong	at	sites	148	and	151	associated	with	(H)RI	by	NAI	drugs	and	located	closely	to	the	NA	active	site.	In	fact,	these	were	the	only	that	were	already	identified	under	PSP,	although	in	just	one	
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previous	study	38.	All	other	previous	studies	detected	a	completely	divergent	set	of	sites	under	PSP,	most	probably	due	 to	 the	much	 smaller	 size	of	 sequence	datasets	 (284	and	345	sequences)	20,36,37.	Both	sites	148	and	151	have,	however,	shown	to	be	implicated	in	cell	 culture	 selection.	 Several	 amino	 acid	 changes	 at	 these	 sites,	 including	 the	 (H)RI-conferring	D151A/G	substitutions	and	the	synergistic	T148I	substitution,	have	only	been	detected	in	cell-grown	virus	isolates	and	not	in	clinical	specimens	45-47.	Considering	that	most	 influenza	 gene	 sequences	 available	 at	 public	 databases	were	 obtained	 from	 virus	isolates,	 it	 is	possible	 that	 the	strong	PSP	detected	at	both	sites	may	be	 just	an	artefact	from	cell	culture.	Based	on	this,	no	inference	can	be	made	about	the	fact	that	both	sites	were	only	under	PSP	in	the	period	of	use	(from	1999	to	2008)	and	increased	use	(from	2009	onwards)	of	NAI	drugs,	and	about	the	increase	in	the	strength	of	PSP	acting	at	site	148	between	the	two	time	periods.	Positively	selected	sites	435	and	468	may	constitute	key	immune	epitope	contacting	residues,	as	evidenced	by	their	location	at	the	surface	of	the	 protein.	 Antibody	 epitopes	 on	 human	 influenza	 N2	 NA	 are	 still	 very	 poorly	characterized	(only	Mem5	epitope	is	completely	mapped	to	date	17)	and	thereby	there	is	still	much	information	missing.			Influenza	B/VIC-lineage	NA	presented	the	highest	number	of	sites	under	PSP,	which	was	unexpected	 considering	 that	 influenza	B	NA	evolves	 at	 a	 two	 to	 three	 times	 lower	 rate	than	seasonal	N1	and	N2	NA	30.	A	total	of	8	sites	were	found	to	be	under	PSP	in	total	time	period,	half	of	them	located	in	the	stalk	and	the	other	half	in	the	catalytic	globular	head	but	apart	from	the	active	site.	Among	these	latter,	it	was	site	395	associated	with	RI	by	OS	and	PER	in	vitro.	All	positively	selected	sites	except	one	(site	73)	were	found	to	be	under	diversifying	PSP.	Considering	that	the	RI-conferring	A395E	amino	acid	substitution	was	one	of	the	polymorphisms	detected	at	site	395,	a	variant	carrying	such	amino	acid	change	can	 be	 at	 potential	 risk	 of	 spreading.	 However,	 latest	 global	 susceptibility	 surveillance	data	(2014/2015	season)	showed	still	no	evidence	of	that	48.	Site	395	was	the	only	to	be	continually	under	PSP	after	the	licencing	of	NAI	drugs	into	the	clinic	(from	1999	to	2008,	and	 from	 2009	 onwards).	 Although	 this	 seemed	 to	 indicate	 a	 potential	 role	 of	 drug-selective	pressure,	it	is	more	likely	that	the	site	was	under	continuous	SP	from	the	host´s	immune	 system,	 based	 on	 its	 location	 at	 the	 surface	 of	 the	 protein.	 According	 to	 its	structural	 location,	 positively	 selected	 site	 465	may	 also	 constitute	 a	 potential	 epitope	contacting	 residue.	 The	 identification	 of	 potential	 antibody	 contacting	 residues	 in	influenza	 B	 NA	 is	 particularly	 relevant	 as	 no	 epitope	was	 completely	mapped	 to	 date.	
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Only	 few	 amino	 acid	 residues	 that	 changed	 in	 antibody-selected	 escape	 mutants	 are	known	49.		All	 positively	 selected	 sites	 in	 B/YAM-lineage	 NA	 in	 total	 time	 period	 appeared	 to	 be	evolving	 under	 directional	 PSP,	 in	 spite	 of	 the	 diversity	 of	 amino	 acid	 polymorphisms	identified	 in	most	of	 them.	Sites	65,	73	and	465	were	also	under	PSP	 in	B/VIC	 lineage,	which	for	site	465	supported	its	potential	role	as	epitope	contacting	residue.	Site	65	was	detected	under	PSP	in	a	previous	study	but	only	for	B/YAM	lineage	38.	Sites	42,	106	and	198	constituted	 the	 remaining	sites	under	PSP.	Due	 to	 its	 location	at	 the	 surface	of	 the	protein,	site	106	may	also	constitute	a	potential	epitope	contacting	residue.	Site	198	near	the	 enzymatic	 active	 site	 was	 the	 most	 strongly	 selected	 site.	 Drug-selective	 pressure	might	have	been	in	the	origin	of	this	stronger	PSP,	as	evidenced	by	the	detection	of	PSP	in	only	the	periods	of	use	(from	1999	to	2008)	and	increased	use	(from	2009	onwards)	of	NAI	 drugs.	 However,	 there	 was	 no	 consensus	 from	 the	 two	 methods	 used	 for	 the	variation	in	the	strength	of	PSP	acting	on	this	site	between	the	two	time	periods.	Site	198	is	not	associated	with	 (H)RI	by	NAI	drugs	but	 lies	adjacently	 to	 site	197	 in	which	have	been	detected	several	amino	acid	substitutions	conferring	(H)RI	by	all	NAIs	except	LAN	(D197E/N/Y)	8.			Positively	selected	sites	 in	2009	pandemic	N1	NA	 in	 total	 time	period	 included	sites	46	and	74	within	the	stalk	domain;	sites	95	and	450	under	selection	of	 the	host´s	 immune	system	(established	epitope	contacting	residues);	and	sites	247	and	275	located	closely	to	the	active	site	and	associated	with	NAI	resistance	and/or	(H)RI.	All	sites	were	found	to	be	 evolving	 under	 diversifying	 PSP,	 except	 site	 275	 in	 which	 was	 only	 detected	 the	H275Y	amino	acid	variant	known	to	confer	clinical	resistance	to	OS	and	(H)RI	by	OS	and	PER	 in	 vitro.	 Site	 275	 was	 also	 found	 to	 be	 experiencing	 stronger	 PSP	 in	 the	 (pre-)	pandemic	 period,	 during	 which	 NAI	 drugs,	 particularly	 OS,	 were	 more	 widely	 used.	However,	 this	may	 be	 just	 a	 sampling	 artefact	 as	most	 NA	H275Y	OS-resistant	 viruses	identified	 in	 this	period	were	recovered	 from	patients	undergoing	OS	 treatment	 50	and,	due	the	 lack	of	 information	on	antiviral	 therapy	in	sequence	databases,	sequences	from	treated	patients	could	not	be	excluded	from	the	study	sample.	The	continuity	of	positive	selection	 throughout	 the	 post-pandemic	 period	 suggested	 that	 PSP	 may	 have	 been	playing	 an	 important	 role	 in	 the	 low-level	 and	 locally	 variable	 spread	 of	 NA	 H275Y	A(H1N1)pdm09	viruses	that	has	been	observed	since	2011,	among	untreated	community	
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patients	 with	 either	 or	 not	 an	 epidemiological	 link	 (cluster)	 51-53.	 Positive	 diversifying	selection	at	site	247	may	also	constitute	a	threat	to	NAI	use	as	both	RI-conferring	S247G	and	 synergistic	 S247N	 amino	 acid	 substitutions	 were	 among	 the	 polymorphisms	identified.	Variants	carrying	such	amino	acid	changes	can	be	therefore	at	potential	risk	of	spreading,	 although	 latest	 global	 susceptibility	 surveillance	 data	 (2014/2015	 season)	showed	 still	 no	 evidence	 of	 that	 48.	 Positive	 selection	 at	 site	 46	may	 be	 in	 part	 related	with	the	gain	of	a	N-linked	glycosylation	site	-	I46T	amino	acid	substitution	(Asparagine	(N)	 at	 position	 44).	 N-linked	 glycosylation	 is	 known	 to	 be	 an	 important	 evolutionary	mechanism	 of	 influenza	 viruses	 and	 the	 increase	 in	 the	 number	 of	 glycosylation	 sites	showed	to	be	characteristic	of	the	early	stages	of	evolution	54.	The	fact	that	the	site	was	only	positively	selected	during	the	(pre-)pandemic	period	supports	this	hypothesis.				
6.2.2.2	 Selective	 Pressure	 on	 the	 Sites	 Associated	 with	 Resistance	 or	 (Highly)	 Reduced	
Inhibition	by	Neuraminidase	Inhibitors	and/or	Contacting	with	the	Drug		
	NA	sites	associated	with	NAI	resistance	or	 (H)RI	and/or	contacting	with	 the	drug	were	essentially	under	negative	 selection	 (A(H3N2),	B/VIC-lineage)	 or	 either	under	negative	selection	or	experiencing	a	n.s.	dN/dS<1	(seasonal	and	2009	pandemic	A(H1N1),	B/YAM-lineage)	in	total	time	period.	This	can	be	explained	by	the	key	functional	role	that	most	of	these	 sites	 have	 on	 the	 sialidase	 activity	 of	 influenza	 NA	 protein,	 considering	 their	position	at	or	near	the	enzymatic	active	site	(drug-binding	pocket).	Moreover,	Lentz	and	colleagues	showed	that	site-directed	mutagenesis	of	active	site	residues	result	mainly	in	a	complete	loss	of	enzymatic	activity	55,	evidencing	that	amino	acid	changes	at	these	sites	are	unlikely	to	be	advantageous.		Positive	selection	at	site	275	in	seasonal	N1	NA	and	sites	148	and	151	in	N2	NA	may	be	simply	 an	 artefact	 from,	 respectively,	 the	 global	 spread	 of	 a	 drug-resistant	 variant	 and	cell	culture,	as	above-mentioned.	The	same	does	not	apply	to	the	positive	selection	at	site	395	 in	 B/VIC-lineage	 NA	 and	 sites	 275	 and	 247	 in	 2009	 pandemic	 N1	 NA	 that	 is	otherwise	 concerning.	NA	A395E	 (influenza	B),	H275Y	and	S247G/N	 (A(H1N1)pdm09)	amino	acid	substitutions	known	to	confer	or	enhance	NAI	resistance	or	 (H)RI	were	 the	single	 or	 one	 of	 the	 polymorphisms	 identified	 at	 these	 sites,	 meaning	 that	 variants	carrying	such	amino	acid	changes	can	be	at	potential	risk	of	spreading.	In	fact,	NA	H275Y	
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drug-resistant	A(H1N1)pdm09	viruses	have	already	spread	 in	 the	 community,	but	only	locally	and	at	low-level,	as	above-mentioned.	Site	199	in	2009	pandemic	N1	NA	and	sites	71	and	149	in,	respectively,	both	B	lineage	or	only	 B/VIC-lineage	 NA,	 should	 also	 be	 closely	 monitored	 as	 were	 found	 to	 be	experiencing	a	n.s.	dN/dS>1	and	the	amino	acid	variant(s)	conferring	and/or	enhancing	(H)RI	was/were	among	the	polymorphisms	identified.			The	SP	profile	of	the	sites	associated	with	resistance	or	(H)RI	and/or	contacting	with	the	drug	 either	not	 varied	 across	 the	different	 time	periods	 (A(H1N1)pdm09,	A(H3N2))	or	varied,	but	with	no	similar	or	particular	trend	that	could	be	explained	by	the	underlying	differences	in	NAI	drug	use	(seasonal	A(H1N1),	influenza	B/VIC	and	B/YAM	lineages).	In	fact,	 it	 is	 possible	 that	 some	 of	 the	 variations	 observed	 were	 just	 related	 with	 the	different	 size	 of	 sequence	 sub-datasets.	 It	 can	 be	 therefore	 assumed	 that	 neither	 the	introduction	 of	 NAI	 drugs	 into	 clinic	 nor	 its	 increased	 use	 during	 2009	 A(H1N1)	pandemic	had	an	apparent	impact	on	the	SP	forces	acting	on	these	particular	sites.	Sites	148	and	151	in	N2	NA	and	site	395	in	B/VIC-lineage	NA	were	continually	under	PSP	after	NAI	 introduction	 into	 clinic	 but,	 as	 above-mentioned,	 positive	 selection	may	 be	 just	 an	artefact	from	cell	culture	(sites	148	and	151)	or	a	result	of	the	selection	from	the	host´s	immune	system	(site	395,	potential	epitope	contacting	residue)	and	not	drug	use.	Also,	only	 the	 differences	 in	 the	 SP	 on	 site	 148	 were	 found	 to	 be	 statistically	 significant	(differential	SP	analysis).	Evidence	for	significant	differences	between	the	different	time	periods	was	also	obtained	for	site	275	in	seasonal	N1	NA	that	was	under	significant	and	n.s.	dN/dS>1	after	the	licensing	of	NAI	drugs,	and	for	few	other	sites	with	a	less	marked	variation	in	their	SP	profile.	Specifically,	site	41	in	N2	NA,	site	294	in	B/VIC-lineage	NA,	sites	154	and	197	in	B/YAM-lineage	NA,	and	sites	136,	247	and	295	in	2009	pandemic	N1	NA.	 	 The	 significant	 S_SP	 acting	 on	 site	 154	 of	 B/YAM-lineage	NA	 from	 2009	 onwards	may	 in	 fact	 be	 associated	 with	 drug-selective	 pressure.	 Not	 only	 the	 increase	 in	 the	strength	of	SP	was	in	agreement	with	the	increase	in	NAI	drug	use,	but	also	site	154	is	a	framework	residue	of	the	active	site,	contacting	indirectly	with	the	drug.	The	significant	S_SP	 acting	 on	 seasonal	 N1	 NA	 site	 275	 in	 both	 from	 1999	 to	 2008	 and	 from	 2009	onwards	periods	may	otherwise	be	just	an	artefact	from	the	global	spread	of	a	NA	H275Y	drug-resistant	 variant,	 as	 above-mentioned,	 while	 the	 position	 of	 site	 41	 in	 the	 stalk	domain	 of	 N2	 NA	 makes	 it	 unlikely	 to	 be	 affected	 by	 drug-selective	 pressure.	 All	
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remaining	significant	differences	in	SP	were	not	in	agreement	with	the	differences	in	NAI	drug	use.			
6.2.2.3	Overall	Site-Specific	Selective	Pressures	in	Human	Influenza	Virus	Neuraminidase	
		Seven	regions	within	the	catalytic	globular	head	domain	were	found	to	be	experiencing	significant	or	n.s.	 dN/dS<1	 in	all	different	 subtypes	or	 lineages	of	human	 influenza	NA,	showing	to	be	suitable	for	drug	targeting.	Specifically,	regions	(1)	87-92;	(2)	164-171;	(3)	177-186;	 (4)	 227-233;	 (5)	 254-261;	 (6)	 275-284;	 and	 (7)	 297-307	 (N2	 coordinates).	Region	227-233	(region	4)	is	partially	included	in	the	only	universally	conserved	region	among	influenza	A	and	B	viruses	(region	222-230).	Due	to	its	highly	conserved	structure,	this	 region	has	 been	 continuously	 considered	 as	 an	 attractive	 new	drug	 target	 and	 the	recent	 study	 of	 Doyle	 et	 al.	 21	 provided	 the	 functional	 evidence	 for	 that,	 showing	 its	critical	 role	 in	 NA	 enzymatic	 activity	 and	 viral	 replication.	 No	 information	 was	 found	about	 any	 of	 the	 other	 regions	 here	 identified.	 The	 150-cavity	 loop	 has	 also	 been	proposed	as	potential	new	target	but,	considering	that	all	sites	within	this	region	except	one	were	experiencing	significant	or	n.s.	dN/dS>1	in	at	least	one	NA	subtype	or	lineage,	this	may	not	be	a	suitable	choice.				
6.2.3	Frequency	of	amino	acid	substitutions	conferring	or	enhancing	neuraminidase	
inhibitor	resistance	or	(highly)	reduced	inhibition	in	vitro	in	sequence	databases			Most	amino	acid	substitutions	known	to	confer	or	enhance	NAI	resistance	or	(H)RI	in	the	different	human	influenza	virus	types	or	subtypes	were	identified	at	very	low	frequencies	(<0.5%)	 in	 public	 influenza	 sequence	 databases.	 These	 very	 low	 frequencies	 were	already	expected	since	all	amino	acid	substitutions	except	N1	NA	H275Y	have	been	only	rarely	 reported	 56.	 In	 this	 study,	 H275Y	 amino	 acid	 substitution	 was	 detected	 in	approximately	40%	of	 the	seasonal	A(H1N1)	virus	sequences,	with	nearly	all	belonging	to	 the	 period	 in	 which	 circulated	 the	 fit	 and	 transmissible	 NA	 H275Y	 drug-resistant	variant	that	spread	globally.	It	was	also	detected	in	more	than	4%	of	the	A(H1N1)pdm09	virus	 sequences,	 occurring	 at	 an	 approximately	 two-fold	 higher	 frequency	 than	 that	reported	 through	 antiviral	 susceptibility	 monitoring	 activities	 (<2%)57.	 This	 difference	
																																																																										Footprints	of	selective	pressure	in	influenza	neuraminidase	|	250																																																	
	
can	be	related	with	the	extremely	high	number	of	sequences	analysed	(3428	sequences)	that	 most	 probably	 included	 sequences	 from	 laboratories	 that	 are	 not	 generating	 and	reporting	 antiviral	 susceptibility	 data.	 Three	 synergistic	 amino	 acid	 substitutions	 -	D199N	 and	 S247N	 (A(H1N1)pdm09)	 and	 T148I	 (A(H3N2)),	 were	 identified	 at	 slightly	higher	frequencies	than	the	majority	of	the	amino	acid	changes	at	that	particular	subtype,	but	 only	 T148I	 was	 identified	 together	 with	 the	 substitution	 conferring	 the	 (H)RI	phenotype	 and	 in	 only	 one	 sequence.	 The	 higher	 frequency	 at	 which	 D151E/G	substitutions	 were	 identified	 in	 A(H3N2)	 subtype	 (0.8%	 and	 1.9%,	 respectively)	 was	probably	 related	 with	 the	 well-known	 association	 of	 the	 site	 to	 cell	 culture	 selection.	Seasonal	 N1	 NA	 N70S	 substitution	 was	 also	 identified	 at	 a	 slightly	 higher	 frequency	(1.8%),	 but	 nearly	 all	 sequences	 harbouring	 this	 amino	 acid	 change	were	 from	 before	1999.	 This	 is	 a	 substitution	 that	 only	 recently	 was	 found	 to	 affect	 the	 in	 vitro	susceptibility	to	ZA	58.	Most	of	the	detected	influenza	B	NA	amino	acid	changes	conferring	(H)RI	 were	 exclusive	 of	 B/VIC	 lineage.	 The	 frequency	 of	 (H)RI-conferring	 NA	substitutions	 has	 already	 showed	 to	 differ	 substantially	 between	 the	 two	 influenza	 B	lineages	 in	 a	 recent	 study	 59,	 but	 this	 preference	 for	 B/VIC	 lineage	 was	 not	 noted.	However,	only	7	positions	in	influenza	B	NA	were	previously	analysed,	contrasting	with	the	 31	 positions	 now	 studied.	 The	 single	 occurrence	 of	 most	 amino	 acid	 changes	 in	B/VIC-lineage	 viruses	 can	 mean	 that	 these	 viruses	 have	 a	 higher	 capacity	 to	 tolerate	(H)RI-conferring	NA	substitutions,	compared	to	B/YAM-lineage	viruses.			
6.3	CONCLUSIONS		This	 is	 one	 of	 the	 most	 comprehensive	 studies	 on	 the	 SP	 acting	 on	 influenza	 NA	performed	 to	 date,	 involving	 the	 analysis	 of	 an	 extremely	 large	 number	 of	 NA	 gene	sequences	 that,	 although	 not	 equally	 distributed	 over	 time	 and	 geographic	 regions,	covered	 extensive	 time	 periods	 and	 all	 5	worldwide	 continents	 and	 18	WHO	 influenza	transmission	zones.	 It	 also	 involved	 the	analysis	of	 all	different	 subtypes	or	 lineages	of	human	 influenza	 NA	 that	 were	 for	 the	 first	 time	 studied	 together,	 under	 the	 same	approaches	 and	methodologies.	 A	 temporal	 splitting	 approach	 based	 on	 differences	 in	NAI	drug	use	was	also	used	for	the	 first	 time,	allowing	to	 infer	about	the	 impact	of	NAI	introduction	into	clinic	and/or	its	increased	use	during	2009	A(H1N1)	pandemic	on	the	global	and	site-specific	SP	acting	on	influenza	NA	(drug	target).	Potential	interferences	of	
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sampling	size	and	cell	culture	implied,	however,	a	careful	interpretation	of	some	results.	Overall,	this	study	contributed	at	a	better	understanding	of	the	SP	forces	acting	on	the	NA	gene	of	all	different	subtypes	or	lineages	of	human	influenza	virus	and	of	the	role	of	PSP	in	the	evolutionary	pathways	to	NAI	resistance	or	(H)RI.	It	also	contributed	at	identifying	potential	epitope	contacting	residues,	which	is	an	area	that	is	still	poorly	studied	for	NA;	and	at	finding	potential	new	druggable	targets,	which	is	now	a	priority	in	influenza	given	the	 limited	 repertoire	 of	 effective	 antivirals	 available.	 In	 a	 broader-sense,	 it	 also	contributed	at	a	better	understanding	of	the	evolutionary	dynamics	of	influenza	NA.					
BOX	6.2	-	MAIN	FINDINGS	
• NSP	forces	of	similar	magnitude	have	been	acting	on	the	NA	gene	of	all	human	influenza	virus	subtypes	or	lineages	(overall	strength	of	selection).	
• Similar	 distribution	 of	 site-specific	 SP	 profiles	 across	 the	 different	 subtypes	 or	 lineages	 of	human	influenza	NA,	with	a	high	percentage	of	sites	under	negative	selection	(41.6%	to	67.3%).	
• Few	positively	selected	sites	(1	to	8	sites,	according	to	the	virus	subtype	or	lineage),	most	lying	at	the	catalytic	globular	head	domain.	
• Influenza	B/VIC-lineage	NA	contained	the	highest	number	of	sites	under	PSP	(8	sites)	
• Sites	435	and	468	in	N2	NA,	395	and	465	in	B/VIC-lineage	NA,	106	and	465	in	B/YAM-lineage	NA,	and	95	and	450	in	2009	pandemic	N1	NA	may	be	under	positive	selection	from	the	host´s	immune	system	-	potential	epitope	contacting	residues.	
• Identification	of	7	potential	new	regions	for	drug	targeting.		
	
Specific	objective	3(a)	
• NA	 sites	 associated	 with	 NAI	 resistance	 or	 (H)RI	 and/or	 contacting	 with	 the	 drug	 were	essentially	 under	 negative	 selection	 (A(H3N2),	 B/VIC-lineage)	 or	 either	 under	 negative	selection	or	experiencing	n.s.	dN/dS<1	(seasonal	and	2009	pandemic	A(H1N1),	B/YAM-lineage).	
• Positive	selection	at	site	275	in	seasonal	N1	NA	and	sites	148	and	151	in	N2	NA	may	be	simply	artefacts	 from,	 respectively,	 the	global	 spread	of	 a	NA	H275Y	drug-resistant	variant	 and	virus	isolation	and	propagation	in	cell	culture.	
• Positive	directional	selection	at	site	275	in	2009	pandemic	N1	NA	may	be	playing	a	role	 in	the	low-level	and	 locally	variable	spread	of	NA	H275Y	drug-resistant	A(H1N1)pdm09	viruses	that	has	been	observed	among	untreated	community	patients.	
• Positive	diversifying	selection	at	site	395	in	B/VIC-lineage	NA	and	site	247	in	2009	pandemic	N1	NA	 may	 lead	 to	 the	 emergence	 and	 spread	 of	 RI	 A395E	 variant	 and	 both	 synergistic	 HRI	H275Y/S247N	and	RI	S247G	variants.	
• Emergence	of	amino	acid	variants	at	site	199	in	2009	pandemic	N1	NA	and	sites	71	and	149	in,	respectively,	 both	 influenza	 B	 lineage	 NA	 and	 only	 B/VIC-lineage	 NA	 should	 be	 closely	monitored	(n.s.	dN/dS>1).		
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BOX	6.2	-	MAIN	FINDINGS	(cont.)	
Specific	objective	3(b)	
• NAI	 introduction	 into	 clinic	 and/or	 its	 increased	 use	 during	 2009	 A(H1N1)	 pandemic	 had	apparently	 no	 impact	 on	 the	 global	 and	 site-specific	 SP	 acting	 on	 the	 different	 subtypes	 or	lineages	of	human	influenza	virus	NA.		
• Framework	 active	 site	 residue	 154	 of	 B/YAM-lineage	 NA	 may	 constitute	 the	 only	 exception,	evolving	under	significant	S_SP	after	the	increased	use	of	NAI	drugs	in	the	pandemic	period.	
	
Complementary	 study	on	 the	 frequency	 of	amino	acid	 substitutions	 conferring	 or	 enhancing	
NAI	resistance	or	(H)RI	in	vitro	
• Amino	acid	substitutions	known	to	confer	or	 enhance	NAI	 resistance	or	 (H)RI	 in	the	different	human	 influenza	 virus	 types	 or	 subtypes	 were	 mainly	 identified	 at	 very	 low	 frequencies	(<0.5%)	in	public	influenza	sequence	databases.		
• N1	 H275Y	 amino	 acid	 substitution	 identified	 in	 ≈40%	 of	 seasonal	 A(H1N1)	 virus	 sequences	(global	spread	of	drug-resistant	variant)	and	in	4%	of	A(H1N1)pdm09	virus	sequences.		
• Higher	 frequency	 of	 D151E/G	 amino	 acid	 substitutions	 among	 A(H3N2)	 virus	 sequences	probably	associated	with	the	implication	of	the	site	in	cell	culture	selection.	
• Most	 detected	 influenza	 B	 NA	 amino	 acid	 changes	 conferring	 (H)RI	 were	 exclusive	 of	 B/VIC	lineage,	 suggesting	 that	 B/VIC-lineage	 viruses	 may	 have	 a	 higher	 capacity	 to	 tolerate	 these	particular	amino	acid	changes,	compared	to	B/YAM-lineage	viruses.			
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Table	S6.1	Former	seasonal	N1	neuraminidase	sites	 identified	as	differentially	selected	between	the	different	time	periods	analysed	(temporal	sub-datasets).			
	Dif:	Difference;	dN:	rate	of	non-synonymous	substitutions;	dS:	rate	of	synonymous	substitutions;	(H)RI:	(Highly)	reduced	 inhibition;	 inf:	 infinite	(dS=0);	NAI:	Neuraminidase	inhibitor;	S_SP:	Stronger	Selective	Pressure;	vs:	versus;	W_SP:	Weaker	Selective	Pressure	Symbol	legend:		 	 		
	Site-by-site	selective	pressures	(SP)	between	two	different	time	periods	were	compared	as	described	in	Table	6.5.	The	dash	(-)	represents	no	significant	difference,	while	significant	differences	involving	stronger	SP	are	highlighted	in	bold	and	italic.					
p"value dN/dS_1" dN/dS_2 DIF p"value dN/dS_2" dN/dS_3 DIF p"value dN/dS_1" dN/dS_3 DIF5 ! 0.045 8.51E910 1.48 S_SP − − − − − − − −12 !! 0.026 0.00 1.24 S_SP − − − − − − − −16 !! 0.021 1222104922.51 0.43 W_SP − − − − − − − −17 !! − − − − 0.055 0.00 0.64 S_SP − − − −20 !! − − − − 0.017 1.36 0.11 W_SP − − − −37 !!! − − − − 0.0059 inf 0.00 W_SP 0.049 inf 4.37E916 W_SP48 !!! 0.019 0.078 713677715.96 S_SP − − − − − − − −62 !!! 0.0039 0.00 2.36 S_SP − − − − − − − −67 !!! − − − − − − − − 0.0072 0.00 inf S_SP80 !!!! − − − − 0.025 inf 0.00 W_SP − − − −89 !!!! 0.048 inf 3.49E909 W_SP − − − − − − − −91 !!!! − − − − 0.019 0.00 inf S_SP − − − −122 !!!! 0.050 4.76E910 77834796.33 S_SP 0.053 inf 0.00 W_SP − − − −125 !!!! − − − − 0.033 0.00 inf S_SP − − − −126 !!!! − − − − 0.036 0.43 0.00 W_SP − − − −131 !!!! 0.025 185788582.22 3.56E909 W_SP − − − − 0.049 inf 0.00 W_SP157 !!!! 0.00020 1066150198.03 3.48E909 W_SP − − − − − − − −168 !!!! − − − − 0.036 9.70E916 0.50 S_SP − − − −177 !!!! − − − − − − − − − − − −214 !!!! − − − − − − − − 0.049 0.00 1.62 S_SP222 !!!! " 0.047 1339322283.05 0.81 W_SP − − − − − − − −232 !!!! − − − − − − − − 0.047 inf 0.00 W_SP236 !!!! 0.038 0.40 8.36E910 W_SP 0.0071 0.00 inf S_SP − − − −248 !!!! # − − − − − − − − 0.053 3.90 0.21 W_SP250 !!!! # − − − − 0.023 0.46 2.03 S_SP − − − −253 !!!! 0.035 inf 4.17E909 W_SP − − − − − − − −263 !!!! 0.050 551573989.33 0.38 W_SP − − − − − − − −264 !!!! − − − − 0.027 0.32 inf S_SP − − − −266 !!!! − − − − 0.018 inf 0.00 W_SP − − − −275 !!!! 0.00061 1.02E909 12.65 S_SP − − − − 0.012 0.00 inf S_SP284 !!!! − − − − − − − − − − − −325 !!!! − − − − − − − − 0.043 0.00 inf S_SP327 !!!! 0.0043 376985575.57 2.08E909 W_SP − − − − − − − −332 !!!! 0.0058 0.078 2.24 S_SP − − − − − − − −336 !!!! − − − − − − − − 0.022 inf 0.00 W_SP338 !!!! # 0.049 1.12E909 0.80 S_SP − − − − − − − −339 !!!! # − − − − 0.046 0.48 inf S_SP − − − −341 !!!! # 0.030 0.00 inf S_SP − − − − 0.022 0.00 inf S_SP346 !!!! − − − − − − − − 0.031 inf 0.072 W_SP354 !!!! 0.031 1.16E909 1.30 S_SP − − − − 0.015 0.00 inf S_SP377 !!!! − − − − 0.016 0.00 inf S_SP − − − −385 !!!! − − − − − − − − 0.037 inf 0.00 W_SP389 !!!! 0.035 857789580.30 0.54 W_SP 0.041 0.54 inf S_SP − − − −416 !!!! − − − − − − − − 0.048 0.00 inf S_SP419 !!!! − − − − − − − − 0.014 0.00 inf S_SP424 !!!! − − − − 0.049 0.00 inf S_SP 0.046 0.00 inf S_SP437 !!!! − − − − 0.047 0.27 inf S_SP − − − −449 !!!! 0.042 5.74E910 0.36 S_SP − − − − − − − −451 !!!! − − − − − − − − 0.039 0.16 inf S_SP452 !!!! − − − − 0.010 0.90 0.00 W_SP − − − −
Codon"site Site"characteristics Before"1999"(1)"vs"199992008"(2) 199992008"(2)"vs"2009"onwards"(3) Before"1999"(1)"vs"2009"onwards"(3)
!
! N"terminal+cytoplasmic+domain !! Transmembrane+domain !!! Stalk+domain !!!! Catalytic+globular+head+domain
! Potential)epitope)contacting)residue)(essential)for)antibody)binding) Associated)with)NAI)clinical)resistance)and)(H)RI)in)vitro!
! Associated*with*a*compensatory*fitness*effect*on*NAI*resistant*or*(H)RI*variants
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Table	 S6.2	 N2	 neuraminidase	 sites	 identified	 as	 differentially	 selected	 between	 the	 different	 time	periods	analysed	(temporal	sub-datasets).			 	
																																																					
p"value dN/dS_1" dN/dS_2 DIF p"value dN/dS_2" dN/dS_3 DIF p"value dN/dS_1" dN/dS_3 DIF2 ! − − − − 0.00015 2.62 0.046 W_SP − − − −10 !! − − − − 0.026 1.84 0.086 W_SP − − − −11 !! − − − − 0.054 0.15 1.1E=15 W_SP − − − −14 !! 0.00026 inf 0.046 W_SP − − − − 0.00026 inf 0.00 W_SP17 !! − − − − − − − − 0.010 inf 0.29 W_SP25 !! 0.027 0.00 inf S_SP − − − − − − − −29 !! − − − − − − − − 0.0054 0.59 1.7E=07 W_SP31 !! − − − − − − − − 0.045 0.37 0.061 W_SP39 !!! 0.016 0.61 0.00 W_SP − − − − − − − −41 !!! " − − − − − − − − 0.042 0.14 0.79 S_SP55 !!! − − − − 0.0092 1.04 0.00 W_SP 0.020 inf 0.00 W_SP60 !!! − − − − 0.047 0.16 0.66 S_SP 0.046 0.00 0.66 S_SP66 !!! − − − − 0.036 0.27 0.00 W_SP − − − −69 !!! 0.020 0.53 inf S_SP − − − − − − − −74 !!! − − − − 0.0039 0.042 0.89 S_SP 0.0095 0.052 0.89 S_SP76 !!!! 0.037 0.00 0.15 S_SP − − − − 0.045 0.00 0.13 S_SP78 !!!! − − − − 0.045 0.31 0.00 W_SP − − − −94 !!!! − − − − − − − − 0.047 0.42 0.00 W_SP120 !!!! 0.032 9.02 1.19 W_SP 0.0012 1.19 3.06E=15 W_SP 9.75E=06 9.02 0.00 W_SP126 !!!! − − − − 0.00071 inf 0.24 W_SP 0.0035 inf 0.24 W_SP141 !!!! 0.0025 3.17 6.37E=16 W_SP 0.0010 0.00 4.38 S_SP − − − −147 !!!! # 0.031 0.49 9.44 S_SP 0.0039 9.44 0.55 W_SP − − − −148 !!!! " 0.012 0.18 5.22 S_SP − − − − 0.0019 0.18 14.64 S_SP150 !!!! # 0.035 0.19 4.48 S_SP − − − − 0.025 0.19 5.38 S_SP153 !!!! # 0.024 inf 0.20 W_SP − − − − 7.63E=05 inf 3.7E=16 W_SP155 !!!! 0.0050 inf 0.10 W_SP − − − − − − − −170 !!!! − − − − 0.054 0.14 0.00 W_SP − − − −195 !!!! − − − − 0.052 0.00 0.062 S_SP − − − −210 !!!! − − − − − − − − 0.0079 0.16 1.95 S_SP215 !!!! 0.027 0.00 1.21 S_SP − − − − 0.011 0.00 3.24 S_SP223 !!!! − − − − 0.010 0.95 0.00 W_SP − − − −231 !!!! − − − − 0.019 0.82 0.058 W_SP − − − −243 !!!! − − − − 0.021 0.00 inf S_SP − − − −248 !!!! # 0.0039 1.58 0.19 W_SP − − − − 1.16E=05 1.58 0.045 W_SP250 !!!! # − − − − 0.054 0.078 0.87 S_SP − − − −254 !!!! 0.036 inf 0.00 W_SP 0.022 0.00 inf S_SP − − − −257 !!!! − − − − 0.037 0.28 3.07 S_SP − − − −262 !!!! − − − − 0.014 0.00 0.22 S_SP − − − −263 !!!! − − − − 0.023 1.04 0.23 W_SP 0.0092 3.28 0.23 W_SP265 !!!! − − − − 0.011 1.09 0.080 W_SP 0.037 0.88 0.080 W_SP269 !!!! − − − − − − − − 0.013 inf 0.15 W_SP270 !!!! − − − − 0.052 0.25 1.7E=19 W_SP − − − −284 !!!! 0.038 0.00 0.24 S_SP − − − − 0.026 0.00 0.30 S_SP285 !!!! 0.0022 inf 0.00 W_SP − − − − 0.0039 inf 2.6E=17 W_SP287 !!!! 0.019 0.00 1.50 S_SP − − − − − − − −302 !!!! 0.013 0.83 0.077 W_SP − − − − 0.023 0.83 0.081 W_SP303 !!!! − − − − − − − − 0.0095 inf 0.12 W_SP311 !!!! − − − − 0.032 0.39 3.2E=17 W_SP − − − −329 !!!! − − − − 0.018 0.48 1.65 S_SP 0.017 0.21 1.65 S_SP331 !!!! − − − − 0.020 0.52 3.24 S_SP − − − −335 !!!! 0.013 0.00 0.72 S_SP − − − − 0.011 0.00 0.76 S_SP349 !!!! − − − − − − − − 0.015 0.31 0.00 W_SP357 !!!! − − − − − − − − 0.022 0.36 1.5E=15 W_SP359 !!!! − − − − 0.048 0.13 7.79E=16 W_SP − − − −366 !!!! − − − − 0.029 0.42 0.00 W_SP − − − −370 !!!! − − − − 0.023 1.97 0.28 W_SP 0.0033 7.24 0.28 W_SP376 !!!! − − − − 0.010 0.19 0.00 W_SP − − − −385 !!!! − − − − − − − − 0.025 0.52 0.068 W_SP393 !!!! − − − − 0.018 0.18 inf S_SP 0.0087 0.00 inf S_SP396 !!!! 0.0052 inf 0.10 W_SP − − − − 0.044 inf 0.48 W_SP418 !!!! 0.050 inf 0.32 W_SP − − − − 0.019 inf 0.25 W_SP426 !!!! 0.051 0.64 4.81E=16 W_SP − − − − 0.043 0.64 2.79E=15 W_SP432 !!!! 0.0033 inf 0.41 W_SP − − − − 0.0018 inf 0.19 W_SP433 !!!! 0.00074 0.00 2.54 S_SP − − − − 0.051 0.00 0.53 S_SP434 !!!! − − − − − − − − 0.017 inf 0.89 W_SP445 !!!! 0.0024 1.41 0.00 W_SP − − − − 0.039 1.41 0.10 W_SP451 !!!! − − − − 0.047 0.40 0.00 W_SP − − − −452 !!!! 0.040 0.00 inf S_SP 0.026 inf 0.00 W_SP − − − −462 !!!! 0.0035 1.81 0.042 W_SP − − − − 0.0082 1.81 0.078 W_SP468 !!!! − − − − 0.016 1.14 inf S_SP − − − −
Codon"site Site"characteristics Before"1999"(1)"vs"1999=2008"(2) 1999=2008"(2)"vs"2009"onwards"(3) Before"1999"(1)"vs"2009"onwards"(3)
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(Footnotes	Table	S6.2)	Dif:	Difference;	dN:	rate	of	non-synonymous	substitutions;	dS:	rate	of	synonymous	substitutions;	(H)RI:	(Highly)	reduced	 inhibition;	 inf:	 infinite	(dS=0);	NAI:	Neuraminidase	inhibitor;	S_SP:	Stronger	Selective	Pressure;	vs:	versus;	W_SP:	Weaker	Selective	Pressure	Symbol	legend:		 	 	
	Site-by-site	selective	pressures	(SP)	between	two	different	time	periods	were	compared	as	described	in	Table	6.5.	The	dash	(-)	represents	no	significant	difference,	while	significant	differences	involving	stronger	SP	are	highlighted	in	bold	and	italic.				
Table	 S6.3	 Influenza	 B/Victoria-lineage	 neuraminidase	 sites	 identified	 as	 differentially	 selected	between	the	different	time	periods	analysed	(temporal	sub-datasets).			
	Dif:	Difference;	dN:	rate	of	non-synonymous	substitutions;	dS:	rate	of	synonymous	substitutions;	(H)RI:	(Highly)	reduced	 inhibition;	 inf:	 infinite	(dS=0);	NAI:	Neuraminidase	inhibitor;	S_SP:	Stronger	Selective	Pressure;	vs:	versus;	W_SP:	Weaker	Selective	Pressure	Symbol	legend:		 	 	Site-by-site	selective	pressures	(SP)	between	two	different	time	periods	were	compared	as	described	in	Table	6.5.	The	dash	(-)	represents	no	significant	difference,	while	significant	differences	involving	stronger	SP	are	highlighted	in	bold	and	italic.		
! N"terminal+cytoplasmic+domain !! Transmembrane+domain !!! Stalk+domain !!!! Catalytic+globular+head+domain
! Epitope'contacting'residue " Associated'with'(H)RI'by'NAIs'in#vitro " Associated'with'a'synergistic'effect'on'NAI'(H)RI
!! Transmembrane)domain !!! Stalk)domain !!!! Catalytic)globular)head)domain
 Framework)residue)NA)active)site ! Potential)epitope)contacting)residue)(antibody)escape)mutants) " Associated)with)(H)RI)by)NAIs)in#vitro
p"value dN/dS_1" dN/dS_2 DIF p"value dN/dS_2" dN/dS_3 DIF p"value dN/dS_1" dN/dS_3 DIF24 !! − − − − 0.016 inf 0.27 W_SP − − − −31 !! 0.052 inf 6.69EA16 W_SP − − − − 0.0022 inf 1.24EA15 W_SP33 !! − − − − 0.049 0.00 inf S_SP − − − −45 !!! − − − − − − − − 0.035 inf 0.40 W_SP47 !!! − − − − 0.050 0.00 0.85 S_SP − − − −51 !!! − − − − − − − − 0.030 0.072 1.23 S_SP54 !!! − − − − 0.017 0.85 inf S_SP 0.0014 0.13 inf S_SP75 !!!! − − − − − − − − 0.044 inf 0.48 W_SP91 !!!! 0.018 0.00 1.76 S_SP − − − − − − − −141 !!!! − − − − 0.045 inf 0.034 W_SP − − − −152 !!!! − − − − 0.054 inf 0.084 W_SP − − − −153 !!!! − − − − 0.017 1.00 1.77EA15 W_SP − − − −187 !!!! − − − − 0.047 0.00 inf S_SP − − − −199 !!!! − − − − − − − − 0.035 0.33 inf S_SP202 !!!! − − − − 0.034 inf 0.00 W_SP 0.0087 inf 0.00 W_SP229 !!!! − − − − 0.00041 inf 4.49EA18 W_SP − − − −237 !!!! 0.046 0.00 inf S_SP 0.0093 inf 2.43EA17 W_SP − − − −246 !!!! − − − − 0.049 0.00 inf S_SP − − − −247 !!!! " − − − − 0.029 0.00 0.56 S_SP − − − −250 !!!! − − − − 0.0030 inf 0.031 W_SP − − − −257 !!!! − − − − 0.040 0.00 0.74 S_SP − − − −263 !!!! − − − − − − − − 0.042 0.00 inf S_SP266 !!!! 0.032 inf 0.084 W_SP − − − − − − − −282 !!!! − − − − 0.034 0.36 0.00 W_SP − − − −286 !!!! − − − − 0.043 0.58 0.00 W_SP − − − −294 !!!!  # − − − − 0.053 0.50 0.00 W_SP − − − −296 !!!! − − − − 0.026 inf 0.00 W_SP − − − −304 !!!! − − − − 0.054 inf 0.00 W_SP − − − −325 !!!! − − − − 0.039 0.40 1.96EA15 W_SP − − − −338 !!!! − − − − 0.013 inf 0.13 W_SP − − − −348 !!!! − − − − 0.028 0.00 0.72 S_SP − − − −396 !!!! − − − − − − − − 0.055 inf 0.19 W_SP416 !!!! 0.017 0.00 inf S_SP − − − − − − − −434 !!!! 0.049 inf 0.00 W_SP − − − − − − − −435 !!!! " 0.051 inf 0.00 W_SP − − − − − − − −436 !!!! 0.036 inf 0.56 W_SP − − − − − − − −439 !!!! 0.034 0.00 inf S_SP 0.013 inf 0.19 W_SP − − − −449 !!!! − − − − 0.024 indet 1.22EA05 − 0.024 indet 1.22EA05 −459 !!!! − − − − 0.033 inf 0.18 W_SP − − − −462 !!!! − − − − − − − − 0.017 inf 1.06EA16 W_SP
Codon"site Site"characteristics Before"1999"(1)"vs"1999A2008"(2) 1999A2008"(2)"vs"2009"onwards"(3) Before"1999"(1)"vs"2009"onwards"(3)
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Table	 S6.4	 Influenza	 B/Yamagata-lineage	 neuraminidase	 sites	 identified	 as	 differentially	 selected	between	the	different	time	periods	analysed	(temporal	sub-datasets).			
	Dif:	Difference;	dN:	rate	of	non-synonymous	substitutions;	dS:	rate	of	synonymous	substitutions;	(H)RI:	(Highly)	reduced	 inhibition;	 inf:	 infinite	(dS=0);	NAI:	Neuraminidase	inhibitor;	S_SP:	Stronger	Selective	Pressure;	vs:	versus;	W_SP:	Weaker	Selective	Pressure	Symbol	legend:		 	
		Site-by-site	selective	pressures	(SP)	between	two	different	time	periods	were	compared	as	described	in	Table	6.5.	The	dash	(-)	represents	no	significant	difference,	while	significant	differences	involving	stronger	SP	are	highlighted	in	bold	and	italic.																	
p"value dN/dS_1" dN/dS_2 DIF p"value dN/dS_2" dN/dS_3 DIF p"value dN/dS_1" dN/dS_3 DIF12 ! − − − − 0.035 0.00 inf S_SP 0.047 0.00 inf S_SP26 !! 0.050 0.19 inf S_SP − − − − − − − −39 !! − − − − 0.034 inf 0.00 W_SP − − − −41 !! − − − − − − − − 0.033 0.00 inf S_SP54 !!! 0.019 0.00 inf S_SP − − − − − − − −57 !!! − − − − 0.025 0.00 inf S_SP − − − −58 !!! − − − − − − − − 0.050 inf 0.00 W_SP72 !!!! − − − − 0.017 0.15 inf S_SP − − − −76 !!!! − − − − 0.052 0.00 0.93 S_SP − − − −78 !!!! 0.050 0.00 inf S_SP − − − − − − − −104 !!!! − − − − 0.051 inf 0.00 W_SP − − − −106 !!!! − − − − − − − − 0.036 0.57 inf S_SP109 !!!! − − − − 0.050 0.00 inf S_SP 0.049 0.00 inf S_SP125 !!!! − − − − 0.012 2.13 0.22 W_SP − − − −148 !!!! − − − − 0.051 inf 0.00 W_SP − − − −154 !!!!  − − − − 0.050 0.00 inf S_SP − − − −172 !!!! − − − − 0.0093 0.00 inf S_SP 0.049 0.00 inf S_SP194 !!!! − − − − 0.052 inf 0.00 W_SP − − − −197 !!!!  " − − − − 0.050 inf 0.32 W_SP − − − −224 !!!! − − − − 0.050 inf 0.00 W_SP 0.051 inf 0.00 W_SP248 !!!! − − − − 0.018 inf 0.45 W_SP − − − −290 !!!! − − − − 0.020 0.00 0.69 S_SP − − − −342 !!!! # − − − − − − − − 0.022 0.00 0.64 S_SP345 !!!! − − − − − − − − 0.021 inf 0.16 W_SP371 !!!! − − − − 0.033 0.00 inf S_SP − − − −384 !!!! − − − − 0.014 0.00 inf S_SP − − − −404 !!!! 0.043 0.074 inf S_SP − − − − − − − −436 !!!! 0.022 inf 0.75 W_SP − − − − 0.014 inf 0.73 W_SP443 !!!! 0.050 0.00 inf S_SP − − − − − − − −463 !!!! 0.031 0.00 1.38 S_SP − − − − 0.031 0.00 1.06 S_SP
Codon"site Site"characteristics Before"1999"(1)"vs"1999K2008"(2) 1999K2008"(2)"vs"2009"onwards"(3) Before"1999"(1)"vs"2009"onwards"(3)
! N"terminal+cytoplasmic+domain !! Transmembrane+domain !!! Stalk+domain !!!! Catalytic+globular+head+domain
 Framework)residue)NA)active)site ! Potential)epitope)contacting)residue)(antibody)escape)mutants) " Associated)with)(H)RI)by)NAIs)in#vitro
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Table	 S6.5	 2009	 pandemic	N1	 neuraminidase	 sites	 identified	 as	 differentially	 selected	 between	 the	different	time	periods	analysed	(temporal	sub-datasets).																																					Dif:	Difference;	dN:	rate	of	non-synonymous	substitutions;	dS:	rate	of	synonymous	substitutions;	(H)RI:	(Highly)	reduced	 inhibition;	 inf:	 infinite	(dS=0);	NAI:	Neuraminidase	inhibitor;	S_SP:	Stronger	Selective	Pressure;	W_SP:	Weaker	Selective	Pressure	Symbol	legend:		 	 	
	Site-by-site	selective	pressures	(SP)	were	compared	as	described	in	Table	6.5.	Significant	differences	involving	stronger	SP	are	highlighted	in	bold	and	italic.							
! N"terminal+cytoplasmic+domain !! Transmembrane+domain !!! Stalk+domain !!!! Catalytic+globular+head+domain
 Framework)residue)NA)active)site ! Epitope)contacting)residue " Associated)with)(H)RI)by)NAIs)in#vitro " Associated)with)a)synergistic)effect)on)NAI)(H)RI
(Pre%)Pandemic-period Post%pandemic-period4 ! 0.012 0.45 0.076 W_SP13 !! 0.041 0.70 2.67 S_SP44 !!! 0.022 0.33 1.29 S_SP50 !!! 0.031 5.21E%07 0.51 S_SP67 !!! 0.0075 0.071 0.68 S_SP69 !!! 0.0074 0.084 2.83 S_SP93 !!!! " 0.0031 0.146 2.18 S_SP117 !!!! 0.0024 0.00 inf S_SP136 !!!! # 0.00090 0.00 2.30 S_SP145 !!!! 0.022 0.00 0.73 S_SP167 !!!! 0.047 0.00 0.24 S_SP170 !!!! 0.0062 0.00 0.46 S_SP181 !!!! 0.042 0.30 0.00 W_SP220 !!!! " 0.022 0.20 1.33 S_SP247 !!!! # # 0.047 2.26 inf S_SP295 !!!!  # 0.019 0.00 0.22 S_SP321 !!!! 0.0081 0.32 4.20 S_SP324 !!!! 0.047 7.40E%17 1.13 S_SP369 !!!! 0.051 1.53 0.35 W_SP388 !!!! " 0.038 1.24 0.15 W_SP406 !!!! 0.053 inf 0.00 W_SP440 !!!! 0.041 1.81E%15 0.23 S_SP443 !!!! 0.0075 0.067 inf S_SP447 !!!! 0.028 0.00 0.81 S_SP461 !!!! 0.034 0.00 inf S_SP462 !!!! 0.024 1.92 0.00 W_SP
Codon-site Site-characteristics p-value dN/dS DIF
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CONCLUDING	REMARKS		This	research	project	has	made	possible	to	have,	at	national	level,	a	solid	and	up-to-date	platform	for	phenotypic	and/or	genotypic	evaluation	of	 influenza	virus	susceptibility	to	antiviral	drugs.	National	antiviral	susceptibility	data	was	gathered	over	a	10-year	period	(2004-2013),	providing	comprehensive	information	and	experience	on	the	susceptibility	of	 circulating	 human	 influenza	 viruses	 and	 on	 its	 natural	 variation	 across	 the	 different	virus	 types	 or	 subtypes	 and	 over	 time.	 It	 is	 essential	 to	 continue	monitoring	 influenza	virus	susceptibility	in	following	winter	seasons,	even	more	when	recent	worldwide	data	suggests	a	potential	risk	for	the	occurrence	of	seasonal	epidemics	of	neuraminidase	(NA)	H275Y	 A(H1N1)pdm09	 drug-resistant	 viruses	 and	 the	 selective	 pressure	 data	 here	obtained	 further	 supports	 that	 (evidence	 of	 positive	 directional	 selection).	 In	 these	following	 testing	 activities,	 it	will	 be	 important	 to	 include	 the	 two	 novel	 NA	 inhibitors	(NAIs)	peramivir	and	 laninamivir	 that,	although	only	available	 in	 limited	markets,	have	potential	for	worldwide	approval.	Both	drugs	were	already	received	in	the	laboratory	for	testing.	 Enhanced	 efforts	 to	 ensure	 that	 more	 specimens	 from	 patients	 undergoing	antiviral	 therapy	 are	 collected	 will	 also	 be	 important.	 This	 will	 not	 only	 allow	 to	determine	 the	 frequency	of	 resistance	or	 reduced	susceptibility	emerging	as	a	 result	of	treatment,	 but	 also	 to	 identify	 which	 shifts	 in	 IC50	 are	 clinically	 relevant	 and	 help	determining	 the	 IC50	 cut	 off	 for	 clinical	 relevance	 in	 NA	 inhibition	 assays.	 The	technological	capacity	and	know-how	now	available	also	allow	us	to	advance	to	a	more	specific	line	of	research	focused	on	elucidating	the	role	of	NA	amino	acid	substitutions	in	NAI	susceptibility,	as	those	here	identified:	R222Q	and	D344N	in	seasonal	N1	NA;	D151N,	S367N	and	K369T	 in	N2	NA;	 I240V,	K219N	and	K373E	 in	B/Victoria-lineage	NA.	 It	will	also	be	 interesting	 to	expand	the	study	 to	hemagglutinin	(HA)	and	elucidate	 the	role	of	H3	 HA	 T135A,	 R142G	 and	 S262N,	 and	 2009	 H1	 HA	 D222G	 amino	 acid	 substitutions.	However,	 for	 this	 it	 will	 be	 necessary	 to	 establish	 an	 in	 vitro	 susceptibility	 assay	accounting	for	HA-mediated	changes,	most	probably	a	red	blood	cell	(RBC)	elution	assay.		
	Whole-genome	 sequencing	 did	 not	 reveal	 any	 possible	 explanation	 for	why	NA	H275Y	drug-resistant	 former	 seasonal	 A(H1N1)	 viruses	 were	 fitter	 and	 spread	 over	 their	sensitive	 counterparts.	 However,	 further	 in	 vitro	 and	 in	 vivo	 studies	 are	 needed	 to	confirm	that	the	PB2	P453S	and	PB1	N642S	amino	acid	substitutions	found	specifically	in	their	 genome	 have	 no	 effect	 on	 virus	 fitness,	 as	 suggested	 by	 their	 location	 onto	 the	
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protein	structure.	The	identification	of	amino	acid	substitutions	known	to	or	that	based	on	their	functional	impact	may	enhance	viral	fitness	in	influenza	viruses	resistant	or	with	decreased	susceptibility	to	NAIs,	highlighted	the	importance	of	extending	genetic	analysis	to	all	segments	of	influenza	genome.	
	Selective	 pressure	 (SP)	 analysis	 was	 mainly	 focused	 on	 the	 NA	 sites	 associated	 with	resistance	or	reduced	susceptibility	to	NAIs	and/or	contacting	with	the	drug,	but	it	also	allowed	 a	 comprehensive	 study	 of	 the	 global	 and	 site-specific	 SP	 acting	 on	 human	influenza	NA.	 Knowing	 now	 that	most	 sites	 associated	with	NAI	 resistance	 or	 reduced	susceptibility	 are	 either	 negatively	 selected	 or	 experiencing	 a	 n.s.	 dN/dS<1,	 it	 will	 be	interesting	to	investigate	the	number	and	type	of	amino	acid	changes	that	have	to	occur	for	 circulating	 viruses	 become	 resistant	 or	 possess	 (H)RI	 in	 vitro	 –	 genetic	 barrier	 to	resistance	or	(H)RI.	Also,	there	is	a	strong	possibility	of	further	studying	the	6	unknown	regions	here	 identified	as	potential	new	druggable	 targets	 in	 the	 context	of	 a	new	PhD	research	project	now	initiated	in	the	laboratory,	focused	on	exploring	NS1	as	a	potential	emerging	antiviral	target.								 It	was	a	true	pleasure	THE	END					
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Influenza A(H1N1)pdm09 Resistance and
Cross-Decreased Susceptibility to Oseltamivir
and Zanamivir Antiviral Drugs
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and Helena Rebelo-de-Andrade1,2*
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Lisbon, Portugal
Neuraminidase inhibitors (NAIs) oseltamivir
and zanamivir are currently the only effective
antiviral drugs available worldwide for the
management of influenza. The potential devel-
opment of resistance is continually threatening
their use, rationalizing and highlighting the
need for a close and sustained evaluation of
virus susceptibility. This study aimed to ana-
lyze and characterize the phenotypic and geno-
typic NAIs susceptibility profiles of A(H1N1)
pdm09 viruses circulating in Portugal from
2009 to 2010/2011. A total of 144 cases of
A(H1N1)pdm09 virus infection from community
and hospitalized patients were studied, includ-
ing three suspected cases of clinical resistance
to oseltamivir. Oseltamivir resistance was con-
firmed for two of the suspected cases. Neur-
aminidase (NA) H275Y resistant marker was
found in viruses from both cases but for one it
was only present in 26.2% of virus population,
raising questions about the minimal percent-
age of resistant virus that should be consid-
ered relevant. Cross-decreased susceptibility to
oseltamivir and zanamivir (2–4 IC50 fold-
change) was detected on viruses from two
potentially linked community patients from
2009. Both viruses harbored the NA I223V
mutation. NA Y155H mutation was found in 18
statistical non-outlier viruses from 2009, having
no impact on virus susceptibility. The muta-
tions at NA N369K and V241I may have con-
tributed to the significantly higher baseline IC50
value obtained to oseltamivir for 2010/2011
viruses, compared to viruses from the pan-
demic period. These results may contribute to
a better understanding of the relationship
between phenotype and genotype, which is
currently challenging, and to the global assess-
ment of A(H1N1)pdm09 virus susceptibility
profile and baseline level to NAIs. J. Med.
Virol. 87:45–56, 2015.
# 2014 Wiley Periodicals, Inc.
KEY WORDS: A(H1N1)2009pandemicvariant;
neuraminidase inhibitors; sus-
ceptibility testing; NA H275Y;
NA I223V; Portugal
INTRODUCTION
A(H1N1)2009 pandemic was the first influenza
pandemic having the assistance of an extensive
preparedness and response planning. Advance stock-
piling of antiviral drugs was one of the key measures
recommend by World Health Organization (WHO),
and neuraminidase inhibitors (NAIs), in particular
oseltamivir, were the antiviral drugs of choice for
many developed countries [WHO, 2005, 2009a; Meijer
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et al., 2007; Oshitani et al., 2008]. Portugal stockpiled
a large amount of oseltamivir phosphate (enough for
2.51 million treatments and 100,000 prophylactic
schemes) and a small quantity of zanamivir (enough
for 42 treatments). This national stockpile was re-
leased on April 24, 2009, immediately after the
activation of the National Contingency Plan due to
A(H1N1)pdm09 virus emergence [DGS, 2010]. Na-
tional progression from the containment to mitigation
pandemic stage on 21st August and availability of
the pandemic vaccine on 26th October required
timely national updates on the recommendations for
antiviral drug use during 2009 [DGS, 2010].
NAIs were an appropriate choice for A(H1N1)2009
pandemic prevention and control. This new variant of
the Orthomyxoviridae family, Influenzavirus A genus,
exhibited natural resistance to M2 protein inhibitors
and clinical effectiveness of NAIs was reported in
observational studies carried out during the pandem-
ic period [CDC, 2009; Dominguez-Cherit et al., 2009;
Jain et al., 2009; Pada and Tambyah, 2011]. Also, the
emergence of resistant variants was only detected for
oseltamivir and limited to sporadic events, largely in
association with drug use and patients with an
immunocompromised condition [WHO, 2011a]. The
first case of oseltamivir resistance was reported by
Denmark Health Authorities 3 months after the emer-
gence of the A(H1N1)2009 variant, demonstrating the
importance of national capability for the rapid detec-
tion of resistant variants [ECDC, 2009]. Since then and
until October 5, 2011, a further 604 cases of oseltami-
vir resistance were detected globally, all harboring the
neuraminidase (NA) H275Y mutation. Person-to-person
transmission of oseltamivir-resistant virus was identi-
fied during the pandemic period but only in three
limited clusters, variable in size, timing and location
[WHO, 2010, 2011a]. During the following 2010/2011
season, national surveillance activities carried out at
the United Kingdom, Japan, and United States re-
ported an increase in the proportion of A(H1N1)pdm09
oseltamivir-resistant virus with no known exposure to
the drug, potentially indicating a low-level transmis-
sion of resistant virus in the community [Lackenby
et al., 2011; WHO, 2011a]. This was confirmed recent-
ly, by the identification of a community cluster of 6
A(H1N1)pdm09 oseltamivir and peramivir-resistant
viruses (H275Y) with no known association to drug use
during the end of 2013 in Japan [Takashita et al.,
2014]. Regarding zanamivir, only one case of reduced
susceptibility was identified to date, in a virus harbor-
ing NA I223R mutation collected from an immunocom-
promised child [WHO, 2011a].
The aim of this study was to analyze and charac-
terize the NAIs susceptibility profiles of influenza
A(H1N1)pdm09 viruses circulating in Portugal, from
the 2009 pandemic period to the 2010/2011 winter
season and in both community and hospital settings,
to NAIs (oseltamivir and zanamivir). Suspected
cases of clinical resistance development were also
studied.
MATERIALS AND METHODS
Clinical Specimens and Virus Strains
Clinical specimens from the upper respiratory tract
of patients positive for influenza A(H1N1)pdm09
virus infection were used. Specimens were provided
by two national reference hospitals—Hospital de
Curry Cabral (HCC) and Hospital Dona Estefaˆnia
(HDE) (Lisbon, Portugal). Specimen collection was
performed in hospitalized and in community patients
attending the hospital emergency unit, from the 2009
pandemic period (June 2009–January 2010) to the
2010/2011 winter season (January–March 2011).
A total of 216 cases of influenza A(H1N1)pdm09
virus infection, 163 from the pandemic period and 53
from 2010/2011, were selected for study. This in-
cludes three suspected cases of clinical resistance
identified by the hospital clinicians during 2010/2011
in non-related hospitalized patients that failed to
respond to oseltamivir treatment (positive for influen-
za after >10 days of therapy), independently of the
timing between symptom onset and initiation of
therapy (< or >48hr) (Table I). Clinical specimens
from these three suspected cases were directly tested
for the presence of the NA H275Y oseltamivir-resistant
marker. These and all the other 213 specimens from
the remaining selected cases underwent viral isolation
in MDCK-SIAT1 cells. A total of 142 A(H1N1)pdm09
virus strains were isolated successfully, 116 from the
pandemic period and 26 from 2010/2011, and evaluated
further for phenotypic antiviral drug susceptibility,
using mainly a second or third cell passage isolate.
This includes the virus strain isolated from suspected
case 2 (A/Portugal/03/2011), that was the only sus-
pected case for which viral isolation was successful
(Table I). Fifty of the 142 virus strains tested pheno-
typically, 44 from the pandemic period and 6 from
2010/2011, were evaluated for genotypic antiviral drug
susceptibility by NA and hemagglutinin (HA) sequenc-
ing. This comprised all virus strains identified as
statistical outliers in the phenotypic evaluation and
approximately 25% of the non-outlier strains (randomly
selected).
Overall, 144 of the total selected 216 cases of
influenza A(H1N1)pdm09 virus infection were stud-
ied. Two cases were only studied genotypically for the
specific presence of H275Y mutation (suspected cases
1 and 3), while the remaining 142 cases (including
suspected case 2) were completely studied through
phenotypic and/or genotypic analysis.
Screening Assay for Rapid Detection of NA
H275Y Oseltamivir-Resistant Marker
Viral extraction was performed using the automat-
ed extractor EasyMag (bioMe´rieux, Linda-a-Velha,
Portugal) according to the manufacturer’s recommen-
dations. The presence of NA H275Y oseltamivir-
resistant marker was searched by real-time RT-PCR,
using a protocol kindly provided by Prof. Martin
J. Med. Virol. DOI 10.1002/jmv
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Curran (Public Health England [PHE], Adden-
brooke’s Hospital, Cambridge, UK). These methodolo-
gies were performed at HCC.
Quantification of H275Y Oseltamivir-Resistant
Quasi-Species
The proportion of wild-type 275H and mutant 275Y
virus in oseltamivir-resistant quasi-species was quan-
tified by pyrosequencing. This method was performed
at the PHE (Colindale, London, UK), following the
standard operating procedure in use [HPA, 2010].
Genotypic Evaluation of Virus
Susceptibility to NAIs
Genotypic evaluation was performed by NA and
HA full-length gene sequencing. RNA extraction was
performed with QIAamp Viral RNA Mini Kit (QIA-
GEN, Hilden, Germany). Sequencing methodology
and analysis included the CDC protocol recommended
by WHO [2009b] and the use of SeqMan application
of Lasergene software v.4.05 (DNASTAR, Inc., Madi-
son, WI), as described previously [Santos et al., 2011;
Giria et al., 2012]. MEGA5 software was used for
multiple sequence alignment by Clustal W method
and for mutational analysis against A/California/07/
2009 vaccine strain sequences. N1 numbering was
used for NA and the signal peptide sequence was not
considered for HA numbering. Phylogenetic analysis
included (1) determination of the best-fit model for
nucleotide substitution according to Akaike Informa-
tion Criterion, using jModelTest v.2.1.2 [Guindon and
Gascuel, 2003; Darriba et al., 2012]; and (2) construc-
tion of phylogenetic trees by maximum-likelihood
method using PhyML 3.0 software available on Sea-
view multiplatform v.4.4.0. Approximate likelihood-
ratio tests (aLRT(SH-like)) were used for measuring
branch support and subtree-pruning-and-regrafting
(SPR) and nearest-neighbor-interchange (NNI) rear-
rangement operations were considered for tree topolo-
gy improvement. NA and HA sequences of A/
California/07/2009 vaccine strain and of reference
strains were included for comparative analysis. These
sequences were retrieved from the Global Initiative
on Sharing All Influenza Data (GISAID) EpiFluTM
Database and from the National Center for Biotech-
nology Information Influenza Virus Resource. Acces-
sion numbers are provided in the phylogenetic trees,
after the sequence name. In addition, the accession
numbers from the sequences downloaded from GI-
SAID database are listed in Table II, to acknowledge
the sequence providers.
Phenotypic Evaluation of Virus
Susceptibility to NAIs
Phenotypic profiling was based on IC50 determina-
tion, using the new WHO IC50 fold-change criteria
that for influenza A viruses is: fold-change increase
<10—normal inhibition (NI); 10–100 fold-change in-
crease—reduced inhibition (RI); fold-change increase
>100—highly reduced inhibition (HRI) [Hurt et al.,
2012; WHO, 2012]. Non-outlier IC50 values from
A(H1N1) seasonal strains that circulated in Portugal
TABLE I. Epidemiological, Clinical, and Laboratorial Information Concerning the Three Cases From 2010/2011 Suspected
of Clinical Resistance Development to Oseltamivir
Case number 1 2 3
Epidemiological and clinical information
Patient
Age (years) 1 27 61
Gender Male Female Male
Underlying risk conditions Premature bronchopulmonary
dysplasia (hospitalized
since birth)
HIVþ; pregnant Not referred
Clinical disease Severe Severe with loss of
the fetus
Severe
Influenza antiviral drug treatment
Antiviral drug Oseltamivir Oseltamivir Oseltamivir
Starting date 11 days after the 1st
positive rt RT-PCR
Not referred Not referred
Evidence of failure rt RT-PCR positive after
15 days of treatment
Not referred rt RT-PCR positive after
10 days of treatment
Time between the start of antiviral
therapy and specimen collection
20 days Not possible to estimate "10 days
Clinical outcome Not referred Deceased Not referred
Other observations — Initiated treatment
with zanamivir;
from Guinea (Africa)
—
Clinical specimen laboratorial results
H275Y oseltamivir-resistant marker Not present Present (Ct¼13) Present as quasi-species
(Ct¼27 for 275Y; Ct¼28
for 275H), representing
26.2% of the virus
population
Virus strain isolated No strain isolated A/Portugal/03/2011 No strain isolated
J. Med. Virol. DOI 10.1002/jmv
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from 2004/2005 to 2008/2009 (N¼ 59 for oseltamivir;
N¼ 70 for zanamivir) [Correia et al., 2010] were used
for performing IC50 A(H1N1) lineage comparative
analysis.
Phenotypic Assay
Phenotypic testing was performed using the in-
house MUNANA-based IC50 fluorescence assay pro-
vided by PHE [HPA, 2006], as described previously in
Correia et al. [2010]. Oseltamivir carboxylate and
zanamivir were provided through a material transfer
agreement by, respectively, F.Hoffmann-La Roche
Ltd (Basel, Switzerland) and GlaxoSmithKline (Hert-
fordshire, UK).
Statistical Analysis
IC50 values were determined through point-to-point
analysis using Microsoft Office Excel 2007. Statistical
outliers were identified by determination of upper
and lower cut offs, with each one including a mild
(1.65 standard deviations [SD] above or below the
median, respectively) and an extreme (3 SD above or
below the median, respectively) level. Cut offs were
determined using Scaled Median Absolute Deviation
(SMAD) statistic method [AMC, 2001]. All outlier
strains were retested twice and the mean IC50 value
was considered for analysis. Median baseline (median
without upper and lower outliers) was used for
determination of the fold-change thresholds"RI (me-
dian# 10) and HRI (median# 100), and of the indi-
vidual fold-changes. Linear regression for time trend
analysis was performed using the Microsoft Office
Excel 2007 Analysis ToolPak. Cut offs, median base-
lines, fold-change thresholds and time trends were
determined separately for each time period analyzed.
Independent sample’s t and paired sample’s t-tests
were performed in SPS Statistics software v17.0 and
a P-value <0.05 was considered as statistically
significant. All phenotypic data were log-transformed
before being used for statistical analysis.
RESULTS
H275Y Mutation Analysis in Clinical Suspected
Resistant Cases
The presence of NA H275Y mutation was detected
in the clinical specimens of both cases 2 and 3,
confirming the suspicion of clinical resistance develop-
ment to oseltamivir. In the specimen of suspected case
1, only wild-type 275H virus was detected by amplifica-
tion. Detailed results are presented in Table I.
Virus Susceptibility Phenotype to NAIs
Oseltamivir. A total of 126 (88.7%; N¼ 142)
A(H1N1)pdm09 virus strains, 104 (89.7%; N¼ 116)
from the pandemic period and 23 (88.5%; N¼ 26)
from 2010/2011, exhibited an IC50 value within the
normal range to oseltamivir (range of values between
mild lower and upper cut offs—median $1.65 SD).
The IC50 values varied from 0.50 to 1.07 nM for
pandemic period strains and from 0.69 to 1.21 nM for
2010/2011 strains. The other 15 (10.6%) strains, 12
(10.3%) from the pandemic period and 3 (11.5%) from
2010/2011, were identified as statistical outliers. Nine
(6.3%) with IC50 values falling over upper cut offs, 4
at extreme level and 5 at mild level, and 6 (5.2%)
with IC50 values falling under lower cut offs (1
extreme and 5 mild). Figure 1A gives information on
oseltamivir outlier strains and IC50 fold-changes
including all IC50 values obtained for oseltamivir,
statistically analyzed and distributed by time. A/
Portugal/03/2011 (isolated from H275Y-confirmed
case 2) was the only strain exhibiting a HRI pheno-
typic profile to oseltamivir, with an %250 fold-change
increase in the IC50 value (2010/2011 RI threshold
¼ 8.85; 2010/2011HRI threshold¼ 88.50). Despite de-
tection of statistical outliers, all the other 141 strains
analyzed showed a NI phenotype to this antiviral
drug.
No apparent time grouping was observed for upper
and/or lower statistical outliers, with exception of the
two upper extreme outliers from 2009 (A/Portugal/17/
2009 and A/Portugal/82/2009), which are from 2
successive weeks (Fig. 1A). These two outlier strains
are from two A(H1N1)pdm09 positive cases closely
related at the geographic level but without epidemio-
logical link.
Considering non-outlier IC50 values, a significant
decreasing trend over time was observed among
the 2009 pandemic period values (P¼ 0.00516, R2¼
0.074172, linear regression fit). However, the very low
R2 value obtained indicates that time is a poor
predictor of IC50 variation. A significant difference was
also observed when comparing the non-outlier IC50
values from the two time periods analyzed (P¼ 0.001,
independent sample’s t-test).
Zanamivir. For zanamivir, 131 (92.3%, N¼ 142)
virus strains, 110 (94.8%; N¼ 116) from the pandemic
period and 21 (80.8%; N¼ 26) from 2010/2011, exhib-
ited an IC50 value within the normal range. Specifi-
cally, the IC50 values from pandemic period strains
varied from 0.40 to 0.99 nM and those from 2010/
2011 strains varied from 0.41 to 0.80 nM. The other
11 (7.7%) strains, 6 (5.2%) from the pandemic period
and 5 (19.2%) from 2010/2011, were identified as
statistical outliers. Six (5.2%) with IC50 values falling
over upper cut offs, one at extreme level and five at
mild level, and five (3.5%) with IC50 values falling
under lower cut offs (one extreme and four mild).
Figure 1B shows information on zanamivir outlier
strains and IC50 fold-changes including all zanamivir
IC50 values, statistically analyzed and distributed by
time. The strains A/Portugal/17/2009, A/Portugal/82/
2009, and A/Portugal/07/2011 exhibited to zanamivir
the same phenotype displayed to oseltamivir, of
upper outlier. Despite detection of statistical outliers,
all the 142 A(H1N1)pdm09 analyzed strains shared a
NI phenotypic profile to zanamivir (RI fold-change
J. Med. Virol. DOI 10.1002/jmv
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Fig. 1. SMAD statistical analysis of the IC50 values
obtained for the 142 A(H1N1)pdm09 virus strains analyzed
phenotypically, 116 from the pandemic period and 26 from
the 2010/2011 season, displayed by week of specimen collec-
tion, for oseltamivir (A) and zanamivir (B). The IC50 values of
virus strains from the pandemic period are coloured in black
and those of virus strains from 2010/2011 are coloured in
white (colored web version: circles represent the IC50 values
of virus strains from the pandemic period and triangles the
IC50 values of virus strains from 2010/2011). The IC50 fold-
change observed in relation to median baseline is indicated in
brackets after the strain designation.
J. Med. Virol. DOI 10.1002/jmv
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threshold¼ 6.20 [pandemic period] or 5.90 [2010/
2011]; HRI fold-change threshold¼ 62.0 [pandemic
period] or 59.0 [2010/2011]).
Time analysis revealed that upper outliers from
the pandemic period grouped between weeks 29 and
32 of 2009, but no epidemiological link was found
(Fig. 1B).
Concerning non-outlier IC50 values, a significant
decreasing trend over time was detected for 2009
pandemic period values (P¼ 0.00481, R2¼ 0.071277,
linear regression fit). However, as observed for oselta-
mivir, the very low R2 value prevents interpretation
of the causal relationship between these two varia-
bles. No significant difference was observed between
the values from the two time periods analyzed
(P¼ 0.374, independent sample’s t-test).
Oseltamivir and zanamivir non-outlier IC50 values
differed significantly (P¼ 0.000, paired sample’s t-
test). A significant difference was also observed for
both NAIs when comparing the non-outlier IC50
values from the A(H1N1)pdm09 strains analyzed
here with those from A(H1N1) seasonal strains that
circulated at national level from 2004/2005 to 2008/
2009 (P¼ 0.000, independent sample’s t-test) (Fig. 2).
A total of 12 A(H1N1)pdm09 virus strains (8 from
the pandemic period and 4 from 2010/2011) were
classified as upper statistical outliers for oseltamivir
and/or zanamivir and thus selected for further inves-
tigation at genotypic level. From these, only A/
Portugal/03/2011 had a known association to drug
use, having been isolated from suspected case 2
clinical specimen.
Virus Susceptibility Genotype to NAIs
NA and HA amino acid mutations found specifically
in the sequences of the 12 phenotypic upper outlier
strains are indicated and characterized in Table III.
NA-specific mutations of oseltamivir extreme outlier
strains A/Portugal/17/2019, A/Portugal/82/2009 and
A/Portugal/03/2011, have a known reduced suscepti-
bility profile (I223V and H275Y). Only A/Portugal/03/
2011 exhibited specific mutations in the HA se-
quence, harboring an N156D mutation, located in an
antigenic site. Regarding all the other oseltamivir
and/or zanamivir outlier strains, no shared mutation
or known association to a reduced susceptibility
profile were identified. In addition, approximately
half of these outliers lacked any specific mutations at
NA or HA sequences (Table III).
Mutation NA Y155H, associated with a HRI pheno-
typic profile to both NAIs in seasonal A(H1N1)
subtype [Nguyen et al., 2012], was found in the
sequence of 18 non-outlier A(H1N1)pdm09 strains
from 2009 (12.7%; 18/142), having no apparent im-
pact on NAIs phenotypic susceptibility (Fig. 3A).
Phylogenetic analysis of NA and HA nucleotide
sequences revealed two important findings: (1) lack of
nucleotide differences between the sequences of the
two upper outlier strains A/Portugal/17/2009 and A/
Portugal/82/2009, with pairwise distance calculations
confirming the 100% identity (results not shown);
and (2) no clustering among all the other outlier
strains, with outlier sequences being closely related
to non-outlier sequences from the same time period
(Fig. 3A and B).
DISCUSSION
This study comprised the analysis of A(H1N1)
pdm09 virus collected from community and from
hospitalized patients, with and without antiviral
drug treatment. Using this integrated approach it
was possible to cover the two possible settings where
influenza antiviral drug resistance or reduced suscep-
tibility can emerge—spontaneously in the community
or associated with drug use.
Oseltamivir resistance was identified for two
A(H1N1)pdm09 cases from 2010/2011, both from
oseltamivir-treated patients (suspected cases 2 and
3). The NA H275Y resistant marker was found in
viruses from both cases but for one (suspected case 3)
it was only detected in 26.2% of the clinical specimen
viral population. The fact that this percentage of
resistant virus could have been sufficient for causing
treatment failure raised questions about the minimal
percentage of resistant virus that should be consid-
ered relevant in quasi-species. For suspected case 2,
the NA H275Y mutation was identified in the entire
viral population of both clinical specimen and virus
isolate (A/Portugal/03/2011 strain). Phenotypic analy-
sis of this virus strain revealed a HRI profile to
oseltamivir (IC50¼ 219.95mM; "250 fold-change re-
duction). When compared with H275Y oseltamivir-
resistant A(H1N1) seasonal strains that circulated
previously at national level (IC50¼ 314.04–1208.84mM;
159–613 fold-change) [Correia et al., 2010], this
A(H1N1)pdm09 strain exhibited a lower IC50 value and
Fig. 2. Comparative analysis of oseltamivir and zanamivir
non-outlier IC50 values obtained for the A(H1N1)pdm09 virus
strains analyzed in this study (N¼126 oseltamivir; N¼132
zanamivir) and for seasonal A(H1N1) virus strains previously
circulating at national level, from 2004/2005 to 2008/2009
(N¼59 oseltamivir; N¼70 zanamivir).
J. Med. Virol. DOI 10.1002/jmv
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a similar IC50 fold-change reduction. Both results
support an over all difference between the oseltamivir
resistance levels of the H275Y viruses from the two
A(H1N1) lineages. In addition to the NA H275Y
mutation, genotypic analysis of A/Portugal/03/2011
identified HA N156D as the only other specific muta-
tion of this virus strain. HA mutations at residue 156
(N156D/S/K/T) had been described in A(H1N1)2009
variant as commonly but not exclusively associated
with virus propagation in MDCK-SIAT1 cells [WHO,
2011b]. In fact, another polymorphism at this residue
(N156K) was observed in this study for one upper
mild outlier. HA sequencing from the clinical specimen
will be essential for confirmation. Also, residue 156 is
located in the antigenic site Sa and therefore N156D
mutation could be associated with the key antigenic
Fig. 3. Phylogenetic analysis of the neuraminidase (A) and
hemagglutinin (B) full-length nucleotide sequences of the 50
A(H1N1)pdm09 virus strains evaluated genotypically, 44 from
the pandemic period and 6 from 2010/2011. Nucleotide substitu-
tion models GTRþG4 (General Time Reversible model with a 4-
category gamma distribution for rate variation among sites)
and HKY85þI (Hasegawa-Kishono-Yano model with optimized
proportion of invariable sites) were used for construction of,
respectively, NA and HA maximum-likelihood trees, as deter-
mined in jModelTest. aLRT (SH-like) branch support values
equal or higher to 0.75 are indicated in the tree. Virus strains
are symbol coded according to their phenotypic outlier classifi-
cation: ### upper extreme outlier; # upper mild outlier; " lower
mild outlier (colored web version: virus strains are colour coded
according to their phenotypic outlier classification - red: upper
extreme outlier; orange: upper mild outlier; green: lower mild
outlier; black: non-outlier). When a virus strain was outlier for
both NAIs but at different categories, the category associated
with a higher IC50 fold-change was used for strain coding.
Additionally, all strains from 2010/2011 are coloured in grey
(colored web version: all strains from 2010/2011 are marked
with the symbol #). Reference virus strains are indicated in
bold and uppercase and A/California/07/2009 vaccine strain is
additionally in italic. All indicated cluster defining amino acid
mutations were identified against vaccine strain sequence. HA
established genetic clades are based in [WHO, 2012].
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role of HA. However, a potential compensatory role for
the H275Y fitness deficit cannot be ruled out and could
be tested through in vitro replication kinetics assays
using wild-type and mutant viruses (without N156D
mutation). HA sequencing is important for the study of
antiviral drug susceptibility not only due to the poten-
tial compensatory role that HA mutations may have
but essentially due to the direct impact that HA
mutations can have on virus susceptibility. It is well-
known that HA and NA proteins work in concert
during viral entry and viral release from the cell. Thus,
if an HA mutation decreases the virus affinity for
binding cell receptors, then it could also reduce the
virus NA activity requirement for viral release and
consequently reduce the virus susceptibility to any NAI
[Zambon and Hayden, 2001].
The identification of the two H275Y oseltamivir-
resistant cases is in agreement with the sporadic
detection of resistant cases that has been observed
worldwide. Oseltamivir-resistant cases have emerged
mainly as a result of antiviral drug use and immuno-
suppressive conditions, both criteria present for sus-
pected case 2 [WHO, 2011a].
The presence of H275Y resistant marker was not
detected in the original specimen from clinical sus-
pected resistant case 1. Therefore, the evidence of
clinical failure observed can be most probably a result
of the high delay between the onset of symptoms and
the start of antiviral therapy (11 days).
Other finding of this study was the identification of
I223V mutation in the NA sequence of two A(H1N1)
pdm09 virus strains exhibiting higher IC50 values to
oseltamivir (three to four fold-change increase) and,
to a lesser extent, to zanamivir (!2-fold-change
increase).These virus strains are from two A(H1N1)
pdm09 community cases from the 2009 pandemic
period. NA I223V mutation was previously associated
to a similar decreased susceptibility pattern in N1
viruses but only in one reverse genetic study [Nguyen
et al., 2012]. During surveillance activities or clinical
studies, this mutation was found in viruses with
reduced susceptibility to oseltamivir (fold-change in-
crease >10) in the A(H3N2) and B subtype/type
[Nguyen et al., 2012]. The clinical impact of I223V, as
of most NAIs reduced susceptibility-conferring muta-
tions, is still unclear. But, mutations at position 223
have previously been associated with clinical NAIs
treatment failure [van der Vries et al., 2012]. No
epidemiological link was known for the two patients
harboring the NA I223V viruses, but the identical
NA and HA sequences of the viruses and the tempo-
ral and geographic proximity of the cases, indicates a
potential relation.
The observed lack of impact of NA Y155H mutation
(HRI NAIs phenotype in A(H1N1) seasonal viruses),
in the NAIs phenotypic profile of A(H1N1)pdm09
viruses can be explained by structural differences on
the NA of A(H1N1) pandemic and seasonal variants.
These structural differences could also explain the
significantly lower IC50 values exhibited by the virus-
es from the pandemic variant. The absence of the
150-cavity, characteristic of N1 virus, in A(H1N1)
pdm09 viruses was initially indicated as the main
structural difference [Li et al., 2010]. However,
a recent study showed the presence of this cavity
in all N1 and, surprisingly, in N2 viruses, raising
new questions about NA structures [Amaro et al.,
2011].
No genetic mechanism was found for the IC50
minor increase (1.4- to 2.1-fold-change) observed for
most of oseltamivir and zanamivir upper outlier virus
strains. No shared mutation was identified and
approximately half of these virus strains lacked any
specific mutations at NA or HA sequences. Addition-
ally, the majority of the specific mutations identified
probably derived from the key antigenic role of these
two glycoproteins, given their location in antigenic
sites or by creating potential N-glycosylation sites
that may prevent accessibility and recognition of
antigenic sites by antibodies [Vigerust et al., 2007].
Other specific mutations, positioned in the stalk
region of the protein, are most likely not related with
antiviral susceptibility. Whole genome sequencing
of upper outlier strains is being performed in order
to find if mutations located in the other genome
segments can be contributing for the IC50 minor
increases observed. The understanding of these minor
increases is one of the major current challenges in
influenza antiviral drug susceptibility evaluation.
A(H1N1)pdm09 viruses were more susceptible to
zanamivir than to oseltamivir. This drug-specific
variation is characteristic of N1 viruses and results
from differences in the intrinsic chemical properties
of the two NAIs [Ferraris and Lina, 2008]. The
chemical similarity that zanamivir exhibits to the
natural substrate of NA (sialic acid) could explain
the different phenotypic results obtained for this
drug [van der Vries et al., 2012]. This includes the
lack of significant differences between the IC50 values
from the two time periods analyzed and the lower
impact of NA I223V mutation on virus susceptibility
(lower IC50 fold-change). Regarding oseltamivir, the
two NA-specific mutations of 2010/2011 virus strains
—N369K and V241I, may have contributed for the
significantly higher IC50 values obtained during that
season. Computational analysis showed that both
mutations improve NA stability of H275Y oseltami-
vir-resistant virus and experimental studies showed
that N369K increases NA surface expression and
activity of this resistant variant [Hurt et al., 2012].
However, the unequal size of the two time period
datasets (N¼ 116 for the pandemic period and N¼ 26
for 2010/2011) may also be contributing for this IC50
temporal difference.
The results obtained in this study may contribute
to a better understanding of the currently challeng-
ing phenotype–genotype relationship. In addition, all
national data presented here may contribute to the
global assessment of A(H1N1)pdm09 virus suscepti-
bility profile and baseline level to NAIs.
J. Med. Virol. DOI 10.1002/jmv
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Background:  Genetic  changes  in  influenza  surface  and  internal  genes  can  alter  viral  fitness  and  virulence.
Mutation  trend  analysis  and  antiviral  drug  susceptibility  profiling  of  A(H1N1)pdm09  viruses  is essential
for  risk  assessment  of  emergent  strains  and  disease  management.
Objective:  To profile  genomic  signatures  and  antiviral  drug  resistance  of  A(H1N1)pdm09  viruses  and  to
discuss  the  potential  role  of  mutated  residues  in human  host  adaptation  and  virulence.
Study  design:  A(H1N1)pdm09  viruses  circulating  in Portugal  during  pandemic  and  post-pandemic  periods
and 2009/2010  season.  Viruses  were  isolated  in MDCK-SIAT1  cell  culture  and  subjected  to  mutation
analysis  of surface  and  internal  proteins,  and  to antiviral  drug  susceptibility  profiling.
Results:  The  A(H1N1)pdm09  strains  circulating  during  the  epidemic  period  in  Portugal  were  resistant
to  amantadine.  The  majority  of the  strains  were  found  to  be susceptible  to  oseltamivir  and  zanamivir,
with  five  outliers  to  neuraminidase  inhibitors  (NAIs)  identified.  Specific  mutation  patterns  were  detected
within  the  functional  domains  of  internal  proteins  PB2,  PB1,  PA,  NP,  NS1,  M1  and  NS2/NEP,  which  were
common  to  all  isolates  and  also some  cluster-specific.
Discussion:  Modification  of  viral  genome  transcription,  replication  and  apoptosis  kinetics,  changes  in
antigenicity  and  antiviral  drug  susceptibility  are  known  determinants  of  virulence.  We report  several
point mutations  with  putative  roles  in viral  fitness  and  virulence,  and  discuss  their potential  to  result in
more  virulent  phenotypes.  Monitoring  of  specific  mutations  and  genetic  patterns  in  influenza  viral  genes
is essential  for  risk  assessing  emergent  strains,  disease  epidemiology  and  public  health  implications.
© 2011 Elsevier B.V. All rights reserved.
1. Background
The emergence of virulent influenza phenotypes is a conse-
quence of genetic changes altering the function of individual
proteins or their functional compatibility.
Genetic changes in the viral surface proteins can impact on virus
binding, entry, assembly, release, induction of the host’s immune
response and antiviral drug resistance.
Within the internal proteins, genetic changes can impact on vir-
ulence and infectivity if they alter the ability of the virus to replicate
or induce cellular apoptosis.1 The viral replication process is multi-
genic and interactive, involving the replication complex and the
structural and functionally associated M1  and NS2/NEP proteins.1,2
The gene segments coding for the proteins involved in replica-
tion, code for additional proteins associated with the induction of
∗ Corresponding author. Tel.: +351 217519332.
E-mail address: h.rebelo.andrade@insa.min-saude.pt (H. Rebelo de Andrade).
cellular apoptosis during viral infection. The (+1)ORF of PB1
encodes PB1-F2 with pro-apoptotic function in the host cells and
the NS gene encodes NS1 protein associated with the activa-
tion of anti-apoptotic mechanisms, permitting viral replication
to occur.3–5 The cassette of internal genes therefore controls the
major processes by which viral fitness is determined: replica-
tion and apoptosis. An increased replication rate or stimulation of
anti-apoptotic mechanisms, produces higher viral loads that can
overcome host immune response, enhance infectivity and result in
a more severe and transmissible disease. The most severe epidemi-
ological situations caused by seasonal influenza viruses occurred in
1947 and 1951 as a consequence of genetic changes within inter-
nal proteins involved in replication of A(H1N1) viruses. The strains
spread worldwide and caused exceptionally high mortality.6
Monitoring evolutionary trends in the genes encoding influenza
virus internal proteins, and profiling antigenic proteins and antivi-
ral drug susceptibility, are therefore essential to risk assessing
influenza virulence, disease epidemiology and public health impli-
cations.
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Fig. 1. Phylogenetic analysis of the aminoacid sequences of HA1 subunit of hemagglutinin (1A) and neuraminidase (1B) genes of influenza A(H1N1)pdm09 strains circulating
in  Portugal.
2. Objectives
With the aim of risk assessing emergent strains, the main
objectives of the study were to profile genomic signatures and
antiviral drug susceptibility of A(H1N1)pdm09 viruses and discuss
the potential putative role of mutated residues in human host adap-
tation and virulence.
3. Study design
A total of 110 specimens from laboratory-confirmed cases of
pandemic influenza were collected in Portugal from July 2009 to
January 2010. Strains were isolated in MDCK-SIAT1 cell culture.
Antigenic surface glycoproteins and M1 and M2  proteins were
genetically characterized and antiviral drug susceptibility was pro-
filed. Genetic characterization of internal proteins was performed
on viruses isolated from subsets of pregnant women, outliers to
NAIs and a 14 years old deceased patient with no risk factors.
Cycle sequencing was performed based on adaptation of a proto-
col from CDC, recommended by WHO.7 Genetic mutation analysis
and phylogenetic analysis were performed with LasergeneV.4.05-
DNASTAR and MEGA4.0, with comparison to sequences of the
A(H1N1)pdm09 2010/2011 vaccine strain (A/California/7/2009)
and published reference A(H1N1)pdm09 strains circulating world-
wide within pandemic and post-pandemic periods. Phenotypic
evaluation of antiviral drug susceptibility was performed by flu-
orescent assay with MUNANA substrate as previously described.8
Minor and major phenotypic outliers were identified through the
establishment of lower and upper IC50 cut offs values.8 Genotypic
evaluation of antiviral drug susceptibility to NAIs and to amanta-
dine was  performed by analysing NA and M2  protein sequences,
respectively. In the M2  sequence the 5 well-defined molecu-
lar markers of resistance to amantadine were analysed: L26F/I;
V27A/D; A30T; S31N and G34E.
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Fig. 2. Phenotypic evaluation of A(H1N1)pdm09 virus susceptibility to NAIs by flu-
orescence assay.
4. Results
Virus isolation was performed for all 110 A(H1N1)pdm09 cases.
Of these, 37 were genetically characterized for antigenic glyco-
proteins and for M protein. Antiviral drug susceptibility profile
was phenotypically evaluated for 103 of the 110 isolates. Ninety-
eight were further sequenced for genotypic evaluation of NAIs
susceptibility and 96 for amantadine susceptibility. Genetic char-
acterization of internal proteins PB2, PB1, PB1-F2, PA, NP, NS1 and
NS2/NEP was performed for 13 of the 37 isolates, including viruses
isolated from cases in the subsets described above.
Within the HA1 domain of the HA, all 37 strains were shown
to contain the mutations P83S and I321V (Fig. 1A). Thirty-three of
the 37 strains had the substitution S203T, and 19 also contained
D222E. Additional point mutations were observed, including A73T
and S185N in individual strains, which are located in the puta-
tive antigenic sites Cb and Sb, respectively. The substitution K119N
which results in the creation of an N–X–S motif, was  observed in
2 strains. In the NA gene, 34 of the 37 strains analysed contained
N248D and V106I substitutions (Fig. 1B). Fifteen strains had Y155H
and two contained I223V in the NA gene.
The genetic characterization of MP  of 37 strains identified
M128L, E201D and M203I substitutions in individual isolates
compared to the A(H1N1)pdm09 2010/2011 vaccine strain MP
sequence, located within the M1  coding region.
Phenotypic evaluation of NAIs susceptibility revealed three
minor and two major outliers to oseltamivir, as shown in Fig. 2. The
three minor outliers exhibited reduced susceptibility of approxi-
mately two-fold and the two major outliers of approximately 3-
and 4-fold, compared to baseline level. The two major outliers were
also found to be minor outliers to zanamivir (MjOOsel/MnOZana),
with reduced susceptibility of approximately two-fold compared to
baseline level. In the NA sequence of these two MjOOselt/MnOZana
strains, the mutation I223V was observed. Genotypic evaluation of
susceptibility to amantadine revealed that all 96 strains analysed
had an aspargine (N) at position 31 in the M2  coding region.
The genetic profile of the internal proteins of 13 A(H1N1)pdm09
isolates analysed revealed substitutions P224S in PA, V100I and
L122Q in NP and I123V in NS1, which were common to all 13 iso-
lates (highlighted in bold and #, Fig. 1), as shown in Table 1. PB1-F2
was present in the truncated non-functional form of 11 amino acids. Ta
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Viruses isolated from the subset of pregnant women, were
observed to have R54K substitution in PB2 in 6 cases, 5 of which
also contained D347N in PA. Of these, 4 also contained S384L in PB1
and a small cluster of 3 isolates was characterized by the additional
substitutions A155V and R211K in NS1, and D54N in NS2/NEP.
The mutation V480I was found only in the PB2 sequence of the
two strains exhibiting a reduced susceptibility profile to both NAIs
(MjOOselt/MnOZana).
5. Discussion
A(H1N1)pdm09 viruses characterized by the HA substitution
S203T and both N248D and V106I in NA, were found to be
the dominant circulating strain throughout the epidemic period
(2009–2010) in Portugal. Previous studies have also reported dom-
inant circulation of this strain worldwide and suggested this is a
consequence of enhanced viral fitness.9,10
Within HA1, there was no evidence of evolutionary trends,
in agreement with the genetic and antigenic homogeneity
of A(H1N1)pdm09.11 The location of amino acid substitutions
observed in HA1 however, suggests these could result in pheno-
typic changes; the D222E substitution is located within a loop of
the receptor-binding site, A73T and S185N within the putative anti-
genic sites Cb and Sb, respectively, and K119N has been reported to
result in creation of a potential N-glycosylation site.9,12 Correlation
of these mutations with particular phenotypes, binding specificity
or clinical outcome of infection however, needs further investiga-
tion.
In the internal genes, the V100I and L122Q substitutions
observed in NP, I123V in NS1 and P224S in PA characterize the
genetic profile of all isolates analysed, reflecting the dominant cir-
culation of this A(H1N1)pdm09 genetic variant in Portugal within
the period analysed. Residues 100 and 122 in NP are located within
the body domain of the protein and are thought to be involved in
PB2 and PB1–NP interaction, which is crucial for RNA replication.
The amino acid substitution V100I was associated with the rais-
ing of the pandemic alert from phase 4 to 6, and is a human to
avian signature change known to translate into enhanced viral fit-
ness probably by increasing viral transmissibility or infectivity.10,13
I123V in NS1 is located in the effector domain, a functional region
regulating cellular apoptosis, and therefore suspected to play a role
in adaptation to the human host and to increase virulence.10 P224S
in PA is located in the N-terminal domain, which has endonuclease
activity. Although no phenotypic outcome for this mutation has
been established to date, endonuclease activity is critical for ini-
tiating transcription and therefore, genetic changes in this region
might be expected to alter replication kinetics.14 Although the phe-
notypic outcome of L122Q has not been established, this mutation
has been previously reported as a virulence factor in H5N1 by
greatly increasing replication.15
In the viruses from pregnant women, in addition to the muta-
tions common to all isolates analysed, a unique profile of 6 genetic
signatures in the functional domains of internal proteins defined a
specific cluster. Considering their genetic location, they present a
high potential for translating into phenotypic changes in fitness
and virulence. Both R54K in PB2 and D347N in PA are located
within functional domains for binding PB1.7,18 Since the function
of the polymerase proteins depends on the formation of a het-
erodimer for optimal viral RNA replication and transcription, these
substitutions together with P224S in PA, may  have impacted on
polymerase subunit binding to PB1 and have had an unpredictable
effect on replication in these strains.16,17 Within NS1, the cluster
is defined by A155V and R211K substitutions, both located within
the C-terminal of the effector domain, as is I123V, which has pre-
viously been found to regulate cellular apoptosis.5,18 Replication
and apoptosis are the major mechanisms that define viral fitness.
The occurrence of different point mutations as occurred in strains in
this cluster, could be compensatory or have had a cumulative effect
leading to a different phenotype. These mutations will continue to
be monitored in non-pregnant patients to evaluate whether they
are subset exclusive, resulting from enhanced function of individual
proteins or increasing functional compatibility of proteins.
The virus isolate from the deceased patient contained a distinc-
tive set of mutations which could have contributed to this more
severe clinical outcome. In addition to N248D and V106I in NA,
S203T in HA, V100I in NP and I123V in NS1, this isolate contained
L122Q in NP, S364N and N614S in PA, and R54K in PB2, all located
in PB1 binding domains of the respective proteins.17 A direct asso-
ciation of PB1 binding to the other polymerase subunits and to
NP with a more virulent phenotype has not been established to
date. However, the formation of PB2–PB1–PA heterodimer and the
binding of PB2 and PB1–NP into ribonucleoproteins both determine
vRNA transcription and cRNA synthesis for genome replication and
therefore, have the potential to greatly affect the viral replication
cycle.17
Within the subset of outliers to NAIs, the two MjOOsel/MnOZana
were defined by I223V in NA and V480I in PB2. Amino acid substi-
tutions at position 223 in NA have previously been shown to affect
virus susceptibility to both oseltamivir and zanamivir, in recent
A(H1N1)pdm09 and seasonal viruses.19,20 Residue 223 is located
in the framework of the NA active site, and thus interacts with the
catalytic residues to which antiviral drugs bind.21 The contribu-
tion of V480I in PB2 to the reduced susceptibility profile observed
is unclear. In addition, no phenotypic impact was observed in
A(H1N1)pdm09 viruses containing NA mutation Y155H, previ-
ously observed in seasonal A(H1N1) viruses resistant to both
NAIs.22
Correlating specific mutations with virulent phenotypes in
the human host is not straightforward. Animal models differ in
their immune response to infection and multiple other factors
interfere with clinical and epidemiology outcomes of infection.
Also, the genetic background of specific mutations is divergent
among influenza strains and can have different phenotypic out-
comes. Several mutations have however, been recognized as
virulence markers. Although some mechanisms remain unclear, the
modification of genome transcription, replication, apoptosis and
antigenicity are determinants of virulence. Additionally to known
molecular markers of virulence, we have placed selected residues
within functional domains of internal proteins that may enhance
viral fitness or increase virulence under genomic surveillance.
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Abstract
Global A(H1N1)2009 genetic characterization, molecular
evolution dynamics, antiviral susceptibility profiles, and
inference of public health implications require nation and
region wide systematic analysis of circulating virus. In this
study we analysed the genetic and antiviral drug suscepti-
bility profiles of pandemic A(H1N1)2009 influenza virus
circulating in Portugal. Genetic profile analysis was per-
formed in 37 isolates to the hemagglutinin (HA), neur-
aminidase (NA) and MP genes, and in six of these isolates
the PB1, PB2, PA, NP and NS genes were also analysed.
Antiviral drug susceptibility profile was analysed for 96 iso-
lates, phenotypically and genotypically to neuraminidase
inhibitors (NAI) and genotypically to amantadine. The
point mutations identified in HA, NA, and MP genes of
different strains do not seem to evidence an evolutionary
trend. This is in agreement with the genetic and antigenic
homogeneity that has being described for A(H1N1) 2009
virus. All analysed strains were found to be resistant to
amantadine, and five of these strains exhibited a reduced
susceptibility profile to NAI, three only for oseltamivir and
two for both inhibitors.
Introduction
In mid-April 2009 a novel variant of A(H1N1) influenza
virus began to spread rapidly throughout the world, caus-
ing the first pandemic of the 21st century. The majority of
the cases associated with this new virus show to be mild,
but severe and fatal cases have been reported. Molecular
markers associated with severity have already been identi-
fied, as is the case of the mutation D222G.1 Resistant
viruses to antiviral drugs have also been identified, high-
lighting the importance of rapid determination of the an-
tiviral drug profile.
Global A(H1N1) 2009 genetic characterization, molecular
evolution dynamics, antiviral susceptibility profiles, and
inference of public health implications require nation and
region wide systematic analysis of circulating virus.
The objective of this ongoing research study was, pri-
marily, to thoroughly characterize the genetic profile and
evolution of the emergent influenza A(H1N1) 2009 virus
circulating in Portugal and its phenotypic expression on
antiviral drugs susceptibility.
Materials and methods
The cases considered in this study were obtained from the
community and from two collaborating hospitals in Lisbon
– a reference hospital for adults (Hospital de Curry Cabral)
and a reference hospital for children (Hospital Dona
Estefaˆnia).
The CDC real-time PCR protocol, recommended by
World Health Organization (WHO), was the method used
to confirmed all influenza A(H1N1) 2009 cases. From a
total of 577 A(H1N1) 2009 positive cases diagnosed and
confirmed, 163 were selected for this study, taking in con-
sideration that they should cover the period of epidemic
activity in Portugal and include cases from persons belong-
ing to risk groups and cases associated with more severe
clinical features. Ninety-six A(H1N1) 2009 strains were iso-
lated in MDCK-SIAT1 cells, from combined naso-oropha-
ryngeal swabs.
For the evaluation of the genetic profile of A(H1N1)
2009 virus circulating in Portugal, 37 of the 96 isolates
DOI:10.1111/j.1750-2659.2011.00221.x
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were characterized by genetic analysis of the HA, NA, and
MP genes. The remaining five gene segments (PB1, PB2,
PA, NS, and NP) were also sequenced for six of this 37 iso-
lates. Briefly, sequencing was performed according to the
protocol developed by CDC and recommended by WHO,2
using BigDye Terminator V.1.1 technology. Nucleotide
sequences were determined in a DNA automatic sequencer
ABI PRISM 3130XL Genetic Analyzer. For each genomic
segment, genetic analysis was performed with Lasergene
V.4.05 software (DNASTAR Inc, USA) using an average of
4–6 overlapping readings, including sense and antisense,
for precise nucleotide and amino acid sequence determina-
tion. Genetic mutation and phylogenetic analysis were per-
formed by neighbor-joining method, using MEGA4.0
software, against published sequences from the vaccine
strain (A ⁄California ⁄ 7 ⁄ 2009) and from selected A(H1N1)
2009 strains available on GISAID EpiFlu Database. All
mutations were identified with reference to the vaccine
strain genome sequence.
Antiviral drug susceptibility profile of A(H1N1) 2009
influenza virus circulating in Portugal was evaluated both
phenotypically and genotypically for NAIs and genotypi-
cally for amantadine.
Phenotypic evaluation to NAIs, oseltamivir and zanami-
vir, was performed for all 96 isolates by IC50 determination
through MUNANA fluorescence assays.3 Genotypic evalua-
tion was performed by searching for mutations associated
with resistance to NAIs in all 37 NA gene sequences.
Amantadine susceptibility profile was performed for all 96
isolates by searching on M2 sequence for the 5 molecular
markers associated with resistance to this antiviral drug
(L26F ⁄ I; V27A ⁄D; A30T; S31N; G34E).
Results
Genetic characterisation of the HA1 subunit of HA reveals
point mutations in different strains. All 37 analysed strains
present P83S and I321V mutations, which distinguish them
from the vaccine strain (Figure 1A). Thirty-three of the 37
sequenced strains group in the S203T branch. This muta-
tion is referred in the literature as being associated with the
putative antigenic site Ca.4 Most of these strains (19) fur-
ther subgroup in the D222E branch, this mutation being
associated with one loop of the receptor-binding site.1
From the early to the late epidemic period, an increased
circulation of virus carrying the mutation S203T was
observed. This is in agreement with the association between
this mutation and an enhanced viral fitness that is
described in the literature.5 Additional mutations were also
observed in a small number of virus, of which we highlight:
(i) mutation A73T in A ⁄Portugal ⁄ 03 ⁄ 2009 and mutation
S185N in A ⁄Portugal ⁄ 14 ⁄ 2009, associated with the putative
antigenic sites Cb and Sb respectively,4 and (ii) mutation
K119N in A ⁄Portugal ⁄ 01 ⁄ 2009 and A ⁄Portugal ⁄ 02 ⁄ 2009
that can result in a new N-glycosilation site, as it originates
an N-X-S motif in the aminoacid sequence.
Regarding the genetic characterisation of NA, the major-
ity of strains analysed (34 of 37) presents the mutations
N248D and V106I (Figure 1B). As mutation S203T in HA
gene, these two NA mutations are described in the litera-
ture as associated with enhanced viral fitness.5 The few
strains not carrying these mutations have circulated in the
beginning of the epidemic period. Fifteen of the 37 analy-
sed strains further subgroup in Y155H branch. Addition-
ally, mutation I223V was identified in two strains.
The analysis of the complete MP gene of 37 strains
revealed three mutations in the M1 protein (M128L in
A ⁄Portugal ⁄ 45 ⁄ 2009, E201D in A ⁄Portugal ⁄ 26 ⁄ 2009, and
M203I in A ⁄Portugal ⁄ 77 ⁄ 2009) and three in the M2 pro-
tein (P10H in A ⁄Portugal ⁄ 26 ⁄ 2009, R18K in A ⁄Portu-
gal ⁄ 03 ⁄ 2009, and E66K in A ⁄Portugal ⁄ 28 ⁄ 2009). However,
no reference to these mutations was found in the literature.
For the remaining gene segments available for the six
analysed strains, the observations include: (i) no previously
described virulence markers in PB2, PB1-F2, and NS1 were
detected; (ii) PB1-F2 protein is present in the truncated
form of 11 amino acids; (iii) the presence of mutations
I123V and L122Q in NS1 and V100I in NP; (iv) the
described association of mutation I123V in NS1 and V100I
in NP genes with viral fitness.5
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Figure 1. Phylogenetic tree of the amino acid sequences of HA1 subunit
of hemagglutinin (A) and neuraminidase (B) genes of Influenza
A(H1N1)2009 strains.
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Phenotypic evaluation of NAIs susceptibility revealed the
existence of three minor and two major outliers to osel-
tamivir (Figure 2). The two minor outliers exhibited a
reduction of approximately twofold in the susceptibility to
this antiviral drug, comparing to the baseline level, while
the reduction exhibited by the two major outliers was of
approximately three- and fourfold.
Regarding zanamivir, two minor outliers were identified
with a reduction of approximately twofold in the suscepti-
bility, compared to the baseline level. These two minor
outliers (A ⁄Portugal ⁄ 17 ⁄ 2009 and A ⁄Portugal ⁄ 82 ⁄ 2009)
correspond to the two major outliers identified for osel-
tamivir.
Genetic analysis revealed the presence of the mutation
I223V in the NA sequence of these two strains. The contri-
bution of this mutation for the profile of reduced suscepti-
bility identified for both NAIs is not known, but a
mutation in the same NA position (I223R) has been
referred to as being associated with a reduction in NAIs
susceptibility.6 Full genome sequence analysis of these
strains shows that both strains also present the V480I
mutation in PB2 gene. However, no association of this
mutation with antiviral drug susceptibility is referred in the
literature.
Concerning genetic evaluation of susceptibility to aman-
tadine, all 96 analysed strains present a Serine in position
31, which is a molecular marker of resistance to M2
inhibitors.
Discussion
These preliminary results allow us to discuss several points.
However, the additional data that is being obtained
through this ongoing study will be essential for a more
complete analysis. For example, more information is
needed to determine if the mutations found alter the biol-
ogy and the fitness of the virus or if there are associated
with an increased prevalence of the virus.
The majority of the mutations identified in HA1 subunit
have been detected in A(H1N1)2009 strains distributed
throughout the epidemic curve, not evidencing a specific
evolutionary trend. This is in agreement with the genetic
and antigenic homogeneity that has being described for
A(H1N1)2009 virus.7
The occurrence of mutations in the position 222 of the
HA1 subunit of A(H1N1)2009 virus have been described.
However, more studies are needed to clarify the outcome
of these mutations, as for example in patients with severe
complications. It could also be relevant to investigate the
presence of single and mixed variants in viruses and in
clinical specimens and the possibility of these mutations
affecting the binding specificity.
Regarding the susceptibility of A(H1N1)2009 pandemic
viruses to antiviral drugs, all analysed strains were found to
be resistant to amantadine. This resistant profile was not
unexpected since the MP gene from this new variant had
originated in the Eurasian swine lineage, which is charac-
terised by being resistant to this antiviral drug.8
The majority of the A(H1N1)2009 strains analysed
revealed to be susceptible to both NAIs, with only five
strains exhibiting a profile of reduced susceptibility, three
to oseltamivir and two to both NAIs. For these last two,
the presence of the I223V mutation in the NA sequence
could explain the reduction observed, but a more complete
analysis is needed to confirm this.
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Abstract
The French national pandemic plan includes an early con-
tainment phase followed by a limitation phase. The effi-
cacy of such a plan depends on pre-existing surveillance
and laboratory networks. The GROG community surveil-
lance network and the hospital lab networks organized by
the two French NICs carried out the virological monitor-
ing of the A(H1N1)2009 pandemic. The NICs set up and
distributed the RT-PCR tools to the lab networks early
May 2009. During the containment phase, all suspected
and virologically confirmed cases were hospitalized and
declared to InVS. During the limitation phase, the clus-
tered cases were monitored, and GROG swabs were col-
lected by practitioners in general population. During the
pandemic, the NICs carried out additional testing for the
monitoring of antiviral resistance and of genetic changes
involved in virus adaptation (PB2) and virulence (HA).
The first imported A(H1N1)2009 influenza cases were
detected at the end of April 2009. Local transmission was
observed at the end of May. Clusters were observed in
schools in June and in summer camps during summer.
Sporadic cases were reported up until October when the
pandemic wave started. One single 10 week-long pan-
demic wave was observed between mid-October and the
end of December. Overall, 103 352 samples have been
tested with 24 279 positives. The weekly positive rate ran-
ged from 0% to 48% with a peak week 48 (3877 posi-
tives). Phylogenetic and antigenic analyses did not show
any emerging genetic or antigenic variants. Eight cases
had a D222G mutation in the HA. Eleven cases had an
oseltamivir-resistant virus (H275Y); one harboured a
reduced sensitivity to zanamivir (additional I223R muta-
tion). All but one resistant virus were detected in treated
immunocompromised patients. According to the profile of
hospitalized cases, A(H1N1)2009 was more virulent than
seasonal viruses. Even if the mortality was limited (312
cases), the age distribution of the deceased patients was
different as compared to seasonal influenza (75% mortal-
ity in <65 years of age). The virological monitoring of the
pandemic was achieved by the preexisting seasonal influ-
enza networks.
Introduction
The French national pandemic plan, prepared in response
to the A(H5N1) pandemic threat, has been implemented in
France since 2003 with updates in 2006 and 2008. This
plan describes the response to a pandemic with an early
containment phase to delay the virus circulation in the
population, followed by a limitation phase to contain as
much as possible virus circulation and avoid excess hospi-
talisations and deaths. These phases should use mitigation
measures, antivirals, and vaccination, if available.
The efficacy of such plan depends on pre-existing influ-
enza surveillance and laboratory networks. In France, the
community surveillance is carried through the GROG sur-
veillance network. In addition, surveillance is also carried
out in hospitals by the RENAL network. This RENAL net-
work is divided in two sub-networks: the so-called H5-labs
network, activated during the containment phase and the
Extended RENAL Lab network activated in the limitation
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a b s t r a c t
A research project on antiviral drug resistance of influenza viruses circulating in Portugal has been carried
out since 2007. Here, the first results obtained regarding the evaluation of susceptibility to amanta-
dine and oseltamivir are presented. Information about antiviral prescription and exposure was available
through the National Influenza Surveillance Programme. Amantadine susceptibility was evaluated by
pyrosequencing for known resistance markers on 178 influenza A strains from 2004/2005 to 2006/2007.
Susceptibility to oseltamivir was evaluated by 50% inhibitory concentration determination on 340 virus
strains from 2004/2005 to 2008/2009, 134 of which were further analyzed by sequencing of the neu-
raminidase gene. This study revealed that influenza antiviral drugs were rarely prescribed at national
level. Resistance to amantadine was observed on only A(H3N2) strain isolated during 2005/2006 and on
38 (74.5%)of the51A(H3N2) strains from2006/2007, all carrying themutationS31N in theirM2sequence.
Oseltamivir resistance was observed in 6 (20.7%) of the 29 A(H1N1) strains from 2007/2008 and in all
strains from 2008/2009, which exhibited extremely high IC50 values and carrying the mutation H275Y
in their neuraminidase sequence. The national data generated and analyzed in this studymay contribute
to increase the knowledge on influenza antiviral drug resistance which is a problem of global concern.
© 2010 Elsevier B.V. All rights reserved.
1. Introduction
Two classes of antiviral drugs are currently licensed for the
prevention and treatment of seasonal, zoonotic and pandemic
influenza: (1)M2 inhibitors or adamantanes, including amantadine
and rimantadine, and; (2) neuraminidase inhibitors (NAIs), such as
oseltamivir and zanamivir (Crusat and de Jong, 2007). In Portugal,
only rimantadine is not licensed for clinical use. Amantadine was
introduced into clinical practice in 1973, followed by zanamivir in
1999 and oseltamivir in 2002, all 3 requiring medical prescription
(information available at www.infarmed.pt).
The introduction of these antiviral drugs into clinical practice
raised public health concerns regarding the potential emergence of
resistance and its impact on the clinical effectiveness of the drugs.
These concerns led to national and global surveillance activities
as well as to specific and detailed research studies on influenza
antiviral drug resistance, particularly after the introduction ofNAIs.
Resistance to M2 inhibitors has been observed with a high fre-
quency not only in the clinic but also in the community settings,
∗ Corresponding author. Tel.: +351 217508159; fax: +351 217526498.
E-mail address: h.rebelo.andrade@insa.min-saude.pt (H.R. de Andrade).
limiting their use on influenza prevention and control.More specif-
ically, resistancewas identified on 30–80% of hospitalized patients,
within 48–72h after onset of antiviral therapy (Democratis et al.,
2006). In addition, a high increase in the frequency of influenza
A(H3N2) virus resistant to M2 inhibitors started to be identi-
fied at global level during the 2002/2003 winter season, with the
most recent data from 2008/2009 revealing a 100% worldwide
frequency of resistance (Bright et al., 2005; WHO, 2009a). High
frequencies of resistance to these inhibitors have also been identi-
fied for A(H5N1) avian influenza viruses, particularly those from
clade 1 and approximately 80% from subclade 2.1. A 100% fre-
quency of resistance was also observed for the recently emerged
A(H1N1) swine 2009 pandemic virus (Crusat and de Jong, 2007;
Hayden, 2007; WHO, 2009b). Resistance to M2 inhibitors has also
been identified for seasonal A(H1N1) influenza virus but on a
minor extent and at variable levels, not only between seasons
but also between countries. This variability is associated with the
co-circulation of 2 hemagglutinin (HA) A(H1N1) lineages, 1 resis-
tant to M2 inhibitors (HA subclade 2C)—represented by A/Hong
Kong/2652/2006, and 1 susceptible to this antiviral drug class
(HA subclade 2B)—represented by A/Brisbane/59/2007 (Barr et
al., 2008; Cheng et al., 2009). However, A/Brisbane/59/2007-like
virus have been spreading at global level since they emerged, dur-
0166-3542/$ – see front matter © 2010 Elsevier B.V. All rights reserved.
doi:10.1016/j.antiviral.2010.01.002
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ing 2007/2008, replacing A/Hong Kong/2652/2006-like virus (see
interim reports from WHO Influenza Centre, London, available
at http://www.nimr.mrc.ac.uk/wic/report/). The most recent data
from 2008/2009 revealed that only 2% of the seasonal A(H1N1)
virus analysed worldwide belong to the M2 resistant A/Hong Kong
lineage (WHO, 2009a).
Regarding the emergence of resistance to NAIs, different sit-
uations have been observed for the 2 antiviral drugs available.
Resistance to zanamivir has been rarely detected, with the 2 cases
identified following treatment of immunocompromised patients
being themost notable (Lackenby et al., 2008a). This rare detection
can be associated with the high similarity that zanamivir exhibits,
at structural level, to the natural substrate of neuraminidase
(NA) (Moscona, 2009). However, it is important to consider that
zanamivir has been rarely used in the management of influenza,
which could also explain the situation observed. Resistance to
oseltamivirwas, until 2007, detected at a low frequency andmainly
following treatment (in 0.32% of the adults and 4.1% of the chil-
dren under therapy) (Aoki et al., 2007). Twohigh frequencies of 18%
and 16.3%were, however, observed in 2 Japanese clinical trials car-
ried out in children infected with A(H3N2) and A(H1N1) influenza
viruses, respectively (Kiso et al., 2004;Wardet al., 2005).During the
2007/2008 winter season, the emergence and widespread circula-
tion of seasonal A(H1N1) influenza virus resistant to oseltamivir,
in the absence of drug selective pressure, were identified at global
level (ECDC, 2008; Lackenby et al., 2008a). This resistant virus per-
sisted and increased in frequency during 2008/2009, representing
96% of the seasonal A(H1N1) virus that circulated worldwide dur-
ing that winter season (WHO, 2009a). Sporadic cases of resistance
to oseltamivir have been identified for A(H5N1) avian influenza
virus, with a total of 5 cases reported (3 in Vietnam and 2 in Egypt),
and on the recently emerged A(H1N1) swine 2009 pandemic virus,
with a total of 39 cases reported as of 23th October 2009. The
majority of these sporadic caseswere associatedwith antiviral drug
use (de Jong et al., 2005; Le et al., 2005; Saad et al., 2007; WHO,
2009c,d).
Since 2007, a research project has being carried out in Portu-
gal aiming at the evaluation and study of influenza antiviral drug
resistance. With the data that has already been obtained, and with
data that is expected to be gathered in the course of this project,
it may become possible to contribute to the information that is
continually being generated at international level, some of which
is summarized above, and to advances in the knowledge on this
specific area of research.
In this study, the first results of evaluation of susceptibility to
oseltamivir and amantadine of seasonal influenza A and B viruses,
circulating in Portugal fromthe2004/2005 to the2008/2009winter
seasons, obtained through the national research projectmentioned
above are reported and discussed.
2. Materials and methods
2.1. Influenza virus strains analysed
The influenza virus strains analysed in this study were isolated
from nasopharyngeal swabs collected from influenza-like illness
patients who consulted with a Sentinel Medical Practitioner or
attended an EmergencyUnit participating in theNational Influenza
Surveillance Programme. The respiratory specimens were accom-
panied by a notification form containing epidemiological and
clinical information related to the patient and, since 2005/2006,
information regarding prescription and exposure (either by direct
use or contact with a patient on therapy) of patients to influenza
antiviral drugs before specimen collection. Every time a notifica-
tion form indicated drug prescription and the presence of influenza
virus was detected on the swab, a second respiratory specimen
from the patient was requested, collected at the end of antiviral
therapy (4th or 5th day).
Viral isolation was performed in MDCK or MDCK-SIAT1 cells,
according to the WHO Manual on Animal Influenza Diagnosis and
Surveillance (2002). Antigenic characterization of viral isolateswas
performed by (1) hemagglutination inhibition assays for determi-
nation of HA type or subtype, following the protocol included in the
WHO Influenza Reagent Kit for Identification of Influenza Isolates,
and; (2) TaqMan real-time PCR for determination of neuraminidase
(NA) influenza A subtype, using a modified version of the protocol
described by Schweiger et al. (2000).
Susceptibility to amantadine was evaluated for a total of 178
influenza A virus strains, 127 of A(H3N2) and 51 of A(H1N1) sub-
type, isolated from the 2004/2005 to the 2006/2007winter seasons
(Table 1). This evaluation was carried out at the Health Protection
Agency (London, United Kingdom) during 2007, using all influenza
A virus strains (from the winter seasons referred) for which a suf-
ficient volume for performing the analysis was available at that
moment. The majority of these strains were tested using a 2nd or
3rd cell passage isolate. A total of 340 influenza virus strains iso-
lated from the 2004/2005 to the 2008/2009 winter seasons, 117 of
A(H3N2) subtype, 93 of A(H1N1) subtype and 130 of B type, were
tested for oseltamivir susceptibility by fluorescence assay (Table 1).
The majority of these strains were tested using a 2nd to 4th cell
passage isolate. From all the strains isolated during the winter sea-
sons considered for this study, only those that did not exhibited a
NA activity equal or higher than 25,000 relative fluorescence units
(RFUs), after all the possible re-isolations procedures for increas-
ing activity, were not tested. Wild-type reference influenza virus
strains susceptible to NAIs were used as assay controls on fluores-
cenceassay. Thesewere:A/Wisconsin/67/2005 (A(H3N2) subtype);
A/Texas/36/1991 (A(H1N1) subtype) and; B/Memphis/20/1991 (B
type). These reference strainswere kindly provided byDr. AlanHay
(National Institute for Medical Research, Mill Hill, London, United
Kingdom). From the 340 virus strains tested with the fluorescence
assay, 134were further analyzed byNA gene sequencing, including
all strains identified as statistical outliers and approximately 25%
of non-outliers (randomly selected) (Table 1).
2.2. Oseltamivir
Oseltamivir carboxylate, the active compound of the ethyl ester
prodrug oseltamivir phosphate, was provided in the form of a d-
tartrate salt by F. Hoffmann-La Roche Ltd. (Basel, Switzerland),
through a material transfer agreement.
2.3. Susceptibility to amantadine
Susceptibility to amantadine was evaluated by pyrosequenc-
ing using the standard operating procedure (SOP) provided by the
European Surveillance Network for Vigilance against Viral Resis-
tance (VIRGIL),which included (1) theamplificationof the influenza
A M2 gene for amantadine sensitivity pyrosequencing and (2) the
preparation of DNA for pyrosequencing using the PyroMark Vac-
uum Prep Workstation. The 2 steps of the VIRGIL SOP were based
on the pyrosequencing manufacturer’s protocol (Biotage, Uppsala,
Sweden) previously described by Bright et al. (2005). Two relevant
modifications were introduced in each step. For the amplification
of the M2 gene, 5!l of viral RNA was used in a 50!l reaction mix-
ture and the number of amplification cycles was increased to 35.
For the preparation of DNA for pyrosequencing, the M2 sequenc-
ing primer was used at a final concentration of 0.44!M and the
duration of the annealing stepwas halved (2min). Pyrogramswere
obtained through a SNP (AQmode) analysis specific for the 5 point
mutations associated with the development of resistance to aman-
tadine: L26F/I; V27A/D; A30T; S31N; and G34E (Hay et al., 1985,
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1991; Hurt et al., 2007). These procedures were carried out at the
Health Protection Agency (London, United Kingdom).
2.4. Susceptibility to oseltamivir
Susceptibility to oseltamivirwas first evaluated by a phenotypic
fluorescence assay and then through sequencing of NA gene coding
region.
2.4.1. Fluorescence assay
Fluorescence assay was performed using the SOP provided
by VIRGIL for determination of influenza virus susceptibility to
neuraminidase inhibitors, available to the general public from
http://www.nisn.org/documents/Zambon - VIRGIL IC50 SOP.pdf.
This SOP is basedon themethoddevelopedbyPotier et al. (1979), in
which the amount of fluorescent product 4-methylumbelliferone
that is cleaved from the substrate 2′,2′-(4-methylumbelliferyl)-
!-d-N-acetylneuraminic acid sodium salt hydrate (MUNANA) by
the NA of influenza viruses is measured. A NA activity assay was
initially performed in order to ensure that equivalent NA activities
were compared against oseltamivir. For each influenza virus strain,
the dilution in the linear portion of the enzyme activity curve to
be used in the subsequent NA inhibition assay was determined.
With this second assay, the concentration of oseltamivir required
to inhibit 50% of the NA activity of each influenza virus strain (IC50
value) was determined.
2.4.2. NA gene sequencing
RNA extraction was performed either using a modified version
of the protocol described by Boom et al. (1990) or the QIAamp Viral
RNAMini Kit (QIAGEN, Germany). A conventional two-step RT-PCR
was used for the amplification of 3 overlapping segments, with a
length varying from 490 to 700bp, which covered the entire NA
gene sequence. RT reaction was performed as described by Ellis et
al. (1997) and the PCR reaction consisted of 10"l of cDNA added
to 40"l of a reaction mixture containing 20mM Tris–HCl (pH 8.4),
50mMKCl, 1mM (N1 subtype and B type) or 1.25mM (N2 subtype)
MgCl2, 12.5pmol (N1 subtype and B type) or 5pmol (N2 subtype)
of each primer, and 1.5U of Taq DNA polymerase. PCR cycling con-
ditions included: 2min at 95 ◦C; 35 cycles of 1min denaturation at
94 ◦C, 1min annealing at 50 ◦C (N1 and N2 subtypes) or 52 ◦C (B
type) and 2min extension at 72 ◦C; and cooling at 8 ◦C. Purification
of the amplified segments was carried out using the QIAquick PCR
Purification Kit (QIAGEN, Germany), and the resulting DNA quanti-
fied by spectrophotometry. Nucleotide sequences of the purified
segments were obtained on an automatic sequencer ABI PRISM
Biosystems 3130XL Genetic Analyser after using the Big Dye Ter-
minator Cycle Sequencing Ready Reactions kit v1.1, both according
to the manufacturer’s instructions (Applied Biosystems). For each
of the 3 different amplified segments, 3 sequencing primers were
used (2 forward and 1 reverse). The 9 overlapping sequences of NA
gene, obtained for each influenza virus strain, were then assem-
bled and edited using the SeqMan II software from the Lasergene
package v4.05 (DNASTAR Inc.). The alignment of the NA coding
sequences obtained for each NA (sub)type was performed with
the Megalign software (from same package) using the neighbour-
joining method. NA sequences of reference influenza virus strains,
obtained from Influenza Sequence Database at https://isd.eiss.org/,
were included in the alignments. The sequences of all primers used
are available from the authors upon request.
2.5. Statistical analysis
The temporal distribution of the notification forms indicating
(1) prescription or (2) no prescription of influenza antiviral drugs,
Author's personal copy
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Table 2
Frequency (number) of influenza-like illness notification forms received with the indication of prescription and of no prescription of antiviral drugs during the 4 winter
seasons for which this information was available (2005/2006 to 2008/2009).
Type Winter season pa
2005/2006 (N=298) 2006/2007 (N=493) 2007/2008 (N=226) 2008/2009 (N=600)
Prescription % (n) 2.0 (6) 2.2 (11) 3.1 (7) 1.0 (6) 0.191
IC95% 0.74–4.33 1.12–3.96 1.25–6.28 0.37–2.16
No prescription % (n) 98.0 (292) 97.8 (482) 96.9 (219) 99.0 (594)
IC95% 95.67–99.26 96.04–98.88 93.72–98.75 97.84–99.63
No information n 240 237 67 129 -
a Pearson’s Chi-Square Test.
was analyzed by a Pearson Chi-Square Test. Additionally, 95% con-
fidence intervals were determined according to Bliss (1967).
Regarding the fluorescence assay, NA activity and IC50 val-
ues were calculated through point-to-point curve fitting using the
Microsoft Office Excel 2003 (Microsoft Office Professional Edition
2003). The identification of outliers was performed through the
determination of lower and upper IC50 cut off values for each
influenza (sub)type andwinter season. The lower cut off value cor-
responded to 1.65 standard deviations (SD) and the upper cut off
value to 3SD above themedian IC50 value, using a robust estimation
of the SD (AMC, 2001). Any influenza virus strainwith an IC50 value
higher than the lower cut off was classified as a minor outlier, and
as a major outlier when the IC50 value was higher than the upper
cut off. All statistical outliers identified were retested twice and
the mean IC50 value was considered for analysis. An IC50 baseline
level was also determined for each influenza (sub)type and winter
season, corresponding to the median value±1 robust SD (outliers
not included). This same determination (median value±1 robust
SD) was performed for each of the 2 influenza B lineages in co-
circulation (B/Yamagata and B/Victoria) but, in this case, outliers
were included. The variation of IC50 values between winter sea-
sons and influenza (sub)types/B lineages was analyzed performing
an ANOVA one-way. If significant differenceswere identified, these
were analyzed, if possible, by Bonferroni’s correction post hoc test.
All data obtained with the fluorescence assay was log-transformed
before being used for statistical analysis in order to be normally
distributed.
All statistical tests were performed using the SPS Statistics soft-
ware v17.0 and, in all of them, a p value <0.05 was considered to be
statistically significant.
3. Results
3.1. Prescription and exposure to influenza antiviral drugs
The information on antiviral drugs indicated on the notification
forms received revealed that, from2005/2006 to2008/2009, antivi-
ral drugs were rarely prescribed for the treatment of influenza-like
illness symptoms. More specifically, indication of antiviral drug
prescription was only found on 30 (0.02%) of the 1617 notification
forms received during the winter seasons analysed. No significant
differences were observed in the prescription frequency through-
out the seasons (Pearson Chi-Square Test, p=0.191) (Table 2).
Of the 30 cases of antiviral drug prescription notified, 27
(90.0%) were received through the Emergency Units Network of
the National Influenza Surveillance Programme (Table 3). No par-
ticular pattern was observed when analysing the distribution of
prescription cases during each winter season and by geographic
origin (cases were from 5 regions of mainland Portugal). The same
was not observedwhen considering the patient age group,with the
majority of antiviral prescriptions occurring in patients belonging
to the 15–44 years age group (22; 73.3%), which includes adoles-
cents and younger adults. Of the 30 notifications of antiviral drug
prescription, 4 (13.3%) were for patients who had previously been
vaccinated for influenza. Two of these notifications, the 1 from
2005/2006 and the first of 2006/2007, occurred at the beginning
of the season and originated on 2 young adults, while the other 2
occurred during the epidemic period of the season and were from
an adult and from an older person (Table 3). Oseltamivir was the
drugmost prescribed, having been indicated in 19 (90.5%) of the 21
known antiviral prescriptions. Laboratory analysis indicated that
influenza viruses were detected in only approximately half of the
nasopharyngeal swabs associated with antiviral prescription (14;
46.7%). However, it is important to notice that in the last season
(2008/2009) there was an absolute association between antiviral
prescription and positive influenza infection (Table 3). The second
respiratory specimen was obtained only from the 2 influenza posi-
tive cases detected in 2007/2008 and from 3 of the 6 ones detected
in 2008/2009. Isolation, however, was unsuccessful.
Regarding the situationof exposure of patients to antiviral drugs
before specimen collection, only 3 cases were notified between
2005/2006 and 2008/2009 (1 in 2006/2007 and 2 in 2008/2009).
However, the antiviral to which the patients were exposed was
not referred and the respiratory specimens that came with these
notifications were negative for influenza virus infection. Because
of this and of the lack of success on viral isolations performed on
the second respiratory specimens, it was not possible to analyse
the impact of antiviral drug use on influenza virus susceptibility to
oseltamivir and amantadine.
3.2. Susceptibility to amantadine
Amantadine resistant marker S31N was identified on the M2
protein sequence of 39 (30.7%) of the 127 influenza A(H3N2)
virus strains analyzed, specifically on the single virus strain
from 2005/2006 and on 38 (74.5%) of the 51 virus strains from
2006/2007. In the origin of this resistance is a G to A substitution
in the second nucleotide of the codon that codes for the amino acid
at position 31 of the M2 protein sequence. Using the epidemiolog-
ical information available, it was possible to observe that A(H3N2)
amantadine resistant strains from 2006/2007 were isolated from
respiratory specimens collected during the whole winter season
and from patients of all age groups and from almost all geographic
regions of mainland Portugal.
Regarding the A(H1N1) subtype, all 51 influenza virus strains
analysed were found to be susceptible to amantadine, since none
of the 5 molecular markers of resistance to this antiviral drug was
identified in their M2 protein sequence.
3.3. Susceptibility to oseltamivir
3.3.1. Fluorescence assay
3.3.1.1. IC50 baseline level. No significant differences were
observed on the IC50 baseline levels obtained for the influenza
A(H3N2) subtype (ANOVA one-way, p=0.303) (Table 4). This
situation was not observed, however, for both influenza A(H1N1)
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Table 4
Oseltamivir IC50 baseline levels for each influenza (sub)type and winter season.
Influenza (sub)type Median± robust SD pa
2004/2005 2005/2006 2006/2007 2007/2008 2008/2009 Between seasons Between
(sub)types
A(H3N2) 0.38±0.13 0.24b 0.41±0.04 c 0.38±0.10 0.303
A(H1N1) 1.71±0.11 1.47±0.49 c 1.88±0.39 526.35±201.75 0.000 (0.044 without 08/09) 0.000
B 13.08±3.47 21.04±3.01 18.82±6.86d 19.59±7.09 38.41b,e 0.000
a ANOVA one-way.
b Only 1 influenza virus strain from this subtype was isolated during this winter season.
c None influenza virus strain from this subtype was isolated during this winter season.
d Only 2 influenza virus strains from this subtype were isolated during this winter season.
e Minor outlier but is the only B IC50 value obtained in this winter season.
Table 5
Oseltamivir IC50 baseline levels for each influenza B HA lineage and winter season.
Influenza B lineage Median± robust SD pa
2004/2005 2005/2006 2006/2007 2007/2008 2008/2009 Between seasons Between (sub)types
Yamagata 13.06±3.13 14.35b 14.19b 20.12±7.12 –c 0.000
0.000Victoria 21.74±3.97d 21.27±3.14 23.45b 16.20±0.81d 38.41b 0.001
pa 0.005 0.011 – 0.254 – –
a ANOVA one-way.
b Only 1 influenza B virus from this lineage was isolated during this winter season.
c None influenza B virus from this lineage was isolated during this winter season.
d Only 2 influenza B virus from this lineage were isolated during this winter season.
subtype and type B viruses. The IC50 baseline levels determined
for the A(H1N1) subtype differed markedly between the first
4 winter seasons analysed and the 2008/2009 season (ANOVA
one-way, p<0.05, Bonferroni’s correction post hoc test). This
high difference of approximately 300-fold, indicates a poten-
tial shift on the antiviral drug profile of A(H1N1) virus, from
susceptible to resistant, between 2007/2008 and 2008/2009.
Additionally, when removing the 2008/2009 IC50 values from the
analysis, A(H1N1) IC50 baseline levels of 2005/2006 and 2007/2008
proved to be significantly different (ANOVA one-way, p<0.05,
Bonferroni’s correction post hoc test). Regarding influenza type
B, IC50 baseline levels varied significantly throughout winter
seasons (ANOVA one-way, p<0.05). However, it was not possi-
ble to perform the analysis of these differences through a post
hoc test due to the existence of a single value for 2008/2009
(Table 4).
Fig. 1. IC50 values obtained by fluorescence assay for the influenza A(H1N1) (a), the influenza A(H3N2) (b) and the influenza B virus strains analyzed (c), in each of the winter
seasons studied. Each (!), (♦) and ( ) represents an IC50 value obtained, being that the last 2 symbols represent also the minor and major outliers identified, respectively.
The (· · ·· · ·) represents the IC50 median value, the ( ) the lower IC50 cut off value and the ( ) the upper IC50 cut off value. Note: Lower and upper cut off values were only
determined when the number of virus strains tested were equal or higher than 10. When this did not occur, we considered for analysis the cut off values of the previous
and/or the following winter season.
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Oseltamivir IC50 baseline levels proved to differ significantly
according to the NA (sub)type of influenza viruses, with NA type B
virus exhibiting thehigher levels, followedby theNAsubtypeA(N1)
and by the NA subtype A(N2) virus (ANOVA one-way, p<0.05)
(Table 4).
Additionally, oseltamivir IC50 baseline levels differed signif-
icantly between the 2 co-circulating influenza B HA lineages,
B/Yamagata and B/Victoria (ANOVA one-way, p<0.05) (Table 5).
B/Yamagata-like virus from 2004/2005 and 2005/2006 showed
significant lower IC50 baseline levelswhen compared to B/Victoria-
like virus from the same winter seasons (ANOVA one-way,
p=0.005/p=0.011). For the remaining 3 seasons, the difference
observed was not statistically significant, or it was not possible to
perform the analysis. Significant differences were also observed
on the IC50 baseline levels obtained for each influenza B lin-
eage throughout the winter seasons (ANOVA one-way, p<0.05).
These differences appeared to occur between the 2007/2008 and
the previous 3 winter seasons for the B/Yamagata lineage and
between the 2008/2009 and the previous 4 winter seasons for
the B/Victoria lineage (Table 5). However, the impossibility of per-
forming a post hoc test does not allow confirmation at statistical
level.
3.3.1.2. IC50 values and outlier determination. Regarding A(H1N1)
influenza subtype, IC50 values ranged from 1.63 to 2.13nM
in 2004/2005, from 0.83 to 2.6nM in 2005/2006, from 0.8
to 2.6nM in 2007/2008 and from 314.04 to 1208.84nM in
2008/2009 (Fig. 1a). All A(H1N1) virus strains from 2008/2009
were directly considered as potential oseltamivir-resistant strains,
as a result of the high IC50 values exhibited by all of them.
During the previous 4 winter seasons, 2 minor and 6 major
A(H1N1) outliers were identified by statistical analysis. The virus
strains classified as minor outliers exhibited an approximately
2-fold decrease in the susceptibility to oseltamivir (based on
the IC50 median value). These were: A/Lisboa/25/2006 (IC50 of
2.85nM), from 2005/2006; and A/Lisboa/8/2008 (IC50 of 3.02nM),
from 2007/2008. The 6 major outliers identified in 2007/2008
were: A/Lisboa/2/2008 (IC50 of 609.09nM); A/Lisboa/3/2008
(IC50 of 584.82nM); A/Lisboa/11/2008 (IC50 of 441.90nM);
A/Lisboa/20/2008 (IC50 of 1064.15nM); A/Lisboa/27/2008 (IC50
of 642.05nM), and; A/Lisboa/28/2008 (IC50 of 511.44nM). These
virus strains exhibited a 230–560-fold decrease in susceptibility to
oseltamivir (based on the IC50 median value), having been, there-
fore, considered as potential oseltamivir-resistant strains (Fig. 1a).
Influenza A(H3N2) IC50 values ranged from 0.18 to 0.61nM
in 2004/2005, from 0.25 to 0.47nM in 2006/2007 and from 0.28
to 0.54nM in 2008/2009 (Fig. 1b). Only 2 A(H3N2) outliers were
identified by statistical analysis, 1 minor and 1 major. These 2
outliers were from the 2006/2007 winter season, corresponding
to the virus strains A/Lisboa/1/2007 (IC50 of 0.52nM—minor) and
A/Lisboa/54/2007 (IC50 of 0.6nM—major) (Fig. 1b). However, the
difference observed between their IC50 values and the seasonal IC50
median value was less than 2-fold.
For influenza type B, IC50 values ranged from 7.73 to
19.39nM in 2004/2005, from 14.35 to 26.72nM in 2005/2006
and from 11.90 to 33.61nM in 2007/2008 (Fig. 1c). A total of
4 minor outliers were identified, corresponding to the virus
strains: B/Lisboa/12/2005 (IC50 of 24.41nM), from 2004/2005;
B/Lisboa/5/2006 (IC50 of 30.51nM) and B/Lisboa/11/2006 (IC50
of 27.53nM), from 2005/2006, and; B/Lisboa/1/2009 (IC50 of
38.41nM), from 2008/2009 (Fig. 1c). Both B/Lisboa/12/2005 and
B/Lisboa/1/2009 outlier strains exhibited an approximately 2-fold
decrease in the susceptibility to oseltamivir (based on the IC50
median value), while for the other 2 outlier strains the difference
observed was less than 2-fold.
3.3.2. NA gene sequencing
The analysis of the A(H1N1) virus NA sequences revealed the
presence of themutation His275Tyr (H275Y, N1 numbering) in the
sequence of the 6 virus strains from 2007/2008 classified as major
outliers on the fluorescence assay, and in all virus strains from
2008/2009. This mutation is associated with a high level of resis-
tance to oseltamivir in theNA subtype (N1) virus, resulting fromaC
to T nucleotide substitution at position 823 of the coding sequence.
Its identification in the NA sequence of the A(H1N1) virus strains
that exhibited high fluorescence IC50 values allowed to confirm
that 6 (20.7%) of the 29 A(H1N1) virus strains from 2007/2008 and
that all (100%) A(H1N1) virus strains from 2008/2009 were resis-
tant to oseltamivir. The NA sequence of these oseltamivir-resistant
viruses is also characterized by the presence of the mutation
Asp354Gly (D354G, N1 numbering), in relation to the reference
strain A/Brisbane/59/2007. No amino acid changes different from
those observed in the other co-circulating A(H1N1) virus strains
were observed in the NA sequence of the 2 strains classified as
minor outliers on the fluorescence assay.
The lack of different amino acid changes that could explain the
reduction observed for oseltamivir susceptibility was also verified
in the NA sequence of the 2 A(H3N2) virus strains classified as out-
liers on the fluorescence assay. However, the presence of a mixed
population of virus with either an Asp (D) or an Asn (N) at residue
151 (G and A peak at position 451 of the N2 coding sequence) was
found in the NA sequence of the non-outlier A/Lisboa/8/2007 virus
strain, from 2006/2007. The mutation D151N has been associated
with a reduction in the susceptibility of influenza A and B viruses to
oseltamivir and/or zanamivir. However, this virus strain exhibited
one of the lowest IC50 values (0.29nM) obtained during 2006/2007.
Regarding influenza type B, the NA sequences of the 4 virus
strains classified as minor outliers in the fluorescence assay were
analysed in relation to NA sequences of reference B virus strains,
and not to NA sequences of co-circulating B virus strains as per-
formed for A(H1N1) and A(H3N2) subtypes. This difference is a
consequence of the low number of influenza B strains isolated dur-
ing 2006/2007 and 2008/2009 and of the few influenza B strains
from 2004/2005 that were sequenced for NA. Two mutations were
found in theNAsequenceof theoutlierB/Lisboa/12/2005: Ile240Val
(I240V) and Glu404Gly (E404G) (B numbering). In the NA sequence
of the outlier B/Lisboa/1/2009, 2 mutations were also identified:
Arg65Leu (R65L) andAla358Glu (A358E).Noneof these4mutations
are associatedwith reduction or with development of resistance to
oseltamivir. In the NA sequence of the 2 outliers from 2005/2006,
B/Lisboa/5/2006 and B/Lisboa/11/2006, no different amino acid
changes were observed that could explain the reduced suscepti-
bility.
4. Discussion
This study revealed that antiviral drugs were rarely prescribed
at national level for the treatment of seasonal influenza, from
2005/2006 to 2008/2009. This may be a direct consequence of
the perception that these antivirals would be crucial and should
only be used during a pandemic. The fact that the information
obtained is limited to the population under observation, in the con-
text of the National Influenza Surveillance Programme, should also
be taken into account. In fact, the information was collected from
patients that use primary and secondary public health care systems
where the delay in consultation upon onset of symptoms leads to
unsuitability of antiviral drug prescription. Most of the antiviral
prescriptions were indicated for patients belonging to the 15–44
age group (adolescents and younger adults), but no information
was available about their risk of developing serious complications
from influenza. This information could have been useful when ana-
lyzing the 4 cases of drug prescription in previously vaccinated
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individuals that, most probably due to recent vaccination, did not
have a sufficient level of immunity against circulating influenza
viruses. Oseltamivir was the antiviral drug most prescribed. The
reasons for this could have been its advantage over zanamivir in
terms of administration route and pharmacokinetics, and the high
level of resistance observed for M2 inhibitors (Democratis et al.,
2006;Deydeet al., 2007). Additionally,M2 inhibitors inPortugal are
essentially used for treatment of Parkinson’s disease. One impor-
tant finding of this study, which raises concerns on how antiviral
drugs are being used, was that approximately half of the pre-
scriptions were made for individuals who were not infected with
influenza.
Resistance to amantadine was only observed for the A(H3N2)
influenza subtype, with the identification of the mutation S31N on
the M2 protein sequence of the only strain isolated in 2005/2006
and of 74.5% of the strains from 2006/2007. This mutation is the
most common mechanism of resistance to M2 inhibitors, being
already known that is occurrence on the M2 protein constricts the
size and increases the polarity of the antiviral drug binding site
(Stouffer et al., 2008; Weinstock and Zuccotti, 2006). The situa-
tion observed at the national level is in agreement with the global
spread of an A(H3N2) virus strain carrying the S31Nmutation that
has been observed since 2002/2003 (Bright et al., 2005).
In respect to oseltamivir, resistance was only observed for sea-
sonal A(H1N1) influenza virus and at an increasing frequency
of 20.7% in 2007/2008 to 100% in 2008/2009. These resistant
viruses exhibited extremely high IC50 values, between 314.04 and
1208.84nM, and carried the mutation H275Y (N1 numbering) in
their NA protein sequence. Themechanism of resistance associated
with the presence of this mutation is already known, consisting
of prevention of formation of the pocket in the NA active site of
influenza N1 subtype virus, which is essential for the high affinity
binding of oseltamivir (Moscona, 2005;Wang et al., 2002). The role
of the D354G mutation that was also found in the NA sequence of
all A(H1N1) oseltamivir-resistant virus is still unclear. The situation
observed at the national level is in agreement with the widespread
and sustained transmission of oseltamivir A(H1N1) resistant virus
observed worldwide since 2007/2008 (ECDC, 2008). Until now, no
clear reasons were found for the emergence and global spread of
this A(H1N1) resistant virus.
No different mutations, comparing to those observed in other
co-circulating strains from the same subtype, were identified in
the NA sequence of the A(H1N1) and A(H3N2) virus strains that
exhibited a reduction for oseltamivir susceptibility at the pheno-
typic level (fluorescence minor outliers). For this reason, a more
detailed genotypic analysis of these strains will be attempted,
involving the sequence of other segments of the genome, partic-
ularly HA. The presence of themixed population of D151wild-type
and N151 mutant virus on the non-outlier A/Lisboa/8/2007 virus
strain is now being further studied, given the described association
of D151Nmutation to a reduction onNAIs susceptibility (McKimm-
Breschkin et al., 2003; Sheu et al., 2008). For influenza type B, due
to the limited number of sequences available, it was not possi-
ble to verify if the 2 mutations identified exclusively on 2 of the
minor outliers (B/Lisboa/12/2005 and B/Lisboa/1/2009) were asso-
ciated with the reduction on oseltamivir resistance, observed at
phenotypic level, or are simply a result of antigenic drift. How-
ever, it has to be taken into consideration that (1) B/Lisboa/12/2005
belongs to theB/Victoria lineageandwas isolatedduringa seasonof
B/Yamagata lineage dominance and; (2) that B/Lisboa/1/2009 was
the only B virus isolated during 2008/2009, a season in which the
occurrence of a HA and NA antigenic drift on the B/Victoria lineage,
from B/Malaysia/2506/2004 to B/Brisbane/60/2008-like virus, was
described. Further genotypic analysis of influenza B virus, involving
NA sequencing and sequencing of other segments of the genome of
outlier virus strains would be essential.
Susceptibility of influenza viruses to oseltamivir proved to dif-
fer significantly according to the NA (sub)type. This difference was
described in previous studies and was expected to occur here,
having been associated with the existence of minor structural dif-
ferences between theNAactive sites of each influenzaNA sub(type)
virus, which would result in different oseltamivir binding affini-
ties (Boivin and Goyette, 2002; Escuret et al., 2008; Ferraris et al.,
2005;Hurt et al., 2004;McKimm-Breschkin et al., 2003). The reduc-
tion in susceptibility to oseltamivir observed from 2005/2006 to
2007/2008 in the A(H1N1) subtype was most probably a result
of NA antigenic drift, from A/New Caledonia/20/1999-like virus to
A/Brisbane/59/2007-like virus, that occurred between thesewinter
seasons (results not shown). The co-circulation of 2 HA B lineages
(B/Yamagata and B/Victoria) could help to explain the variation
observed in the susceptibility of influenza B virus during the period
of this study. These 2 lineages differed significantly in their sus-
ceptibility to oseltamivir, with B/Yamagata-like virus exhibiting
significant lower IC50 values for 2 of the 3winter seasons for which
this analysiswas possible to be performed. Additionally, this differ-
ence between B lineages has already been described by Lackenby
et al. (2008b).
For the comingwinter season(s), itwouldbeof great importance
to continue these studies and to advance to more specific research
studies, even more now that the importance and critical role of
antiviral drugs, particularly oseltamivir, has been demonstrated
and highlighted for the A(H1N1) 2009 influenza pandemic.
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